

ISHLT2024

44th Annual Meeting & Scientific Sessions

9 April | Preconference
10-13 April | Annual Meeting

Prague Congress Centre
PRAGUE, CZECH REPUBLIC

FINAL PROGRAM

ishlt.org/ishlt2024
#ISHLT2024



X @ISHLT
f @TheISHLT
@TheISHLT
in /company/ishlt

ANNUAL MEETING GENERAL INFORMATION

Download the **ISHLT2024 Mobile Meeting App** for the most up-to-date program information: <https://www.isHLT.org/annual-meeting>

Meeting Location

The ISHLT 44th Annual Meeting & Scientific Sessions will be held in person at the Prague Congress Center in Prague, Czech Republic. Full details about the meeting are available at [isHLT.org/isHLT2024](https://www.isHLT.org/isHLT2024).

Continuing Medical Education (CME) Information

Please visit the [ISHLT2024 Continuing Education Information](#) page for full details.

2023-2024 Board of Directors

Jason D Christie, MD, MS, USA, President
Christian Benden, MD, MBA, FCCP, President-Elect
Andreas Zuckerman, MD, Austria, Past President
Martin Goddard, FRCS, MRCPa, United Kingdom, Treasurer
Peter Hopkins, FRACP, Australia, Secretary
Caron Burch, RN, MSN, FNP, CCTC, USA, Director
Marc De Perrot, MD, MSc, Canada, Director
Daniel Dilling, MD, USA, Director
Mardi Gomberg-Maitland, MD, MSc, USA, Director
Angela Lorts, MD, MBA, USA, Director
Jignesh Patel, MD, PhD, USA, Director
Yael Peled, MD, Israel, Director
Diyar Saeed, MD, PhD, Germany, Director
Laurie Snyder, MD, MHS, USA, Director
Josef Stehlik, MD, MPH, USA, Director
Simon Urschel, MD, Canada, Director

ISHLT Staff

Greg Schultz, CAE, Chief Executive Officer
Aaron Adair, Chief Operating Officer
Jacky Schweinzger, CMP, Director of Meetings and Industry Partnerships
Sue Bessner, Director of Education and Research
Jess Burke, CAE, IOM, Director of Marketing and Communications
Megan Barrett, Programs Manager
Lisa Collins, Meetings and Industry Partnerships Manager
Susie Newton, Scientific Programs Manager
Juliet Osazemwinde, Governance and Communities Administrator
Alyssa Simpson, Marketing and Communications Manager
Joanne Singletary, CAE, Membership Manager
Olivia Taylor Penninger, Education Program Administrator

141 West Jackson Suite 1340

Chicago, IL 60604 USA

Phone: +1-312-224-1277

www.isHLT.org

ISHLT2024 ANNUAL MEETING SCIENTIFIC PROGRAM PLANNING COMMITTEE

The ISHLT would like to thank the following individuals who worked tirelessly to build an outstanding scientific program for the ISHLT Annual Meeting and Scientific Sessions.

❖ Denotes Team Leader

Executive Program Committee:

Goran Dellgren, MD, PhD, Sweden, ISHLT2024 Scientific Program Chair
Jason D Christie, MD, MS, USA, ISHLT President
Howard Eisen, MD, USA, ISHLT2023 Scientific Program Chair
Kiran Khush, MD, MAS, USA, ISHLT2025 Scientific Program Chair

Advanced Heart Failure and Transplantation Team:

Pre-Transplant:

❖ Melissa Cousino, PhD, USA
Cristiano Amarelli, MD, Italy
Javier Carbone, MD, PhD, Spain
Chesney Castleberry, MD, USA
Sharon Chih, MBBS, Canada
Eugene DePasquale, MD, USA
Jonathan Hand, MD, USA
Erik Henriksen, PharmD, USA
Harveen Lamba, MD, MSc, USA
Clive Lewis, MA MBBChir, PhD, FFICM, FRCP, United Kingdom
Dylan Miller, MD, USA
Arne Neyrinck, MD, PhD, Belgium

Post Transplant:

❖ David Baran, MD, USA
Estela Azeka, MD, PhD, Brazil
Jennifer Conway, MD, USA
Fabienne Dobbels, MSc, PhD, Belgium
Cesar Guerrero-Miranda, MD, FACC, USA
Ivan Knezevic, MD, PhD, Slovenia
Jill Krisl, PharmD, USA
Rebecca Kumar, MD, USA
Anna Meyer, MD, Germany
Nina Pilat, MSc, PhD, Austria
Carmela Tan, MD, USA
Alessandra Verzelloni Sef, MD, United Kingdom

Advanced Lung Failure and Transplantation Team:

❖ Wiebke Sommer, MD, Germany
Brandi Bottiger, MD, USA
Silvia Campos, PhD, Brazil
Carol Farver, MD, USA
John Greenland, MD, PhD, USA
Don Hayes, MD, USA
Steven Ivulich, Bpharm, Australia
Brittany Koons, PhD, USA
Jesper Magnusson, MD, PhD, Sweden
Monique Malouf, FRACP, Australia
Tereza Martinu, MD, MS, Canada
Michael Perch, MD, Denmark
Dirk Van Raemdonck, MD, PhD, Belgium

Mechanical Circulatory Support Team:

❖ Palak Shah, MD, MS, USA
Yaron Barac, MD, PhD, Israel
Jen Cook, MD, USA
Hannah Copeland, MD, USA
Jose Gonzalez-Costello, MD, Spain
Edward Horn, PharmD, USA
Oliver Miera, MD, Germany
Ezequiel Molina, MD, USA
Sarah Schettle, PA-C, MS, MBA, USA
Thomas Schöglhofer, MSc, Austria
Jaimin Trivedi, MD, MPH, USA
Barbara Wilkey, BSN, MPAS, MD, USA

Pulmonary Vascular Disease (PAH & CTEPH) Team:

❖ Raymond Benza, MD, USA
Bailey Colvin, PharmD, USA
Clara Hjalmarsson, MD, PhD, Sweden
Rebecca Klingbeil, MSN, DNP, USA
Christoph Knosalla, MD, Germany
Nicholas Kolaitis, MD, USA
Deborah Levine, MD, USA
Micheal McInnis, MD, Canada
Erika Rosenzweig, MD, USA
Stefan Soderberg, MD, PhD, Sweden

SYMPOSIUM PROPOSAL SUBMITTERS

The ISHLT would like to thank the following individuals who submitted symposium proposals for consideration to the meeting.

Sophia Airhart, USA
Waqas Akhtar, United Kingdom
Mohammad Al-Ani, USA
Ana Alba, Canada
Chonyang Albert, USA
Shahnawaz Amdani, USA
Mads Andersen, Denmark
Michaela Anderson, USA
Annalisa Angelini, Italy
Scott Auerbach, USA
Lindsey Aurora, USA
Maria Avila, USA
Dipanjan Banerjee, USA
Sven-Erik Bartfay, Sweden
Luke Benvenuto, USA
Anju Bhardwaj, USA
Arvind Bhimaraj, USA
Mena Botros, USA
Yevgeniy Brailovsky, USA
Nicolas Brozzi, USA
Rossa Brugha, United Kingdom
Mirnela Byku, USA
Daniel Calabrese, USA
Pedro Catarino, USA
Sandra Chaparro, USA
Richard Cheng, USA
Jennifer Chow, USA
Colin Church, Scotland
Katherine Clark, USA
Adam Cochrane, USA
Maria Dolores Cosio, Spain
Rachel Crackett, United Kingdom
Adrian daSilva-deAbreu,
Kavita Dave, United Kingdom
Teresa De Marco, USA
Eric de Waal, Netherlands
Nhue Do, USA
Jonathan Edelson, USA
Maryjane Farr, USA
Julien Fessler, France
Gregory Fishbein, USA
Maria Gamero, USA
Lakshmi Gokanapudy Hahn, USA
Jason Goldberg, USA
Livia Goldraich, Brazil
Daniel R. Goldstein, USA
Harpreet Grewal, USA
Donna Guadiz, USA
Kieran Halloran, Canada
Thomas Hanff, USA
Courtney Harris, USA
Heather Henderson, USA
Ilene Hollin, USA
Ian Hollis, USA
Are Holm, Norway
Luise Holzhauser, USA
Rachel Hopper, USA
Eileen Hsich, USA
Amanda Ingemi, USA
Arun Jose, USA
Stephen Juvet, Canada
Manreet Kanwar, USA
Brian Keller, USA
Kyung-Hee Kim, South Korea
Stephen Kirkby, USA
Amy Kiskaddon, USA
Jamila Kremer, Germany
Mrinalini Krishnan, USA
Jasleen Kukreja, USA
Matthew Lander, USA
Pia Lanmueller, Germany
Carli Lehr, USA
Francesca Lunardi, Italy
Maricar Malinis, USA
Archer Martin, USA
Marco Masetti, Italy
Yasbanoo Moayed, Canada
Deepa Mokshagundam, USA
Andrew Morley-Smith, United Kingdom
Mrudula Munagala, USA
Catherine Myers, USA
Nandini Nair, USA
Emil Najjar, Sweden
Jonathan Nattiv, USA
Andriana Nikolova, USA
Katherine Nordick, USA
Caroline Patterson, United Kingdom
David Peng, USA
Federica Pezzuto, Italy
Ishna Poojary, USA
Stephanie Pouch, USA
Lynn Punnoose, USA
Indranee Rajapreyar, USA
Aniket Rali, USA
María Renedo, Argentina
Yogita Rochlani, USA
Anja Roden, USA
Sandeep Sahay, USA
Jenna Scheffert, USA
Sarah Schroeder, USA
Unmil Shah, India
Osnat Shtraichman, Israel
Kirandeep Sidhu, USA
Daniel Silverman, USA
Jonathan Singer, USA
Mark Snyder, USA
Pallavi Solanki, USA
Lakshmi Sridharan, USA
Kristin Stawiarski, USA
Gerin Stevens, USA
Eugene Storozynsky, USA
Kaitlin Swanner, USA
Van-Khue Ton, USA
Madeleine Townsend, USA
Pedro Undurraga, Chile
Jean-Luc Vachier, Belgium
Ajay Vaidya, USA
Linda Van Laake, Netherlands
Bart Vanaudenaerde, Belgium
Tara Veasey Rackley, USA
Mrinalini Venkata Subramani, USA
Katharina Wassilew, United Kingdom
Shawn West, USA
Brigitte Willemse, Netherlands
Aaron Wolfson, USA
Ann Woolley, USA
Yu Wu, USA
Melana Yuzefpolskaya, USA
Lorenzo Zaffiri, USA

SYMPOSIUM PROPOSAL REVIEWERS

The ISHLT would like to thank the following individuals who served as symposium proposal reviewers for the meeting.

Rayid Abdulqawi, Saudi Arabia
Ashraf Abou, USA
Dimpna Albert, Saudi Arabia
Juan Alejos, USA
Amrut Ambardekar, USA
Mads Andersen, Denmark
Lori Anderson, USA
Annalisa Angelini, Italy
Selim Arcasoy, USA
Sonali Arora, USA
Carl Atkinson, USA
Bill Auger, USA
Nicholas Avdimiretz, USA
Monica Avila, Brazil
Fernando Bacal, Brazil
Maurice Beghetti, Switzerland
Luke Benvenuto, USA
Sai Bhagra, United Kingdom
Filio Billia, Canada
Nancy Blumenthal, USA
Udo Boeken, Germany
Carmel Bogle, USA
Edith Boyes, USA
Nicolas Brozzi, USA
Rossa Brugha, United Kingdom
Mark Buckland, Australia
Tiffany Buda, USA
Elizabeth Bullen, United Kingdom
Fay Burrows, Australia
Mirnela Byku, USA
Daniel Calabrese, USA
Fiorella Calabrese, Italy
Marisa Cevasco, USA
Sandra Chaparro, USA
Krish Chaudhuri, New Zealand
Richard Cheng, USA
Colin Church, Scotland
Tamara Claridge, USA
Adam Cochrane, USA
Johanna Contreras, USA
Maria Correias, Australia
Nahir Cortes-Santiago, USA
Marc De Perrot, Canada
Eric de Waal, Netherlands
Caitlin Demarest, USA
Mary Amanda Dew, USA
Gundeep Dhillon, USA
Stavros Drakos, USA
Julia Dumfarth, Austria
Lucas Eastaugh, Australia
Emily Eichenberger, USA
Stephan Ensminger, Germany
Melanie Everitt, USA
Christine Falk, Germany
Marta Farrero Torres, Spain
Gregory Fishbein, USA
Meg Fregoso, USA
Louise Fuller, Australia
Tji Gan, Netherlands
Claudia Gidea, USA
Mónica Gilbert, Ecuador
Martin Goddard, United Kingdom
Hilary Goldberg, USA
Daniel J. Goldstein, USA
Mardi Gomborg-Maitland, USA
Matthew Goodwin, USA
Alice Gray, USA
Megan Greene, USA
Finn Gustafsson, Denmark
Alexander Hajduczuk, USA
Kieran Halloran, Canada
Istvan Hartyanszky, Hungary
Jan Havlin, Czech Republic
Jaime Hernandez Montfort, USA
Borah Hong, USA
Rachel Hopper, USA
Brian Houston, USA
Eileen Hsich, USA
Kathryn Hughes, USA
Maria Hurskainen, Finland
Shahid Husain, Canada
Teruhiko Imamura, Japan
Amanda Ingemi, USA
Claire Irving, Australia
Debra Isaac, Canada
Fabio Ius, Italy
Aamir Jeewa, Canada
Marc Katz, USA
Brian Keller, USA
Christopher King, USA
Amy Kiskaddon, USA
Christiane Kugler, Germany
Hrishikesh Kulkarni, USA
Sharon Larson, USA
Nancy Law, USA
Sangjin Lee, USA
Sern Lim, United Kingdom
Virginia Linacre, Chile
Sandra Lindstedt, Sweden
Asbjorn Lunnan, Norway
Me-Linh Luong, Canada
Haifa Lyster, United Kingdom
Sofia Martin-Suarez, Italy
Marco Masetti, Italy
Jacob Mathew, Australia
Colleen McIlvennan, USA
Yasbanoo Moayed, Canada
Andrew Morley-Smith, United Kingdom
Eric Morrell, USA
Nicolas Mueller, Switzerland
Maja Nackenhorst, Austria
Dave Nagpal, USA
Takeshi Nakatani, Japan
Alina Nicoara, USA
Jonatan Oras, Sweden
Anthony Panos, USA
Caroline Patterson, United Kingdom
David Peng, USA
Nitipong Permpalung, USA
Marina Pieri, Italy
Evgenij Potapov, Germany
Stephanie Pouch, USA
Lynn Punnoose, USA
Danny Ramzy, USA
Vivek Rao, Canada
Anna Reed, United Kingdom
Maria Renedo, Argentina
Anja Roden, USA
Katrine Rolid, Norway
Victor Rossel, Chile
Berta Saez Gimenez, Spain
Sandeep Sahay, USA
Christian Said, Australia
Marcos Samano, USA
Melissa Sanchez, United Kingdom
Joanna Schaenman, USA
Akira Shiose, Japan
Aman Sidhu, Canada
Marc Simon, USA
Kathleen Simpson, USA
Cumara Sivathasan, Singapore
Jeff Teuteberg, USA
Josef Thul, Germany
Nir Uriel, USA
Jean-Luc Vachier, Belgium
Maryam Valapour, USA
Cassandra Vale, Australia
Caroline Van De Wauwer, Netherlands
Tara Veasey Rackley, USA
Angela Velleca, USA
Mauricio Villavicencio, USA
Andre Vincentelli, France
Oksana Volod, USA
Glen Westall, Australia
Connie White-Williams, USA
Brigitte Willemse, Netherlands
Andrew Woods, United Kingdom
Lydia Wright, USA
Jonathan Yeung, Canada
Lorenzo Zaffiri, USA
Michael Zakliczynski, Poland
Dyan Zhang, Singapore

ABSTRACT REVIEWERS

The ISHLT would like to thank the following individuals who served as abstract reviewers for the meeting.

Rayid Abdulqawi, Saudi Arabia
Rosalyn Adigun, USA
Maxwell Afari, USA
Aasim Afzal, USA
Richa Agarwal, USA
Akanksha Agrawal, USA
Miriam Aguilar Perez, Spain
Mustafa Ahmed, USA
Clemens Aigner, Austria
Nathan Airhart, USA
Sophia Airhart, USA
Waqas Akhtar, United Kingdom
Olufemi Akindipe, USA
Mohammad Al-Ani, USA
Ana Alba, Canada
Chonyang Albert, USA
Juan Alejos, USA
Natasha Aleksova, Canada
Kevin Alexander, USA
Tamas Alexy, USA
Hazim AL-Haideri, United Kingdom
Rami Alharethi, USA
Othman Aljohani, USA
Sammar Alsunaid, USA
Kaushik Amancherla, USA
Amrut Ambardekar, USA
Shahnawaz Amdani, USA
Javier Amione Guerra, USA
Allen Anderson, USA
Annalisa Angelini, Italy
Fatima Anjum, USA
Samantha Anthony Canada
Martine Antoine, Belgium
Beatrice Aramini, Italy
Sonali Arora, India
Ambalavanan Arunachalam, USA
Awais Ashfaq, USA
Carl Atkinson, USA
John Aubert, Switzerland
William Auger, USA
Kamal Ayyat, USA
Dipanjan Banerjee, USA
Markus Barten, Germany
Sylvie Baudart, USA
Maurice Beghetti, Switzerland
Mark Belkin, USA
Christian Benden, Switzerland
David Bennett, Italy
Alejandro Bertolotti, Italy
Alan Betensley, USA
Sai Bhagra United Kingdom
Anju Bhardwaj, USA
Sanjeeb Bhattacharya, USA
Filio Billia, Canada
Katharine Black, USA
Peggy Blood USA
Matthew Bock, USA
Udo Boeken, Germany
Brent Boettcher USA
Carmel Bogle, USA
Entela Bollano, Sweden
Hakki Bolukoglu, USA
Vaibhav Bora USA
Stephanie Bowman, USA
Andrew Boyle, USA
Stacey Brann, USA
Paul Brown, USA
Marie Budev, USA
Caron Burch, USA
Michael Burke, USA
Fay Burrows, Australia
Errol Bush, USA
Marco Caccamo, USA
Daniel Calabrese, USA
Fiorella Calabrese, Italy
Kara Calhoun, USA
Kadir Caliskan, Netherlands
Paul Callan, United Kingdom
Elizabeth Calle, USA
Jose Campo-Canaeral de la Cruz, Spain
Marlene Cano, USA
Charles Canter, USA
Charles Canver, USA
Michael Carboni, USA
François Carlier, Belgium
Waldemar Carlo, USA
William Carlson, USA
Andres Carmona Rubio, USA
Anthony Carnicelli, USA
Thomas Cascino, USA
Alfred Casillan, USA
Maria Castel, Spain
Javier Castrodeza, Spain
Pedro Catarino, USA
Lourdes Chacon, USA
Alice Chan, USA
Kevin Chan, USA
Michael Chan, Canada
Wandy Chan, Australia
Sanjay Chandrasekhar, USA
Satish Chandrashekar, USA
Sandy Chang, USA
Sandra Chaparro, USA
Prangthip Charoenpong, USA
Nathalie Chateauvert, Canada
Khaled Chatila, USA
Vinh Chau, USA
Sanjay Chaudhary USA
Sunit-Preet Chaudhry, USA
Krish Chaudhuri, New Zealand
Dhaval Chauhan, USA
Patricia Chavez, USA
Leway Chen, USA
Robert Chen, USA
Jesse Cheng, USA
Toyofumi Chen-Yoshikawa, Japan
Laveena Chhatwani, USA
Lin-Chiang Chou, USA
Jennifer Chow, USA
Colin Church, United Kingdom
Jose Cifrian, Spain
Tamara Claridge, USA
Stephen Clark, United Kingdom
Brian Clarke, Canada
Kevin Clerkin, USA
Adam Cochrane, PharUSA
Erin Coglianes, USA
Bernice Coleman, USA
Monica Colvin, USA
Johanna Contreras, USA
John Anthony Coppola, USA
Maria Dolores Cosio, Spain
Jenalee Coster, USA
Sarah Cotter, USA
William Cotts, USA
Jennifer Cowger, USA
Laura Coyle, USA
Maria Crespo, USA
Luke Cunningham, USA
Maria Currie, USA
Tarun Dalia, USA
Lara Danziger-Isakov, USA
John Dark, United Kingdom
Bibhuti Das, USA
Hiroshi Date, Japan
Kavita Dave, United Kingdom
Oveimar De La Cruz, USA
Teresa De Marco, USA
Marc De Perrot, Canada
Ersilia DeFilippis, USA
Mark Joshua Dela Cruz, USA
Caitlin Demarest, USA
Mary Amanda Dew, USA
Oliver Dewald, Germany
Niti Dham, USA
Ravi Dhingra, USA
Joshua Diamond, USA
Laura DiChiacchio, USA
Carles Diez-Lopez, Spain
Michelle Dimza, USA
Nhue Do, USA
John Dollerschell, USA
Karen Doucette, Canada
Robert Dowling, USA
Alexander Dragnich, USA
Mark Drazner, USA
Anique Ducharme, Canada
Juan Duero Posada, Canada
Debi Dumas-Hicks, USA
Lucian Durham, USA
Chidiebere Peter Echih, Niger

Dawn Eck, USA
Peter Eckman, USA
Jeffrey Edelman, USA
Thomas Egan, USA
Emily Eichenberger, USA
Harald Eichstaedt, Germany
Aly El Banayosy, USA
Magdy El-Sayed Ahmed, USA
Sam Emmanuel, Australia
Fabian Emrich, Germany
Amir Emtiazjoo, USA
Eric Epailly, France
Paul Estes, USA
Melanie Everitt, USA
Patrick Evrard, Belgium
Gregory Ewald, USA
Elie Fadel, France
Tara Fallah, USA
Alexander Fardman, Israel
Sara Farghaly, USA
Maryjane Farr, USA
Savitri Fedson, USA
Juan Fernandez, USA
Julien Fessler, France
Jordan Foland, USA
Alejandro Folch Sandoval, USA
Katrina Ford, United Kingdom
Stephen Forest, USA
Erik Frandsen, USA
Meg Fregoso, USA
Miriam Freundt, USA
Joshua Friedland-Little, USA
Ashley Fritz, USA
Sheng Fu, USA
Louise Fuller, Australia
Erik Fung, Hong Kong
Michele Gallo, USA
Tji Gan, Netherlands
Asvin Ganapathi, USA
Puneet Garcha, USA
Jose Garcia, USA
Bradley Gardiner, Australia
Sonia Garg, USA
Theresa Gelzinis, USA
Hussam Ghalib, United Arab Emirates
Alessia Giarraputo, Italy
Claudia Gidea, USA
Patricia Ging, Ireland
Elian Giordanino, Argentina
Christine Girard, USA
Reda Girgis, USA
Allan Glanville, Australia
Laurent Godinas, Belgium
Jason Goldberg, USA
Livia Goldraich, Brazil
Hilda Gonzalez Bonilla, USA
Oscar Gonzalez Fernandez, United Kingdom
Jeffrey Gossett, USA
Jens Gottlieb, Germany
Douglas Gouchoe, USA

Kathleen Grady, USA
Alexander Graham, USA
Hanno Grahn, Germany
Emily Granger, Australia
Alice Gray, USA
Vanessa Gregoriotti, Argentina
Sabine Greil, Austria
Harpreet Grewal, USA
Jagpreet Grewal, USA
Cynthia Gries, USA
Jan Griffin, USA
Eric Griffiths, USA
Paolo Grossi, Italy
Ashrith Guha, USA
Julien Guihaire, France
Dipankar Gupta, USA
Shuchita Gupta, USA
Alexander Hajduczuk, USA
Jennifer Hajj, USA
Shelley Hall, USA
Kieran Halloran, Canada
Eman Hamad, USA
Wayne Hancock, USA
Thomas Hanff, USA
Maja Hanuna, Germany
Takashi Harano, USA
Courtney Harris, USA
Kimberly Harrison, USA
Christina Hartje-Dunn, USA
Z. Hashmi, USA
Stephanie Heaton, USA
Christian Heim, Germany
Vagish Hemmige, USA
Marta Hernandez Meneses, Spain
Donna Hickling, Australia
Sayed Himmat, Canada
Hitoshi Hirose, USA
Kelley Hitchman, USA
Karlee Hoffman, USA
Emil Holmstrom, Finland
Luise Holzhauser, USA
Robert Hooker, USA
Kyle Hope, USA
Peter Hopkins, Australia
David Hormuth, USA
Brian Hsi, USA
Chih-Hsin Hsu, Taiwan
Stephen Huddleston, USA
Kathryn Hughes, USA
Teruhiko Imamura, Japan
Claire Irving, Australia
Ilker Iskender, Switzerland
Michael Ison, USA
Peter Ivak, Czech Republic
Gregory Jackson, USA
Abhishek Jaiswal, USA
Peter Jaksch, Austria
Christina Janetzke, USA
Daniel Jane-Wit, USA
George Javorsky, Australia
Hallie Jefferson, Canada

David Jenkins, United Kingdom
Mylvaganam Jeyakanthan, United Kingdom
Carrie Johnson, USA
Jonathan Johnson, USA
Maryl Johnson, USA
Mandisa-Maia Jones, USA
Arun Jose, USA
Aditya Joshi, USA
Ravi Joshi, USA
Jose Ernesto Juarez Leon, Mexico
Rebecca Juhl, USA
Sung-Ho Jung, South Korea
Stephen Juvet, Canada
Soma Jyothula, USA
Dima Kabbani, Canada
David Kaczorowski, USA
Viktoriya Kagan, USA
Forum Kamdar, USA
Andrew Kao, USA
Nandkishore Kapadia, India
Siddhartha Kapnadak, USA
Maria Karas, USA
Sumiha Karunagaran, Canada
Hayah Kassis, USA
Rachna Kataria, USA
Olivia Kates, MA, USA
Tomoko Kato, Japan
Christina Kaufman, USA
Mitsuaki Kawashima, Japan
Katherine Kearney, Australia
Anita Kelkar, USA
Brian Keller, USA
Jamie Kennedy, USA
Umit Kervan, Turkey
Suresh Keshavamurthy, USA
Wissam Khalife, USA
Adnan Khan, USA
Basha Khan, India
Mohd. Shahbaaz Khan, India
Michael Kiernan, USA
Maxwell Kilcoyne, USA
Ahmet Kilic, USA
Michael Killian, USA
In-Cheol Kim, South Korea
Ju Kim, USA
Kyung-Hee Kim, South Korea
Miae Kim, USA
Steven Kindel, USA
Sonya Kirmani, USA
Veraprapas Kittipibul, USA
Audrey Kleet, USA
Livi Klein, USA
Ken Knecht, USA
Sudheer Koganti, India
Takushi Kohmoto, USA
Kevin Koomalsingh, USA
Christine Koval, USA
Katherine Kozarek, USA
Annemarie Krauss, Germany
Jamilia Kremer, Australia

J. Yasha Kresh, USA
Selim Krim, USA
Kewal Krishan, USA
Mrinalini Krishnan, USA
Krithika Krishnarao, USA
Christiane Kugler, Germany
Jasleen Kukreja, USA
Akshay Kumar, USA
Sharanya Kumar, India
Anna Kydd, United Kingdom
Moiz Lalani, India
Matthew Lander, USA
Caroline Landry, Canada
Nathaniel Langer, USA
Pia Lanmueller, Germany
Sharon Larson, USA
Daniel Laskey, USA
Daniel Laskey, USA
Rachel Lavelle, USA
Tatyana Lawrecki, USA
Adrian Lawrence, USA
Marzia Leacche, USA
Loriana Leard, USA
Erika Lease, USA
Andy Lee, USA
Dae Hyun Lee, USA
Roy Lee, USA
Sangjin Lee, USA
Hong Liang, USA
Janice Liebler, USA
Virginia Linacre, Chile
Sandra Lindstedt, Sweden
Antonio Loforte, Italy
James Lordan, United Kingdom
Erin Lowery, USA
Brian Lowes, USA
Renzo Loyaga-Rendon, USA
Lucian Lozonschi, USA
Fabio Luciano, Italy
Francesca Lunardi, Italy
Scott Lundgren, USA
Me-Linh Luong, Canada
Aine Lynch, Canada
Haifa Lyster, United Kingdom
Dennis Lyu, USA
Siu Ma, USA
Guy MacGowan, United Kingdom
John Mackintosh, Australia
Shivank Madan, USA
Gabriela Magda, USA
Valmiki Maharaj, USA
Julia Maheshwari, USA
Amber Malhotra, USA
Jorge Mallea, USA
Chirantan Mangukia, USA
Yosef Manla, United Arab Emirates
Hannah Mannem, USA
Charles Marboe, USA
Fabiana Marcondes-Braga, Brazil
Nicholas Marschalk, USA
Archer Martin, USA

Cindy Martin, USA
Gabriella Masciocco, Italy
Marco Masetti, Italy
Ioannis Mاستoris, USA
Nikki Matos DNP, USA
Matylda Mazur, USA
Amanda McCormick, USA
Allison McLarty, USA
Aditya Mehta, USA
Bruno Meiser, Germany
Ernestina Melicoff-Portillo, USA
Federica Meloni, Italy
Jondavid Menteeer, USA
Olaf Mercier, France
Aurelie Merlo, USA
Kumi Mesaki, Canada
Sebastian Michel, Germany
Levent Midyat, USA
Daniel Miklin, USA
Assi Milwidsky, Israel
Sonia Mirabet Perez, Spain
Kiran Mirza, Denmark
Aaron Mishkin, USA
Roxana Moayedifar, Austria
Kanika Mody, USA
Omar Mohamedaly, USA
Thalachallour Mohanakumar, USA
Nandan Mondal, USA
Jiyong Moon, USA
Carolina Moore, USA
Paola Morejon Barragan, Ecuador
Jonathan Moreno, USA
Letizia Corinna Morlacchi, Italy
Andrew Morley-Smith, United Kingdom
Eric Morrell, USA
Matthew Morrell, USA
Tina Morris, NE-BC, USA
Orla Morrissey, Australia
Nicolas Mueller, Switzerland
Mary Mullen, USA
Mrudula Munagala, USA
Travis Murphy, USA
Margaret Murray, USA
Raghav Murthy, USA
Monica Nable, USA
Arun Nair, United Kingdom
Nandini Nair, USA
Emil Najjar, Sweden
Takeshi Nakatani, Japan
Sanem Nalbantgil, Turkey
Sraavanthi Nandavaram, USA
Vinodh Nanjajya, Australia
Basil Nasir, Canada
Kristen Nelson McMillan, USA
Alina Nicoara, USA
Afzal Nikaein, USA
Lazaros Nikolaidis, USA
Andriana Nikolova, USA
Johan Nilsson, Sweden
Daryl Nnani, USA
Kentaro Noda, USA

Pierre-Emmanuel Noly, Canada
Katherine Nordick, USA
René Novosedlák, Czech Republic
Matthew O'Connor, USA
Michal Odermarsky, Sweden
Marish Oerlemans, Netherlands
Suguru Ohira, USA
Anne Olland, France
Minoru Ono, Japan
Jonatan Oras, Sweden
Juan Ortega-Legaspi, USA
Carlos Ortiz-Bautista, Spain
Melissa Owen, USA
Robert Padera, USA
Francis Pagani, USA
Siddharth Pahwa, USA
Alessandro Palleschi, Italy
Stephen Pan, USA
Ameeka Pannu, USA
Anthony Panos, USA
Federico Pappalardo, Italy
John Parent, USA
William Parker, USA
Hamang Patel, USA
Kapil Patel, USA
Snehal Patel, USA
Caroline Patterson, United Kingdom
Amit Pawale, USA
Simon Pecha, Germany
Yael Peled, Israel
Matthias Peltz, USA
David Peng, USA
Alvaro Perazzo, Brazil
Mark Peterzan, United Kingdom
Michael Petty, USA
Federica Pezzuto, Italy
Christine Pham, USA
Christina Phelps, USA
Marina Pieri, Italy
Richard Pierson, III, USA
Sean Pinney, USA
Jamie Pintens, USA
Matthew Pipeling, USA
Michelle Ploutz, USA
Gregor Poglajen, Slovenia
Ishna Poojary, USA
Evgenij Potapov, Germany
Stephanie Pouch, USA
Jack Price, USA
Kriti Puri, USA
Muhammad Rafiq, United Kingdom
Salwa Rahman, USA
Axel Rahmel, Germany
Vijil Rahulana, India
Eugenia Raichlin, USA
Jayant Raikhelkar, USA
Kishore Raja, USA
Navin Rajagopalan, USA
Indranee Rajapreyar, USA
Aniket Rali, USA
Reinaldo Rampolla, USA

Bhavadharini Ramu, USA
Danny Ramzy, USA
Karthikeyan Ranganathan, USA
Sowmith Rangu, USA
Roopa Rao, USA
Ravi Kumar Ratnagiri, India
Yazhini Ravi, USA
Ashwin Ravichandran, USA
Nicole Reagan, USA
Filip Rega, Belgium
Matthew Regan, USA
Hermann Reichensperner, Germany
João Eurico Reis, Portugal
Benjamin Renaud-Picard, France
Gustavo Ribeiro, Brazil
Marc Richmond, USA
Peter Riddell, Ireland
Ilaria Righi, Italy
Jun-Neng Roan, Taiwan
Desiree Robson, Australia
Yogita Rochlani, USA
Anja Roden, USA
Ingrid Rodgers, USA
Inez Rodrigus, Belgium
Sebastian Rojas, Germany
Geurys Rojas Marte, USA
Nicola Ronan, Ireland
Andrew Rosenbaum, USA
Justin Rosenheck, USA
David Rosenthal, USA
Joseph Rossano, USA
Ana Roussoulieres, Belgium
Antonio Rubino, United Kingdom
Christina Ruggia-Check, USA
Siavosh Saatee, USA
Marwa Sabe, USA
Sahar Saddoughi, USA
Lars Saemann, Germany
Andrew Sage, Canada
Christian Said, Australia
Satoshi Saito, Japan
Tomohito Saito, Japan
Christopher Salerno, USA
Pablo Sanchez, USA
Elena Sandoval, Spain
Ricardo Sandoval, Mexico
Pedro Santos, USA
Sajed Sarwar, USA
David Sayah, USA
Lara Schaheen, USA
Marc Schechter, USA
Janet Scheel, USA
David Schibilsky, Germany
Kelly Schlendorf, USA
Lindsay Schmidt, USA
Stephan Schueler, United Kingdom
Alexander Schutz, USA
Davide Scozzi, USA
Harish Seethamraju, USA
Javier Segovia-Cubero, Spain
Leslie Seijo, USA
Purav Shah, USA
Esther Shao, USA
Ashish Sharma, USA
Gaurav Sharma, USA
Fawwaz Shaw, USA
Shahriar Shayan, USA
Farooq Sheikh, USA
Aryaz Sheybani, USA
Renata Shih, USA
Akira Shimamoto, Japan
Yasuhiro Shudo, USA
Sara Shumway, USA
Xin Si, USA
Aleem Siddique, USA
Kirandeep Sidhu, USA
Jorge Silva Enciso, USA
Daniel Silverman, USA
Marc Simon, USA
Kathleen Simpson, USA
Daniel Sims, USA
Kai Singbartl, USA
Jonathan Singer, USA
Tajinder Singh, USA
Aditi Singhvi, India
Pranava Sinha, USA
Cumara Sivathasan, Singapore
Bronwyn Small, USA
Joshua Smith, USA
Sophie Smith, United Kingdom
Laurie Snyder, USA
Mark Snyder, USA
Miranda So, Canada
George Sokos, USA
Pallavi Solanki, USA
Tae Song, USA
Steven Sorci, USA
Lakshmi Sridharan, USA
Shelly Stark, USA
Kristin Stawiarski, USA
Gerin Stevens, USA
Ulrich Stock, United Kingdom
Heather Strah, USA
Samir Sultan, USA
Benjamin Sun, USA
Swethika Sundaravel, USA
David Sutcliffe, USA
Stanley Swat, USA
Hanna Tadros, USA
Laneshia Tague, USA
Edlira Tam, USA
Daniel Tang, USA
W.H. Wilson Tang, USA
Natalie Tapaskar, USA
Inna Tchoukina, USA
Chiara Tessari, Italy
Paul Tessmann, USA
Timea Teszak, Hungary
Jeffrey Teuteberg, USA
Sarumathi Thangavel, India
Josef Thul, Germany
Drishti Tolani, USA
Rade Tomic, USA
Van-Khue Ton, USA
Laurens Tops, Netherlands
Diana Torpoco Rivera, USA
Keri Townsend, USA
Madeleine Townsend, USA
Maxime Tremblay-Gravel, Canada
Anil Trindade, USA
Dirk Troitzsch, Germany
Michael Trotter, Australia
Anna Tsirka, USA
Zuzana Tucanova, Czech Republic
Sebastian Tume, USA
Arunkumar Ulaganathan, India
Marian Urban, USA
Nir Uriel, USA
Simon Urschel, Canada
Ajay Vaidya, USA
Jaromir Vajter, Czech Republic
Cassandra Vale, Australia
Vincent Valentine, USA
Saraschandra Vallabhajosyula, USA
Adriana Valverde Zuñiga, Canada
Adrian Van Bakel, USA
Caroline Van De Wauwer, Netherlands
Niels van der Kaaij, Netherlands
Linda Van Laake, Netherlands
Anup Varghese, India
Manu Varma, USA
Rhea Varughese, Canada
Tara Veasey Rackley, USA
Angela Velleca, MHDS, USA
Mrinalini Venkata Subramani, USA
Geert Verleden, Belgium
Amanda Vest, USA
George Vetrovec, USA
Jorge Villalpando, USA
Andre Vincentelli, France
Scott Visovatti, USA
Jan von der Thusen, Netherlands
Robin Vos, Belgium
Julie Wacker, Switzerland
Morgan Wahl, USA
Nathan Waldron, USA
Rajat Walia, USA
James Walsh, Australia
Katharina Wassilew, United Kingdom
Cara Wasywich, New Zealand
Tatsuaki Watanabe, Japan
Kenneth Wei, USA
Shawn West, USA
Bryan Whitson, USA
Markus Wilhelm, Switzerland
Keith Wille, USA
Stephanie Witek, USA
Chad Witt, USA
Carol Wittlieb-Weber, USA
Cameron Wolfe, USA
Aaron Wolfson, USA
Joyce Wong, United Kingdom
Ann Woolley, USA

Yu Wu, USA
Yu Xia, USA
Qingyong Xu, USA
Yoshito Yamada, Japan
Roh Yanagida, USA
Xiucheng Yang, China
Amin Yehya, USA

Jessie Yester, USA
Daniel Yip, USA
Jong-Chan Youn, South Korea
Rayan Yousefzai, USA
David Youssef, Australia
Melana Yuzepolskaya, USA
Lorenzo Zaffiri, USA

Andrea Zajacova, Czech Republic
Ahmad Zeeshan, USA
Adriana Zeevi, USA
Xiaohai (Sam) Zhang, USA
Pei Jun Zhao, USA
Tomasz Zielinski, Poland
Daniel Zlotoff, USA

SCIENTIFIC CONTENT



For the most up-to-date version of the scientific program, download the **ISHLT2024** Mobile App.

ISHLT2024

Looking for CME Information?

Visit ishlt.org/ishlt2024 and find CME Information on the Scientific Program page.

Still have questions? Send an email to meetings@ishlt.org.

WEDNESDAY, 10 APRIL, 2024

8:00 - 9:30 a.m.

PLENARY 1: Opening General Session

Location: Congress Hall

Core Therapies: HEART, LUNG, MCS, PVD

Practice Areas: Anesthesiology and Critical Care, Cardiology, Cardiothoracic Surgery, Infectious Diseases, Nursing and Allied Health, Pathology, Pediatrics, Pharmacy, Pulmonology, Research and Immunology

Session Summary: General Sessions at ISHLT2024 offer engaging speakers, comprehensive scientific reviews, and featured abstracts highlighting critical research in a range of fields.

Moderators: Jason Christie, MD, MS, University of Pennsylvania, Philadelphia, PA, USA
Goran Dellgren, MD, PhD, Sahlgrenska University Hospital, Goteborg, Sweden

8:01 a.m. ***Early Career Featured Video***

8:02 a.m. ***ISHLT Scientific Program Chair Report***
Goran Dellgren, MD, PhD, Sahlgrenska University Hospital, Göteborg, Sweden

The Program Chair will provide an overview report of the ISHLT2024 Scientific Program.

8:13 a.m. ***ISHLT President's Report***
Jason Christie, MD, MS, University of Pennsylvania, Philadelphia, PA, USA

The President of the ISHLT will address the members and meeting delegates.

8:33 a.m. ***Featured Late-Breaking Abstract Presentation:***

(1) A Prospective Randomized Controlled Trial of Direct Oral Anticoagulant Therapy with a Fully Magnetically Levitated LVAD: The DOT-HM3 Study

I. Netuka¹, Z. Tucanova¹, P. Ivak¹, S. Gregor¹, D. M. Kolesar¹, T. Marek¹, V. Melenovsky¹, J. Binova¹, Z. Dorazilova¹, M. Hegarova¹, M. Podolec², H. Riha¹, J. Connors³, M. R. Mehra³. ¹Institute for Clinical and Experimental Medicine, Prague, Czech Republic, ²Institute for Clinical and Experimental Medicine, Prague, Czech Republic, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA

8:43 a.m. ***Q&A with Interactive Discussant***
Hannah Copeland, MD, Lutheran Medical Group, Fort Wayne, IN, USA

8:50 a.m. ***Transplantation in the Time of War***
Borys Todurov, MD, PhD, Gavruno Kovtun, MD, PhD, Sofia Chaikovska, MD, Serhii Sudakevych, MD, PhD, Mykola Melnyk, MD, Heart Institute of the Ministry of Health, Kiev, Ukraine.

The speaker will discuss overcoming obstacles to continue to provide heart and lung transplantation in Ukraine during war and what can be done going forward to continue to support transplantation efforts worldwide.

WEDNESDAY, 10 APRIL, 2024

10:00 - 11:15 a.m.

SYMPOSIUM 01: Novel MCS Technologies: Where Are We Heading?

Location: Congress Hall

Core Therapies: MCS, HEART

Practice Areas: Cardiothoracic Surgery, Anesthesiology and Critical Care, Cardiology, Infectious Diseases, Nursing and Allied Health, Pediatrics, Pharmacy

Session Summary: There is an explosion of novel MCS devices in development and early stage clinical trials for advanced heart failure patients requiring intermediate or durable MCS support. This session will highlight novel MCS technologies and discuss what the future of MCS therapy holds for our patients with cardiogenic shock and recalcitrant heart failure. A panel discussion with all speakers including audience Q&A, led by the session moderators, will conclude this session.

Moderators: Thomas Schloeglhofer, MSc, Medical University of Vienna, Vienna, Austria
Barbara Wilkey, BSN, MPAS, MD, University of Colorado, Denver, CO, USA

10:00 a.m. ***Forging the Future: Engineering Novel Durable Mechanical Circulatory Support Devices***

Mandeep Mehra, MBBS, MSc, FRCP, Harvard Medical School, Boston, MA, USA

The talk will showcase groundbreaking MCS advances, including devices without external cables and with biocompatible surfaces that are bacteriostatic. The challenges of "bio-VADs" will be addressed as well as other novel devices that will revolutionize MCS and minimize infections.

10:12 a.m. ***Pump Up the Jam, Pump It Up: Eliminating the Gap between Temporary and Durable MCS***

Jane Wilcox, MD, MSc, Northwestern Univ Feinberg SoM, Chicago, IL, USA

The speaker will discuss contemporary data regarding the development and use of temporary microaxial pumps for intermediate-term patient support as bridge to heart transplant or myocardial recovery, including indications, contraindications, access options, duration of support and complications.

10:24 a.m. ***When Replacing One Ventricle is Insufficient***

Anna Meyer, MD, Universitätsklinikum Heidelberg, Heidelberg, Germany

This talk aims to explore the unmet needs of total artificial heart (TAH) support and provide a comprehensive review of the devices currently under development, shedding light on the innovations and challenges in the realm of TAH technology.

10:36 a.m. ***Let's Bring the Pulse Back: Novel Wave Membrane Durable LVADs***

Pascal Leprince, MD, PhD, Hopital de La Pitie Salpetriere, Sorbonne University, Paris, France.

The speaker will describe new durable LVAD technologies that include enhanced preload/afterload sensitivity and pulsatility as well as the potential of this technology to enhance outcomes for patients requiring durable MCS therapy.

10:48 a.m. ***What Do the Next Generation Centrifugal-Flow LVADs Promise?***

Francis Pagani, MD, PhD, University of Michigan, Ann Arbor, MI, USA

The speaker will describe new centrifugal-flow LVAD technologies and its potential benefits over current generation LVADs.

11:00 a.m. ***Panel Discussion led by Moderators***

WEDNESDAY, 10 APRIL, 2024

10:00 - 11:15 a.m.

SYMPOSIUM 02: Looking Forward: The Evolving Landscape of Heart Allocation and Donor Selection Strategies

Location: Forum Hall

Core Therapies: HEART, LUNG, MCS

Practice Areas: Cardiology, Anesthesiology and Critical Care, Cardiothoracic Surgery, Nursing and Allied Health, Pediatrics, Pharmacy

Session Summary: This session will explore the current landscape of donor allocation and utilization. This will encompass discussion of the global challenges in increasing donor use as well as the ethical allocation of donor organs with attention to multiorgan transplantation. A panel discussion with all speakers including audience Q&A, led by the session moderators, will conclude this session.

Moderators: Kyung-Hee Kim, MD, PhD, Incheon Sejong Hospital, Seoul, South Korea
Matthew Lander, MD, Allegheny Health Network, Pittsburgh, PA, USA

10:00 a.m. ***Learning From Our Worldly Neighbors: Heart Allocation Strategies From Around the Globe***

Carine Jasseron, Agence de la Biomédecine, Paris, France.

This talk will review heart allocation systems across the globe identifying the successes and challenges to creating an ideal system.

10:12 a.m. ***Climate Changes in Multiorgan Allocation***

Maryjane Farr, MD MSc, University of Texas Southwestern Medical Center, Dallas, TX, USA

Increase in multiorgan transplant has led to the re-evaluation of allocation strategies given the implicit ethical considerations. This talk will serve to highlight allocation approaches to multiorgan transplant, implications for waiting list and transplant outcomes, and future policy development.

10:24 a.m. ***The Heat is On: Challenges with Donor Availability and Acceptance in Heart Transplantation***

Ivan Knezevic, MD, PhD, University Medical Centre Ljubljana, Ljubljana, Slovenia.

This talk will highlight the global state of organ availability and acceptance rates for heart transplantation and discuss challenges and strategies to help increase the donor pool and donor utilization.

10:36 a.m. ***Tiny Hearts, Big Mountains: Unraveling the Complexity of Donor Selection for Pediatric Heart Transplantation***

Kae Watanabe, MD, Texas Children's Hospital, Houston, TX, USA

This talk will discuss the challenges in donor selection for pediatric heart transplantation and factors that impact donor utilization.

10:48 a.m. ***Is the Future Here?: Beyond the Horizon with Xenotransplantation***

Muhammad Mohiuddin, MBBS, UMB Cardiac Xenotransplantation, Baltimore, MD, USA

This talk will discuss the advances in xenotransplantation and present a roadmap for its future use in meeting the growing need for organs.

11:00 a.m. ***Panel Discussion led by Moderators***

WEDNESDAY, 10 APRIL, 2024

10:00 - 11:15 a.m.

SYMPOSIUM 03: Respiratory Viruses in Lung Transplantation: With or Without SARS-COV-2

Location: South Hall 1

Core Therapies: LUNG, PVD

Practice Areas: Infectious Diseases, Cardiothoracic Surgery, Pediatrics, Pharmacy, Pulmonology

Session Summary: Respiratory viruses' infections have negative impact in lung transplant recipient outcome and donor pool. This session will review the epidemiology, new approaches to prevent and treat these RVI and understanding key complications, including post-viral Aspergillus, acute rejection and CLAD. Data about lifesaving lung transplant for SARS-CoV-2 PCR positive pre-lung transplant candidates and donors will also be discussed. A panel discussion with all speakers including audience Q&A, led by the session moderators, will conclude this session.

Moderators: Rayid Abdulqawi, MD, PhD, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
Monique Malouf, FRACP, St. Vincent's Hospital, Sydney, Australia

10:00 a.m. ***Prevention of RSV and Influenza in Lung Transplantation***
Karen Doucette, MD, MSc, University of Alberta, Edmonton, AB, Canada

This talk will summarize the new prevention strategies for respiratory syncytial virus and influenza in lung transplantation. Vaccines will be discussed.

10:10 a.m. ***Respiratory Virus Positive Recipients: How Long Should We Wait?***
Letizia Corinna Morlacchi, MD, Università degli Studi di Milano, Milano, Italy.

The speaker will discuss whether and when to proceed a lifesaving lung transplant for SARS-CoV-2 PCR positive pre-lung transplant candidates.

10:20 a.m. ***The Lung Donor With a History of a Respiratory Viral Illness: How Long Should We Wait?***
Ricardo La Hoz, MD, UT Southwestern MC, Dallas, TX, USA

The COVID-19 pandemic taught us many important lessons, including the use of NAT+ donor organs for non-lung, then lung transplant candidates. The lessons learned could be applied to other viruses to safely expand the donor pool

10:30 a.m. ***Fungal Infections after RVI: Epidemiology, Prevention, and Treatment Options***
Me-Linh Luong, MD, Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada

This talk will focus on the incidence of fungal infections after RVI, with focus on risk factors, prevention, and outcomes.

10:40 a.m. ***Impact of RVI on Acute Rejection and CLAD in Lung Transplantation***
Michael Perch, MD, Rigshospitalet, Copenhagen, Denmark.

This talk will review available data on epidemiology of acute rejection and CLAD after RVI with a focus on the basic science data to understand pathogenesis.

10:50 a.m. ***Panel Discussion led by Moderators***

WEDNESDAY, 10 APRIL, 2024

10:00 - 11:15 a.m.

SYMPOSIUM 04: Come Together: Improving Survival in Pulmonary Arterial Hypertension

Location: South Hall 2

Core Therapies: PVD, HEART, LUNG

Practice Areas: Pulmonology, Cardiology, Nursing and Allied Health, Pharmacy, Research and Immunology

Session Summary: This session will highlight the areas of unmet need in PAH which are responsible for poor survival. It will review the progress made through clinical trials and drug development and ongoing paucities in treatment of PH. A panel discussion with all speakers including audience Q&A, led by the session moderators, will conclude this session.

Moderators: Rachel Crackett, MSc, Freeman Hospital, Newcastle Upon Tyne, United Kingdom
Ioana Preston, MD, Tufts Medical Center, Boston, MA, USA

10:00 a.m. ***The Long and Winding Road: Factors Contributing to Poor Survival in PAH***
Sandeep Sahay, MD, MSc, Houston Methodist Hospital, Houston, TX, USA

This talk will focus on the variety of factors which are implicated in poor survival of patients with PAH. The speaker will start with the factors affecting delayed diagnosis, and then discuss variability in the treatment approaches affecting survival in PAH.

10:12 a.m. ***Something: Novel Therapies and New Directions***
Ryan Davey, MD, FRCPC, London Health Sciences Centre, Western University, London, ON, Canada

This talk will focus on novel therapies for PAH that target vascular remodeling pathways. Aside from sotatercept, several medications are being evaluated for use against new treatment targets. The speaker will include information on the pathophysiology of metabolic dysfunction, inflammation, and other neurohormonal changes in PAH and then discuss the role of medications targeting these specific pathways. Will ultimately discuss the use of upfront triple combination treatment and the possible expansion to quadruple therapies based on these new pharmacologic developments.

10:24 a.m. ***Don't Let Me Down: Underrepresentation of Patients with Comorbidities, How Do We Treat Them?***
Stephan Rosenkranz, MD, University of Cologne, Cologne, Germany

PAH therapies are offered to patients with comorbidities, who are underrepresented in randomized controlled trials. There are minimal data to help guide the use of PAH therapies in these patient populations. This talk will focus on the inclusion of these patients in trials and how to approach treatment with limited supporting data.

10:36 a.m. ***Help! Risk Stratification in Adults to Improve Survival***
Sophia Airhart, MD, Saint Alphonsus Medical Center, Boise, ID, USA

Guidelines have recommended performing objective risk assessment and goal-oriented therapy as standard of care. Achieving low risk status is recommended as goal of treatment, but is achieving low risk status a surrogate for long term survival?

10:48 a.m. ***Here Comes the Sun: Developments in Risk Stratification in Pediatrics***
Allen Everett, MD, Johns Hopkins University School of Medicine, Baltimore, MD, USA

To ensure appropriate initial treatment of pediatric patients with PAH, a useful risk assessment must be used. This talk will discuss developments in risk assessment in pediatric patients and the use of stratification tools in clinical practice to improve management and hopefully survival in this patient population.

11:00 a.m. ***Panel Discussion led by Moderators***

WEDNESDAY, 10 APRIL, 2024

10:00 - 11:15 a.m.

SYMPOSIUM 05: The Computer will See you Now: AI and Machine Learning in Heart Transplantation

Location: Panorama Hall

Core Therapies: HEART, LUNG

Practice Areas: Cardiology, Nursing and Allied Health, Pathology, Research and Immunology

Session Summary: The explosion (and hype) around artificial intelligence has been enormous, particularly with the advent of ChatGPT and other publicly available large language models that simulate human intelligence. Advances in other areas such as machine vision and machine learning are also finding applications in medicine and medical research. This session will explore the basics of AI, and machine learning, and then focus on transplant related applications that are in evolution. A panel discussion with all speakers including audience Q&A, led by the session moderators, will conclude this session.

Moderators: Francesca Lunardi, MD, ScD, PhD, University of Padova, Padova, Italy
Sudhir Kushwaha, MD, Mayo Clinic, Rochester, MN, USA

10:00 a.m. **Overview: Deep Learning, Large Language Models, AI Oh My!**
Eileen Hsich, MD, Cleveland Clinic Foundation, Cleveland, OH, USA

Introductory talk to discuss the breadth of AI, Machine learning, large language models and dispel myths and misconceptions. Details about the 30,000 foot view is provided and subsequent talks will hone in on specifics.

10:15 a.m. **Through New Eyes: Computer Vision Applied to Heart and Lung Biopsies**
Eliot Peyster, MD, MSc, Penn Medicine, Philadelphia, PA, USA

This talk will review the value of computer vision / machine learning as applied to endomyocardial and lung biopsy slides. The opportunities and challenges of applying machine learning image-based tools to clinical practice will be covered.

10:30 a.m. **Application of Classical Machine Learning in Thoracic Transplantation: Rationale, Best Use, and Challenges**
Kevin Clerkin, MD, MSc, Columbia University Irving MC, New York, NY, USA

Machine learning techniques can generate new insights in large data sets which are not apparent with usual analytic techniques. The talk will focus on use of supervised and unsupervised approaches to analysis with a discussion of potential utility of this approach.

10:45 a.m. **Where Are We Going? Machine Learning to Predict Post-Transplant Trajectory**
Johan Nilsson, MD, PhD, Skanes University Hospital, Lund, Sweden

Recent work has identified ways to predict long term development of cardiac allograft vasculopathy and segment patients into trajectories. The utilization of machine learning to find patterns in data which lead to actionable insights is reviewed.

11:00 a.m. **Panel Discussion led by Moderators**

WEDNESDAY, 10 APRIL, 2024

10:00 - 11:15 a.m.

SYMPOSIUM 06: Surviving and Thriving After Cardiothoracic Transplantation

Location: North Hall

Core Therapies: LUNG, HEART

Practice Areas: Nursing and Allied Health, Cardiology, Pediatrics, Pulmonology, Research and Immunology

Session Summary: The goal of cardiothoracic transplantation is to improve patient survival and quality of life. Quality of life reflects the impact of long-term physical and psychological sequelae. This session will discuss the psychological challenges experienced by patients and their caregivers after cardiothoracic transplantation and explore strategies to optimize wellbeing and overall quality of life after transplantation. A panel discussion with all speakers including audience Q&A, led by the session moderators, will conclude this session.

Moderators: Meg Fregoso, MSN, NP-BC CCTC, Inova Fairfax Hospital, Falls Church, VA, USA
Christiane Kugler, PhD, Albert-Ludwigs University Freiburg, Freiburg, Germany

10:00 a.m. ***Surviving But Not Thriving: Psychological Challenges After Cardiothoracic Transplantation***
Melissa Sanchez, BSc Hons, PGDip, DClinPsy, MSc, Central and North West London NHS Foundation Trust, London, United Kingdom

Psychological well-being and adaptation to transplantation contribute to overall quality of life. This talk will include a video recording of a patient's experience after cardiothoracic transplantation followed by a summary of the state of the science of the most pressing psychological challenges experienced by patients after cardiothoracic transplantation including mental health, organ integration, and suicidal ideation concerns.

10:12 a.m. ***Caring for the Caregiver***
Michael Petty, PhD, RN, APRN, CNS, CCNS, Minnesota Health Fairview, Univ of Minnesota MC, Minneapolis, MN, USA

Lay-caregivers are integral to transplant care and outcomes but their transplant knowledge, mental health, and their potential to benefit from targeted support and intervention can be under-recognized. This talk will include a video recording of a caregiver's perspective on transplant caregiving followed by a summary of the state of the science of transplant caregiving including the physical, emotional, and economic impact of caregiving on the transplant caregiver, and the caregivers' impact on transplant patient outcomes.

10:24 a.m. ***Ease Your Mind: Mindfulness-Based Interventions for Cardiothoracic Transplant***
Stephanie Hsiao, MD, Stanford Health Care/Palo Alto VA, Palo Alto, CA, USA

Cardiothoracic transplant recipients are at risk for psychological distress. This talk will focus on novel mindfulness-based interventions to improve psychological symptoms and wellbeing after cardiothoracic transplant.

10:36 a.m. ***Developing a Support Network Through the Use of Peer Support***
Samantha Anthony, PhD, MSW, Hospital for Sick Children, Toronto, ON, Canada

Peer-to-peer support can increase connectedness, reduce isolation, facilitate knowledge acquisition and promote self-empowerment. This talk will consider the role of peer support and peer mentorship for informational and emotional support pre and post-transplant in both the adult and pediatric populations.

10:48 a.m. ***Integrating Palliative Care Into Cardiothoracic Transplantation***
Rebecca Colman, MD, MSc, FRCPC, University Health Network, Toronto, ON, Canada

This talk will discuss integration of palliative care into pre- and post-cardiothoracic transplant care in children and adults and also those determined to be unsuitable for cardiothoracic transplantation and when transplant fails. Palliative care needs in cardiothoracic transplantation include managing symptoms, facilitating advanced care planning, and end of life decision-making, and supporting families.

11:00 a.m. ***Panel Discussion led by Moderators***

WEDNESDAY, 10 APRIL, 2024

11:45 a.m. - 12:45 p.m.

SPECIAL SESS 1: Non-CME: ISHLT en Español: Why is Heart Transplant Behind All Other Organs in Latin America? (¿Por qué el trasplante de corazón está detrás de los demás órganos en América Latina?)

Location: Congress Hall

Core Therapies: HEART, MCS

Practice Areas: Cardiology, Cardiothoracic Surgery, Nursing and Allied Health

Session Summary: Heart failure prevalence is higher in Latin America in comparison to other continents. Paradoxically, heart transplant centers are underdeveloped, even in countries with established transplant programs. Latin American culture and economy pose unique challenges requiring tailored solutions. This session will address these issues with five 8-minute presentations followed by 20 minutes of Q&A/Panel Discussion with all speakers at the end of the session, led by the moderators. **This session will be conducted entirely in English to encourage participation by everyone. CME is not offered for this session.**

Resumen de la sesión: La prevalencia de insuficiencia cardíaca es mayor en América Latina en comparación con otros continentes. Paradójicamente, los centros de trasplante de corazón están subdesarrollados, incluso en países con programas de trasplante establecidos. La cultura y la economía latinoamericanas plantean desafíos únicos que requieren soluciones customizadas. Esta sesión abordará estos temas con cinco presentaciones de 8 minutos seguidas de 20 minutos de preguntas y respuestas / panel de discusión con todos los oradores al final de la sesión, dirigidos por los moderadores. **Esta sesión se llevará a cabo en inglés para estimular la participación de todos. CME no se ofrece para esta sesión.**

Moderators: María Renedo, MD, Hospital Universitario Fundación Favaloro, Buenos Aires, Argentina
Ana Alba, MD, PhD, Toronto General Hospital, Toronto, ON, Canada

11:45 a.m. **Heart Transplant in Latin America? Burden of Heart Failure and Heart Transplant Activity in Latin America (¿Trasplante de corazón en América Latina? Censo de la insuficiencia cardíaca y la actividad del trasplante cardíaco en América Latina)**
Viviana Navas, MD, NCH Heart Institute, Naples, FL, USA

This talk will describe current status of heart transplant centers in Latin America and their reported challenges from patient selection to post-transplant care based on results from a recent survey. (Esta charla describirá el estado actual de los centros de trasplante cardíaco en América Latina y los desafíos reportados desde la selección de pacientes hasta la atención posterior al trasplante en base a resultados de una encuesta reciente.)

11:53 a.m. **Choosing the Right Recipient at the Right Time: Is It Too Complicated? Is It Too Late? (Elegir el receptor adecuado en el momento adecuado: ¿Es demasiado complicado? ¿Es demasiado tarde?)**
Lorena Montes, MD, Fundación Cardiovascular de Colombia, Floridablanca, Colombia

This presentation will describe challenges related to recipient selection and limitations of therapeutic options in patients with advanced heart failure in Latin America. (En esta presentación se describirán los desafíos relacionados con la selección de receptores y las limitaciones de las opciones terapéuticas en pacientes con insuficiencia cardíaca avanzada en América Latina.)

12:01 p.m. **(Donor Selection: Too Many Candidates and Few Donors (Selección de donantes: demasiados candidatos y pocos donantes)**
Sebastian Rojas, MD, Heart and Diabetes Center, Bad Oeynhausen, Germany

This presentation will describe challenges related to donor availability and management in Latin America and propose creative ways to deal with them. (En esta presentación se describirán los desafíos relacionados con la disponibilidad y gestión de donantes en América Latina y se propondrán formas creativas de abordarlos.)

12:09 p.m. **Post-Transplant Outcomes and Care: Hope for the Best But Prepare for the Worst (Resultados y cuidados posteriores al trasplante: espere lo mejor, pero prepárese para lo peor)**
Douglas Greig, MD, MSc, P. Universidad Católica de Chile, Santiago, Chile

This presentation will describe challenges in the post-transplant care related to Latin American culture, societal and economic factors. (Esta presentación describirá los desafíos en la atención post-trasplante relacionados a factores culturales, sociales y económicos latinoamericanos.)

12:17 p.m.

How to Develop a Successful Transplant Center (Cómo desarrollar un centro de trasplantes exitoso)

Juan Ivey-Miranda, MD, Instituto Mexicano del Seguro Social, Mexico City, Mexico

This presentation will discuss potential solutions to the unique challenges imposed by the Latin American special circumstances, highlighting the key requirements to build and maintain a successful transplant program while ensuring optimal patient outcomes. (Esta presentación discutirá las posibles soluciones a los desafíos únicos impuestos por las circunstancias especiales de América Latina, destacando los requisitos clave para construir y mantener un programa de trasplante exitoso y, al mismo tiempo, garantizar resultados óptimos para los pacientes.)

12:25 p.m.

Panel Discussion with Q&A (Panel de discusión con Q&A)

WEDNESDAY, 10 APRIL, 2024

1:15 - 2:30 p.m.

SYMPOSIUM 07: JHLT Year in Review

Location: Congress Hall

Core Therapies: HEART, LUNG, MCS, PVD

Practice Areas: Anesthesiology and Critical Care, Cardiology, Cardiothoracic Surgery, Infectious Diseases, Nursing and Allied Health, Pathology, Pediatrics, Pharmacy, Pulmonology, Research and Immunology

Session Summary: Editors will introduce some of the most influential papers published in JHLT from 2023. The Top 6 original research papers, one from each area of adult HTX, adult LTX, pediatric, adult MCS, PH, and ID, will be presented by Early Career Editors or Members followed by a brief Q&A discussion after each presentation, led by the Senior Editor. After each speaker's presentation, the session moderators will lead a brief audience Q&A segment.

Moderators: Yael Peled, MD, Sheba Medical Center, Tel Aviv, Israel
Christine Lau, MD, MBA, University of Maryland, Baltimore, MD, USA
Raymond Benza, MD, Mount Sinai Icahn School of Medicine, New York, NY, USA
Joseph Rossano, MD, The Children's Hospital, Philadelphia, PA, USA

1:15 p.m. **Presentation of the JHLT and the Selection of the Presented Papers**

Yael Peled, MD, Sheba Medical Center, Tel Aviv, Israel.

The presenter will go over some brief data on JHLT metrics and will describe the process of how these JHLT papers were selected.

1:20 p.m. **An Influential JHLT Adult MCS Paper in 2023**

Elian Giordanino, MD, Fundacion Favalaro, Buenos Aires, Argentina.

This presentation will describe one of the most influential JHLT papers in the adult MCS space. The presenter will go over the rationale for the study, the key findings, and how it moves the field forward.

1:25 p.m. **Q&A Led by Moderator (Benza)**

1:35 p.m. **An Influential JHLT Adult Lung Transplant Paper in 2023**

Anna Niroomand, PhD, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA

This presentation will describe one of the most influential JHLT papers in the adult lung transplant space. The presenter will go over the rationale for the study, the key findings, and how it moves the field forward.

1:40 p.m. **Q&A Led by Moderator (Lau)**

1:45 p.m. **An Influential JHLT Adult Pulmonary Arterial Hypertension Paper in 2023**

Thomas Cascino, MD, MSc, University of Michigan, Ann Arbor, MI, USA

This presentation will describe one of the most influential JHLT papers in the area of adult Pulmonary Arterial Hypertension. The presenter will go over the rationale for the study, the key findings, and how it moves the field forward.

1:50 p.m. **Q&A Led by Moderator (Benza)**

1:55 p.m. **An Influential JHLT Infectious Diseases Paper in 2023**

Emily Eichenberger, MD, MHS, Emory University School of Medicine, Atlanta, GA, USA

This presentation will describe one of the most influential JHLT papers in the area of Infectious Diseases. The presenter will go over the rationale for the study, the key findings, and how it moves the field forward.

2:00 p.m. **Q&A Led by Moderator (Lau)**

2:05 p.m. **An Influential JHLT Adult Heart Transplant Paper in 2023**
Livia Goldraich, MD, MSc, Hospital de Clínicas, Porto Alegre, Brazil.

This presentation will describe one of the most influential JHLT papers in the adult heart transplant space. The presenter will go over the rationale for the study, the key findings, and how it moves the field forward.

2:10 p.m. **Q&A Led by Moderator (Peled)**

2:15 p.m. **An Influential JHLT Pediatric Transplant Paper in 2023**
Jack Luxford, BA, MD, Children's Hospital at Westmead, Sydney, Australia

This presentation will describe one of the most influential JHLT papers in the pediatric transplant space. The presenter will go over the rationale for the study, the key findings, and how it moves the field forward.

2:20 p.m. **Q&A Led by Moderator (Rossano)**

2:25 p.m. **Closing Remarks**

WEDNESDAY, 10 APRIL, 2024

1:15 - 2:30 p.m.

SYMPOSIUM 08: Till Explant Do Us Part: Patient Optimization and Transitioning Out of Temporary Mechanical Circulatory Support

Location: Forum Hall

Core Therapies: MCS, HEART

Practice Areas: Cardiology, Anesthesiology and Critical Care, Cardiothoracic Surgery, Nursing and Allied Health

Session Summary: A large percentage of patients receiving a durable LVAD or transplant are being transitioned from a temporary support device (VA-ECMO or IABP or Impella). This session focuses on best practices surrounding the transitions. A panel discussion with all speakers including audience Q&A, led by the session moderators, will conclude this session.

Moderators: Angela Lorts, MD, MBA, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
Christopher Allen, MBBS, FRACP, Fiona Stanley Hospital, Perth, Australia

1:15 p.m. ***Patient Selection, Surgical Techniques, Procedural Considerations for Temporary MCS Devices***
Jonathan Nattiv, USC, Keck Medical Center, Los Angeles, CA, USA

This presentation will review options for tMCS device therapy and review appropriate patient selection. The speaker will cover anatomic considerations, patient characteristics, surgical implant/and explant techniques and clinical scenarios that guide referral for tMCS cannulation.

1:27 p.m. ***Stress Test for RV Pre LVAD: Lessons From a Trans-Valvular Pump***
Marta Farrero Torres, MD, PhD, Hospital Clinic de Barcelona, Barcelona, Spain

This talk will focus on when and how to optimize the RV pre LVAD using MCS support and how to apply that information on post op pump speed management.

1:39 p.m. ***Mobilizing Patients on Temporary MCS: How to Empower Your ICUs***
Katrine Rolid, MSc, PhD, The Research Council of Norway, Oslo, Norway.

This talk will focus on practical approach to mobilize pre LVAD patients cannulated with tMCS.

1:51 p.m. ***Extra-Cardiac Care for Patients Supported on Temporary MCS Pre LVAD***
Sern Lim, MD, University Hospitals Birmingham NHS Trust, Birmingham, United Kingdom

This talk will focus on the non-cardiac care aspects of patients supported on tMCS including pulmonary, nutrition, vascular and renal optimization.

2:03 p.m. ***Anticoagulation Strategies for tMCS: Drugs, Therapeutic Targets, and Monitoring Strategies***
Sara Strout, PharmD, John Hopkins Medicine, Baltimore, MD, USA

This talk will review current practices and evidence for anticoagulation in patients receiving tMCS.

2:15 p.m. ***Panel Discussion led by Moderators***

WEDNESDAY, 10 APRIL, 2024

1:15 - 2:30 p.m.

SYMPOSIUM 09: Durable LVAD: Full Circle from Pre-Op Optimization to Long-Term Outcomes

Location: South Hall 3

Core Therapies: MCS

Practice Areas: Cardiology, Cardiothoracic Surgery

Session Summary: Durable LVAD therapy can dramatically improve the quality of life and outcomes of patients with advanced heart failure. However, significant challenges remain that limit more widespread use of this therapy. In this session we will focus on pre-op optimization with short-term mechanical circulatory support before durable LVAD implant. After LVAD implant, complications can still limit long-term outcomes. The long term outcomes of durable VAD therapy will also be discussed - predictors of successful longevity and a good quality of life with a durable LVAD. A panel discussion with all speakers including audience Q&A, led by the session moderators, will conclude this session.

Moderators: Linda Van Laake, MD, PhD, University Medical Center, Utrecht, Netherlands
Arvind Bhimaraj, MD, Houston Methodist Hospital, Houston, TX, USA

1:15 p.m. **DEBATE: Pre-op Optimization with Temporary MCS Enhances Outcomes for Patients Receiving a Durable LVAD (PRO)**
Carles Diez-Lopez, MD, PhD Student, Bellvitge University Hospital, Barcelona, Spain

Pro discussion for the role of pre-op optimization of patients undergoing durable LVAD, using temporary MCS. The presentation will start with a brief case supporting the PRO position.

1:27 p.m. **DEBATE: Pre-op Optimization with Temporary MCS Enhances Outcomes for Patients Receiving a Durable LVAD (CON)**
Peter Ivak, M.D., Ph.D., IKEM, Prague, Prague, Czech Republic.

Con discussion for the role of pre-op optimization of patients undergoing durable LVAD, using temporary MCS. The presentation will start with a brief case supporting the CON position.

1:39 p.m. **A Bloody Mess: How to Prevent and Manage Gastrointestinal Bleeding**
Ulrich Jorde, MD, Montefiore Medical Center, New York, NY, USA

As the time on durable VAD progresses, complications may develop and the most common hemocompatibility-related adverse event is GI bleeding. The speaker will focus on what's new in the physiopathology behind GI bleeding, how to prevent, and how to treat it.

1:54 p.m. **Predictors of Longevity on an LVAD**
Manreet Kanwar, MD, Allegheny General Hospital, Pittsburgh, PA, USA

There is a subset of patients who do extremely well on LVAD, some live on device support for > 10 years. This talk will discuss what defines those patients, what can we learn from these cases, and can we predict which patients will do well for a at least 5 years or longer?

2:06 p.m. **Panel Discussion led by Moderators**

WEDNESDAY, 10 APRIL, 2024

1:15 - 2:30 p.m.

SYMPOSIUM 10: Small Candidates in a Big World: The Impact of Organ Allocation Systems in Adult and Pediatric Lung Transplantation

Location: South Hall 1

Core Therapies: LUNG

Practice Areas: Cardiothoracic Surgery, Pediatrics, Pulmonology

Session Summary: In 2023 the Composite allocation score was implemented in the US to allocate donor lungs did it improve access in all age groups? Donor lungs for small recipients are scarce. The current session places in issue in perspective and debates how well the CAS improves the organ-matching process with a special focus on pediatric patients. A panel discussion with all speakers including audience Q&A, led by the session moderators, will conclude this session.

Moderators: Selim Arcasoy, MD, MPH, Columbia University, New York, NY, USA
Brigitte Willemse, MD, PhD, University Medical Center Groningen, Groningen, Netherlands

1:15 p.m.

How to Find the Perfect Fit for Small Candidates?

Rossa Brugha, BMBCh MA(Oxon) MRCPCH PhD, Great Ormond Street Hospital, London, United Kingdom

This talk will describe the different lung allocation systems throughout the world focusing on allocation for infants/children and small adults. What is the better and more ethically correct approach?

1:30 p.m.

Composite Allocation Score: Moving Lung Allocation in the Right Direction?

Erika Lease, MD, University of Washington, Seattle, WA, USA

This talk will review the state of lung transplantation globally and provide an international perspective and will describe the critical elements of the current lung allocation system in the US and detail preliminary data on how it has achieved its goals.

1:45 p.m.

DEBATE: Composite Allocation Score - We've Never Been Better, CAS is the Best! (PRO)

Edward Cantu, MD, MSCE, University of Pennsylvania, Philadelphia, PA, USA

The speaker will argue in favor of the newly implemented composite allocation score (CAS) in lung transplantation, focusing on the improvements over the LAS system, particularly in relation to reducing waiting list mortality and describing how the composite score structure is well suited to continuing improvement.

2:00 p.m.

DEBATE: Composite Allocation Score - We've Never Been Better, CAS is the Best! (CON)

Stuart Sweet, MD, PhD, Washington University, St. Louis, MO, USA

The speaker will argue that although the newly implemented composite allocation score (CAS) has significant merit, it comes with both unintended consequences and unexplored methods to improve the underlying survival models.

2:15 p.m.

Panel Discussion led by Moderators

WEDNESDAY, 10 APRIL, 2024

1:15 - 2:30 p.m.

SYMPOSIUM 11: A Touch of Grey: Aging Biology and Holistic Clinical Care in Cardiothoracic Transplantation

Location: South Hall 2

Core Therapies: LUNG, HEART

Practice Areas: Pulmonology, Cardiology, Infectious Diseases, Nursing and Allied Health, Pathology, Pharmacy, Research and Immunology

Session Summary: The average age of cardiothoracic transplant recipients is on the rise, but we continue to learn that age is more than a number. This session will focus on the clinical, translational, and basic research highlighting the unique challenges relevant to older cardiothoracic transplant candidates, recipients, and their caregivers. A panel discussion with all speakers including audience Q&A, led by the session moderators, will conclude this session.

Moderators: Bart Vanaudenaerde, PhD, KU Leuven, Leuven, Belgium
Joshua Diamond, MD, University of Pennsylvania, Philadelphia, PA, USA

1:15 p.m. ***Immunosenescence, Telomere Dysfunction, and Epigenetics in Aging: Effects on Transplant***

Mark Snyder, MD, University of Pittsburgh MC, Pittsburgh, PA, USA

Immunosenescence refers to the aging-related changes in the immune response contributing to many age-related disorders. The primary goal of this talk will discuss the impact of telomere dysfunction and epigenetic changes on the immune response with age, and discuss how this may impact rejection and infection risk, as well as tolerance of post-transplant medications.

1:27 p.m. ***The Molecular Underpinnings of Frailty in Transplant Candidates and Recipients***

John Greenland, MD, PhD, University of California, San Francisco, CA, USA

While frailty is an age-associated clinical syndrome linked to poor cardiothoracic transplant outcomes, it also reflects aging-associated biologic processes. This talk will explore mitochondrial dysfunction, cytokine dysregulation, and cellular senescence that may lead to sarcopenia, fatigue, disability, and even rejection.

1:39 p.m. ***Heaven Can Wait: Evaluation of Older Cardiothoracic Transplant Candidates***

Osnat Shtraichman, MD, Rabin Medical Center, Petah Tiqva, Israel.

This talk will discuss the multidimensional nature of evaluating older adults for cardiothoracic transplantation including the impact of frailty, comorbidity burden, and other geriatric conditions on candidate selection. This talk will also consider the ethical challenges related to allocating organs to older individuals.

1:51 p.m. ***Post-Transplant Self-Care Considerations for the Older Patient-Caregiver Dyad***

Brittany Koons, PhD, Villanova University M. Louise Fitzpatrick College of Nursing, Philadelphia, PA, USA

Robust caregiver support is critical for transplant listing, adherence to a complex post-transplant self-care regimen, and overall success in cardiothoracic transplantation. This talk will focus on the role of the patient-caregiver dyad in cardiothoracic transplant self-care and unique factors to consider among older patient-caregiver dyads.

2:03 p.m. ***Quality of Life Following Cardiothoracic Transplantation: Does Recipient Age Matter?***

Lianne Singer, MD, FRCPC, University Health Network, Toronto, ON, Canada

Do older recipients achieve similar or different outcomes compared to younger recipients? This talk will review the impact of recipient age on clinical and quality of life outcomes post-cardiothoracic transplantation.

2:15 p.m. ***Panel Discussion led by Moderators***

WEDNESDAY, 10 APRIL, 2024

1:15 - 2:30 p.m.

SYMPOSIUM 12: Fragile - Handle with Care: Organ Management and Transportation

Location: Panorama Hall

Core Therapies: HEART, LUNG, MCS

Practice Areas: Cardiothoracic Surgery, Anesthesiology and Critical Care, Cardiology, Nursing and Allied Health

Session Summary: Over time, we have expanded selection criteria and adopted new preservation techniques for cardiac allografts. Nevertheless, many geographical disparities in the access and implementation of these preservation technologies still exist. After each speaker's presentation, the session moderators will lead a brief audience Q&A segment.

Moderators: David Baran, MD, Cleveland Clinic Heart, Vascular and Thoracic Institute, Weston, FL, USA
Yee Weng Wong, MBBS, MHS, FRACP, FCSANZ, Mayo Clinic, Rochester, MN, USA

1:15 p.m. ***Risky Business: How Novel Risk Scores Will Affect Donation***
Kiran Khush, MD, MAS, Stanford University, Stanford, CA, USA

This talk will focus on donor risk factors and donor management strategies as they affect recipient outcomes including primary graft dysfunction. Novel donor risk scores will be reviewed.

1:30 p.m. ***Carrier Beware: Cellular Biology and Molecular Changes of an Ex-Vivo Donor Heart***
Filio Billia, MD, PhD, University Health Network, Toronto, ON, Canada

This talk will feature discussion of the molecular changes that occur in donor heart after procurement. Cell-based and novel treatment strategies to enhance graft and recipient outcomes will be highlighted.

1:45 p.m. ***A Secure Delivery: Strategies for Procurement, Preservation and Transport***
David McGiffin, MB,BS, FRACS, DMedHS, Alfred Health, Melbourne, Australia

This talk will discuss and briefly compare current strategies for procurement, preservation and transport of cardiac allografts, and how these may improve organ function and expand the donor pool. Highlights of future challenges and opportunities will be addressed.

2:00 p.m. ***DEBATE: Cold Storage is Best in DBD and DCD Preservation and Transportation (PRO)***
Elena Sandoval, MD FEBCTS, Hospital Clinic, Barcelona, Spain

Two speakers will debate the optimal approaches to DBD and DCD donor organ preservation and transportation. Speaker 1 will present in favor of cold storage. Speaker 2 will present in favor of ex-vivo. Each speaker will present for 10 minutes followed by 10 minutes for rebuttal and discussion among debaters.

2:10 p.m. ***DEBATE: Cold Storage is Best in DBD and DCD Preservation and Transportation (CON)***
Hassiba Smail, MD, Royal Papworth Hospital, NHS Trust, Cambridge, United Kingdom

Two speakers will debate the optimal approaches to DBD and DCD donor organ preservation and transportation. Speaker 1 will present in favor of cold storage. Speaker 2 will present in favor of ex-vivo. Each speaker will present for 10 minutes followed by 10 minutes for rebuttal and discussion among debaters.

WEDNESDAY, 10 APRIL, 2024

1:15 - 2:30 p.m.

SYMPOSIUM 13: Unraveling Cardiac Allograft Vasculopathy (CAV): Pathogenesis to Prevention

Location: North Hall

Core Therapies: HEART, MCS

Practice Areas: Cardiology, Research and Immunology

Session Summary: This symposium seeks to illuminate the complex world of CAV, from its pathogenesis to prevention strategies. It will feature state-of-the-art discussions on diagnostic biomarkers, multimodality imaging, and strategic planning for disease management. A panel discussion with all speakers including audience Q&A, led by the session moderators, will conclude this session.

Moderators: Howard Eisen, MD, Thomas Jefferson University, Philadelphia, PA, USA
Anique Ducharme, MD, MSc, Université de Montréal, Montreal, QC, Canada

1:15 p.m. ***Defining the Landscape: CAV Pathogenesis***
Tor Clemmensen, MD, PhD, DMSc, Aarhus University Hospital, Denmark.

This talk will review and provide insights on key novel concepts of pathogenesis surrounding cardiac allograft vasculopathy, pointing to potential innovative therapeutic avenues.

1:25 p.m. ***Cutting Edge: Biomarkers for Detection and Prognostication***
Maxime Tremblay-Gravel, MD, MSc, Montreal Heart Institute, Montreal, QC, Canada

Since there is a lack of validated biomarkers for CAV diagnosis or prognostication, this talk will explore roles of latest biomarkers within this inflammatory milieu.

1:35 p.m. ***Weeding Out the Competition: CAV Toolbox of Multimodality Imaging***
Sharon Chih, MBBS, University of Ottawa Heart Institute, Ottawa, ON, Canada

This talk will focus on the multimodality imaging approach including noninvasive and invasive tests to detect early CAV.

1:45 p.m. ***The Forest and the Trees: CAV Prevention and Goals***
Lindsey Aurora, MD, Henry Ford Hospital, Detroit, MI, USA

Main strategies for CAV prevention and treatment will be discussed. Assays to monitor immune response and potential for individualized methods for immune modulation will be presented.

1:55 p.m. ***The Road to Perdition: Defining Trajectories for the Development of CAV***
Guillaume Coutance, MD, PhD, Pitié-Salpêtrière Hospital, Paris, France.

This talk will discuss novel approaches for defining the natural history of developing CAV in patients.

2:05 p.m. ***Panel Discussion led by Moderators***

WEDNESDAY, 10 APRIL, 2024

3:00 - 4:15 p.m.

ORAL SESSION 01: Donation after Circulatory Death (DCD) Heart Transplantation: How Are We Doing?

Location: Congress Hall

Core Therapies: HEART

Practice Areas: Cardiothoracic Surgery, Anesthesiology and Critical Care, Cardiology

Session Summary: Donation after Circulatory Death (DCD) has significantly increased heart transplantation over the last decade. Emerging data on DCD expansion will be discussed including controversies in this developing clinical practice area.

Each presenter will give a **10-minute** PowerPoint presentation, followed by a **5-minute** question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: Sai Bhagra, MRCP(UK), Royal Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom
Michiel Erasmus, MD, PhD, University Medical Center Groningen, Groningen, Netherlands

- 3:00 p.m. **(4) Early Outcomes and Trends in Use of Donation After Circulatory Death (DCD) Donors for Multi-Organ Heart Transplantation (HT) in US**
J. Teitelbaum¹, S. R. Patel², C. Diez-Lopez², J. A. Ovalle Ramos², O. Saeed², Y. Rochlani², S. Vukelic², S. Murthy², J. Shin², D. Sims², S. Forest², J. Borgi², D. J. Goldstein², U. P. Jorde², S. Madan². ¹Albert Einstein College of Medicine, Bronx, NY, ²Montefiore Medical Center, Bronx, NY
- 3:10 p.m. **Q&A**
- 3:15 p.m. **(5) Cardiac Donation After Circulatory Death in Adult Congenital Heart Disease: Early Experiences and Outcomes**
A. M. Wisniewski, M. Weber, J. Beller, L. Yarboro. University of Virginia, Charlottesville, VA
- 3:25 p.m. **Q&A**
- 3:30 p.m. **(6) Real-World Clinical Outcomes of DCD Heart Transplantation from the OCS Heart Perfusion (OHP) Registry: Benchmarking to Other Preservation Methods**
C. Milano¹, J. Schroder¹, M. Daneshmand², D. D'Alessandro³, S. Pham⁴, G. Couper⁵, A. Shah⁶, J. Pal⁷, L. Klein⁸, F. Esmailian⁹, R. Davis¹⁰, M. Villavicencio¹¹, A. Shaffer¹², B. Sun¹³, K. Takeda¹⁴, D. Pham¹⁵, R. Malyala¹⁶, H. Mallidi¹⁷, J. Haft¹⁸, D. Meyer¹⁹, L. Durham²⁰, D. Goldstein²¹, M. Funamoto²², S. Ohira²³, D. Kaczorowski²⁴, Y. Shudo²⁵, J. Stehlik²⁶, S. Pinney²⁷, M. Farr²⁸, L. Lozonschi²⁹. ¹Duke Univ Medical Center, Raleigh, NC, ²Emory Univ, Atlanta, GA, ³MGH, Boston, MA, ⁴Mayo Clinic Florida, Jacksonville, FL, ⁵Tufts Medical Center, Boston, MA, ⁶Vanderbilt Univ Medical Center, Nashville, TN, ⁷Univ of Washington, Seattle, WA, ⁸Univ of California San Francisco, San Francisco, CA, ⁹Cedars-Sinai Heart Institute, Los Angeles, CA, ¹⁰Yale New Haven Hospital, New Haven, CT, ¹¹Mayo Clinic Hospital Minnesota, Minneapolis, MN, ¹²Univ of Minnesota, Fairview, MN, ¹³Minneapolis Heart Institute, Minneapolis, MN, ¹⁴Columbia Univ, New York, NY, ¹⁵Northwestern Medicine, Chicago, IL, ¹⁶Univ of Kentucky Medical Center, Lexington, KY, ¹⁷Brigham and Women's Hospital / HMS, Boston, MA, ¹⁸Univ of Michigan - Michigan Medicine, Ann Arbor, MI, ¹⁹Baylor Scott and White Health, Baylor Univ Medical Center, Dallas, TX, ²⁰Medical College of Wisconsin, Milwaukee, WI, ²¹Montefiore Medical Center, New York, NY, ²²Methodist Specialty and Transplant Hospital, San Antonio, TX, ²³Westchester Medical Center, New York Medical College, Westchester, NY, ²⁴Univ of Pittsburgh Medical Center, Pittsburgh, PA, ²⁵Stanford Univ, Stanford, CA, ²⁶Univ of Utah, Salt Lake City, UT, ²⁷Mount Sinai Morningside, New York, NY, ²⁸Univ of Texas Southwestern MC, Dallas, TX, ²⁹Univ of South Florida, Tampa General Hospital, Tampa, FL
- 3:40 p.m. **Q&A**
- 3:45 p.m. **(7) Impact of Institutional Volume on Outcomes Following DCD Heart Transplantation in the United States**
K. N. Potel¹, D. Y. Tam², Q. Chen², D. Emerson², M. Bowdish², J. Chikwe², D. Megna², P. Catarino². ¹School of Medicine, Queen's University Belfast, Belfast, United Kingdom, ²Cedars-Sinai Medical Center, Los Angeles, CA
- 3:55 p.m. **Q&A**
- 4:00 p.m. **Late-Breaking Abstract Presentation:**
(238) Role of Traditional Cardiac Biomarkers in Donation After Circulatory Death Heart Transplantation
M. Urban, S. Lundgren, R. Garvin, L. Fristoe, B. Lowes, A. Castleberry, J. Um. University of Nebraska Medical Center, Omaha, NE
- 4:10 p.m. **Q&A**

WEDNESDAY, 10 APRIL, 2024

3:00 - 4:15 p.m.

ORAL SESSION 02: Philip K. Caves Candidates Award Session

Location: Forum Hall

Core Therapies: HEART, LUNG, MCS, PVD

Practice Areas: Anesthesiology and Critical Care, Cardiology, Cardiothoracic Surgery, Infectious Diseases, Nursing and Allied Health, Pathology, Pediatrics, Pharmacy, Pulmonology, Research and Immunology

Session Summary: Established in 1982, the Philip K. Caves Award encourages and rewards original high-quality research performed by residents, fellows, trainees, and graduate students. Five candidates have been selected to present their high-scoring research in this session. At the conclusion of the session, the best research presentation will be selected by a panel of judges and the winner will be recognized during the Awards Presentations in the General (Plenary) Session on Saturday, 13 April.

Each presenter will give a **10-minute** PowerPoint presentation, followed by a **5-minute** question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: Josef Stehlik, MD, MPH, University of Utah, Salt Lake City, UT, USA
Peter Hopkins, FRACP, The Prince Charles Hospital, Brisbane, Australia

3:00 p.m. **(8) CRISPR-Cas Genome Editing in Ex Vivo Human Lungs**
K. Mesaki¹, H. Yamamoto¹, S. Juvet¹, J. Yeung², Z. Guan¹, Y. Yao¹, M. Chen¹, H. Gokhale¹, H. Shan¹, A. Wang¹, G. Wilson¹, A. Mariscal¹, J. Hu², A. Davidson², B. Kleinstiver³, M. Cypel¹, M. Liu¹, S. Keshavjee¹. ¹University Health Network, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Massachusetts General Hospital & Harvard Medical School, Boston, MA

3:10 p.m. **Q&A**

3:15 p.m. **(9) High-Dimensional Lung Tissue Imaging Reveals Temporal Changes in Immune Cell Populations and Cell Interactions During Progression of Chronic Lung Allograft Dysfunction (CLAD)**
S. Bos¹, B. Hunter², D. McDonald², G. Mercus², G. Sheldon³, P. Pradere⁴, J. Majo⁵, J. Pulle⁵, A. Vanstapel⁶, B. Vanaudenaerde⁶, R. Vos⁷, A. J. Filby², A. J. Fisher¹. ¹Translational & Clinical Research Inst, Newcastle Univ, Newcastle upon Tyne, UK, ²Innovation Methodology and Application Research Theme, Biosciences Inst, Newcastle University, Newcastle upon Tyne, UK, ³Newcastle Univ, Newcastle upon Tyne, UK, ⁴Hopital Marie Lannelongue, Paris, France, ⁵Newcastle Upon Tyne Hospitals NHS Foundation Trust Royal Victoria Infirmary, Newcastle upon Tyne, UK, ⁶Katholieke Univ, Leuven, Belgium, ⁷Univ Hosps, Leuven, Belgium

3:25 p.m. **Q&A**

3:30 p.m. **(10) Physiological Mechanisms of Reverse Pulmonary Vascular Remodeling in PH Due to Left Heart Disease**
D. Tian¹, M. Kucherenko¹, P. Sang², N. Veetil², C. Knosalla³, W. Kuebler⁴. ¹Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charité (DHZC), Institute of Physiology, Charité - Universitätsmedizin Berlin, Berlin, Germany, ²Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charité (DHZC), Institute of Physiology, Charité-Universitätsmedizin Berlin, Berlin, Germany, ³Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charité (DHZC), Berlin, Germany, ⁴Institute of Physiology, Charité - Universitätsmedizin Berlin, Berlin, Germany

3:40 p.m. **Q&A**

3:45 p.m. **(11) Quantification of Myocardial DNA Damage Predicts Prognosis of Heart Failure from Various Underlying Diseases**
T. Ko¹, M. Hatano¹, M. Ono². ¹Cardiovascular Medicine, The University of Tokyo Hospital, Tokyo, Japan, ²Cardiac Surgery, The University of Tokyo Hospital, Tokyo, Japan

3:55 p.m. **Q&A**

4:00 p.m. **(12) Short-Term Immuno-Molecular Landscape in 10-Gene Edited Pig-to-Human Heart Xenografts**
A. Giarraputo¹, E. Morgand¹, V. Goutaudier¹, F. Mezine¹, G. Coutance¹, K. Khalil², S. Mehta², N. Narula², H. Pass², D. Ayares³, B. Keating⁴, J. Kim², V. Tatapudi², J. Stern², P. Bruneval¹, N. Moazami², D. Smith², A. Reyentovitch², M. Mangiola², J. Boeke², A. Griesemer², R. Montgomery², A. Loupy¹. ¹Paris Institute for Transplantation and Organ Regeneration, Université Paris Cité, INSERM, U-970, AP-HP, Paris, France, ²NYU Langone Transplant Institute, NYU Langone Health, New York, NY, ³Revivacor, Blacksburg, VA, ⁴Div of Transplantation, Dept of Surgery, Perelman School of Med, The Univ of Pennsylvania, Philadelphia, PA
This presenter is also one of five finalists for the 2024 Early Career Scientist Award. Winner will be announced after the meeting.

4:10 p.m. **Q&A**

WEDNESDAY, 10 APRIL, 2024

3:00 - 4:15 p.m.

ORAL SESSION 03: Candidate Assessment and Access to Lung Transplant: Lungs and the Deathly Hallows Part I

Location: South Hall 3

Core Therapies: LUNG

Practice Areas: Pulmonology, Cardiology, Cardiothoracic Surgery, Nursing and Allied Health, Research and Immunology

Session Summary: Candidate selection for lung transplantation remains a challenge. This session focuses on pre-transplant risk factors for poor outcomes after lung transplantation, with a specific focus on candidates undergoing urgent inpatient evaluations, patients who are physically frail, and patients with esophageal dysmotility. Abstracts in this session will discuss how these risk factors impact wait list decisions and patient outcomes.

Each presenter will give a **10-minute** PowerPoint presentation, followed by a **5-minute** question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: Cassie Kennedy, MD, Mayo Clinic, Rochester, MN, USA
Daniel Dilling, MD, Loyola University Chicago, Stritch School of Medicine, Maywood, IL, USA

3:00 p.m. **(13) A Crash Without the Burn: Urgent Inpatient Evaluations for Lung Transplant, a Feasible Path to Transplant**
E. Scott¹, R. Anderson², M. Weder², C. Scott¹, P. Carrott¹, H. Mannem³. ¹Surgery, University of Virginia, Charlottesville, VA, ²Medicine, University of Virginia, Charlottesville, VA, ³University of Virginia, Charlottesville, VA

3:10 p.m. **Q&A**

3:15 p.m. **(14) To List or Not List? Frailty and Lung Transplant Wait List Decision-Making**
B. Koons¹, S. Aryal², A. Courtwright³, N. Blumenthal², D. Zaleski⁴, C. Bermudez³, M. Crespo³, E. Cantu⁵, J. Diamond⁵, J. Singer⁶, J. Christie⁵, B. Riegel². ¹Villanova University M. Louise Fitzpatrick College of Nursing, Villanova, PA, ²University of Pennsylvania School of Nursing, Philadelphia, PA, ³Hospital of the University of Pennsylvania, Philadelphia, PA, ⁴Good Shepherd Penn Partners, Philadelphia, PA, ⁵University of Pennsylvania, Philadelphia, PA, ⁶UC San Francisco, San Francisco, CA

3:25 p.m. **Q&A**

3:30 p.m. **(15) Removing Barriers to Lung Transplantation: Assessing Outcomes in Patients with Pre-Transplant Esophageal Dysmotility**
D. Nord¹, B. Styskel², C. Atkinson¹, M. Amaris³, A. Pelaez⁴. ¹Division of Pulmonary, Critical Care, & Sleep Medicine, University of Florida, Gainesville, FL, ²Gastroenterology, Hepatology & Nutrition, Cleveland Clinic, Cleveland, OH, ³Division of Gastroenterology, Hepatology, & Nutrition, University of Florida, Gainesville, FL, ⁴Miami Transplant Institute, Miller School of Medicine, University of Miami, Miami, FL

3:40 p.m. **Q&A**

3:45 p.m. **(16) Waitlist Stratification and Outcomes in Lung Transplantation for Severe Pulmonary Hypertension**
S. Kruszona¹, K. Aburahma¹, M. Franz¹, N. D. de Manna¹, M. Avsar¹, D. Bobylev¹, N. Schwert², A. Weymann¹, A. Ruhparwar¹, T. Welte³, M. M. Hoepfer³, C. Kuehn¹, J. Salman¹, M. Greer³, F. Ius¹. ¹Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany, ²Department of Pediatric Pneumology Allergology and Neonatology, Hannover Medical School, Hannover, Germany, ³Department of Respiratory Medicine and Infectious Diseases, Hannover Medical School, Hannover, Germany

3:55 p.m. **Q&A**

4:00 p.m. **(17) Guardians of the Graft: High-Density Lipoprotein-Cholesterol's Protective Effects in Lung Transplantation**
K. Ayyat, H. Elgharably, T. Okamoto, A. Tantawi, M. Budev, K. McCurry, J. Smith. Cleveland Clinic, Cleveland, OH

4:10 p.m. **Q&A**

WEDNESDAY, 10 APRIL, 2024

3:00 - 4:15 p.m.

ORAL SESSION 04: Lung Preservation and the Chamber of Secret Temperature

Location: South Hall 1

Core Therapies: LUNG

Practice Areas: Cardiothoracic Surgery, Anesthesiology and Critical Care, Pulmonology, Research and Immunology

Session Summary: This session focuses on lung preservation at 10°C vs. static cold preservation at 4°C. Outcomes and Techniques will be discussed.

Each presenter will give a **10-minute** PowerPoint presentation, followed by a **5-minute** question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: Maximilian Franz, MD, Hannover Medical School, Hannover, Germany
Laneshia Tague, MD, MSCI, Washington Univ in St. Louis, St. Louis, MO, USA

- 3:00 p.m. **(18) Protective Effect of 10°C Storage on Donor Lungs with Lipopolysaccharide-Induced Acute Lung Injury**
K. Yamanashi¹, A. Wang¹, C. Bellissimo², G. Siebiger¹, P. Oliveira¹, Y. Zhang¹, J. Yune¹, J. Montagne¹, G. Garza¹, N. Furie¹, M. Liu¹, E. Goligher², S. Keshavjee¹, M. Cypel¹. ¹Latner Thoracic Surgery Research Laboratories, University Health Network, Toronto General Hospital Research Institute, Toronto, ON, Canada, ²Division of Respiriology, Department of Medicine, University Health Network, Toronto, ON, Canada
- 3:10 p.m. **Q&A**
- 3:15 p.m. **(19) Evaluating Effects of 10°C Preservation on Warm Ischemia Injured Lungs**
J. Montagne¹, A. Wang², G. Loesch Siebiger³, J. Yune⁴, T. Lima¹, Y. Zhang¹, K. Yamanashi¹, G. Garza¹, P. Oliveira¹, A. Ali⁵, M. Liu¹, S. Keshavjee¹, M. Cypel¹. ¹Latner Thoracic Research Laboratories - TGHRI, University Health Network, Toronto, ON, Canada, ²Toronto General Hospital Research Institute, Toronto, ON, Canada, ³Latner Thoracic Research Laboratories - TGHRI, University of Toronto, Toronto, ON, Canada, ⁴University Health Network, Toronto, ON, Canada, ⁵Toronto General Hospital, Canada
- 3:25 p.m. **Q&A**
- 3:30 p.m. **(20) Prolonged Donor Lung Preservation of Up to 24h Using 10C Storage Does Not Impact Clinical Outcomes After Lung Transplantation**
K. Hoetzenecker¹, A. Ali², J. Campo-Canaeral de la Cruz³, S. Schwarz¹, S. Crowley³, A. Romero Román³, M. Aladaileh², P. Jaksch¹, M. Aversa², S. Keshavjee², M. Cypel². ¹Medical University of Vienna, Vienna, Austria, ²University of Toronto, Toronto, ON, Canada, ³Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain
- 3:40 p.m. **Q&A**
- 3:45 p.m. **(21) One-Year Clinical Outcomes of a Prospective Trial of Extended Static Lung Preservation at 10C**
C. M. Bobba¹, B. Saha², Y. Stukov³, M. Purlee³, C. Gries², W. B. Weir¹, A. Emtiazjoo², M. Rackauskas¹. ¹Division of Thoracic Surgery, University of Florida, Gainesville, FL, ²Division of Pulmonary, Critical Care & Sleep Medicine, University of Florida, Gainesville, FL, ³Congenital Heart Center, University of Florida, Gainesville, FL
- 3:55 p.m. **Q&A**
- 4:00 p.m. **(22) Largest Real-World Multi-Center Study Outcomes Reported with Controlled Hypothermic Preservation of Donor Lungs**
J. Haney¹, M. Hartwig², N. Langer³, P. Sanchez⁴, P. Carrott⁵, H. Huang⁶, L. Ceulemans⁷, J. Kukreja⁸, E. Bush⁹. ¹Duke University, Durham, NC, ²Duke University Medical Center, Durham, NC, ³Massachusetts General Hospital, Boston, MA, ⁴University of Pittsburgh Medical Center, Pittsburgh, PA, ⁵University of Virginia, Charlottesville, VA, ⁶Houston Methodist J.C. Walter Jr. Transplant Center, Houston, TX, ⁷University Hospitals Leuven, Leuven, Belgium, ⁸University of California San Francisco, San Francisco, CA, ⁹Johns Hopkins, Baltimore, MD
- 4:10 p.m. **Q&A**

WEDNESDAY, 10 APRIL, 2024

3:00 - 4:15 p.m.

ORAL SESSION 05: Multi-Organ Transplants: Heart's Plus One (or Two)

Location: South Hall 2

Core Therapies: HEART

Practice Areas: Cardiology, Anesthesiology and Critical Care, Cardiothoracic Surgery

Session Summary: Multi-organ transplantation is increasingly common. Outcomes of multiorgan transplant as well as issues of allocation are explored.

Each presenter will give a **10-minute** PowerPoint presentation, followed by a **5-minute** question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: Maria Dolores Cosio, MD, PhD, Hospital 12 Octubre, Madrid, Spain
Lawrence Czer, MD, Cedars-Sinai Medical Center, Los Angeles, CA, USA

- 3:00 p.m. **(23) New Kidney-After-Heart Allocation Policy: Who Would Benefit from a Rescue Kidney?**
A. L. Zhou¹, A. F. Akbar², J. M. Ruck¹, E. L. Larson¹, S. Rokui¹, D. C. Paneitz¹, E. A. King¹, A. Kilic¹. ¹Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, ²Department of Surgery, Johns Hopkins School of Medicine, Baltimore, MD
- 3:10 p.m. **Q&A**
- 3:15 p.m. **(24) Bridge to Simultaneous Heart-Kidney Transplantation via Extracorporeal Life Support: National Outcomes in the New Heart Allocation Policy Era**
I. Feng¹, P. A. Kurlansky², K. S. Patel¹, M. K. Moroi¹, A. V. Vinogradsky¹, F. Latif³, G. T. Sayer³, N. Uriel³, Y. Naka¹, K. Takeda¹.
¹Division of Cardiothoracic and Vascular Surgery, Department of Surgery, Columbia University Irving Medical Center, New York, NY, ²Department of Surgery, Center of Innovation and Outcomes Research, Columbia University Irving Medical Center, New York, NY, ³Department of Cardiology, Columbia University Irving Medical Center, New York, NY
- 3:25 p.m. **Q&A**
- 3:30 p.m. **(25) Surviving to Safety Net? Post-Transplant Outcomes of Heart Transplant Recipients with Low EGFR**
A. Jawaid, F. Hussain, R. Morlend, C. Wrobel, N. S. Hendren, S. Garg, E. A. Hardin, J. L. Grodin, F. Araj, J. T. Thibodeau, M. Drazner, M. Peltz, M. Farr, L. K. Truby. University of Texas Southwestern Medical Center, Dallas, TX
- 3:40 p.m. **Q&A**
- 3:45 p.m. **(26) Recent Trends in Heart-Liver Transplantation for CHD versus Non-CHD Patients: Has It Changed?**
M. V. Desai¹, A. Mehdizadeh-Shrifi², K. Kulshrestha³, D. Morales⁴. ¹University of Cincinnati, Cincinnati, OH, ²The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Cardiothoracic Surgery, University of Cincinnati, Cincinnati, OH, ⁴Cardiothoracic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
- 3:55 p.m. **Q&A**
- 4:00 p.m. **(27) Combined Triple-Organ Transplantation: Review of Survival Outcomes**
E. G. Dunbar¹, M. Ambrosio², I. F. Tchoukina³, K. B. Shah³, D. A. Bruno⁴, W. A. Julliard⁵, J. Chery⁵, V. Kasirajan⁵, Z. A. Hashmi⁵.
¹Virginia Commonwealth University School of Medicine, Richmond, VA, ²Virginia Commonwealth University School of Medicine, Richmond, VA, ³Division of Cardiology, Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, ⁴Division of Abdominal Transplant, Hume-Lee Transplant Center, Virginia Commonwealth University, Richmond, VA, ⁵Division of Cardiothoracic Surgery, Pauley Heart Center, Virginia Commonwealth University, Richmond, VA
- 4:10 p.m. **Q&A**

WEDNESDAY, 10 APRIL, 2024

3:00 - 4:15 p.m.

ORAL SESSION 06: Now What?! Achieving the Best Outcomes after LVAD

Location: Panorama Hall

Core Therapies: MCS

Practice Areas: Nursing and Allied Health, Cardiology, Cardiothoracic Surgery

Session Summary: This session will explore novel assessments and strategies to achieve the best outcomes for LVAD patients.

Each presenter will give a **10-minute** PowerPoint presentation, followed by a **5-minute** question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: Esther Vorovich, MD, Northwestern University, Chicago, IL, USA
Mahyar Pourriahi, MD, University of Cincinnati, Cincinnati, OH, USA

3:00 p.m. **(28) Inconceivable: Outcomes of Contraception in LVAD-Supported Women of Childbearing Age**
S. Schettle¹, C. Weaver², S. Inglis¹, A. daSilva-deAbreu¹, P. Tang¹, A. Rosenbaum¹. ¹Mayo Clinic, Rochester, MN, ²Abbott Northwestern Hospital, Minneapolis, MN

3:10 p.m. **Q&A**

3:15 p.m. **(29) Social Work Evaluation Domains Related to Caregiver Support and Mental Health are Strong Predictors of Risk of Readmission or Driveline Infection After HeartMate 3 (HM3)**
A. Ladanyi¹, M. R. Carey¹, S. Deluty², C. Shahidi¹, G. M. Mondellini¹, M. Tiburcio², B. Murphy², G. Sayer¹, Y. Kaku¹, N. Uriel¹, K. Takeda¹, M. Pavol¹, M. Yuzefpolskaya¹, P. C. Colombo¹. ¹Columbia University Irving Medical Center, New York, NY, ²New York Presbyterian Hospital, New York, NY

3:25 p.m. **Q&A**

3:30 p.m. **(30) Glucagon-Like Peptide-1 Agonist Use for Obesity Treatment in Patients with Left Ventricular Assist Devices**
M. Edwards, M. Thomas, D. Varghese, L. Truby, C. Wrobel, E. Hardin, J. Thibodeau, M. Drazner, M. Peltz, M. Farr, J. Grodin, N. Hendren. University of Texas Southwestern Medical Center, Dallas, TX

3:40 p.m. **Q&A**

3:45 p.m. **Late-Breaking Abstract Presentation:**

(321) International Multicenter Report on Long Term Outcomes After LVAD Weaning: The VAD Wean Registry
S. R. Patel¹, J. Knerim², E. Birks³, F. Riesgo Gil⁴, D. Goldstein⁵, H. Lamba⁶, A. Nair⁷, B. Sun⁸, J. Schmitto⁹, S. Lundgren¹⁰, P. Shah¹¹, M. Kanwar¹², J. Wald¹³, F. Billia¹⁴, A. Ravichandran¹⁵, R. Cogswell¹⁶, J. Schultz¹⁶, G. MacGowan¹⁷, S. Silvestry¹⁸, U. Jorde¹⁹, F. Sera²⁰, C. Selzman²¹, E. Potapov²², S. Drakos²¹. ¹Montefiore-Einstein, Bronx, NY, ²Deutsches Herzzentrum Berlin, Berlin, Germany, ³University of Kentucky, Louisville, KY, ⁴Harefield Hospital, Harefield, United Kingdom, ⁵Montefiore, New York, NY, ⁶Baylor College of Medicine, Houston, TX, ⁷Baylor, Houston, TX, ⁸Minneapolis Heart Institute, Minneapolis, MN, ⁹Hannover Medical School, Hannover, Germany, ¹⁰University of Nebraska Medical Center, Omaha, NE, ¹¹Inova Heart and Vascular Institute, Washington DC, DC, ¹²Allegheny General Hospital, Pittsburgh, PA, ¹³University of Pennsylvania, Philadelphia, PA, ¹⁴University Health Network, Ontario, ON, Canada, ¹⁵Ascension St. Vincent Indianapolis, Indianapolis, IN, ¹⁶University of Minnesota, Minneapolis, MN, ¹⁷Freeman Hospital, London, United Kingdom, ¹⁸AdventHealth Transplant Institute, Orlando, FL, ¹⁹Montefiore Medical Center, Bronx, NY, ²⁰Osaka University, Osaka, Japan, ²¹University of Utah, Salt Lake City, UT, ²²German Heart Institute, Berlin, Germany

3:55 p.m. **Q&A**

4:00 p.m. **(32) Long-Term Outcomes of Substance Abusers Who Received a Durable Left Ventricular Assist Device (LVAD)**
T. R. Ryan¹, J. Nohl², S. Lehn², M. Urban³. ¹Nebraska Medical Center, Omaha, NE, ²Nebraska Medicine, Omaha, NE, ³UNMC, Omaha, NE

4:10 p.m. **Q&A**

WEDNESDAY, 10 APRIL, 2024

3:00 - 4:15 p.m.

ORAL SESSION 07: From A(spergillus) to Z(oster): Infections Post-Heart Transplant

Location: North Hall

Core Therapies: HEART

Practice Areas: Infectious Diseases, Anesthesiology and Critical Care, Cardiology, Cardiothoracic Surgery, Pediatrics, Pharmacy

Session Summary: Abstracts presented during this session will discuss infectious complications post heart transplant.

Each presenter will give a **10-minute** PowerPoint presentation, followed by a **5-minute** question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: Fabio Luciano, MD, Università degli studi della Campania, Napoli, Italy
Aaron Mishkin, MD, Temple University Hospital, Philadelphia, PA, USA

3:00 p.m. **(33) Pre- and Post-Transplant Diabetes Mellitus and the Risk of Infection and Mortality After Heart Transplantation**
E. Zweck¹, E. Mostofsky¹, S. Gupta¹, M. Kelm², A. Polzin², M. A. Mittleman¹. ¹Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, ²Department of Cardiology, Pulmonology and Vascular Medicine, University Hospital Duesseldorf, Duesseldorf, Germany

3:10 p.m. **Q&A**

3:15 p.m. **Late-Breaking Abstract Presentation:**

(34) Multicenter Clinical Trial to Evaluate the Efficacy of a Preventive Strategy Against Cytomegalovirus Infection in Heart Transplant Patients Based on the Specific T Cells Response

E. García-Romero¹, C. Diez-Lopez¹, O. Bestard², V. Donoso Trenado³, M. García-Cosío⁴, C. Ortiz-Bautista⁵, F. Hernández-Pérez⁶, D. Couto-Mallon⁷, F. Gonzalez-Vilchez⁸, L. De la fuente Galán⁹, L. López-López¹⁰, A. Grande Trillo¹¹, M. Gómez Molina¹², L. Rosenfeld Vilalta¹³, S. Ibáñez Caballero¹³, L. Donadeu Casassas², N. Sabé¹³, J. Gonzalez-Costello¹. ¹Department of Cardiology, Bioheart Group (IDIBELL), Ciber Cardiovascular Group (CIBER-CV), Bellvitge University Hospital, Barcelona, Spain, ²Vall d'Hebron University Hospital, Barcelona, Spain, ³La Fe University Hospital, Valencia, Spain, ⁴12 Octubre University Hospital, Madrid, Spain, ⁵Gregorio Marañón University Hospital, Madrid, Spain, ⁶Puerta de Hierro University Hospital, Madrid, Spain, ⁷A Coruña University Hospital Complex, A Coruña, Spain, ⁸Marqués de Valdecilla University Hospital, Santander, Spain, ⁹Valladolid University Hospital, Valladolid, Spain, ¹⁰Santa Creu i Sant Pau Hospital, Barcelona, Spain, ¹¹Virgen del Rocío University Hospital, Sevilla, Spain, ¹²Virgen de la Arrixaca University Hospital, Murcia, Spain, ¹³Bellvitge University Hospital, Barcelona, Spain

3:25 p.m. **Q&A**

3:30 p.m. **(35) Tolerability and Clinical Efficacy of Letermovir for Primary Cytomegalovirus Prophylaxis After Heart Transplantation**
J. Chow¹, A. Vest², D. DeNofrio², D. Snyderman¹. ¹Infectious Disease, Tufts Medical Center, Boston, MA, ²Cardiology, Tufts Medical Center, Boston, MA

3:40 p.m. **Q&A**

3:45 p.m. **(36) Varicella Zoster Virus Infections Following Pediatric Heart Transplantation: A Review of the Pediatric Health Information System (PHIS) Database**

S. S. Phillip¹, S. Jani¹, L. D. Glass¹, C. M. Mery², C. D. Fraser², C. D. Castleberry¹. ¹Pediatrics, Dell Children's Medical Center, Dell Medical School at The University of Texas at Austin, Austin, TX, ²Department of Surgery & Perioperative Care, Dell Children's Medical Center, Dell Medical School at the University of Texas at Austin, Austin, TX

3:55 p.m. **Q&A**

4:00 p.m. **(37) Fungal Infections After Heart Transplantation: A Single Center Observational Study**

C. A. Trottier¹, A. Martino², M. I. Short³, A. M. Strand¹, A. Vest⁴, M. S. Kiernan⁴, D. Snyderman¹, J. Chow¹. ¹Geographic Medicine and Infectious Diseases, Tufts Medical Center, Boston, MA, ²Internal Medicine, Tufts Medical Center, Boston, MA, ³Tufts Medical Center, Boston, MA, ⁴Cardiology, Tufts Medical Center, Boston, MA

4:10 p.m. **Q&A**

WEDNESDAY, 10 APRIL, 2024

4:30 - 5:45 p.m.

ORAL SESSION 08: The Right Device at the Right Time in Cardiogenic Shock

Location: Congress Hall

Core Therapies: MCS

Practice Areas: Cardiothoracic Surgery, Anesthesiology and Critical Care, Cardiology, Pulmonology

Session Summary: Timing is everything. Implanting the right device at the right time will help guide practitioner of how and when to select which devices and the risks and benefits of all.

Each presenter will give a **10-minute** PowerPoint presentation, followed by a **5-minute** question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: Anthony Panos, MD, MSc, FRCSC, FACS, University of Iowa Hospital and Clinics, Iowa City, IA, USA
Gloria Faerber, MD, Universitätsklinikum des Saarlandes UKS, Homburg/Saar, Germany

- 4:30 p.m. **(38) Clinical Outcomes Among Impella 5.0/5.5 Recipients with Cardiogenic Shock: A Report from The Cardiogenic Shock Working Group**
M. Farr¹, J. Fried², J. Hernandez Montfort³, S. Sinha⁴, M. Kanwar⁵, A. Garan⁶, N. Uriel⁷, B. Li⁸, Q. Kong⁸, P. Sangal⁸, D. Burkoff⁹, N. Kapur¹⁰. ¹University of Texas Southwestern Medical Center, Dallas, TX, ²Columbia University Medical Center, New York, NY, ³Baylor Scott and White Health, Temple, TX, ⁴Inova Fairfax Medical Campus, Fairfax, VA, ⁵Allegheny General Hospital, Pittsburgh, PA, ⁶Beth Israel Deaconess Medical Center, Boston, MA, ⁷New York Presbyterian, New York, NY, ⁸Tufts University Medical Center, Boston, MA, ⁹Cardiovascular Research Foundation, New York, NY, ¹⁰Tufts Medical Center, Boston, MA
- 4:40 p.m. **Q&A**
- 4:45 p.m. **(39) The Impact of the Heart Allocation Policy Change on Pre-LVAD Temporary Mechanical Circulatory Support Utilization and on Outcomes**
J. Money¹, T. Alexy¹, K. Mudy², S. Airhart³, A. Shaffer⁴, J. Kay⁵, D. Emerson⁶, A. Castleberry⁷, M. Hyden⁸, A. Christophy⁹, B. Sun¹⁰. ¹University of Minnesota, Minneapolis, MN, ²Baptist Health, Little Rock, AR, ³Saint Alphonsus, Boise, ID, ⁴Univ of Minnesota, Minneapolis, MN, ⁵Providence, Portland, OR, ⁶Cedars-Sinai Medical Center, Los Angeles, CA, ⁷University of Nebraska Medical Center, Omaha, NE, ⁸Univ of Nebraska Med Ctr, Omaha, NE, ⁹Scripps Clinic, San Diego, CA, ¹⁰Minneapolis Heart Institute, Minneapolis, MN
- 4:55 p.m. **Q&A**
- 5:00 p.m. **(40) Acute Limb Ischemia is an Important Target of Therapy to Decrease In-Hospital Mortality and is Associated with Endovascular Acute Mechanical Circulatory Support in Cardiogenic Shock**
N. K. Kapur¹, S. Vallabhajosyula², A. Kochar³, S. Sinha⁴, B. Li¹, C. Kong¹, P. Natov¹, M. Kanwar⁵, J. Hernandez Montfort⁶, A. Garan⁷, K. John¹, P. Sangal¹, K. Walec¹, P. Zazzali¹, D. Burkhoff⁸. ¹Tufts Medical Center, Boston, MA, ²Warren Alpert Medical School of Brown University, Providence, RI, ³Brigham and Women's Hospital, Boston, MA, ⁴Inova Fairfax Medical Campus, Fairfax, VA, ⁵Allegheny General Hospital, Pittsburgh, PA, ⁶Baylor Scott and White Health, Austin, TX, ⁷Beth Israel Deaconess Medical Center, Boston, MA, ⁸Cardiovascular Research Foundation, New York, NY
- 5:10 p.m. **Q&A**
- 5:15 p.m. **(41) Clinical Outcomes with Intra-Aortic Balloon Pump in Cardiogenic Shock Due to Acute Myocardial Infarction or Heart Failure: A Report from the Cardiogenic Shock Working Group**
A. Bhimaraj¹, N. Kapur², A. Garan³, M. Kanwar⁴, S. Sinha⁵, J. Hernandez Montfort⁶, B. Li², P. Sangal², K. Walec², P. Zazzali², Q. Kong², D. Burkoff⁷. ¹Houston Methodist Hospital, Houston, TX, ²Tufts Medical Center, Boston, MA, ³Beth Israel Deaconess Medical Center, Boston, MA, ⁴Allegheny General Hospital, Pittsburgh, PA, ⁵Inova Fairfax Medical Campus, Arlington, VA, ⁶Baylor Scott and White Health, Big Rock, TX, ⁷Cardiovascular Research Foundation, New York, NY
- 5:25 p.m. **Q&A**
- 5:30 p.m. **(42) ECMO as a Bridge to Thoracic Multi-Organ Transplantation**
E. E. Heng, A. Krishnan, S. Elde, A. Garrison, M. Fawad, C. Ruaengsri, Y. Shudo, B. A. Guenthart, J. Woo, J. W. MacArthur. Cardiothoracic Surgery, Stanford University, Palo Alto, CA
- 5:40 p.m. **Q&A**

WEDNESDAY, 10 APRIL, 2024

4:30 - 5:45 p.m.

ORAL SESSION 09: Inside the Black Box: Insights into Cardiac Organ Preservation

Location: Forum Hall

Core Therapies: HEART

Practice Areas: Cardiothoracic Surgery, Cardiology, Research and Immunology

Session Summary: This session gives information about optimal cold static storage. Furthermore, it showed results on static perfusion compared to hypothermic and normothermic perfusion.

Each presenter will give a **10-minute** PowerPoint presentation, followed by a **5-minute** question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: Jacob Schroder, MD, Duke University Medical Center, Durham, NC, USA
Richard Pierson, MD, Massachusetts General Hospital, Boston, MA, USA

4:30 p.m. **(43) A Newly Produced Polymerized Bovine Hemoglobin and Hemoglobin-Based Heart Preservation Solution Prolonged Preservation Duration of Donor Heart in Cold Static Storage and Reduced Myocardial Injury After Allograft Transplantation**

Z. Zhang¹, X. Wang², C. Niu¹, J. Ji¹, X. Pan¹, P. Zhou¹, S. Zheng¹. ¹Department of Cardiovascular Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, ²Department of Human Anatomy, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China

4:40 p.m. **Q&A**

4:45 p.m. **(44) 12-Hour Hypothermic Heart Preservation in a Pig Model**

G. Mainardi Aguiar da Silva¹, M. J. Wagner¹, S. Hatami¹, P. Hassanzadeh¹, X. Wang¹, J. Nagendran¹, D. Freed². ¹University of Alberta, Edmonton, AB, Canada, ²Stollery Children's Hospital, Edmonton, AB, Canada

4:55 p.m. **Q&A**

5:00 p.m. **(45) Utilizing All the Tools in the 'Box' for Heart Transplantation**

Y. Joshi¹, J. Villanueva², S. Emmanuel¹, D. Cornelius¹, S. Scheuer¹, C. Soto¹, J. Cropper¹, A. Dinale¹, D. Kaye³, D. McGiffin³, A. Iyer¹, A. Watson¹, M. Connellan¹, E. Granger¹, P. Jansz¹, P. MacDonald¹. ¹St Vincent's Hospital Sydney, Sydney, Australia, ²Victor Chang Cardiac Research Institute, Sydney, Australia, ³Alfred Hospital, Melbourne, Australia

5:10 p.m. **Q&A**

5:15 p.m. **(46) Outcomes of DCD Heart Transplant: NRP and OCS**

E. J. Bashian¹, G. B. Gardner¹, M. Ambrosio², I. Tchoukina³, K. Shah³, J. Chery⁴, V. Kasirajan⁵, Z. Hashmi⁴. ¹Department of Surgery, Virginia Commonwealth University, Richmond, VA, ²Virginia Commonwealth University School of Medicine, Richmond, VA, ³Department of Cardiology, Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, ⁴Division of Cardiothoracic Surgery, Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, ⁵Division of Cardiothoracic Surgery, Pauley Heart Center, VCU Health, Richmond, VA

5:25 p.m. **Q&A**

5:30 p.m. **(47) Prolonged Warm Ischemia and Cold Storage Promote Myocardial Edema in Human Hearts Donated After Circulatory Death via Accumulation of Cyclic Guanosine Monophosphate and Aquaporin 1**

N. K. Mondal¹, S. Li¹, K. V. Nordick¹, A. E. Elsenousi¹, R. Bhattacharya¹, R. P. Kirby¹, A. Mattar¹, C. Hochman-Mendez², T. K. Rosengart¹, K. K. Liao¹. ¹Department of Surgery, Baylor College of Medicine, Houston, TX, ²Regenerative Medicine Research, Texas Heart Institute, Houston, TX

5:40 p.m. **Q&A**

WEDNESDAY, 10 APRIL, 2024

4:30 - 5:45 p.m.

ORAL SESSION 10: The Riddle of Antibody-Mediated Rejection: Lungs and the Half-Blood Prince Part I

Location: South Hall 3

Core Therapies: LUNG

Practice Areas: Pulmonology, Cardiothoracic Surgery, Research and Immunology

Session Summary: This session aids in better understanding the mechanisms of pulmonary humoral rejection. It will also outline the impact of antibodies on graft function and survival.

Each presenter will give a **10-minute** PowerPoint presentation, followed by a **5-minute** question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: Gregory Snell, MBBS, FRACP, MD, Alfred Hospital, Melbourne, Australia
Andrew Fisher, FRCP, PhD, Newcastle University, Newcastle upon Tyne, United Kingdom

- 4:30 p.m. **(48) Banff Human Organ Transplant Panel for Detecting Antibody-Mediated Rejection in Lung Transplant Biopsies**
M. Sablik¹, N. Belousova², F. Mezzine¹, J. Dagobert¹, M. Raynaud¹, P. Bruneval¹, O. Aubert¹, C. Lefaucheur¹, A. Loupy¹, A. Roux².
¹Paris Institute for Transplantation and Organ Regeneration, Université Paris Cité, INSERM, U-970, AP-HP, Paris, France, ²Lung Transplantation Department, Foch Hospital, Suresnes, France
- 4:40 p.m. **Q&A**
- 4:45 p.m. **(49) Distinct Non-HLA Antibody Signatures Correlate with Endothelial Crossmatch Status and Lung Function Decline in Lung Transplant Recipients**
M. Bandy¹, F. Alhamdan², A. Coppolino¹, M. Khan¹, A. Sheikh¹, N. Sharma¹. ¹Brigham and Women's Hospital, Boston, MA, ²Boston Children's Hospital, Boston, MA
This presenter is also one of five finalists for the 2024 Early Career Scientist Award. Winner will be announced after the meeting.
- 4:55 p.m. **Q&A**
- 5:00 p.m. **(50) A Serum Autoantibody (AAB) Signature is Associated with Future CLAD**
D. Vosoughi¹, A. Ulahannan¹, A. Chruscinski¹, P. Lombardi¹, J. Semenchuk², T. Martinu³, S. Juvet¹. ¹University Health Network, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Toronto General Hospital/UHN, Toronto, ON, Canada
- 5:10 p.m. **Q&A**
- 5:15 p.m. **(51) A Molecular Criteria for Antibody Mediated Rejection in Lung Transplant Recipients is Associated with an Increased Risk of the Composite Outcome of CLAD and Death**
M. Keller¹, M. Alnababteh¹, L. Ponor², P. Shah³, J. Mathew³, R. Bower¹, H. Kong⁴, T. Andargie⁵, W. Park⁶, A. Charya⁷, T. Intrieri⁸, H. Luikart⁹, S. Aryal¹⁰, S. Nathan¹⁰, J. Orens³, K. Khush¹¹, M. Jang⁶, S. Agbor-Enoh¹. ¹National Institutes of Health, Bethesda, MD, ²Johns Hopkins School of Medicine, Baltimore, MD, ³Johns Hopkins University, Baltimore, MD, ⁴National Heart, Lung, and Blood Institute (NHLBI), NIH, Bethesda, MD, ⁵National Heart, Lung, and Blood Institute, Bethesda, MD, ⁶NHLBI/NIH, Bethesda, MD, ⁷University of Maryland Medical Center, Baltimore, MD, ⁸Stanford University Hospital, Palo Alto, CA, ⁹Stanford Hospital, Palo Alto, CA, ¹⁰Inova Fairfax Hospital, Falls Church, VA, ¹¹Stanford University, Palo Alto, CA
- 5:25 p.m. **Q&A**
- 5:30 p.m. **(52) Transient versus Persistent Donor Specific Antibodies and Outcomes After Lung Transplantation**
S. Auner¹, C. Hillebrand¹, P. M. Boehm¹, J. Boecker¹, D. Koren², S. Schwarz¹, Z. Kovacs¹, G. Murakoezy¹, E. Hielle-Wittmann¹, G. Fischer², C. Aigner¹, K. Hoetzenecker¹, P. Jaksch¹, A. Benazzo¹. ¹Department of Thoracic Surgery, Medical University of Vienna, Vienna, Austria, ²Department of Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, Austria
- 5:40 p.m. **Q&A**

WEDNESDAY, 10 APRIL, 2024

4:30 - 5:45 p.m.

ORAL SESSION 11: Novel Pharmacotherapies for Healing: Lungs and the Goblet of Fire

Location: South Hall 1

Core Therapies: LUNG

Practice Areas: Pharmacy, Cardiothoracic Surgery, Pulmonology, Research and Immunology

Session Summary: This session focuses on novel pharmacotherapies after lung transplantation. It will discuss approaches to guide immunosuppression strategies after transplant, incorporation of novel agents into drug regimens after transplant, as well as the use of newer treatments for rejection.

Each presenter will give a **10-minute** PowerPoint presentation, followed by a **5-minute** question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: Adam Cochrane, PharmD, MPH, Inova Fairfax Hospital, Falls Church, VA, USA
Tara Fallah, PharmD, Ohio State University Wexner Medical Center, Columbus, OH, USA

4:30 p.m. **(53) Pre-Transplant T Lymphocyte Mycophenolic Acid Resistance is Associated with Aberrant Cytokine Production and Acute Rejection Among Lung Transplant Recipients**

L. K. Tague¹, R. Ebenezer², H. Anthony², R. Hachem³, A. Gelman⁴. ¹Department of Medicine, Division of Pulmonary & Critical Care, Washington University in St. Louis, Saint Louis, MO, ²Washington University School of Medicine, St. Louis, MO, ³Washington University School of Medicine, St. Louis, MO, ⁴Washington University School of Medicine, St. Louis, MO

4:40 p.m. **Q&A**

4:45 p.m. **(54) Survival in Alpha-1 Antitrypsin (A1AT) Deficient Lung Transplant Recipients by Use of A1AT Augmentation Therapy**

A. Oak¹, J. Ruck¹, A. Casillan¹, R. Riojas¹, P. Shah¹, J. Ha¹, S. Strout¹, A. Massie², D. Segev², C. Merlo¹, E. Bush¹. ¹Johns Hopkins Medicine, Baltimore, MD, ²NYU Grossman School of Medicine, New York, NY

4:55 p.m. **Q&A**

5:00 p.m. **(55) CD38 Antibody Daratumumab as an Add-On Rescue Therapy for AMR - First Report in Clinical Lung Transplantation**

C. Hillebrand¹, S. Auner¹, D. Koren², G. Fischer², Z. Kovacs¹, P. M. Boehm¹, C. Aigner¹, K. Hoetzenecker¹, F. Calabrese³, P. Jaksch¹, A. Benazzo¹. ¹Department of Thoracic Surgery, Medical University of Vienna, Vienna, Austria, ²Department of Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, Austria, ³Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy

5:10 p.m. **Q&A**

5:15 p.m. **Late-Breaking Abstract Presentation:**

(56) The Multicenter KOALA Study: The Effects of Kaftrio After Lung Transplantation in Cystic Fibrosis

J. P. van Gemert¹, B. Luijk², M. Hellemons³, K. A. Visser¹, C. M. Hansen⁴, R. van der Meer⁵, T. Gan¹, H. van der Vaart¹, O. Akkerman¹, W. N. Steenhuis¹, H. G. Heijerman², E. A. Verschuuren¹. ¹Dept of Pulmonary Diseases and Tuberculosis, University MC Groningen, Groningen, Netherlands, ²Dept of Respiratory Medicine, University MC Utrecht, Utrecht, Netherlands, ³Dept of Respiratory Diseases, Erasmus University MC, Rotterdam, Netherlands, ⁴Dept of Clinical Pharmacy and Pharmacology, University MC Groningen, Groningen, Netherlands, ⁵Dept of Pulmonology, Haha Teaching Hospital, The Hague, Netherlands

5:25 p.m. **Q&A**

5:30 p.m. **Late-Breaking Abstract Presentation:**

(57) Randomized Controlled Trial Comparing Immediate versus Extended Release Tacrolimus; Reducing Calcineurin Inhibitor Related Toxicity in Lung Transplantation Patients; The Revolution Trial

H. Grootjans¹, E. Verschuuren², H. Kerstjens², S. Bakker³, W. Steenhuis⁴, S. Berger⁵, T. Gan². ¹Pulmonology, Tuberculosis and Lung Transplantation, and Internal Medicine, Div of Nephrology, Univ MC Groningen, Groningen, Netherlands, ²Pulmonology, Tuberculosis and Lung Transplantation, Univ MC Groningen, Groningen, Netherlands, ³Dept of Internal Medicine, Div of Nephrology, Univ MC Groningen, Groningen, Netherlands, ⁴Dept of Pulmonology, Tuberculosis and Lung Transplantation, Univ MC Groningen, Groningen, Netherlands, ⁵Internal Medicine, Div of Nephrology, Univ MC Groningen, Groningen, Netherlands

5:40 p.m. **Q&A**

WEDNESDAY, 10 APRIL, 2024

4:30 - 5:45 p.m.

ORAL SESSION 12: Bridging Bench Research to Bedside LVAD Solutions

Location: South Hall 2

Core Therapies: MCS

Practice Areas: Research and Immunology, Anesthesiology and Critical Care, Cardiology, Cardiothoracic Surgery

Session Summary: Translational research is fundamental in order to improve outcomes in LVAD patients. This session presents 5 abstracts that aim to clarify the pathophysiology behind the complications derived from LVAD support and their possible solutions, as well as the benefits derived from LVAD support as bridge to heart transplantation.

Each presenter will give a **10-minute** PowerPoint presentation, followed by a **5-minute** question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: Jose Gonzalez-Costello, MD, MSc, PhD, Bellvitge Hospital, Barcelona, Spain
Melana Yuzepolskaya, MD, Columbia University Medical Center, New York, NY, USA

- 4:30 p.m. **(58) Digoxin Reverses Angiogenic Dysregulation During HeartMate 3 Support by Inhibiting the HIF1- α Signaling Cascade and is Associated with Decreased Risk for Gastrointestinal Bleeding**
S. Vukelic¹, Y. Rochlani¹, C. Diez-Lopez², S. Patel¹, S. Madan¹, D. Fauvel¹, O. Saeed¹, D. Sims¹, J. Borgi³, S. Forest³, D. Goldstein¹, U. Jorde¹. ¹Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY, ²Bellvitge Hospital, Barcelona, Spain, ³Department of Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY
- 4:40 p.m. **Q&A**
- 4:45 p.m. **(59) Myocardial Offloading with a Left Ventricular Assist Device Reduces End Organ Injury**
T. Andargie¹, T. Hill², A. Park¹, N. Redekar², W. Park¹, H. Kong¹, A. Sanders¹, R. Brower¹, I. Cavagna³, J. Goldberg³, M. Jang¹, P. Shah³, H. Valentine⁴, S. Agbor-Enoh¹. ¹National Heart, Lung, and Blood Institute (NHLBI), Bethesda, MD, ²National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, ³Inova Heart and Vascular Institute, Falls Church, VA, ⁴Stanford University School of Medicine, Stanford, CA
- 4:55 p.m. **Q&A**
- 5:00 p.m. **(60) Dynamic and Structural Ophthalmic Evaluation of Continuous-Flow Left Ventricular Assist Device Patients**
P. S. Nanayakkara¹, A. Schulz², C. L. Fraser³, G. Liew⁴, N. Olsen¹, M. Butlin², D. Robson⁵, S. Graham², C. Hayward⁵, K. Muthiah⁵. ¹University of New South Wales, Sydney, Australia, ²Macquarie University, Sydney, Australia, ³The University of Sydney, Sydney, Australia, ⁴Westmead Institute for Medical Research, Sydney, Australia, ⁵St. Vincent's Hospital, Sydney, Australia
- 5:10 p.m. **Q&A**
- 5:15 p.m. **(61) Computational Fluid Dynamics Modelling of the Effect of Outflow Graft Flow on Vessel Wall Deformation: Possible Implications for Aortic Regurgitation Development in Patients with Continuous-Flow LVAD**
G. B. Lopez-Santana¹, S. W. Grant², S. Kore³, A. Sharman⁴, A. De Rosis¹, A. Keshmiri¹, R. Venkateswaran³. ¹Faculty of Science and Engineering, The University of Manchester, Manchester, United Kingdom, ²Division of Cardiovascular Sciences, School of Medical Sciences, The University of Manchester, Manchester, United Kingdom, ³Department of Cardiothoracic Transplantation and Mechanical Circulatory Support, University Hospital of South Manchester Wythenshawe Hospital, Manchester, United Kingdom, ⁴Radiology Department, University Hospital of South Manchester Wythenshawe Hospital, Manchester, United Kingdom
- 5:25 p.m. **Q&A**
- 5:30 p.m. **(62) Sildenafil Modifies Platelet Activation and Reduces Mediators of Vascular Remodeling During Durable Left Ventricular Assist Device Support: A Double-Blind, Placebo-Controlled, Randomized Study**
O. Saeed¹, M. Farooq¹, S. Patel¹, M. Reyes Gil², D. Goldstein¹, J. Kizer³, K. Yazdanbakhsh⁴, U. Jorde¹. ¹Montefiore-Einstein Center for Heart and Vascular Care, Bronx, NY, ²Cleveland Clinic, Cleveland, OH, ³University of California San Francisco, San Francisco, CA, ⁴New York Blood Center, New York, NY
- 5:40 p.m. **Q&A**

WEDNESDAY, 10 APRIL, 2024

4:30 - 5:45 p.m.

ORAL SESSION 13: What's Hot in Pediatric Cardiac Waitlist, Donor Selection, and Management?

Location: Panorama Hall

Core Therapies: HEART

Practice Areas: Pediatrics, Cardiology, Cardiothoracic Surgery

Session Summary: This session features leading pediatric pre-transplant science.

Each presenter will give a **10-minute** PowerPoint presentation, followed by a **5-minute** question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: Melanie Everitt, MD, Children's Hospital Colorado, Aurora, CO, USA
Josef Thul, MD, Children's Heart Center/University of Giessen, Giessen, Germany

- 4:30 p.m. **(63) Decreased Risk of Primary Graft Dysfunction with the SherpaPak Cardiac Transport System in Pediatric Heart Transplant Recipients**
M. R. Varma¹, T. Nasirov², A. B. Goldstone³, E. Lee⁴, M. E. Richmond¹, E. L. Profita⁵. ¹Division of Pediatric Cardiology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, ²Department of Cardiothoracic Surgery, Stanford University School of Medicine, Palo Alto, CA, ³Division of Cardiac, Thoracic, and Vascular Surgery, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, ⁴Solid Organ Transplant Procurement, Lucile Packard Children's Hospital Stanford, Palo Alto, CA, ⁵Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA
- 4:40 p.m. **Q&A**
- 4:45 p.m. **(64) Exception Requests and Approval Rates After Implementation of the National Heart Review Board for Pediatrics**
R. Harris¹, D. Bearl², L. Wright³. ¹Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN, ²Vanderbilt University, Nashville, TN, ³Nationwide Children's Hospital, Columbus, OH
- 4:55 p.m. **Q&A**
- 5:00 p.m. **(65) History of Donor Drug Use and Post-Transplant Survival in Pediatric Heart Transplant Recipients: A Propensity Score Matched Analysis**
P. Estes¹, K. Gauvreau¹, C. Milligan¹, L. Vo², F. Fynn-Thompson³, E. Blume¹, T. Singh¹. ¹Cardiology, Boston Children's Hospital, Boston, MA, ²Cardiology, Boston Children's Hospital, Boston, MA, ³Cardiac Surgery, Children's Hospital, Boston, MA
- 5:10 p.m. **Q&A**
- 5:15 p.m. **(66) Double Bridge to Heart Transplantation: Outcomes of Early vs Delayed ECMO Crossover in the Pediatric Population - An Analysis of the ACTION Registry**
K. Raja¹, M. Shezad², M. O'Connor³, S. M. Peer¹, P. Sinha¹. ¹University of Minnesota, Minneapolis, MN, ²Cincinnati Children's Hospital, Cincinnati, OH, ³Children's Hospital of Philadelphia, Philadelphia, PA
- 5:25 p.m. **Q&A**
- 5:30 p.m. **(67) Making the Most of a Bad Situation: ECMO as a Bridge to Cardiac Transplant**
J. T. Kennedy¹, K. Kulshrestha², J. Greenberg², D. Morales². ¹University of Cincinnati Medical Center, Cincinnati, OH, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH
- 5:40 p.m. **Q&A**

WEDNESDAY, 10 APRIL, 2024

4:30 - 5:45 p.m.

ORAL SESSION 14: Beyond Histology: Looking at Heart Rejection in New Ways

Location: North Hall

Core Therapies: HEART

Practice Areas: Cardiology, Cardiothoracic Surgery, Nursing and Allied Health, Pathology, Research and Immunology

Session Summary: This session focuses on blood based techniques such as cell free DNA and molecular techniques applied to tissue biopsies.

Each presenter will give a **10-minute** PowerPoint presentation, followed by a **5-minute** question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: Anna Kydd, BMedSci, MBChB, MD, Papworth Hospital, Cambridge, United Kingdom
Andrew Kao, MD, St Luke's Health System Kansas City Mid America Heart Institute, Kansas City, MO, USA

- 4:30 p.m. **(68) The Trifecta-Heart Study: Comparing Plasma Donor-Derived Cell-Free DNA to Gene Expression in Endomyocardial Biopsies and a Comparison to Results in Kidney Transplant**
P. F. Halloran¹, M. Mackova², K. S. Madill-Thomsen², Z. Demko³, M. Olymbios³, P. Campbell⁴, V. Melenovsky⁵, T. Gong⁶, S. Hall⁶, J. Stehlik⁷. ¹University of Alberta, Edmonton, AB, Canada, ²Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada, ³Natera, Inc., San Carlos, CA, ⁴Baptist Health Institute, Little Rock, AR, ⁵IKEM, Prague, Czech Republic, ⁶Baylor Scott & White Health, Dallas, TX, ⁷University of Utah, Salt Lake City, UT
- 4:40 p.m. **Q&A**
- 4:45 p.m. **Late-Breaking Abstract Presentation:**
- (69) Heart Transplant Outcomes in the Contemporary Era: Results from the SHORE Registry**
K. Khush¹, N. Uriel², P. Shah³, S. Patel⁴, N. Raval⁵, S. Pinney⁶, S. Hall⁷, E. DePasquale⁸, K. Oreschak⁹, J. Kobulnik⁹, S. Wang⁹, X. Bai⁹, J. Teuteberg¹⁰. ¹Stanford University, Palo Alto, CA, ²New York Presbyterian, New York, NY, ³Inova Heart and Vascular Institute, Fairfax, VA, ⁴Montefiore-Einstein, Bronx, NY, ⁵AdventHealth Transplant Institute, Orlando, FL, ⁶Mount Sinai Morningside, New York, NY, ⁷Baylor University MC, Dallas, TX, ⁸USC, Los Angeles, CA, ⁹CareDx, Brisbane, CA, ¹⁰Stanford University SoM, Palo Alto, CA
- 4:55 p.m. **Q&A**
- 5:00 p.m. **(70) PCR-Based Absolute Quantification of Donor-Derived Cell-Free DNA After Heart Transplantation**
J. Boehmer¹, C. Wasslavik², H. Wahlander², K. Karason², S. Nilsson³, A. Stahlberg⁴, J. Asp⁵, M. Jonsson⁵, A. Ricksten⁵, G. Dellgren². ¹Department of Pediatrics, Institution for Clinical Sciences, Sahlgrenska Academy, Univ of Gothenburg, Göteborg, Sweden, ²Sahlgrenska Univ Hospital, Gothenburg, Sweden, ³Univ of Gothenburg, Gothenburg, Sweden, ⁴Clinical Genomics, Univ of Gothenburg, Gothenburg, Sweden, ⁵Clinical Chemistry, Sahlgrenska Univ Hospital, Gothenburg, Sweden
- 5:10 p.m. **Q&A**
- 5:15 p.m. **(71) Genome-Wide Molecular Analysis of Heart Transplant Endomyocardial Biopsies Separately Analyzing Rejection and Parenchymal Injury**
P. F. Halloran¹, K. S. Madill-Thomsen², M. Mackova², A. Z. Aliabadi-Zuckermann³, M. Cadeiras⁴, M. Crespo-Leiro⁵, M. Deng⁶, J. Goekler³, S. Hall⁷, A. Jamil⁸, D. H. Kim¹, J. Kobashigawa⁹, P. MacDonald¹⁰, J. Patel¹¹, L. Potena¹², K. Shah¹³, J. Stehlik¹⁴, A. Zuckermann³. ¹University of Alberta, Edmonton, AB, Canada, ²Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada, ³Medical University of Vienna, Vienna, Austria, ⁴University of California, Davis, Los Angeles, CA, ⁵A Coruña University Hospital, A Coruña, Spain, ⁶University of California Los Angeles, Los Angeles, CA, ⁷Baylor University Medical Center, Dallas, TX, ⁸Baylor, Scott & White Health, Dallas, TX, ⁹Cedars-Sinai Heart Institute, Los Angeles, CA, ¹⁰St. Vincent 's Hospital, Sydney, Australia, ¹¹Cedars-Sinai Smidt Heart Institute, Los Angeles, CA, ¹²IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, ¹³Virginia Commonwealth University, Richmond, VA, ¹⁴University of Utah, Salt Lake City, UT
- 5:25 p.m. **Q&A**
- 5:30 p.m. **(72) Concomitant Cell-Free DNA and Donor Specific Antibodies: Do They Predict Outcomes After Heart Transplant?**
J. Patel¹, M. Kittleson¹, E. Kransdorf¹, A. Velleca², N. Bhatnagar¹, A. Kanungo¹, M. Lee¹, J. Kermanshahchi¹, L. Czer¹, R. Cole¹, F. Esmailian¹, J. Kobashigawa¹. ¹Cedars-Sinai Smidt Heart Institute, Los Angeles, CA, ²Cedars-Sinai Smidt Heart Institute and Comprehensive Transplant Center, Los Angeles, CA
- 5:40 p.m. **Q&A**

WEDNESDAY, 10 APRIL, 2024

6:00 - 7:00 p.m.

POSTER SESSION 1: Cardiology (Non-CME)

Location: Poster Hall

Core Therapies: HEART, LUNG, MCS, PVD

Practice Areas: Cardiology, Anesthesiology and Critical Care, Cardiothoracic Surgery, Infectious Diseases, Nursing and Allied Health, Pathology, Pediatrics, Pharmacy, Pulmonology, Research and Immunology

Session Summary: Posters in this session include presentations on multiple topics where the Practice Areas of the research is focused in Cardiology. Designated Poster Discussants will circulate through the poster hall during the session to engage poster presenters in quality discussions of their abstracts. **CME is not offered for poster sessions.**

Poster Discussants: Arif Albulushi, USA, Tamas Alexy, USA, Rami Alharethi, USA, Natasha Altman, New Zealand, Shahnawaz Amdani, USA, Markus Barten, Germany, Anju Bhardwaj, USA, Entela Bollano, Sweden, Kelly Bryce, USA, Maria Castel, Spain, Nathalie Chateauvert, Canada, Erin Coglianese, USA, Jennifer Conway, Canada, Jennifer Cook, USA, John Anthony Coppola, USA, Howard Eisen, USA, Eric Epailly, France, Paul Estes, USA, Alexander Fardman, Israel, Alejandro Folch Sandoval, USA, Catalina Gallego, Columbia, Claudia Gidea, USA, Elian Giordanino, Argentina, Hilda Gonzalez Bonilla, USA, Jose Gonzalez Costello, Spain, Hanno Grahn, Germany, Dipankar Gupta, USA, Marta Hernández-Meneses, Spain, Maryl Johnson, USA, Andrew Kao, USA, Michael Kiernan, USA, Steven Kindel, USA, Sudheer Koganti, India, Clive Lewis, UK, Renzo Loyaga-Rendon, USA, Cindy Martin, USA, Sonia Mirabet Perez, Spain, Mrudula Munagala, USA, Nandini Nair, USA, Daryl Nnani, USA, Michal Odermarsky, Sweden, Marish Oerlemans, Netherlands, Carlos Ortiz-Bautista, Spain, Yael Peled, Israel, Christina Phelps, USA, Sowmith Rangu, USA, Roopa Rao, USA, Matthew Regan, USA, Christian Said, Canada, Gaurav Sharma, USA, Aditi Singhvi, India, George Sokos, USA, Swethika Sundaravel, USA, Hanna Tadros, USA, Sarumathi Thangavel, India, Diana Torpoco Rivera, USA, Madeleine Townsend, USA, Jean Luc Vachier, Belgium, George Vetrovec, USA, Rayan Yousefzai, USA

(369) A-Antigen Re-Expression and Prevention of Hyperacute Rejection Following In Vivo Enzymatic Treatment in a Model of ABO-Incompatible Transplantation; T. Erickson¹, B. Motyka¹, K. Tao¹, J. Pearcey¹, P. Rahfeld², J. N. Kizhakkedathu³, M. Cypel⁴, P. J. Cowan⁵, S. G. Withers⁶, L. J. West¹. ¹Pediatrics, University of Alberta, Edmonton, AB, Canada, ²Avivo Biomedical Inc., Vancouver, BC, Canada, ³Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada, ⁴Surgery, University of Toronto, Toronto, ON, Canada, ⁵St. Vincent's Hospital Melbourne, Melbourne, Australia, ⁶Chemistry, University of British Columbia, Vancouver, BC, Canada

(370) Statins Reduce Inflammation, Oxidative Stress and Endothelial Cell Activation in a Model of Venous Congestion in Systolic Heart Failure Patients; F. Castagna¹, B. Z. Wang², B. Fine², S. Jelic², D. Onat², A. Ladanyi², K. Wong², R. A. Friedman², F. Cali², A. Pinsino², R. Demmer³, M. Yuzefpolskaya², P. C. Colombo². ¹Montefiore Medical Center, New York, NY, ²Columbia University Irving Medical Center, New York, NY, ³Mayo Clinic, Rochester, MN

(371) Heart Failure Hospitalizations are Associated with Changes in Gut and Oral Microbiome; B. Bohn¹, A. Ladanyi², E. DeFilippis², K. Clerkin², P. A. Kurlansky², G. Sayer², N. Uriel², K. Takeda², P. C. Colombo², R. Demmer³, M. Yuzefpolskaya². ¹University of Minnesota, Minneapolis, MN, ²Columbia University Irving Medical Center, New York, NY, ³Mayo Clinic, Rochester, MN

(372) Molecular Microscope (MMDx) Results in the Sensitized Heart Transplant Recipient; A. Rahman¹, C. Moeller¹, A. Fernandez Valledor², W. Rzechorzek¹, S. Rahman³, J. Baranowska¹, G. Rubinstein⁴, D. Oren⁵, C. Lee⁶, K. Oh⁷, D. Bae⁸, J. Raikhelkar⁶, D. Lotan⁷, E. DeFilippis⁷, K. Theodoropoulos⁷, J. Fried⁸, K. Clerkin⁷, F. Latif⁹, G. Sayer⁷, N. Uriel¹⁰. ¹Columbia University Irving Medical Center, New York, NY, ²New York Presbyterian, New York, NY, ³Columbia University Medical Center, New York, NY, ⁴Columbia University, New York, NY, ⁵New York Presbyterian, Columbia University, NY, NY, ⁶Columbia University, NY, NY, ⁷Columbia University Irving Medical Center, NY, NY, ⁸Columbia University Medical Center, NY, NY, ⁹NY Presbyterian Hospital, NY, NY, ¹⁰New York Presbyterian, NY, NY

(373) Right Ventricular Dysfunction Correlates with Decreased Endothelial Progenitor Cell Mobilisation and Impaired Angiogenesis in HFpEF Patients; S. Frljak, G. Poglajen, A. Cerar, G. Zemljic, B. Vrtovec. UMC Ljubljana, Ljubljana, Slovenia

(374) Human Myocardial Mitochondrial Function is Impaired in Cardiac Light Chain Amyloidosis but Not in Transthyretin Amyloidosis; F. Voss¹, E. Zweck², F. Nienhaus³, D. Oehler², H. Schultheiss⁴, M. Roden⁵, M. Kelm⁶, J. Szendroedi⁷, A. Polzin⁸, D. Scheiber². ¹University Hospital Duesseldorf, Duesseldorf, Germany, ²University Hospital Düsseldorf, Duesseldorf, Germany, ³University Hospital, Duesseldorf, Germany, ⁴IKDT, Berlin, Germany, ⁵University of Duesseldorf, German Diabetes Center, Duesseldorf, Germany, ⁶Cardiology, University Hospital, Duesseldorf, Germany, ⁷Endocrinology, University Hospital, Heidelberg, Germany, ⁸Cardiology, University Hospital, Duesseldorf, Germany

(375) Uncoupling Iron Deficiency and Anemia in Advanced Heart Failure; C. Diez-Lopez¹, J. Ovalle Ramos², F. Castagna², S. Patel², S. Vukelic², Y. Rochlani², S. Madan², S. Murthy², O. Saeed², J. Shin², D. Sims², J. Gonzalez-Costello¹, J. Comin-Colet¹, U. Jorde². ¹Institut de Recerca Biomedica de Bellvitge, Barcelona, Spain, ²Montefiore Medical Center, Bronx, NY

(376) Phenotyping Iron Deficiency in Advanced Heart Failure Patients: Time to Reconsider Our Evaluation?; C. Diez-Lopez¹, J. Ovalle Ramos², F. Castagna², S. Patel², S. Vukelic², Y. Rochlani², S. Madan², S. Murthy², O. Saeed², J. Shin², D. Sims², J. Gonzalez-Costello¹, J. Comin-Colet¹, U. Jorde². ¹Institut de Recerca Biomedica de Bellvitge, Barcelona, Spain, ²Montefiore Medical Center, Bronx, NY

(377) The Effects of Different Perfusion Parameters on Cardiac Graft Behavior During Langendorff; M. Bolger-Chen¹, M. Lopera Higuaita², C. A. Pendexter¹, M. Mojoudi¹, A. A. Osho³, S. Rabi³, S. N. Tessier². ¹Center for Engineering in Medicine and Surgery, Mass General Hospital, Boston, MA, ²Center for Engineering in Medicine and Surgery, Massachusetts General Hospital - Harvard Medical School, Boston, MA, ³Division of Cardiac Surgery, Massachusetts General Hospital, Boston, MA

(378) Genome-Wide DNA Methylation Profiling in Human Dilated Cardiomyopathy; K. Dhar¹, D. Liescheski¹, M. Urban², A. Burdorf¹, J. Um², B. Lowes¹. ¹Cardiology, University of Nebraska Medical Center, Omaha, NE, ²Surgery, University of Nebraska Medical Center, Omaha, NE

(379) Monogenic and Polygenic Contributions to Early Onset Advanced Heart Failure Based on Whole Genome Sequencing; E. Linner¹, T. Czuba², O. Gidlöf², J. Lundgren², E. Bollano³, M. Hellberg², S. Celik², N. Pimpalwar², P. Rentzsch⁴, M. Martorella⁵, A. Gummesson⁶, O. Melander⁷, S. Albinsson², G. Dellgren³, J. Borén⁶, A. Jeppsson⁸, T. Lumbers⁹, S. Shah¹⁰, J. Nilsson¹¹, P. Natarajan¹², T. Lappalainen⁵, M. Levin⁶, H. Ehrencrona², J. Smith⁶. ¹Department of Cardiology, Lund Univ, Lund, Sweden, ²Lund Univ, Lund, Sweden, ³Sahlgrenska Univ Hospital, Gothenburg, Sweden, ⁴KTH Royal Institute of Technology, Stockholm, Sweden, ⁵Columbia Univ, New York, NY, ⁶Gothenburg Univ, Gothenburg, Sweden, ⁷Lund Univ, Malmö, Sweden, ⁸Salgrenska Univ Hospital, Gothenburg, Sweden, ⁹Univ College London, London, United Kingdom, ¹⁰Univ of Queensland, St Lucia, Australia, ¹¹Skanes Univ Hospital, Lund, Sweden, ¹²Massachusetts General Hospital, Boston, MA

(380) Sudden Cardiac Death: The Utility of Genetic Screening Using NGS in Kazakhstan; A. Akilzhanova¹, M. Zhalbinova¹, A. Chamoieva¹, D. Samatkyzy¹, T. Shahmarova¹, Z. Mirmanova¹, S. Rakhimova¹, G. Akilzhanova², U. Kozhamkulov¹, K. Akilzhanov², U. Kairov³, T. Polyakova⁴, T. Zhakupova⁴, M. Bekbosynova⁵, D. Sarbassov⁶. ¹Laboratory of Genomic and Personalized Medicine, Center for Life Sciences, National Laboratory Astana, Nazarbayev University, Astana, Kazakhstan, ²Semey Medical University, Pavlodar Branch, Pavlodar, Kazakhstan, ³Laboratory of Bioinformatics and Computational Systems Biology, Center for Life Sciences, National Laboratory Astana, Nazarbayev University, Astana, Kazakhstan, ⁴Medical University Astana, Center for Forensic Medicine, Astana, Kazakhstan, ⁵National Research Cardiac Surgery Center, Astana, Kazakhstan, ⁶School of Science and Humanities, Center for Life Sciences, National Laboratory Astana, Nazarbayev University, Astana, Kazakhstan

(381) WITHDRAWN

(382) Genetic Screening of Associated Cardiac Disease in a Single Center Heart Transplant Cohort; S. Lee¹, M. Y. Ju², M. Y. In Young³. ¹Cardiology, Pusan National University Yangsan H., Yangsan, South Korea, ²Cardiovascular Surgery, Pusan National University Yangsan Hospital, Yangsan, South Korea, ³Pusan National University Yangsan Hospital, Yangsan, South Korea

(383) Real World Use of the Cardiac Allograft Vasculopathy (CAV) Score to Monitor for CAV After Heart Transplant; J. Kobashigawa¹, M. Kittleson², D. Chang², B. Azarbal², M. Lee², N. Bhatnagar², A. Kanungo², E. Kransdorf², M. Hamilton², L. Czer², F. Esmailian², J. Patel². ¹Cedars-Sinai Heart Institute, Los Angeles, CA, ²Cedars-Sinai Smidt Heart Institute, Los Angeles, CA

(384) Early Onset Malignancy in the First-Year After Heart Transplantation; O. Babalola¹, N. Motayagheni¹, J. Patel¹, M. Kittleson², A. Kanungo¹, N. Bhatnagar¹, M. Lee¹, D. Chang¹, R. Cole¹, T. Gunn¹, L. Czer¹, J. Kobashigawa¹. ¹Cedars-Sinai Smidt Heart Institute, Los Angeles, CA, ²Cedars-Sinai Heart Institute, Los Angeles, CA

(385) Coronary Artery Bypass Grafting After Orthotopic Heart Transplantation; S. Chandrasekhar¹, A. Agrawal², R. Wu¹, J. Shoemaker¹, D. Rinde-Hoffman¹. ¹Heart Failure Center, Heart & Vascular Institute, University of South Florida Morsani College of Medicine and Tampa General Hospital, Tampa, FL, ²AdventHealth Medical Group Transplant Institute, Orlando, FL

(386) Lower Platelet Count Following Induction with Antithymocyte Globulin is Associated with a Lower Incidence of Cardiac Allograft Vasculopathy; B. Skoric¹, D. Fabijanovic², P. Mjehovic², A. Nekić², N. Jakus², I. Planinc², M. Pasalic², H. Jurin², J. Samardzic¹, M. Cikes¹, H. Gasparovic³, Z. Colak⁴, D. Milicic¹. ¹Department of Cardiovascular Diseases, University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Croatia, ²Department of Cardiovascular Diseases, University Hospital Centre Zagreb, Zagreb, Croatia, ³Department of Cardiac Surgery, University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Croatia, ⁴Department of Anesthesiology, Resuscitation and Intensive Care Medicine, University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Croatia

(387) Circulating Progenitor Cells, Cardiac Allograft Vasculopathy, and Outcomes in Heart Transplant; K. Patel¹, M. E. Gold, A. Yadalam, Y. Ko, P. Patel, J. Waller, A. S. Gillet, A. Panagopoulos, A. Alkholder, Z. Siddiqui, O. Khawaja, H. Allaqaband, S. Sakr, A. Rahbar, Y. Haroun, H. Hashmi, A. Shamim, K. Ejaz, D. Gupta, W. Book, A. A. Quyyumi. Emory University, Atlanta, GA

(388) Effect of Basiliximab versus Rabbit Anti-Thymocyte Globulin on Cardiac Allograft Vasculopathy Progression After Heart Transplantation; E. Ródenas Alesina¹, L. Kugathasan¹, F. Foroutan², M. McDonald³, H. Ross³, A. Alba³. ¹University Health Network, Toronto, ON, Canada, ²Ted Rogers Centre for Heart Research, Toronto, ON, Canada, ³Toronto General Hospital, Toronto, ON, Canada

(389) CAV Trajectories Among Patients with No or Mild CAV at 10 Years Post-Transplant; E. S. Harris, N. Prasad, D. Skoll, J. Fried, V. K. Topkara, J. Raikhelkar, E. M. DeFilippis, F. Latif, M. Yuzefpolskaya, P. C. Colombo, G. Sayer, N. Uriel, K. J. Clerkin. *Columbia University Irving Medical Center, New York, NY*

(390) CAV Grading by PET Provides Improved Risk Stratification Compared to CA; N. Prasad, E. S. Harris, J. Fried, V. K. Topkara, J. Raikhelkar, E. M. DeFilippis, F. Latif, M. Yuzefpolskaya, P. C. Colombo, G. Sayer, N. Uriel, A. J. Einstein, K. J. Clerkin. *Columbia University Irving Medical Center, New York, NY*

(391) CAV by PET/MBF Has Robust Negative Predictive Value for Development of Moderate to Severe CAV; N. Prasad, E. S. Harris, J. Fried, V. K. Topkara, J. Raikhelkar, E. M. DeFilippis, F. Latif, M. Yuzefpolskaya, P. C. Colombo, G. Sayer, N. Uriel, A. J. Einstein, K. J. Clerkin. *Columbia University Irving Medical Center, New York, NY*

(392) Intravascular Imaging Volumetric Analysis of Early Cardiac Allograft Vasculopathy: Head-to-Head Comparison of Serial Paired Intravascular Ultrasound and Optical Coherence Tomography; R. Bajaj¹, S. Chih², V. Dzavik³, D. So¹, N. Aleksova⁴, C. Overgaard⁵, R. S. Beanlands¹, G. A. Wells¹, J. Bernick¹, L. Mielniczuk², E. Stadnick², C. McGuinty¹, H. Ross⁴, A. Chong¹. ¹*Ottawa Heart Institute, Ottawa, ON, Canada*, ²*University of Ottawa Heart Institute, Ottawa, ON, Canada*, ³*University of Toronto, Toronto, ON, Canada*, ⁴*Toronto General Hospital, Toronto, ON, Canada*, ⁵*Southlake Regional Healthcare Centre, Ottawa, ON, Canada*

(393) Longitudinal Physiologic and Anatomic Assessment of Cardiac Allograft Vasculopathy in Heart Transplant Recipients; A. Birs¹, A. Park², E. Adler², F. Contijoch³, K. Hong². ¹*UC San Diego Health, La Jolla, CA*, ²*UC San Diego Health, San Diego, CA*, ³*UC San Diego, Bioengineering and Radiology, San Diego, CA*

(394) Consistent Sublingual Microvascular Health Among Heart Transplant Recipients Regardless of Coronary Allograft Vasculopathy Status; C. M. Moeller, A. Fernandez Valledor, D. Oren, C. Lee, S. Rahman, J. Baranowska, G. Rubinstein, D. Lotan, E. M. DeFilippis, J. K. Raikhelkar, K. J. Clerkin, J. A. Fried, F. Latif, N. Uriel, G. T. Sayer. *Columbia University Irving Medical Center, New York, NY*

(395) Implications of ABO Unmatched Donors on Cardiac Allograft Rejection Assessed by the Molecular Microscope (MMDx); C. M. Moeller, A. Fernandez Valledor, D. Oren, J. Baranowska, G. Rubinstein, C. Lee, S. Rahman, K. Oh, D. Bae, D. Lotan, E. M. DeFilippis, J. Fried, K. Theodoropoulos, K. Clerkin, F. Latif, J. Raikhelkar, N. Uriel, G. T. Sayer. *Columbia University Irving Medical Center, New York, NY*

(396) Sex Differences in Allograft Rejection After Heart Transplantation (HT). Molecular Microscope (MMDx) Results; C. Moeller¹, A. Fernandez Valledor¹, S. Rahman¹, D. Oren¹, D. Lotan¹, G. Rubinstein¹, Y. Mehlman¹, J. Raikhelkar¹, M. Yuzefpolskaya², E. M. DeFilippis¹, J. Fried², K. Clerkin¹, N. Uriel³, G. T. Sayer¹. ¹*Columbia University Irving Medical Center, New York, NY*, ²*Columbia University Medical Center, New York, NY*, ³*New York Presbyterian, New York, NY*

(397) Heart Allograft Recovery Using Temperature-Controlled Cold Storage is Associated with Decreased Myocardial Injury; L. K. Truby, H. Beaini, J. S. Murala, C. Heid, A. Weston, A. Gorrai, S. Garg, M. Farr, M. Peltz. *UT Southwestern Medical Center, Dallas, TX*

(398) Donor-Derived Cell-Free DNA is Elevated in Donation After Circulatory Death; I. Dumitru¹, V. Ravichandran², D. Lee³, E. Matthews¹, B. Mackie¹. ¹*Tampa General Hospital, Tampa, FL*, ²*CareDx, Los Angeles, CA*, ³*University of South Florida, Tampa, FL*

(399) Association Between Pre-Transplant Mechanical Circulatory Support Status and Donor-Derived Cell-Free DNA Levels and Gene Expression Profiling Following Heart Transplant; A. Ravichandran¹, I. Dumitru², M. Kamath³, M. Deng⁴, K. Oreschak⁵, P. Hanson⁵, S. Wang⁵, S. Hall⁶. ¹*Ascension St. Vincent Indianapolis, Indianapolis, IN*, ²*Tampa General Hospital, Tampa, FL*, ³*UCLA, Los Angeles, CA*, ⁴*David-Geffen Sch Med, Los Angeles, CA*, ⁵*CareDx, Brisbane, CA*, ⁶*Baylor University Medical Center, Dallas, TX*

(400) Outcome of Implementation of a Cardiogenic Shock Program in a Large Quaternary Center; I. Dumitru¹, D. Rinde-Hoffman², L. Schnell¹, M. Seviliano¹. ¹*Tampa General Hospital, Tampa, FL*, ²*Tampa General Med Grp, Tampa, FL*

(401) Effect of the Organ Care System on the Number of Transplants and Waiting Time; B. Schnegg¹, M. Martinelli¹, J. Consiglio¹, H. Roger², P. Tozzi², A. Flammer³, M. Wilhelm³, T. Aigner³, N. Kruegel⁴, F. Immer⁴, M. Siepe¹, D. Reineke¹. ¹*Univ Hospital of Bern, Inselspital, Bern, Switzerland*, ²*Lausanne Univ Hospital, Lausanne, Switzerland*, ³*Univ Hospital Zürich, Zürich, Switzerland*, ⁴*SwissTransplant, Bern, Switzerland*

(402) Post-Transplant VO2peak, It's Time for a New Standard!; B. Schnegg, J. Bruno, M. Wilhelm, N. Brugger, L. C. Hunziker Munsch, M. Martinelli, S. Georgios. *University Hospital of Bern, Inselspital, Bern, Switzerland*

(403) Outcomes of Biopsy Negative but MMDx-Positive Biopsies After Heart Transplant: Are There Consequences?; M. Kittleson, J. Patel, A. Nikolova, D. Geft, M. Lee, N. Bhatnagar, A. Kanungo, P. Deckerman, J. Moriguchi, L. Czer, D. Emerson, J. Kobashigawa. *Cedars-Sinai Smidt Heart Institute, Los Angeles, CA*

(404) Rationale, Design and Patient Characteristics from The DevelopmEnt of Non-Invasive Cell-Free DNA to Supplant INvasivE Biopsy in Heart Transplantation (DEFINE-HT) Study; P. Shah¹, K. H. Schlendorf², P. J. Kim³, J. L. Kennedy¹, O. Wever-Pinzon⁴, J. N. Nativi Nicolau⁵, E. Hsich⁶, M. M. Givertz⁷, A. D. DeVore⁸, K. Ghafourian⁹, E. Kransdorf¹⁰, J. Patel¹⁰, M. M. Colvin¹¹, H. J. Eisen¹², K. Marshall¹³, S. Carey¹³, M. Olymbios¹³, M. R. Mehra⁷, J. Stehlik⁴. ¹Inova Schar Heart and Vascular Institute, Falls Church, VA, ²Vanderbilt Univ MC, Nashville, TN, ³UC San Diego, La Jolla, CA, ⁴Univ of Utah SoM, Salt Lake City, UT, ⁵Mayo Clinic, Jacksonville, FL, ⁶Cleveland Clinic, Cleveland, OH, ⁷Brigham and Women's Hosp and Harvard Med Sch, Boston, MA, ⁸Duke Univ SoM, Durham, NC, ⁹Northwestern Memorial Hosp, Chicago, IL, ¹⁰Smidt Heart Institute, Cedars-Sinai MC, Los Angeles, CA, ¹¹Univ of Michigan Health System, Midland, MI, ¹²Jefferson Health, Philadelphia, PA, ¹³Natera, Inc., Austin, TX

(405) Accuracy of Clinical Diagnosis in Advanced Heart Failure Patients Undergoing Transplantation and Impact of Genetic Testing; W. Watson, S. Mathai, C. Papadopoulou, S. Preston, M. Goddard, S. Bhagra, C. Lewis, L. Martinez Marin, S. Pettit, J. Parameshwar, A. Kydd. *Transplant Department, Royal Papworth Hospital, Cambridge, United Kingdom*

(406) WITHDRAWN

(407) Screening of Advanced Heart Failure Features Among Patients with LVEF <35%; S. Vila-Sanjuán, E. Ródenas-Alesina, A. Olivella, T. Soriano-Colome, A. Mendez Fernandez, A. Uribarri, I. Ferreira-González. *Vall d'Hebron University Hospital, Barcelona, Spain*

(408) A Two-Threshold dd-cfDNA Algorithm for Detection of Rejection After Heart Transplant; P. J. Kim¹, M. Olymbios², K. Sideris³, O. Wever-Pinzon³, T. Tran¹, N. Kaur², S. Carey², Y. Chen², D. Barnes², E. Ahmed², Z. P. Demko², A. Prewett², E. Adler¹, J. Stehlik³. ¹University of California San Diego, La Jolla, CA, ²Natera, Inc., Austin, TX, ³University of Utah School of Medicine, Salt Lake City, UT

(409) ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography Can be a Novel Diagnostic Tool for Detecting Acute Cellular Rejection Following Heart Transplantation; T. Yoshitake¹, T. Fujino², S. Yamamoto¹, T. Hashimoto¹, T. Suenaga¹, K. Shinohara¹, S. Matsushima¹, Y. Kitamura³, H. Komman⁴, M. Toyosawa⁴, T. Ide¹, A. Shiose⁵, S. Kinugawa¹. ¹Cardiovascular Medicine, Kyushu University, Fukuoka, Japan, ²Advanced Cardiopulmonary Failure, Kyushu University, Fukuoka, Japan, ³Clinical Radiology, Kyushu University, Fukuoka, Japan, ⁴Nursing, Kyushu University Hospital, Fukuoka, Japan, ⁵Cardiovascular Surgery, Kyushu University, Fukuoka, Japan

(410) Free-Breathing Cardiac Magnetic Resonance CMR Oedema Assessment in Acute Cardiac Rejection; H. Rajabali, N. Quaife, N. Miaris, C. Borguezan Daros, S. Hadjiphilippou, O. Dar, F. Riesgo Gil, A. Morley-Smith, R. Bannerjee, M. Usman, O. Mukhtar, J. Dunning, K. Chow, P. Kellman, C. Buccarelli-Ducci, J. Wong. *Harefield Hospital, Royal Brompton and Harefield Hospitals, London, United Kingdom*

(411) Ultrasound Assessment of Pulmonary Artery Stiffening Associated with Pulmonary Hypertension in Left Heart Disease; M. M. Kucherenko¹, M. Kukucka¹, P. Sang¹, N. Hegemann², F. Hennig¹, R. Yeter¹, T. Gransar¹, A. Mladenow¹, A. Emmerich¹, A. Orsenigo¹, J. Grune², V. Falk¹, W. M. Kuebler², C. Knosalla³. ¹Deutsches Herzzentrum der Charité, Berlin, Germany, ²Charité – Universitätsmedizin Berlin, Berlin, Germany, ³Deutsches Herzzentrum Berlin, Berlin, Germany

(412) Linking Anatomical and Functional Insights: A Study of Coronary Computed Tomography Angiography in Heart Transplant Patients; M. Belmonte¹, P. Paolisso², M. Viscusi², J. Bartunek³, M. Vanderheyden⁴. ¹Cardiovascular Center OLV Aalst, Belgium, Aalst, Belgium, ²Cardiovascular Center OLV Aalst, Aalst, Belgium, ³OLV Hospital, Aalst, Belgium, ⁴Cardiovascular Center, OLV Hospital, Aalst, Belgium

(413) Outcomes of Heart Transplant Recipients with Highly Elevated Donor-Derived Cell-Free DNA Values: A Single Center Experience; I. Bole, B. Foreman, V. Franco, G. Haas, A. Hasan, V. Patel, A. Vallakati, B. Lampert. *The Ohio State Univ Wexner Medical Center, Columbus, OH*

(414) Diminished Microvascular Health in Heart Transplant Recipients Relative to Healthy Controls; A. Fernandez Valledor¹, C. Moeller¹, D. Oren¹, G. Rubenstein¹, J. Baranowska¹, S. Rahman¹, C. Lee¹, K. Oh¹, D. Bae¹, J. Raikhelkar¹, V. Topkara¹, M. Yuzefpolskaya¹, P. Colombo¹, D. Lotan¹, E. M. DeFilippis¹, K. Theodoropoulos¹, J. Fried¹, E. Lin¹, D. Majure², K. Clerkin¹, F. Latif¹, G. Sayer¹, N. Uriel¹. ¹Columbia University Irving Medical Center, New York, NY, ²Weill Cornell Medical College, New York, NY

(415) Microvascular Responses to Donor Specific HLA Antibodies in Heart Transplantation. Sidestream Dark Field Imaging Results; A. Fernandez Valledor, C. Moeller, J. Baranowska, S. Rahman, C. Lee, G. Rubinstein, D. Oren, K. Theodoropoulos, K. Oh, F. Latif, J. Fried, G. Sayer, N. Uriel. *Columbia University Irving Medical Center, New York, NY*

(416) Impact of Race Mismatch in Allograft Rejection After Heart Transplantation. Molecular Microscope (MMDx) Results; A. Fernandez Valledor, C. M. Moeller, J. Baranowska, D. Oren, G. Rubinstein, S. Rahman, C. Lee, Y. Mehlman, S. Slomovich, D. Lotan, E. M. DeFilippis, D. Bae, A. Rahman, R. Shah, K. Oh, J. Fried, K. Clerkin, K. Theodoropoulos, G. T. Sayer, N. Uriel, F. Latif. *Columbia University Irving Medical Center, New York, NY*

(417) Clinical Implications of Borderline Rejection Assessed by Molecular Microscope; A. Fernandez Valledor¹, G. Rubinstein¹, C. M. Moeller¹, S. Slomovich¹, D. Oren¹, J. Baranowska¹, S. Rahman¹, C. Lee¹, K. Oh¹, D. Bae¹, J. Raikhelkar¹, V. Topkara¹, M. Yuzefpolskaya¹, P. Colombo¹, D. Lotan¹, E. M. DeFilippis¹, K. Theodoropoulos¹, J. Fried¹, R. Salazar¹, J. Lindkens¹, B. Fuselier¹, C. Heineken¹, E. Lin¹, D. Majure², K. Clerkin¹, F. Latif¹, N. Uriel¹, G. Sayer¹. ¹Columbia University Irving Medical Center, New York, NY, ²Weill Cornell Medical College, New York, NY

(418) Clinical Utility of Molecular Microscope Diagnostic System (MMDx) in Heart Transplant Recipients: Moving Towards a New Paradigm; A. Fernandez Valledor¹, C. M. Moeller¹, G. Rubinstein¹, S. Rahman¹, J. Baranowska¹, C. Lee¹, D. Oren¹, Y. Mehlman¹, S. Slomovich¹, J. Lindekens¹, B. Fuselier¹, R. Salazar¹, C. A. Hennecken¹, E. M. DeFilippis¹, K. Theodoropoulos¹, V. Topkara¹, M. Yuzefpolskaya¹, P. Colombo¹, D. Lotan¹, D. Bae¹, E. Lin¹, K. Oh¹, D. Majure², J. Fried¹, J. Raikhelkar¹, K. Clerkin¹, F. Latif¹, G. T. Sayer¹, N. Uriel¹. ¹Division of Cardiology, Center of Advanced Cardiac Care, Columbia University Irving Medical Center, New York, NY, ²Weill Cornell Medical College, New York, NY

(419) Impact of MTOR Inhibitors on Heart Allograft Rejection Using Tissue-Based Gene-Expression Profiling. Molecular Microscope (MMDx) Results; A. Fernandez Valledor¹, C. M. Moeller¹, G. Rubinstein¹, D. Oren¹, S. Rahman¹, J. Baranowska¹, C. Lee¹, S. Slomovich¹, D. Lotan¹, J. Fried¹, E. M. DeFilippis¹, J. Raikhelkar¹, K. Theodoropoulos¹, F. Latif¹, M. Yuzefpolskaya¹, K. Clerkin¹, G. T. Sayer¹, N. Uriel¹, D. Majure². ¹Columbia University Irving Medical Center, New York, NY, ²Weill Cornell Medical College, New York, NY

(420) Trajectories of Early Hemodynamic Changes After Heart Transplantation: The Evil is in the Details; M. Masetti¹, A. Piermartiri¹, M. Scuppa¹, L. Giovannini¹, P. Prestinenzi¹, M. Silenzi¹, M. Sabatino¹, L. Borgese², S. Martin Suarez³, L. Potena¹. ¹Heart Failure and Transplant Unit, IRCCS Azienda Ospedaliero-Univ di Bologna, Bologna, Italy, ²Heart Failure and Transplant Unit, IRCCS Azienda Ospedaliero-Univ di Bologna, Univ of Bologna, Bologna, Italy, ³Div of Cardiac Surgery, Cardiac Surgery Dept, IRCCS, Azienda Ospedaliero-Univ di Bologna, Bologna, Italy

(421) The Enigma of Elevated Donor-Derived Cell-Free DNA with Negative Endomyocardial Biopsy; M. Gamero¹, M. Liotta¹, S. Marek-Iannucci¹, G. Gibson², S. Masri³, J. Rame¹, E. Storzynsky¹, H. Eisen⁴, R. Alvarez⁴, I. Rajapreyar¹, Y. Brailovsky¹. ¹Thomas Jefferson Univ Hosp, Philadelphia, PA, ²Northwell, Philadelphia, PA, ³Univ of Wisconsin, Philadelphia, PA, ⁴Thomas Jefferson Univ, Philadelphia, PA

(422) Acquisition of High-Quality Pulmonary Ultrasound Images in the Heart Failure Clinic Following a Short Period of Training; D. Golombek, R. Khandokar, D. Fu, A. Provenzale, M. McGee, M. Lin, D. Rossi, S. Maybaum. Department of Cardiology, Northwell Health, Zucker School of Medicine at Hofstra/Northwell; North Shore University Hospital, Manhasset, NY

(423) Essential Strategies to Sustain the First Cardiac Transplant Program in an Ultraperipheral Region: Extended Criteria Donor Hearts and Donation After Circulatory Death; M. Groba Marco¹, M. Galvan-Ruiz², M. Fernandez-de-Sanmamed², J. Bautista-Garcia², M. Tout-Castellano³, S. Urso⁴, Y. Sosa-Dominguez⁵, C. Ridings-Figueroa⁵, A. Torres-Clares⁴, E. Caballero-Dorta², A. Garcia-Quintana². ¹Universidad de Las Palmas de Gran Canaria, Las Palmas, Spain, ²Cardiology, Hospital Universitario de Gran Canaria Dr. Negrin, Las Palmas, Spain, ³Transplant Coordination, Hospital Universitario de Gran Canaria Dr. Negrin, Las Palmas, Spain, ⁴Cardiac Surgery, Hospital Universitario de Gran Canaria Dr. Negrin, Las Palmas, Spain, ⁵Critical Care Unit, Hospital Universitario de Gran Canaria Dr. Negrin, Las Palmas, Spain

(424) Outcomes with Normothermic Regional Perfusion: Comparison with Core-Cooling During DCD Heart Transplantation; G. Vaidya, A. Elezaby, R. Ha, E. Nishime, H. Parekh, D. Scoville, B. Varr, C. Woo, S. Adatya. Kaiser Permanente Medical Center, Santa Clara, CA

(425) Exploring Innovative Approaches to Enhance Donor Heart Utilization: Moving Beyond the Ideal Donor Paradigm; A. Venkatraman¹, L. Pi¹, M. Signorile², C. Fan², D. Belzile³, A. Alba¹, C. Shelton⁴, J. Duero Posada¹, N. Aleksova⁵, A. Luk¹, H. Ross¹, M. McDonald¹, J. Alvarez¹, Y. Moayed¹. ¹University Health Network, Toronto, ON, Canada, ²Ted Rogers Computational Program, University Health Network, Toronto, ON, Canada, ³IUCPQ, Quebec City, QC, Canada, ⁴Ajmera Transplant Centre, University Health Network, Toronto, ON, Canada, ⁵University Health Network, Women's College Hospital, Toronto, ON, Canada

(426) Impact of Occurrence of Cardiac Arrest on Post-transplant Survival in Brain-Dead Donors : A French National Cohort Study; N. Abdoul¹, C. Legeai¹, S. Varnous², S. Pattier³, V. Chalignac⁴, C. Goeminne⁵, K. Nubret⁶, F. Kerbaul¹, R. Dorent¹. ¹Agence de la Biomédecine, Saint-Denis, France, ²Hosp Pitie Salpetriere, Paris, France, ³Hosp Nord G Et R Laennec, Nantes, France, ⁴Hopital Timone Adultes, Marseille, France, ⁵Ctre Hosp Reg. Univ De Lille, Lille, France, ⁶Hospital De Haut Leveque, Bordeaux, France

(427) Waitlist and Post-Transplant Outcomes of Patients Listed for Heart-Lung Transplantation After Implementation of the 2018 French Heart Allocation System; N. Abdoul¹, C. Legeai¹, J. Le Pavec², L. Savale³, S. Renard⁴, S. Hascoet², C. Merveilleux du Vignaux⁵, O. Mercier², F. Kerbaul¹, R. Dorent¹. ¹Agence de la Biomédecine, Saint-Denis, France, ²Hôpital Marie Lannelongue, Le Plessis-Robinson, France, ³Bicetre Hospital, Paris, France, ⁴La Timone Hospital APHM, Marseille, France, ⁵Hôpital Louis Pradel, Bron, France

(428) Characteristics of Potential Circulatory-Death Heart Donors in France; G. Santin¹, N. Abdoul¹, C. Legeai², R. Bronchard¹, C. Antoine¹, F. Kerbaul¹, R. Dorent². ¹Agence de la Biomedecine, Saint Denis, France, ²Agence de la Biomédecine, Saint Denis, France

(429) Early Cardiac and Renal Complication Risk in Donor After Circulatory Death Heart Transplantation; J. N. Njoroge¹, E. Henricksen², K. Khush¹. ¹Stanford University, Palo Alto, CA, ²Stanford Healthcare, Palo Alto, CA

(430) Myocardial Bridge in Donor Heart is Not Associated with Worse Survival After Orthotopic Heart Transplant; T. Alexy¹, S. Madan², Y. Rochlani², R. John¹, S. Patel², C. Gjelaj², O. Saeed², D. Sims², J. Borgi³, S. Forest³, D. Goldstein², U. Jorde², S. Vukelic². ¹Cardiovascular Division and Lillehei Heart Institute, University of Minnesota School of Medicine, Minneapolis, MN, ²Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY, ³Department of Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY

(431) Prognostic Value of Ambulatory Status at Transplant in Older Heart Transplant Recipients: Implications for Organ Allocation Policy; J. Youn¹, J. Hyun², H. Kim¹, S. Lee², D. Kim³, I. Kim⁴, H. Lee⁵, S. Kang⁶, J. Choi³. ¹Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea, ²Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea, ³Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁴Keimyung University Dongsan Hospital, Daegu, South Korea, ⁵Seoul Nat'l Univ Hospital Seoul National University Hospital, Seoul, South Korea, ⁶Severance Cardiovascular Hospital, Yonsei University of College of Medicine, Seoul, South Korea

(432) Impact of Blood Type on Pre- and Post-Transplant Outcomes in Patients with Continuous-Flow Left Ventricular Assist Devices Listed for Orthotopic Heart Transplant; E. Flattery¹, S. D. Maidman², A. Singh¹, A. Reyentovich¹, D. E. Smith³, N. Moazami³, R. I. Goldberg¹. ¹Division of Cardiology, NYU Langone Medical Center, New York, NY, ²Division of Cardiology and Cardiovascular Surgery, Mount Sinai Health System, New York, NY, ³Division of Cardiothoracic Surgery, NYU Langone Medical Center, New York, NY

(433) Impact of the New 2018 US Donor Heart Allocation System on the Long-Term Outcomes in Patients with Hypertrophic Cardiomyopathy; M. Mazur¹, A. Carmona Rubio², E. Popjes³, G. Bhat⁴, R. Dowling⁵, H. Eisen⁶. ¹Heart & Vascular Institute, Kaufman Center for Heart Failure, Cleveland Clinic, Cleveland, OH, ²Heart & Vascular Institute, Kaufman Center for Heart Failure, Cleveland Clinic, Cleveland, OH, ³Heart & Vascular Institute, Milton S. Hershey MC, Hershey, PA, ⁴Heart & Vascular Center, The Christ Hospital, Cincinnati, OH, ⁵Heart & Vascular Center, The Christ Hospital & Lindner Research & Education Center, Cincinnati, OH, ⁶Div of Cardiology, Thomas Jefferson Univ, Philadelphia, PA

(434) Long-Term Outcomes of HCV-Positive Heart Recipients Based on UNOS Registry; M. Mazur¹, M. Nunez², B. Pisani³, G. Bhat⁴, H. Eisen⁵. ¹Heart & Vascular Institute, Kaufman Center for Heart Failure, Cleveland Clinic, Cleveland, OH, ²Dept of Internal Med, Section of Infectious Diseases, Wake Forest SoM, Winston-Salem, NC, ³Dept of Med, Section on Cardiology, Atrium Health Wake Forest Baptist MC, Winston-Salem, NC, ⁴Heart and Vascular Center, The Christ Hospital, Cincinnati, OH, ⁵Div of Cardiology, Thomas Jefferson Univ, Philadelphia, PA

(435) Sex-Specific Trends in the Use of Temporary Mechanical Circulatory Support in Patients Listed for Orthotopic Heart Transplant Before and After The UNOS Allocation System Change; N. Cyrille¹, R. Garcia¹, B. N. White², D. S. Danford¹, L. Harmon¹, S. Bernardo¹, H. Rose¹, S. Patel³, A. D. DeVore⁴, S. Nandkeolyar¹, J. Mishkin¹. ¹Atrium Health Carolinas Med Center, Charlotte, NC, ²Wake Forest University School of Medicine, Winston Salem, NC, ³Montefiore-Einstein, Bronx, NY, ⁴Duke University, Raleigh, NC

(436) Association of Sex Mismatch with Allograft Rejection After Heart Transplantation (HT) - Molecular Microscope (MMDx) Results; J. Baranowska¹, C. M. Moeller¹, A. Fernandez Valledor¹, M. Regan¹, S. Rahman¹, C. Lee¹, D. Oren¹, G. Rubinstein¹, K. Oh¹, A. Rahman¹, D. Bae¹, V. Topkara¹, M. Yuzefpolskaya¹, J. Raikhelkar¹, D. Lotan¹, E. DeFilippis¹, K. Theodoropoulos¹, J. Fried¹, E. Lin¹, D. Majure², K. Clerkin¹, F. Latif¹, P. Colombo¹, G. Sayer¹, N. Uriel¹. ¹Columbia University Irving Medical Center, New York, NY, ²Weill Cornell Medical College, New York, NY

(437) Have Heart Transplant Allocation Policy Changes Brought Improvements in Mortality for Children and Adults with Cardiomyopathy? A UNOS Database Analysis; L. Wooster¹, M. O'Connor¹, X. Zhang², C. Mavroudis³, K. Maeda³, H. Ahmed¹, J. Edwards¹, K. Y. Lin¹, C. Wittlieb-Weber¹, J. Rossano¹, J. Edelson¹. ¹Div of Cardiology, Children's Hosp of Philadelphia, Philadelphia, PA, ²4 Div of Biostatistics and Data Management, Children's Hosp of Philadelphia, Philadelphia, PA, ³Div of Cardiothoracic Surgery, Children's Hosp of Philadelphia, Philadelphia, PA

(438) Impact of the 2018 Heart Transplant System Allocation Change on Older Adults; S. Godfrey¹, L. Truby², A. Gorraji³, S. Garg¹, N. Hendren¹, C. Wrobel³, E. Hardin⁴, M. Drazner¹, M. Peltz¹, M. Farr². ¹UT Southwestern Medical Center, Dallas, TX, ²University of Texas Southwestern Medical Center, Dallas, TX, ³UT Southwestern, Dallas, TX, ⁴UT Southwestern Medical Center UT Southwestern, Dallas, TX

(439) Disparities in Heart Transplantation Allocation and Outcomes by Blood Type in Korea (2010-2022); K. Kim, B. Oh. Incheon Sejong Hospital, Incheon, South Korea

(440) Second Opinion Heart Transplantation After a Previous Contra-Indication in Another Center is Associated with Favorable Post-Transplant Outcomes. A Single High-Volume Center Experience; G. Coutance, E. Desiré, G. Lebreton, A. Bouglé, S. Varnous, P. Leprince. Pitié-Salpêtrière Hospital, Paris, France

(441) An Ocean of Difference? Donor and Recipient Risk Factor Perception from a Cross-National Survey; S. P. Guenther¹, K. K. Khush², L. Hoepner¹, K. Schaeper³, H. Fox¹, W. Hiesinger⁴, Y. Shudo⁴, M. Morshuis¹, J. Woo⁴, J. Teuteberg², J. F. Gummert¹, R. Schramm¹, B. J. Wayda². ¹Clinic for Thoracic and Cardiovascular Surgery, Heart and Diabetes Center North Rhine-Westphalia, Ruhr-University Bochum, Bad Oeynhausen, Germany, ²Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, ³Institute of Anesthesiology and Pain Therapy, Heart and Diabetes Center North Rhine-Westphalia, Ruhr-University Bochum, Bad Oeynhausen, Germany, ⁴Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA

(442) Donor "Left Ventricular Hypertrophy" is Often Transient and/or Spurious; B. Wayda¹, H. Luikart², J. H. Mahar², Y. Weng³, S. Zhang³, R. P. Wood⁴, J. Nieto⁴, T. Groat⁵, D. Malinoski⁵, N. Neidlinger⁶, K. K. Khush². ¹Stanford Cardiovascular Institute, Stanford University School of Medicine, Palo Alto, CA, ²Cardiology, Stanford University School of Medicine, Palo Alto, CA, ³Quantitative Sciences Unit, Stanford University School of Medicine, Palo Alto, CA, ⁴LifeGift Organ Procurement Organization, Houston, TX, ⁵Trauma, Critical Care, and Acute Care Surgery, Oregon Health and Science University, Portland, OR, ⁶Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI

(443) Worse Risk-Adjusted Post-Transplant Survival for Women in the New Heart Transplant Allocation System; M. Jani¹, M. Leacche², A. Galle¹, J. Oliai¹, E. Purohit³, S. Hoeksema⁴, N. Manandhar-Shrestha⁵, R. Loyaga-Rendon¹. ¹Div of Cardiovascular Dis, Corewell Health, Grand Rapids, MI, ²Cardiothoracic Surg, Corewell Health, Grand Rapids, MI, ³Michigan State Univ SoM, Michigan State Univ/Corewell Health, Grand, MI, ⁴Div of Cardiovascular Dis, Spectrum Health, Grand Rapids, MI, ⁵Dept of Cardiovascular Research, Corewell Health, Grand Rapids, MI

(444) Similar Waitlist and Post-Lung Transplant Outcomes in Pulmonary Arterial Hypertension Patients When Compared with Other Etiologies of End-Stage Lung Disease, a Propensity-Match Analysis; R. Loyaga-Rendon¹, S. Krishnan¹, W. Berjaoui¹, G. Khirfan¹, N. Shrestha¹, R. Girgis². ¹Corewell Health, Grand Rapids, MI, ²Corewell Health, Michigan State University, Grand Rapids, MI

(445) Longer Time from Death Determination Using Neurologic Criteria (DNC) to Cross Clamp is Associated with Worse Cardiac Transplant Outcomes; D. Li¹, M. Slessarev², J. Basmaji², G. Fisher³, R. Davey³, D. Nagpal⁴, S. J. Smith³. ¹Dept of Med, London Health Sciences Centre, Western Univ, London, ON, Canada, ²Div of Critical Care Med, Dept of Med, London Health Sciences Centre, Western University, London, ON, Canada, ³Div of Cardiology, Dept of Med, London Health Sciences Centre, Western Univ, London, ON, Canada, ⁴Div of Cardiac Surgery, Dept of Surgery, London Health Sciences Centre, Western Univ, London, ON, Canada

(446) Cardiometabolic Outcomes Associated with the use of Semaglutide After Heart Transplantation; E. M. Donald, J. Choe, E. Driggin, J. Fried, J. Raikhelkar, S. Lee, E. Lin, K. Oh, K. Theodoropoulos, M. Yuzefpolskaya, P. Colombo, F. Latif, G. Sayer, N. Uriel, E. M. DeFilippis. New York Presbyterian, Columbia University Irving Medical Center, New York, NY

(447) The ABCs of DSAs: Incidence, Class, Gene and Strength of Donor Specific Antibody Development in the First Year After Heart Transplant; J. Teuteberg¹, E. Henricksen², T. Intrieri¹, S. Adaty³, J. Njoroge⁴, A. Varshney⁴, H. Luikart¹, Y. Moayed⁵, K. Khush¹, M. Zhang¹. ¹Stanford University, Stanford, CA, ²Stanford Healthcare, Stanford, CA, ³Kaiser Permanente, Santa Clara, CA, ⁴Stanford, Stanford, CA, ⁵UHN, Toronto, ON, Canada

(448) Exploring the Potential: GLP-1 Receptor Agonists for Advanced Therapies in End-Stage Heart Failure; A. Azmeen¹, A. Basheer¹, H. Brink², R. Zolty¹. ¹University of Nebraska Medical Center, Omaha, NE, ²Nebraska Medical Center, Omaha, NE

(449) Heart Transplant in Light Chain Cardiac Amyloidosis: A Single-Center Experience; M. Chedid El Helou¹, J. Estep², C. Albert¹, P. Alvarez¹, P. Bhat¹, S. Bhattacharya¹, A. Carmona Rubio¹, J. Finet¹, A. Higgins¹, K. Hoffman¹, R. Lee¹, M. Tong³, A. Weiss³, E. Soltesz³, R. Starling¹, E. Hsich¹, M. Hanna¹. ¹Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, ²Cardiovascular Medicine, Cleveland Clinic Florida, Weston, FL, ³Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH

(450) Heart Transplant in Transthyretin Cardiac Amyloidosis: A Single-Center Experience; M. Chedid El Helou¹, M. Jacob¹, K. James¹, T. Martyn¹, M. Mountis¹, Z. Taimeh¹, W. Tang¹, N. Brozzi², C. Sheffield², E. Soltesz³, M. Tong³, S. Unai³, J. Estep⁴, R. Starling¹, E. Hsich¹, M. Hanna¹. ¹Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, ²Cardiovascular Surgery, Cleveland Clinic Florida, Weston, FL, ³Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH, ⁴Cardiovascular Medicine, Cleveland Clinic Florida, Weston, FL

(451) Allocation Policy Change is Associated with Higher Rates of Myocardial Recovery in Ambulatory, Non-MCS Heart Transplant Candidates; V. Singh¹, J. S. Chung², A. Wolfson³, A. Vaidya⁴. ¹USC Keck, Los Angeles, CA, ²USC, Los Angeles, CA, ³Keck Medicine of USC, Los Angeles, CA, ⁴Keck Medical Center of USC, Los Angeles, CA

(452) Comparative Analysis of Fontan Transplant Outcomes; L. F. Murguia¹, E. Weber¹, R. McQueen², N. Singh¹, S. Ginde¹, S. Kindel¹, L. Zhang², A. Pan², A. Raskin¹. ¹Children's Wisconsin, Milwaukee, WI, ²Medical College of Wisconsin, Milwaukee, WI

(453) Soluble Urokinase Plasminogen Activator Receptor Levels Predict Adverse Outcomes Following Heart Transplantation; A. K. Yadalam¹, M. E. Gold¹, K. J. Patel¹, Y. Ko², A. Alkhoder³, Z. A. Siddiq³, O. Khawaja³, H. Allaqaband³, S. Sakr³, A. Rahbar³, Y. Haroun³, A. Shamim³, H. Hashmi³, A. A. Quyyumi¹. ¹Dept of Medicine, Div of Cardiology, Emory Univ School of Medicine, Atlanta, GA, ²Dept of Biostatistics and Bioinformatics, Emory Univ Rollins School of Public Health, Atlanta, GA, ³Emory Clinical Cardiovascular Research Institute, Atlanta, GA

(454) The Impact of Pre-Heart Transplant Body Mass Index on Long-Term Clinical Outcomes According to the Age Distribution; I. Kim¹, J. Youn², D. Kim³, S. Lee⁴, W. Chang⁵, D. S. Kim⁶, T. Singer-Englar⁶, D. Chang⁶, E. Kransdorf⁶, M. Kittleson⁷, J. Patel⁸, R. Cole⁶, A. Nikolova⁶, F. Esmailian⁷, L. Czer⁶, J. Kobashigawa⁶. ¹Cardiology, Keimyung Univ Dongsan Hosp, Dalseo-Gu, South Korea, ²Seoul St. Mary's Hosp, The Catholic Univ of Korea, Seoul, South Korea, ³Samsung MC, Seoul, South Korea, ⁴Keimyung Univ Dongsan Hosp, Daegu, South Korea, ⁵Cardiothoracic Surgery, Keimyung Univ Dongsan Hosp, Daegu, South Korea, ⁶Cedars-Sinai MC, Beverly Hills, CA, ⁷Cedars-Sinai Heart Inst, Beverly Hills, CA, ⁸Cedars-Sinai Smidt Heart Inst, Beverly Hills, CA

(455) Impact of Ventricular-Vascular Interactions on Long-Term Outcome After Heart Transplantation; M. Coriano¹, A. Golfetto¹, V. Tarzia², A. Angelini³, A. Gambino², C. Tessari², M. Fedrigo³, N. Pradegan², T. Giuseppe², S. Iliceto¹, G. Gerosa², F. Tona¹. ¹Dept of Cardiac, Thoracic, Vascular Sci & Public Health, Univ Hospital Padua, Padua, Italy, ²Cardiac Surgery Unit, Dept of Cardiac, Thoracic, Vascular Sci, & Public Health, Univ of Padua, Padua, Italy, ³Pathology & Path Anatomy Unit, Dept of Cardiac, Thoracic, Vascular Sci & Public Health, Univ of Padova, Padua, Italy

- (456) Geographic Destiny, Investigating Mortality Among Heart Transplant Recipients Based on Residential Regions;** C. R. Zoni¹, M. Dean², C. Lemoine¹, C. Sai-Sudhakar¹, Y. Ravi¹. ¹UConn Health, Farmington, CT, ²Virginia Commonwealth University Health System, Richmond, VA
- (457) Adverse In-Hospital Outcomes of Left Ventricular of Ventricular Assist Device Recipients Developing Acute Kidney Injury;** S. Chamay¹, S. X. Morita¹, N. Barrera², A. Briasoulis³. ¹SBH Health System, New York, NY, ²SBH Health System, New York, IA, ³University of Iowa Hospitals & Clinics, Iowa City, IA
- (458) History of Malignancy and Rejection Outcomes Assessed by Molecular Microscope (MMDx);** G. Rubinstein¹, A. Fernandez Valledor², C. M. Moeller², S. Slomovich², D. Oren², J. Baranowska², S. Rahman², C. Lee², K. Oh², D. Bae², V. Topkara², M. Yuzefpolskaya², P. Colombo², D. Lotan², E. M. DeFilippis², K. Theodoropoulos², J. Fried², E. Lin², D. Majure³, K. Clerkin², F. Latif², G. Sayer², N. Uriel², J. Raikhelkar². ¹Columbia University Irving Medical Center and Jacobi Medical Center - Albert Einstein College of Medicine, New York, NY, ²Columbia University Irving Medical Center, New York, NY, ³Weill Cornell Medical College, New York, NY
- (459) Vitamin D Levels Predict Mortality Following Heart Transplantation;** M. E. Gold¹, S. E. Kulkarni², A. Yadalam¹, K. Patel¹, Y. Ko², V. Jain¹, D. A. Gold¹, A. Razavi¹, N. Vatsa¹, A. Alkhdar¹, K. Ejaz¹, S. Sakr¹, Y. Haroun¹, A. Rahbar¹, M. Owais¹, Z. A. Siddiqui¹, A. A. Quyyumi¹. ¹Emory University School of Medicine, Atlanta, GA, ²Rollins School of Public Health, Emory University, Atlanta, GA
- (460) Impact of Donor Pulmonary Pressures on Recipient Outcomes in Adult Heart Transplantation;** Z. Jedeon¹, W. Baker², K. Singh³, A. Pillai³, I. Konstantinidis³, A. Jaiswal⁴. ¹Cardiology, University of Connecticut- Hartford Hospital, Hartford, CT, ²Pharmacy, University of Connecticut, Farmington, CT, ³Medicine, University of Connecticut, Farmington, CT, ⁴Cardiology, Hartford Hospital, Hartford, CT
- (461) Impact of the UNOS Donor Heart Allocation System in Adult Heart Transplant Recipients with Hypertrophic Cardiomyopathy in the United States;** Z. Jedeon¹, N. Patel², I. Konstantinidis³, A. Pillai⁴, K. Singh⁴, W. Baker⁵, A. Jaiswal². ¹Cardiology, University of Connecticut- Hartford Hospital, Hartford, CT, ²Cardiology, Hartford Hospital, Hartford, CT, ³Medicine, University of Connecticut, Hartford, CT, ⁴Medicine, University of Connecticut, Farmington, CT, ⁵Pharmacy, University of Connecticut, Farmington, CT
- (462) Heart Transplant Outcomes in Adults with Hypertrophic Cardiomyopathy: A Contemporary Analysis;** Z. Jedeon¹, I. Konstantinidis², N. Patel³, K. Singh², A. Pillai², W. Baker⁴, A. Jaiswal³. ¹Cardiology, University of Connecticut- Hartford Hospital, Hartford, CT, ²Medicine, University of Connecticut, Farmington, CT, ³Cardiology, Hartford Hospital, Hartford, CT, ⁴Pharmacy, University of Connecticut, Farmington, CT
- (463) Heart Transplantation in Young Adults: Comparison of Demographics and Outcomes at Pediatric and Adult Centers Following The 2018 Heart Allocation Policy Change;** E. Kalb¹, S. Choudhry¹, J. Cho¹, I. Adachi¹, C. Broda², A. Nair², K. Watanabe¹. ¹Texas Children's Hospital, Houston, TX, ²Baylor College of Medicine, Houston, TX
- (464) Days Alive out of the Hospital After Placement of A Contemporary Left Ventricular Assist Device and Heart Transplantation;** J. A. Ovalle Ramos¹, R. Fletcher¹, R. Islam², A. Mehta³, B. Ferrell¹, C. Diez-Lopez⁴, Y. Rochlani¹, S. Madan¹, S. Murthy¹, J. Shin¹, S. Vukelic¹, S. Forest¹, D. Sims¹, S. Patel¹, U. Jorde¹, D. Goldstein¹, O. Saeed¹. ¹Montefiore MC, Bronx, NY, ²Albert Einstein College of Medicine, Albert Einstein College of Medicine, Bronx, NY, ³Jacobi MC / Albert Einstein College of Medicine, Bronx, NY, ⁴Bellvitge Univ Hospital, Barcelona, Spain
- (465) Survival After Heart Transplantation in Chagas Cardiomyopathy Compared to Other Heart Failure Etiologies;** L. Echeverria, S. Gomez-Ochoa, N. Bernal Aragón, G. Prieto González, A. Serrano García, L. Muñoz, M. Cantillo-Reines, A. Jurado, L. Rojas, D. Botero, F. Garnica Cañizares, L. Salazar, C. Pizarro, V. Castillo. *Fundación Cardiovascular de Colombia, Floridablanca, Colombia*
- (466) Characterizing Patients with Inherited Dilated Cardiomyopathy Requiring Heart Transplantation;** A. Elezaby¹, T. Moscarello², L. Tran³, E. Henricksen², V. N. Parikh¹, F. Haddad¹, W. Hiesinger¹, K. Khush¹, J. Teuteberg¹, K. Sallam¹. ¹Stanford University School of Medicine, Stanford, CA, ²Stanford Health Care, Stanford, CA, ³Cedars-Sinai Medical Center, Los Angeles, CA
- (467) Amyloidosis & Cardiac Transplant: A New Frontier;** J. Farina¹, M. Lyle², E. Wiedmeier-Nutor¹, V. Lindpere¹, M. Klanderma¹, D. Steidley¹, J. Nativi³, A. Clavell⁴, M. Grogan⁴, A. Dispenzieri⁴, R. Fonseca¹, B. Hardaway¹, P. Patel³, T. Sher³, J. L. Rosenthal¹. ¹Mayo Clinic, Phoenix, AZ, ²Mayo Clinic Mayo Clinic Rochester, MN, Jacksonville, FL, ³Mayo Clinic, Jacksonville, FL, ⁴Mayo Clinic, Rochester, MN
- (468) Late-Breaking Abstract: Use of Hearts from SARS-CoV-2 Positive Donors for Transplantation: An Analysis of Trends, Provider Perceptions, Safety, and Outcomes;** S. P. Guenther¹, J. Wadewitz², B. J. Wayda³, A. Rogge¹, H. Fox¹, A. Costard-Jaeckle¹, Y. Shudo⁴, W. Hiesinger⁴, M. Morshuis¹, J. Woo⁴, J. Teuteberg³, R. Schramm¹, J. F. Gummert¹, K. K. Khush³, A. Rahmel². ¹Clinic for Thoracic and Cardiovascular Surgery, Heart and Diabetes Center North Rhine-Westphalia, Ruhr-University Bochum, Bad Oeynhausen, Germany, ²German Organ Procurement Organisation (DSO), Frankfurt am Main, Germany, ³Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, ⁴Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA
- (469) Cardiac Magnetic Resonance (CMR) Metrics of Pulmonary Hypertension are Associated with ITU Length of Stay After Lung Transplantation;** N. Miaris, C. Borguezan Daros, A. Verzelloni Sef, G. Sarri, A. McDermott, M. McCurry, J. Dunning, U. Stock, F. Chua, M. Usman, C. Buccarelli-Ducci, K. Dave, V. Gerovasili, N. Marczin, M. Carby, A. Reed, J. Wong. *Harefield Hosp, Royal Brompton Harefield Hosp, London, UK*

(470) LVAD/Stem Cell Combination Therapy in Nonischemic Dilated Cardiomyopathy Patients: Proof-of-Concept Study; B. Vrtovec¹, G. Poglajen¹, S. Frljak¹, G. Zemljic¹, A. Cerar¹, I. Knezevic¹, R. Radovancevic², U. Jorde³, I. Gregoric². ¹UMC Ljubljana, Ljubljana, Slovenia, ²The University of Texas Health Science Center at Houston, Houston, TX, ³Montefiore Medical Center, New York, NY

(471) Pre-Operative INTERMACS Profile as a Predictor of Outcomes in Durable LVAD Patients in the Modern Era; J. Guiry, A. M. Pico, A. Ramsay, K. Drezek, T. Winship, D. D'Alessandro, G. Lewis, V. Ton, E. Michel, E. Coglianese. *Massachusetts General Hospital, Boston, MA*

(472) Regional Systems of Care in Cardiogenic Shock Can Improve Outcomes: Penn Medicine Shock Team and Community Relationships; J. W. Wald¹, A. Parikh², W. Clay³, A. Brown⁴, A. Spelde⁴, K. Hoenisch⁴, S. Olia⁴, J. Giri⁴, D. Frankel⁴, E. Gordon⁴, M. Cevasco⁵, C. Bermudez⁵. ¹University of Pennsylvania, Narberth, PA, ²Cardiology, Penn Medicine, Philadelphia, PA, ³Chester County Hospital, Philadelphia, PA, ⁴Penn Medicine, Philadelphia, PA, ⁵Hospital of the University of Pennsylvania, Philadelphia, PA

(473) Mechanically Reducing Cardiac Preload to Maximize Left Ventricular Unloading with a Trans-Valvular Micro-Axial Flow Pump: The PrePella Concept; N. K. Kapur, L. Reyelt, K. Everett, E. Mahmoudi, M. Kapur, J. Ellis, L. Swain, S. Bhave, X. Qiao, G. Sunagawa. *Tufts Medical Center, Boston, MA*

(474) Passive Femoral Bypass Fails to Normalize Limb Perfusion in the Setting of Acute Limb Ischemia; N. K. Kapur, K. John, L. Reyelt, E. Mahmoudi, K. Everett, L. Swain, X. Qiao, G. Sunagawa. *Tufts Medical Center, Boston, MA*

(475) Temporal Trends of Vasopressor and Inotrope Use in Cardiogenic Shock: A Cardiogenic Shock Working Group Report; S. Vallabhajosyula¹, A. Faugno², B. Li², S. Sinha³, J. Hernandez Montfort⁴, M. Kanwar⁵, A. R. Garan⁶, G. Hickey⁷, J. Abraham⁸, C. Mahr⁹, P. Sangal², Q. Kong², A. Khalif⁵, K. Walec², P. Zazzali², R. Kataria¹, M. Pahuja¹⁰, V. Blumer³, V. Ton¹¹, N. Harwani², D. Wencker⁴, S. Nathan¹², E. Vorovich¹³, S. Hall⁴, W. Khalife¹⁴, S. Li⁹, A. Schwartzman¹⁵, J. Kim¹⁶, O. Vishnevsky¹⁷, D. Burkhoff¹⁸, N. Kapur². ¹Warren Alpert Medical School of Brown University, Providence, RI, ²Tufts University School of Medicine, Boston, MA, ³Inova Fairfax Medical Campus, Fairfax, VA, ⁴Baylor Scott and White Health, Dallas, TX, ⁵Allegheny General Hospital, Pittsburgh, PA, ⁶Beth Israel Deaconess Medical Center, Boston, MA, ⁷University of Pittsburgh Medical Center, Pittsburgh, PA, ⁸Providence St. Vincent's Medical Center, Portland, OR, ⁹Medical City - Dallas, Dallas, TX, ¹⁰University of Oklahoma Health Science Center, Oklahoma City, OK, ¹¹Massachusetts General Hospital, Boston, MA, ¹²University of Chicago Pritzker School of Medicine, Chicago, IL, ¹³Northwestern University Feinberg School of Medicine, Chicago, IL, ¹⁴UTMB John Sealy School of Medicine, Galveston, TX, ¹⁵Maine Medical Center, Portland, ME, ¹⁶Houston Methodist Hospital, Houston, TX, ¹⁷Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, PA, ¹⁸Columbia University Medical Center, New York, NY

(476) Impact of Cumulative Vasopressor and Inotrope Medications on Outcomes in Cardiogenic Shock: A Cardiogenic Shock Working Group Report; S. Vallabhajosyula¹, A. Faugno², B. Li², S. Sinha³, J. Hernandez Montfort⁴, M. Kanwar⁵, A. R. Garan⁶, G. Hickey⁷, J. Abraham⁸, C. Mahr⁹, P. Sangal², Q. Kong², A. Khalif¹⁰, K. Walec², P. Zazzali², R. Kataria¹, M. Pahuja¹¹, V. Blumer³, V. Ton¹², N. Harwani², D. Wencker⁴, S. Nathan¹³, E. Vorovich¹⁴, S. Hall⁴, W. Khalife¹⁵, S. Li⁹, A. Schwartzman¹⁶, J. Kim¹⁷, O. Vishnevsky¹⁸, D. Burkhoff¹⁹, N. Kapur². ¹Warren Alpert Medical School of Brown University, Providence, RI, ²Tufts University School of Medicine, Boston, MA, ³Inova Fairfax Medical Campus, Fairfax, VA, ⁴Baylor Scott and White Health, Dallas, TX, ⁵Allegheny General Hospital, Pittsburgh, PA, ⁶Beth Israel Deaconess Medical Center, Boston, MA, ⁷University of Pittsburgh Medical Center, Pittsburgh, PA, ⁸Providence St. Vincent Medical Center, Portland, OR, ⁹Medical City - Dallas, Dallas, TX, ¹⁰Allegheny General Hospital, Pittsburgh, PA, ¹¹University of Oklahoma Health Science Center, Oklahoma City, OK, ¹²Massachusetts General Hospital, Boston, MA, ¹³University of Chicago Pritzker School of Medicine, Chicago, IL, ¹⁴Northwestern University Feinberg School of Medicine, Chicago, IL, ¹⁵UTMB John Sealy School of Medicine, Galveston, TX, ¹⁶Maine Medical Center, Portland, ME, ¹⁷Houston Methodist Hospital, Houston, TX, ¹⁸Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, PA, ¹⁹Columbia University Medical Center, New York, NY

(478) Optimized Procedural, Therapeutic, ICU and X-Ray Imaging to Reduce Adverse Events in Patients Bridged with Axillary Intraaortic Balloon Pump (OPTIX-IABP); S. S. Inglis, H. Gonzalez Bonilla, A. Kanwar, S. Singh, J. Y. Pearson, M. Abbas, L. A. Folkens, N. N. Ou, P. J. Spencer, M. A. Villavicencio, A. L. Clavell, R. P. Frantz, A. N. Rosenbaum, A. Behfar. *Mayo Clinic, Rochester, MN*

(479) Extent of Pulmonary Vascular Resistance Reduction with Temporary Mechanical Circulatory Devices Among Patients Awaiting Cardiac Transplantation; A. Kabirpour¹, M. Saad¹, M. Aziz¹, V. Itare¹, R. J. Ochoa¹, A. Sharma¹, K. Callichurn¹, J. Wheeler¹, S. Itagaki², M. Cagliostro³, M. Bargash¹, D. Mancini⁴, S. Pinney⁵, A. Anyanwu⁶, N. Moss¹, A. Lalatrindade¹. ¹Mount Sinai Hospital, New York, NY, ²Mount Sinai Medical Center Mount Sinai Hospital, New York, NY, ³Icahn School of Medicine at Mount Sinai, New York, NY, ⁴Mount Sinai, New York, NY, ⁵Mount Sinai Morningside, New York, NY, ⁶Mount Sinai Med Ctr, New York, NY

(480) Impella Malrotation Adversely Impacts Hemodynamics in Cardiogenic Shock; L. Baldetti¹, D. Romagnolo¹, M. Festi¹, A. Beneduce², A. D. Frias³, M. Gramegna¹, S. Sacchi¹, F. Calvo¹, V. Pazzanese¹, M. Pieri¹, S. Ajello¹, A. Scandroglio¹. ¹IRCCS "San Raffaele" Hospital, Milan, Italy, ²Groupe Cardiovasculaire Interventionnel, Clinique Pasteur, Toulouse, France, ³Centro Hospitalar Universitário de Santo António, Porto, Portugal

(481) Risk of Bacteremia is Higher in Cardiogenic Shock Patients Supported with Multiple tMCS Devices; K. Dodson¹, L. B. Bunting¹, J. Hajji¹, A. Carnicelli¹, A. Kilic¹, L. Witer¹, J. McMurray¹, J. Yourshaw², J. Griffin¹, J. Atkins¹, C. Inampudi¹, G. Jackson¹, A. Van Bakel¹, M. Summer¹, R. Tedford¹, B. Houston¹. ¹Medical University of South Carolina, Charleston, SC, ²Med Univ of South Carolina, Charleston, SC

- (482) Complications and Outcomes of Two Percutaneous Right Ventricular Assist Device Configurations;** S. Khattak, D. Quinn, C. Chue, S. Barua, S. Lim. *University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom*
- (483) Validating a 3D Biventricular Heart Model in a Mock Circulatory Loop;** A. Kasavaraj¹, P. Jain², C. Said³, J. Jiang¹, A. Adji², C. Hayward⁴. ¹University of New South Wales, Kensington, Australia, ²St Vincent's Hospital, Darlinghurst, Australia, ³St Vincents Hospital, Darlinghurst, Australia, ⁴St. Vincent's Hospital, Darlinghurst, Australia
- (484) Impact of Ventricular Interdependence and Frank-Starling Mechanism on V-A ECMO;** A. Kasavaraj¹, P. Jain², C. Said³, J. Jiang¹, A. Adji², C. Hayward⁴. ¹University of New South Wales, Kensington, Australia, ²St Vincent's Hospital, Darlinghurst, Australia, ³St Vincents Hospital, Darlinghurst, Australia, ⁴St. Vincent's Hospital, Darlinghurst, Australia
- (485) Effects of Balloon Atrial Septostomy on ECHO and Hemodynamic Parameters in VA-ECMO;** R. Smoller¹, D. Asemota¹, S. Shah², C. Saikus², Z. Kon², S. Rangasamy², M. Alvarez Villela¹. ¹Lenox Hill Hospital, Donald and Barbara Zucker School of Medicine at Hofstra., New York, NY, ²North Shore University hospital, Donald and Barbara Zucker School of Medicine at Hofstra., Manhasset, NY
- (486) Correlation Between High-Sensitivity Troponin-T and Molecular Microscope Results (MMDx);** S. Rahman¹, C. Moeller¹, A. Fernandez Valledor¹, G. Rubinstein¹, J. Baranowska¹, C. Lee¹, D. Bae¹, K. Oh¹, K. Theodoropoulos¹, K. Clerkin¹, E. DeFilippis¹, D. Lotan¹, J. Fried¹, J. Raikhelkar¹, F. Latif¹, G. T. Sayer¹, D. Majure², N. Uriel¹. ¹Columbia Univ Irving MC, New York, NY, ²Weill Cornell Medical College, New York, NY
- (487) Microcirculatory Dysfunction Across SCAI Stages of Cardiogenic Shock;** S. Rahman¹, C. Lee¹, J. Baranowska¹, T. Miller¹, C. Moeller¹, A. Fernandez Valledor¹, G. Rubinstein¹, D. Oren¹, D. Lotan¹, A. Rahman¹, E. DeFilippis¹, K. Oh¹, D. Bae¹, J. Raikhelkar¹, Y. Kaku², K. Takeda², M. Yuzefpolskaya¹, P. Colombo¹, D. Majure³, D. Burkhoff¹, K. Clerkin¹, G. Sayer¹, J. Fried¹, N. Uriel¹. ¹Medicine- Cardiology, Columbia University Irving Medical Center, New York, NY, ²Columbia University Irving Medical Center, New York, NY, ³Weill Cornell Medical College, New York, NY
- (488) Microcirculatory Dysfunction in Cardiogenic Shock;** S. Rahman¹, J. Baranowska¹, C. Lee¹, T. Miller¹, C. Moeller¹, A. Fernandez Valledor¹, D. Oren¹, G. Rubinstein¹, A. Rahman¹, J. Raikhelkar¹, D. Bae¹, K. Oh¹, E. DeFilippis¹, D. Lotan¹, V. Topkara¹, M. Yuzefpolskaya¹, P. Colombo¹, Y. Kaku², K. Takeda², K. Clerkin¹, D. Majure³, D. Burkhoff¹, G. Sayer¹, J. Fried¹, N. Uriel¹. ¹Medicine- Cardiology, Columbia University Irving Medical Center, New York, NY, ²Columbia University Irving Medical Center, New York, NY, ³Weill Cornell Medical College, New York, NY
- (489) Association of ECMO Flow Index and Survival in Adults with Cardiogenic Shock Receiving Venoarterial Extracorporeal Membrane Oxygenation with Concomitant Left Ventricular Mechanical Unloading Device: An ELSO Registry Analysis;** L. Aguilar¹, A. Delgado², K. Kennedy², J. Fried³, K. Takeda⁴, A. Kirtane³, N. Kapur⁵, J. E. Tonna⁶, P. Quintero², M. Sabe², J. Ho², R. Sriwattanakomen², L. Labrada⁷, A. Rali⁸, A. Garan², E. Grandin². ¹Cardiology, Beth Israel Deaconess Medical Center, and Harvard T.H. Chan School of Public Health, Boston, MA, ²Cardiology, Beth Israel Deaconess Medical Center, Boston, MA, ³Cardiology, Columbia University, New York, NY, ⁴Cardiac Surgery, Columbia University, New York, NY, ⁵Cardiology, Tufts Medical Center, Boston, MA, ⁶CT Surgery and Emergency Medicine, University of Utah, Salt Lake City, UT, ⁷Cardiology, Temple University Hospital, Philadelphia, PA, ⁸Cardiology, Vanderbilt University Medical Center, Nashville, TN
- (490) Frailty in Cardiogenic Shock - Prevalence and Utilization of Temporary Mechanical Circulatory Support;** A. Rali¹, S. Taduru², L. Tran³, A. Butcher⁴, J. Lindenfeld¹, K. Rengel¹, S. Zalawadiya¹. ¹Vanderbilt University Medical Center, Nashville, TN, ²University of Kansas Medical Center, Kansas City, KS, ³University of Texas Southwestern, Dallas, TX, ⁴Northshore Medical, New York, NY
- (491) Factors Associated with Pulmonary Artery Catheter Use in Cardiogenic Shock Treated with Mechanical Circulatory Support;** M. Bayat Mokhtari¹, S. Datta², R. Smoller¹, S. Ahmad¹, S. Majdalawieh¹, D. Asemota³, S. Rangasamy³, M. Kamel², A. Sharma⁴, M. J. Pierce⁵, M. Alvarez Villela³. ¹Internal Medicine, Lenox Hill Hosp - Northwell Health, New York, NY, ²North Shore Univ Hosp, Manhasset, NY, ³Cardiology, Lenox Hill Hosp - Northwell Health, New York, NY, ⁴Icahn SoM at Mount Sinai, New York, NY, ⁵Cardiology, North Shore Univ Hosp, Manhasset, NY
- (492) Effect of Mechanical Unloading in Venoarterial Extracorporeal Membrane Oxygenation on Hemolysis, Bleeding and Renal Function;** S. Ahmad¹, D. Varrias², R. Smoller¹, M. Bayat Mokhtari¹, S. Rangasamy³, M. J. Pierce⁴, M. Alvarez Villela⁵. ¹Lenox Hill Hospital, New York, NY, ²Jacobi/Albert Einstein College of Medicine, New York, NY, ³Albert Einstein College of Medicine Montefiore Medical Center, New York, NY, ⁴Northwell Health, New York, NY, ⁵Lenox Hill Hospital - Northwell Health, New York, NY
- (493) Effects of Impella 5.5 on Right Ventricular Load and Adaption;** M. Silkowski¹, A. Carnicelli², J. P. Yourshaw², R. Moore², R. Higginbotham², J. Slovensky², B. Houston². ¹Cardiovascular Department, Medical University of South Carolina, Charleston, SC, ²Medical University of South Carolina, Charleston, SC

WEDNESDAY, 10 APRIL, 2024

6:00 - 7:00 p.m.

POSTER SESSION 1: Cardiothoracic Surgery (Non-CME)

Location: Poster Hall

Core Therapies: HEART, LUNG, MCS, PVD

Practice Areas: Cardiothoracic Surgery, Anesthesiology and Critical Care, Cardiology, Infectious Diseases, Nursing and Allied Health, Pathology, Pediatrics, Pharmacy, Pulmonology, Research and Immunology

Session Summary: Posters in this session include presentations on multiple topics where the Practice Areas of the research is focused in Cardiothoracic Surgery. Designated Poster Discussants will circulate through the poster hall during the session to engage poster presenters in quality discussions of their abstracts. **CME is not offered for poster sessions.**

Poster Discussants: Clemens Aigner, Austria, Cristiano Amarelli, Italy, Alexander Bernhardt, Germany, Alejandro Bertolotti, Italy, Brandi Bottiger, USA, Marco Caccamo, USA, Alfred Casillan, USA, Pedro Catarino, USA, Lin-Chiang P Chou, USA, Stephen Clark, UK, Bernice Coleman, USA, Göran Dellgren, Sweden, Caitlin Demarest, USA, Chidiebere Peter Echieh, Nigera, Magdy El-Sayed Ahmed, USA, Fabian Emrich, Germany, Peter Ivak, Czech Republic, Mitsuki Kawashima, Japan, Ivan Knezevic, Slovenia, Virginia Linacre, Chile, Antonio Loforte, Italy, Lucian Lozonschi, USA, Shivank Madan, USA, Allison McLarty, USA, Roxana Moayedifar, Austria, Ezequiel Molina, USA, Takeshi Nakatani, Japan, Basil Nasir, Canada, Alessandro Palleschi, Italy, Anthony Panos, USA, Muhammad Rafiq, UK, Eduardo Rame, USA, Danny Ramzy, USA, Yazhini Ravi, USA, Jun-Neng Roan, Taiwan, Siavosh Saatee, USA, Fawwaz Shaw, USA, Yasuhiro Shudo, USA, Aleem Siddique, USA, Ulrich Stock, UK, Benjamin Sun, USA, Zuzana Tucanova, Czech Republic, Anup Varghese, India, Barbara Wilkey, USA, Roh Yanagida, USA, Ahmad Zeeshan, USA

(494) Donor Chimerism Duration Correlates with Heart Allograft Tolerance in Combined Heart and Bone Marrow Transplantation in Nonhuman Primates; J. M. Muoio¹, J. T. Nawalaniec¹, S. M. Landino¹, J. M. O¹, A. Dehnadi¹, C. L. Miller¹, D. Muldoon¹, I. M. Hanekamp¹, J. C. Madsen², J. S. Allan³. ¹Center for Transplantation Sciences, Mass Gen Hosp, Boston, MA, ²Center for Transplantation Sci, Div of Cardiac Surgery, Mass Gen Hosp, Boston, MA, ³Center for Transplantation Sci, Div of Thoracic Surgery, Mass Gen Hosp, Boston, MA

(495) Hypothermic Physical Phase Transition of Mineralocorticoid Receptors Determine Donor Heart Function; I. Lei¹, W. Huang², H. Sicim¹, P. Noly³, M. R. Pergande⁴, M. C. Wilson⁴, W. Gao¹, L. Liu², A. Abou², M. Jiang⁵, S. Saddoughi¹, J. L. Platt², M. Cascalho², J. S. Pober⁶, F. D. Pagani⁷, Y. Chen², B. Pitt², Z. Wang², R. M. Mortensen², Y. Ge⁴, P. C. Tang¹. ¹Mayo Clinic, Rochester, MN, ²University of Michigan-Ann Arbor, Ann Arbor, MI, ³Montreal Heart Institute, Montreal, QC, Canada, ⁴University of Wisconsin-Madison, Madison, WI, ⁵Massachusetts Institute of Technology, Boston, MA, ⁶Yale University, New Haven, CT, ⁷University of Michigan-Ann Arbor, Ann Arbor, MI

(496) Ex Vivo Heart Perfusion vs. Cold Storage of Healthy Hearts in Extended Preservation Time: A Juvenile Porcine Experimental Model; Y. Kobayashi¹, J. Li¹, M. Parker¹, Y. Zahiri¹, J. Ingarao¹, K. Runeckles², C. Fan², O. Honjo¹. ¹The Hospital for Sick Children, Toronto, ON, Canada, ²University Health Network, Toronto, ON, Canada

(497) Ultrastructural Characteristics of Porcine and Human Hearts During Normothermic Ex Situ Heart Perfusion; M. T. Vervoorn¹, A. S. Scheren¹, S. Van Tuijl², E. M. Ballan¹, P. H. Van der Kraak¹, S. E. Kaffka Genaamd Dengler¹, S. C. De Jager¹, R. Goldschmeding¹, A. Vink¹, J. P. Sluiter¹, P. A. Doevendans¹, L. W. Van Laake¹, N. P. van der Kaaij¹. ¹UMC Utrecht, Utrecht, Netherlands, ²LifeTec Group, Eindhoven, Netherlands

(498) High Perfusate Hemoglobin Concentration Exacerbates Functional Decline During Working Mode Normothermic Ex-Situ Heart Perfusion; M. J. Wagner¹, G. Mainardi Aguiar da Silva¹, S. Hatami², P. Hassanzadeh¹, X. Wang¹, J. Nagendran¹, D. H. Freed¹. ¹Department of Surgery, University of Alberta, Edmonton, AB, Canada, ²Department of Medicine, University of Alberta, Edmonton, AB, Canada

(499) Plasma Proteins Ameliorate Loss of Coronary Vascular Resistance During Working Mode Normothermic Ex-Situ Heart Perfusion; M. J. Wagner¹, G. Mainardi Aguiar da Silva¹, S. Hatami², P. Hassanzadeh¹, X. Wang¹, J. Nagendran¹, D. Freed¹. ¹Department of Surgery, University of Alberta, Edmonton, AB, Canada, ²Department of Medicine, University of Alberta, Edmonton, AB, Canada

(500) A Carbon-13-Labeled Pyruvate Test as Real-Time Metabolic Assessment of Ex-Situ Perfused Donor Hearts; S. J. Langmuur¹, E. H. Küçükerbil², J. Amesz¹, O. C. Manintveld³, J. de Jonge², Y. J. Taverne¹. ¹Department of Cardiothoracic Surgery, Erasmus University Medical Center, Rotterdam, Netherlands, ²Department of Surgery, Division of Hepatopancreaticobiliary and Transplant Surgery, Erasmus University Medical Center, Rotterdam, Netherlands, ³Department of Cardiology, Erasmus University Medical Center, Rotterdam, Netherlands

(501) Transcriptomic Signatures of Human Donor Hearts Preserved Using a Hypothermic Perfusion System; G. Sharma¹, R. Vela¹, L. Powell¹, C. R. Malloy², M. Jessen¹, M. Peltz¹. ¹Cardiovascular and Thoracic Surgery, UT Southwestern Medical Center, Dallas, TX, ²Advanced Imaging Research Center, UT Southwestern Medical Center, Dallas, TX

(502) Pirfenidone and Nintedanib Monotherapy Reduce Cardiac Allograft Vasculopathy in a Murine Transplantation Model; C. Gräbner¹, M. Scheunchen¹, F. Theil¹, A. Kuckhahn¹, N. Vogg², A. Gessner², N. Fritz¹, M. Ramsperger-Gleixner¹, O. Dewald¹, C. Heim¹. ¹Department of Cardiac Surgery, University Hospital Erlangen, Erlangen, Germany, ²Department of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

(503) Myocardial Support During Low Flow Hypothermic Perfusion Does Not Compromise Tissue Perfusion of the Dependent Region; G. Mainardi Aguiar da Silva¹, M. J. Wagner¹, S. Hatami¹, P. Hassanzadeh¹, X. Wang¹, J. Nagendran¹, D. H. Freed². ¹University of Alberta, Edmonton, AB, Canada, ²Stollery Children's Hospital, Edmonton, AB, Canada

(504) Storing Hearts at Room Temperature Using Gas Persufflation; W. A. Pavey¹, R. Hahn¹, H. Ludewick¹, A. Ngui¹, K. Ho², L. Hool³. ¹Heart & Lung Research Institute WA, Perth, Australia, ²Fiona Stanley Hospital, Perth, Australia, ³University of Western Australia, Perth, Australia

(505) Does dd-cf DNA Correlates with CAV in Stable Heart Transplant Patients?; A. Dralov¹, M. Bulfoni², S. Sponga³, A. Beltrami², C. Nalli⁴, F. Curcio², U. Livi⁵, I. Vendramin⁴. ¹University Hospital "Santa Maria della Misericordia", Udine Italy, Udine, Italy, ²University Hospital of Udine, Department of Medicine, Udine, Italy, ³University of Udine, Udine, Italy, ⁴University Hospital of Udine, Cardiac Surgery Unit, Udine, Italy, ⁵Az. Osp. S. Maria Della Misericordia, Udine, Italy

(506) Thymectomy Duration in Congenital Heart Disease Patients Correlates with Early Coronary Allograft Vasculopathy Development in Pediatric Heart Transplant; A. Ramineni¹, S. Hogue¹, K. Kulshrestha¹, S. Stark², C. Chin², B. S. Mantell², D. L. Morales¹, C. Moore¹. ¹Cardiothoracic Surgery, Cincinnati Children's Hospital MC, Cincinnati, OH, ²Cardiology, Cincinnati Children's Hospital MC, Cincinnati, OH

(507) Novel Pediatric Ex-Vivo Preservation System for Low-Weight Donor Hearts in a Porcine Model; A. Sharir¹, Y. Palagani¹, P. Choi¹, C. Ruaengsri¹, J. Sleasman², O. Jehadi², M. Ma¹. ¹Cardiothoracic Surgery Department, Stanford University, Palo Alto, CA, ²Operating Room-Main, Stanford Children's Health, Palo Alto, CA

(508) Promising Biochemical and Hemodynamic Trends in Ex-Vivo Heart Perfusion Using a Physiologic Loading Configuration; M. Lopera Higuaita¹, M. Bolger-Chen², S. S. Li³, E. O. Ajenu², G. B. Olverson⁴, N. Minie³, J. Catricala³, A. Pitti³, W. Michaud³, S. Kenneth³, D. Vincent⁵, D. D'Alessandro³, S. N. Tessier¹, A. A. Osho³, S. Rabi³. ¹Center for Engineering in Medicine and Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, ²Center for Engineering in Medicine and Surgery, Massachusetts General Hospital, Boston, MA, ³Division of Cardiac Surgery, Corrigan Minehan Heart Center, Massachusetts General Hospital, Boston, MA, ⁴Division of Cardiac Surgery, Massachusetts General Hospital, Boston, MA, ⁵VentriFlo True Pulse Pumps, Pelham, NH

(509) Performance of the National OCS Program (NOP) in US Heart and Lung Transplants; W. Hassanein¹, F. Zafar², A. Hassanein¹, M. Al Salih³, S. Reddy⁴, N. Dang⁵, K. Ihnken⁶, A. Kaw⁷, S. LaFrancesca⁸, M. Omara⁹, L. Tsonis⁷, Y. Huang¹⁰, P. Lezberg², A. Jothidasan¹¹, L. Damme², X. Zhou¹, F. Gensini¹², S. Brann¹³, T. Khayal¹. ¹TransMedics, Inc., Andover, MA, ²TransMedics, Andover, MA, ³TransMedics, Inc., Tampa, FL, ⁴TransMedics, Durham, NC, ⁵TransMedics, Honolulu, HI, ⁶TransMedics, San Francisco, CA, ⁷TransMedics, Chicago, IL, ⁸TransMedics, Los Angeles, CA, ⁹TransMedics, Cleveland, OH, ¹⁰TransMedics, Oklahoma City, OK, ¹¹TransMedics, Dallas, TX, ¹²TransMedics, Seattle, WA, ¹³TransMedics, Inc., Philadelphia, PA

(510) Effect of Cytomegalovirus Prophylaxis with Immunoglobulins or Antiviral Drugs on Lymphoproliferative Disease After Heart Transplantation: Single-Center Experience in 300 Patients; U. Boeken¹, V. Hettlich¹, F. Jenkins¹, D. Sigetti¹, C. Böttger¹, D. Scheiber², A. Polzin², F. Voss², H. Dalyanoglu¹, B. Ramadan¹, H. Aubin¹, A. Lichtenberg¹. ¹Cardiac Surgery, University Hospital, Düsseldorf, Germany, ²Cardiology, University Hospital, Düsseldorf, Germany

(511) Cardiac Vasoplegia Syndrome: An Important Clinical Entity in Need of a Unified Definition. A Systematic Review and Meta-Analysis; O. Papazisi¹, M. M. van der Schoot², R. R. Berendsen², S. M. Arbous³, S. le Cessie⁴, O. M. Dekkers⁵, R. J. Klautz¹, N. Marczin⁶, M. Palmen¹, E. E. de Waal⁷. ¹Department of Cardiothoracic Surgery, Leiden University Medical Center, Leiden, Netherlands, ²Department of Anesthesiology, Leiden University Medical Center, Leiden, Netherlands, ³Department of Intensive Care, Leiden University Medical Center, Leiden, Netherlands, ⁴Department of Clinical Epidemiology, Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, Netherlands, ⁵Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, Netherlands, ⁶Division of Anesthesia, Pain Medicine and Intensive Care, Imperial College London, London, United Kingdom, ⁷Department of Anesthesiology, University Medical Center Utrecht, Utrecht, Netherlands

(512) Are the Bleeding and Thrombosis Complications in Left Ventricular Assist Device Patients as Impactful as Infection and Rejection in Heart Transplant Recipients?; B. E. Ferrell¹, J. Khoury², J. A. Olivera², R. Zhu¹, J. A. Ovalle-Ramos³, S. Patel³, D. Goldstein¹. ¹Department of Cardiothoracic and Vascular Surgery, Montefiore Medical Center, Bronx, NY, ²Albert Einstein School of Medicine, Bronx, NY, ³Department of Cardiology, Montefiore Medical Center, Bronx, NY

(513) Utilization of Distressed Communities Index to Examine the Impact of Socioeconomic Status on Left Ventricular Assist Device Outcomes; B. E. Ferrell¹, J. A. Olivera², R. Zhu¹, I. O. Faith², S. Patel³, D. Goldstein¹. ¹Department of Cardiothoracic and Vascular Surgery, Montefiore MC, Bronx, NY, ²Albert Einstein School of Medicine, Bronx, NY, ³Dept of Cardiology, Montefiore MC, Bronx, NY

(514) Diaphragm Dysfunction from Phrenic Nerve Injuries During LVAD or Heart Transplants: Positive Role of Diaphragm Pacing; R. Onders, M. Elmo, N. Carl, Y. Abu-Omar, Y. Elgudin, R. Aorora, K. Gray, M. Pelletier. *Univ Hospitals Cleveland Medical Center, Cleveland, OH*

(515) Outcomes with Donation After Circulatory Death Heart Transplantation Using Normothermic Regional Perfusion Protocol - A Single Center Experience; A. Kumar¹, S. Hussain², L. James³, A. Reyentovich⁴, B. Kadosh⁵, R. Goldenberg⁶, N. Moazami¹, D. Smith¹. ¹Cardiothoracic Surgery, NYU Langone Health, New York, NY, ²Cardiothoracic Surg, NYU Langone, New York, NY, ³Gen Surg, NYU Langone, New York, NY, ⁴Cardiology, NYULMC, New York, NY, ⁵Cardiology, NYU Langone Health, New York, NY, ⁶Cardiology, NYU Langone, New York, NY

(516) The Potential for Heart Donation After Death Determination by Circulatory Criteria (DCC) in the Province of Quebec; T. Herrera Fortin¹, E. Calin², A. Ducharme³, Y. Lamarche⁴, N. Noiseux⁵, M. Carrier², P. Noly². ¹University of Montreal, Montreal, QC, Canada, ²Department of Cardiac Surgery, Montreal Heart Institute, University of Montreal, Montreal, QC, Canada, ³Department of Cardiology, Montreal Heart Institute, University of Montréal, Montreal, QC, Canada, ⁴Montreal Heart Institute, University of Montreal, Montreal, QC, Canada, ⁵Department of Cardiac Surgery, Centre Hospitalier Universitaire de Montréal, Montreal, QC, Canada

(517) Donation After Circulatory Death Heart Transplantation with Ex-Vivo Perfusion: Is It Ready for Prime Time?; J. Trivedi¹, E. Schumer¹, M. Gallo¹, R. Samson², S. Fu¹, S. Moore¹, S. Pahwa³, M. Slaughter⁴. ¹Univ of Louisville, Louisville, KY, ²Univ of Louisville Health System, Louisville, KY, ³Univ of Louisville Physicians Cardiovascular and Thoracic Surgery, Louisville, KY, ⁴Univ of Louisville School of Medicine, Louisville, KY

(518) Donation After Circulatory Death Donors for Heart Transplantation: Does Center Volume Matter?; S. S. Scott¹, D. Satija¹, D. A. Gouchoe², E. Y. Cui², D. Ferrari-Light², M. C. Henn², K. Choi², A. Vallakati³, B. Lampert³, N. A. Mokadam², B. A. Whitson², A. M. Ganapathi². ¹The Ohio State University College of Medicine, Columbus, OH, ²Division of Cardiac Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, ³The Ohio State University Wexner Medical Center, Columbus, OH

(519) Overcoming the Boundaries: A Very Long-Term Heart Transplantation Single-Center Experience Using Elderly Donors; N. Pradegan¹, G. Guerra¹, C. Tessari¹, A. Gambino¹, A. D'Onofrio¹, V. Tarzia², G. Toscano³, A. Angelini⁴, G. Gerosa¹. ¹University of Padova, Padova, Italy, ²Università di Padova Az. Osp. Padova, Padova, Italy, ³University of Padova, Padova, Italy, ⁴University of Padua, Padova, Italy

(520) Twenty-Minute No-Touch Period Before Controlled DCD Heart Retrieval: Is There Still a Chance for Successful Recovery? The Italian Experience; G. Gerosa¹, N. Pradegan¹, V. Tarzia¹, T. Lena¹, P. Zanatta², A. Galeone³, L. Gottin³, F. Onorati³, M. Boffini⁴, M. Zanierato⁴, L. Botta⁵, S. Martin Suarez⁵, M. Feccia⁶, P. Lilla Della Monica⁶, A. Oliveti⁷, D. Pacini⁵, M. Rinaldi⁴, G. B. Luciani³, M. Cardillo⁷. ¹University of Padova, Padova, Italy, ²Treviso Hospital, Treviso, Italy, ³University of Verona, Verona, Italy, ⁴University of Torino, Torino, Italy, ⁵University of Bologna, Bologna, Italy, ⁶San Camillo Hospital, Roma, Italy, ⁷Transplant National Center, Roma, Italy

(521) Out-Of-Hospital Cardiac Arrest Donor (OHCA) Hearts: A Single-Center Experience; G. Fischetti¹, L. Giovannico², A. d'Errico Ramirez³, D. Parigino⁴, V. Santeramo¹, L. Savino¹, A. Silva¹, N. Di Bari¹, T. Bottio¹, a. milano¹. ¹Policlinico di Bari, Bari, Italy, ²Università degli Studi di Bari, Bari, Italy, ³Policlinico Hospital of Bari, Bari, Italy, ⁴Università degli Studi di Bari Aldo Moro, Bari, Italy

(522) Heart and Lung Recovery Team Refusal May Lead to Donation After Circulatory Death Underutilization; A. F. Akbar¹, A. L. Zhou¹, J. M. Ruck², A. Kalra³, R. A. Riojas², A. J. Casillan², J. S. Ha², C. A. Merlo⁴, A. Kilic², E. L. Bush². ¹Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, ²Department of Surgery, Johns Hopkins Hospital, Baltimore, MD, ³Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, ⁴Department of Medicine, Johns Hopkins Hospital, Baltimore, MD

(523) Save a Trip: Clinical Outcomes of Cardiac Allografts Recovered by Local Surgeons Compared to Recipient Center Surgeons; A. DeBose-Scarlett, R. Kamal, E. A. Adjei, C. D. Keck, S. R. Scholl, A. Shah, S. Bommareddi, C. Pasrija, J. Trahanas. *Vanderbilt University Medical Center, Nashville, TN*

(524) Predictors of Severe Graft Dysfunction After DCD Heart Transplantation with Direct Procurement and Preservation; L. Martinez Marin¹, H. Smail¹, S. Bhagra¹, R. Hogg², D. Jenkins¹, P. Kaul¹, A. Kydd¹, S. Large¹, C. Lewis¹, S. Messer³, J. Nunes¹, J. Parameshwar¹, M. Rafiq¹, L. Simmonds², S. Tsui¹, S. Pettit¹, M. Berman¹. ¹Royal Papworth Hospital, Cambridge, United Kingdom, ²NHS Blood and Transplant, Bristol, United Kingdom, ³Golden Jubilee National Hospital, Glasgow, United Kingdom

(525) The Impact of Functional Warm Ischemia Time in DCD Heart Transplantation; S. Kim¹, Y. Hanna², R. Fajardo², P. Tessmann², J. Hermsen², Y. Xia³. ¹UCLA, Los Angeles, CA, ²University of Wisconsin, Madison, WI, ³University of Wisconsin, Madison, WI

(526) Misalignment of Ethics and Statistical Risk Models in Organ Allocation; R. Dale¹, M. Cheng², K. Pines¹, M. Currie¹. ¹Department of Cardiothoracic Surgery, Stanford University, Stanford, CA, ²University of California, Berkeley, Berkeley, CA

(527) Impact of Citizenship Status on Waitlist and Post Heart Transplantation Outcomes in Pediatrics; H. F. Ahmed¹, A. Ramineni¹, K. Kulshrestha², A. Mehdizadeh-Shriffi¹, S. Hogue¹, C. Chin³, A. Ashfaq⁴, D. Morales¹. ¹The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³The Heart Institute, Cincinnati Children's Hospital, Cincinnati, OH, ⁴The Heart Institute, Cincinnati Children's Hospital, Cincinnati, OH

(528) New Pattern of Racial Disparity in Heart Transplant Outcomes: A National Inpatient Sample Analysis; Y. Zhan¹, M. Zhu², C. Sun², L. Lee¹, M. Kawabori¹, G. Couper¹, F. Chen¹. ¹Tufts Medical Center, Boston, MA, ²Tufts University School of Medicine, Boston, MA

(529) Gender and Ethnicity Interacts and Predicts Incidence of Chronic Kidney Disease Post Heart Transplantation: A UNOS Registry Report; V. Antonov¹, R. Perez-Vicente¹, D. Medved², O. Braun³, J. Nilsson². ¹Department of Translational Medicine, Thoracic Surgery and Bioinformatics, Lund University, Malmö, Sweden, ²Department of Thoracic and Vascular Surgery and Department of Translational Medicine, Lund University and Skånes University Hospital, Lund, Sweden, ³Department of Clinical Sciences Lund, Cardiology, Lund University and Skånes University Hospital, Lund, Sweden

(530) Disparities in Heart Transplant Survival: A Regional and Racial Perspective; R. Patel¹, T. Oliveira¹, G. Frady², M. Dean³, T. Moore², C. Lemoine⁴, C. Sai-Sudhakar⁴, Y. Ravi⁴, C. Zoni⁴. ¹UConn School of Medicine, Farmington, CT, ²University of Connecticut, Storrs, CT, ³Virginia Commonwealth University, Richmond, VA, ⁴UConn Health, Farmington, CT

(531) Kinetics of Procalcitonin, CRP, IL-6 and Presepsin in Heart Transplant Patients Undergoing Induction with Anti-Thymocyte Globulin (rATG); L. Giovannico, G. Fischetti, D. Parigino, V. Santeramo, L. Savino, A. Silva, G. Fiore, N. Di Bari, A. D. Milano, T. Bottio. Department of Precision and Regenerative Medicine and Ionian Area (DiMePRE-J), Bari Medical School, Bari, Italy

(532) Combined Heart-Liver Transplantation: Indications, Outcomes, and Risk Factors; Y. C. Kwon¹, E. Dunbar¹, G. Gardner², M. Ambrosio¹, I. Tchoukina³, K. Shah³, D. Bruno⁴, J. Chery⁵, V. Kasirajan⁵, Z. A. Hashmi⁵. ¹Virginia Commonwealth University School of Medicine, Richmond, VA, ²Department of Surgery, Virginia Commonwealth University, Richmond, VA, ³Division of Cardiology, Virginia Commonwealth University, Richmond, VA, ⁴Division of Abdominal Transplant Surgery, Hume-Lee Transplant Center, Virginia Commonwealth University, Richmond, VA, ⁵Division of Cardiothoracic Surgery, Pauley Heart Center, Virginia Commonwealth University, Richmond, VA

(533) Adults with “Fontan Associated Liver Failure”- Is Combined Heart Liver Transplantation Always Necessary?; T. Malik¹, J. Murala¹, Y. Tan¹, A. Weisberg², C. Heid¹, M. Jessen¹, M. Farr³, M. Drazner³, W. Ring¹, M. Peltz¹. ¹Department of Cardiovascular and Thoracic Surgery, University of Texas Southwestern Medical Center, Dallas, TX, ²Cardiovascular Surgery Department, Cleveland Clinic, Cleveland, OH, ³Department of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX

(534) Failure to Rescue in Heart Lung Transplantation: Progress Over 30 Years; E. E. Heng, S. Elde, A. Krishnan, A. Garrison, M. Fawad, C. Ruaengsri, Y. Shudo, B. A. Guenthart, J. Woo, J. W. MacArthur. Cardiothoracic Surgery, Stanford University, Palo Alto, CA

(535) Heart Transplant in Chagas Disease: A 10-Years Follow-Up Using Hearts with More Than 4 Hours Ischemic Time in a High-Volume Center in Brazil; R. Honorado Santos¹, S. Steffen¹, F. Gaiotto¹, S. Gaspar¹, D. Lourenço Filho¹, B. Orlandi², F. Jatene¹, F. Bacal³, R. Kalil Filho¹. ¹Adult Heart Transplant Group, Heart Institute of the University of São Paulo Medical School, São Paulo, Brazil, ²Heart Institute of the University of São Paulo Medical School, São Paulo, Brazil, ³Adult Heart Transplant Group, University of Sao Paulo, São Paulo, Brazil

(536) Combined Heart-Liver Transplant versus Isolated Heart or Liver Transplant in Amyloidosis; C. Song¹, D. Rekhman¹, A. Iyengar², N. Weingarten², M. Shin², S. Kim¹, N. Ganjoo¹, S. Lee¹, M. Helmers², P. Atluri². ¹Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ²Division of Cardiovascular Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA

(537) Comparative Outcomes of Simultaneous Heart-Kidney Transplantation from DBD and DDC-NRP Donors; M. J. Kearns¹, A. Ayer¹, E. Silver², A. Brubaker¹, C. Weber¹, D. Olaso¹, H. Tran¹, E. Adler¹, G. Schnickel¹, M. Urey¹, V. Pretorius¹. ¹UC San Diego Health, San Diego, CA, ²University of Connecticut School of Medicine, Storrs, CT

(538) Donation After Circulatory Death: Two-Year Outcomes in a Propensity-Matched Cohort; E. Silver¹, N. Reddy², R. Barriola Rubarth², A. Lin², V. Pretorius², M. Urey², M. Kearns². ¹Univ of Connecticut School of Medicine, Farmington, CT, ²Univ of California San Diego, La Jolla, CA

(539) Impact of Donor-Recipient Race Matching on Survival of Patients with Adult Congenital Heart Disease After Heart Transplantation; A. C. Garrison, D. M. Mullis, A. Krishnan, E. E. Heng, D. Alnasir, Y. J. Woo, J. W. MacArthur. Cardiothoracic Surg, Stanford Univ SoM, Palo Alto, CA

(540) Increased Incidence of Stroke After Heart Transplant in the New Allocation System Era; A. Lin¹, Y. Zhao¹, P. Kurlansky¹, A. Vinogradsky¹, I. Feng¹, C. Wang¹, F. Latif², G. Sayer², N. Uriel², Y. Naka¹, K. Takeda¹. ¹Division of Cardiac, Thoracic & Vascular Surgery, Department of Surgery, Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, New York, NY, ²Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, New York, NY

(541) Utilization of High Sequence “Hard to Place” Donor Hearts Does Not Negatively Affect Clinical Outcomes After Heart Transplantation; A. Ali¹, J. Hammond¹, P. Vlismas², X. Mai², J. Bell², A. Scatola², S. Arora², J. Gluck², A. Feingold², J. Radojevic², A. Jaiswal². ¹Cardiac Surgery, Hartford Hospital, Hartford, CT, ²Cardiology, Hartford Hospital, Hartford, CT

(542) Donation After Circulatory Death: A Pathway to Heart Transplant for Lower Status Candidates; A. L. Zhou¹, A. F. Akbar², J. M. Ruck¹, A. A. Rizaldi¹, D. C. Paneitz¹, S. Rokui¹, A. Kilic¹. ¹Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, ²Department of Surgery, Johns Hopkins School of Medicine, Baltimore, MD

(543) Have Changes to the Heart Allocation Scoring System Improved Mortality?; P. Hernandez¹, A. Kashem², H. Kehara³, R. Yanagida⁴, K. Krishan⁵, S. Gonipati³, N. Shigemura⁶, Y. Toyoda². ¹Lewis Katz School of Medicine, Philadelphia, PA, ²Temple University School of Medicine, Philadelphia, PA, ³Temple University, Philadelphia, PA, ⁴Temple University Hospital, Philadelphia, PA, ⁵Temple University Hospital, Philadelphia, PA, ⁶Temple University Health System and Lewis Katz School of Medicine, Philadelphia, PA

(544) Does HLA Matching in Prior Blood Transfusions Impact Lung Transplant Survival Outcomes?; A. Firoz¹, S. Ide Bolet¹, A. Kashem², A. Liacini³, R. Yanagida², N. Shigemura², Y. Toyoda². ¹Lewis Katz School of Medicine at Temple University, Philadelphia, PA, ²Division of Cardiovascular Surgery, Department of Surgery, Temple University Hospital, Philadelphia, PA, ³Department of Pathology and Laboratory Medicine, Temple University Hospital, Philadelphia, PA

(545) Does ABO Incompatibility Affect HLA Mismatch Lung Transplant Outcomes?; A. Firoz¹, W. Worrilow¹, A. Kashem², A. Liacini³, R. Yanagida², N. Shigemura², Y. Toyoda². ¹Lewis Katz School of Medicine, Philadelphia, PA, ²Div of Cardiovascular Surgery, Dept of Surgery, Temple University Hospital, Philadelphia, PA, ³Dept of Pathology and Laboratory Medicine, Temple University Hospital, Philadelphia, PA

(546) Association of the 2018 US Heart Allocation Policy Change and the Survival Benefit of Heart Transplantation; S. Tolmie¹, R. Gibbons², N. Narang³, W. Parker⁴. ¹University of Chicago, Pritzker School of Medicine, Chicago, IL, ²Dept of Public Health Sciences, The Univ of Chicago, Chicago, IL, ³Advocate Christ Medical Center, Chicago, IL, ⁴Section of Pulmonary Critical Care, Univ of Chicago Medicine, Chicago, IL

(547) Building the Future: Novel Procurement Network Model to Support Rapidly Growing Cardiothoracic Transplantation Volumes; J. Gramm¹, J. Rubelowsky², C. St. Marie¹. ¹Paragonix Technologies, Waltham, MA, ²Louis Stokes VA Medical Center, Cleveland, OH

(548) Outcome and Expense Between the Group of Patients with Heartmate 3 and Receiving Heart Transplant - Analysis from the Expense Point; C. Tsao¹, Y. Yung¹, C. Wang², N. Chi², S. Huang², H. Yu², R. Hsu², Y. Chen². ¹Nursing, National Taiwan University Hospital, Taipei, Taiwan, ²Cardiovascular Surgery, National Taiwan University Hospital, Taipei, Taiwan

(549) Effect of AAT Augmentation Therapy on Bronchiolitis Obliterans (BO) Development in Mice Model; T. Nakagiri¹, S. Kokilavani², F. Ius³, J. Sabina-Marija². ¹Hannover Medical School, Hannover, Germany, ²Department of Respiratory Medicine, Hannover Medical School, Hannover, Hannover, Germany, ³Department of Cardiothoracic, Transplantation, and Vascular Surgery, Hannover Medical School, Hannover, Germany

(550) A Comparative Multicenter Prospective Study About Mitochondrial Damage Depending on the Type of Donation: Brain Death Donor or Controlled Donor After Circulatory Death. DACMEDAMPs Study; I. Bello¹, R. Martí², E. Coll³, L. Sánchez⁴, E. Miñambres⁵, A. Gomez⁶, J. Campo-Cañaverl⁷, M. Pérez-Redondo⁸, E. Fieira⁹, F. Mosteiro¹⁰, T. Pont⁶, A. Sandiumenge⁶. ¹Thoracic Surgery, Hospital Clínic, Barcelona, Spain, ²VHIR, Barcelona, Spain, ³ONT, Madrid, Spain, ⁴Thoracic Surgery, Hospital Universitario Marqués de Valdecillas, Santander, Spain, ⁵Transplant Coordination Department, Hospital Universitario Marqués de Valdecillas, Santander, Spain, ⁶Transplant Coordination Department, Hospital Universitario Vall d'Hebron, Barcelona, Spain, ⁷Thoracic Surgery, Hospital Puerta de Hierro de Majadahonda, Madrid, Spain, ⁸Intensive Care Unit, Hospital Puerta de Hierro de Majadahonda, Madrid, Spain, ⁹Thoracic Surgery, Complejo Hospitalario Universitario A Coruña, A Coruña, Spain, ¹⁰Intensive Care Unit, Complejo Hospitalario Universitario A Coruña, A Coruña, Spain

(551) Cell Origin of Donor-Derived cfDNA in the Early Post-Transplant Period is Primarily Leukocyte Origin, Not Donor Lung Origin; H. Yamamoto, A. Sundby, J. Allen, S. Keshavjee, G. Wilson, J. Yeung. Toronto Lung Transplant Program and Latner Thoracic Research Laboratories, Toronto General Hospital Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada

(552) Dynamic Profiling of Endothelin-1 Levels During Ex Vivo Lung Perfusion Varies Across Donation Type and is Associated with Post-Transplant Outcome; A. McCaig¹, E. Zhou¹, M. Cypel², S. Keshavjee², A. Sage³, M. Liu³. ¹Institute of Medical Science, Toronto, ON, Canada, ²University Health Network, Toronto, ON, Canada, ³Toronto General Hospital, Toronto, ON, Canada

(553) Indirect Recognition HLA Score as a Predictor of CLAD in Lung Transplant; L. Hoyos Mejia¹, T. Papanotiropoulos², I. Iskender³, M. Schuurmans⁴, R. Hage³, J. Nilsson⁵, G. Lang⁶, I. Opitz⁷. ¹Universtiy Hospital Zurich, Zurich, Switzerland, ²University Hospital of Zurich, Zurich, Switzerland, ³University Hospital Zurich, Zurich, Switzerland, ⁴Univ of Zurich, Zurich, Switzerland, ⁵University Hospital Zurich, Zurich, Switzerland, ⁶University of Vienna, Zurich, Austria, ⁷Universitätsspital Zürich, Zurich, Switzerland

(554) Lung Transplant Outcomes After Implementation of a Hospital-Based 10°C Refrigeration for Cold Organ Preservation; A. Abramov¹, R. Asija², J. Costa¹, L. Benvenuto³, G. Magda³, L. Shah³, A. Dimango³, H. Robbins³, S. Arcasoy³, B. P. Stanifer¹, P. Lemaitre¹, J. Sonett¹, F. D'Ovidio¹. ¹Surgery, Columbia University Irving Medical Center, New York, NY, ²Community Memorial Health Systems, Ventura, CA, ³Pulmonology, Columbia University Irving Medical Center, New York, NY

(555) CRISPR Genome Engineering in Donor Lung During Cyclic EVLP with 10°C Preservation: Usage of TorEx Lung Perfusion System; N. Yoshiyasu, A. Mariscal, A. Salvador, O. Hough, H. Yamamoto, H. Gokhale, H. Shan, M. Chen, Z. Guan, Y. Suzuki, Y. Yao, K. Mesaki, A. Nagoya, S. Juvet, T. K. Waddell, M. Liu, M. Cypel, S. Keshavjee. Toronto Lung Transplant Program and Latner Thoracic Research Laboratories, Toronto General Hospital Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada

(556) Preservation of Bronchial Artery Circulation on Ex-Vivo Lung Perfusion; A. Krishnan¹, M. Fawad², S. Elde², A. Garrison², J. Simmons³, G. N. Cywinska², J. P. McNulty³, B. Chadwick³, E. Heng², C. Ruaengsri², J. Woo², J. W. MacArthur², B. A. Guenthart². ¹Cardiothoracic Surg, Stanford Univ, Palo Alto, CA, ²Cardiothoracic Surg, Stanford Univ SoM, Palo Alto, CA, ³Cardiothoracic Surg, Stanford Health Care, Palo Alto, CA

(557) Tracheal Auto-Transplantation as a Model of Airway Ischemia in Lung Transplantation; A. Krishnan, E. Heng, A. Garrison, D. Alnasir, M. Fawad, S. Elde, B. A. Guenthart, J. Woo, J. W. MacArthur. *Cardiothoracic Surgery, Stanford University School of Medicine, Palo Alto, CA*

(558) Mobile Thermoelectric Cooler for 10 °C Lung Preservation; M. Fawad¹, M. Massey¹, C. Lu¹, A. Krishnan¹, S. Elde¹, W. Trope², Y. Wang³, J. Simmons¹, C. Stark¹, G. Cywinska¹, J. MacArthur¹, Y. Shudo¹, C. Ruaengsri¹, J. Woo¹, B. A. Guenthart¹. ¹Stanford University, Palo Alto, CA, ²Yale University, New Haven, CT, ³University of Michigan, Ann Arbor, MI

(559) Mitochondrial DNA and Ischemia Reperfusion Injury: Development of an Experimental Extra Corporeal Lung Perfusion (EVL) Rat Model; L. Rosso¹, A. Zanella², M. Pinti³, M. Cattaneo⁴, M. Battistin⁵, F. Damarco⁴, V. Selleri³, G. Sinigaglia³, L. Caterina⁶, I. Righi⁷. ¹Thoracic Surgery and Lung Transplantation Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, ²University of Milan, Milan, Italy, ³Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy, ⁴Thoracic and Lung Transplantation Unit, Fondazione IRCCS Ca' Granda Ospedale Policlinico di Milano, Milan, Italy, ⁵Department of Preclinical Research, Fondazione IRCCS Ca' Granda Ospedale Policlinico di Milano, Milan, Italy, ⁶Fondazione IRCCS Ca' Granda Ospedale Policlinico di Milano, Milan, Italy, ⁷Thoracic and Lung Transplantation Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy

(560) WITHDRAWN

(561) Leveraging Advanced Light and Electron Microscopy to Explore the Spatial Biology of Primary Graft Dysfunction; N. Bechet¹, Q. Wang¹, M. Mittendorfer¹, E. Boden¹, G. Hirdman¹, A. Niroomand¹, M. Stenlo², S. Hyllen², H. Ghaidan², L. Pierre², F. Olm¹, S. Lindstedt³. ¹Dept of Clinical Sciences, Lund Univ, Lund, Sweden, ²Dept of Cardiothoracic Surgery, Anesthesia and Intensive Care and Transplantation, Lund Univ Hospital, Lund, Sweden, ³Dept of Cardiothoracic Surgery, Anesthesia and Intensive Care and Transplantation, Lund Univ, Lund, Sweden

(562) COVID-19-Associated ARDS: Not a Risk Factor for Chronic Allograft Dysfunction in Lung Transplant Patients; B. Thomae¹, T. Kaiho¹, A. Bharat¹, G. Buddinger², C. Kurihara¹. ¹Division of Thoracic Surgery, Department of Surgery, Northwestern Univ Feinberg School of Medicine, Chicago, IL, ²Div of Pulmonary and Critical Care Medicine, Department of Medicine, Northwestern Univ Feinberg School of Medicine, Chicago, IL

(563) Midregional-Proadrenomedullin as Biomarker for Heart Failure and Postoperative Outcome After LVAD Implantation; J. Kremer¹, A. Hoerstensmeyer², S. Decker³, M. Karck², A. L. Meyer². ¹Department of Cardiothoracic Surgery, St Vincent's Hospital Sydney, Sydney, Australia, ²Department of Cardiac Surgery, University Hospital Heidelberg, Heidelberg, Germany, ³Department of Anaesthesiology, University Hospital Heidelberg, Heidelberg, Germany

(564) Relation Between Indexed Surgery and Outcomes in Postcardiotomy Venoarterial Extracorporeal Life Support; Y. Hohri¹, Y. Zhao¹, H. Takayama¹, A. Vinogradsky¹, Y. Kaku¹, M. Yuzefpoksya², P. C. Colombo², G. Sayer², N. Uriel², J. Fried², K. Takeda¹. ¹Cardiothoracic and Vascular Surgery, Columbia University Medical Center, New York, NY, ²Cardiology, Columbia University Medical Center, New York, NY

(565) Role of Acquired Von Willebrand Syndrome in the Development of Bleeding Complications in Patients Treated Using Right Ventricular Microaxial Flow Pump Devices: A Retrospective Cohort Study; M. Oezkur¹, S. Reda², H. Rühl³, T. Nils⁴, S. Kreyer⁴, G. D. Duerr⁵, E. Charitos⁶, M. Medina⁷, S. Zimmer⁸, C. Putensen⁴, H. Treede⁷. ¹Cardiovascular Surgery, University Medicine Mainz, Mainz, Germany, ²Department of Haematology, University Hospital of Bonn, Bonn, Germany, ³Department of Haematology, Bonn, Germany, ⁴Department of Anesthesiology and Intensive Care Medicine, University Hospital of Bonn, Bonn, Germany, ⁵Department of Cardiovascular Surgery, University Hospital Mainz, University Hospital Mainz, Germany, ⁶Kerckhoff-Klinik GmbH, Bad Nauheim, Germany, ⁷Department of Cardiovascular Surgery, University Hospital Mainz, Mainz, Germany, ⁸Department of Cardiology, University Hospital of Bonn, Bonn, Germany

(566) Outcome of Right Ventricular Microaxial Pump Support in Patients Undergoing Cardiac Surgery; M. Oezkur¹, T. Nils², G. D. Duerr³, S. Zimmer⁴, M. Medina⁵, H. Treede⁵. ¹Department of Cardiovascular Surgery, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany, ²Department of Anesthesiology and Intensive Care Medicine, University Hospital of Bonn, Bonn, Germany, ³Department of Cardiovascular Surgery, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany, ⁴Department of Cardiology, University Hospital of Bonn, Bonn, Germany, ⁵Department of Cardiovascular Surgery, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany

(567) Short-Term Mechanical Circulatory Support Over 65 Years. Is It Worth the Effort?; E. Sandoval¹, F. Sbraga², A. Eixeres³, S. Villar⁴, M. Perez Guillen⁵, I. Morales-Rey¹, L. Garcia Alcalde⁶, E. Perez de la Sota³, J. Sarralde⁶. ¹Cardiovascular Surgery Department, Hospital Clinic, Barcelona, Spain, ²Cardiac Surgery Dept, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Spain, ³Cardiac Surgery Dept, Hospital Universitario 12 de Octubre, Madrid, Spain, ⁴Cardiac Surgery Dept, Hospital Universitario Puerta de Hierro, Majadahonda-Madrid, Spain, ⁵Cardiac Surgery Dept, Hospital La Fe, Valencia, Spain, ⁶Cardiovascular Surgery Dept, Hospital Marques de Valdecilla, Santander, Spain

(568) Outcomes Comparison of Extracorporeal Membrane Oxygenation Support for Cardiogenic Shock with Acute Decompensated Heart Failure versus Acute Myocardial Infarction; G. E. Almodovar-Cruz, Y. Zhao, A. Vinogradsky, T. Powley, A. Lin, Y. Kaku, M. Yuzefpolskaya, P. Colombo, G. Sayer, N. Uriel, J. Fried, K. Takeda. *Columbia University Irving Medical Center, New York, NY*

(569) Temporary Centrimag BiVAD Support as a Bridge to Heart Transplantation: The Last Decade of Experience at Royal Papworth Hospital; S. Aurovind¹, Z. Abdul Aziz², A. Shafi³, S. Poon³, L. Wang³, S. Das De³, B. Al-Alao³, A. Al-Adhami³, K. Wang³, C. Lewis³, A. Kydd³, L. Martinez Marin³, S. Bhagra³, J. Parameshwar³, M. Rafiq³, P. Kaul³, S. Pettit³, M. Berman³, D. Jenkins³, S. Tsui³, H. Smail³. ¹*Cardiothoracic Transplant, Royal Papworth Hospital, Cambridge, UK*, ²*NHCS, Singapore, Singapore*, ³*Royal Papworth Hospital, Cambridge, UK*

(570) Short-Term Outcomes of Patients Presented with Cardiogenic Shock and Treated with the Impella 5.x Mechanical Circulatory Support; S. Shehada¹, A. Dimitriou², S. Jahrkas², I. Balaj², A. Sven³, M. Thielmann², A. Koch², N. Pizanis², H. Ali², M. Kamler². ¹*Dept of Thoracic & CV Surg, West German Heart & Vascular Ctr, Univ Hosp Essen, Univ Duisburg-Essen, Essen, Germany*, ²*Dept of Thoracic & CV Surg, West German Heart & Vascular Ctr, Univ Hosp Essen, Essen, Germany*, ³*Dept of Anesthesiology & Intensive Care Medicine, Univ Hosp Essen, Essen, Germany*

(571) Propella: Single-Center Experience and Outcomes; A. Ramamurthi, B. Seadler, W. Andrews, A. Ubert, L. Durham. *Medical College of Wisconsin, Milwaukee, WI*

(572) Utilization of ECMO in Peri-Partum and Post-Partum Patients; K. Chickerillo¹, J. Okray¹, A. Chincio¹, V. Kagan², C. LaBuhn¹, K. Meehan³, K. Moore⁴, R. Rose⁵, A. Alund¹, T. Song¹. ¹*University of Chicago, Chicago, IL*, ²*Northwestern Memorial Hospital, Chicago, IL*, ³*University of Chicago Medical Center, Chicago, IL*, ⁴*The University of Chicago, Chicago, IL*, ⁵*University of Chicago Medicine, Chicago, IL*

(573) Durable Left Ventricular Assist Device Implantation in Jehovah's Witness Patients; K. Chickerillo¹, K. Meehan², A. Chincio¹, C. LaBuhn¹, K. Moore³, J. Okray¹, N. Wright¹, V. Hwang¹, S. Jain¹, V. Jeevanandam². ¹*University of Chicago, Chicago, IL*, ²*University of Chicago Medical Center, Chicago, IL*, ³*The University of Chicago, Chicago, IL*

(574) Acute Hemodynamic and Echocardiographic Consequences of Surgically-Implanted Axial Flow Pumps in Patients with Cardiogenic Shock; A. Iyengar¹, M. Asher¹, M. Helmers¹, N. Weingarten¹, D. Rekhman¹, C. Song¹, J. DePaolo¹, M. Shin¹, A. Brown¹, J. Wald¹, M. Cevasco². ¹*University of Pennsylvania, Philadelphia, PA*, ²*Hospital of the University of Pennsylvania, Philadelphia, PA*

(575) Axillary Temporary Mechanical Circulatory Support to Bridge Cardiogenic Shock Patients to Heart Transplantation; R. A. Aleman¹, F. A. Napoli¹, D. A. Baran², M. A. Velez³, J. A. Estep³, C. A. Sheffield¹, J. L. Navia¹, N. Brozzi¹. ¹*CardioThoracic Surgery, Cleveland Clinic Florida, Weston, FL*, ²*Cardiology, Cleveland Clinic Heart, Vascular and Thoracic Institute, Weston, FL*, ³*Cardiology, Cleveland Clinic Florida, Weston, FL*

(576) Assessment of Platelet Response to Aspirin Therapy and Hemocompatibility-Related Adverse Events in HeartMate 3 Left Ventricular Assist Device Recipients; T. Schloeglhofer¹, H. Al Asadi², T. Abart², C. Schwarz², H. Schima¹, J. Riebandt², C. Marko², D. Wiedemann², B. Messner², D. Zimpfer³. ¹*Department of Cardiac Surgery, Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria*, ²*Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria*, ³*Department of Cardiac Surgery, Medical University of Graz and Medical University of Vienna, Graz and Vienna, Austria*

(577) Evaluation of Hemolysis in One Hundred Sixty Nine Impella 5.5-Supported Patients; J. S. Clothier¹, L. Lester¹, S. Kobsa¹, M. Bojko¹, N. D. Rajeev¹, J. Praeger¹, H. A. Theeuwen¹, B. Abt¹, J. Greenberg¹, J. Nattiv², A. Vaidya², K. Johnston¹, R. Lee¹. ¹*Division of Cardiac Surgery, Keck School of Medicine of University of Southern California, Los Angeles, CA*, ²*Division of Cardiovascular Medicine, Keck School of Medicine of University of Southern California, Los Angeles, CA*

(578) A Case Series of Gastrointestinal Bleeding Related to Arteriovenous Malformations with Impella 5.5; Y. Matsuzaki, C. Kunavarapu, M. Kwan, M. Shah, T. Amer, M. Funamoto. *Heart and Lung Inst, Heart Failure and Transplant Ctr, Methodist Hosp San Antonio, San Antonio, TX*

(579) The Effects on Renal Function with Impella 5.5 Heart Pump Supports on Patients with Cardiorenalsyndrome Who Underwent Heart Transplantation; Y. Matsuzaki, C. Kunavarapu, M. Kwan, M. Shah, T. Amer, M. Funamoto. *Heart and Lung Institute, Heart Failure and Transplant Cneter, Methodist Hospital San Antonio, San Antonio, TX*

(580) Impact of Stroke After Durable LVAD Implantation in Patients Bridged with Micro-Axial Flow Pump: Insights from an International Registry; A. Loforte¹, G. Gallone¹, D. Lewin², A. Bernhardt³, S. Rojas⁴, M. Billion⁵, A. Meyer⁶, I. Netuka⁷, J. Kooij⁸, M. Pieri⁹, M. Szymanski¹⁰, C. Moeller¹¹, P. Akhyari¹², K. Jawad¹³, B. Schmack¹⁴, G. Farber¹⁵, M. Medina¹⁶, A. Haneya¹⁷, D. Zimpfer¹⁸, G. Nersesian², P. Lanmueller², A. Spitaleri¹, M. Oezkur¹⁶, I. Djordjevic¹⁹, D. Saeed¹³, J. Stein², A. O. Kraaijeveld¹⁰, G. M. De Ferrari¹, M. Boffini¹, F. Gustafsson¹¹, A. Scandroglio⁹, B. Meyns⁸, S. Hofmann⁵, J. Belohlavek⁷, J. Gummert⁴, E. Potapov², M. Rinaldi¹. ¹*Univ of Turin, Turin, Italy*, ²*Deutsches Herzzentrum der Charité, Berlin, Germany*, ³*Univ Heart & Vascular Ctr, Hamburg, Germany*, ⁴*Heart & Diabetes Ctr, Bad Oeynhausen, Germany*, ⁵*Schüchtermann Clinic, Bad Rothenfelde, Germany*, ⁶*Universitätsklinikum, Heidelberg, Germany*, ⁷*IKEM, Prague, Czech Republic*, ⁸*Univ Hospitals, Leuven, Belgium*, ⁹*Ospedale San Raffaele, Milan, Italy*, ¹⁰*Univ MC, Utrecht, Netherlands*, ¹¹*Rigshospitalet, Copenhagen, Denmark*, ¹²*Univ Hosp, Duesseldorf, Germany*, ¹³*Leipzig Heart Ctr, Leipzig, Germany*, ¹⁴*Univ of Essen, Essen, Germany*, ¹⁵*Univ Hospital, Jena, Germany*, ¹⁶*Univ of Mainz, Mainz, Germany*, ¹⁷*Unif of Kiel, Kiel, Germany*, ¹⁸*Medical Univ of Vienna, Vienna, Austria*, ¹⁹*Univ Hospital, Cologne, Germany*

(581) Effect of the Fully Magnetically Levitated Left Ventricular Assist Device at Low and High RPM on Hemolysis and Thrombosis: In Vitro Evaluation; N. Kocak¹, U. Kervan¹, F. Can², D. E. Sert¹, M. Akdi¹, O. Kahvecioglu¹, Z. Catav¹. ¹Cardiovascular Surgery, Ankara Bilkent City Hospital, Ankara, Turkey, ²Hematology, Ankara Bilkent City Hospital, Ankara, Turkey

(582) Implantation of a Novel Stent Graft Accessory for Left Ventricular Assist Devices in a Pig; F. Meissner, M. Schoen, H. Vestner, M. Schimmel, M. Costa Galbas, H. Straky, M. Czerny, W. Bothe. Dept of Cardiovascular Surgery, MC - Univ of Freiburg, Freiburg, Germany

(583) Impact of Left Ventricular Size on Outcomes Following Heartmate 3 Left Ventricular Assist Device Implantation; G. Nersesian¹, A. Jaiswal², J. Stein¹, E. Potapov³, D. Baran⁴. ¹German Heart Centre of Charite, Berlin, Germany, ²Hartford HealthCare, Hartford, CT, ³German Heart Institute, Berlin, Germany, ⁴Cleveland Clinic Heart, Vascular and Thoracic Institute, Cleveland, OH

(584) Predictors of Return to Operating Room for Bleeding After Left Ventricular Assist Device; A. Jones¹, S. Hoffman¹, B. Hauser¹, A. Elangovan¹, M. Hoque¹, A. Goodman², M. Fryer², J. Dalton², Y. Gu³, I. Gosev⁴, K. Wood². ¹School of Medicine and Dentistry, University of Rochester, Rochester, NY, ²Department of Surgery, Division of Cardiac Surgery, University of Rochester Medical Center, Rochester, NY, ³Department of Anesthesia and Perioperative Care, University of Rochester Medical Center, Rochester, NY, ⁴University of Rochester Medical Center

(585) Is Cold Gold? Equivalence Between Intercostal Nerve Cryoablation and Multimodal Analgesia with Regional Nerve Blocks in Less Invasive LVAD Implantation; A. Goodman¹, A. Elangovan², A. Jones², B. Hauser², S. Hoffman², I. Gosev¹, K. Wood¹. ¹Dept of Surgery, Div of Cardiac Surgery, Univ of Rochester Medical Center, Rochester, NY, ²Univ of Rochester School of Medicine and Dentistry, Rochester, NY

(586) Severe Peripheral Arterial Disease is Associated with Increased Limb Complications and Stroke Rate Post LVAD Implantation, but Not Associated with Increased Mortality; M. Williams, P. Tasoudis, A. Sukhvasi, S. Buckeridge, W. Mostertz, M. Byku, A. Merlo. University of North Carolina, Chapel Hill, NC

(587) Predicting Mortality in the Fully Magnetically Levitated Era: Does Including Older Generation Devices Improve Modeling?; B. A. Singletary¹, S. Lewis¹, B. Jeager², D. Koehl¹, R. Cantor¹, R. Rudraraju¹, J. Mehaffey³, P. Shah⁴, F. Pagani⁵, J. K. Kirklín¹. ¹Kirklin Solutions, Hoover, AL, ²Wake Forest University School of Medicine, Winston-Salem, NC, ³West Virginia University, Morgantown, WV, ⁴Inova Heart and Vascular Institute, Falls Church, VA, ⁵University of Michigan, Ann Arbor, MI

(588) Surgical Interventions for Accumulation of Biodebris Causing Outflow Graft Obstruction and Thrombosis Following HeartMate 3; A. V. Vinogradsky¹, M. A. Hynds¹, Y. Kaku¹, J. S. Leb², M. Yuzefpolskaya³, P. Colombo³, G. Sayer³, N. Uriel³, Y. Naka¹, K. Takeda¹. ¹Division of Cardiac, Thoracic & Vascular Surgery, Department of Surgery, Columbia University Irving Medical Center, New York, NY, ²Columbia University Irving Medical Center, New York, NY, ³Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, NY

(589) Liberal Use of Venoarterial Extracorporeal Membrane Oxygenation in Combined Sequential Heart-Liver Transplantation; A. V. Vinogradsky¹, S. N. Nguyen¹, A. Mathur², K. Takeda¹. ¹Division of Cardiac, Thoracic & Vascular Surgery, Department of Surgery, Columbia University Irving Medical Center, New York, NY, ²Department of Surgery & Center for Liver Disease and Transplantation, Columbia University Irving Medical Center, New York, NY

(590) Outcome of Left Ventricular Assist Device Implantation with Concomitant Aortic Valve Procedure; O. D. Bhadra¹, J. Pausch², C. Volgmann¹, Y. Alassar¹, M. Barten², H. Reichenspurner³, A. Bernhardt². ¹University Heart & Vascular Center Hamburg, Hamburg, Germany, ²University Heart and Vascular Center Hamburg, Hamburg, Germany, ³University Hospital Hamburg-Eppendorf, Hamburg, Germany

(591) Outcomes of Concomitant Tricuspid Valve Repair with Contemporary Ventricular Assist Device Implantation Outcomes of Concomitant Tricuspid Valve Repair with Contemporary Left Ventricular Assist Device Implant; A. Brandt, E. Chung, S. Emani, A. Mehal, J. Stokes, S. Gupta, C. Bartone, G. Answini, G. Egnaczyk. The Christ Hospital Health Network, Cincinnati, OH

WEDNESDAY, 10 APRIL, 2024

6:00 - 7:00 p.m.

POSTER SESSION 1: Pulmonology (Non-CME)

Location: Poster Hall

Core Therapies: HEART, LUNG, MCS, PVD

Practice Areas: Pulmonology, Anesthesiology and Critical Care, Cardiology, Cardiothoracic Surgery, Infectious Diseases, Nursing and Allied Health, Pathology, Pediatrics, Pharmacy, Pulmonology, Research and Immunology

Session Summary: Posters in this session include presentations on multiple topics where the Practice Areas of the research is focused in Pulmonology. Designated Poster Discussants will circulate through the poster hall during the session to engage poster presenters in quality discussions of their abstracts. **CME is not offered for poster sessions.**

Poster Discussants: Christian Benden, Switzerland, Marie Budev, USA, Fay Burrows, Australia, François Carlier, Belgium, Kevin Chan, USA, Satish Chandrashekar, USA, Joshua Diamond, USA, Alex Dragnich, USA, Emily Eichenberger, USA, Meg Fregoso, USA, Laurent Godinas, Belgium, Alexander Graham, USA, Are Holm, Norway, Peter Jaksch, Austria, Brian Keller, USA, Adrian Christopher Lawrence, USA, James Lordan, UK, Erin Lowery, USA, Gabriela Magda, USA, Jorge Mallea, USA, Hannah Mannem, USA, Letizia Corinna Morlacchi, Italy, Reinaldo Rampolla, USA, Leslie Seijo, USA, Vincent Valentine, USA, Adriana Valverde Zuniga, Costa Rica, Mrinalini Venkata Subramani, USA, Erik Verschuuren, Netherlands, Rajat Walia, USA, Andrea Zajacova, Czech Republic

(592) Toll-Like Receptor 4, Type 1 Interferon and Type 2 Interferon Independently Induce a Pro-Inflammatory Phenotype in Alveolar Macrophages from Lung Transplant Recipients; J. Semenchuk¹, S. Moshkelgoshia², A. Duong², T. Martinu³, S. Juvet². ¹University of Toronto, Toronto, ON, Canada, ²University Health Network, Toronto, ON, Canada, ³Toronto General Hospital/UHN, Toronto, ON, Canada

(593) Activation of Fibroblast LRP1 by AT2-Secreted MDK Affects OTUB1/SLC7A11 Ubiquitination to Inhibit Fibroblast Ferroptosis in Idiopathic Pulmonary Fibrosis; H. Wenjie¹, W. Zitao², G. Fei², W. Dong², C. Jingyu². ¹Jiangnan University, Jiangsu, Wuxi, China, ²The affiliated Wuxi People's Hospital of Nanjing Medical University, Jiangsu, Wuxi, China

(594) Clinical Relevance of Multi-Parametric CFDNA Study for Diagnosis of Early Events After Lung Transplantation; P. Pedini¹, B. Coiffard², A. Sébastien¹, S. Casas³, A. Basire¹, C. Frassati¹, J. Chiaroni¹, M. Reynaud⁴, C. Picard¹. ¹Immunogenetics Laboratory, Etablissement Français du Sang, Marseille, France, ²Lung Transplant Department, APHM Hospital Nord, Marseille, France, ³CareDx, Stockholm, Sweden, ⁴Lung Transplant Department, APHM Hospital Nord, Marseille, France

(595) Utility of Breath Volatome Analysis in Lung Transplant Recipients; M. Ledenko¹, L. Mercado¹, D. A. Trujillo², K. Yost³, T. Patel¹, F. Alvarez³, T. Narula³. ¹Transplantation, Mayo Clinic, Jacksonville, FL, ²Pulmonary, Allergy and Sleep Medicine, Mayo Clinic, Jacksonville, FL, ³Lung Failure and Transplant, Mayo Clinic, Jacksonville, FL

(596) NKG2D - A Potential Target for Alloreactive CD8 T Cells; K. Moghbeli, M. Lipp, A. Craig, J. Sembrat, M. Bueno, O. Eickelberg, M. Snyder. University of Pittsburgh, Pittsburgh, PA

(597) The Airway Transcriptome Identifies Co-Expression Modules of Innate and Adaptive Immune Activation in CLAD; K. Moghbeli, C. Iasella, S. Lieber, I. Popescu, K. Chen, J. McDyer. University of Pittsburgh, Pittsburgh, PA

(598) The Effect of Resolvin D1, Resolvin E1, and Their Precursors on Lung Ischemia-Reperfusion Injury; Y. Morimura, S. Tanaka, M. Takahashi, Y. Yutaka, A. Ohsumi, D. Nakajima, H. Date. Thoracic Surgery, Kyoto University Hospital, Kyoto, Japan

(599) Contribution of Donor White Blood Cells to Lactate Levels During Ex Vivo Lung Perfusion; C. Chan¹, L. Chacon², A. Farooqui³, A. Elsenousi³, A. Mattar⁴, G. Loo⁴, Y. Wang¹. ¹Innovative Device and Engineering Applications, Texas Heart Institute, Houston, TX, ²Biorepository Core, Texas Heart Institute, Houston, TX, ³Texas Heart Institute, Houston, TX, ⁴Baylor College of Medicine, Houston, TX

(600) Assessment of the Effect of Temperature on Hemocompatibility and Organ Stability During Prolonged Ex Vivo Lung Perfusion - A Proof of Concept Study; C. Chan¹, A. Farooqui¹, H. Al-Sahl¹, L. Chacon², A. Elsenousi³, A. Matter³, G. Loo³, Y. Wang¹. ¹IDEA lab, Texas Heart Inst, Houston, TX, ²Biorepository and Biospecimen Process Center, Texas Heart Inst, Houston, TX, ³Baylor College of Medicine, Houston, TX

(601) Decoding T Cell Clonal Dynamics in Acute Lung Rejection; A. Potter¹, K. Wikenheiser-Brokamp¹, D. Hildeman¹, N. Sharma², M. Gu¹, K. Patel³, M. Qureshi³, M. M. Khan², C. Wallace¹, A. Ziady¹, D. Hayes¹. ¹Cincinnati Children's Hospital Medical Center / Univ of Cincinnati, Cincinnati, OH, ²Brigham & Women's Hospital / Harvard Medical School, Boston, MA, ³Univ of South Florida / Tampa General Hospital, Tampa, FL

(602) Gene Expression Analysis of B and T Cells in De Novo mTOR Inhibitor Recipients Over Time; H. Akyildiz¹, S. Nasrollahi Shirazi², S. Auner³, K. Hoetzenecker³, P. Jaksch⁴, A. Benazzo³. ¹Med Uni Vienna, Vienna, Austria, ²Thoracic Surgery, Medical University of Vienna, Vienna, Austria, ³Medical University of Vienna, Vienna, Austria, ⁴Medical University Vienna, Austria, Vienna, Austria

(603) High-Grade Eosinophils on Diagnostic Transbronchial Biopsy are Associated with Chronic Lung Allograft Dysfunction After Lung Transplantation; D. R. Darley¹, V. Sivasubramaniam², M. Qiu², W. Barrett², S. Wong², L. Thwe¹, K. Tonga³, T. Martinu⁴, P. MacDonald⁵, M. Plit¹. ¹Lung Transplant Unit, St Vincent's Hospital, Sydney, Australia, ²Pathology, St Vincent's Hospital, Sydney, Australia, ³St Vincent's Hospital, Sydney, Australia, ⁴Toronto General Hospital/UHN, Toronto, ON, Canada, ⁵Heart Transplant Unit, St Vincent's Hospital, Sydney, Australia

(604) FEV₁ Monitoring of Allograft Function: Virtual or Reality?; M. Greer¹, S. Dumschat¹, S. Kruszona², N. de Manna², J. Salman², T. Welte¹, A. Ruhparwar², F. Ius². ¹Dept. of Respiratory Medicine and Infectious Diseases, Hannover Medical School, Hannover, Germany, ²Dept. of Cardiothoracic, Vascular and Transplantation Surgery, Hannover Medical School, Hannover, Germany

(605) Outcomes in Lung Transplantation: Going Beyond a One-Size Fits All Approach?; M. Greer¹, B. Liu², S. Dumschat¹, N. D. de Manna³, J. Salman³, D. DeLuca², A. Ruhparwar³, T. Welte¹, C. Falk⁴, F. Ius³. ¹Dept. of Respiratory Medicine & Infectious Diseases, Hannover Medical School, Hannover, Germany, ²DZL/BREATH, German Center for Lung Research, Hannover, Germany, ³Clinic for Cardiothoracic, Vascular, and Transplantation Surgery, Hannover Medical School, Hannover, Germany, ⁴Hannover Medical School, MHH, Hannover, Germany

(606) Long-Term Maintenance of Pulmonary Function in the Contralateral Unaffected Lung with Chronic Lung Allograft Dysfunction After Bilateral Living-Donor Lobar Lung Transplantation; M. Umeda¹, S. Sugimoto², T. Hayashi¹, T. Ryuko¹, H. Ujike¹, S. Kawana¹, Y. Kubo¹, S. Tanaka², H. Choshi², M. Ishihara², K. Hashimoto², K. Miyoshi², M. Okazaki², S. Toyooka¹. ¹Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ²Okayama University Hospital, Okayama, Japan

(607) Extracorporeal Photopheresis for CLAD: The Relationship Between Cycle Modification and Response; V. Vertui¹, K. Mucaj², D. F. Briganti¹, C. Mortellaro³, C. Perotti³, C. Klersy⁴, F. Meloni¹, C. Del Fante³. ¹Transplant Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, ²Dept of Internal Med and Medical Therapeutics, Univ of Pavia, Pavia, Italy, ³Immunohaematology and Transfusion Service, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, ⁴SSD Biostatistics e Clinical Trial Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

(608) Exosomal Microrna-17-5p and Microrna-150-5p in Plasma as Diagnostic Markers of Chronic Lung Allograft Dysfunction After Lung Transplantation; S. Kawana, S. Sugimoto, H. Choshi, S. Tanaka, K. Miyoshi, T. Hayashi, M. Umeda, T. Ryuko, H. Ujike, Y. Kubo, K. Hashimoto, K. Shien, K. Suzawa, H. Yamamoto, M. Okazaki, S. Toyooka. Okayama University Hospital, Okayama, Japan

(609) Longitudinal Increases in Bronchoalveolar Lavage Interleukin-6, Interleukin-8, Macrophage Inflammatory Protein-1a, and Transforming Growth Factor β Predict Progressive Chronic Lung Allograft Dysfunction; B. O'Sullivan¹, M. Tan¹, S. H. Apte¹, T. de Silva¹, P. Groves¹, V. P. Lutzky¹, G. Westall², D. Darley³, M. Musk⁴, A. Glanville³, M. Malouf³, C. Holmes-Liew⁵, M. Sturm⁶, S. Lawrence⁴, D. Bushell², L. Holsworth², N. Lawson⁴, L. Singleton³, S. Timmins¹, D. Enever¹, H. Wildermuth⁷, O. Daka¹, B. Cooper¹, A. Pham¹, L. Winks¹, S. Haines², L. Zhang¹, B. Levvey², Y. Cristiano², M. Yaw⁴, S. Yerkovich⁸, G. Snell², M. Trotter¹, A. Carew¹, M. Holmes⁵, A. Fiene¹, C. Divithotawela¹, J. A. Mackintosh¹, P. Hopkins¹, D. C. Chambers¹. ¹Queensland Lung Transplant Service, The Prince Charles Hospital, Brisbane, Australia, ²The Alfred Hospital, Melbourne, Australia, ³St. Vincent's Hospital, Sydney, Australia, ⁴Fiona Stanley Hospital, Perth, Australia, ⁵Royal Adelaide Hospital, Adelaide, Australia, ⁶Isopogen Pty Ltd, Western Australia, Australia, ⁷Queensland Lung Transplant Service, The Prince Charles Hospital, Brisbane, United Kingdom, ⁸Menzies School of Health Research and Faculty of Health, Queensland University of Technology, Brisbane, Australia

(610) Bronchoalveolar Lavage and Plasma Proteomes Identify Features of Disease That Segregate Lung Transplant Recipients with versus without Bronchiolitis Obliterans Syndrome; E. J. Skala¹, M. E. Siefert¹, A. S. Potter², N. Sharma³, D. Hayes², A. G. Ziady¹. ¹Division of Bone Marrow Transplantation, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Heart Institute/Pulmonary Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Transplant Program, Brigham & Women's Hospital, Boston, MA

(611) Evaluation of Use of Tacrolimus vs. Cyclosporine on CLAD Incidence and Allograft Survival in the ISHLT Registry; M. P. Combs¹, K. Walter², H. Hixson², E. A. Belloli¹, K. M. Chan¹, A. C. Chang³, D. M. Lyu¹. ¹Medicine, University of Michigan, Ann Arbor, MI, ²Pharmacy, Michigan Medicine, Ann Arbor, MI, ³Surgery, University of Michigan, Ann Arbor, MI

(612) Ten Years Since Photopheresis. Have We Change our Clinical Practice?; M. Aguilar Perez, R. Laporta Hernandez, J. Bueno Cabrera, C. Garcia Fadul, M. Erro Iribarren, M. Lazaro Carrasco de la Fuente, C. Almonacid Sanchez, P. Ussetti Gil. University Puerta de Hierro Majadahonda Hospital, Majadahonda, Spain

(613) Post-Transplant Use of Renin-Angiotensin Inhibitors and Chronic Lung Allograft Dysfunction (CLAD); G. Berra¹, S. Wang², L. Levy¹, M. Kawashima¹, B. Renaud-Picard¹, R. Ghany¹, S. Farkona³, S. Keshavjee¹, M. Aversa¹, L. Singer¹, A. Konvalinka³, J. Tikkanen¹, E. Huszti², T. Martinu¹. ¹Toronto Lung Transplant Program, Toronto, ON, Canada, ²Biostatistics Research Unit, UHN, Toronto, ON, Canada, ³Toronto General Hospital Research Institute, Toronto, ON, Canada

(614) Radiographic Phenotypes and Inter-Rater Agreement at Chronic Lung Allograft Dysfunction (CLAD) Onset; M. Dianti¹, G. Rani Karur², A. Rai², C. Houbois², L. Levy¹, M. Aversa¹, C. Chow¹, T. Martinu¹, M. McClinnis². ¹Toronto Lung Transplant Program, UHN, Toronto, ON, Canada, ²UHN, Toronto, ON, Canada

(615) Repair of Endothelial Glycocalyx Improves Lung Function During Human Ex Vivo Lung Perfusion; S. Hogan¹, C. Givens¹, L. Buie¹, L. Wade¹, S. Popa², B. Wannberg³, J. Benjamin³, T. Petersen¹. ¹United Therapeutics, Durham, NC, ²Lung Bioengineering Inc., Silver Springs, MD, ³Lung Bioengineering, Jacksonville, FL

(616) Development of a Machine Learning-Based Lung Allocation System for the Maximum Benefit of Lung Transplantation; W. Cho¹, H. Yeo¹, M. Ha², Y. Kim³. ¹Pusan National University Yangsan Hospital, Yangsan, South Korea, ²Pusan National University Medical Research Institute, Busan, South Korea, ³Pusan National University School of Medicine, Busan, South Korea

(617) Does Prolonged Cold Ischemia Time Associate with an Increased Risk of Airway Complications in Lung Transplantation; A. Khan, A. Yuen, R. Rampolla, L. Zaffiri. Cedars-Sinai Medical Center, Los Angeles, CA

(618) Evidence of Alloimmune Activation Early After Lung Transplantation and its Impact on Graft Survival; S. Tanaka¹, N. Tanimine², M. Takahashi¹, S. Nishikawa¹, Y. Yutaka¹, A. Ohsumi¹, M. Hamaji¹, D. Nakajima¹, Y. Tanaka², H. Ohdan², H. Date¹. ¹Thoracic Surgery, Kyoto University Hospital, Kyoto, Japan, ²Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan

(619) De Novo Donor Specific Antibodies is Associated with Death from Graft Failure in Lung Transplantation; A. T. Logan¹, E. Heiman², K. Patel³, M. Qureshi³. ¹Pharmacy, Tampa General Hospital, Tampa, FL, ²Intermountain Medical Center, Salt Lake City, UT, ³University of South Florida/Tampa General Hospital, Tampa, FL

(620) Association of Donor-Derived Cell-Free DNA Levels with the Development of De Novo Donor-Specific Antibodies and Risk of Death in Lung Transplant Recipients; M. Alnababteh¹, M. Keller², L. Ponor³, P. Shah⁴, H. Kong⁵, J. Mathew⁶, T. Andargie⁷, R. Brower², W. Park⁸, A. Charya⁹, H. Luikart¹⁰, T. A. Intrieri¹¹, S. Aryal¹², S. Nathan¹³, J. Orens⁶, K. Khush¹⁴, M. Jang⁸, S. Agbor-Enoh¹⁵. ¹Critical Care Medicine, NIH, Bethesda, MD, ²NIH, Bethesda, MD, ³Johns Hopkins SoM, Baltimore, MD, ⁴Johns Hopkins Univ SoM, Baltimore, MD, ⁵NHLBI, NIH, Bethesda, MD, ⁶Johns Hopkins Univ, Baltimore, MD, ⁷NHLBI, Bethesda, MD, ⁸NHLBI/NIH, Bethesda, MD, ⁹NHLBI, Bethesda, MD, ¹⁰Stanford Hospital, Stanford, CA, ¹¹Stanford, Stanford, CA, ¹²Inova, Fairfax, VA, ¹³Inova Fairfax Hospital, Fairfax, VA, ¹⁴Stanford Univ, Stanford, CA, ¹⁵NIH, Bethesda, MD

(621) Bronchoalveolar Lavage Fluid Eosinophilia Associated with Worse Outcomes After Lung Transplant; J. Hwang, D. Brezhnev, L. Shitanishi, P. Chen, R. Rampolla, L. Zaffiri. Cedars-Sinai Medical Center, Los Angeles, CA

(622) Novel Treatment Protocol with Perioperative Plasmapheresis and Eculizumab for Highly Sensitized Lung Transplant Patients; T. Kaiho¹, A. Arunachalam², L. Jeffrey², B. Thomae¹, R. Tomic², S. Budinger², A. Bharat¹, C. Kurihara¹. ¹Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL

(623) Evaluating Mortality Risk in Elderly Lung Transplant Patients; T. Kaiho¹, A. Arunachalam², B. Thomae³, R. Tomic², S. Budinger², A. Bharat³, C. Kurihara³. ¹Surgery, Northwestern University, Chicago, IL, ²Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ³Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL

(624) Belatacept-Based Immunosuppression Regimen Can Stabilize Allograft Function in Patients with Antibody-Mediated Rejection; P. Kumar¹, A. Ishaq¹, M. Younis², V. Kaza¹, J. Murala¹, A. Lawrence¹, S. Bollineni¹, N. Ladikos³, M. Mohanka¹, J. Weston¹, M. Wait¹, L. Mahan¹, M. Peltz¹, C. Heid¹, L. Huffman¹, S. Keshavmurthy¹, F. Torres¹, A. Emtiazoo², I. Timofte¹. ¹UT Southwestern Medical Center, Dallas, TX, ²University of Florida, Gainesville, FL, ³Texas Tech University Health Scientist Center, Dallas, TX

(625) TTV Guided Belatacept Conversion After Lungtransplantation: Report of 7 Cases; P. Jaksch¹, Z. Kovacs², G. Muraközy³, E. Hielle-Wittmann⁴, C. Aigner⁵, K. Hötzenecker⁶, A. Benazzo⁵. ¹Medical University Vienna, Austria, Wien, Austria, ²Thoracic Surgery, Medical University Vienna, Vienna, Austria, ³Thoracic Surgery, Medical University Vienna, wien, Austria, ⁴Medical University Vienna, Austria, ⁵Thoracic Surgery, Medical University of Vienna, Vienna, Austria, ⁶Thoracic Surgery, Medical University Vienna, Wien, Austria

(626) Immune Cell Function Assay as a Monitoring Tool While on Augmented or Unconventional Immunosuppression; S. Nandavaram, X. Mei, M. Anstead. University of Kentucky, Lexington, KY

(627) Renal Function Early After Lung Transplantation with Immunosuppression Based on Tacrolimus versus Ciclosporin (The ScanCLAD Study); T. K. Lund¹, J. Magnusson², P. Raivio³, I. Leuckfeld⁴, J. Svahn⁵, E. Holmberg⁶, P. Bredahl Jensen⁷, M. Perch⁸, G. Dellgren⁹. ¹Section for Lung Transplantation, Dept. of Cardiology, Rigshospitalet, Univ Hosp of Copenhagen, Copenhagen, Denmark, ²Dept. of Pulmonology, Sahlgrenska Univ Hosp, Gothenburg, Sweden, ³Dept. of Cardiac Surg, Heart & Lung Ctr, Helsinki Univ Hosp, Helsinki, Finland, ⁴Dept. of Resp Med, Oslo Univ Hosp, Oslo, Norway, ⁵Dept. of Pulm and Allergology, Skåne Univ Hosp, Lund, Sweden, ⁶Dept. of Oncology, Inst of Clinical Sci, Univ of Gothenburg, Gothenburg, Sweden, ⁷Dept. of Thoracic Anesthesia, Rigshospitalet, Univ Hosp, Copenhagen, Denmark, ⁸Section for Lung Transplantation, Dept of Cardiology, Rigshospitalet, Copenhagen, Denmark, ⁹Dept. of CT Surgery, Transplant Inst, Sahlgrenska Univ Hosp, Gothenburg, Sweden

(628) Real World Evaluation of Lung Transplant Antibody Mediated Rejection Treatment; R. Florez, N. Kolaitis, J. Greenland, L. Leard, J. Kukreja, B. Yen, S. Hays, J. Singer, D. Calabrese. *University of California San Francisco, San Francisco, CA*

(629) Renal Sparing Immunosuppression Regimens in Lung Transplant Recipients; H. Kleiboeker¹, M. Mahesri², M. Carns³, S. Mohsin³, C. Myers⁴, A. Arunachalam¹, B. Bemiss⁵, R. Tomic⁶, M. Venkata Subramani⁶. ¹*Northwestern Memorial Hospital, Chicago, IL*, ²*Brigham and Women's Hospital, Boston, MA*, ³*Office of Research, Northwestern University Feinberg School of Medicine, Chicago, IL*, ⁴*Northwestern Feinberg School of Medicine, Chicago, IL*, ⁵*Northwestern University Feinberg School of Medicine, Chicago, IL*, ⁶*Northwestern University, Chicago, IL*

(630) Post-Reperfusion Complement Deposition Predicts Primary Graft Dysfunction Following Lung Transplantation; C. Kurihara, T. Kaiho, A. Bharat. *Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL*

(631) Invasive Mechanical Ventilation Status at 72 Hours May be a Pragmatic and Valid Early Outcome Associated with Post-Lung Transplant Survival; M. Aversa¹, S. Keshavjee¹, M. Cypel¹, T. Martinu¹, A. Sage¹, J. Singer², S. Palmer³, E. Cantu⁴, J. Diamond⁴, J. Christie⁴, M. Anderson⁴. ¹*UHN, Toronto, ON, Canada*, ²*UCSF, San Francisco, CA*, ³*Duke Univ, Durham, NC*, ⁴*Univ of Pennsylvania, Philadelphia, PA*

(632) Predicting Renal Function After Lung Transplantation; J. Gouda¹, K. Kaur¹, A. Hirji¹, J. Weinkauff¹, D. Lien¹, R. Varughese¹, L. van den Bosch¹, J. Weatherald¹, P. Gauthier², K. Halloran¹. ¹*University of Alberta, Edmonton, AB, Canada*, ²*Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada*

(633) Comparison Between Waiting List Diagnosis for Lung Transplantation for Pulmonary Interstitial Disease and Explant Analysis from the Largest Lung Transplantation Group of Brazil; A. C. Avila¹, F. P. Reis², B. G. Baldi³, S. L. dos Santos², J. P. Leão², L. G. Abdalla², L. M. Fernandes², S. Campos³, P. C. Bueno de Camargo³, P. Pego-Fernandes². ¹*Thoracic Surgery, INCOR, São Paulo, Brazil*, ²*Lung Transplantation, INCOR, São Paulo, Brazil*, ³*Pulmonology, INCOR, São Paulo, Brazil*

(634) Evaluation of a Screening Protocol for Telomere Biology Disorders in Patients Referred for Lung Transplant; D. Zhu, D. V. Babushok, N. B. Patel, C. A. Bermudez, M. Crespo, A. M. Courtwright. *Hospital of the University of Pennsylvania, Philadelphia, PA*

(635) Abdominal Image Screening for Lung Transplant Candidates; B. L. Small¹, S. Hoover², J. Rosenheck³, V. Ramsammy², S. Kirkby⁴, K. Choi⁵, M. Henn⁶, N. Mokadam⁷, D. Nunley⁶, A. Ganapathi⁸, B. Whitson². ¹*Pulmonary, Critical Care and Sleep, The Ohio State University, Columbus, OH*, ²*Ohio State University, Columbus, OH*, ³*Ohio State University Hospital, Columbus, OH*, ⁴*Nationwide Children's Hospital, Columbus, OH*, ⁵*The Ohio State, Columbus, OH*, ⁶*The Ohio State University, Columbus, OH*, ⁷*The Ohio State University Wexner Medical Center, Columbus, OH*, ⁸*Ohio State University Wexner Medical Center, Columbus, OH*

(636) Impact of Left Atrial Appendage Procedures on Outcomes Following Lung Transplantation; B. Small¹, V. Ramsammy¹, S. Kirkby², D. R. Nunley¹, N. A. Mokadam¹, B. A. Whitson¹, M. Henn¹, A. M. Ganapathi¹, K. Choi¹, S. Hoover³, J. Mohr¹, K. Maas¹, J. P. Rosenheck¹. ¹*The Ohio State University, Columbus, OH*, ²*Nationwide Children's Hospital, Columbus, OH*, ³*Ohio State University, Columbus, OH*

(637) Long-Term Outcomes of Lung Transplantation in the Elderly: An Analysis Using the UNOS Database; J. Meyer¹, O. Shtraichman², A. Zur¹, D. Aravot¹, Y. Peysakhovich¹, Y. Shostak², M. R. Kramer², Y. D. Barac¹. ¹*The Division of Cardiovascular and Thoracic Surgery, Rabin Medical Center, Petach-Tikva, and Tel Aviv University, Faculty of Medicine, Tel Aviv, Israel*, ²*Tel Aviv University, Faculty of Medicine, Tel Aviv, and Pulmonary Institute, Rabin Medical Center, Petach-Tikva, Israel*

(639) Late-Breaking Abstract: Dynamic Contrast-Enhanced MRI in Lung Transplantation Recipients with and without CLAD; M. Hill Pierre-Louis¹, A. Susnjar², M. Allison¹, Y. I. Zhou², S. Montesi¹. ¹*Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, MA*, ²*Athinoula A. Martinos Center for Biomedical Imaging, Institute for Innovation in Imaging, Massachusetts General Hospital, Boston, MA*

(641) The Role of miRNA in Pre-Capillary Pulmonary Hypertension: A Comparison Between Group 1 and Group 3 PH; E. Salvaterra¹, S. Bozzini², F. Antonacci¹, M. Palazzini¹, F. Dardi¹, N. Daddi³, I. Magnani¹, F. Giunchi¹, N. Galie³, F. Meloni². ¹*IRCCS AOU Bologna, Bologna, Italy*, ²*IRCCS Policlinico San Matteo Foundation, Pavia, Italy*, ³*University of Bologna, Bologna, Italy*

(642) Investigating Pulmonary Vascular Disease in Patients with Long COVID Using Methylation Patterns in Cell-Free DNA; F. Iqbal¹, E. Ehteshami Afshar¹, J. Lewis¹, M. Thakrar¹, M. Kularatne¹, D. Helmersen¹, N. Hirani¹, S. Mak², J. Granton³, S. Greenway⁴, J. Weatherald⁵. ¹*University of Calgary, Calgary, AB, Canada*, ²*Mount Sinai Hospital, Toronto, ON, Canada*, ³*University of Toronto, Toronto, ON, Canada*, ⁴*Alberta Children's Hospital, Calgary, AB, Canada*, ⁵*University of Alberta, Edmonton, AB, Canada*

(643) High Incidence of Pulmonary Artery Thrombosis After Balloon Pulmonary Angioplasty in Patients with Chronic Thromboembolic Pulmonary Hypertension Receiving Low-Dose Direct Oral Anticoagulants; T. Suetomi¹, H. Shimokawahara², Y. Sugiyama², A. Miyagi², Y. Fukuda², M. Kanazawa², K. Suruga², K. Hayashi², S. Kobashi², M. Shigetoshi², I. Tabuchi², A. Watanabe², A. Ogawa², H. Matsubara². ¹*Yamaguchi University, Ube, Japan*, ²*National Hospital Organization Okayama Medical Center, Okayama, Japan*

- (644) Long-Term Outcome of Patients with Chronic Thromboembolic Pulmonary Hypertension Following Pulmonary Thromboendarterectomy Surgery - Results from a Referral Centre in India;** B. Khan¹, A. Singhvi¹, S. K. Dhar², V. Shetty¹, J. Punnen¹, B. Rahguraman¹, B. Murali Mohan¹, V. Raj¹, S. J. Tousheed¹, S. Patangi¹, T. Gupta¹, G. Cherian¹, D. Shetty¹. ¹Narayana Healthcare, Bengaluru, India, ²Computational Biology, Mazumdar Shaw Medical Foundation, Bengaluru, India
- (645) Clinical Features in Adolescent and Adult Cases with Pulmonary Hypertension Associated with Congenital Portosystemic Shunt;** S. Ishii, M. Hatano, S. Minatsuki, S. Ando, K. Hirose, A. Saito, H. Yagi, M. Shimbo, K. Soma, C. Konoeda, M. Sato. *The University of Tokyo Hospital, Tokyo, Japan*
- (646) Rate of Physician Visits and Hospitalizations in Pulmonary Arterial Hypertension in Argentina, Brazil, Colombia, and Mexico;** R. Klok¹, C. Vizza², J. Harley³, M. Small³, J. White⁴, D. Lautsch¹. ¹Center for Observational and Real-world Evidence, Merck & Co., Inc., Rahway, NJ, ²Pulmonary Hypertension Unit, Department of Cardiovascular and Respiratory Disease, La Sapienza University of Rome, Rome, Italy, ³Adelphi Real World, Bollington, United Kingdom, ⁴University of Rochester Medical Center, Rochester, NY
- (647) Journey from Symptoms to Diagnosis in Pulmonary Arterial Hypertension: Results from a Cross-Sectional Survey of Real-World Patients in Latin America;** J. White¹, R. Klok², J. Harley³, M. Small³, C. Vizza⁴, D. Lautsch². ¹University of Rochester Medical Center, Rochester, NY, ²Center for Observational and Real-world Evidence, Merck & Co., Inc., Rahway, NJ, ³Adelphi Real World, Bollington, United Kingdom, ⁴Pulmonary Hypertension Unit, Department of Cardiovascular and Respiratory Disease, La Sapienza University of Rome, Rome, Italy
- (648) Mean Pulmonary Artery Pressure and Disability in Pulmonary Hypertension: An Analysis of the STELLAR Trial;** A. Watzker, A. Alsumali, J. Chevure, J. de Oliveira Pena, D. Lautsch. Merck & Co., Inc., Rahway, NJ
- (649) Changes in Lung Transplant Waitlist Outcomes for Primary Pulmonary Hypertension (PPH) After Revision of Lung Allocation System: A UNOS Analysis;** R. Girgis¹, S. Krishnan², W. Berjaoui², G. Khirfan², N. Shrestha², R. Loyaga-Rendon². ¹Corewell Health, Michigan State University, Grand Rapids, MI, ²Corewell Health, Grand Rapids, MI
- (650) Age and its Relationship to Six-Minute Walk Distance, Functional Class, and Right Ventricular Function in Pulmonary Arterial Hypertension;** N. Villasmil Hernandez¹, N. Nunez¹, J. Xu², H. W. Farber³, S. Sahay⁴. ¹Department of Medicine, Houston Methodist Research Institute, Houston, TX, ²Center for Health Data Science and Analytics, Houston Methodist Research Institute, Houston, TX, ³Division of Pulmonary, Sleep and Critical Care Medicine, Tufts Medical Center, Boston, MA, ⁴Division of Pulmonary, Sleep and Critical Care Medicine, Houston Methodist Hospital, Houston, TX
- (651) The Effect of Antifibrotics on the Progression of Pulmonary Hypertension in Patients with Interstitial Lung Disease Listed for Lung Transplantation;** C. Thomas¹, A. Chandel², M. Zineddin³, C. Tang⁴, V. Khangoora¹, C. King¹, O. Shlobin¹, S. Nathan¹. ¹Inova Fairfax Hospital, Falls Church, VA, ²Walter Reed National Military Medical Center, Bethesda, MD, ³University of Virginia, Charlottesville, VA, ⁴Rensselaer Polytechnic Institute, Troy, NY
- (652) Hospital Outcomes Among Patients Admitted with Pulmonary Hypertension Due to Interstitial Lung Diseases;** S. Chaparro¹, M. Rubens¹, M. Roy¹, A. Saxena¹, G. Vaidean², J. Jimenez¹. ¹Baptist Health South Florida, Miami, FL, ²Florida International University, Miami, FL
- (653) Heart Rate Variability (HRV) as a Marker of Treatment Response in PAH;** A. Jose¹, A. D. Moseley², R. E. O'Donnell², J. Elwing³. ¹University of Cincinnati, Mason, OH, ²Cardiovascular Disease, University of Cincinnati, Cincinnati, OH, ³Internal Medicine, University of Cincinnati, Cincinnati, OH

WEDNESDAY, 10 APRIL, 2024

6:00 - 7:00 p.m.

POSTER SESSION 1: Research and Immunology (Non-CME)

Location: Poster Hall

Core Therapies: HEART, LUNG, MCS, PVD

Practice Areas: Research and Immunology, Anesthesiology and Critical Care, Cardiology, Cardiothoracic Surgery, Infectious Diseases, Nursing and Allied Health, Pathology, Pediatrics, Pharmacy, Pulmonology, Research and Immunology

Session Summary: Posters in this session include presentations on multiple topics where the Practice Areas of the research is focused in Research and Immunology. Designated Poster Discussants will circulate through the poster hall during the session to engage poster presenters in quality discussions of their abstracts. **CME is not offered for poster sessions.**

Poster Discussants: Annalisa Angelini, Italy, Marc de Perrot, Canada, Anique Ducharme, Canada, Melanie Everitt, USA, Kelley Hitchman, USA, Ilker Iskender, Switzerland, Stephen Juvet, Canada, Francesca Lunardi, Italy, Federica Meloni, Italy, Nandan Mondal, USA, Federica Pezzuto, Italy, Gregor Poglajen, Slovenia, Ashish Sharma, USA, Katharina Wassilew, UK, Xiaohai (Sam) Zhang, USA

(654) CD40 Ligand and NKG7 Mark Distinct Alloeffector CD4 T Cell Populations in Acute Lung Rejection; I. Popescu¹, M. Snyder¹, S. Lieber¹, K. Devonshire¹, C. Iasella², M. Sciuolo¹, S. Hannan¹, R. Koshy¹, R. Burke¹, J. Sembrat¹, J. Pilewski³, C. Hage¹, P. Sanchez³, K. Chen¹, J. McDyer¹.

¹Div of Pulmonary, Allergy, and Critical Care Med, Dept of Med, Univ of Pittsburgh, Pittsburgh, PA, ²Sch of Med Sch of Pharmacy, Univ of Pittsburgh, Pittsburgh, PA, ³Div of Pulmonary, Allergy, and Critical Care Med, Dept of Med, Univ of Pittsburgh Medical Center, Pittsburgh, PA

(655) Macrophage and CD8 T Cell Discordance are Associated with Acute Lung Allograft Dysfunction Progression; D. R. Calabrese¹, S. Yellamilli², C. Ekstrand², J. Singer², S. Hays³, L. Leard⁴, R. Shah², A. Venado⁴, M. Kleinhenz², J. Kukreja⁴, J. Golden², A. Combes², J. Greenland².

¹University of California, San Francisco, Mill Valley, CA, ²University of California, San Francisco, San Francisco, CA, ³University of California, San Francisco, San Francisco, CA, ⁴University of California San Francisco, San Francisco, CA

(656) The Role of CD31 in Acute Cellular Rejection Following Clinical Lung Transplantation; R. Novysedlák¹, J. Tavandzis¹, J. Balko², V. Tovazhnianska², A. Slavcev³, K. Vytytilova³, J. Simonek¹, R. Lischke¹, J. Vachtenheim¹, B. Vanaudenaerde⁴, L. J. Ceulemans⁴, Z. Ozaniak Strizova⁵. ¹Prague Lung Transplant Program, 3rd Dept of Surg, First Faculty of Med, Charles Univ and Motol Univ Hosp, Prague, Czech Republic, ²Dept of Pathology and Molecular Med, Second Faculty of Med, Charles Univ and Motol Univ Hosp, Prague, Czech Republic, ³Dept of Immunogenetics, Inst for Clinical and Experimental Med, Prague, Czech Republic, ⁴Laboratory of Respiratory Diseases and Thoracic Surg, BREATHE, Dept of Chrometa, KU Leuven, Leuven, Belgium, ⁵Dept of Immunology, Second Faculty of Med, Charles Univ and Motol Univ Hosp, Prague, Czech Republic

(657) Longitudinal Dynamics of the NK Cell Repertoire After Lung Transplantation and Their Potential Role for Control in CMV Reactivation; N. Hagen¹, A. Hitz¹, R. Bellmàs-Sanz¹, E. Chichelnitskiy¹, K. Beushausen¹, J. Keil¹, B. Wiegmann², G. Warnecke³, W. Sommer³, A. Ruhparwar⁴, F. Ius⁴, J. Kuehne¹, C. Falk¹. ¹Inst of Transplant Immunology, Hannover Med Sch, German Center for Lung Research (DZL/BREATH), German Center for Infection Research (DZIF), Braunschweig, Hannover, Germany, ²Dept for Cardiothoracic, Transplantation and Vascular Surg, Hannover Med Sch, Lower Saxony Center for Biomedical Engineering, Implant Research and Development, German Center for Lung Research (DZL), BREATHE site, Hannover, Germany, ³Dept of Cardiac Surg, Univ Hosp Schleswig-Holstein, Kiel, Germany, ⁴Dept for Cardiothoracic, Transplantation and Vascular Surg, Hannover Med Sch, German Center for Lung Research (DZL), BREATHE site, Hannover, Germany

(658) Blockade of ICAM-1 and LFA-1 Early After Transplantation Prevents Acute Cellular Rejection and Fibrotic Progression in Allogeneic Murine Lung Transplantation Model; Y. Goda, S. Tanaka, K. Mineura, M. Takahashi, A. Ohsumi, D. Nakajima, H. Date. Kyoto University Hospital, Kyoto, Japan

(659) Cell-Free DNA to Unveil Potential Mechanisms of Racial Disparities in Lung Transplant; A. A. Sanders¹, T. Andargie¹, M. Alnababteh², A. Charya³, M. Jang¹, M. Keller², J. Mathew⁴, S. Aryal⁵, H. Kong¹, W. Park¹, R. Brower², G. Berry⁶, C. Marboe⁷, J. Orens⁴, P. Shah⁴, S. Nathan⁵, H. Valentine⁶, S. Agbor-Enoh². ¹National Heart, Lung, and Blood Institute, Bethesda, MD, ²National Institutes of Health, Bethesda, MD, ³University of Maryland, College Park, MD, ⁴Johns Hopkins University, Baltimore, MD, ⁵Inova Fairfax Hospital, Falls Church, VA, ⁶Stanford University School of Medicine, Stanford, CA, ⁷Columbia University Vagelos College of Physicians & Surgeons, New York City, NY

(660) Protective Effect of Club Cell Secretory Protein (CCSP) in Mouse Lung Ischemia Reperfusion Injury; K. Nakata¹, B. Hughes¹, I. Alderete¹, K. Francine², X. Nie¹, M. Zhang¹, A. Hassan¹, N. Aykun¹, A. S. Barbas¹, J. L. Todd², M. G. Hartwig¹. ¹Department of Surgery, Duke University Medical Center, Durham, NC, ²Department of Medicine, Duke University Medical Center, Durham, NC

(661) Chronic Viral Infections Drive CD8 T Cells to Acquire Effector Functions That Are Resistant to Immunosuppressive Drugs;

D. R. Nettere¹, L. Snyder², J. Pollara³, M. Hartwig⁴. ¹School of Medicine, Duke University, Durham, NC, ²Department of Medicine, Duke University, Durham, NC, ³Department of Surgery, Duke University, Durham, NC, ⁴Department of Surgery, Duke University Medical Center, Durham, NC

(662) Torque Teno Virus Level as Predictor of Acute Rejection in Lung Transplant Recipients; M. Svorcova¹, P. Hubacek², A. Zajacova³,

M. Vaculova¹, J. Pozniak¹, J. Kolarik¹, J. Vachtenheim¹, J. Tavandzis¹, R. Novyzedlak¹, J. Simonek¹, R. Lischke¹, J. Havlin¹. ¹Prague Lung Transplant Program, 3rd Department of Surgery, Motol University Hospital and 1st Faculty of Medicine, Charles University In Prague, Prague, Czech Republic, ²Department of Medical Microbiology, Motol University Hospital and 2nd Faculty of Medicine, Charles University In Prague, Prague, Czech Republic, ³Prague Lung Transplant Program, Department of Pneumology, Motol University Hospital and 2nd Faculty of Medicine, Charles University In Prague, Prague, Czech Republic

(663) BAL-EVs from Lung Transplanted Patients are of Leukocytic Origin and Activates IL17 Pathway in Respiratory Cells; V. Vaira¹,

A. M. Storaci¹, N. Mansour¹, S. Franzì², M. De Filippo², H. Eidgah², V. S. Musso¹, L. Morlacchi², V. Rossetti², F. Blasi¹, L. Rosso³, M. Nosotti¹, S. Ferrero¹, A. Paleschi⁴. ¹University of Milan, Milan, Italy, ²Fondazione IRCCS Ca' Granda, Milan, Italy, ³Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, ⁴University of Milan (Italy); Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico of Milan, Milan, Italy

(664) MerTK-Dependent Efferocytosis by Monocytic MDSCs Contributes to the Resolution of Lung Ischemia-Reperfusion Injury; V. Leroy¹,

D. J. Kollareth¹, Z. Tu², M. Woollet-Stockton¹, J. Valisno¹, M. Rackauskas¹, A. Emtiajoo¹, C. Atkinson², G. R. Upchurch Jr.¹, A. Sharma¹. ¹Surgery, University of Florida, Gainesville, FL, ²Medicine, University of Florida, Gainesville, FL

(665) Evidence for Regulatory T Cell Dysfunction in Chronically Rejected Human Lungs; K. F. Bei¹, S. Moshkelgosha¹, A. Duong¹, T. Martinu²,

S. Juvet². ¹Latner Thoracic Research Laboratories, Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²Toronto Lung Transplant Program, Ajmera Transplant Centre, University Health Network, Toronto, ON, Canada

(666) Role of miR-21 in Pulmonary Fibrosis and its Correlation with Mesenchymal Markers; E. Bozza, S. Bozzini, C. Bagnera, G. Melloni,

G. Baietto, G. Ferrario, F. Inzani, F. Meloni. IRCCS Policlinico San Matteo, Pavia, Italy

(667) Ex-Vivo Model of EMT: Efficacy of MVs from Bone Marrow Mesenchymal Stromal Cells; C. Bagnera, S. Bozzini, E. Bozza, P. Comoli,

M. Avanzini, S. Croce, G. Baietto, G. Melloni, F. Meloni. IRCCS Policlinico San Matteo Foundation, Pavia, Italy

(668) Dissection of the Role of B Cells in a Murine Model of Ischemia-Reperfusion Injury-Augmented Lung Allograft Chronic Rejection;

S. Karunakaran¹, J. Oliver², T. Watanabe², F. Cui¹, J. Allen², S. Keshavjee³, T. Martinu³, S. Juvet³. ¹Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada, ²Toronto General Hospital Research Institute, Toronto, ON, Canada, ³Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada

(669) Lung Transplant Recipients Have High Secretory Phospholipase A2 Levels in the Alveoli: First Insight into a Possible Silent Inflammatory Pattern; E. Floris, C. Camillo, L. Benvenuto, F. D'Ovidio. Columbia University Irving Medical Center, New York, NY

(670) Deglycosylation of Lung Reactive Autoantibodies Ameliorates Graft Injury Post Lung Transplant; H. Moussa¹, Z. Tu¹, A. Stratton²,

A. Emtiajoo¹, A. Sharma¹, J. Christie³, T. Mohanakumar⁴, B. Prentice², C. Atkinson¹. ¹University of Florida, Gainesville, FL, ²Chemistry, University of Florida, Gainesville, FL, ³University of Pennsylvania, Philadelphia, PA, ⁴St. Joseph's Hospital and Medical Center, Phoenix, AZ

(671) Intermediate Term Clinical Outcomes Using Donor Derived Cell-Free DNA Testing After Lung Transplantation; M. N. Person¹,

C. R. Ensor², A. M. Ramirez³. ¹U of L Health Jewish Hospital, Louisville, KY, ²CareDx, Brisbane, CA, ³University of Louisville, Louisville, KY

(672) Transient Heat Stress Protects from Endothelial Injury During Prolonged Ex-Vivo Perfusion of Warm Ischemic Rat Lungs;

R. Parapanov¹, A. Debonneville¹, J. Lugrin¹, M. Allouche¹, M. Gonzalez¹, J. Perentes¹, L. Liaudet², T. Krueger¹. ¹Division of Thoracic Surgery, Lausanne University Hospital, Lausanne, Switzerland, ²Adult Intensive Care Medicine, Lausanne University Hospital, Lausanne, Switzerland

(673) Necroptosis Induced by Prolonged Cold Static Preservation of Lungs Depends on the cGAS-Sting Pathway; J. Lugrin, A. Debonneville,

R. Parapanov, M. Allouche, L. Liaudet, T. Krueger. Lausanne University Hospital, Lausanne, Switzerland

(674) Preliminary Study of Applying Novel Antibiotic Combinations to Improve the Quality of Bacteria Infected Donor Lung Based on EVLP Platform; F. Xiao¹, Z. Wang¹, X. Wang², Q. Yu¹, J. Zhang¹, Y. Yang³, C. Liang¹. ¹China-Japan Friendship Hospital, Beijing, China, ²Capital Medical University, Beijing, China, ³Beihang University, Beijing, China

(675) Angiotensin-Converting Enzyme 2 Activation Attenuates Inflammation After Rat Lung Transplantation; P. Melo¹, N. Nepomuceno¹,

L. Ruiz¹, A. Correia¹, V. Vilela¹, G. Manzuti¹, K. Braga¹, F. Pola¹, E. Kennedy², A. Wang³, M. Cypel³, P. Pego-Fernandes¹. ¹Departamento de Cardiopneumologia, Laboratório de Pesquisa em Cirurgia Torácica, Instituto do Coração, Faculdade de Medicina HCFMUSP, University of Sao Paulo, Sao Paulo, Brazil, ²Departamento de Ciências da Saúde, Universidade Federal Rural do Semi-Árido, Mossoró, Brazil, ³Latner Thoracic Surgery Research Laboratories, Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada

(676) Donor-Specific Blood Transfusion is Feasible and Safe in Mice: A Proof-of-Concept Study; X. Jin¹, J. Kaes², C. Hooff², J. Van Slambrouck¹, N. Marain², G. Aerts², B. Özsoy³, J. Ma⁴, S. Zhao³, G. Vande Velde⁵, J. Pirenne⁶, R. Vos⁷, B. M. Vanaudenaerde², L. J. Ceulemans¹. ¹Department of Thoracic Surgery, UZ Leuven, Leuven, Belgium, ²Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium, ³Department of Oncology, KU Leuven, Leuven, Belgium, ⁴Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium, ⁵Department of Imaging & Pathology, KU Leuven, Leuven, Belgium, ⁶Department of Abdominal Transplant Surgery and Coordination, UZ Leuven, Leuven, Belgium, ⁷Department of Respiratory Diseases, UZ Leuven, Leuven, Belgium

(677) Seeing is Believing: Mouse Orthotopic Vascularized Right Lung Transplantation; J. Zhao¹, X. Yang², B. Yue³, J. Chen³. ¹Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Hangzhou, China, ²Dept of Lung Transplant, Second Affiliated Hosp, Zhejiang Univ SoM, Hangzhou, China, ³Dept of Lung Transplantation, Second Affiliated Hospital of Zhejiang Univ SoM, Hangzhou, Hangzhou, China

(678) A Model for Mouse Ex Vivo Lung Perfusion (EVLV) Followed by Orthotopic Lung Transplantation; Y. Suzuki, J. Oliver, B. Joe, K. F. Bei, N. Yoshiyasu, M. Liu, T. Martinu, S. Keshavjee, S. Juvet. Toronto Lung Transplant Program and Latner Thoracic Research Laboratories, Toronto General Hospital Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada

(679) Lung-on-a-Chip: A Novel Tool for Modeling Lung Transplant Ischemia Reperfusion Injury; L. Langerude, B. Gill, A. Emtiazjoo, A. Sharma, C. Atkinson. Medicine, University of Florida, Gainesville, FL

(680) Itaconate Supplementation in Preservation Solution Leads to Lung Function Improvement After Extended Hypothermic Preservation; G. Loesch Siebiger¹, A. Wang², J. Yune³, J. Montagne², G. Garza², T. Lima⁴, K. Yamanashi², P. Oliveira³, F. Gao¹, Y. Zhang³, A. Ali⁵, M. Liu², S. Keshavjee², M. Cypel². ¹Latner Thoracic Research Laboratories - Toronto General Hospital Research Institute, University of Toronto, Toronto, ON, Canada, ²University Health Network, Toronto, ON, Canada, ³Latner Thoracic Research Laboratories - Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ⁴University Health Network, Toronto, ON, Canada, ⁵Toronto General Hospital, Canada

(681) Mitochondrial DNA Quantification of Brazilian Lung Transplant During Ischemia and Reperfusion; F. Pola¹, J. Silva Nunes², J. Carneiro Leao³, L. Souza e Silva², V. Moraes de Paiva Roda², R. P. Madeira², L. Moro Cariste², L. Abdalla³, S. Lucas Santos³, P. Oliveira Melo³, S. Vidal Campos³, L. Matos Fernandes³, E. Cunha-Neto², P. Pego-Fernandes³. ¹Lung Transplant Group, Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina da USP, Sao Paulo, Brazil, ²Immunology Laboratory, Instituto do Coracao, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil, ³Lung Transplant Group, Instituto do Coracao, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil

(682) Developing a Multidimensional Immunological Toolset to Facilitate Rejection Diagnosis and Mechanistic Understanding of Chronic Lung Allograft Dysfunction After Human Lung Transplantation; J. Fu¹, W. Jiao¹, K. D. Long¹, T. Young¹, C. Bay Muntznich¹, A. Prada Rey¹, K. Rogers¹, A. Valena², J. Costa³, L. Benvenuto¹, J. Sonett³, P. Lemaitre³, F. D'Ovidio³, S. Arcasoy¹. ¹Department of Medicine, Columbia University, New York, NY, ²NewYork-Presbyterian Hospital, New York, NY, ³Department of Surgery, Columbia University, New York, NY

(683) Assessment of the Degree of Immunosuppression Measured by Residual Expression of Genes Regulated by T-Cell Nuclear Factor (NFAT-RGE) in Lung Transplant Recipients; M. Boada Pérez¹, V. Ruiz¹, M. Erro², P. Ussetti³, S. Rosado², R. Castejón², M. Aguilar², E. Revilla⁴, C. Bravo Masgoret⁵, B. Saez Gimenez⁶, M. Zapata⁷, C. Berastegui Garcia⁸, M. Lopez Meseguer⁹, Y. Villena¹⁰, J. Vima Bofarull⁷, V. Monforte¹¹, S. Gomez¹. ¹Vall d'Hebron Research Institute, Barcelona, Spain, ²Hosp Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ³Hosp Puerta de Hierro, Barcelona, Spain, ⁴Hosp Universitario Vall d'Hebron, Barcelona, Spain, ⁵Hosp Vall d'Hebron. Barcelona, Barcelona, Spain, ⁶Hosp Universitari Vall Hebron, Barcelona, Spain, ⁷Vall d'Hebron Hosp Universitari, Barcelona, Spain, ⁸Hosp Vall d'Hebron, Barcelona, Spain, ⁹Hosp Vall D'Hebron Universitari, Barcelona, Spain, ¹⁰Hosp Universitari Vall d'Hebron, Barcelona, Spain, ¹¹Hosp Universitari Vall d'Hebron, Barcelona, Spain

(684) Comprehensive Characterization of Immune Cell Phenotypes in Lung Transplant Patients Receiving Belatacept; H. O. Berezinskiy¹, S. N. Shirazi², Z. Kovacs³, S. Auner⁴, C. Hillebrandt², P. Boehm⁵, G. Muraközy², K. Hoetzenecker⁴, P. Jaksch⁶, A. Benazzo⁴. ¹Thoracic Surgery, Medical University of Vienna, Vienna, Austria, ²Medical University of Vienna, Vienna, Austria, ³Medical University Vienna, Austria, ⁴Medical University of Vienna, Austria, ⁵Medical University Vienna, Austria, Austria

(685) Development of an Easy-to-Use Flow Cytometric Panel for Monitoring B Regulatory Cells in Transplant Recipients; H. O. Berezinskiy¹, S. N. Shirazi², Z. Kovacs³, S. Auner⁴, C. Hillebrandt², P. Boehm⁵, K. Hoetzenecker⁴, P. Jaksch⁶, A. Benazzo⁴. ¹Thoracic Surgery, Medical University of Vienna, Vienna, Austria, ²Medical University of Vienna, Vienna, Austria, ³Medical University Vienna, Austria, ⁴Medical University of Vienna, Austria, ⁵Medical University Vienna, Vienna, Austria

(686) Carbon Monoxide Inhalation Therapy Administered After Transplantation Does Not Contribute to Prolonged Engraftment of Transplanted Lungs in CLAWN Miniature Swine; H. Sahara¹, K. Takeuchi², Y. Ichinari³, A. Shimizu⁴. ¹Div of Experimental Large Animal Research, Center for Advanced Science Research and Promotion, Kagoshima University, Kagoshima, Japan, ²Div of Experimental Large Animal Research, Center for Advanced Science Research and Promotion, Kagoshima, Japan, ³Div of Experimental Large Animal Research, Center for Advanced Science Research and Promotion, Kagoshima, Japan, ⁴Dept of Analytic Human Pathology, Nippon Medical School, Tokyo, Japan

- (687) Is Chronic Lung Allograft Dysfunction More Common After Lung Transplantation for Pulmonary Complications of Hematopoietic Stem Cell Transplantation?**; H. Date¹, S. Tanaka¹, H. Hiramatsu², J. Kanda³, M. Takahashi¹, Y. Yutaka¹, A. Ohsumi¹, D. Nakajima¹. ¹Thoracic Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan, ²Pediatrics, Kyoto University Graduate School of Medicine, Kyoto, Japan, ³Hematology and Oncology, Kyoto University Graduate School of Medicine, Kyoto, Japan
- (688) Angioinvasive Molds and Mycobacterium are Associated with Airway Inflammation and Decreased CLAD-Free Survival**; A. Haile, E. Lydon, R. Mohanty, J. Singer, S. Hays, L. Leard, R. Shah, A. Venado, M. Kleinhenz, J. Golden, N. Kolaitis, A. Perez, J. Kukreja, C. Langelier, D. Calabrese, J. Greenland. University of California, San Francisco, San Francisco, CA
- (689) Computational Fluid Dynamics Shows Airflow and Pressure to be Greatly Changed in Bronchiolitis Obliterans Syndrome**; P. Kerckhof¹, Y. Mohamady¹, H. Beeckmans², J. Kaes¹, V. Geudens¹, C. Hooft¹, J. Van Slambrouck³, G. Aerts¹, L. Willems¹, A. Vermaut¹, X. Jin¹, L. Dupont⁴, L. Godinas⁵, G. Verleden⁶, D. Van Raemdonck³, L. Ceulemans³, G. Gayan-Ramirez¹, J. McDonough⁷, B. Vanaudenaerde¹, R. Vos⁵. ¹KU Leuven, Leuven, Belgium, ²KU Leuven, Leuven, Belgium, ³University Hospitals Leuven, Leuven, Belgium, ⁴University Hospital Gasthuisberg, Leuven, Belgium, ⁵UZ Leuven, Leuven, Belgium, ⁶University Hospital Leuven, Leuven, Belgium, ⁷Yale University School of Medicine, Yale, NY
- (690) Spectral and Intrabreath Oscillometry for Early Diagnosis of Chronic Lung Allograft Dysfunction**; A. Fu¹, A. Vasileva¹, N. Hanafi¹, S. Rajyam¹, G. Tanumihardja¹, N. Belousova², J. Wu², E. Huszti², Z. Hantos³, C. Chow¹. ¹University of Toronto, Toronto, ON, Canada, ²University Health Network, Toronto, ON, Canada, ³Semmelweis University, Budapest, Hungary
- (691) Single Cell Analysis of Bronchiolar Brushings Identifies Basal Cell Loss in CLAD**; E. Brunet-Ratnasingham¹, H. Guo¹, A. Haile¹, R. Mohanty², T. Tsao¹, S. Hays¹, M. Kleinhenz¹, J. Singer¹, J. Golden¹, L. Leard¹, N. Kolaitis¹, R. Shah¹, A. Venado¹, J. Kukreja¹, D. Calabrese¹, J. Greenland¹. ¹Medicine, UCSF, San Francisco, CA, ²UCSF, San Francisco, CA
- (692) Proteomic Analysis of Transbronchial Biopsies Identifies Novel Tissue Biomarkers for Chronic Lung Allograft Dysfunction**; E. Tahmaspour¹, A. Philp², A. Ravipati³, C. Thomson¹, M. Raftery⁴, S. Grey⁵, M. Plit⁶, D. Darley⁷. ¹St Vincent's Hospital, Sydney, Australia, ²St Vincent's Clinical School, UNSW Medicine, Sydney, Australia, ³Bioanalytical Mass Spectrometry Facility, UNSW, Sydney, Australia, ⁴Bioanalytical Mass Spectrometry Facility, UNSW, Sydney, Australia, ⁵Transplantation Immunology, Garvan Institute of Medical Research, Sydney, Australia, ⁶St Vincent's Hospital, Sydney, Australia, ⁷St Vincent's Hospital Darlinghurst, Sydney, Australia
- (693) Clinical Utility of 1:16 Serum Dilution as a Predictor of Response to Therapeutic Plasma Exchange for HLA Antibody-Mediated Rejection Treatment in Lung Transplant Recipients: A Two Center Study**; M. Elrefaei¹, T. Narula¹, F. Alvarez¹, E. Godbey¹, G. Criner², F. Cordova³, N. Shigemura⁴, Y. Toyoda⁵, O. Timofeeva⁶. ¹Mayo Clinic, Jacksonville, FL, ²Temple University Sch of Medicine, Philadelphia, PA, ³Temple Univ Hospital, Philadelphia, PA, ⁴Temple University Health System and Lewis Katz School of Medicine, Philadelphia, PA, ⁵Temple University School of Medicine, Philadelphia, PA, ⁶Georgetown University School of Medicine, Washington, DC
- (694) Impact of KIR Haplotype Matching on Lung Transplantation**; Y. Li¹, D. Chen². ¹Department of pathology, Beth Israel Deaconess Medical Center, Boston, MA, ²Department of Pathology, Duke University Medical Center, Durham, NC
- (695) WITHDRAWN**
- (696) The Impact of Preformed Donor-Specific Antibodies on Outcome After Lung Transplantation: A Retrospective Single-Center Experience**; S. Auner, C. Hillebrand, P. Boehm, S. Schwarz, Z. Kovacs, G. Murakozy, E. Hiele-Wittmann, C. Aigner, K. Hoetzenecker, P. Jaksch, A. Benazzo. Department of Thoracic Surgery, Medical University of Vienna, Vienna, Austria
- (697) Lung Waitlist Desensitization Requires Timely Transplantation for Durable Removal of HLA Antibodies**; D. F. Pinelli¹, J. Wright², A. Arunachalam², M. Venkata Subramani², C. Kurihara¹, A. Bharat¹, R. Tomic², C. Myers². ¹Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL
- (698) Ten-Year Experience with Peritransplant Desensitization in Patients with Preformed Donor Specific Antibodies in Lung Transplantation**; M. Franz¹, A. Saipbaev¹, N. D. De Manna¹, N. Schwerk², M. Greer³, M. Avsar¹, A. Weymann¹, A. Ruhparwar¹, C. Kuehn¹, J. Salman¹, F. Ius¹. ¹Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany, ²Department of Paediatrics, Hannover Medical School, Hannover, Germany, ³Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany
- (699) Ten-Year Results of an IgA- and IgM-Enriched Human Immunoglobulin-Based Therapy for Early Detectable Anti-HLA Donor Specific Antibodies After Lung Transplantation**; K. Aburahma¹, M. Franz¹, N. D. De Manna¹, A. Saipbaev¹, S. Tavit¹, M. Avsar¹, N. Schwerk², M. Greer³, C. Falk⁴, A. Weymann¹, A. Ruhparwar¹, C. Kuehn¹, J. Salman¹, F. Ius¹. ¹Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany, ²Department of Paediatrics, Hannover Medical School, Hannover, Germany, ³Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany, ⁴Institute of Transplant Immunology, Hannover Medical School, Hannover, Germany

(700) Inhaled Cyclosporine-Based Immunosuppression Regimen Can Decrease Systemic Calcineurin Inhibitors Nephrotoxicity in Lung Transplant Patients; L. Timofte¹, C. Manthuruthil¹, N. Ladikos², N. Costa³, A. Gandhi⁴, V. Kaza¹, A. Lawrence¹, S. Bollineni¹, L. D. Mahan¹, M. Mohanka¹, F. Torres¹, M. Terrin⁵, A. Iacono⁶. ¹UT Southwestern Medical Center, Dallas, TX, ²Texas Tech University Health Scientist Center, Dallas, TX, ³Medstar Health, Washington DC, DC, ⁴NIH, Baltimore, MD, ⁵University of Maryland, Maryland, MD, ⁶Northwell Health, New York, NY

(701) Home Spirometry Combined with Telehealth Reduces Lung Transplant Outpatient Clinic Visits and Patient Travel Costs Without Increasing Healthcare Utilization or Mortality; A. W. Liu¹, A. Y. Odisho¹, L. Pierce², C. Sorric³, A. R. Maiorano³, O. M. Bigazzi³, L. Leard⁴, R. Shah⁴, A. Venado⁴, A. Perez⁴, J. Golden⁴, M. Kleinhenz⁴, N. Kolaitis⁴, J. Maheshwari⁴, B. Trinh⁵, J. Kukreja⁵, J. Greenland⁴, D. Calabrese⁴, J. Singer⁴, S. Hays⁴. ¹Center for Digital Health Innovation, Urology, University of California, San Francisco, San Francisco, CA, ²Center for Digital Health Innovation, Medicine, University of California, San Francisco, San Francisco, CA, ³Center for Digital Health Innovation, University of California, San Francisco, San Francisco, CA, ⁴Medicine, University of California, San Francisco, San Francisco, CA, ⁵Surgery, University of California, San Francisco, San Francisco, CA

(702) Cell-Free DNA Exposes Tissue Injury Profiles Leading to Primary Graft Dysfunction; H. Kong¹, A. Casillan², J. Sun³, T. Hill³, N. Redekar³, M. Jang¹, T. Andargie¹, W. Park¹, R. Brower¹, M. Alnababteh⁴, P. Shah⁵, S. Aryal⁶, J. Orens⁵, S. Nathan⁶, M. Keller⁴, J. Diamond⁷, E. Cantu⁷, E. Bush², S. Agbor-Enoh¹. ¹Laboratory of Applied Precision Omics, Division of Intramural Research, National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD, ²Division of Thoracic Surgery, Department of Surgery, Johns Hopkins Hospital, Johns Hopkins University, Baltimore, MD, ³Integrated Data Sciences Section, Research Technologies Branch, National Institute of Allergy and Infectious Diseases, Bethesda, MD, ⁴Critical Care Medicine Department, Clinical Center, NIH, Bethesda, MD, ⁵Johns Hopkins University, Baltimore, MD, ⁶Inova Fairfax Hospital, Falls Church, VA, ⁷University of Pennsylvania, Philadelphia, PA

(703) Bile Acids Aspiration Induces Fibrosis and Disrupts Surfactant Homeostasis in Human Lungs; C. Camillo¹, S. Russum¹, E. Floris¹, M. Della Zoppa², B. Kim¹, S. Ryeom¹, L. Benvenuto¹, F. D'Ovidio¹. ¹Columbia University Irving Medical Center, New York City, NY, ²Università degli studi di Pavia, Pavia, Italy

(704) Late-Breaking Abstract: Multicenter Validation of Large Airway Bronchial Wash (LABW) Bile Acid Signature for the Diagnosis of Aspiration and Prediction of Chronic Lung Allograft Dysfunction; C. Camillo¹, R. Ramendra², A. Sage³, J. Havlin⁴, M. Leiva-Juarez¹, E. Floris¹, R. Nandakumar¹, S. Cremers¹, E. Huszti⁵, L. Benvenuto¹, S. Arcasoy¹, S. Keshavjee⁶, T. Martinu⁷, F. D'Ovidio¹. ¹Columbia University Irving Medical Center, New York City, NY, ²Ajmera Transplant, University Health Network, Toronto, ON, Canada, ³Toronto General Hospital, Toronto, ON, Canada, ⁴University Hospital Motol, Prague, Czech Republic, ⁵University Health Network, Toronto, ON, Canada, ⁶UHN, Toronto, ON, Canada, ⁷Toronto General Hospital/UHN, Toronto, ON, Canada

(705) Late-Breaking Abstract: Interplay and Divergent Effects of PIRCHE-II Scores and EPLET Mismatch Loads on De Novo DSA Development and Clinical Parameters in Lung Transplantation; M. Taniguchi¹, M. Niemann², M. Mangiola³, M. Kashem¹, B. Dale⁴, H. Kehara¹, A. Liacini¹, N. Shigemura¹. ¹Temple University, Lewis Katz School of Medicine, Philadelphia, PA, ²PIRCHE, AG, Berlin, Germany, ³NYU Langone Transplant Institute, New York, NY, ⁴PIRCHE, AG, Medfield, MA

(706) Late-Breaking Abstract: Clonal Hematopoiesis, Telomere Biology Disorders, and the Combined Influence on Post-Transplant Outcomes; L. Tague¹, R. Ebenezer², H. Anthony², A. Gelman³. ¹Washington Univ in St. Louis, Saint Louis, MO, ²Washing University School of Medicine, St. Louis, MO, ³Washington University School of Medicine, St. Louis, MO

(707) Renal Denervation Improves Right Ventricular Function and Restores Norepinephrine Levels in Rat Model of Heart Failure Induced by Aorto-Caval Fistula; M. Miklovic¹, O. Gawrys², Z. Honetschlagerova², P. Kala³, Z. Huskova², S. Kikerlova², Z. Vanourkova², H. Maxova⁴, G. Puertas-Frias⁵, T. Mracek⁵, D. Sedmera⁶, V. Melenovsky⁷. ¹Institute Of Clinical And Experimental Medicine, Prague, Czech Republic, ²Institute for Clinical and Experimental Medicine, Prague, Czech Republic, ³Motol University Hospital, Prague, Czech Republic, ⁴Department of Pathophysiology, Charles University, Prague, Czech Republic, ⁵Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic, ⁶Institute of Anatomy, Charles University, Prague, Czech Republic, ⁷IKEM Dept. of Cardiology, Prague, Czech Republic

(708) Preservation of Ventricular Contractility of Old Donor Hearts During Static Cold Storage by the Senomorphic Agent Ruxolitinib is More Effective in Hearts from Female Donors; L. Saemann¹, B. Kozar¹, A. Hoffmeister¹, S. Pohl¹, L. Wernstedt², Y. Gong¹, A. Simm¹, G. Szabó¹. ¹Department of Cardiac Surgery, University Hospital Halle, Halle (Saale), Germany, ²Department of Cardiac Surgery, University Hospital Halle, Halle, Germany

(1060) Direct Procurement and Perfusion Supplemented with the Senomorphic Agent Ruxolitinib Improves the Microvascular Coronary Flow in Hearts Donated After Circulatory Death in Dependence on Donor Sex and Age; L. Saemann, A. Hoffmeister, S. Pohl, S. Soyer, L. Wernstedt, J. Luise, B. Kozar, A. Simm, G. Szabó. Department of Cardiac Surgery, University Hospital Halle, Halle (Saale), Germany

THURSDAY, 11 APRIL, 2024

8:00 - 9:15 a.m.

SYMPOSIUM 14: AMR in Cardiothoracic Transplantation: View from the Heart Side with Lessons for the Lung

Location: Forum Hall

Core Therapies: HEART, LUNG

Practice Areas: Anesthesiology and Critical Care, Cardiology, Cardiothoracic Surgery, Infectious Diseases, Nursing and Allied Health, Pathology, Pediatrics, Pharmacy, Pulmonology, Research and Immunology

Session Summary: This session aims to help clinicians identify and manage the risk of transplantation in highly sensitized patients as well as manage short-and long-term immunologic issues. This session will focus on understanding of HLA and non-HLA antibodies in transplant recipients, learning about innovative research in transplantation tolerance, exploring the use of non-invasive tools for evaluation of AMR, discussion of transplant options across a positive crossmatch and contemporary use of photopheresis in acute rejection. Speakers will highlight similarities and differences between heart and lung AMR throughout the talks. A panel discussion with all speakers including audience Q&A, led by the session moderators, will conclude this session.

Moderators: Deepa Mokshagundam, MD, Washington University, St. Louis, MO, USA
Erik Henriksen, PharmD, Stanford Healthcare, Stanford, CA, USA

8:00 a.m. **Two Sides of the Same Coin: Significance of HLA and Non-HLA Antibodies**

Adriana Zeevi, PhD, University of Pittsburgh, Pittsburgh, PA, USA

Most centers can test for HLA antibodies, but few look for non-HLA antibodies. The speaker will review the significance of both HLA and non-HLA antibodies and describe the clinical scenarios in heart and lung tx when non-HLA antibodies should be assessed.

8:10 a.m. **The Holy Grail of (B cell) Tolerance: Current Status and Novel Approaches**

Joren Madsen, MD, DPhil, Massachusetts General Hospital, Boston, MA, USA

The induction of donor specific tolerance would effectively eliminate the need for chronic immunosuppression and significantly improve long term outcome after cardiothoracic transplantation. In this talk, the audience can expect an overview about innovative research in this field: aiming for the holy grail of tolerance (or to be more realistic, tolerance favouring protocols that allow reduction of immunosuppressive burden) but with focus on humoral tolerance as there are numerous new approaches in preclinical development and entering clinical trials. e.g. the mixed chimerism approach, Treg therapy, graft modulation (MHC downregulation), low dose IL-2 therapy and many more.

8:20 a.m. **Cardiothoracic Transplant Across a Positive Crossmatch: International Perspectives on Donors, Management, and Outcomes**

Claire Irving, MBChB, MRCPCH, MD, Children's Hospital Westmead, Sydney, Australia

The purpose of this talk is to offer an international perspective on the consideration of highly sensitized patients for heart transplantation in regions where donor availability may be limited. Does this lead to more acceptance of positive crossmatch heart transplantation? What are the differences in the treatment? Are the outcomes including overall survival, development of CAV, risks and incidence of AMR, and retransplantation effected? Experience from lung tx across positive crossmatch will be outlined.

8:30 a.m. **Time to Change: Non-Invasive Biomarkers for Antibody-Mediated Rejection in Heart and Lung Transplants**

Sean Agbor-Enoh, MD, PhD, National Institutes of Health, Bethesda, MD, USA

Non-invasive tools have remarkable advantages over the traditional methods. The speaker will review if non-invasive monitoring can be used for those with higher immunological risks and if non-invasive tools could aid in treatment decisions for de novo DSA formation and during episodes of antibody-mediated rejection in heart and lung transplantation.

8:40 a.m. **Come to the Light: Use of Extracorporeal Photopheresis in the Management of Antibody-Mediated Rejection in Heart Transplantation**

Andreas Zuckermann, MD, Medical University of Vienna, Vienna, Austria.

Photopheresis is more commonly used for chronic rejection, with recent use in acute rejection and as induction in high-risk patients. The speaker will address contemporary clinical practice, research, and logistics in the use of photopheresis for the treatment of antibody-mediated rejection as additive therapy to intensified immunosuppression.

8:50 a.m. **Panel Discussion led by Moderators**

THURSDAY, 11 APRIL, 2024

8:00 - 9:15 a.m.

SYMPOSIUM 15: Don't Leave Us Behind: Heart Failure Management Outside of Guidelines, Trials, and Transplant Centers

Location: South Hall 3

Core Therapies: HEART, PVD

Practice Areas: Cardiology, Infectious Diseases, Nursing and Allied Health, Pediatrics, Pharmacy

Session Summary: This session aims to share best practices for the medical management of certain heart failure and cardiomyopathy populations where current guidelines are lacking, clinical trials have not adequately been conducted, and/or care is being provided outside of VAD/Transplant Centers. After each speaker's presentation, the session moderators will lead a brief audience Q&A segment.

Moderators: Dylan Miller, MD, Intermountain Central Lab, Murray, UT, USA
Shelley Zieroth, MD, St Boniface General Hosp, Winnipeg, MB, Canada

8:00 a.m. ***How Small is Too Small? Pushing Boundaries with Reverse Remodeling in Small Children***

David Newland, PharmD, MS, Seattle Children's Hospital, Seattle, WA, USA

This talk will cover the use of reverse remodeling heart failure therapies in small children down to infants with Heart Failure with Reduced Ejection Fraction. Pediatric experience on which medications have been used, dosing, monitoring, and adverse effects will be shared.

8:12 a.m. **Q&A**

8:15 a.m. ***The Right Medications for the Failing Right Heart***

Jean-Luc Vachery, MD, HUB Hôpital Erasme, Anderlecht, Belgium

Important differences between chronic sub-pulmonary right heart failure and chronic left heart failure will be discussed. Medical management options for chronic right heart failure will be reviewed.

8:27 a.m. **Q&A**

8:30 a.m. ***A Heart Bitten by a Bug***

Rebecca Kumar, MD, Georgetown University Hospital Center, Washington, DC, USA

This talk will review the current burden and management of parasitic cardiomyopathies focusing on Chagas disease, strongyloides and other relevant parasites.

8:42 a.m. **Q&A**

8:45 a.m. ***So Far Away: Managing Stage D Heart Failure Patients Outside of LVAD/Transplant Centers***

Dipanjan Banerjee, MD MS, University of Hawai'i, Honolulu, HI, USA

This talk will focus on practices to enhance care of the increasing end stage heart failure patients being managed outside of centers which perform LVAD implants and heart transplants. Discussion points will include delineating responsibility for care, how to best implement remote monitoring, standardize handoffs between institutions and triage emergent situations such as patient transfers.

8:57 a.m. **Q&A**

9:00 a.m. ***The Latest and Greatest for Specific Cardiomyopathies***

Laurens Tops, MD, Leiden University Medical Center, Leiden, Netherlands.

This talk will cover medical treatment advances for hypertrophic cardiomyopathy and other relevant specific cardiomyopathies such as sarcoidosis, arrhythmogenic cardiomyopathy and Duchenne muscular dystrophy.

9:12 a.m. **Q&A**

THURSDAY, 11 APRIL, 2024

8:00 - 9:15 a.m.

SYMPOSIUM 16: Controversies in Management of End-Stage Pulmonary Hypertension

Location: South Hall 1

Core Therapies: PVD, LUNG, MCS

Practice Areas: Pulmonology, Cardiology, Cardiothoracic Surgery, Pediatrics

Session Summary: This session will focus on controversies in management of end-stage pulmonary hypertension, with a focus on comparing and contrasting adult and pediatric care topics. This will include pros and cons of interventional interatrial and Potts shunts versus surgical Potts shunt procedures.

Moderators: Rachel K Hopper, MD, Stanford University, Palo Alto, CA, USA
Sebastien Hascoet, MD, PhD, Hopital Marie Lannelongue, Le Plessis-Robinson, France

8:00 a.m. ***Mechanical Support Strategies as Bridge to Transplant in Adults with Pulmonary Hypertension***
John Granton, MD, University of Toronto, Toronto, ON, Canada

A review of mechanical support strategies in adults as a bridge to transplantation in patients with severe pulmonary hypertension and right heart failure, with a focus on the different surgical approaches and support options.

8:20 a.m. ***Why Technical Support Bridging Strategies Don't Work Well in Children With Severe Pulmonary Hypertension***
Sabrina Law, MD, Columbia University, New York, NY, USA

An overview of limitations to mechanical support strategies (MCS) as bridge to transplant in children, with specific focus on risks and complications of MCS as well as diagnoses and clinical factors that preclude MCS.

8:40 a.m. ***DEBATE: Transcatheter Inter-atrial and Potts Shunt Procedures are the Best Approach (PRO)***
Damien Bonnet, MD, Hôpital Necker-Enfants Malades, Paris, France.

The speaker will argue in favor of percutaneous inter-atrial and Potts shunt technique with a focus on potential advantages over surgical approach.

8:55 a.m. ***DEBATE: Transcatheter Inter-atrial and Potts Shunt Procedures are the Best Approach (CON)***
David Morales, MD, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA

The speaker will argue against percutaneous inter-atrial and Potts shunt procedures with a focus on the global experience and on potential advantages over interventional procedures. Will provide perspective of lung transplantation after Potts Shunt.

9:10 a.m. **Q&A**

THURSDAY, 11 APRIL, 2024

8:00 - 9:15 a.m.

SYMPOSIUM 17: Take My Breath Away: Lung Transplants Using Smaller Grafts and Shorter Incisions

Location: South Hall 2

Core Therapies: LUNG, PVD

Practice Areas: Cardiothoracic Surgery, Pulmonology

Session Summary: This session focuses on surgical innovations in the field of lung transplantation, exploring new sizing approaches for donor organs in donor-recipient matching followed by a debate discussing the pros and cons for robotic assisted lung transplantations. A 7-minute Q&A will take place before and after the debate.

Moderators: Jasleen Kukreja, MD, MPH, University of California San Francisco, San Francisco, CA, USA
Edouard Sage, MD, PhD, Hôpital Foch, Suresnes, France

8:00 a.m. ***Lung Dimensions in Harmony: Strategies in Measuring Donor and Recipient Lung Size***
Sahar Saddoughi, MD, PhD, Mayo Clinic, Rochester, MN, USA

This talk will primarily focus on various strategies to size match organs such as pTLC vs height vs BMI including use of CT vs CXRs, sex, and pediatric donors to adult recipients etc.

8:12 a.m. ***Measure Twice Cut Once: Surgical Innovations in Lung Re-sizing***
Dirk Van Raemdonck, MD, PhD, University Hospitals Leuven, Leuven, Belgium

This talk will cover surgical techniques for volume reducing lungs such as lobar, non anatomic resection, which lobes to take out, how to decide between anatomic vs non-anatomic, living donors, techniques to match vasculature and airways.

8:24 a.m. ***Outcomes of Size Matching versus Mismatching in Lung Transplantation***
Deborah Levine, MD, Stanford University, Stanford, CA, USA

The speaker will review the available literature, experience for outcomes of under vs oversized matching for different metrics including pTLC, height, weight etc.

8:36 a.m. ***Q&A led by Moderators***

8:43 a.m. ***DEBATE: Robotically-Assisted Lung Transplant - We Are Ready! (PRO)***
Albert Jauregui, MD, PHD, Vall d'Hebron University Hospital, Barcelona, Spain

The speaker will defend the use of robotic-assisted surgery for lung transplantation. The benefit of having a magnified view provide enhanced depth perception and improves accuracy. The initial experiences with this new approach is discussed.

8:55 a.m. ***DEBATE: Robotically-Assisted Lung Transplant - We Are Ready! (CON)***
Konrad Hoetzenecker, MD, Medical University of Vienna, Vienna, Austria.

The talk will question that robotic surgery is applicable in lung transplantation, discuss the feasibility especially for small centers, mention the surgical training required to perform a robotic lung transplant and will also ask how big is the benefit for the individual patient?

9:07 a.m. ***Q&A led by Moderators***

THURSDAY, 11 APRIL, 2024

8:00 - 9:15 a.m.

SYMPOSIUM 18: LVAD on the Margins

Location: Panorama Hall

Core Therapies: MCS, HEART

Practice Areas: Cardiology, Anesthesiology and Critical Care, Cardiothoracic Surgery, Nursing and Allied Health

Session Summary: This session will explore LVAD candidacy among special patient populations. The first session will discuss women of childbearing age. The rest of the session will be a series of two debates: the first focusing on extreme age and the second on marginal renal function. A panel discussion with all speakers including audience Q&A, led by the session moderators, will conclude this session.

Moderators: Chonyang Albert, MD, Robert Wood Johnson University Hospital, New Brunswick, NJ, USA
Juliane Vierecke, MD, UC Health- university of Cincinnati, Cincinnati, OH, USA

8:00 a.m. ***Unique Challenges for Women with LVADs***
Juliane Vierecke, MD, UC Health- university of Cincinnati, Cincinnati, OH, USA

This presenter will highlight unique challenges experienced by female patients and LVAD therapies. Focus on sizing, outcomes, as well as the complicated issue of pregnancy in VAD patients.

8:12 a.m. ***DEBATE: LVAD in the Elderly Should Be Considered Standard of Care (PRO)***
Dominic Emerson, MD, Cedars-Sinai Medical Center, Los Angeles, CA, USA

Review data supporting the use of LVAD therapy in the elderly. Highlight outcomes after LVAD implant.

8:24 a.m. ***DEBATE: LVAD in the Elderly Should Be Considered Standard of Care (CON)***
Evgenij Potapov, MD, PhD, German Heart Institute, Berlin, Germany

Review evidence against the use of LVAD therapy in the elderly. Highlight frailty, sarcopenia and impact on clinical outcomes.

8:36 a.m. ***DEBATE: Patients with Chronic Kidney Disease Should Be Considered for LVAD Therapy (PRO)***
Jeffrey Teuteberg, MD, Stanford University SoM, Stanford, CA, USA

This talk will review chronic kidney disease in heart failure and argue that patients should be considered for LVAD. Should venture into the feasibility of dialysis.

8:48 a.m. ***DEBATE: Patients with Chronic Kidney Disease Should Be Considered for LVAD Therapy (CON)***
Finn Gustafsson, MD, PhD, Rigshospitalet, Copenhagen, Denmark.

This talk will argue the counterpoint that patients with chronic kidney disease should not receive LVAD due to risk of dialysis. Should explore impact of CKD and dialysis on LVAD outcomes.

9:00 a.m. ***Panel Discussion led by Moderators***

THURSDAY, 11 APRIL, 2024

8:00 - 9:15 a.m.

SYMPOSIUM 19: Tiny Bugs versus Mighty Machines: Navigating MCS Infections

Location: North Hall

Core Therapies: MCS, HEART

Practice Areas: Infectious Diseases, Cardiology, Cardiothoracic Surgery, Nursing and Allied Health, Pathology, Pediatrics, Pharmacy, Research and Immunology

Session Summary: This session will explore infectious considerations of MCS. Topics will include LVAD-associated infections and unique prevention and treatment approaches. A panel discussion with all speakers including audience Q&A, led by the session moderators, will conclude this session.

Moderators: Mirnela Byku, MD, University of North Carolina, Chapel Hill, NC, USA
Yee Weng Wong, MBBS, MHS, FRACP, FCSANZ, Mayo Clinic, Rochester, MN, USA

8:00 a.m. **Spotless and Fortified, No Pests Inside: VAD Driveline Management Strategies**
Sophie Smith, University Hospitals Birmingham, Birmingham, United Kingdom

This talk will focus on best strategies to manage the driveline – cleaning, showering, trauma, anchoring etc. -in order to prevent infections.

8:12 a.m. **Combatting Infections in LVAD Patients: Unique Strategies for Prevention, Diagnosis, and Amelioration**
Ann Woolley, MD, MPH, Brigham & Women's Hospital, Boston, MA, USA

This talk will focus on innovative approaches to prevent and treat LVAD infections, including cold atmospheric plasma therapy and phage treatment, as well as the role of PET/CT and tagged WBC scans to diagnose VAD infections. The updated ISHLT infection definitions for MCS-supported patients will be covered.

8:24 a.m. **Like Soap to Bugs: Will This Problem Stick Around?**
Stephanie Pouch, MD, MS, Emory University, Atlanta, GA, USA

This talk will discuss various antibiotic management strategies in MCS patients, with special focus on early aggressive versus no treatment (more specifically on oral versus IV antibiotics, duration of treatment, long term prophylaxis, and surveillance strategies).

8:36 a.m. **Surgical Rescue: Treating Refractory LVAD Infections When Transplant is Not an Option**
Julia Riebandt, MD, PhD, Medical University Vienna, Vienna, Austria.

The talk will delve into surgical strategies for refractory LVAD infections, focusing on the critical role for device explantation vs driveline repositioning vs debridement vs urgent transplant. Multiple cases and studies will be presented to illustrate innovative surgical techniques to treat LVAD infections.

8:48 a.m. **The Bridging Dilemma: Transplanting Patients with VAD Infections**
Maria Avila, MD, Northwell Health, West Islip, NY, USA

The talk will discuss strategies to bridge patients with VAD infections to transplant and their outcomes after transplant.

9:00 a.m. **Panel Discussion led by Moderators**

THURSDAY, 11 APRIL, 2024

9:45 - 11:15 a.m.

PLENARY 2: General Session II

Location: Congress Hall

Core Therapies: HEART, LUNG, MCS, PVD

Practice Areas: Anesthesiology and Critical Care, Cardiology, Cardiothoracic Surgery, Infectious Diseases, Nursing and Allied Health, Pathology, Pediatrics, Pharmacy, Pulmonology, Research and Immunology

Session Summary: General Sessions at ISHLT2024 offer engaging speakers, comprehensive scientific reviews, and featured abstracts highlighting critical research in a range of fields.

Moderators: Hermann Reichenspurner, MD, PhD, University Hospital Hamburg-Eppendorf, Hamburg, Germany
Jon Kobashigawa, MD, Cedars-Sinai Heart Institute, Los Angeles, CA, USA

9:46 a.m. **Early Career Featured Video**

9:47 a.m. **Featured Late-Breaking Abstract Presentation:**

(3) Non-Ischemic Preservation of the Donor Heart in Heart Transplantation - A Randomized, Controlled, Multicenter Trial Using The Xvivo Heart Assist Preservation System for Hypothermic Oxygenated Perfusion (NIHP2019)

F. Rega¹, G. Lebreton², M. Para³, S. Michel⁴, R. Schramm⁵, E. Begot², K. Vandendriessche¹, C. Kamla⁴, G. Gerosa⁶, M. Berman⁷, U. Boeken⁸, S. Clark⁹, A. Ranasinghe¹⁰, F. Ius¹¹, A. Forteza¹², F. Hennig¹³, S. Gunter⁵, A. Zuckermann¹⁴, C. Knosalla¹³, G. Dellgren¹⁵, A. Wallinder¹⁶. ¹Cardiac Surgery, Univ Hospitals Leuven, Leuven, Belgium, ²Cardiac Surgery, Pitié-Salpêtrière Hosp, APHP, Sorbonne Univ, Paris, France, ³CV Surg and Transpl, Bichat Hosp, Univ Paris Cité, Paris, France, ⁴Clinic of Cardiac Surg, Ludwig-Maximilians-Univ (LMU), Munich, Germany, ⁵Clinic for Thoracic- and CV Surg, Heart & Diabetes Ctr North Rhine Westfalia, Ruhr-Univ Bochum, Bad Oeynhausen, Germany, ⁶Cardiac, Thoracic, Vascular Sci and Public Health, Univ of Padua, Padua, Italy, ⁷Royal Papworth Hosp NHS Foundation Trust, Cambridge, UK, ⁸Cardiac Surg, Med Faculty, Heinrich Heine Univ, Duesseldorf, Germany, ⁹CT Ctr, Freeman Hosp, Newcastle upon Tyne, UK, ¹⁰Queen Elizabeth Hospital, Univ Hospitals Birmingham NHS Trust, Birmingham, UK, ¹¹CT, Transpl and Vascular Surg, Hannover Med Sch, Hannover, Germany, ¹²Cardiac Surg, Puerta de Hierro Majadahonda Univ Hosp, Madrid, Spain, ¹³CT & Vascular Surg, Deutsches Herzzentrum der Charité (DHZC), Berlin, Germany, ¹⁴Cardiac Surg, Med Univ of Vienna, Vienna, Austria, ¹⁵CT Surgery, Sahlgrenska Univ Hosp, Gothenburg, Sweden, ¹⁶XVIVO Perfusion, Gothenburg, Sweden

9:57 a.m. **Q&A with Interactive Discussant**

David McGiffin, MBBS, FRACS, DMedHS. Alfred Health, Melbourne, Australia

10:03 a.m. **Humanitarian Crisis - in General**

Jill John-Kall, MD, MSc, International Medical Corps, Los Angeles, CA, USA

The Humanitarian Crisis talk will be given by two speakers. This speaker will outline the general pattern and characteristics of a humanitarian crisis, its development and dynamics, its issues, and consequences, and how it is managed by a government funded non-profit organization.

10:18 a.m. **Humanitarian Crisis - in Ukraine**

Yana Martyshyna, MD, International Medical Corps, Kyiv, Ukraine

The Humanitarian Crisis talk will be given by two speakers. This speaker will focus on the humanitarian crisis occurring in Ukraine during the Russo-Ukrainian war.

10:30 a.m. **The HeArt of the Possible – My Patient Journey**

Glen Kelley, The Mended Hearts, Minneapolis, MN, USA

Follow Glen's remarkable journey from a cornfield in the Midwestern United States to around the world. A life's journey marked by relentless battles with cancer, advanced heart failure, renal failure; while undergoing therapies of bone marrow transplantation, heart transplantation, dialysis, and eventual kidney transplantation. Through facing these adversities, he discovered his call to patient advocacy and support and will share thoughts and perspectives on disease and treatments with the purpose of increasing understanding among all professions of how such a life is lived.

10:45 a.m. **Introduction to 2024 ISHLT Lifetime Achievement Award Recipient**

Simon Urschel, MD, University of Alberta, Edmonton, AB, Canada

10:50 a.m. **2024 ISHLT Lifetime Achievement Award Recipient Lecture**

Lori West, MD, DPhil, University of Alberta, Edmonton, AB, Canada

THURSDAY, 11 APRIL, 2024

11:45 a.m. – 12:45 p.m.

SPECIAL SESSION 2: Non-CME: ECP Immunomodulation in Thoracic Transplantation Challenge Grant Finalist Presentation Session

Location: Congress Hall

Core Therapies: LUNG

Practice Areas: Pulmonology, Research and Immunology

Session Summary: CME is not offered for this session.

Moderators: Alberto Benazzo, PhD, Medical University of Vienna, Vienna, Austria
Andrew Gelman, PhD, Washington University, St. Louis, MO, USA

11:45 a.m. ***Immunomodulation using Extracorporeal Photopheresis in Human-Xenogeneic Cross-Circulation***
Marc Petrovic, MS. Vanderbilt University Medical Center, Nashville, TN, USA

11:53 a.m. **Q&A**

11:57 a.m. ***Attenuation of Immune-Mediated Cardiac Injury after Extracorporeal Photopheresis: Insight from Isolated Heart Perfusion using a Swine Cross-Circulation Model***
Ayyaz Ali, MD, PhD. Hartford Hospital, Hartford, CT, USA

12:05 p.m. **Q&A**

12:09 p.m. ***Extracellular Vesicles as Novel Tools in the Management of ECP for Chronic Lung Allograft Dysfunction (EVENT-CLAD)***
Rachel Crossland, PhD. Newcastle University, Newcastle upon Tyne, United Kingdom

12:17 p.m. **Q&A**

12:21 p.m. ***Effect of Extracorporeal Photopheresis Therapy in Heart Transplant Recipients with DSA and Presumptive AMR***
Andrea Fernandez Valledor, MD, New York Presbyterian – Columbia Irving Medical Center, New York, NY, USA

12:29 p.m. **Q&A**

12:33 p.m. ***Immunomodulation with a Combination of Extracorporeal Photopheresis (ECP) with Ultra Low Dose Il2 and Jak 1/2 Inhibitors***
Samuel Priyaranjan, MBBS, DTCD, DNB, Krishna Institute of Medical Sciences, Hyderabad, India

12:41 p.m. **Q&A**

THURSDAY, 11 APRIL, 2024

1:15 - 2:30 p.m.

SYMPOSIUM 20: I'll Tell You What I Want, What I Really Really Want: Advice for Early Career Professionals

Location: Congress Hall

Core Therapies: HEART, LUNG, MCS, PVD

Practice Areas: Anesthesiology and Critical Care, Cardiology, Cardiothoracic Surgery, Infectious Diseases, Nursing and Allied Health, Pathology, Pediatrics, Pharmacy, Pulmonology, Research and Immunology

Session Summary: This session, designed by the Early Career and Trainees Committee, will provide an overview of advice for early career professionals as they start their careers, take on leadership roles (locally or within the society), become teachers/mentors, and navigate work-life balance including parenthood, while avoiding burnout. This session also will be of great value for leaders and those in more advanced stages of their careers. A panel discussion with all speakers including audience Q&A, led by the session moderators, will conclude this session.

Moderators: Edith Boyes, MSN, FNP-BC, CHFNP, Ascension IL Alexian Brothers, Chicago, IL, USA
Tara Veasey Rackley, PharmD, BCTXP, Allegheny General Hospital, Pittsburgh, PA, USA

1:15 p.m. ***I Want to Work in Transplantation: Positioning for a Successful Clinical Career***

Julien Fessler, MD, Foch Lung Transplant Group, Paris, France.

This speaker will provide advice for the early career professional seeking a clinical career in thoracic transplant.

1:23 p.m. ***I Want a Family: How Parenthood and Career are Totally Compatible***

Hannah Copeland, MD, Lutheran Medical Group, Fort Wayne, IN, USA

This speaker will discuss the balance of parenthood with career, with emphasis on the different challenges in different geographic locations.

1:31 p.m. ***I Want to Educate: What Makes a Great Teacher and How to Get Results***

Daniel Chambers, MBBS, MRCP, FRACP, MD, The Prince Charles Hospital, Brisbane, Australia

This speaker will pull from their experience as a successful program director and will provide advice for teaching learners. They will discuss both how to teach and how to train others to teach.

1:39 p.m. ***You Don't Need To Do Basic Science as an Early Career To Be Successful in Academia!***

Shahnawaz Amdani, MD, Cleveland Clinic, Cleveland, OH, USA

This talk will focus on highlighting how clinical research using large scale databases or designing and running clinical trials can be leveraged to position yourself as a clinician scientist.

1:47 p.m. ***I Really Really Want to Survive: Self-Care and Avoiding Burnout***

Melissa Cousino, PhD, University of Michigan, Ann Arbor, MI, USA

This speaker will discuss the cultures that push professionals to take on too much, especially early in their career. They will describe risk factors for burnout and give advice on how to successfully build your career while avoiding burnout.

1:59 p.m. ***Panel Discussion led by Moderators***

THURSDAY, 11 APRIL, 2024

1:15 - 2:30 p.m.

SYMPOSIUM 21: A New Formula 1 Team: The Drive Ahead in DCD

Location: Forum Hall

Core Therapies: HEART, LUNG

Practice Areas: Cardiology, Anesthesiology and Critical Care, Cardiothoracic Surgery

Session Summary: Transplant volumes have surged across the globe with the advent of Donation after Circulatory Death (DCD). The short-term post-transplant outcomes are on par with DBD heart transplants. With more programs embarking on the DCD journey - is this the holy grail to mitigate organ shortage? A panel discussion with all speakers including audience Q&A, led by the session moderators, will conclude this session.

Moderators: Bronwyn Levvey, RN, BEd Stu, Grad Dip Clin Epi, The Alfred Hospital, Melbourne, Australia
Clive Lewis, MA, MB, BChir, PhD, FFICM, FRCP, Royal Papworth Hospital, Cambridge, United Kingdom

1:15 p.m. **G-Force: DCD Expansion**
Steven Tsui, MD, FRCS, Royal Papworth Hospital, Cambridge, United Kingdom

This talk will focus on the current limitations of further expansion of the use of DCD, from the technology itself to programmatic and economic considerations. Include a beginner's guide for developing a DCD program from scratch.

1:27 p.m. **Downforce: Normothermic Regional Perfusion or Pulsatile Perfusion in 2024?**
Jamila Kremer, MD, University Hospital Heidelberg, Heidelberg, Germany

This talk will review the benefits and discuss technical pitfalls, patient characteristics favorable for TA NRP, and success rate of organ utilization from DCD heart donation using TA NRP. It should include up to date evidence in pathophysiology of brain death in context of circulatory arrest, with emphasis on reversibility of brain function. Are there different donor phenotypes that would be suitable for a certain organ procurement strategy and how this might impact donor selection in clinical practice.

1:39 p.m. **Pedal to Metal: Ex-Vivo Heart Perfusion in DCD**
John Um, MD, Nebraska Medicine, Omaha, NE, USA

This talk will discuss the nuances of donor selection for DCD including factors that predict donor progression to allow successful organ procurement given strict limits for fWIT and indicators of the agonal phase. Include use of ex-vivo perfusion for transportation, benefits and technical pitfalls, patient characteristics, and success rate of organ utilization. Consider TA NRP followed by cold storage.

1:51 p.m. **Torque: Maneuvering the Ethical Edge**
John Trahanas, MD. Vanderbilt University Medical Center, Nashville, TN, USA

In this session, the speaker will explore the ethical considerations of DCD, including a discussion about the determination of death and timely organ retrieval. Discuss ethics around TA NRP and brain blood flow. Discuss controversies around TA NRP followed by cold storage. Consider both countries/jurisdictions where DCD heart transplantation is being done and those without a DCD program.

2:03 p.m. **Safety Car: Long-term Outcomes of DCD Heart Transplantation**
Niels van der Kaaij, MD, PhD, UMC Utrecht, Utrecht, Netherlands.

This presentation will discuss current outcomes of patients transplanted at pioneer centers, who have over 3-5 years of experience with DCD Heart donation, comparing outcomes with standard death brain donors. Include outcomes from TA NRP vs DPP and machine perfusion vs cold storage.

2:15 p.m. **Panel Discussion led by Moderators**

THURSDAY, 11 APRIL, 2024

1:15 - 2:30 p.m.

SYMPOSIUM 22: Breaking New Ground in AMR Science: Lung Perspective with Insights for the Heart

Location: South Hall 3

Core Therapies: LUNG, HEART

Practice Areas: Research and Immunology, Cardiothoracic Surgery, Nursing and Allied Health, Pathology, Pediatrics, Pharmacy, Pulmonology

Session Summary: This session will review novel insights into the pathophysiology of cardiothoracic antibody-mediated rejection (AMR) that are paving the way for new translational approaches. Recent progress in AMR science raises hope for mechanism-targeted diagnostics and therapeutics. After each speaker's presentation, the session moderators will lead a brief audience Q&A segment.

Moderators: Christine Falk, PhD, Hannover Medical School, MHH, Hannover, Germany
Jan Havlin, MD, University Hospital Motol, Prague, Czech Republic

1:15 p.m. ***Lymphocytes in Pulmonary AMR: NK and T cells as Novel Predictors of Graft Failure and Treatment Targets***
Daniel Calabrese, MD, University of California, San Francisco, San Francisco, CA, USA

This talk will describe how T cells and NK cells participate in AMR, including follicular helper cells priming B cells, and NK cell-mediated antibody dependent cell cytotoxicity. This talk will discuss T and NK cells as predictors of CLAD, the interaction between NK cell responses to CMV and AMR, and the lymphocytes as diagnostic and therapeutic targets.

1:27 p.m. **Q&A**

1:30 p.m. ***Complement Activation: What Does It Mean in AMR?***
Hrishikesh Kulkarni, MD, MSCI, Washington University School of Medicine, St. Louis, MO, USA

Complement activation is considered a major mediator in AMR but is it required? Typically measured by C4d staining, challenges in this marker limit its reliability. This talk will explore complement activation biomarkers, including C1q and S6-phosphorylation, and related treatment approaches.

1:42 p.m. **Q&A**

1:45 p.m. ***Not Just Victims: The Active Role of Endothelial Cells in Thoracic AMR Pathogenesis***
Elaine Reed, PhD, UCLA Immunogenetics Center, Los Angeles, CA, USA

While the endothelium is the physical barrier between donor and recipient, evidence suggests that the endothelium may participate in propagation of graft inflammation. This talk will review mechanisms of interactions between endothelial cells and innate and adaptive immune responses during AMR. This talk will also describe how donor specific antibody binding to HLA molecules can exert damaging effects on the endothelium and explore strategies to target HLA-antibody interactions.

1:57 p.m. **Q&A**

2:00 p.m. ***AMR Tissue Molecular Diagnostics: Are Endotypes Hidden in the Transcriptional Oracle Bones?***
Ondrej Viklicky, IKEM Hospital, Prague, Czech Republic.

This talk will review genomic signatures of AMR across solid organ transplantation and describe areas in which pulmonary and cardiac AMR differs from other organs. This talk will review potential endotypes of graft inflammation in AMR and their molecular correlates of airway brushing or biopsy tissue. This talk will also examine emerging AMR diagnostics, including S6 phosphorylation.

2:12 p.m. **Q&A**

2:15 p.m. ***HLA Eplet Matching: Time to Move Beyond Epitopes?***
Lucy Sullivan, PhD, Australian Red Cross Lifeblood, Women's and Children's Hospital, North Adelaide, Australia

This talk will provide the audience with an overview of what an HLA eplet is and how it is distinct from an HLA epitope, what constitutes a high-risk HLA eplet, and how HLA eplet matching can integrate with clinical practice, including the potential benefits and risk of this approach.

2:27 p.m. **Q&A**

THURSDAY, 11 APRIL, 2024

1:15 - 2:30 p.m.

SYMPOSIUM 23: The Next Frontier In Pediatric Mechanical Circulatory Support

Location: South Hall 1

Core Therapies: MCS, HEART

Practice Areas: Pediatrics, Cardiology, Cardiothoracic Surgery, Nursing and Allied Health

Session Summary: This session will explore hot topics in pediatric mechanical circulatory support (MCS) that are clinically challenging with controversial therapeutic options. A panel discussion with all speakers including audience Q&A, led by the session moderators, will conclude this session.

Moderators: Lucas Eastaugh, MBBS, FRACP, FCSANZ, Royal Children's Hospital, Melbourne, Australia
Oliver Miera, MD, Deutsches Herzzentrum der Charité, Berlin, Germany

1:15 p.m. ***Take Tour Time or Full Steam Ahead? Recovery in Pediatric MCS***
Matthew Fenton, MD, Great Ormond Street Hospital, London, United Kingdom

The speaker will explore the controversy of whether to immediately list for heart transplant after VAD or delay listing to allow for possible recovery in pediatric patients with durable VADs.

1:27 p.m. ***It Might Be Shocking: Should We Be Implanting ICDs in Children With VADs?***
Martin Schweiger, MBA, FABS, FEBS, Children's Hospital Zurich, Zurich, Switzerland.

This speaker will discuss the evidence for placement of ICDs in children with VAD and other risk factors, such as severely decreased function and/or tachyarrhythmias.

1:39 p.m. ***Is There Ever a Right Time? Right Ventricular Assist Device versus Medical Therapy for Right Heart Failure After LVAD***
Jennifer Conway, MD, Stollery Children's Hospital, Edmonton, AB, Canada

This speaker will discuss the outcomes and treatment of right ventricular failure in children with LVAD, including initial biventricular VAD support strategy as well as medical management versus subsequent RVAD.

1:51 p.m. ***Does Size Really Matter? Consideration for Bariatric Surgery in Children with Obesity and a VAD***
Steven J. Kindel, MD, Medical College of Wisconsin, Milwaukee, WI, USA

This speaker will discuss the affect obesity on outcomes of pediatric VAD and whether bariatric surgery or medical intervention are viable options to improve outcomes in obese pediatric patients on VAD support.

2:03 p.m. ***Paracorporeal VADs in Children: Can We Overcome the Barriers to Discharge?***
Oliver Dewald, MD, University Hospital of Erlangen, Erlangen, Germany

The speaker will discuss requirements and barriers to discharge of small children on paracorporeal VADs supported with the novel drive unit.

2:15 p.m. ***Panel Discussion led by Moderators***

THURSDAY, 11 APRIL, 2024

1:15 - 2:30 p.m.

SYMPOSIUM 24: To ECMO or Not to ECMO, That is the Question: A Noble Bridge for the Unlisted Lung Transplant Candidate?

Location: South Hall 2

Core Therapies: LUNG, MCS, PVD

Practice Areas: Pulmonology, Anesthesiology and Critical Care, Cardiothoracic Surgery, Infectious Disease, Nursing and Allied Health, Pediatrics, Pharmacy, Research and Immunology

Session Summary: This session will provide highlights of the ISHLT consensus statement on the perioperative utilization of ECLS in lung transplantation. After an overview of ECMO bridging to lung transplantation, we will dive into molecular and morphological changes for patients on ECMO, and conclude with a pro/con debate on bridge to listing decision in lung transplantation for pediatric candidates. A panel discussion with all speakers including audience Q&A, led by the session moderators, will conclude this session.

Moderators: Brandi Bottiger, MD, Duke University Hospital, Durham, NC, USA
Arne Neyrinck, MD, PhD, Leuven University Hospitals, Leuven, Belgium

1:15 p.m. ***Back to the Future: Histological and Molecular Studies to Improve ECMO Treatment***

Martin Goddard, FRCS, FRCPath, Papworth Hospital, Cambridge, United Kingdom

There is little evidence of pathological/molecular findings for patients on ECMO. Pathology experts in the field will discuss recent morphological and molecular data whose knowledge represents an important step in the development and improvement of ECMO devices.

1:27 p.m. ***When the Pink Flags are Raised: Candidate Selection for ECMO Bridge to Lung Transplantation***

Sandra Lindstedt, MD, PhD, Wallenberg Centre for Molecular Medicine, Lund University, Lund, Sweden

The speaker will review specific controversial topics, such as likelihood of support to ambulation in specific candidates, including underlying disease physiology, candidate age, physical therapy potential, HLA sensitization status, candidate size and other challenges when making a decision

1:39 p.m. ***DEBATE: We Can Do This! Pediatric ECMO Bridge to Decision for Listing is Acceptable (PRO)***

Don Hayes, MD, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA

In this debate, the speaker will make a case for ECMO bridging critically ill patients to decision for listing. ICU resources, candidate age, underlying disease, transfer to transplant center, evaluation testing and psychosocial assessment, consenting as well as other challenges will be reviewed. Case Stem: An awake 16 y.o. post-COVID ARDS presents for evaluation of ECMO bridging and potential lung transplantation. Challenges include non-CF bronchiectasis with multidrug resistant organisms, lack of social support, adherence to medical therapy and follow-up.

1:51 p.m. ***DEBATE: We Can Do This! Pediatric ECMO Bridge to Decision for Listing is Acceptable (CON)***

Nicolaus Schwerk, MD, Hannover Medical School, Hannover, Germany

Responding to the previous debate talk, the speaker will make a case against ECMO bridge to decision for lung transplantation. ICU resources, candidate age, underlying disease, transfer to transplant center, evaluation testing and psychosocial assessment, consenting as well as other challenges will be reviewed as obstacles. Case Stem: An awake 16 y.o. post-COVID ARDS presents for evaluation of ECMO bridging and potential lung transplantation. Challenges include non-CF bronchiectasis with multidrug resistant organisms, lack of social support, adherence to medical therapy and follow-up.

2:03 p.m. ***Panel Discussion led by Moderators***

THURSDAY, 11 APRIL, 2024

1:15 - 2:30 p.m.

SYMPOSIUM 25: It's a Wonderful Life: Strategies to Live Better and Longer

Location: Panorama Hall

Core Therapies: HEART, LUNG, MCS

Practice Areas: Cardiology, Cardiothoracic Surgery, Infectious Diseases, Nursing and Allied Health, Pediatrics, Pharmacy

Session Summary: This session will focus on behavioral and psychosocial strategies to ensure both adult and pediatric transplant patients can reach the best health and quality of life possible. A panel discussion with all speakers including audience Q&A, led by the session moderators, will conclude this session.

Moderators: Donna Guadiz, R.N., BSN, CCTC, Children's Hospital of Los Angeles, Los Angeles, CA, USA
Maricar Malinis, MD, Yale School of Medicine, New Haven, CT, USA

1:15 p.m. ***Gonna Make you Sweat: Physical Activity Recommendations for Thoracic Transplant Recipients***
Louise Fuller, PhD, BApp Sc (Physio), Alfred Hospital, Melbourne, Australia

From pumping iron to 5ks to HIIT workouts, physical activity plays a major role in overall health and wellness. This talk will focus on the current data surrounding physical activity for thoracic transplant patients, unique physiologic characteristics, as well as counseling for patients - especially those who were very athletic pre-transplant.

1:27 p.m. ***Let's App-ly Ourselves: Tools for Medication Adherence***
Fay Burrows, BPharm, St Vincent's Hospital, Sydney, Australia

Managing medication adherence post-transplant can be a challenge for both pediatric and adult patients. Digital tools and strategies for medication education and adherence will be explored in this presentation, as well as tests for early detection of medication non-adherence.

1:39 p.m. ***You Are the Sunshine of My Life ... But Stay Out of the Sun!***
Angela Velleca, MHDS, BSN, RN, CCTC, Cedars-Sinai Smidt Heart Institute, Los Angeles, CA, USA

This speaker will focus on skin cancer in the thoracic transplant recipient. Epidemiology of skin cancer types, diagnostic evaluation, and unique challenges faced by transplant patients will be discussed.

1:51 p.m. ***Be Our Guest: What is Safe to Eat After Transplantation?***
Sonya Trinh, MD, Ochsner Health, New Orleans, LA, USA

This speaker will discuss epidemiology of food-borne infections and the appropriate measures to mitigate risk for food borne infections.

2:03 p.m. ***Let's Talk About Sex, Baby! Safe Sex Practices After Transplantation***
Jessica Lum, MD, Cleveland Clinic Foundation, Cleveland, OH, USA

Good clinical practice to assess for STI risk will be discussed. Preventive and treatment strategies for STIs, with focus on Mpox, HIV, HPV, will be reviewed.

2:15 p.m. ***Panel Discussion led by Moderators***

THURSDAY, 11 APRIL, 2024

1:15 - 2:30 p.m.

SYMPOSIUM 26: I Get By With a Little Help From My Friends: Multidisciplinary Care in Durable MCS

Location: North Hall

Core Therapies: MCS, HEART

Practice Areas: Nursing and Allied Health, Cardiology

Session Summary: The purpose of this symposium is to discuss the clinical use and understanding of the QoLVAD questionnaire, discuss nutritional outcomes, psychological changes, changes in activity, rehabilitative strategies, and holistic care of the LVAD patient. A panel discussion with all speakers including audience Q&A, led by the session moderators, will conclude this session.

Moderators: Sarah Schettle, PA-C, MS, MBA, Mayo Clinic, Rochester, MN, USA
Yu Wu, DNP, UCSF Health, San Francisco, CA, USA

1:15 p.m. ***Don't Stop Believing in Quality of Life After LVAD Implantation***
Sarah E. Schroeder, PhD, ACNP-BC, MSN RN, Bryan Heart, Lincoln, NE, USA

Quality of life is an important post-VAD factor to assess the success of VAD therapy. Heart failure should be resolved post-implant, leaving a gap of a multi-dimensional assessment options for QOL. This speaker will discuss in depth the domains of the QoLVAD questionnaire post-implant.

1:27 p.m. ***Hungry Like the Wolf: Nutritional Outcomes Post LVAD Implant***
Desiree Robson, RN, BSc (Hons), St. Vincent's Hospital, Sydney, Australia

Nutritional efforts after any surgery can be challenging due to lack of appetite, persistent cachexia, and changes in taste as well as weight management post-LVAD. The purpose of this talk is to describe nutritional changes post-LVAD implantation and challenges with cachexia as well as obesity post-LVAD.

1:39 p.m. ***Somebody That I Used to Know: Patient-Reported Emotional Health Changes Post-LVAD***
Lindsay May, MD, University of Utah, Salt Lake City, UT, USA

Patients go through a whole world of emotions when facing distress due to a medical illness, let alone having an LVAD placed. The purpose of this talk is to walk the audience through some of the most common psychological changes that patients experience post-LVAD.

1:51 p.m. ***I Like to Move It, Move It: Post-Rehabilitation and Activity Following LVAD Implantation***
Andrew Woods, BSc, Newcastle Upon Tyne NHS Foundation Trust, Newcastle upon Tyne, United Kingdom

Being active post-LVAD is a measure of success. Programs have unique ways of empowering LVAD patients to be active. This speaker will describe the importance of post-LVAD rehab and increased activity, including the description of the "Electric Cranks" (electric bikes) for rehabilitation.

2:03 p.m. ***Heart and Soul: Dignity and Holistic Care at End of Life***
Savitri Fedson, MD, MA, Michael E. DeBakey VA Medical Center, Houston, TX, USA

The speaker will discuss the approach to provide holistic care for patients at end of life on LVAD support.

2:15 p.m. ***Panel Discussion led by Moderators***

THURSDAY, 11 APRIL, 2024

3:00 - 4:15 p.m.

ORAL SESSION 15: Early Career and Trainees Clinical Case Dilemmas: The Best of the Best Award Session

Location: Congress Hall

Core Therapies: HEART, LUNG, MCS, PVD

Practice Areas: Anesthesiology and Critical Care, Cardiology, Cardiothoracic Surgery, Infectious Diseases, Nursing and Allied Health, Pathology, Pediatrics, Pharmacy, Pulmonology, Research and Immunology

Session Summary: This award session recognizes excellence by early career and trainees from top abstracts submitted in the Early Career Clinical Case Reports category. Four early career finalists have been selected to present their work in this session.

Each presenter will give a **5-minute** PowerPoint presentation, followed by a **5-minute** presentation by an expert senior discussant who will discuss the intricacies of the case, applying clinical insights and wisdom to expand the learning experience for the viewing audience. This will be followed by an **8-minute** question and answer period with the audience, led by the session moderators.

At the conclusion of the session, the best case presentation will be selected by a panel of judges and the winner will be recognized during the Awards Presentations in the Plenary Session on Saturday, 13 April.

Moderators: Lara Danziger-Isakov, MD, MPH, Cincinnati Children's Hospital MC, Cincinnati, OH, USA
Tara Veasey, PharmD, BCTXP, Allegheny General Hospital, Pittsburgh, PA, USA

- 3:00 p.m. **(73) Favorable Use of Daratumumab in Highly Sensitized Pediatric Heart Transplant Candidates and Recipients**
M. Husain¹, L. C. Reardon², N. J. Halnon¹, R. S. Khan¹, A. Fan³, M. M. Si⁴, R. M. Biniwale⁴, J. C. Alejos¹. ¹Dept of Pediatrics, Div of Pediatric Cardiology, UCLA Mattel Children's Hosp, Los Angeles, CA, ²Dept of Med and Pediatrics, Div of Adult Congenital/Pediatric Cardiology, UCLA Mattel Children's Hosp, Los Angeles, CA, ³Dept of Pharmacy, UCLA, Los Angeles, CA, ⁴Dept of Surgery, Div of Congenital Cardiothoracic Surgery, UCLA Mattel Children's Hospital, Los Angeles, CA
- 3:05 p.m. **Expert Discussant in Heart Failure and Transplantation**
Simon Urschel, MD, University of Alberta, Edmonton, AB, Canada
- 3:10 p.m. **Q&A**
- 3:18 p.m. **(74) Ruxolitinib Prevents Pulmonary Function Decline Due to CLAD-BOS in an Adolescent Lung Transplant Recipient**
S. M. Yasechko¹, J. Simpson², D. Hayes³. ¹Pharmacy, Cincinnati Children's, Cincinnati, OH, ²Respiratory Care, Cincinnati Children's, Cincinnati, OH, ³Pulmonary Med, Cincinnati Children's / Univ of Cincinnati, Cincinnati, OH
- 3:23 p.m. **Expert Discussant in Lung Failure and Transplantation**
Marie Budev, DO, Cleveland Clinic, Cleveland, OH, USA
- 3:28 p.m. **Q&A**
- 3:36 p.m. **(75) Absent Sounds: Use of Haptic Devices for LVAD Alarms in a Patient with Hearing Loss**
A. Jawaid, M. Thomas, F. Hussain, S. Garg, J. T. Thibodeau, R. Morlend, E. A. Hardin, C. Wrobel, J. Nixon, M. Peltz, M. Farr. University of Texas Southwestern Medical Center, Dallas, TX
- 3:41 p.m. **Expert Discussant in Mechanical Circulatory Support**
Kathleen Grady, PhD, RN, MS, FAAN, Northwestern University, Chicago, IL, USA
- 3:46 p.m. **Q&A**
- 3:54 p.m. **(76) Case Report: A Pulmonary and Peripheral Arteriovenous Malformation in a Pulmonary Hypertension Patient with an Underlying BMPR2 Mutation**
L. Hardy¹, G. Aerts¹, L. Willems¹, J. Verhaegen¹, G. Maleux², T. Verbelen², B. Vanaudenaerde¹, L. Ceulemans², R. Vos², C. Belge², R. Quarck¹, M. Delcroix², L. Godinas². ¹KU Leuven, Leuven, Belgium, ²UZ Leuven, Leuven, Belgium
- 3:59 p.m. **Expert Discussant in Pulmonary Vascular Disease**
Mardi Gomberg-Maitland, MD, MSc, George Washington University, Washington, DC, USA
- 4:04 p.m. **Q&A**

THURSDAY, 11 APRIL, 2024

3:00 - 4:15 p.m.

ORAL SESSION 16: When More is Less and Less is More: Antithrombotic Therapy in Durable MCS

Location: Forum Hall

Core Therapies: MCS

Practice Areas: Pharmacy, Cardiology, Cardiothoracic Surgery, Research and Immunology

Session Summary: Antithrombotic pharmacotherapy practices continue to evolve in durable MCS patients. This session will explore data from clinical trials, as well as center specific experiences, to advance antithrombotic management strategies.

Each presenter will give a **10-minute** PowerPoint presentation, followed by a **5-minute** question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: Emma Birks, FRCP, MD, PhD, University of Kentucky, Lexington, KY, USA
Martin Strueber, MD, Baptist Medical Group, Memphis, TN, USA

3:00 p.m. **(77) The Impact of Genetic Polymorphism on Complications Development in Heart Failure Patients**
M. Zhalbinova¹, S. Rakhimova¹, S. Andosova², S. Akilzhanova³, A. Chinybayeva⁴, M. Bekbosynova², A. Akilzhanova¹. ¹National Laboratory Astana, Nazarbayev University, Astana, Kazakhstan, ²JSC "National Research Cardiac Surgery Center", UMC, Nazarbayev University, Astana, Kazakhstan, ³Pavlodar Cardiology Center, Pavlodar, Kazakhstan, ⁴Republic Diagnostic Center, CF "University Medical Center", Astana, Kazakhstan

3:10 p.m. **Q&A**

3:15 p.m. **Late-Breaking Abstract Presentation:**

(78) Impact of Vitamin K Antagonist Therapy on Outcomes in a Randomized Controlled Trial of Aspirin Removal in Left Ventricular Assist Device Patients - A Pre-Specified Analysis from The ARIES Trial
J. Connors, M. R. Mehra. Brigham and Women's Hospital and Harvard Medical School, Boston, MA

3:25 p.m. **Q&A**

3:30 p.m. **(79) Prevalence and Outcomes of Reduced Intensity Anticoagulation in Patients Supported with Left Ventricular Assist Devices**
C. Stang, S. Shin, Q. Huang, S. Sudat, B. Sheridan, M. Pham. California Pacific Medical Center, San Francisco, CA

3:40 p.m. **Q&A**

3:45 p.m. **(80) A Single-Center Experience with Delayed Heparin Initiation Following Heartmate3 Implantation**
H. Beaini¹, M. Thomas², L. Truby³, C. Wrobel², D. Varghese⁴, M. Edwards⁴, M. Farr³, M. Peltz⁴. ¹Cardiology, UT Southwestern Medical Center, Dallas, TX, ²UT Southwestern, Dallas, TX, ³University of Texas Southwestern Medical Center, Dallas, TX, ⁴UT Southwestern Medical Center, Dallas, TX

3:55 p.m. **Q&A**

4:00 p.m. **Late-Breaking Abstract Presentation:**

(81) A Comprehensive Analysis of Bleeding Outcomes with Aspirin Removal with a Fully Magnetically Levitated LVAD - The International Randomized Controlled ARIES Trial
U. Jorde¹, M. R. Mehra². ¹Montefiore MC, New York, NY, ²Brigham and Women's Hospital and Harvard Med Sch, Boston, MA

4:10 p.m. **Q&A**

THURSDAY, 11 APRIL, 2024

3:00 - 4:15 p.m.

ORAL SESSION 17: Mystical Mechanisms of Lung Allograft Dysfunction: Lungs and the Philosopher's Stone

Location: South Hall 3

Core Therapies: LUNG

Practice Areas: Pulmonology, Pathology, Pharmacy, Research and Immunology

Session Summary: Survival after lung transplantation remains limited due to multiple types of allograft dysfunction, from ischemia reperfusion injury (IRI), to baseline (BLAD), acute (ALAD), and chronic lung allograft dysfunction (CLAD). Exact mechanisms of allograft injury in these contexts remain elusive. This session will describe translational studies that assess the pathogenesis of allograft dysfunction and propose novel diagnostic and therapeutic targets for future clinical application.

Each presenter will give a **10-minute** PowerPoint presentation, followed by a **5-minute** question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: Alberto Benazzo, PhD, Medical University of Vienna, Vienna, Austria
Anja Roden, MD, Mayo Clinic, Rochester, MN, USA

- 3:00 p.m. **(82) The cGAS-Sting Pathway Drives Alveolar Epithelial Cell Death via Non-Canonical PKR Signaling During Lung Ischemia-Reperfusion Injury**
P. Gao¹, C. Li², H. Liu³, C. Chen⁴, J. Wu⁵. ¹Tongji University School of Medicine, Shanghai, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China, ²Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China, ³Shanghai Key Laboratory of Respiratory Disease, Tongji University, Shanghai, China, ⁴Shanghai Pulmonary Hospital, Tongji University, Shanghai, China, ⁵Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China
- 3:10 p.m. **Q&A**
- 3:15 p.m. **(83) Early Post-Transplant Airway II-5 and Eosinophilia Are Associated with Baseline Lung Allograft Dysfunction and Impaired Allograft Survival**
R. Ramendra¹, C. Camillo², M. Leiva-Juarez³, X. Zhou⁴, L. Benvenuto⁵, S. Arcasoy², S. Keshavjee⁶, E. Huszti⁴, A. Sage⁷, F. D'Ovidio⁵, T. Martinu⁸. ¹Ajmera Transplant, University Health Network, Toronto, ON, Canada, ²Columbia University, New York, NY, ³Columbia University Irving Medical Centre, New York, NY, ⁴University Health Network, Toronto, ON, Canada, ⁵Columbia University Medical Center, New York, NY, ⁶UHN, Toronto, ON, Canada, ⁷Toronto General Hospital, Toronto, ON, Canada, ⁸Toronto General Hospital/UHN, Toronto, ON, Canada
- 3:25 p.m. **Q&A**
- 3:30 p.m. **(84) Early Posttransplant Bronchoalveolar Lavage Fluid (BALF) Hyaluronan is an Independent Risk Marker for Chronic Lung Allograft Dysfunction (CLAD)**
J. Rim¹, J. Weber¹, M. Neely¹, F. Kelly¹, A. Nagler¹, L. Eason¹, P. McArthur¹, J. Belperio², M. Budev³, J. Reynolds¹, P. Shah⁴, L. Singer⁵, L. Snyder¹, S. Palmer¹, J. Todd¹. ¹Duke University Medical Center, Durham, NC, ²University of California Los Angeles, Los Angeles, CA, ³Cleveland Clinic, Cleveland, OH, ⁴Johns Hopkins University, Baltimore, MD, ⁵University Health Network, Toronto, ON, Canada
- 3:40 p.m. **Q&A**
- 3:45 p.m. **(85) An Exploration of Gene Expression Patterns Underlying Restrictive and Obstructive Chronic Lung Allograft Dysfunction (CLAD) Phenotypes Using Non-Negative Matrix Factorization**
T. Ishiwata, J. Allen, G. Berra, R. Ghany, S. Keshavjee, G. Wilson, J. Yeung, S. Juvet, T. Martinu. Toronto Lung Transplant Program, Ajmera Transplant Center, University Health Network, Toronto, ON, Canada
- 3:55 p.m. **Q&A**
- 4:00 p.m. **(86) Divergent Transcriptional Features of Obstructive and Restrictive Forms of Chronic Lung Allograft Rejection Modeled in a Single Mouse Strain Combination**
T. Watanabe¹, J. Allen², S. Keshavjee², Y. Okada¹, J. Yeung², T. Martinu³, S. Juvet². ¹Tohoku University, Sendai, Japan, ²UHN, Toronto, ON, Canada, ³Toronto General Hospital/UHN, Toronto, ON, Canada
- 4:10 p.m. **Q&A**

THURSDAY, 11 APRIL, 2024

3:00 - 4:15 p.m.

ORAL SESSION 18: Frontiers in Cardiac Transplantation: New Insights and Hazards

Location: South Hall 1

Core Therapies: HEART

Practice Areas: Research and Immunology, Cardiology, Cardiothoracic Surgery, Pediatrics

Session Summary: Experimental work in the field of cardiac transplantation increases the possibilities of solving the problem of a severe and insurmountable disproportion between the number of available donor hearts and recipients on the waiting list. An extraordinary breakthrough in the field of research in recent years offers us new successful solutions, but at the same time it opens up new issues and concerns

Each presenter will give a **10-minute** PowerPoint presentation, followed by a **5-minute** question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: Albert Hicks, MD, MPH, University of Maryland, Baltimore, MD, USA
Brian Lowes, MD, PhD, University of Nebraska Medical Center, Omaha, NE, USA

- 3:00 p.m. **(87) Integrative Multi-Omics Profiling in Human Decedents Receiving Genetically Modified Pig Hearts Reveals Early Immune-Cell Responses Indicative of Perioperative Cardiac Xenograft Dysfunction**
B. Keating¹, E. schmauch², N. Moazami³, M. Snyder⁴, B. Piening⁵, R. Montgomery⁶. ¹Surgery, New York University Langone, New York City, NY, ²Broad Institute, MIT and Harvard, Cambridge, MA, ³Surgery, NYU Grossman School of Medicine, New York, NY, ⁴Genetics, Stanford University, Palo Alto, CA, ⁵Molecular Pathology, Providence St. Joseph Health, Portland, OR, ⁶Surgery, NYU Langone Health, New York, NY
- 3:10 p.m. **Q&A**
- 3:15 p.m. **(88) Extended Survival of 9- and 10-Gene-Edited Pig Heart Xenografts with Ischemia Minimization and Cd154 Costimulation Blockade-Based Immunosuppression**
R. Chaban¹, I. Ilek¹, K. Kinoshita¹, Z. Habibabady¹, S. Lederman², L. Burdorf¹, W. Eyestone³, R. Prather⁴, R. Pierson¹. ¹Massachusetts General Hospital, Boston, MA, ²Tonix Pharmaceuticals Inc., Chatham, NJ, ³Revivicor, Blacksburg, VA, ⁴National Swine Resource and Research, Columbia, MO
- 3:25 p.m. **Q&A**
- 3:30 p.m. **(89) Pilot Evaluation of a Clinical Xeno Heart Transplant Regimen in A Preclinical Model**
R. Chaban¹, I. Ilek¹, K. Kinoshita¹, Z. Habibabady¹, S. Low², K. Whitworth³, R. Pierson¹. ¹Massachusetts General Hospital, Boston, MA, ²eGenesis, Cambridge, MA, ³National Swine Resource and Research Center, Columbia, MO
- 3:40 p.m. **Q&A**
- 3:45 p.m. **(90) Heart Allograft Survival in Juvenile Nonhuman Primates Undergoing Mixed Chimerism Conditioning is Prolonged by Donor Thymus Co-Transplantation**
J. Nawalaniec, S. Landino, J. O, J. Muoio, N. Hays, D. Muldoon, A. Dehnadi, I. Hanekamp, J. Allan, J. Madsen. Massachusetts General Hospital, Boston, MA
- 3:55 p.m. **Q&A**
- 4:00 p.m. **(91) IL-6 Receptor Blockade Induces Tolerance of Heart Allografts in NHPs in a Simultaneous but Not Delayed Mixed-Chimerism Protocol**
J. O, C. Miller, J. Nawalaniec, S. Landino, N. Hays, A. Dehnadi, J. M. Muoio, C. Winter, I. Hanekamp, G. Benichou, J. Allan, J. Madsen. Massachusetts General Hospital, Boston, MA
- 4:10 p.m. **Q&A**

THURSDAY, 11 APRIL, 2024

3:00 - 4:15 p.m.

ORAL SESSION 19: Out of Body Experiences: Ex Vivo Donor Heart Perfusion Techniques

Location: South Hall 2

Core Therapies: HEART

Practice Areas: Cardiothoracic Surgery, Cardiology, Research and Immunology

Session Summary: This session covers the latest developments regarding ex vivo donor heart perfusion including cold and warm techniques

Each presenter will give a **10-minute** PowerPoint presentation, followed by a **5-minute** question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: Markus Barten, Prof., University Heart and Vascular Center Hamburg, Hamburg, Germany
Joseph Rogers, MD, Texas Heart Institute, Houston, TX, USA

- 3:00 p.m. **(92) Optimizing Hearts for Transplantation Using Small Interfering RNA-Based Therapies During Ex Vivo Machine Perfusion**
J. E. Buchwald¹, H. H. Fakh¹, M. Bolger-Chen², M. Lopera Higuera³, R. Pierson⁴, A. A. Osho⁴, S. Tessier³, A. Khvorova¹, S. Rabi⁴.
¹RNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, MA, ²Massachusetts General Hospital, Boston, MA, ³Center for Engineering in Medicine and Surgery, Massachusetts General Hospital - Harvard Medical School, Boston, MA, ⁴Division of Cardiac Surgery, Massachusetts General Hospital, Boston, MA
This presenter is also one of five finalists for the 2024 Early Career Scientist Award. Winner will be announced after the meeting.
- 3:10 p.m. **Q&A**
- 3:15 p.m. **(93) Longer Duration of Ex-Vivo Perfusion is Associated with Worse Survival in Donation After Circulatory Death Heart Recipients: A National Database Analysis**
K. Punu¹, R. Singh², G. Olverson², S. A. Brownlee², A. Kreso², S. Rabi², E. Michel², G. Lewis³, D. D'Alessandro², A. Osho².
¹University of Pittsburgh School of Medicine, Pittsburgh, PA, ²Division of Cardiac Surgery, Massachusetts General Hospital, Boston, MA, ³Division of Cardiology, Massachusetts Gen Hosp, Boston, MA
- 3:25 p.m. **Q&A**
- 3:30 p.m. **(94) Organ Care System (OCS) Perfusion Time During Donation After Circulatory Death (DCD) Heart Transplantation: Not Too Little, Not Too Much : There Safety Lie**
H. Smail¹, L. Martinez Marin¹, S. Pettit¹, P. Kaul¹, M. Rafiq¹, S. Tsui¹, D. Jenkins¹, S. Large¹, S. Bhagra¹, A. Kydd¹, L. Simmonds², R. Hogg², J. Parameshwar¹, C. Lewis¹, J. Nunes¹, S. Messer³, A. Page¹, A. Al-Adhami¹, M. Berman¹. ¹Cardio-Thoracic Transplantation, Royal Papworth Hospital, Cambridge, United Kingdom, ²NHSBT, Bristol, United Kingdom, ³Golden Jubilee National Hospital, Glasgow, United Kingdom
- 3:40 p.m. **Q&A**
- 3:45 p.m. **(95) Impact of Ex Vivo Machine Perfusion on Post-Transplant Survival in Extended Criteria Hearts Donated After Brain Death**
Y. Hong, N. Hess, L. Ziegler, A. Dorken-Gallastegi, M. Abdullah, N. Agrawal, I. Sultan, G. Hickey, M. Keebler, D. Kaczorowski.
University of Pittsburgh Medical Center, Pittsburgh, PA
- 3:55 p.m. **Q&A**
- 4:00 p.m. **(96) Initial Single Centre Experience with The XVIVO Hypothermic Perfusion System: Outcomes from the First 32 Cases**
S. Emmanuel¹, P. MacDonald², C. Hayward³, K. Muthiah³, A. Watson⁴, A. Iyer⁵, M. Connellan³, E. Granger¹, D. Kaye⁶, D. McGiffin⁷, P. Jansz⁴. ¹St Vincent's Hospital Sydney, Darlinghurst, Australia, ²St. Vincent 's Hospital, Darlinghurst, Australia, ³St. Vincent's Hospital, Darlinghurst, Australia, ⁴St Vincent's Hospital, Darlinghurst, Australia, ⁵St Vincent 's Hospital, Darlinghurst, Australia, ⁶Alfred Hospital, Melbourne, Australia, ⁷Alfred Health, Melbourne, Australia
- 4:10 p.m. **Q&A**

THURSDAY, 11 APRIL, 2024

3:00 - 4:15 p.m.

ORAL SESSION 20: Patient-Centered Outcomes After Lung Transplantation: Lungs and the Deathly Hallows Part II

Location: Panorama Hall

Core Therapies: LUNG

Practice Areas: Nursing and Allied Health, Pharmacy, Pulmonology, Research and Immunology

Session Summary: This session focuses on important patient-centered outcomes in lung transplantation including health literacy, grit and resilience, frailty, exercise capacity and palliative care needs of lung transplant recipients.

Each presenter will give a **10-minute** PowerPoint presentation, followed by a **5-minute** question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: Patricia Ging, MSc, Mater Misericordiae University Hospital, Dublin, Ireland
Kathryn Hughes, MSN, Vanderbilt University Medical Center, Nashville, TN, USA

- 3:00 p.m. **(97) Health Literacy in Lung Transplant Patients: An Area for Improvement**
L. Schoel¹, J. Vinales², K. Walter², J. Shevket², B. Hunt², V. Sood², S. Zaiantz², J. Clay², K. Lagisetty¹, R. Sagana². ¹Department of Surgery, University of Michigan, Ann Arbor, MI, ²University of Michigan, Ann Arbor, MI
- 3:10 p.m. **Q&A**
- 3:15 p.m. **(98) The Impact of Pre-Transplant Mental Toughness on Short-Term Outcomes in Lung Allograft Recipients**
A. G. Dragnich, K. C. Chapin, K. Xu, J. Liu, L. Lipworth, C. M. Shaver, A. J. Trindade. Vanderbilt University Medical Center, Nashville, TN
- 3:25 p.m. **Q&A**
- 3:30 p.m. **(99) Comparison of Frailty Trajectories in Lung Transplantation**
A. Rajkumar¹, N. Chowdhury¹, D. Rozenberg¹, P. Riddell², K. Rockwood³, S. Mathur⁴, L. G. Singer¹. ¹University Health Network, Toronto, ON, Canada, ²Mater Misericordiae University Hospital, Dublin, Ireland, ³Dalhousie University, Halifax, NS, Canada, ⁴Queens University, Kingston, ON, Canada
- 3:40 p.m. **Q&A**
- 3:45 p.m. **(100) Determinants and Predictors of Improved Exercise Capacity Following Pulmonary Rehabilitation in Lung Transplant Recipients**
J. Yang¹, J. M. Saavedra², T. Narula¹, F. Alvarez¹, B. Taylor¹. ¹Mayo Clinic, Jacksonville, FL, ²Iowa State University, Ames, IA
- 3:55 p.m. **Q&A**
- 4:00 p.m. **(101) End-of-Life Care for Lung Transplant Recipients: A New Role for Palliative Medicine**
L. Morlacchi¹, M. Pappalettera¹, V. Rossetti¹, I. Righi², F. Damarco², M. Nosotti², R. Moroni Grandini³, F. Blasi¹. ¹Internal Medicine Department, Respiratory Unit and Cystic Fibrosis Adult Centre, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano; Università degli Studi di Milano, Milano, Italy, ²Thoracic Surgery and Lung Transplantation Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano; Università degli Studi di Milano, Milano, Italy, ³Hospice and Palliative Care - Cascina Brandezzata, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano; Università degli Studi di Milano, Milano, Italy
- 4:10 p.m. **Q&A**

THURSDAY, 11 APRIL, 2024

3:00 - 4:15 p.m.

ORAL SESSION 21: HCV Positive Cardiac Donors: Refining the Standard-of-Care

Location: North Hall

Core Therapies: HEART

Practice Areas: Infectious Diseases, Cardiology, Cardiothoracic Surgery, Pathology, Pharmacy, Pulmonology, Research and Immunology

Session Summary: Hepatitis C donor heart transplantation for hepatitis C negative recipients is standard-of-care in parts of the world. This session features abstracts evaluating opportunities to improve current practices.

Each presenter will give a **10-minute** PowerPoint presentation, followed by a **5-minute** question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: Snehal Patel, MD, Montefiore-Einstein, Bronx, NY, USA
Cameron Wolfe, MD, Duke University Medical Center, Durham, NC, USA

- 3:00 p.m. **(102) Efficacy of Short Course Direct Acting Antivirals and Ezetimibe vs Longer Course of Direct Acting Antivirals to Prevent Hepatitis C Infection in Thoracic Transplant Recipients of Hepatitis C Viremic Donors**
P. K. Burcham¹, T. Fallah¹, B. A. Whitson², B. C. Lampert³, J. P. Rosenheck³, A. M. Ganapathi², M. C. Henn², N. Marschalk³, K. T. Kissling¹. ¹Pharmacy, The Ohio State University Wexner Medical Center, Columbus, OH, ²Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, ³Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH
- 3:10 p.m. **Q&A**
- 3:15 p.m. **(103) Prophylaxis of Donor-Derived HCV Infection in Cardiothoracic Transplant Recipients with Short-Course DAA Therapy**
J. M. Kozuch¹, S. Aslam². ¹Department of Pharmacy, UC San Diego Health, La Jolla, CA, ²Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, La Jolla, CA
- 3:25 p.m. **Q&A**
- 3:30 p.m. **(104) Intermediate Term Outcomes of CAV Screening in Heart Transplant Recipients from Hepatitis C Viremic Donors versus Non-Hepatitis C Donors**
K. Paternostro, A. Birs, E. Adler, K. Hong, S. Aslam, N. Wettersten. University of California San Diego, San Diego, CA
- 3:40 p.m. **Q&A**
- 3:45 p.m. **(105) Impact and Outcomes of Hepatitis C Viremic Donors (HCV-NAAT) on Donor-Derived Cell-Free DNA Levels and Gene-Expression Profiling (GEP-Allomap) in Heart Transplant Recipients**
C. M. Moeller¹, A. Fernandez Valledor¹, D. Oren¹, A. Rahman¹, G. Rubinstein¹, S. Rahman¹, C. Lee¹, J. Baranowska¹, M. Regan¹, Y. Mehlman¹, D. Lotan¹, E. M. DeFilippis¹, K. Theodoropoulos¹, J. Fried¹, V. Topkara¹, D. Majure², P. Colombo¹, J. Raikhelkar¹, M. Yuzefpolskaya¹, K. Clerkin¹, F. Latif¹, G. T. Sayer¹, N. Uriel¹. ¹Columbia University Irving Medical Center, New York, NY, ²Weill Cornell Medical College, New York, NY
- 3:55 p.m. **Q&A**
- 4:00 p.m. **(106) Racial and Ethnic Disparities in Transplantation of Hearts from HCV-Infected Donors into HCV-Negative Recipients**
H. Hannan¹, D. Goldberg². ¹University of Michigan, Ann Arbor, MI, ²University of Miami Miller School of Medicine, Miami, FL
- 4:10 p.m. **Q&A**

THURSDAY, 11 APRIL, 2024

4:30 - 5:30 p.m.

MINI ORAL 01: DCD Hearts: The New Frontier

Location: Congress Hall

Core Therapies: HEART

Practice Areas: Cardiothoracic Surgery, Anesthesiology and Critical Care, Cardiology, Nursing and Allied Health, Pathology, Research and Immunology

Session Summary: Donation after Circulatory Death (DCD) has significantly increased heart transplantation over the last decade. Emerging data on DCD expansion will be discussed including controversies in this developing clinical practice area.

Each presenter will give a **4-minute** "rapid fire" PowerPoint summation of the key learning points of the research, followed by a **2-minute** question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: Muhammad Rafiq, FRCS-CTh, Royal Papworth Hospital, Cambridge, United Kingdom
Marian Urban, MD, PhD, University of Nebraska MC, Omaha, NE, USA

- 4:30 p.m. **(229) Cardiac Donation After Circulatory Death Utilizing Normothermic Regional Perfusion: The Three-Year Vanderbilt Experience**
C. Pasrija¹, A. DeBose-Scarlett¹, P. Mark¹, S. Bommareddi¹, T. Absi², H. Siddiqi³, K. Amancherla³, D. Brinkley³, J. Lindenfeld¹, J. Menachem¹, H. Ooi⁴, D. Pedrotty⁵, L. Punnoose⁶, A. Rali³, S. Sacks¹, M. Wigger², S. Zalawadiya³, S. DeVries¹, C. Keck¹, S. Scholl¹, A. Lepore¹, M. War Hoover¹, K. Schlendorf³, A. Shah³, J. Trahanas³. ¹Vanderbilt University, Nashville, TN, ²Vanderbilt Medical Center, Nashville, TN, ³Vanderbilt University Medical Center, Nashville, TN, ⁴Vanderbilt U Med Ctr, Nashville, TN, ⁵Vanderbilt Heart and Vascular Institute, Nashville, TN, ⁶Vanderbilt University School of Medicine, Nashville, TN
- 4:34 p.m. **Q&A**
- 4:36 p.m. **(230) Never Too Old to Join the Pool - Heart Transplantation From Older Donation After Circulatory Death Donors in Australia**
Y. Joshi¹, K. Wang², J. Villanueva³, L. Gao³, J. Wu³, A. Doyle³, S. Scheuer¹, H. Chew³, A. Iyer¹, A. Watson¹, M. Connellan¹, E. Granger¹, P. Jansz¹, P. MacDonald¹. ¹St Vincent's Hospital Sydney, Sydney, Australia, ²University of New South Wales, Sydney, Australia, ³Victor Chang Cardiac Research Institute, Sydney, Australia
- 4:40 p.m. **Q&A**
- 4:42 p.m. **(231) Outcomes in Donation After Circulatory Death Cardiac Transplantation Following Direct Procurement and Perfusion Compared with Normothermic Regional Perfusion**
M. J. Kearns, A. Ayer, A. Birs, A. Topik, E. Adler, M. Urey, V. Pretorius. UC San Diego Health, San Diego, CA
- 4:46 p.m. **Q&A**
- 4:48 p.m. **(232) Direct Procurement Followed by Hypothermic Oxygenated Perfusion in DCD Heart Transplantation**
J. Brouckaert¹, K. Vandendriessche¹, M. Lamberigts¹, B. Meyns¹, T. Verbelen¹, I. Jochmans², H. Roderick³, F. Rega¹. ¹Cardiac Surgery, University Hospitals Leuven, Leuven, Belgium, ²Abdominal Transplantation Surgery, University Hospitals Leuven, Leuven, Belgium, ³Cardiovascular Sciences, KU Leuven, Leuven, Belgium
- 4:52 p.m. **Q&A**
- 4:54 p.m. **(233) Donation After Circulatory Death Heart Transplantation - Withdrawal Practices and Location Matter!**
Y. Joshi¹, R. Fritis-Lamora¹, K. Wang², J. Villanueva², S. Kim¹, A. Kasavaraj², C. Soto¹, A. Iyer¹, A. Watson¹, M. Connellan¹, E. Granger¹, P. Jansz¹, P. MacDonald¹. ¹St Vincent's Hospital Sydney, Sydney, Australia, ²Victor Chang Cardiac Research Institute, Sydney, Australia
- 4:58 p.m. **Q&A**
- 5:00 p.m. **(234) Organ Care System Heart Perfusion (OHP) Registry Annual Report - Donation After Circulatory Death Heart Transplant Outcomes**
M. A. Daneshmand¹, J. Schroder², D. D'Alessandro³, S. Pham⁴, L. Lozoschi⁵, G. Couper⁶, A. Shah⁷, J. Pal⁸, L. Klein⁹, F. Esmailian¹⁰, R. Davis¹¹, M. Villavicencio¹², A. Shaffer¹³, B. Sun¹⁴, K. Takeda¹⁵, D. Pham¹⁶, R. Malyala¹⁷, H. Mallidi¹⁸, J. Haft¹⁹, D. Meyer²⁰, L. Durham²¹, D. Goldstein²², M. Funamoto²³, S. Ohira²⁴, D. Kaczorowski²⁵, J. Stehlik²⁶, S. Pinney²⁷, M. Farr²⁸, C. Milano², Y. Shudo²⁹. ¹Surgery, Emory University, Atlanta, GA, ²Duke University Medical Center, Durham, NC, ³MGH, Boston, MA, ⁴Mayo Clinic, Jacksonville, FL, ⁵University of South Florida, Tampa General Hospital, Tampa, FL, ⁶Tufts Medical Center, Boston, MA,

⁷Vanderbilt University Medical Center, Nashville, TN, ⁸University of Washington, Seattle, WA, ⁹University of California San Francisco, San Francisco, CA, ¹⁰Cedars-Sinai Heart Institute, Los Angeles, CA, ¹¹Yale, New Haven, CT, ¹²Mayo Clinic, Rochester, MN, ¹³Univ of Minnesota, Minneapolis, MN, ¹⁴Minneapolis Heart Institute, Minneapolis, MN, ¹⁵Columbia university, New York, NY, ¹⁶Northwestern Medicine, Chicago, IL, ¹⁷University of Kentucky, Lexington, KY, ¹⁸Brigham and Women 's Hospital / HMS, Boston, MA, ¹⁹University of Michigan - Michigan Medicine, Ann Arbor, MI, ²⁰Baylor Scott and White Health, Baylor University Medical Center, Dallas, TX, ²¹Medical College of Wisconsin, Milwaukee, WI, ²²Montefiore, New York, NY, ²³Methodist Heart and Lung Institute, San Antonio, TX, ²⁴Westchester Medical Center, New York Medical College, Valhalla, NY, ²⁵University of Pittsburgh Medical Center, Pittsburgh, PA, ²⁶University of Utah, Salt Lake City, UT, ²⁷Mount Sinai Morningside, New York, NY, ²⁸University of Texas Southwestern Medical Center, Dallas, TX, ²⁹Stanford University, Palo Alto, CA

5:04 p.m.

Q&A

5:06 p.m.

(235) 8-Year Single-Centre Experience of DCD Heart Transplantation: Temporal Trends in Outcomes, Procedural and Recipient Characteristics

L. Martinez Marin¹, H. Smail¹, S. Bhagra¹, R. Hogg², D. Jenkins¹, P. Kaul¹, A. Kydd¹, S. Large¹, C. Lewis¹, S. Messer³, J. Nunes¹, J. Parameshwar¹, M. Rafiq¹, L. Simmonds², S. Tsui¹, M. Berman¹, S. Pettit¹. ¹Royal Papworth Hospital, Cambridge, United Kingdom, ²NHS Blood and Transplant, Bristol, United Kingdom, ³Golden Jubilee National Hospital, Glasgow, United Kingdom

5:10 p.m.

Q&A

5:12 p.m.

(236) Outcomes of Multi-Organ Heart Transplant Between Donation After Circulatory Death and Brain Death

T. Endo, S. Moore, S. Fu, R. Samson, M. Gallo, S. Pahwa, M. S. Slaughter, E. M. Schumer. *University of Louisville, Louisville, KY*

5:16 p.m.

Q&A

5:18 p.m.

(237) Donation After Circulatory Death for Heart Transplantation

P. D. Cho¹, S. T. Kim², A. Nsair³, R. Biniwale², A. Ardehali². ¹Drexel College of Medicine, Philadelphia, PA, ²UCLA School of Medicine, Los Angeles, CA, ³UCLA Ronald Regan Medical Center, Los Angeles, CA

5:22 p.m.

Q&A

THURSDAY, 11 APRIL, 2024

4:30 - 5:30 p.m.

MINI ORAL 02: Temporizing Cardiogenic Shock to Success

Location: Forum Hall

Core Therapies: MCS

Practice Areas: Anesthesiology and Critical Care, Cardiology, Cardiothoracic Surgery

Session Summary: This session discusses device implementation in cardiogenic shock for superior outcomes.

Each presenter will give a **4-minute** "rapid fire" PowerPoint summation of the key learning points of the research, followed by a **2-minute** question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: Sharon Larson, DO, Baptist Memorial Hospital Memphis, Memphis, TN, USA
Dave Nagpal, MD, FRCSC, London Health Sciences Centre, London, ON, Canada

- 4:30 p.m. **(239) Relationship of Systemic Vascular Resistance with Mortality in Cardiogenic Shock**
M. Chavez¹, S. Monte², E. Sheffield², M. Anderson³, B. Kogelachatz², J. Leon², I. Taleb⁴, C. Kyriakopoulos⁵, E. Dranow¹, M. Goodwin⁶, E. Maneta¹, R. Hamouche¹, J. Fang⁷, S. Drakos¹, T. Hanff¹. ¹Cardiovascular Medicine, University of Utah, Salt Lake City, UT, ²Internal Medicine, University of Utah, Salt Lake City, UT, ³University of Utah Health, Salt Lake City, UT, ⁴Cardiovascular Medicine, University of California San Diego, San Diego, CA, ⁵Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, ⁶Cardiothoracic Surgery, University of Utah, Salt Lake City, UT, ⁷Cardiovascular Medicine, Univ of Utah Health Sciences Center, Salt Lake City, UT
- 4:34 p.m. **Q&A**
- 4:36 p.m. **(240) Methods and Preliminary Results of Implementation of Multi-Center Early Impella® Support in Patients with ST-Segment Elevation Myocardial Infarction Complicated by Cardiogenic Shock (RECOVER IV) Trial Under Exception from Informed Consent**
G. Nichol¹, N. Dickert², K. Adams³, D. Morse⁴, S. Morse⁴, C. Facemire⁵, K. Shah⁶, S. Dasari⁵, J. Bodnar⁵, N. Kapur⁷, W. O'Neill⁸, G. W. Stone⁹. ¹University of Washington-Harborview Center for Prehospital Emergency Care, Seattle, WA, ²Emory University School of Medicine, Atlanta, GA, ³University of Washington, Seattle, WA, ⁴Harborview Medical Center, Seattle, WA, ⁵Abiomed, Danvers, MA, ⁶J&J medtech, Danvers, MA, ⁷Tufts Medical Center, Hanover, MA, ⁸Henry Ford Hospital, Detroit, MI, ⁹Icahn School of Medicine at Mount Sinai, New York, NY
- 4:40 p.m. **Q&A**
- 4:42 p.m. **(241) Clinical Outcomes and the Impact of SCAI Stage Among Protek Duo Right Ventricular Assist Device Recipients with Cardiogenic Shock: A Report from the Cardiogenic Shock Working Group**
J. Hernandez Montfort¹, M. Kanwar², A. Garan³, S. Sinha⁴, P. Sangal⁵, Q. Kong⁵, B. Li⁵, K. Walec⁵, P. Zazzali⁵, D. Burckoff⁶, N. Kapur⁵. ¹Baylor Scott and White Health, Red Rock, TX, ²Allegheny General Hospital, Pittsburgh, PA, ³Beth Israel Deaconess Medical Center, Boston, MA, ⁴Inova Fairfax Medical Campus, Arlington, VA, ⁵Tufts Medical Center, Boston, MA, ⁶Cardiovascular Research Foundation, New York, NY
- 4:46 p.m. **Q&A**
- 4:48 p.m. **(242) Catheter-Based Microaxial Flow Pump Preconditioning of Patients Undergoing Durable Left Ventricular Device Implantation: A Propensity Score Analysis of a Single Center Experience**
Y. Hrytsyna, P. Lanmüller, D. Lewin, G. Nersesian, S. Ott, J. Mulzer, F. Kaufmann, C. Hoermandinger, C. Starck, V. Falk, E. Potapov. Deutsches Herzzentrum der Charité, Berlin, Germany
- 4:52 p.m. **Q&A**
- 4:54 p.m. **(243) Association of ECMO Flow Index and Mortality in Adults with Cardiogenic Shock Receiving Venoarterial Extracorporeal Membrane Oxygenation: An ELSO Registry Analysis**
A. A. Delgado¹, L. Aguilar¹, K. Kennedy¹, J. A. Fried², K. Takeda³, A. J. Kirtane², N. K. Kapur⁴, J. E. Tonna⁵, P. Quintero¹, M. Sabe¹, J. E. Ho¹, R. Sriwattanakomen¹, L. Labrada⁶, A. S. Rali⁷, A. R. Garan¹, E. W. Grandin¹. ¹Cardiology, Beth Israel Deaconess Medical Center, Boston, MA, ²Cardiology, Columbia University Medical Center, New York, NY, ³Cardiac Surgery, Columbia University Medical Center, New York, NY, ⁴Cardiology, Tufts Medical Center, Boston, MA, ⁵Cardiothoracic Surgery & Emergency Medicine, University of Utah Health, Salt Lake City, UT, ⁶Cardiology, Temple University Hospital, Philadelphia, PA, ⁷Cardiology, Vanderbilt University Medical Center, Nashville, TN
- 4:58 p.m. **Q&A**

- 5:00 p.m. **(244) Impact of Hemolysis During Micro-Axial Flow Pump Support on Early Outcomes After Durable LVAD Implantation: Insights from an International Registry**
A. Loforte¹, G. Gallone¹, D. Lewin², A. Bernhardt³, S. Rojas⁴, M. Billion⁵, A. Meyer⁶, I. Netuka⁷, J. Kooij⁸, M. Pieri⁹, M. Szymanski¹⁰, C. Moeller¹¹, P. Akhyari¹², K. Jawad¹³, I. Krasivskyj¹³, B. Schmack¹⁴, G. Farber¹⁵, M. Medina¹⁶, A. Haneya¹⁷, D. Zimpfer¹⁸, G. Nersesian², P. Lanmueller², A. Spitaleri¹, M. Oezkur¹⁶, I. Djordjevic¹⁹, D. Saeed¹³, J. Stein², A. Kraaijevald¹⁰, G. M. De Ferrari¹, M. Boffini¹, F. Gustafsson¹¹, A. Scandroglio⁹, B. Meyns²⁰, S. Hofmann⁵, J. Belohlavek⁷, J. Gummert⁴, E. Potapov², M. Rinaldi¹.
¹University of Turin, Turin, Italy, ²Deutsches Herzzentrum der Charité, Berlin, Germany, ³University Heart and Vascular Center Hamburg, Hamburg, Germany, ⁴Heart and Diabetes Center Bad Oeynhausen, Bad Oeynhausen, Germany, ⁵Schüchtermann Clinic, Bad Rothenfelde, Germany, ⁶Universitätsklinikum Heidelberg, Heidelberg, Germany, ⁷Institute for Clinical and Experimental Medicine, Prague, Czech Republic, ⁸University Hospitals Leuven, Leuven, Belgium, ⁹Ospedale San Raffaele, Milan, Italy, ¹⁰University Medical Center Utrecht, Utrecht, Netherlands, ¹¹Rigshospitalet, Copenhagen, Denmark, ¹²University Hospital Duesseldorf, Duesseldorf, Germany, ¹³Leipzig Heart Center, Leipzig, Germany, ¹⁴University of Essen, Essen, Germany, ¹⁵University Hospital Jena, Jena, Germany, ¹⁶University of Mainz, Mainz, Germany, ¹⁷Unif of Kiel, Kiel, Germany, ¹⁸Medical University of Vienna, Vienna, Austria, ¹⁹University Hospital Cologne, Cologne, Germany, ²⁰UZ Leuven, Leuven, Belgium
- 5:04 p.m. **Q&A**
- 5:06 p.m. **(245) Practice Variation in Temporary MCS Device Choice in Cardiogenic Shock**
S. Li¹, A. Bahl², M. Kanwar³, B. Li⁴, S. Sinha⁵, J. Hernandez Montfort⁶, Q. Kong⁴, P. Sangal⁴, D. Burkhoff⁷, C. Mahr¹, N. Kapur⁴.
¹Medical City Healthcare, Dallas, TX, ²University of Washington, Seattle, WA, ³Allegheny General Hospital, Pittsburgh, PA, ⁴Tufts Medical Center, Boston, MA, ⁵Inova Fairfax Medical Campus, Falls Church, VA, ⁶Baylor Scott and White Health, Dallas, TX, ⁷Cardiovascular Research Foundation, New York, NY
- 5:10 p.m. **Q&A**
- 5:12 p.m. **(246) Short to Mid-Term Outcomes in Patients Bridged to Recovery Using Impella 5.5**
E. Faridmoayer¹, G. Dardik¹, T. R. Powley¹, A. P. Lin¹, M. Biscotti², J. R. Gower², J. A. Fried², M. Yuzefpolskaya², P. C. Colombo², G. T. Sayer², N. Uriel², G. Ferrari¹, K. Takeda², Y. Kaku². ¹Columbia University Irving Medical Center, New York, NY, ²NewYork-Presbyterian Hospital/Columbia, New York, NY
- 5:16 p.m. **Q&A**
- 5:18 p.m. **(247) Outcomes of Transport on Venoarterial Extracorporeal Life Support in Cardiogenic Shock Patients**
C. G. Yang¹, I. Feng¹, A. Vinogradsky¹, J. R. Gower¹, M. Biscotti¹, M. Yuzefpolskaya², P. Colombo², G. Sayer², N. Uriel², Y. Kaku¹, J. Fried², K. Takeda¹. ¹Division of Cardiothoracic Surgery, Department of Surgery, Columbia University Irving Medical Center, New York, NY, ²Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, NY
- 5:22 p.m. **Q&A**
- 5:24 p.m. **(248) Impact of Cardiogenic Shock Etiology on the Relationship Between Systemic Vascular Resistance and Mortality**
M. Anderson¹, K. Wartgow², C. Mackenzie², M. Chavez³, M. Scott⁴, E. Sheffield², C. Kyriakopoulos⁵, I. Taleb⁶, E. Dranow⁷, M. Goodwin⁸, E. Maneta⁷, R. Hamouche⁷, J. Fang⁹, S. Drakos³, T. Hanff³. ¹Cardiovascular Medicine, University of Utah Health, Salt Lake City, UT, ²Internal Medicine, University of Utah, Salt Lake City, UT, ³Cardiovascular Medicine, University of Utah, Salt Lake City, UT, ⁴Internal Medicine, University of Utah Health, Salt Lake City, UT, ⁵Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, ⁶Cardiovascular Medicine, University of California San Diego, San Diego, CA, ⁷Division of Cardiology, University of Utah, Salt Lake City, UT, ⁸Division of Cardiothoracic Surgery, University of Utah, Salt Lake City, UT, ⁹Cardiovascular Medicine, Univ of Utah Health Sciences Center, Salt Lake City, UT
- 5:28 p.m. **Q&A**

THURSDAY, 11 APRIL, 2024

4:30 - 5:30 p.m.

MINI ORAL 03: Fantastical Lung Transplant Recipients and How to Manage Them

Location: South Hall 3

Core Therapies: LUNG

Practice Areas: Pulmonology, Cardiothoracic Surgery, Infectious Diseases, Pathology, Pediatrics, Pharmacy, Research and Immunology

Session Summary: In this session, attendees will gain new insights into lung transplant recipient challenges.

Each presenter will give a **4-minute** "rapid fire" PowerPoint summation of the key learning points of the research, followed by a **2-minute** question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: Carli Lehr, MD, PhD, Cleveland Clinic Foundation, Cleveland, OH, USA
Kavita Dave, MBBS, Harefield Hospital, London, United Kingdom

4:30 p.m. **(249) Machine Learning Outperforms Standard Prediction Models for 3 Year Prognosis Following Lung Transplantation**
Z. Brennan, J. Malas, J. Chikwe, D. Emerson, M. Bowdish, P. Catarino, D. Megna. Cedars-Sinai Medical Center, Los Angeles, CA

4:34 p.m. **Q&A**

4:36 p.m. **(250) Long-Term Outcomes of Invasive Aspergillosis and Aspergillus Colonization in Lung Transplant Recipient - A Nationwide Cohort Study**
C. G. Crone¹, H. Lawaetz Schultz², S. T. Shahri³, M. C. Arendrup⁴, M. Helleberg², M. Perch². ¹CHIP/PERSIMUNE, University Hospital of Copenhagen, Rigshospitalet, Copenhagen Oe, Denmark, ²Rigshospitalet, Copenhagen, Denmark, ³CHIP/PERSIMUNE, University Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark, ⁴Statens Serum Institut, Copenhagen, Denmark

4:40 p.m. **Q&A**

4:42 p.m. **(251) Benchmarking Supervised Machine Learning Models for the Classification of Primary Graft Dysfunction**
B. Ozsoy¹, A. Khan¹, J. Van Slambrouck², C. Vandervelde², C. Vanluyten², X. Jin², A. Barbarossa², J. Kaes¹, L. Schoonjans¹, R. Vos³, D. Van Raemdonck², P. Carmeliet¹, L. Ceulemans². ¹Center for Cancer Biology, Department of Oncology, VIB-KU Leuven, Leuven, Belgium, ²Department of Thoracic Surgery, University Hospitals Leuven, Leuven, Belgium, ³Department of Respiratory Diseases, University Hospitals Leuven, Leuven, Belgium

4:46 p.m. **Q&A**

4:48 p.m. **(252) Impact of COVID-19 Infection on the Development of Chronic Lung Allograft Dysfunction (CLAD) After Lung Transplantation**
F. Albaiz¹, A. Benazzo², M. Aversa¹, Q. Li³, S. Wang³, E. Huszti³, R. Ghany⁴, J. T. Solera⁵, D. Kumar⁶, S. Keshavjee⁷, T. Martinu⁸, S. Juvel⁸. ¹Div of Respiriology, Dept of Medicine, Toronto Lung Transplant Program, Toronto, ON, Canada, ²Div of Thoracic Surgery, Dept of Surgery, Toronto Lung Transplant Program, Toronto, ON, Canada, ³Biostatistical Research Unit, University Health Network, Toronto, ON, Canada, ⁴Toronto Lung Transplant Program, Latner Thoracic Research Laboratories, Toronto General Hospital Research Inst, Toronto, ON, Canada, ⁵Div of Infectious Diseases, Dept of Medicine, Ajmera Transplant Centre, Toronto, ON, Canada, ⁶Div of Infectious Diseases, Dept of Medicine, Ajmera Transplant Centre, Toronto General Hospital Research Inst, Toronto, ON, Canada, ⁷Div of Thoracic Surgery, Dept of Surgery, Toronto Lung Transplant Program, Latner Thoracic Research Laboratories, Toronto General Hospital Research Inst, Toronto, ON, Canada, ⁸Div of Respiriology, Dept of Medicine, Toronto Lung Transplant Program, Latner Thoracic Research Laboratories, Toronto General Hospital Research Inst, Toronto, ON, Canada

4:52 p.m. **Q&A**

4:54 p.m. **(253) Pulmonary Function Tests at 12 Months Post-Transplant Defines Long-Term Trajectories**
L. Luo¹, S. Moshin², M. Carns², A. Arunachalam³, C. Myers⁴, R. Tomic⁵, A. Misharin⁶, M. Venkata Subramani⁷. ¹Northwestern University Feinberg School of Medicine, Northwestern University, Chicago, IL, ²Pulmonary and Critical Care, Northwestern University, Chicago, IL, ³Northwestern Memorial Hospital, Chicago, IL, ⁴Northwestern Feinberg School of Medicine, Chicago, IL, ⁵Northwestern University, Chicago, IL, ⁶Pulmonary and Critical Care, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁷Canning Thoracic Institute, Northwestern University, Chicago, IL

4:58 p.m. **Q&A**

5:00 p.m. **(254) Lung Transplantation Outcomes in the United States Before and During the COVID-19 Pandemic**
M. Brown, A. Kashem, R. Yanagida, Y. Toyoda. Division of Cardiovascular Surgery, Temple University Hospital, Philadelphia, PA

5:04 p.m. **Q&A**

- 5:06 p.m. **(255) Non-HLA Antibodies Are Associated with Chronic Lung Allograft Dysfunction in Lung Transplant Recipients**
K. Vyskocilová¹, M. Röder², K. Vychytilová², A. Glosová², A. Zajacova¹, T. Kotowski¹, A. Dutkova¹, L. Fila¹, R. Lischke³, A. Slavčev², J. Havlin³. ¹Prague Lung Transplant Program, Department of Pneumology, Second Faculty of Medicine, Charles University, University Hospital Motol, Prague, Czech Republic, ²Department of Immunogenetics, Institute of Clinical and Experimental Medicine, Prague, Czech Republic, ³Prague Lung Transplant Program, 3rd Department of Surgery, First Faculty of Medicine, Charles University, University Hospital Motol, Prague, Czech Republic
- 5:10 p.m. **Q&A**
- 5:12 p.m. **(256) Corticosteroid Dose Impacts Early Outcomes in Lung Allograft Recipients: A Dual-Center Study**
D. Rudym¹, T. C. Lewis¹, L. Angel², S. Chang¹, D. B. Erasmus³, M. Bacchetta³, A. J. Trindade³. ¹NYU Langone Health, New York, NY, ²NYU Langone Medical Center, New York, NY, ³Vanderbilt University Medical Center, Nashville, TN
- 5:16 p.m. **Q&A**
- 5:18 p.m. **(257) Efficacy and Safety if JAK2 Inhibitor Plus Extracorporeal Photopheresis in Chronic Lung Allograft Dysfunction: A Single Centre Experience**
M. Negigowda, V. Rahulan, M. Lalani, O. Tisekar, S. Priyaranjan, P. Dutta, A. Mohandas, M. B N, M. M, M. Sameer, S. Attawar. Institute of Heart and Lung Transplantation, KIMS Hyderabad, Hyderabad, India
- 5:22 p.m. **Q&A**
- 5:24 p.m. **Late-Breaking Abstract Presentation:**
(258) The 4-Year Outcome of the ScanCLAD Study
G. Dellgren¹, T. Kromann Lund², P. Raivio³, I. Leuckfeld⁴, J. Svahn⁵, E. C. Holmberg⁶, J. Magnusson⁷. ¹Cardiothoracic Surgery and Transplant Institute, Sahlgrenska University Hospital, Göteborg, Sweden, Sweden, ²Section for Lung Transplantation, Dept. of Cardiology, Thomas Kromann Lund, Rigshospitalet, Copenhagen University Hospital, Denmark, ³Dept. of Cardiac Surgery, Heart and Lung Center., Helsinki University Hospital, Helsinki, Finland, ⁴Dept. of Respiratory Medicine, Oslo University Hospital, Oslo, Norway, ⁵Dept. of Pulmonology and Allergology, Skåne University Hospital, Lund, Sweden, ⁶Dept. of Oncology, Institute of Clinical Science, University of Gothenburg, Gothenburg, Sweden, ⁷Pulmonology and Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden
- 5:28 p.m. **Q&A**

THURSDAY, 11 APRIL, 2024

4:30 - 5:30 p.m.

MINI ORAL 04: Total Eclipse of the Heart: Complications and Adverse Events with MCS

Location: South Hall 1

Core Therapies: MCS

Practice Areas: Cardiology, Anesthesiology and Critical Care, Cardiothoracic Surgery, Research and Immunology

Session Summary: Complications and adverse event post mechanical circulatory support will be discussed including right heart failure, mitral regurgitation, pulmonary artery waveforms, and integration of LVAD imaging studies, screening, indices.

Each presenter will give a **4-minute** "rapid fire" PowerPoint summation of the key learning points of the research, followed by a **2-minute** question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: Mustafa Ahmed, MD, University of Florida, Gainesville, FL, USA
Andrew Rosenbaum, MD, Mayo Clinic, Rochester, MN, USA

- 4:30 p.m. **(259) Impact of Right Heart Failure During the First Year of LVAD Support on Subsequent Survival and Late RHF Events Beyond 1 Year: An STS Intermacs Analysis**
I. Rajapreyar¹, J. Teuteberg², J. Kirklin³, F. Pagani⁴, P. Atluri⁵, E. Grandin⁶, J. Jacobs⁷, B. Singletary³, R. Cantor⁸, G. Oliveira⁹, J. Rame¹, M. Kiernan¹⁰. ¹Thomas Jefferson University Hospital, Philadelphia, PA, ²Stanford University School of Medicine, Stanford, CA, ³Kirklin Solutions, Birmingham, AL, ⁴University of Michigan, Ann Arbor, MI, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Beth Israel Deaconess Med Ctr, Boston, MA, ⁷University of Florida, Gainesville, FL, ⁸Kirklin Solutions, Birmingham, AL, ⁹University of South Florida, Tampa, FL, ¹⁰Tufts Medical Center, Boston, MA
- 4:34 p.m. **Q&A**
- 4:36 p.m. **(260) Cystatin C-Based Estimated Glomerular Filtration Rate is Independently Associated with Long-Term Mortality in HeartMate3 Patients**
G. M. Mondellini, A. Pinsino, M. A. Hynds, A. Vinogradsky, A. Ladanyi, G. Sayer, Y. Kaku, N. Uriel, K. Takeda, S. A. Husain, S. Mohan, P. C. Colombo, M. Yuzefpolskaya. Columbia University Irving Medical Center, New York, NY
- 4:40 p.m. **Q&A**
- 4:42 p.m. **(261) Evaluation of Pulmonary Vasodilator Efficacy in LVAD Patients Using Invasive Right Heart Catheter Stress Testing**
S. Takenaka¹, T. Sato¹, T. Nagai¹, K. Omote¹, K. Kamiya¹, T. Konishi¹, Y. Kobayashi¹, A. Tada¹, Y. Mizuguchi¹, Y. Takahashi¹, S. Naito¹, K. Saiin¹, S. Kazui¹, Y. Yasui¹, T. Hamaya¹, Y. Mori¹, S. Ishizaka¹, S. Wakasa², T. Anzai¹. ¹Department of Cardiovascular Medicine, Hokkaido University, Sapporo, Japan, ²Department of Cardiovascular Surgery, Hokkaido University, Sapporo, Japan
- 4:46 p.m. **Q&A**
- 4:48 p.m. **(262) Intermacs Analysis of Impact of Significant Post-LVAD Mitral Regurgitation on Outcomes**
M. Pienta¹, J. Pegasus¹, T. Cascino², J. Cowger³, A. Rosenbaum⁴, R. B. Hawkins⁵, M. Colvin⁶, K. Aaronson⁷, J. Yang¹, D. Likosky¹, F. Pagani⁸, P. C. Tang⁹. ¹Cardiac Surgery, University of Michigan-Ann Arbor, Ann Arbor, MI, ²University of Michigan, Ann Arbor, MI, ³Internal Medicine, Henry Ford Hospitals, Detroit, MI, ⁴Internal Medicine, Mayo Clinic, Rochester, MN, ⁵University of Michigan-Ann Arbor, Ann Arbor, MI, ⁶University of Michigan Health System, Ann Arbor, MN, ⁷Internal Medicine, Univ of Michigan Med Ctr, Ann Arbor, MI, ⁸Cardiac Surgery, University of Michigan, Ann Arbor, MI, ⁹Mayo Clinic, Rochester, MN
- 4:52 p.m. **Q&A**
- 4:54 p.m. **(263) Pulsatility of Pulmonary Artery Waveforms Before and After Left Ventricular Assist Device is Associated with Right Ventricular Failure**
A. Rosenbaum¹, A. Behfar², T. Rossman³, S. Lundgren⁴. ¹Mayo Clinic, Rochester, MN, ²Cardiovascular Medicine, Mayo Clinic, Rochester, MN, ³Engineering, Mayo Clinic, Rochester, MN, ⁴University of Nebraska Medical Center, Omaha, NE
- 4:58 p.m. **Q&A**
- 5:00 p.m. **(264) Sublingual Microcirculation in Acute Mechanical Circulatory Support in Cardiogenic Shock**
S. Rahman¹, C. Lee¹, J. Baranowska¹, C. Moeller¹, A. Fernandez Valledor¹, G. Rubinstein¹, D. Oren¹, T. Miller¹, D. Lotan¹, A. Rahman¹, Y. Kaku², J. Raikhelkar¹, K. Takeda², E. DeFilippis¹, M. Yuzefpolskaya¹, P. Colombo¹, D. Majure³, K. Clerkin¹, D. Burkhoff¹, G. Sayer¹, N. Uriel¹, J. Fried¹. ¹Medicine- Cardiology, Columbia University Irving Medical Center, New York, NY, ²Columbia University Irving Medical Center, New York, NY, ³Weill Cornell Medical College, New York, NY
- 5:04 p.m. **Q&A**

- 5:06 p.m. **(265) The Serum Sarcopenia Index is Associated with Post LVAD Mortality**
J. Schultz¹, A. Keefe², V. Maharaj¹, T. Alexy¹, B. Ramu¹, T. Thenappan¹, M. Pritzker¹, F. Kamdar¹, D. Garry¹, A. Shaffer³, R. John³, R. Cogswell¹. ¹Department of Medicine, Division of Cardiology, University of Minnesota, Minneapolis, MN, ²Department of Medicine, University of Minnesota, Minneapolis, MN, ³Department of Surgery, Division of Cardiothoracic Surgery, University of Minnesota, Minneapolis, MN
- 5:10 p.m. **Q&A**
- 5:12 p.m. **(266) Percutaneous Right Ventricular Mechanical Circulatory Support After LVAD Implantation: A Monocentric Retrospective Study**
A. Martin¹, R. Acard², E. Lang³, E. Bichara¹, B. Cholley³, E. Marjion⁴, P. Achouh². ¹Advanced Heart Failure Unit, European Hospital Georges Pompidou, Paris, France, ²Cardiac Surgery, European Hospital Georges Pompidou, Paris, France, ³Anesthesiology and Critical Care, European Hospital Georges Pompidou, Paris, France, ⁴Cardiology, European Hospital Georges Pompidou, Paris, France
- 5:16 p.m. **Q&A**
- 5:18 p.m. **(267) Cardiac Transplantation Patient Outcomes After LVAD Implantation via Sternotomy versus Bilateral Thoracotomy**
M. L. Fryer¹, A. Jones¹, I. Gosev², K. Wood². ¹University of Rochester, Rochester, NY, ²University of Rochester Medical Center, Rochester, NY
- 5:22 p.m. **Q&A**
- 5:24 p.m. **(268) Percutaneous Biventricular Assist Devices Require Fewer Transfusions and Returns to the Operating Room Compared to Classic Surgical Alternative**
J. S. Clothier¹, M. Bojko¹, S. Kobsa¹, J. Praeger¹, A. Dhillon², A. Vaidya², A. Wolfson², J. Nattiv², A. Hackmann³, R. Lee¹. ¹Division of Cardiac Surgery, Keck School of Medicine of University of Southern California, Los Angeles, CA, ²Division of Cardiovascular Medicine, Keck School of Medicine of Univ of Southern California, Los Angeles, CA, ³Brigham and Women's Hospital, Boston, MA
- 5:28 p.m. **Q&A**

THURSDAY, 11 APRIL, 2024

4:30 - 5:30 p.m.

MINI ORAL 05: Primary Lung Graft Dysfunction, Pulmonary Edema, Primates, Pigs, and Polyjuice Potion

Location: South Hall 2

Core Therapies: LUNG

Practice Areas: Research and Immunology, Anesthesiology and Critical Care, Cardiothoracic Surgery, Infectious Diseases, Pharmacy, Pulmonology

Session Summary: This mini-oral session presents the top basic science abstracts on lung transplant early complications and tolerance.

Each presenter will give a **4-minute** "rapid fire" PowerPoint summation of the key learning points of the research, followed by a **2-minute** question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: Andrew Gelman, PhD, Washington University School of Medicine, St. Louis, MO, USA
Catherine Myers, MD, Northwestern Feinberg School of Medicine, Chicago, IL, USA

4:30 p.m. **(269) Inhibition of ALOX12-12-HETE Alleviates Lung Ischemia Reperfusion Injury by Reducing Endothelial Ferroptosis-Mediated Neutrophil Extracellular Traps Formation**

C. Li, P. Gao, F. Zhuang, Z. Wang, Z. Zhou, G. Wu, T. Wang, C. Chen, J. Wu. Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China

4:34 p.m. **Q&A**

4:36 p.m. **(270) Defining the Transcripts Associated with a History of Severe Primary Graft Dysfunction in Lung Transplant Transbronchial Biopsies**

M. Mackova¹, P. Gauthier¹, A. Hirji², J. Weinkauff², S. Juvet³, S. Keshavjee³, J. Havlin⁴, A. Zajacova⁴, G. Snell⁵, G. Westall⁵, P. Halloran², K. Halloran². ¹Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada, ²University of Alberta, Edmonton, AB, Canada, ³University Health Network, Toronto, ON, Canada, ⁴Prague Lung Transplant program, University Hospital Motol, Prague, Czech Republic, ⁵Alfred Hospital, Melbourne, Australia

4:40 p.m. **Q&A**

4:42 p.m. **(271) Mitochondrial Xenotransplantation During Ex Vivo Lung Perfusion: Leveraging Rodents as a Fresh Organelle Source to Tackle Ischemia Reperfusion Injury**

N. B. Bechet¹, A. Celik¹, Q. Wang¹, T. Huzevka², M. Mittendorfer¹, A. Niroomand¹, E. Boden¹, G. Hirdman¹, G. Kjellberg³, L. Pierre², F. Olm¹, J. D. McCully⁴, S. Lindstedt². ¹Dept of Clinical Sci, Lund Univ, Lund, Sweden, ²Dept of Cardiothoracic Surgery, Anesthesia & Intensive Care and Transplantation, Lund Univ Hosp, Lund, Sweden, ³Dept of Thoracic Surgery and Anaesthesiology, Uppsala Univ Hosp, Uppsala, Sweden, ⁴Div of Cardiac Surgery, Boston Children's Hosp and Harvard Med Sch, Boston, MA

4:46 p.m. **Q&A**

4:48 p.m. **(272) Triangular Associations Between the Lower Airway Microbiome, Host Immune Tone, and Primary Graft Dysfunction in Lung Transplantation**

J. G. Natalini¹, N. C. Nelson¹, K. K. Wong¹, I. J. Mahoney¹, B. G. Wu¹, T. Malik¹, D. Rudym¹, M. B. Lesko¹, S. Qayum¹, S. H. Chang², J. C. Chan², T. C. Geraci², T. C. Lewis³, F. A. Tiripicchio³, Y. Li¹, P. Pamar¹, J. Schnier¹, R. Singh¹, D. E. Collazo¹, M. Chang¹, Y. Kyeremateng¹, C. McCormick¹, S. Patel¹, F. Darawshy¹, C. R. Barnett¹, J. J. Tsay¹, S. B. Brosnahan¹, S. Singh¹, H. I. Pass², L. F. Angel¹, L. N. Segal¹. ¹Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, New York University Grossman School of Medicine, New York, NY, ²Department of Cardiothoracic Surgery, New York University Grossman School of Medicine, New York, NY, ³NYU Langone Transplant Institute, NYU Langone Health, New York, NY

4:52 p.m. **Q&A**

4:54 p.m. **(273) Machine Learning Using Multi-Site Cytokine Levels is Predictive of Primary Graft Dysfunction Following Lung Transplantation**

J. C. Brunson¹, D. Nord², L. Langerude², H. Moussa², T. Machuca³, M. Rackauskas⁴, A. Sharma⁴, C. Lin⁵, A. Emtiazjoo², C. Atkinson². ¹Laboratory for Systems Medicine, University of Florida, Gainesville, FL, ²Division of Pulmonary, Critical Care, and Sleep Medicine, University of Florida, Gainesville, FL, ³Department of Surgery, University of Miami, Miami, FL, ⁴Department of Surgery, University of Florida, Gainesville, FL, ⁵Department of Medicine, University of California, San Diego, San Diego, CA

4:58 p.m. **Q&A**

- 5:00 p.m. **(274) Radiographic Assessment of Lung Edema (RALE) Score on Day 3 After Lung Transplantation is Associated with Poor Clinical Outcomes**
C. M. Shaver¹, T. Koyama¹, M. Oyster², L. Kalman², J. Diamond², J. Christie², L. Ware¹. ¹Vanderbilt University Medical Center, Nashville, TN, ²University of Pennsylvania, Philadelphia, PA
- 5:04 p.m. **Q&A**
- 5:06 p.m. **(275) An In Vitro Study of Virus-Like Particle Mediated CRISPR Gene Editing to Support Gene Modulation in the Human Ex Vivo Lung**
P. Kortleven¹, J. Van Slambrouck², M. Bulcaen³, R. Quarck¹, R. Gijssbers³, L. J. Ceulemans², M. S. Carlon¹. ¹Dep. of Chronic Diseases and Metabolism, BREATHE Laboratory, KU Leuven, Belgium, ²Dep. of Thoracic Surgery, University Hospitals Leuven, Leuven, Belgium, ³Dep. Pharmaceutical & Pharmacological Sciences, Laboratory for Molecular Virology & Gene Therapy, KU Leuven, Belgium
- 5:10 p.m. **Q&A**
- 5:12 p.m. **(276) WITHDRAWN**
- 5:18 p.m. **(277) IL-6 Blockade Promotes Tolerance of Heart but Not Lung Allografts in Non-Human Primate Simultaneous Organ and Bone Marrow Transplantation Protocols**
S. M. Landino¹, J. T. Nawalaniec¹, J. O¹, A. Dehnadi¹, N. Hays¹, J. Muoio¹, C. Winter¹, I. Hanekamp¹, J. Madsen², J. S. Allan³. ¹Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA, ²Center for Transplantation Sciences, Division of Cardiac Surgery, Massachusetts General Hospital, Boston, MA, ³Center for Transplantation Sciences, Division of Thoracic Surgery, Massachusetts General Hospital, Boston, MA
- 5:22 p.m. **Q&A**
- 5:24 p.m. **(278) Porcine IgG Remains within Human Lung After Xenogeneic Cross-Circulation and Human Blood Re-Exposure**
K. M. Tracy¹, T. R. Harris², M. Cortelli², S. A. François², W. D. Tucker², S. DeVries², C. A. Johnson², W. Wu¹, N. L. Cardwell², M. Petrovic³, T. T. Adesanya⁴, A. K. Fortier⁴, K. Raietparvar⁴, E. Simonds⁵, Y. Shishido¹, C. Pasrija², R. Ukita², C. Demarest⁶, C. Shaver⁷, M. Bacchetta². ¹Department of Surgery, Vanderbilt University Medical Center, Nashville, TN, ²Department of Cardiac Surgery, Vanderbilt University Medical Center, Nashville, TN, ³Department of Biomedical Engineering, Vanderbilt University, Nashville, TN, ⁴Vanderbilt University, Nashville, TN, ⁵Vanderbilt University School of Medicine, Nashville, TN, ⁶Department of Thoracic Surgery, Vanderbilt University Medical Center, Nashville, TN, ⁷Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
- 5:28 p.m. **Q&A**

THURSDAY, 11 APRIL, 2024

4:30 - 5:30 p.m.

MINI ORAL 06: A Medley of the Latest and Greatest in Heart Transplant Research

Location: Panorama Hall

Core Therapies: HEART

Practice Areas: Cardiology, Anesthesiology and Critical Care, Cardiothoracic Surgery, Nursing and Allied Health, Pathology, Pharmacy

Session Summary: Join for a medley of some of the latest and greatest science in heart failure and heart transplant. This session features science on transplantation during war times, studies assessing sex and gender in heart failure outcomes, and more. It will be a quick blitz through trending topics!

Each presenter will give a **4-minute** "rapid fire" PowerPoint summation of the key learning points of the research, followed by a **2-minute** question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: Jaimin Trivedi, MD, MPH, University of Louisville, Louisville, KY, USA
Jong-Chan Youn, MD, PhD, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea

4:30 p.m. **(279) CD 34+ Cell Therapy is Associated with Improved Myocardial Perfusion in Heart Failure with Preserved Ejection Fraction**
G. Poglajen¹, R. Zbačnik², S. Frljak¹, G. Zemljic¹, A. Cerar¹, N. Žorž¹, R. Okrajsek¹, M. Sebestjen¹, B. Vrtovec¹. ¹Advanced Heart Failure and Transplantation Center, Dept. of Cardiology, UMC Ljubljana, Ljubljana, Slovenia, ²UMC Ljubljana, Ljubljana, Slovenia

4:34 p.m. **Q&A**

4:36 p.m. **(280) Ukrainian National Transplant Program During Active Military Invasion**
D. Koval¹, A. Karamian¹, V. Strilka², V. Liashko², Y. Stukov³. ¹Specialized State Institution «Ukrainian Transplant Coordination Center», Kyiv, Ukraine, ²Ministry of Health of Ukraine, Kyiv, Ukraine, ³Congenital Heart Center, Division of Cardiovascular Surgery, Department of Surgery, University of Florida, Gainesville, FL

4:40 p.m. **Q&A**

4:42 p.m. **(281) Rethinking Heart Retransplantation - Institutional Success Over Last Decade**
J. Malas¹, A. Bakshi¹, Q. Chen¹, D. Megna¹, D. Emerson¹, T. Gunn¹, M. Kittleson², J. Patel², J. Chikwe¹, J. Kobashigawa², M. E. Bowdish¹, F. Esmailian¹. ¹Department of Cardiac Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, ²Department of Cardiology, Cedars-Sinai Medical Center, Los Angeles, CA

4:46 p.m. **Q&A**

4:48 p.m. **(282) Long Term Follow-Up of the Randomized, Prospective Scandinavian Heart Transplant Everolimus De Novo Study with Early Calcineurin Inhibitors Avoidance (SCHEDULE) Trial**
E. Bollano¹, A. Andreassen², H. Eiskjaer³, F. Gustafsson⁴, G. Radegran⁵, E. Gude⁶, T. Halden⁷, L. Gullestad⁸, K. Broch⁹, K. Karason¹⁰, S. Bartfay¹, N. Bergh¹¹. ¹Sahlgrenska University Hospital, Gothenburg, Sweden, ²Oslo University Hosp, Oslo, Norway, ³Aarhus University Hospital, Aarhus, Denmark, ⁴Rigshospitalet, Copenhagen, Denmark, ⁵Skane Univ Hospital, Lund, Sweden, ⁶Oslo Univ Hosp, Oslo, Norway, ⁷Novartis, Oslo, Norway, ⁸Oslo Univ Hospital, Oslo, Norway, ⁹Oslo U Hospital, Oslo, Norway, ¹⁰Sahlgrenska University Hospital, Gotheburg, Sweden, ¹¹Sahlgrenska University Hospital, Göteborg, Sweden

4:52 p.m. **Q&A**

4:54 p.m. **(283) Sex and Gender Differences in Patients Referred for Advanced Heart Failure Therapies**
M. McLendon¹, V. Cusi², P. Bijlani³, H. Kim², J. Chak², A. Birs⁴, E. Adler¹, M. Urey¹, P. J. Kim⁴. ¹Advanced Heart Failure, University of California, San Diego, San Diego, CA, ²University of California, San Diego, San Diego, CA, ³Research, University of California, San Diego, San Diego, CA, ⁴Advanced Heart Failure, University of California San Diego, San Diego, CA

4:58 p.m. **Q&A**

5:00 p.m. **(284) Serial Assessment of MBFR Identifies Heart Transplant Recipients with an Increased Risk of Mortality**
N. Prasad¹, E. S. Harris¹, J. Fried¹, V. K. Topkara¹, J. Raikhelkar¹, E. M. DeFilippis¹, F. Latif¹, M. Yuzefpolskaya¹, P. C. Colombo², G. Sayer¹, N. Uriel¹, A. J. Einstein¹, K. J. Clerkin¹. ¹Columbia University Irving Medical Center, New York, NY, ²Columbia University, New York, NY

5:04 p.m. **Q&A**

- 5:06 p.m. **(285) Sex Based Differences in Severe Primary Graft Dysfunction: An Analysis from the International Consortium on PGD**
Y. Moayed¹, L. Truby², F. Foroutan³, E. Henricksen⁴, J. Han⁵, E. Ródenas Alesina¹, J. Guzman Bofarull⁶, M. Sabatino⁷, R. Moayedifar⁸, H. Luikart⁹, G. Kim¹⁰, D. Couto-Mallon¹¹, M. Crespo-Leiro¹¹, J. Feliuss¹², S. Hall¹³, B. Clarke¹⁴, L. Potena¹⁵, J. Lerman¹⁶, M. Tremblay-Gravel¹⁷, K. Takeda¹⁸, P. Noly¹⁹, R. Miller²⁰, M. Rivas-Lasarte²¹, J. Segovia-Cubero²², A. Devore¹⁶, S. Chih²³, A. Zuckermann²⁴, M. Farrero Torres⁶, M. Farr², H. Ross²⁵, K. Khush²⁶. ¹University Health Network, Toronto, ON, Canada, ²University of Texas Southwestern Medical Center, Dallas, TX, ³Ted Rogers Centre for Heart Research, Toronto, ON, Canada, ⁴Stanford Healthcare, Stanford, CA, ⁵University of Chicago Medical Center, Chicago, IL, ⁶Hospital Clinic de Barcelona, Barcelona, Spain, ⁷Institute of Cardiology S.Orsola-Malpighi Hospital, Bologna, Italy, ⁸Medical University Vienna General Hospital Vienna, Vienna, Austria, ⁹Stanford Hospital, Stanford, CA, ¹⁰University of Chicago, Chicago, IL, ¹¹Hospital Universitario A Coruña, A Coruña, Spain, ¹²Baylor Univ Med Ctr, Baylor, TX, ¹³Baylor University Medical Center, Baylor, TX, ¹⁴St. Paul's Hospital, University of British Columbia, Vancouver, ON, Canada, ¹⁵IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, ¹⁶Duke Medical Center, Durham, NC, ¹⁷Montreal Heart Institute, Montreal, QC, Canada, ¹⁸Columbia university, NYC, NY, ¹⁹Montreal Heart Institute, Montreal, QC, ²⁰University of Calgary, Calgary, AB, Canada, ²¹Hospital Puerta de Hierro, Madrid, Madrid, Spain, ²²Hospital Puerta de Hierro, Madrid, Spain, Madrid, Spain, ²³University of Ottawa Heart Institute, Ottawa, ON, Canada, ²⁴Medical University of Vienna, Vienna, Austria, ²⁵Toronto General Hospital, Toronto, ON, Canada, ²⁶Stanford University, Stanford, CA
- 5:10 p.m. **Q&A**
- 5:12 p.m. **(286) Induction Therapy Confers Survival Advantage in Mechanically Supported Patients Regardless of Peak CPRA in Heart Transplantation**
N. Bahatyrevich¹, R. Dale², M. Leipzig², K. Casselman Pines², S. Jimenez³, M. Currie². ¹Department of Surgery, University of California, Davis, Sacramento, CA, ²Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA, ³Division of Cardiovascular Medicine, University of California, Davis, Sacramento, CA
- 5:16 p.m. **Q&A**
- 5:18 p.m. **(287) Safety of Sodium Glucose Co-Transporter 2 Inhibitor Exposure Prior to Heart Transplantation**
L. M. Raven¹, C. A. Muir¹, C. Kessler Iglesias², N. K. Bart², K. Muthiah², E. Kotlyar², C. S. Hayward², P. S. Macdonald², A. Jabbour², J. R. Greenfield¹. ¹Department of Diabetes and Endocrinology, St Vincent's Hospital, Sydney, Australia, ²Department of Heart and Lung Transplantation, St Vincent's Hospital, Sydney, Australia
- 5:22 p.m. **Q&A**
- 5:24 p.m. **(288) Trends in Mechanical Circulatory Support and Time to Transplant in Adult Congenital Heart Disease Patients**
M. P. Weber, A. Wisniewski, J. Beller, L. Yarboro. University of Virginia, Charlottesville, VA
- 5:28 p.m. **Q&A**

THURSDAY, 11 APRIL, 2024

4:30 - 5:30 p.m.

MINI ORAL 07: Keeping Up with Our Kids: What's Trending in Pediatric Heart Failure and Transplant Research?

Location: North Hall

Core Therapies: HEART

Practice Areas: Pediatrics, Cardiology, Cardiothoracic Surgery, Research and Immunology

Session Summary: We may be small, but we are mighty. The science of pediatric heart failure and transplantation continues to rapidly advance through collaboration. This session features noteworthy pediatric abstracts across the field.

Each presenter will give a **4-minute** "rapid fire" PowerPoint summation of the key learning points of the research, followed by a **2-minute** question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: Paul Estes, MD PhD, Boston Children's Hospital, Boston, MA, USA
Julie Wacker, MD, University Hospitals of Geneva, Geneva, Switzerland

- 4:30 p.m. **(289) SGLT2i Use in Pediatric Heart Failure: Multicenter Study**
R. Butts¹, D. Nandi², B. Hong³, A. Lorts⁴, E. Profita⁵, J. Spinner⁶. ¹Children's Medical Center of Dallas/University of Texas Southwestern, Dallas, TX, ²Nationwide Children's Hospital, Columbus, OH, ³Seattle Children's Hospital, Seattle, WA, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Stanford University, Palo Alto, CA, ⁶Baylor College of Medicine, Houston, TX
- 4:34 p.m. **Q&A**
- 4:36 p.m. **(290) VAD Support Can Effectively Bridge Pediatric Patients to Heart Re-Transplant: An ACTION Study**
S. Lukich¹, H. Tadros², K. Boucek³, S. Ghaleb⁴, E. Hayes⁵, S. Hussain⁶, N. Ikeda⁷, B. Langanacha⁸, I. Masood⁹, J. McAllister¹⁰, C. Mejia¹¹, S. Rangu¹², M. Shezad⁷, D. Tolani¹³, W. Xu¹⁰, M. Zinn¹⁵, J. Spinner², A. Joong¹⁶. ¹Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ³Ochsner Health Center for Children, New Orleans, LA, ⁴University of Texas Southwestern, Dallas, TX, ⁵Nationwide Children's Hospital, Columbus, OH, ⁶Riley Children's Health, Indianapolis, IN, ⁷Cincinnati Children's Hospital, Cincinnati, OH, ⁸The Hospital for Sick Children, Toronto, ON, Canada, ⁹Children's Hospital of Philadelphia, Philadelphia, PA, ¹⁰Morgan Stanley Children's Hospital, New York, NY, ¹¹Medical College of Wisconsin, Children's Wisconsin, Milwaukee, WI, ¹²Pediatric Cardiology, Stanford University, Lucile Packard Children's Hospital, Palo Alto, CA, ¹³Stanford University, Lucile Packard Children's Hospital, Palo Alto, CA, ¹⁵Children's Hospital of Pittsburgh, Pittsburgh, PA, ¹⁶Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL
- 4:40 p.m. **Q&A**
- 4:42 p.m. **(291) Outcomes of Pediatric Heart Transplantation Recipients with Cocaine-Use Donors: A Review of the United Network for Organ Sharing (UNOS) Research Database**
S. S. Philip¹, S. Jani¹, L. Glass¹, C. M. Mery², C. D. Fraser², C. Castleberry¹. ¹Dept of Pediatrics, Dell Children's Medical Center, Dell Medical School at the University of Texas at Austin, Austin, TX, ²Dept of Surgery & Perioperative Care, Dell Children's Medical Center, Dell Medical School at the University of Texas at Austin, Austin, TX
- 4:46 p.m. **Q&A**
- 4:48 p.m. **(292) Clinical Deterioration in Stage 1 and 2 Single Ventricle Patients Awaiting Heart Transplant**
D. Tolani, J. Murray, J. Dykes, B. Kaufman, C. Chen, A. Nair, A. Sinha, K. Catton, E. Martin, M. Ma, D. Rosenthal, S. Chen. Lucile Packard Children's Hospital/Stanford University, Palo Alto, CA
- 4:52 p.m. **Q&A**
- 4:54 p.m. **(293) Pediatric Heart Transplantation Using Donation After Circulatory Death: An Analysis of the ISHLT Registry**
H. F. Ahmed¹, M. Faateh², A. Mehdizadeh-Shrifi², K. Kulshrestha¹, M. Hossain³, Y. Zhang³, T. Ryan¹, D. Hayes⁴, D. Lehenbauer¹, D. Morales¹, A. Ashfaq¹. ¹The Heart Institute, Cincinnati Children's Hospital, Cincinnati, OH, ²The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Cincinnati Children's Hospital Medical Center / University of Cincinnati, Cincinnati, OH
- 4:58 p.m. **Q&A**
- 5:00 p.m. **(294) How Could DCD Heart Donation Affect Organ Availability for Congenital Heart Programs?**
S. Cheon, K. Kulshrestha, H. F. Ahmed, B. S. Mantell, C. Chin, D. Morales, A. Ashfaq. Cincinnati Children's Hospital Medical Center, Cincinnati, OH
- 5:04 p.m. **Q&A**

- 5:06 p.m. **(295) Pediatric Heart Transplantation in Donation After Circulatory Death Using Normothermic Regional Perfusion - Early Experience with Small Donors**
D. Overbey, B. Aykut, C. Medina, L. Parker, J. Schroder, Z. Beckerman, J. Turek. *Duke University Medical Center, Durham, NC*
- 5:10 p.m. **Q&A**
- 5:12 p.m. **(296) Machine Learning Models as an Accurate Predictor of Survival in Pediatric Heart Transplant**
Z. Brennan¹, O. Sharaf², D. Emerson¹, J. Chikwe¹, R. Kim¹, G. Peek³, M. Bleiweis³, J. Jacobs³. ¹*Cedars-Sinai Medical Center, Los Angeles, CA*, ²*University of Florida College of Medicine, Gainesville, FL*, ³*University of Florida, Gainesville, FL*
- 5:16 p.m. **Q&A**
- 5:18 p.m. **Late-Breaking Abstract Presentation:**
(297) Micro-RNA Biomarkers of Allograft Rejection in Pediatric Heart Transplantation
J. Goldberg¹, B. Feingold², K. Rose-Felker², A. Mercado¹, P. Bagchi³, M. Zinn², S. West², S. Miller², P. Shah¹. ¹*Inova Heart and Vascular Institute, Falls Church, VA*, ²*UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA*, ³*George Mason University, Fairfax, VA*
- 5:22 p.m. **Q&A**
- 5:24 p.m. **Late-Breaking Abstract Presentation:**
(298) Partial Heart Transplant: The Founding Institutional Experience
B. Aykut, D. Overbey, C. Medina, E. Shea, M. Carboni, Z. Beckerman, T. Joseph. *Duke University, Durham, NC*
- 5:28 p.m. **Q&A**

THURSDAY, 11 APRIL, 2024

4:30 - 5:30 p.m.

POSTER SESSION 2: Anesthesiology and Critical Care (Non-CME)

Location: Poster Hall

Core Therapies: HEART, LUNG, MCS, PVD

Practice Areas: Anesthesiology and Critical Care, Cardiology, Cardiothoracic Surgery, Infectious Diseases, Nursing and Allied Health, Pathology, Pediatrics, Pharmacy, Pulmonology, Research and Immunology

Session Summary: Posters in this session include presentations on multiple topics where the Practice Areas of the research is focused in Anesthesiology and Critical Care. Designated Poster Discussants will circulate through the poster hall during the session to engage poster presenters in quality discussions of their abstracts. **CME is not offered for poster sessions.**

Poster Discussants: Brandi Bottiger, USA, Kelly Bryce, USA, Julien Fessler, France, Basha Khan, India, Rebecca Klingbeil, USA, Jorge Mallea, USA, Archer Martin, USA, Sowmith Rangu, USA, Jun-Neng Roan, Taiwan, Siavosh Saatee, USA, Jaromir Vajter, Czech Republic, Anup Varghese, India, Alessandra Verzelloni Sef, UK, Barbara Wilkey, USA

(709) Dobutamine Appears Advantageous Over Epinephrine as Inotropic Therapy for Heart Transplantation; M. B. Immohr¹, V. H. Hettlich¹, D. Sigetti¹, D. Scheiber², A. Mehdiani¹, A. Moza³, H. Aubin¹, P. Akhyari¹, U. Boeken¹, A. Lichtenberg¹. ¹Dept. of Cardiac Surgery, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany, ²Dept. of Cardiology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany, ³Dept. of Cardiac Surgery, RWTH Aachen University, Aachen, Germany

(710) Implications of Molecular Markers in Brain-Dead Donors in Primary Graft Dysfunction and Rejection After Heart Transplantation: The Potential Role of Preconditioning; L. Herrador-Galindo¹, J. Gonzalez-Costello¹, J. Niubo-Bosch¹, M. Farrero Torres², A. Maestro Benedicto³, T. Blasco Peiro⁴, R. Lopez-Vilella⁵, E. Zatarain⁶, I. Garrido Bravo⁷, F. Gran Ipiña⁸, A. Grande-Trillo⁹, N. Manito¹, G. Moreno-Gonzalez¹. ¹Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain, ²Hospital Clinic de Barcelona, Barcelona, Spain, ³Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁴Miguel Servet Hospital, Spain, ⁵Hospital Universitario y Politécnico La Fe, Valencia, Spain, ⁶University Hospital Gregorio Marañón, Madrid, Spain, ⁷H Virgen de la Arrixaca, Murcia, Spain, ⁸Vall d'Hebron University Hospital, Barcelona, Spain, ⁹Hospital Universitario Virgen del Rocío, Seville, Spain

(711) How we Do More Than 200 Heart Transplantation in a Year: Pretransplant Vaecmo and Marginal Donor Programs; V. Poptsov¹, V. Zaharevich¹, E. Spirina¹, A. Solodovnikova², A. Ignatkina¹, A. Kuznetsova¹. ¹Shumakov National Medical Research Center of Transplantology and Artificial Organs, Moscow, Russian Federation, ²National Medical Research Center of Transplantology and Artificial Organs named after V.I.Shumakov, Moscow, Russian Federation

(712) Preventive Peripheral VA ECMO in Heart Transplantation with Extremely Long Allograft Ischemic Time; V. Poptsov¹, V. Zaharevich², E. Spirina³, A. Skokova², A. Solodovnikova⁴, A. Kuznetsova², A. Ignatkina², G. Glinkin². ¹Fed Res Ctr of TX, Moscow, Russian Federation, ²Shumakov National Medical Research Center of Transplantology and Artificial Organs, Moscow, Russian Federation, ³Fed Res Ctr of Tx, Moscow, Russian Federation, ⁴National Medical Research Center of Transplantology and Artificial Organs named after V.I.Shumakov, Moscow, Russian Federation

(713) A Systematic Review of Reporting and Handling of Missing Data in Observational Studies Using the UNOS Database; W. L. Baker¹, T. E. Moore², E. Baron³, M. Kittleston⁴, W. Parker⁵, A. Jaiswal⁶. ¹UConn School of Pharmacy, Storrs Mansfield, CT, ²University of Connecticut, Storrs Mansfield, CT, ³Servier Pharmaceuticals, Boston, MA, ⁴Cedars-Sinai Heart Institute, Los Angeles, CA, ⁵University of Chicago Medicine, Chicago, IL, ⁶Hartford HealthCare, Hartford, CT

(714) Primary Graft Failure in the Black Heart Transplant Recipient; M. Jones¹, V. Tangel², K. Thomas³, L. Q. Rong¹. ¹Anesthesiology, Weill Cornell NY Presbyterian, New York, NY, ²Anesthesiology, Weill Cornell Medicine, New York, NY, ³Duke University, Durham, NC

(715) The Influence of Basiliximab Induction Therapy on the Early Postoperative Outcomes / on Acute Cellular Rejection of Heart Transplant Recipients; P. Nadziakiewicz¹, M. Wajda-Pokrontka². ¹Slaski Uniwersytet Medyczny w Katowicach, Poland, Katowice, Poland, ²Slaski Uniwersytet Medyczny, Katowice, Poland

(716) Meticulous Donor Evaluation Makes Transplantation of Hearts with Takotsubo Syndrome Possible; R. Doueh¹, G. Dellgren², J. Oras². ¹Anesthesia and Intensive Care, Sahlgrenska University Hospital, Gothenburg, Sweden, ²Sahlgrenska University Hospital, Gothenburg, Sweden

(717) Ex Vivo Lung Perfusion (EVLV): An Algorithm Proposal to Identify Acceptable Organs for Transplantation; C. Magri¹, F. Madotto¹, A. Palleschi², L. Rosso², F. Valenza³, G. Grasselli¹, A. Zanella¹. ¹Anesthesia, Critical Care and Emergency, Fondazione IRCCS Ca' Granda Ospedale Maggiore, Milano, Italy, ²Fondazione IRCCS Ca' Granda Ospedale Maggiore, Milano, Italy, ³Università degli Studi di Milano, Milano, Italy

(718) Assessment of Primary Hemostasis During Lung Transplantation Procedure with Use of Intraoperative Extracorporeal Membrane Oxygenation (ECMO) Support; M. Garaj¹, A. Francesconi², M. Durila³. ¹Department of Anesthesiology and Intensive Care Medicine, Motol University Hospital, Prague, Czech Republic, ²University of L'Aquila, L'Aquila, Italy, ³University Hospital Motol, Charles University, Prague, Czech Republic

(719) Acute Kidney Injury After Lung Transplantation: Incidence, Pre- and Intraoperative Risk Factors - A Swedish Nationwide Retrospective Study; E. Grins¹, J. Wijk², H. Bjursten³, S. Lindstedt⁴, G. Dellgren⁵, P. Ederoth¹, L. Lannemyr². ¹Department of Anesthesiology and Intensive Care, Department of Clinical Sciences, Lund University, Lund, Sweden, ²Department of Anesthesiology and Intensive Care Medicine at the Sahlgrenska Academy, University of Gothenburg and Section for Cardiothoracic Anesthesia and Intensive Care, Sahlgrenska University Hospital, Gothenburg, Sweden, ³Department of Cardiothoracic and Vascular Surgery, Anesthesia, and Intensive Care, Skåne University Hospital, Lund, Sweden, ⁴Wallenberg Centre for Molecular Medicine, Lund University, Lund, Sweden, ⁵Sahlgrenska University Hospital, Gothenburg, Sweden

(720) Perioperative Extracorporeal Circulatory Support and Early Postoperative Outcomes After Lung Transplantation; J. Wijk¹, E. Grins², H. Bjursten³, S. Lindstedt⁴, G. Dellgren⁵, L. Lannemyr¹, P. Ederoth². ¹Department of Anesthesiology and Intensive Care Medicine at the Sahlgrenska Academy, University of Gothenburg and Section for Cardiothoracic Anesthesia and Intensive Care, Sahlgrenska University Hospital, Gothenburg, Sweden, ²Department of Anesthesiology and Intensive Care, Department of Clinical Sciences, Lund University, Lund, Sweden, ³Department of Cardiothoracic and Vascular Surgery, Anesthesia, and Intensive Care, Skåne University Hospital, Lund, Sweden, ⁴Wallenberg Centre for Molecular Medicine, Lund University, Lund, Sweden, ⁵Sahlgrenska University Hospital, Gothenburg, Sweden

(721) Current Utilization of Diaphragm Pacing in Lung Transplant Patients: Identifying and Treating Phrenic and Diaphragm Function Abnormalities; R. Onders¹, M. Elmo¹, N. Carl¹, Y. Elgudin², Y. Abu-Omar¹, K. Gray¹, M. Pelletier¹, R. Arora¹, S. Kilaru³, R. Schilz⁴. ¹University Hospitals Cleveland Medical Center, Cleveland, OH, ²University Hospitals Cleveland Medical Center, Cleveland, OH, ³University Hospitals of Cleveland, Cleveland, OH, ⁴Case Western Reserve University, Cleveland, OH

(722) Donor Lung Weight and its Association to Early Extubation and Early Discharge from the ICU; A. Martinsson¹, J. Magnusson¹, S. Ricksten¹, A. Thorèn¹, J. Oras¹, A. Wallinder². ¹Sahlgrenska University Hospital, Gothenburg, Sweden, ²XVIVO, Gothenburg, Sweden

(723) Lung Ultrasound for Diagnosis of Primary Graft Dysfunction in Lung Transplantation Recipients; E. O'Brien¹, S. Curry¹, A. Rubino¹, A. Barker¹, A. Miller², J. Parmar¹. ¹Royal Papworth Hospital, Cambridge, United Kingdom, ²Shrewsbury and Telford Hospital NHS Trust, Shrewsbury, United Kingdom

(724) Acute Normovolemic Hemodilution in a Lung Transplant Patient; A. Fritz¹, A. Shapiro². ¹Cardiovascular and Thoracic Anesthesiology, Mayo Clinic, Jacksonville, FL, ²Mayo Clinic, Jacksonville, FL

(725) Flow Controlled Ventilation: A Promising Ventilation Strategy for Single Lung Transplantation; S. E. Guzzella¹, R. W. Schüpbach¹, G. Lang², I. Opitz³, M. Schläpfer¹. ¹Institute of Anaesthesiology, Universitätsspital Zürich, Zürich, Switzerland, ²University of Vienna, Vienna, Austria, ³Universitätsspital Zürich, Zürich, Switzerland

(726) Sars-Cov-2 Infection Immediately Following Lung Transplantation: A Presentation of Two Clinical Cases; D. Dessolin¹, A. Olland², B. Renaud-Picard³, R. Kessler³, C. Tacquard¹, M. Solis⁴, O. Collange¹. ¹Anesthesiology and Intensive Care Unit, Hopitaux Universitaires de Strasbourg, Strasbourg, France, ²Thoracic Surgery, University Hospital Strasbourg, Strasbourg, France, ³Pulmonary Medicine, Nouvel Hopital Civil, Strasbourg, France, ⁴Virology, Hopitaux Universitaires de Strasbourg, Strasbourg, France

(727) Transpulmonary Pressures Evaluation for Optimizing Ventilation in Bilateral Lung Transplants Recipients; B. Franco¹, M. Giunta¹, A. Costamagna², D. Pasero³, A. Trompeo¹, M. Boffini², L. Brazzi². ¹Anaesthesia and ICU, Città della Salute e della Scienza Hospital, Torino, Italy, ²University of Turin, Torino, Italy, ³University of Sassari, Sassari, Italy

(728) Trajectory of Vasoactive-Inotropic Scores for Patients on Extracorporeal Membrane Oxygenation: A Linear Mixed Model Analysis; M. A. Hockstein¹, S. P. Keller². ¹MedStar Washington Hospital Center, Washington, DC, ²Johns Hopkins University, Baltimore, MD

(729) Cardiac Shock and ECMO: Does Etiology Matter?; I. Ingvarsdottir¹, A. Westerlind², I. Lepore Lagerberg³, G. Dellgren⁴. ¹Anesthesia and Intensive Care, Sahlgrenska Univ Hospital, Gothenburg, Sweden, ²Cardiothoracic Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden, ³Cardiothoracic Surgery, University of Gothenburg, Gothenburg, Sweden, ⁴Sahlgrenska University Hospital, Göteborg, Sweden

(730) GDMT in Patients on Impella 5.0/5.5 Support: Feasibility and Trend Over Time; M. Pieri¹, L. Baldetti², S. Altizio², P. Nardelli², A. Ortalda², E. Fominskiy², S. Ajello², A. Scandroglio³. ¹Vita-Salute San Raffaele University, Milan, Italy, ²IRCCS San Raffaele Scientific Institute, Milan, Italy, ³Ospedale San Raffaele, Milan, Italy

(731) Role of Tmcs with Impella as Bridge to LVAD After AMI Related Cardiogenic Shock; S. Ajello¹, M. Pieri², S. Dormio¹, L. Baldetti¹, S. Altizio¹, F. Consolo³, P. Nardelli¹, A. Ortalda¹, A. Scandroglio⁴. ¹IRCCS San Raffaele Scientific Institute, Milan, Italy, ²Vita Salute San Raffaele, Milan, Italy, ³Università Vita Salute San Raffaele, Milan, Italy, ⁴Ospedale San Raffaele, Milan, Italy

(732) Diaphragmatic Palsy -A Common Complication After LVAD Implantation; M. Zaleska Kociecka¹, M. Celińska Spodar², K. Paszyń², S. Mielczarek¹, K. Byczkowska¹, J. Szymanski³, A. Tomaszek¹, P. Litwiński³, P. Góral¹, K. Marcinkiewicz¹, P. Kolsut⁴, P. Leszek¹. ¹Department of Mechanical Circulatory Support and Transplantation, National Institute of Cardiology, Warsaw, Poland, ²Anaesthesiology and Critical Care Unit, National Institute of Cardiology, Warsaw, Poland, ³Cardiac Surgery and Heart Transplantation Unit, National Institute of Cardiology, Warsaw, Poland, ⁴Cardiac Surgery and Transplantation Unit, National Institute of Cardiology, Warszawa, Poland

(733) Bi-Atrial Inflow Cannulation with BVAD: A Novel Approach for Bridging Restrictive Cardiomyopathy Patients to Heart Transplantation; Y. Eltayeb¹, A. Hussain¹, A. Al Ghamdi², A. Arifi², A. Hussanat³, N. Selimovic⁴. ¹Cardiac Critical Care, King Abdelaziz Cardiac Centre-National Guard Health Affair, Riyadh, Saudi Arabia, ²Cardiac Surgery, King Abdelaziz Cardiac Centre-National Guard Health Affair, Riyadh, Saudi Arabia, ³Adult Cardiology and Heart Transplant, King Abdelaziz Cardiac Centre-National Guard Health Affair, Riyadh, Saudi Arabia, ⁴King Abdul Aziz Cardiac Centre, Ministry of National Guard, Riyadh, Riyadh, Sweden

THURSDAY, 11 APRIL, 2024

4:30 - 5:30 p.m.

POSTER SESSION 2: Cardiology (Non-CME)

Location: Poster Hall

Core Therapies: HEART, LUNG, MCS, PVD

Practice Areas: Cardiology, Anesthesiology and Critical Care, Cardiothoracic Surgery, Infectious Diseases, Nursing and Allied Health, Pathology, Pediatrics, Pharmacy, Pulmonology, Research and Immunology

Session Summary: Posters in this session include presentations on multiple topics where the Practice Areas of the research is focused in Cardiology. Designated Poster Discussants will circulate through the poster hall during the session to engage poster presenters in quality discussions of their abstracts. **CME is not offered for poster sessions.**

Poster Discussants: Mustafa Ahmed, USA, Sophia Airhart, USA, Waqas Akhtar, UK, Arif Albulushi, USA, Tamas Alexy, USA, Rami Alharethi, USA, Natasha Altman, New Zealand, Shahnawaz Amdani, USA, Sonali Arora, India, Sai Bhagra, UK, Anju Bhardwaj, USA, Marco Caccamo, USA, Kadir Caliskan, Netherlands, Maria Castel, Spain, Javier Castrodeza, Spain, Wandy Chan, Australia, Sanjay Chandrasekhar, USA, Erin Coglianesi, USA, Bailey Colvin, USA, Jennifer Conway, Canada, John Anthony Coppola, USA, Alejandro Folch Sandoval, USA, Catalina Gallego, Columbia, Lakshmi Gokanapudy Hahn, USA, Livia Goldraich, Brazil, Mardi Gomberg-Maitland, USA, Hilda Gonzalez Bonilla, USA, Jeffrey Gossett, USA, Hanno Grahn, Germany, Dipankar Gupta, USA, Thomas Hanff, USA, Claire Irving, Australia, George Javorsky, Australia, Andrew Kao, USA, Jamie Kennedy, USA, Steven Kindel, USA, Jon Kobashigawa, USA, Sudheer Koganti, India, Mrinalini Krishnan, USA, Anna Kydd, UK, Matthew Lander, USA, Hae-young Lee, South Korea, Clive Lewis, UK, Renzo Loyaga-Rendon, USA, Aine Lynch, Canada, Shivank Madan, USA, Matylda Mazur, USA, Sonia Mirabet Perez, Spain, Mrudula Munagala, USA, Emil Najjar, Sweden, Takeshi Nakatani, Japan, Daryl Nnani, USA, Marish Oerlemans, Netherlands, Juan Ortega-Legaspi, USA, Carlos Ortiz-Bautista, Spain, William Parker, USA, Christina Phelps, USA, Salwa Rahman, USA, Roopa Rao, USA, Matthew Regan, USA, Joseph Rogers, USA, Christian Said, Canada, Daniel Silverman, USA, Marc Simon, USA, Aditi Singhvi, India, Steven Sorci, USA, Swethika Sundaravel, USA, Hanna Tadros, USA, Sarumathi Thangavel, India, Madeleine Townsend, USA, Maxime Tremblay-Gravel, Canada, Jean Luc Vachery, Belgium, Adrian Van Bakel, USA, Linda Van Laake, Netherlands, George Vetrovec, USA, Amin Yehya, USA, Rayan Yousefzai, USA, Daniel Zlotoff, USA

(734) Associations of Outpatient Administration of Monoclonal Antibody Therapy for COVID-19 Infection in Orthotopic Thoracic Organ Transplant Recipients; M. U. Ahmed¹, F. Wright², S. Munoz³, A. Albrecht³, P. Weber³, S. Hassan¹, N. K. Manandhar Shrestha¹, C. Kerndt³, J. McDermott¹, R. Hadley², M. Gonzalez¹, M. Tamae Kakazu², R. Loyaga-Rendon¹, B. Trethowan¹. ¹Corewell Health Frederik Meijer Heart & Vascular Inst/Michigan State Univ College of Human Med, Grand Rapids, MI, ²Corewell Health Dept of Pulm & Critical Care Med/Michigan State Univ College of Human Med, Grand Rapids, MI, ³Corewell Health Dept of Internal Med/Michigan State Univ College of Human Med, Grand Rapids, MI

(735) Amiodarone Use in Post-Orthotopic Transplant Patients - A Pilot Study; A. Chanda¹, G. Panza², A. Jaiswal³, A. Feingold⁴, L. O'Bara⁴, A. Scatola³. ¹Dept of Internal Med, Univ of Connecticut SoM, Farmington, CT, ²Research Admin, Hartford HealthCare, Hartford, CT, ³Dept of Advanced HF and Transplant Cardiology, Hartford HealthCare, Hartford, CT, ⁴Heart Transplant Program, Hartford HealthCare, Hartford, CT

(736) Molecular Microscope (MMDx) After COVID-19 Vaccination in Heart Transplant Recipients; A. Rahman¹, A. Fernandez Valledor², C. Moeller², W. Rzechorzek², S. Rahman³, G. Rubinstein⁴, J. Baranowska², C. Lee⁵, D. Oren⁶, K. Oh², D. Bae³, J. Raikhelkar⁷, K. Theodoropoulos⁸, D. Lotan², J. Fried³, E. DeFilippis², K. Clerkin², F. Latif⁹, G. Sayer², N. Uriel¹⁰. ¹Division of Cardiology, Columbia University Irving Medical Center, New York, NY, ²Columbia University Irving Medical Center, New York, NY, ³Columbia University Medical Center, New York, NY, ⁴Columbia University, New York, NY, ⁵Columbia University, NY, NY, ⁶New York Presbyterian, Columbia University, New York, NY, ⁷Columbia University, New York, NY, ⁸Columbia University Irving Medical Center, NY, NY, ⁹NY Presbyterian Hospital, New York, NY, ¹⁰New York Presbyterian, New York, NY

(737) Association of Sarcopenia, Obesity and Sarcopenic Obesity with Inflammation in Advanced Heart Failure; M. R. Carey, A. Ladanyi, G. M. Mondellini, A. Pinsino, F. Cali, C. Shahidi, G. Sayer, K. Takeda, N. Uriel, P. C. Colombo, M. Yuzefpolskaya. Columbia University Irving Medical Center, New York, NY

(738) Temporary Mechanical Circulatory Support as Bridge-to-Transplant and its Implications for Allosensitization Risk; K. Sideris¹, E. Lázár-Molnár², C. Kyriakopoulos¹, I. Taleb¹, D. Hurst², S. Ugolini¹, C. Selzman³, L. Brinker¹, S. Drakos¹, J. Tonna³, L. Geer¹, M. Goodwin³, O. Wever-Pinzon¹, T. Hanff¹, S. Carter¹, J. Stehlik¹. ¹Division of Cardiovascular Disease, University of Utah School of Medicine, Salt Lake City, UT, ²Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT, ³Division of Cardiothoracic Surgery, University of Utah School of Medicine, Salt Lake City, UT

(739) Transfusion-Induced HLA Antibodies Are Transient in Heart Transplant Patients; O. A. Aljohani¹, B. Shy², J. Cunniffe², S. Maruthamuthu², K. Cunniffe², G. Wieselthaler³, R. Rajalingam². ¹Department of Pediatrics, University of California San Francisco, San Francisco, CA, ²Immunogenetics and Transplantation Laboratory, Department of Surgery, University of California San Francisco, San Francisco, CA, ³Heart Transplant and Mechanical Circulatory Support Program, Department of Surgery, University of California, San Francisco, CA

- (740) Impact of Epstein-Barr Virus (EBV) Mismatch on Gene-Expression Profiling (MMDx) and Rejection;** C. M. Moeller, A. Fernandez Valledor, D. Oren, G. Rubinstein, S. Rahman, J. Baranowska, C. Lee, D. Lotan, D. Bae, E. M. DeFilippis, J. Fried, K. Oh, K. Theodoropoulos, K. Clerkin, F. Latif, N. Uriel, G. T. Sayer, J. Raikhelkar. *Columbia University Irving Medical Center, New York, NY*
- (741) Does Multiorgan Transplantation Correlate with Reduced Rates of Rejection as Evaluated by the Molecular Microscope (MMDx)?;** C. M. Moeller¹, A. Fernandez Valledor¹, D. Oren¹, G. Rubinstein¹, S. Rahman¹, J. Baranowska¹, C. Lee¹, J. Raikhelkar¹, E. M. DeFilippis¹, J. Fried¹, D. Lotan¹, M. Yuzefpolskaya¹, P. Colombo¹, K. Clerkin¹, K. Theodoropoulos¹, D. Majure², G. Sayer¹, N. Uriel¹, F. Latif¹. ¹*Division of Cardiology, Center of Advanced Cardiac Care, Columbia University Irving Medical Center, New York, NY*, ²*Weill Cornell Medical College, New York, NY*
- (742) Contemporary Incidence and Outcomes of Invasive Pulmonary Aspergillosis in Heart Transplant Recipients;** R. O. Valderrama Reyes¹, C. Ortiz Bautista¹, M. Machado Vilchez², M. Valerio Minero², Z. Blazquez Bermejo¹, J. Castrodeza Calvo¹, E. Zatarain¹, A. Villa Arranz¹, A. Estévez Prieto², M. Patricia², B. Javier¹. ¹*Cardiology, Hospital General Universitario Gregorio Marañón, Hospital General Universitario Gregorio Marañón, Spain*, ²*Clinical Microbiology and Infectious Diseases Department, Hospital General Universitario Gregorio Marañón, Hospital General Universitario Gregorio Marañón, Spain*
- (743) Does Racial Difference Affect Outcome After Heart-Kidney Transplantation?;** B. Coleman¹, M. Welton², J. Patel², E. Kransdorf², M. Lee², F. Esmailian², D. Chang², L. Czer², J. Kobashigawa². ¹*Cedars Sinai Medical Center, Los Angeles, CA*, ²*Cedars-Sinai Smidt Heart Institute, Los Angeles, CA*
- (744) Ecmo Bridged SKHT Recipients and Their Outcomes Following 2018 Guideline Change;** H. Patel¹, K. Agarwal², M. Kiernan³. ¹*GME Internal Medicine, Willis Knighton health System, Shreveport, LA*, ²*Tufts Medical Center, Boston, MA*, ³*Cardiovascular Medicine, Tufts Medical Center, Boston, MA*
- (745) Gene Expression Profiling and Donor-Derived Cell-Free DNA in Clinically Stable Heart-Kidney Transplant Recipients;** P. Prasad¹, K. Pinney², P. Hanson², S. Wang², L. Shen², K. Oreschak², N. Raval³, E. Czinn⁴, S. Pinney⁵, L. Chen⁴, T. De Marco¹. ¹*University of California, San Francisco, San Francisco, CA*, ²*CareDx Inc, Brisbane, CA*, ³*AdventHealth Transplant Institute, Orlando, FL*, ⁴*University of Rochester Medical Center, Rochester, NY*, ⁵*Mount Sinai Morningside, New York, NY*
- (746) Size Matching in Combined Heart-Kidney and Heart-Liver Transplant: An Undersized Donor-Recipient Weight Ratio is Associated with Increased Mortality in Heart-Kidney Transplant;** H. Ahmed¹, J. Edelson², X. Zhang², K. Lin², J. Edwards², J. Berger², C. Mavroudis², K. Terakawa², I. Masood², C. Wittlieb-Weber², J. Rossano², M. O'Connor², K. Maeda². ¹*Children's Hospital of Philadelphia, Philadelphia, PA*, ²*Children's Hospital of Philadelphia, Philadelphia, PA*
- (747) Does the Number of Donor Specific Antibodies Crossed at the Time of Heart Transplant Impact Post-Transplant Outcome?;** J. Kobashigawa, M. Kittleson, E. Kransdorf, M. Welton, G. Jamero, A. Kanungo, M. Lee, N. Bhatnagar, L. Stern, A. Nikolova, L. Czer, F. Esmailian, J. Patel. *Cedars-Sinai Smidt Heart Institute, Los Angeles, CA*
- (748) Does Insulin-Dependent Diabetes in a Donor Impact Outcome After Heart Transplantation?;** J. Patel¹, M. Kittleson¹, D. Chang¹, M. White², A. Kanungo¹, M. Lee¹, N. Bhatnagar¹, R. Patel¹, A. Hage¹, L. Czer¹, D. Megna¹, J. Kobashigawa¹. ¹*Cedars-Sinai Smidt Heart Institute, Los Angeles, CA*, ²*Cedars-Sinai Comprehensive Transplant Center, Los Angeles, CA*
- (749) Is Treatment of Asymptomatic Isolated C1 Q Positive Donor Specific Antibody After Heart Transplant Efficacious?;** R. Shrestha, J. Patel, M. Kittleson, E. Kransdorf, A. Velleca, N. Bhatnagar, A. Kanungo, M. Lee, Z. Wakefield, A. Nikolova, L. Czer, F. Esmailian, J. Kobashigawa. *Cedars-Sinai Smidt Heart Institute, Los Angeles, CA*
- (750) Post-Transplant Outcome in Recipients on Veno-Arterial Extracorporeal Membrane Oxygenation;** G. Masciocco¹, G. Ruzzenenti¹, G. Olivieri², M. Varrenti¹, S. Ghidini¹, N. Conti¹, M. Palazzini¹, A. Verde¹, A. Garascia¹, M. Mondino³, C. Russo². ¹*Heart Failure and Transplant Unit, Ospedale Niguarda, Milano, Italy*, ²*Cardiac Surgery Unit, Ospedale Niguarda, Milano, Italy*, ³*Anesthesiology and Intensive Care Unit, Ospedale Niguarda, Milano, Italy*
- (751) Outcomes of Hepatitis B Positive Donor Hearts in Heart Transplantation: An Analysis of the OPTN Database;** M. Alarfaj¹, Z. Shah¹, H. Shah¹, A. Goyal¹, H. Farhoud¹, J. Baker², J. Hu², J. Stehlik³, A. Vidic¹. ¹*Cardiovascular Medicine, Univ of Kansas Medical Center, Kansas City, KS*, ²*BioStatistics & Data Science, Univ of Kansas Medical Center, Kansas City, KS*, ³*Cardiovascular Medicine, Univ of Utah, Salt Lake, KS*
- (752) Estimating Prognosis Among Advanced Heart Failure Patients Referred for Advanced Heart Failure Therapies at the University Health Network;** T. A. Buchan¹, M. Casciato¹, R. Uxa¹, I. Tan¹, F. Foroutan¹, G. Guyatt², A. Alba¹. ¹*Ted Rogers Centre for Heart Research, Toronto, ON, Canada*, ²*Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada*
- (753) Direct Oral Anticoagulants in Pre-Heart Transplant Patients: A Promising Approach;** J. Conway, R. Loungani, A. Robbins, M. Griffith, E. Molina. *Piedmont Heart Institute - Samsky Advanced Heart Failure Center, Atlanta, GA*

(754) "Frequent Flyer" is a "Frequent Dier" - Intermacs Profile Prior Heart Transplantation Predicts Long Term Survival; A. Dyla¹, W. Mielnicki¹, K. Ignor², K. Krzyzak³, M. Karczewski⁴, J. Waszak⁵, H. Szurmiak⁶, M. Zembala⁷. ¹Anaesthesiology and Intensive Care Unit, District Hospital, Olawa, Poland, ²Dept of Anaesthesiology and Intensive Care, Municipal Hospital, Nowa Sol, Poland, ³Dept of Cardiac Surgery, Cardiac and Lung Transplantation, Mechanical Circulatory Support, Silesian Center for Heart Disease, Zabrze, Poland, ⁴Dept of Applied Mathematics, Wroclaw University of Environmental and Life Sciences, Wroclaw, Poland, ⁵Faculty of Medicine, WSB Academy, Dabrowa Gornicza, Poland, ⁶Anaesthesiology and Intensive Care Unit, Specialist Hospital in Gorlice, Gorlice, Poland, ⁷The John Paul II Catholic Univ, Lublin, Poland

(755) Comparable Outcome and Survival in On- and Off-Hours Heart Transplantation; D. Oehler¹, M. Immohr², C. Boettger³, D. Sigetti⁴, P. Herzum¹, J. Haschemi¹, E. Zweck⁵, D. Scheiber¹, H. Aubin⁶, P. Akhyari⁷, A. Polzin¹, M. Kelm¹, A. Lichtenberg¹, U. Boeken⁴. ¹Department for Cardiology, University Hospital Düsseldorf, Düsseldorf, Germany, ²Department for Cardiac Surgery, RWTH Aachen University, Aachen, Germany, ³Department for Interventional Radiology, University Hospital Düsseldorf, Düsseldorf, Germany, ⁴Department for Cardiac Surgery, University Hospital Düsseldorf, Düsseldorf, Germany, ⁵Department for Cardiology, University of Dusseldorf, Düsseldorf, Germany, ⁶Department for Cardiac Surgery, University Hospital Duesseldorf, Düsseldorf, Germany, ⁷Department for Cardiac Surgery, University Hospital Aachen, Aachen, Germany

(756) Impact of Reactivity Against Lymphocyte Panel and Virtual Crossmatch on Post-Cardiac Transplant Survival and Hospitalization Time; G. Aulicino¹, S. Mangini², F. Marcondes-Braga³, L. Seguro⁴, M. Avila⁵, I. Wosniak⁶, F. Gaiotto⁶, F. Bacal⁷. ¹Heart Transplant, University of São Paulo, São Paulo, Brazil, ²Heart Institue, São Paulo, Brazil, ³Heart Institute (InCor), Hospital das Clínicas, Universidade de Sao Paulo, São Paulo, Brazil, ⁴INCOR (Heart Insitute) - São Paulo Hospital das Clínicas da FMUSP, São Paulo, Brazil, ⁵Heart Institute (InCor) FMUSP, São Paulo, Brazil, ⁶Heart Institute, São Paulo, Brazil, ⁷University of Sao Paulo, São Paulo, Brazil

(757) WITHDRAWN

(758) Donor Left Ventricular Hypertrophy is Not Associated with Graft Survival in the Contemporary Era; J. H. Mahar¹, B. Wayda², Y. Weng³, S. Zhang³, J. Zaroff⁴, K. K. Khush². ¹Stanford Cardiovascular Institute, Stanford Univ SoM, Palo Alto, CA, ²Cardiology, Stanford Univ SoM, Palo Alto, CA, ³Quantitative Sciences Unit, Stanford Univ SoM, Palo Alto, CA, ⁴Cardiology, Kaiser San Francisco Medical Center, San Francisco, CA

(759) Using Global Longitudinal Strain in Heart Transplant Patients to Predict Adverse Events; E. Loftspring¹, E. Abaza¹, A. Ramachandran¹, S. Maidman¹, C. Gidea², A. Reyentovich³, M. Saric³, S. Rao³, S. Katz³, R. Goldberg³, S. Riggio³, N. Moazami⁴, K. Clark⁵, N. Sikand⁵. ¹Department of Medicine, NYU Grossman School of Medicine, New York, NY, ²Newark Beth Israel Medical Center, Newark, NJ, ³Leon H. Charney Division of Cardiology, NYU Grossman School of Medicine, New York, NY, ⁴Department of Cardiothoracic Surgery, NYU Grossman School of Medicine, New York, NY, ⁵Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT

(760) Improving Risk Stratification for Incident Heart Failure with Reduced Ejection Fraction Using Electronic Health Record Data; S. Adatya¹, R. Parikh², A. Bhatt³, A. Axelrod⁴, H. Dinh⁵, T. Tan², K. Lee⁶. ¹Kaiser Permanente, Santa Clara, CA, ²Kaiser Permanente, Oakland, CA, ³Kaiser Permanente, San Francisco, CA, ⁴Kaiser Permanente, Vallejo, CA, ⁵Kaiser Permanente, South Sacramento, CA, ⁶Kaiser Permanente, Santa Clara, CA

(761) Cardiopulmonary Exercise Testing and Post-Heart Transplant Outcomes; M. Dean¹, C. Zoni², K. Fox³, L. Copeland⁴, J. Silverman⁵, C. Lemoine², Y. Ravi², C. Sai Sudhakar². ¹Department of Internal Medicine, Virginia Commonwealth University Health System, Richmond, VA, ²Department of Surgery, University of Connecticut Health Center, Farmington, CT, ³Department of Cardiology, Virginia Commonwealth University Health System, Richmond, VA, ⁴Department of Population Health and Quantitative Health Sciences, University of Massachusetts Chan Medical School, Worcester, MA, ⁵University of Connecticut, Farmington, CT

(762) Molecular Microscope Findings in Low-Grade Histological Rejection: A Less Benign Reality Than Assumed; G. Rubinstein¹, A. Fernandez Valledor², C. M. Moeller², S. Slomovich², D. Oren², J. Baranowska², S. Rahman², C. Lee², K. Oh², D. Bae², J. Raikhelkar², V. Topkara², D. Lotan², E. M. DeFilippis², K. Theodoropoulos², J. Fried², E. Lin², D. Majure³, K. Clerkin², P. Colombo², M. Yuzefpolskaya², F. Latif², G. Sayer², N. Uriel². ¹Columbia University Irving Medical Center and Jacobi Medical Center - Albert Einstein College of Medicine, New York, NY, New York, NY, ²Columbia University Irving Medical Center, New York, NY, ³Weill Cornell Medical College, New York, NY

(763) Decreased Cardiac Mass in Cancer Survivors with Anthracycline Induced Cardiotoxicity Undergoing Heart Transplantation; J. Raikhelkar¹, C. Lee¹, M. Regan², K. Clerkin¹, J. Fried¹, K. Axsom¹, D. Majure³, Y. Naka⁴, Y. Kaku¹, K. Takeda¹, F. Latif¹, G. Sayer¹, N. Uriel⁴. ¹Columbia University Irving Medical Center, New York, NY, ²New York Presbyterian Hospital- Columbia University and Weill Cornell, New York, NY, ³Weill Cornell Medical College, New York, NY, ⁴New York Presbyterian, New York, NY

(764) Genetic Signatures in Heart Transplant and LVAD Patients: Unraveling Their Association with Hypertrophic and Dilated Cardiomyopathy Subtypes; K. Kim. Incheon Sejong Hospital, Incheon, South Korea

(765) Milrinone Contributes to Vasoplegia and Delayed Severe Graft Dysfunction Post-Heart Transplantation - Part 3; S. Kwok¹, S. Pettit², S. Bhagra², M. Berman², S. Lim³, J. Mascaro³. ¹Dept of Cardiology, Univ Hospitals of North Midlands NHS Trust, Stoek-on-Trent, United Kingdom, ²Royal Papworth Hosp, Cambridge, United Kingdom, ³Univ Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom

(766) Two Phenotypes of Severe Early Graft Dysfunction Post-Heart Transplantation Based on Clinical Course - Part 1; S. Kwok¹, S. Pettit², S. Bhagra², M. Berman², J. Mascaro³, S. Lim³. ¹Dept of Cardiology, Univ Hospitals of North Midlands NHS Trust, Stoke-on-Trent, United Kingdom, ²Royal Papworth Hosp, Cambridge, United Kingdom, ³Univ Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom

(767) Diastolic Indices of Vasoplegia Identify Delayed Severe Early Graft Dysfunction Post-Heart Transplantation - Part 2; S. Kwok¹, S. Pettit², S. Bhagra², M. Berman², S. Lim³. ¹Dept of Cardiology, University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, United Kingdom, ²Royal Papworth Hospital, Cambridge, United Kingdom, ³University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom

(768) Mitigating Risk by Using the Primary Graft Dysfunction-Artificial Intelligence (PGD-AI) Calculator in a Contemporary Toronto Cohort: An Analysis from The International Consortium on PGD; Y. Moayed¹, I. Raslan², A. Venkatraman², F. Foroutan³, L. Truby⁴, J. Han⁵, E. Henriksen⁶, J. Guzman Bofarull⁷, D. Couto Mallon⁸, R. Moayedifar⁹, H. Luikart¹⁰, G. Kim¹¹, M. Crespo-Leiro¹², J. Felius¹³, S. Hall¹⁴, A. Devore¹⁵, M. Sabatino¹⁶, L. Potena¹⁷, M. Rivas-Lasarte¹⁸, J. Segovia-Cubero¹⁹, M. Farrero Torres²⁰, M. Tremblay-Gravel²¹, P. Noly²¹, R. Miller²², S. Chih²³, A. Zuckermann²⁴, B. Clarke²⁵, K. Khush²⁶, C. Fan²⁷, H. Ross². ¹UHN, Toronto, ON, Canada, ²UHN, Toronto, ON, Canada, ³Ted Rogers Centre for Heart Research, Toronto, ON, Canada, ⁴Univ of Texas Southwestern MC, Dallas, TX, ⁵Univ of Chicago MC, Chicago, IL, ⁶Stanford Healthcare, Stanford, CA, ⁷Hospital Clinic, Barcelona, Spain, ⁸A Coruna, A Coruna, Spain, ⁹Medical Univ Vienna General Hospital Vienna, Vienna, Austria, ¹⁰Stanford Hospital, Stanford, CA, ¹¹Univ of Chicago, Chicago, IL, ¹²Hospital Universitario A Coruña, A Coruna, Spain, ¹³Baylor Univ Med Ctr, Baylor, TX, ¹⁴Baylor Univ MC, Baylor, TX, ¹⁵Duke Medical Centre, Durham, NC, ¹⁶Institute of Cardiology S.Orsola-Malpighi Hospital, Bologna, Italy, ¹⁷IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, ¹⁸Hospital Puerta de Hierro, Madrid, Madrid, Spain, ¹⁹Hospital Puerta de Hierro, Madrid, Spain, Madrid, Spain, ²⁰Hospital Clinic de Barcelona, Barcelona, Spain, ²¹Montreal Heart Institute, Montreal, QC, Canada, ²²Univ of Calgary, Calgary, AB, Canada, ²³Univ of Ottawa Heart Institute, Ottawa, ON, Canada, ²⁴Medical Univ of Vienna, Vienna, Austria, ²⁵St. Paul's Hospital, Univ of British Columbia, Vancouver, BC, Canada, ²⁶Stanford Univ, Stanford, CA, ²⁷UHN, Canada

(769) Peripheral Versus Central Cannulation of VA-ECMO for Primary Graft Dysfunction After Heart Transplantation: A Systematic Review and Metanalysis; E. Ródenas Alesina¹, A. Olivella¹, A. Orchanian-Cheff², F. Foroutan³, A. Alba⁴, Y. Moayed⁵, V. Rao⁴, F. Billia², H. Ross⁴, N. Aleksova⁶. ¹Vall d'Hebron Univ Hospital, Barcelona, Spain, ²UHN, Toronto, ON, Canada, ³Ted Rogers Centre for Heart Research, Toronto, ON, Canada, ⁴Toronto General Hospital, Toronto, ON, Canada, ⁵UHN, Toronto, ON, Canada, ⁶UHN, Women's College Hospital, Toronto, ON, Canada

(770) Comparative Regional Analysis of Severe Primary Graft Dysfunction: Insights from The International Consortium on PGD; E. Ródenas Alesina¹, J. Guzman Bofarull², Y. Moayed³, L. Truby⁴, F. Foroutan⁵, C. Fan¹, J. Han⁶, D. Couto-Mallon⁷, R. Moayedifar⁸, H. Luikart⁹, E. Henriksen¹⁰, G. Kim¹¹, M. Crespo-Leiro⁷, S. Hall¹², J. Felius¹³, A. DeVore¹⁴, K. Takeda¹⁵, J. B. Lerman¹⁶, M. Sabatino¹⁷, M. Tremblay-Gravel¹⁸, P. Noly¹⁸, H. Ross¹⁹, K. Khush²⁰, R. Miller²¹, S. Chih²², B. Clarke²³, A. Zuckermann²⁴, J. Segovia-Cubero²⁵, M. Rivas-Lasarte²⁶, M. Farrero Torres²⁷. ¹UHN, Toronto, ON, Canada, ²Hospital Clinic de Barcelona, Barcelona, Spain, ³UHN, Toronto, ON, Canada, ⁴Univ of Texas Southwestern MC, Dallas, TX, ⁵Ted Rogers Centre for Heart Research, Toronto, ON, Canada, ⁶Univ of Chicago MC, Chicago, IL, ⁷Hospital Universitario A Coruña, A Coruna, Spain, ⁸Medical Univ Vienna General Hospital Vienna, Vienna, Austria, ⁹Stanford Hospital, Stanford, CA, ¹⁰Stanford Healthcare, Stanford, CA, ¹¹Univ of Chicago, Chicago, IL, ¹²Baylor Univ MC, Waco, TX, ¹³Baylor Univ Med Ctr, Waco, TX, ¹⁴Duke Univ MC, Durham, NC, ¹⁵Columbia Univ, New York, NY, ¹⁶Duke Univ School of Medicine, Durham, NC, ¹⁷Institute of Cardiology S.Orsola-Malpighi Hospital, Bologna, Italy, ¹⁸Montreal Heart Institute, Montreal, QC, Canada, ¹⁹Toronto General Hospital, Toronto, ON, Canada, ²⁰Stanford Univ, Stanford, CA, ²¹Univ of Calgary, Calgary, AB, Canada, ²²Univ of Ottawa Heart Institute, Ottawa, ON, Canada, ²³St. Paul's Hospital, Univ of British Columbia, Vancouver, BC, Canada, ²⁴Medical Univ of Vienna, Vienna, Austria, ²⁵Hospital Puerta de Hierro, Madrid, Spain, Madrid, Spain, ²⁶Hospital Puerta de Hierro, Madrid, Madrid, Spain, ²⁷Hospital Clinic de Barcelona, Barcelona, Spain

(771) Amiodarone Association with PGD After Heart Transplant; N. Stringer Dorsey¹, A. Biscopink¹, J. Atkins¹, S. K. O'Connor², A. Carnicelli¹, V. Rao¹, L. Witer¹, C. Inampudi¹, D. Silverman¹, A. Van Bakel¹, G. Jackson¹, B. Houston¹, A. Kiliç¹, R. J. Tedford¹, J. M. Griffin¹. ¹Medical University of South Carolina, Charleston, SC, ²Cornell University, Ithaca, NY

(772) Incidence of Moderate and Severe Primary Graft Dysfunction in DBD vs. DCD Heart Transplantation in Patients with Pre-Existing Durable LVAD Support; G. K. Bhattal¹, L. Keyt², M. Kearns³, V. Pretorius⁴, H. Tran⁵, N. Wettersten⁶. ¹Advanced Heart Failure and Transplant Cardiology, University of California, San Diego, La Jolla, CA, ²UC San Diego, La Jolla, CA, ³UC San Diego Health, La Jolla, CA, ⁴UCSD, La Jolla, CA, ⁵University of California, San Diego, La Jolla, CA, ⁶Advanced Heart Failure and Transplant Cardiology, UC San Diego, La Jolla, CA

(773) Donor and Recipient Risk Factors for Post-Transplant Graft Dysfunction: A French National Cohort Study; N. Abdoul¹, C. Legeai¹, J. Guihaire², E. Flecher³, G. Lebreton⁴, R. Abi Akar⁵, A. Vincentelli⁶, F. Kerbaul¹, R. Dorent¹. ¹Agence de la Biomédecine, Saint-Denis, France, ²Marie Lannelongue Hospital, University of Paris Saclay, Le Plessis-Robinson, France, ³Rennes University Hospital, Rennes, France, ⁴La Pitié Salpêtrière Hospital, Paris, France, ⁵Georges Pompidou European Hospital, Paris, France, ⁶CHU de Lille Hospital, Lille, France

(774) Impact of Early Graft Dysfunction on Conditional 1-Year Post-Transplant Survival: A French National Cohort Study; N. Abdoul¹, C. Legeai¹, G. Coutance², G. Baudry³, L. Sebbag⁴, J. Guihaire⁵, P. Battistella⁶, F. Kerbaul¹, R. Dorent¹. ¹Agence de la Biomédecine, Saint-Denis, France, ²Pitié-Salpêtrière Hospital, Paris, France, ³Nancy Univ Hosp, Vandoeuvre-les-Nancy, France, ⁴Hospices Civils De Lyon Hospital Louis Pradel, Lyon, France, ⁵Marie Lannelongue Hospital, Univ of Paris Saclay, Le Plessis-Robinson, France, ⁶Montpellier Univ Hosp, Montpellier, France

(775) An Analysis of ECMO Use Post-Transplant in the GUARDIAN Heart Registry; U. Jorde¹, N. Uriel², D. Goldstein³, S. Patel⁴, M. Leacche⁵, A. Vidic⁶, S. Pham⁷, L. Klein⁸, J. Smith⁸, J. Jacobs⁹, J. Teuteberg¹⁰, M. Kawabori¹¹, D. D'Alessandro¹². ¹Montefiore Medical Center, New York, NY, ²New York Presbyterian, New York, NY, ³Montefiore, New York, NY, ⁴Montefiore-Einstein, New York, NY, ⁵Corewell Health, Grand Rapids, MI, ⁶University of Kansas Health System, Kansas City, KS, ⁷Mayo Clinic, Jacksonville, FL, ⁸University of California San Francisco, San Francisco, CA, ⁹University of Florida Health Shands, Gainesville, FL, ¹⁰Stanford Univ SoM, Stanford, CA, ¹¹Tufts Medical Center, Boston, MA, ¹²MGH, Boston, MA

(776) Does Crossing DSA and Its Binding Levels at the Time of Heart Transplant Impact Post-Transplant Outcomes?; I. Balachandran, J. Patel, M. Kittleson, G. Jamero, A. Kanungo, M. Lee, N. Bhatnagar, A. Nikolova, A. Hage, M. Bowdish, L. Czer, J. Kobashigawa. Cedars-Sinai Smidt Heart Institute, Los Angeles, CA

(777) Routine Screening for HLA Antibodies in Heart Transplant Patients - Does It Affect Clinical Decision Making?; T. Clemmensen¹, J. Baatrup², K. Bjerre³, E. Lichscheidt³, P. Koefoed-Nielsen², H. Eiskjaer³. ¹Aarhus University Hospital, Aarhus N, Denmark, ²Dept of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark, ³Dept of Cardiology, Aarhus University Hospital, Aarhus, Denmark

(778) Correlation Between the Subtype of Anti-HLA Donor Specific Antibodies and Rejection Assessed by Molecular Microscope; A. Fernandez Valledor¹, C. M. Moeller¹, J. Baranowska¹, C. Lee¹, G. Rubinstein¹, S. Rahman¹, Y. Mehlman¹, A. Rahman¹, D. Lotan¹, D. Oren¹, E. DeFilippis¹, D. Bae¹, K. Oh¹, D. Majure², K. Theodoropoulos¹, E. Lin¹, V. Topkara¹, P. Colombo¹, M. Yuzefpolskaya¹, J. Fried¹, J. Raikhelkar¹, K. Clerkin¹, F. Latif¹, G. Sayer¹, N. Uriel¹. ¹Division of Cardiology, Center of Advanced Cardiac Care, Columbia University Irving Medical Center, New York, NY, ²Weill Cornell Medical College, New York, NY

(779) Correlation Between Peripheral Gene-Expression Profiling (GEP-Allomap) and Tissue Gene-Expression in T-Cell Mediated Rejection Detection; A. Fernandez Valledor¹, C. M. Moeller¹, D. Oren¹, G. Rubinstein¹, S. Rahman¹, J. Baranowska¹, C. Lee¹, A. Rahman¹, S. Slomovich¹, Y. Mehlman¹, D. Lotan¹, E. M. DeFilippis¹, D. Bae¹, K. Oh¹, V. Topkara¹, P. Colombo¹, M. Yuzefpolskaya¹, E. Lin¹, J. Fried¹, K. Theodoropoulos¹, D. Majure², K. Clerkin¹, J. K. Raikhelkar¹, G. T. Sayer¹, N. Uriel¹, F. Latif¹. ¹Division of Cardiology, Center of Advanced Cardiac Care, Columbia University Irving Medical Center, New York, NY, ²Weill Cornell Medical College, New York, NY

(780) Impact of Cytomegalovirus (CMV) Mismatch on Rejection Assessed by Molecular Microscope (MMDx); A. Fernandez Valledor¹, C. M. Moeller¹, G. Rubinstein¹, D. Oren¹, S. Rahman¹, J. Baranowska¹, C. Lee¹, S. Slomovich¹, D. Bae¹, E. M. DeFilippis¹, D. Lotan¹, J. Fried¹, K. Theodoropoulos¹, K. Oh¹, F. Latif¹, M. Yuzefpolskaya¹, K. Clerkin¹, D. Majure², J. Raikhelkar¹, N. Uriel¹, G. T. Sayer¹. ¹Columbia University Irving Medical Center, New York, NY, ²Weill Cornell Medical College, New York, NY

(781) What is Behind the Guilty Effect? Molecular Microscope Insights; A. Fernandez Valledor¹, C. M. Moeller¹, G. Rubinstein¹, C. Lee¹, J. Baranowska¹, S. Rahman¹, R. Shah¹, A. Rahman¹, Y. Mehlman¹, D. Oren¹, E. M. DeFilippis¹, D. Lotan¹, D. Bae¹, K. Oh¹, K. Theodoropoulos¹, J. Raikhelkar¹, D. Majure², J. Fried¹, K. Clerkin¹, F. Latif¹, G. T. Sayer¹, N. Uriel¹. ¹Columbia University Irving Medical Center, New York, NY, ²Weill Cornell Medical College, New York, NY

(782) Inflammatory Cardiomyopathies are Associated with Higher Rates of T-Cell Mediated Rejection. Molecular Microscope Results; A. Fernandez Valledor, C. M. Moeller, R. Shah, G. Rubinstein, J. Baranowska, D. Oren, S. Rahman, C. Lee, A. Rahman, K. Oh, D. Lotan, E. M. DeFilippis, D. Bae, K. Clerkin, K. Theodoropoulos, J. Fried, J. Raikhelkar, G. T. Sayer, N. Uriel, F. Latif. Columbia University Irving Medical Center, New York, NY

(783) Is There A Correlation Between a High Immuknow Level and Increased Rates of Rejection? Insights from Molecular Microscope (MMDx); A. Fernandez Valledor¹, C. M. Moeller¹, G. Rubinstein¹, D. Oren¹, S. Rahman¹, J. Baranowska¹, C. Lee¹, D. Lotan¹, E. M. DeFilippis¹, K. Theodoropoulos¹, D. Bae¹, K. Oh¹, K. Clerkin¹, J. Fried², J. Raikhelkar¹, F. Latif¹, N. Uriel¹, G. Sayer¹. ¹Columbia University Irving Medical Center, New York, NY, ²Columbia University Medical Center, New York, NY

(784) Donor Derived Cell Free DNA is a Reliable Marker in High Risk Heart Transplant Patients; R. Rao, A. Abdelkader, J. Sama, W. Khatri, M. Guglin. Indiana University, Indianapolis, IN

(785) Transitions Between Molecular Rejection Classes in Heart Endomyocardial Biopsies; K. S. Madill-Thomsen¹, M. Barner², A. Aliabadi-Zuckermann³, M. Cadeiras⁴, M. Crespo-Leiro⁵, M. Deng⁴, E. Despasquale⁴, J. Goekler³, S. Hall⁶, D. H. Kim⁷, A. Jamil⁸, J. Kobashigawa⁹, P. MacDonald¹⁰, J. Patel¹¹, L. Potena¹², K. Shah¹³, J. Stehlik¹⁴, A. Zuckermann³, P. F. Halloran⁷. ¹Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada, ²Kashi Clinical Laboratories, Portland, OR, ³Med Univ of Vienna, Vienna, Austria, ⁴UCLA, Los Angeles, CA, ⁵A Coruña Univ Hosp, A Coruña, Spain, ⁶Baylor Univ MC, Dallas, TX, ⁷Univ of Alberta, Edmonton, AB, Canada, ⁸BSWRI, Dallas, TX, ⁹Cedars-Sinai Heart Institute, Los Angeles, CA, ¹⁰St. Vincent 's Hospital, Sydney, Australia, ¹¹Cedars-Sinai Smidt Heart Institute, Los Angeles, CA, ¹²IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, ¹³Virginia Commonwealth University, Richmond, VA, ¹⁴Univ of Utah, Salt Lake City, UT

(786) Donor-Derived Cell-Free DNA (dd cf-DNA) for Non-Invasive Monitoring of Allograft Health After Cardiac Transplant in a Tertiary Care Hospital; S. Thangavel¹, A. Ramani², A. Ramani², B. Kumar², G. Bhavani², R. Chandrasekaran¹, R. Kumar¹, M. Krishna¹, R. Ratnagiri¹, S. Rao¹, K. Balakrishnan¹. ¹MGM Healthcare, Chennai, India, ²Trunome, Acrannolife Genomics Pvt, Chennai, India

(787) Prognostic Risk Factors After Antibody Mediated Rejection in Heart Transplantation; M. Scuppa¹, G. Coutance², M. Lescroart², M. Masetti³, M. Corrado⁴, C. Baldovini⁵, L. Borgese¹, S. Varnous², G. Barberio⁶, D. Pacini⁷, L. Potena³. ¹Heart Failure and Heart Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, ²Department of Cardiac Surgery, Institute of Cardiology, La Pitié-Salpêtrière Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), Sorbonne Université - Medical School, Paris, France, ³Heart Failure and Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, ⁴Internal Medicine Unit for the Treatment of Severe Organ Failure, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, ⁵Pathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, ⁶Division of Cardiac Surgery, Cardiac Surgery Department, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, ⁷Division of Cardiac Surgery, Cardiac Surgery Department, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, University of Bologna, Bologna, Italy

(788) The Outcome of Biopsy Negative Rejection After Heart Transplantation: Does Severity of BNR Matter?; J. Zhang, M. Kittleson, J. Patel, D. Chang, M. Lee, N. Bhatnagar, A. Kanungo, J. Hu, B. Azarbal, M. Bowdish, L. Czer, J. Kobashigawa. Cedars-Sinai Smidt Heart Institute, Los Angeles, CA

(789) Outcomes in Patients with Acute Cellular Rejection Grade 1R: Is the Debate Over?; B. Lampert¹, C. Williams², J. Hernandez Montfort³, R. Kursel O'Brien⁴, C. Aggarwal-Gupta⁵, A. Ravichandran⁶, R. Rao⁷, P. T. Campbell⁸, D. Yaranov⁹, S. Carey¹⁰, M. Olymbios¹⁰, M. Armer-Cabral¹⁰, Z. Zhang¹⁰, S. Hall¹¹. ¹Ohio State University Wexner Medical Center, Columbus, OH, ²Henry Ford Hospital, Detroit, MI, ³Baylor Scott and White Health, Temple, TX, ⁴Medical College of Wisconsin, Milwaukee, WI, ⁵Westchester Medical Center, Valhalla, NY, ⁶Ascension St. Vincent Hospital Indianapolis, Indianapolis, IN, ⁷Indiana University School of Medicine, Indianapolis, IN, ⁸Baptist Health Heart Failure and Transplant Institute, Little Rock, AR, ⁹Baptist Memorial Hospital, Memphis, TN, ¹⁰Natera, Inc., Austin, TX, ¹¹Baylor University Medical Center, Dallas, TX

(790) Clinical Monitoring with Donor-Derived Cell-Free DNA, Time to End the Surveillance Endomyocardial Biopsy?; A. Mehta¹, M. Topor¹, A. B. Cochrane¹, P. Bagchi², S. Ma¹, A. Kulshrestha¹, J. Kennedy¹, M. Psocka¹, D. Tang¹, K. Klein¹, S. Desai¹, S. S. Sinha¹, I. Isseh¹, A. Rollins¹, P. Shah¹. ¹Inova Schar Heart and Vascular, Falls Church, VA, ²George Washington University, Washington D.C., DC

(791) Heart Transplantation for Cardiac Amyloidosis: The Road Less Traveled; A. Mehta, M. Psocka, A. Rollins, V. Khangoora, P. Shah, J. Kennedy. Inova Schar Heart and Vascular, Falls Church, VA

(792) Cardiogenic Shock Due to Culture Negative Mitral Valve Endocarditis; A. Mehta, I. Vavilin, E. Sarin, Q. Zhao, K. Kumaran, S. Sinha. Inova Schar Heart and Vascular, Falls Church, VA

(793) Outcomes of Heart Transplant Recipients with Giant Cells or Eosinophils on Endomyocardial Biopsy; G. Petersen, M. Woodham, M. McLennon, M. Philbrick, A. Topik, A. Kumar, M. A. Urey, K. Hong, J. Silva Enciso. University of California San Diego, San Diego, CA

(794) Clinical Utility of Combination Testing of Gene-Expression Profiling and Donor-Derived Cell-Free DNA in Heart Transplantation; M. Topor¹, A. Mehta¹, A. B. Cochrane², P. Bagchi³, S. Ma¹, M. Maydosz¹, A. Thatcher¹, K. Bussa¹, C. Falke¹, D. Tang², K. Klein², J. Kennedy¹, P. Shah¹. ¹Inova Schar Heart and Vascular, Falls Church, VA, ²Inova Fairfax Hospital, Falls Church, VA, ³George Washington University, Washington, DC

(795) Local Laboratory-Run Donor-Derived Cell-Free DNA Assay for Heart Transplant Rejection Surveillance - First Year of Clinical Experience; T. Teszak¹, C. Bödör², L. Hegyi², L. Levay², B. Nagy², A. Fintha², B. Merkely¹, B. Sax¹. ¹Heart and Vascular Centre, Semmelweis University, Budapest, Hungary, ²Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary

(796) WITHDRAWN

(797) The Role of Multimodal Imaging in Guiding Myocardial Recovery: A Case of LVAD Explantation Following Concurrent Lymphocytic and COVID-19 Myocarditis; O. Al-Abboud¹, A. Bindra². ¹Baylor Scott and White The Heart Hospital, Plano, TX, ²Baylor University Medical Center, Dallas, TX

(798) Salvage Therapy with IVIG for Parainfluenza-3 Viral Pneumonia, Acute Respiratory Distress Syndrome, and Multiorgan Dysfunction in a Heart Transplant Recipient; O. Al-Abboud¹, C. W. Spak², S. Hall², R. Montealegre², A. Afzal², R. L. Gottlieb². ¹Baylor Scott & White The Heart Hospital, Plano, TX, ²Baylor University Medical Center, Dallas, TX

(799) Cardiac Tamponade Associated to an Early EBV-Induced Lymphoma After Heart Transplantation: A Case Report; F. Valente¹, C. Dewachter², C. Stefanidis³, A. Wolfrom³, J. Vachieri⁴, A. Roussoulieres⁵. ¹Department of Cardiology, Erasme Hospital, Brussels, Belgium, ²Erasme Hospital (Belgium), Brussels, Belgium, ³Erasme Hospital, Brussels, Belgium, ⁴HUB Hôpital Erasme, Brussels, Belgium, ⁵Cliniques Universitaires de Bruxelles, Brussels, Belgium

(800) Successful Left Ventricle Assist Device Implant in a Patient with Acute Heart Failure with Biventricular Dysfunction; R. Sadraldin¹, A. Bakhsh², A. Alkhaldi³, A. Ezzaldeen². ¹Prince Sultan Cardiac Center, Riyadh, Saudi Arabia, ²PSCC, Riyadh, Saudi Arabia, ³King Abdulaziz Medical Center, Riyadh, Saudi Arabia

(801) Debilitating Tremor and Hallucinations After Tacrolimus in a Heart Transplant Patient; D. Jenca, V. Melenovsky, J. Kautzner. Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic

(802) WITHDRAWN

(803) Orthotopic Heart Transplantation Complicated by Chylopericardium: Management and Intervention; A. Challa¹, H. Valand², M. J. Thomas¹, K. Felpel¹, A. Haleem¹, L. Lagazzi¹, J. Mehaffey¹, A. Toker¹, M. Caccamo¹, G. Sokos¹, C. Bianco¹. ¹West Virginia University, Morgantown, WV, ²Trinity Health System, Steubenville, OH

(804) Eosinophilic Myocarditis After Heart Transplantation; M. Heringer¹, G. Campos¹, S. Moraes¹, S. Mangini¹, X. José Leudo¹, A. Barbara¹, F. Bacal². ¹Hospital Israelita Albert Einstein, São Paulo, Brazil, ²University of Sao Paulo, São Paulo, Brazil

(805) Reactivation of Chagas Disease; S. M. Moraes¹, M. Heringer¹, G. Campos¹, L. Xavier¹, S. Mangini², F. Bacal³. ¹Hospital Israelita Albert Einstein, Sao Paulo, Brazil, ²Heart Institute, São Paulo, Brazil, ³University of Sao Paulo, Sao Paulo, Brazil

(806) Recurrent CardioMEMS Device-Related Infection Post Heart Transplant; A. Aijaz¹, Y. A. Wahid², J. Amione Guerra¹, J. Gorthi¹. ¹Advanced Heart Failure and Transplant Cardiology, Houston Methodist Hospital, Houston, TX, ²Aga Khan University, Karachi, Pakistan

(807) Gender Trends of Left Ventricular Assist Device Insertion in Australia; N. Raftopoulos¹, L. Nedkoff¹, N. Bart². ¹The Victor Chang Cardiac Research Institute, Sydney, Australia, ²St Vincent's Hospital, Sydney, Australia

(808) Ethnic Disparities in Clinical Characteristics and Outcomes of LVAD Implantation: A Comparative Analysis Between Hispanic and Non-Hispanic Patients; P. O. Diaz, Jr.¹, J. Fleites², R. Severdija², U. Hooda², Y. Natori¹, J. Simkins³, J. M. Hare¹, J. Bauerlein¹, H. Butrous², A. Phanco¹, S. Anjan³, M. Munagala³. ¹University of Miami Miller School of Medicine, Miami, FL, ²University of Miami / Jackson Health System, Miami, FL, ³University of Miami Miller School of Medicine / Miami Transplant Institute, Miami, FL

(809) Racial Disparities in Clinical Characteristics and Outcomes of LVAD Implantation: A Comparative Analysis Between Black and White Patients; P. O. Diaz, Jr.¹, J. Fleites², R. Severdija², U. Hooda², Y. Natori¹, J. Simkins³, J. M. Hare¹, J. Bauerlein¹, H. Butrous², A. Phanco¹, S. Anjan³, M. Munagala³. ¹University of Miami Miller School of Medicine, Miami, FL, ²University of Miami / Jackson Health System, Miami, FL, ³University of Miami Miller School of Medicine / Miami Transplant Institute, Miami, FL

(810) Right Heart Reserve Function Assessed with Fluid Loading Test Predicts Late Right Heart Failure in Patients Undergoing Left Ventricular Assist Device Implantation; M. Tsujii, T. Kurihara, Y. Isotani, C. Bujo, J. Ishida, E. Amiya, M. Hatano, M. Kimura, S. Shimada, M. Ando, M. Ono, I. Komuro. The University of Tokyo, Tokyo, Japan

(811) Left Ventricular Assist Device Recipients with a History of Cardiovascular Disease or Cardiothoracic Surgery Have Increased Mortality; B. O'Connor¹, S. S. Scott¹, S. Smith². ¹The Ohio State University Wexner Medical Center, Columbus, OH, ²Department of Cardiovascular Medicine, The Ohio State University Wexner Medical Center, Columbus, OH

(812) Novel Machine Learning Algorithms for Predicting Early Right Heart Failure Post Left Ventricular Assist Device Implantation: An Analysis from Theeuromacs Registry; M. Abdelshafy¹, O. Soliman², A. Simpkin³, K. Veen⁴, A. Elkoumy³, H. Elzomor³, T. De By⁵, B. Logstrup⁶, A. Loforte⁷, F. Schoenrath⁸, E. Potapov⁹, L. Paluszkiwicz¹⁰, J. Gummert¹¹, P. Mohacs¹², B. Meyns¹³, K. Caliskan¹⁴. ¹National University of Ireland Galway (NUIG), Galway, Ireland, ²National University of Ireland Galway, Galway, Ireland, ³University of Galway, Galway, Ireland, ⁴Erasmus MC, Rotterdam, Netherlands, ⁵EACTS House, Windsor, United Kingdom, ⁶Aarhus Univ Hospital, Aarhus, Denmark, ⁷University of Turin, Turin, Italy, ⁸Deutsches Herzzentrum Berlin, Berlin, Germany, ⁹German Heart Institute, Berlin, Germany, ¹⁰Heart and Diabetes Centre NRW, Ruhr-University Bochum, Bad Oeynhausen, Germany, ¹¹Herz und Diabeteszentrum NRW, Bad Oeynhausen, Germany, ¹²HerzGefässZentrum im Park, Zurich, Switzerland, ¹³UZ Leuven, Leuven, Belgium, ¹⁴Cardiology, Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands

(813) Outcomes Associated with Protekduo Right Ventricular Assist Device; M. Atienza, U. Jorde, D. Goldstein, O. Saeed, S. Vukelic, S. Patel, S. Murthy, M. Uehara, S. Forest, J. Borgji, D. Sims. Montefiore Medical Center, Bronx, NY

(814) Pre-Implant Pulmonary Artery Pulsatility Index and Its Relationship with Early Right Ventricular Failure After Left Ventricular Assist Device Implantation: An INTERMACS Analysis; V. Truong¹, T. Ngo², S. Pham³, E. Chung⁴, I. Rajapreyar⁵, J. Rame⁵. ¹Nazareth Hospital, Philadelphia, PA, ²Pham Ngoc Thach University of Medicine, Ho Chi Minh, Viet Nam, ³Mayo Clinic, Jacksonville, FL, ⁴The Christ Hospital Health Network, Cincinnati, OH, ⁵Thomas Jefferson University Hospital, Philadelphia, PA

(815) Pre-Implant Right Ventricular Strain Predicts Right Heart Failure After Left Ventricular Assist Device Therapy: A Systematic Review and Meta-Analysis; V. Truong¹, T. Ngo², D. Huynh³, A. Ngo⁴, N. Tran⁵, I. Rajapreyar⁶, J. Rame⁶, E. Chung⁷. ¹Nazareth Hospital, Philadelphia, PA, ²Pham Ngoc Thach University of Medicine, Ho Chi Minh, Viet Nam, ³See Mar Marysville, Marysville, WA, ⁴University of Pittsburgh Medical Center, McKeesport Hospital, Pittsburgh, PA, ⁵Weiss Memorial Hospital, Chicago, IL, ⁶Thomas Jefferson University Hospital, Philadelphia, PA, ⁷The Christ Hospital Health Network, Cincinnati, PA

(816) Best Practices to Manage Right Ventricular Dysfunction in Patients with Left Ventricular Assist Device Therapy; J. Stokes¹, A. Brandt¹, S. Gupta¹, S. Emami¹, G. Answini¹, A. Mehal², C. Bartone¹, E. S. Chung³, G. Egnaczyk³. ¹Christ Hospital, Cincinnati, OH, ²University of Cincinnati, Cincinnati, OH, ³The Christ Hospital, Cincinnati, OH

(817) Successful Plasma Exchange to Remove Heparin-Induced-Thrombocytopenia Antibodies Prior to LVAD Implantation: A Case Series; D. Agakishiev¹, A. Ngo-Hamilton¹, B. Ramu¹, M. Mazepa¹, M. Reding¹, C. Martin², T. Alexy¹, J. Schultz¹, V. Maharaj¹, R. John¹, A. Shaffer¹, F. Kamdar¹, D. Garry¹, R. Cogswell¹. ¹University of Minnesota, Minneapolis, MN, ²Methodist DeBakey Heart & Vascular Center, Houston Methodist Hospital, Houston, MN

(818) Anti-Factor Xa and Activated Partial Thromboplastin Time Strategies for Heparin Dosing After HeartMate3 Left Ventricular Assist Device Implantation; I. Feng¹, P. A. Kurlansky², T. R. Powley¹, A. V. Vinogradsky¹, M. A. Hynds¹, C. G. Yang¹, J. M. Hastie³, L. D. Sutherland³, H. Shih¹, M. Yuzefpolskaya⁴, P. C. Colombo⁴, G. T. Sayer⁴, Y. Naka¹, N. Uriel⁴, K. Takeda¹. ¹Division of Cardiothoracic and Vascular Surgery, Department of Surgery, Columbia University Irving Medical Center, New York, NY, ²Department of Surgery, Center of Innovation and Outcomes Research, Columbia University Irving Medical Center, New York, NY, ³Department of Anesthesiology, Columbia University Irving Medical Center, New York, NY, ⁴Department of Cardiology, Columbia University Irving Medical Center, New York, NY

(819) Evaluation of Platelet Activation by Flow Cytometry in Contemporary Continuous Flow Left Ventricular Assist Device Support; K. Muthiah¹, D. Connor², H. Eckford¹, D. Robson¹, J. Joseph², C. Hayward¹. ¹St. Vincent's Hospital, Sydney, Australia, ²St Vincent's Center for Applied Medical Research, Sydney, Australia

(820) Enhancing Outpatient LVAD Care: Utilizing Enoxaparin Bridging to Reduce Hospital Readmissions and Improve Patient Outcomes; D. Varghese¹, J. Raju¹, M. Thomas¹, M. Edwards¹, C. Fitzsimmons¹, K. Rosales¹, K. Holzwarth¹, L. K. Truby¹, M. Farr¹, S. Garg¹, N. S. Hendren¹, F. Araj¹, A. A. Amin². ¹UT Southwestern Medical Center, Dallas, TX, ²Texas Health Heart and Vascular Fort Worth and Texas Health Fort Worth Hospital, Fort Worth, TX

(821) Influence of Environmental Temperature on the Occurrence of Driveline Infection in LVAD Patients; F. Cali¹, A. Pinsino¹, A. Ladanyi¹, G. M. Mondellini¹, C. Maguire², G. Alonzo², J. Green², C. Lee¹, G. Sayer¹, Y. Kaku¹, N. Uriel¹, K. Takeda¹, M. Yuzefpolskaya¹, P. C. Colombo¹. ¹Columbia University Irving Medical Center, New York, NY, ²New York Presbyterian Hospital, New York, NY

(822) Routine vs. Selective Distal Perfusion Catheter Use in Venous-Arterial Extracorporeal Membrane Oxygenation?; K. G. Buda¹, E. Cravero², L. Stanberry², P. M. Eckman¹, K. Hryniewicz¹. ¹Allina Health-Minneapolis Heart Institute, Minneapolis, MN, ²Minneapolis Heart Institute Foundation, Minneapolis, MN

(823) Hemodynamic Effects of Pacing in Patients with Durable Left Ventricular Assist Devices (LVAD); R. E. Akdogan¹, E. Kozaily¹, M. Rofael², S. Fu³, D. Silverman¹, J. Atkins¹, C. Inampudi¹, G. Jackson¹, J. M. Griffin¹, V. Rao¹, J. Hajj¹, L. Witer¹, A. Kilic¹, B. Houston¹, R. Tedford¹, A. Carnicelli¹. ¹Medical University of South Carolina, Charleston, SC, ²Prisma Health, Columbia, SC, ³University of Louisville, Lexington, KY

(824) Comparison of Microcirculatory Function in Patients with HeartMate 3 LVAD and Healthy Controls; J. Baranowska¹, C. Lee¹, S. Rahman¹, A. Fernandez Valledor¹, C. Moeller¹, G. Rubinstein¹, D. Oren¹, K. Oh¹, A. Rahman¹, D. Bae¹, J. Raikhelkar¹, V. Topkara¹, M. Yuzefpolskaya¹, D. Lotan¹, E. DeFilippis¹, K. Theodoropoulos¹, E. Lin¹, D. Majure², K. Clerkin¹, F. Latif¹, J. Fried¹, P. Colombo¹, G. Sayer¹, N. Uriel¹. ¹Columbia University Irving Medical Center, New York, NY, ²Weill Cornell Medical College, New York, NY

(825) Demographics and Clinical Parameters That Impact the Long-Term Survival of LVAD Patients - A Trinetx Database Analysis; N. Nair¹, D. Du². ¹Medicine/Cardiology, Penn State Health/Milton S Hershey Med Ctr, Hershey, PA, ²Industrial, Manufacturing & Systems Engineering, Texas Tech University, Lubbock, TX

(826) Mental Health/Substance Use Disorders in VAD Patients - A Trinetx Database Analysis; N. Nair¹, C. Grzyb², D. Du³. ¹Medicine/Cardiology, Penn State Health/Milton S Hershey Med Ctr, Hershey, PA, ²Medicine, Penn State College of Medicine, Hershey, PA, ³Industrial, Manufacturing & Systems Engineering, Texas Tech University, Lubbock, TX

(827) Use of Speckle Tracking Echo to Predict Right Heart Failure Following Left Ventricular Assist Device Implantation: A Systematic Review and Meta-Analysis; J. Frye, M. Tao, E. Tam, M. Goldschmidt, N. Dianati, S. Kort. Stony Brook University Hospital, Stony Brook, NY

(828) Comparing a Low/No Warfarin Population versus Therapeutic in a Heartmate 3 Population; M. Osorio Nader¹, D. Gupta². ¹Emory University School of Medicine, Atlanta, GA, ²Advanced Heart Failure and Transplant Cardiology, Emory University School of Medicine, Atlanta, GA

(829) The Forgotten Pump - Waitlist & Post-Transplant Outcomes of Heart Transplant Recipients Supported by Heartware HVAD Before & After Device Recall; F. Hussain, A. Jawaid, R. Morlend, M. Thomas, N. Hendren, J. Weston, C. Heid, K. Ginder, E. Hardin, F. Araj, M. Farr, M. Peltz, L. Truby. UT Southwestern Medical Center, Dallas, TX

(830) Guideline-Directed Medical Therapy Use in a Contemporary Multicenter Cohort of Hm3 LVAD Recipients; M. Zhao¹, M. Cevasco², H. Billard³, A. DeVore⁴, C. Milano⁵, F. Sheikh⁶, M. Genuardi¹, L. Blue⁵, K. Dougherty¹, J. Marble⁷, K. Kurcik¹, M. Hallman¹, T. Sharkoski¹, H. Vidula¹. ¹University of Pennsylvania, Philadelphia, PA, ²Hospital of the University of Pennsylvania, Philadelphia, PA, ³Duke Univ Med Ctr, Durham, NC, ⁴Duke University, Durham, NC, ⁵Duke University Medical Center, Durham, NC, ⁶MedStar Heart and Vascular Institute, Georgetown University School of Medicine, Washington DC, DC, ⁷Univ of Pennsylvania, Philadelphia, PA

(831) Outcomes of Patients with Peripartum Cardiomyopathy Requiring LVAD Support: A Single-Center Experience; A. Radakrishnan¹, M. Cagliostro², J. Roldan², S. Bonenfant², T. Sparaco², S. Itagaki³, A. Anyanwu³, J. Contreras², N. Moss². ¹Dept of Med, Icahn SoM at Mount Sinai, New York, NY, ²Div of Cardiology, Icahn SoM at Mount Sinai, New York, NY, ³Dept of CV Surgery, Icahn SoM at Mount Sinai, New York, NY

(832) The Utility of Conventional and Novel Hm3 Pump Parameters in the Assessment of Haemodynamic Changes: A Mock Loop Study; M. N. Saweris¹, R. Campos Deveza e Silva², C. Hayward³, P. Jain⁴, S. Barua⁴, K. Muthiah³, T. Abart⁵, T. Schloeglhofer⁶. ¹Mechanical Circulatory Support Team, St Vincent's Hospital, Sydney, Australia, ²St Vincent's Hospital, Sydney, Australia, ³St. Vincent's Hospital, Sydney, Australia, ⁴St Vincent's Hospital, Sydney, Australia, ⁵Medizinische Universität Wien, Vienna, Austria, ⁶Medical University of Vienna, Vienna, Austria

(833) The Impact of Body Surface Area and Left Ventricular Size on Outcomes Following Durable LVAD Implantation; A. Zviman¹, G. Rubin¹, E. Molina², S. Rao¹, J. Chou³, N. Afari-Armah¹, A. Kadakkal⁴, M. Pinilla Vera⁴, M. Krishnan¹, R. Gupta¹, M. Rodrigo⁴, M. Hofmeyer¹, K. Balsara¹, P. H. Lam¹, F. Sheikh¹. ¹MedStar Heart and Vascular Institute, Georgetown Univ SoM, Washington, DC, ²Piedmont Heart Institute - Samsky Advanced Heart Failure Ctr, Atlanta, GA, ³MedStar Health Research Inst, Washington, DC, ⁴MedStar Heart and Vascular Inst, Washington, DC

(834) Markers of Recovery in CF-VAD Patients: Tool for Predicting Outcomes or Not?; A. M. Pico, K. Drezek, J. Guiry, A. Ramsay, T. Winship, D. D'Alessandro, E. Coglianese. Massachusetts General Hospital, Boston, MA

(835) Peri-Implant Renal Replacement Therapy and Mortality in a Contemporary Multicenter Registry of Heartmate 3 LVAD Recipients; M. V. Genuardi¹, M. Zhao¹, N. Moss², A. Radakrishnan³, A. Kilic⁴, B. Welch⁴, O. Saeed⁵, P. Mendapara⁵, A. Jawaid⁶, S. Shah⁷, G. Marecki⁸, D. Moin⁹, S. Chawla¹⁰, M. Mehta¹¹, P. Atluri¹, H. Vidula¹. ¹Univ of Pennsylvania, Philadelphia, PA, ²Mount Sinai Hosp, New York, NY, ³Mount Sinai Hosp, New York, NY, ⁴Med Univ of South Carolina, Charleston, SC, ⁵Montefiore Med Ctr, New York, NY, ⁶UT Southwestern, Dallas, TX, ⁷Northwell, New York, NY, ⁸Northwell, New York, NY, ⁹NYU Langone, New York, NY, ¹⁰Robert Wood Johnson, New Brunswick, NJ, ¹¹Tufts Univ, Boston, MA

(836) Mechanism and Clinical Impact of Late Tricuspid Regurgitation in Patients with Heartmate 3; H. Hayashi¹, A. Vinogradsky², H. Melissa¹, M. Yuzefpolskaya³, P. Kuransky¹, P. Colombo⁴, G. Sayer⁵, N. Uriel⁶, Y. Naka⁷, K. Takeda⁴. ¹Cardiothoracic Surgery, Columbia University Medical Center: Columbia University Irving Medical Center, New York, NY, ²Cardiothoracic Surgery, Columbia University Irving Medical Center, New York, NY, ³Columbia University Medical Center, New York, NY, ⁴Columbia University, New York, NY, ⁵Columbia University Irving Medical Center, New York, NY, ⁶New York Presbyterian, New York, NY, ⁷New York Presbyterian Hospital, New York, NY

(837) Trending Renal Function Pre- and Post-Left Ventricular Assist Device (LVAD) Implantation; N. Newman, A. Sharma, M. T. Brown, J. Cobb, M. Abdou. Emory University, Atlanta, GA

(838) Sodium Glucose Transporter 2 Inhibitors and Clinical Outcomes in Patients with Left Ventricular Assist Devices; A. Fardman¹, E. Masalha², E. Maor², E. Potapov³, V. Falk⁴, M. Müller⁵, C. Hoermandinger⁵, I. Just-Lauer⁵, F. Schoenrath⁶, J. Mulzer³. ¹Chaim Sheba Medical Center, Ramat-Gan, Israel, ²Cardiology, Sheba Medical Center, Ramat-Gan, Israel, ³German Heart Institute, Berlin, Germany, ⁴Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charité, Berlin, Germany, ⁵Deutsches Herzzentrum der Charité, Berlin, Germany, ⁶Deutsches Herzzentrum Berlin, Berlin, Germany

(839) Cessation of Anticoagulation in Patients with Fully Magnetically Levitated Ventricular Assist Device - A Case Series; V. J. Copeland, Y. Wasserstrum, A. Morgan, A. Grupper, Y. Peled, A. Fardman. Chaim Sheba Medical Center, Tel-Hashomer, Israel

(840) Exercise Test and Hemodynamic Outcomes in Heart Transplant Patients Treated with Long-Term Mechanical Circulatory Support as Bridge to Transplantation; S. Esmaily¹, E. Bobbio¹, M. Holmberg², K. Karason¹, E. Bollano¹, S. Bartfay¹. ¹Sahlgrenska University Hospital, Gothenburg, Sweden, ²University of Gothenburg, Gothenburg, Sweden

(841) Association of Longitudinal Changes in NT-proBNP Following HeartMate 3 Implant with Subsequent Long-Term Clinical Outcomes; A. Jawaid, J. D. Alexis, A. Godishala, L. Chen, S. Thomas, M. Tallman, S. McNitt, B. Polonsky, S. Sherazi, K. Wood, I. Gosev, I. Goldenberg. University of Rochester Medical Center, Rochester, NY

(842) Ramp Tests in LVAD Patients: Let's Have a Look to Your Numbers or the Position of Your Pump?; M. Masetti¹, L. Riccò², C. Marcelli³, V. Sacchetti³, L. Giovannini³, L. Borgese⁴, L. Botta⁵, S. Martin Suarez⁵, M. Antonini², D. Pacini⁶, L. Potena¹. ¹HF and Transplant Unit, IRCCS Azienda Ospedaliero-Univ di Bologna, Bologna, Italy, ²Dept of Biomedical, Metabolic & Neural Sci, Univ of Modena and Reggio Emilia, Modena, Italy, ³HF and Transplant Unit, IRCCS Azienda Ospedaliero-Univ di Bologna,, Bologna, Italy, ⁴HF and Transplant Unit, IRCCS Azienda Ospedaliero-Univ di Bologna,, Univ of Bologna, Bologna, Italy, ⁵Div of Cardiac Surg, Cardiac Surg Dept, IRCCS, Azienda Ospedaliero-Univ di Bologna, Bologna, Italy, ⁶Div of Cardiac Surg, Cardiac Surg Dept, IRCCS, Azienda Ospedaliero-Univ di Bologna, Univ of Bologna, Bologna, Italy

(843) Continuous Flow VAD in Adult Patients with Fontan Circulation; M. Guglin, R. Rao, K. Soghoyan. *Indiana University, Indianapolis, IN*

(844) Characterization and Treatment of Iron Deficiency in Left Ventricular Assist Device Patients; K. Fox¹, M. Dean², R. Acheson³, J. Chery⁴, Z. Hashmi⁴, V. Kasirajan⁴, R. Cooke³, H. Patel³, K. Rao³, I. Tchoukina³, M. Smallfield³, K. Shah³. ¹*Cardiovascular Disease, Virginia Commonwealth University Health System, Richmond, VA*, ²*Internal Medicine, Virginia Commonwealth University Health System, Richmond, VA*, ³*Advanced Heart Failure and Transplant, Virginia Commonwealth University Health System, Richmond, VA*, ⁴*Cardiothoracic Surgery, Virginia Commonwealth University Health System, Richmond, VA*

(845) The R-Wave Amplitude Negatively Correlates with Preload in Stable Ventricular Assist Device Patients During Acute Postural Changes; S. A. Dual¹, P. Jain², M. Schmid Daners³, C. Hayward⁴. ¹*Biomedical Engineering and Health Systems, KTH Royal Institute of Technology, Stockholm, Sweden*, ²*Royal Prince Alfred Hospital, Sydney, Australia*, ³*Institute for Dynamic Systems and Control, ETH Zurich, Zurich, Switzerland*, ⁴*St. Vincent's Hospital, Sydney, Australia*

(846) A Multidisciplinary Approach to Reduce Length of Stay Post Ventricular Assist Device Implant; D. Ly¹, T. Pidborochynski², H. Buchholz¹, L. Carter³, L. Carter¹, L. Mowat¹, A. Racic¹, J. Engerdahl¹, O. Zelaya¹, N. Shanahan¹, P. Butterfield¹, N. Moyo¹, J. Conway⁴. ¹*University of Alberta Hospital, Edmonton, AB, Canada*, ²*University of Alberta, Edmonton, AB, Canada*, ³*Canada*, ⁴*Stollery Children's Hospital, Edmonton, AB, Canada*

(847) Predictive Value of the DBIL/TBIL Ratio for Early Right Heart Failure Following Left Ventricular Assist Device Implantation; Q. Ping, S. Zhao, X. Wang, J. Du, L. Zou, X. Zhou, H. Chen, F. Duan, S. Yuan, J. Shi, B. Ji, S. Hu. *State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China*

(848) Heartmate 3 Risk Score Predicts 30-Day Mortality After LVAD Implantation; A. Ramsay, K. Drezek, J. Guiry, A. Pico, G. Lewis, E. Coglianese, B. Yang. *Massachusetts General Hospital, Boston, MA*

(849) The Ability of CPET to Predict TR Dynamics Post LVAD; B. Elad, D. Lotan, C. Lee, A. Rahman, W. Rzechorzek, G. Sayer, R. Shah, P. Colombo, M. Yuzefpolskaya, J. Raikhelkar, K. Clerkin, J. Fried, K. Takeda, Y. Kaku, N. Uriel. *Columbia University Irving Medical Center, New York, NY*

(850) Measured Resting Energy Expenditure and Predicted Basal Metabolic Rate Early After Left Ventricular Assist Device Implantation; D. Celkupa¹, B. Sweigart², S. Hummel³, J. Chery⁴, E. Saltzman⁵, A. Vest². ¹*Touro College of Osteopathic Medicine, New York, NY*, ²*Tufts Medical Center, Boston, MA*, ³*Univ of Michigan, Ann Arbor, MI*, ⁴*Tufts University School of Medicine, Boston, MA*, ⁵*Friedman School of Nutrition Science and Policy, Tufts University, Boston, MA*

(851) A Terrible Bloody Tamponade: A Case of Delayed Hemorrhagic Cardiac Tamponade Post Left Atrial Appendage Occlusion; S. Allihien¹, S. Ibrahim², S. Shreyas³, D. B. Haithcock⁴, T. Magruder³, C. Marti⁵. ¹*Piedmont Athens Regional Medical Center, Piedmont Athens Regional, GA*, ²*Piedmont Arthens Regional, Athens, GA*, ³*Piedmont Athens Regional, Athens, GA*, ⁴*Piedmont Heart Institute Athens, Athens, GA*, ⁵*Piedmont Heart Institute, Athens, GA*

(852) Daratumumab Monotherapy in Combination with VA ECMO as a Bridge to Heart Transplantation for AI Amyloid Cardiomyopathy; A. Doshi¹, S. Nandkeolyar¹, N. Cyrille¹, R. Garcia¹, P. Patel¹, T. Frank², S. Gulati², S. Zouzoulas¹, J. Singh¹, J. Mishkin¹. ¹*Sanger Heart and Vascular Institute, Charlotte, NC*, ²*Sanger Heart & Vascular Institute, Charlotte, NC*

(853) Concomitant Diagnosis of Myotonic Dystrophy (DM) and Takotsubo Cardiomyopathy (CM) Treated with Extracorporeal Membrane Oxygenation (ECMO); M. Jacobs¹, E. Katznelson¹, R. Murphy¹, C. Liu¹, C. Zhang¹, L. Kim¹, B. Worku², Y. Naka³, R. Bhatt⁴, N. Wan⁴, J. McLeod⁴, D. Lu¹, I. Sobol¹. ¹*Weill Cornell Medicine-New York Presbyterian, New York, NY*, ²*NYP Weill Cornell Medical Center, New York, NY*, ³*New York Presbyterian Hospital, New York, NY*, ⁴*New York Presbyterian - Queens, New York, NY*

(854) From Prescription to Predicament: Hydroxychloroquine (HCQ)-Induced Cardiogenic Shock (CS); L. Pi¹, A. Al-Busaidi¹, R. Gilead¹, D. H. Brahmhatt¹, Y. Xie², N. Aleksova¹, A. Luk¹, J. Duero Posada¹, Y. Moayed¹, M. A. Seidman³, M. Laflamme³, R. J. Cusimano⁴, J. Alvarez⁴, E. Fan⁵, H. Faghfoury⁶, F. Billia¹. ¹*Division of Cardiology, Department of Medicine, University Health Network, Toronto, ON, Canada*, ²*Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada*, ³*Laboratory Medicine Program, University Health Network, Toronto, ON, Canada*, ⁴*Division of Cardiothoracic Surgery, Department of Surgery, University Health Network, Toronto, ON, Canada*, ⁵*Interdepartmental Division of Critical Care Medicine, University Health Network, Toronto, ON, Canada*, ⁶*Fred A. Litwin Family Centre in Genetic Medicine, University Health Network & Mount Sinai Hospital, Toronto, ON, Canada*

(855) Total Artificial Heart as Bridge to Transplant in a Patient with Cardiogenic Shock, Biventricular Thrombi, and Multisystem Thromboembolic Events; E. Flattery¹, A. Kumar², R. I. Goldberg¹, B. Kadosh¹, A. Singh¹, A. Reyentovich¹, D. E. Smith², N. Moazami². ¹*Division of Cardiology, NYU Langone Medical Center, New York, NY*, ²*Division of Cardiothoracic Surgery, NYU Langone Medical Center, New York, NY*

- (856) Enhancing Exercise Capacity in Exercise-Induced Pulmonary Hypertension: A Retrospective Study of Riociguat Therapy;** A. Basheer, R. Vunnam, A. Azmeen, R. Zolty. *University of Nebraska Medical Center, Omaha, NE*
- (857) Improvements in Pulmonary Artery Compliance After Balloon Pulmonary Angioplasty Depend on Baseline Pulmonary Vascular Resistance;** M. S. Delfiner¹, E. Oliveros², H. Zhao³, A. Vaidya², V. Lakhter², P. R. Forfia², W. Auger⁴, R. Bashir². ¹Cardiovascular Medicine, Perelman SoM at the Univ of Pennsylvania, Philadelphia, PA, ²Cardiovascular Medicine, Lewis Katz SoM at Temple Univ, Philadelphia, PA, ³Department of Biomedical Education and Data Science, Temple Univ, Philadelphia, PA, ⁴Univ of California, San Diego, San Diego, CA
- (858) A Transthoracic Echocardiography (TTE) Based PH Detection Model Using View Agnostic Classifier;** P. Damasceno¹, S. Fadnavis¹, N. Emaminejad¹, A. Ulloa Cerna¹, C. Parmar², K. Standish², T. Mansi³, P. Dunnmon³, T. Yardibi¹, M. Selej¹. ¹Johnson & Johnson Innovative Medicine, Boston, MA, ²Johnson & Johnson Innovative Medicine, La Jolla, CA, ³Johnson & Johnson Innovative Medicine, New Brunswick, NJ
- (859) Treatment Patterns for Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH) in Finland Between 2008 and 2020 - A Descriptive Real-World Cohort Study (FINPAH);** M. Pentikäinen¹, P. Simonen², H. Tuunanen³, P. Leskelä⁴, T. Harju⁵, P. Jääskeläinen⁶, C. Asseburg⁷, M. Oksanen⁷, E. Soini⁷, C. Wennerström⁸, A. Puhakka⁹. ¹Helsinki Univ Hospital, Helsinki, Finland, ²Helsinki Univ Hospital, Helsinki, Finland, ³Turku Univ Hospital, Turku, Finland, ⁴Tampere Univ Hospital, Tampere, Finland, ⁵Oulu Univ Hospital, Oulu, Finland, ⁶Kuopio Univ Hospital, Kuopio, Finland, ⁷Esior Oy, Kuopio, Finland, ⁸Janssen-Cilag AB, Solna, Sweden, ⁹Janssen-Cilag Oy, Espoo, Finland
- (860) Prognostic Significance of Positive Vasoreactivity Test in Pulmonary Arterial Hypertension is Affected by Age;** C. Hjalmarsson¹, G. Radegran², E. Björklund³, A. Hjalmarsson⁴, M. Nisell⁵, J. Papageorgiou⁶, S. Soderberg⁷, H. Wahlander⁸, B. Kjellström⁹. ¹Cardiology, Sahlgrenska Univ Hospital, Göteborg, Sweden, ²Cardiology, Clinical Sciences Lund, Clinical Physiology, Skane Univ Hospital, Lund, Sweden, ³Cardiology, Hospital of Uppsala, Uppsala, Sweden, ⁴Sahlgrenska Academy, Gothenburg Univ, Göteborg, Sweden, ⁵Lung Unit, Department of Medicine, Karolinska Institute and Karolinska Univ Hospital, Stockholm, Sweden, ⁶Cardiology, Univ Hospital in Linköping, Sweden, Linköping, Sweden, ⁷Department of Public Health, Clinical Medicine and Heart Centre, Umeå Univ, Umeå, Sweden, ⁸Pediatric Heart Center, The Queen Silvia Children's Hospital, Sahlgrenska Univ Hospital, Gothenburg, Sweden, ⁹Clinical Sciences Lund, Clinical Physiology, Skane Univ Hospital, Lund, Sweden
- (861) Low Right Atrial Emptying Fraction is a Better Predictor of Incident Atrial Fibrillation and Flutter in Patients with Pulmonary Arterial Hypertension;** P. Worapongsatitaya, D. Mohama, F. Kazmirczak, K. Prins, S. Z. Prisco, E. K. Weir, T. Thenappan. *University of Minnesota, Minneapolis, MN*
- (862) Comparison of the Prognostic Value of Right Atrial Volume, Area, and Emptying Fraction in Patients with Pulmonary Artery Hypertension;** D. Mohama¹, P. Worapongsatitaya², F. Kazmirczak¹, K. Prins¹, S. Prisco³, W. Edward¹, T. Thenappan¹. ¹Internal Medicine, Cardiovascular Division, University of Minnesota, Minneapolis, MN, ²Internal Medicine, Cardiovascular Division, University of Minnesota Medical School, Minneapolis, MN, ³University of Minnesota, Minneapolis, MN
- (863) Camphor Quality of Life Scores for Patients Diagnosed with Pulmonary Arterial Hypertension in Brazil and Colombia;** C. Vizza¹, R. Klok², J. Harley³, M. Small³, J. White⁴, D. Lautsch². ¹Pulmonary Hypertension Unit, Department of Cardiovascular and Respiratory Disease, La Sapienza University of Rome, Rome, Italy, ²Center for Observational and Real-world Evidence, Merck & Co., Inc., Rahway, NJ, ³Adelphi Real World, BOLLINGTON, United Kingdom, ⁴University of Rochester Medical Center, Rochester, NY
- (864) Endothelin-1 Levels in Exercise-Induced Pulmonary Hypertension;** R. Zolty¹, H. Brink², K. Dhar³, B. Lowes⁴. ¹Cardiology, University of Nebraska Medical Center, Omaha, NE, ²Pharmacology, Nebraska Medical Center, Omaha, NE, ³Cardiology, Univ of Nebraska Med Ctr, Omaha, NE, ⁴University of Nebraska Medical Center, Omaha, NE
- (865) Hemodynamically Derived Right Ventricular Diastolic Stiffness Predicts Mortality in Pulmonary Arterial Hypertension;** R. Vanderpool¹, Z. Liu¹, C. Fauvel², S. Lin¹, P. Correa-Jaque¹, M. Kanwar³, J. Kraisangka⁴, A. Perer⁵, A. Everett⁶, R. Benza⁷. ¹The Ohio State University, Columbus, OH, ²CHU Charles Nicolle, Rouen, Rouen, France, ³Allegheny General Hospital, Pittsburgh, PA, ⁴Mahidol University, Mahidol, Thailand, ⁵Carnegie Mellon University, Pittsburgh, PA, ⁶Johns Hopkins University SoM, Baltimore, MD, ⁷Mount Sinai Icahn School of Medicine, New York City, NY
- (866) Right Ventricular Contractile Reserve in Cardiopulmonary Diseases: A Simultaneous Hemodynamic and 3D Echocardiographic Study;** C. Baratto¹, C. Dewachter², D. Muraru³, G. Perego³, M. Senni⁴, L. P. Badano¹, G. Parati⁵, J. Vachiéry⁶, S. CARAVITA⁷. ¹Cardiology, IRCCS Istituto Auxologico Italiano Ospedale San Luca, Milano, Italy, ²Erasme Hospital, Brussels, Belgium, ³IRCCS Istituto Auxologico Italiano Ospedale San Luca, Milano, Italy, ⁴Cardiovascular Department, ASST Papa Giovanni XXIII, Bergamo, Italy, ⁵Cardiology, IRCCS Istituto Auxologico Italiano Ospedale San Luca, Milan, Italy, ⁶Cardiology, Erasme Hospital, Brussels, Italy, ⁷University of Bergamo and Istituto Auxologico Italiano IRCCS Ospedale S Luca, Bergamo, Italy
- (867) Echocardiography in Pulmonary Arterial Hypertension Using Deep Learning Segmentation Algorithms;** B. E. Celestin¹, S. P. Bagherzadeh², E. Santana², M. Frost³, I. Mathias³, A. J. Sweatt⁴, R. Zamanian⁵, Y. Hummel³, M. Sandros⁶, G. Gomez Rendon⁷, M. Salerno⁴, F. Haddad⁸. ¹SoM, Stanford University, Palo Alto, CA, ²SoM, Stanford, Palo Alto, CA, ³US2.AI, Singapore, Singapore, ⁴Stanford, Palo Alto, CA, ⁵Stanford Univ Med Ctr, Palo Alto, CA, ⁶Johnson & Johnson, Titusville, NJ, ⁷Janssen, Titusville, NJ, ⁸Stanford University, Palo Alto, CA

(868) Fully Automated versus Core Laboratory Analysis of Tricuspid Regurgitation Maximal Velocity in Patients with Pulmonary Hypertension; B. Celestin¹, S. Bagherzadeh², E. Santana², M. Frost³, M. Iversen³, A. Sweatt², R. Zamanian⁴, Y. Hummel³, M. Sandros⁵, G. Gomez Rendon⁶, M. Salerno², F. Haddad¹. ¹Stanford University, Palo Alto, CA, ²Stanford, Palo Alto, CA, ³US2.AI, Singapore, Singapore, ⁴Stanford Univ Med Ctr, Palo Alto, CA, ⁵Johnson & Johnson, Titusville, NJ, ⁶Janssen, Titusville, NJ

(869) Transcriptional Changes in Dilated Cardiomyopathy After LVAD Treatment; K. Dhar, D. Liescheski, H. Basma, M. Urban, A. Burdorf, J. Um, B. Lowes. University of Nebraska Medical Center, Omaha, NE

(870) Intermediate-Term Outcomes of Reversed Potts Shunt in Children with Suprasystemic Pulmonary Arterial Hypertension: A Short Series of Three Chinese Patients; J. Shi¹, K. Lun², C. Hui², B. Rocha³, T. Au³. ¹Paediatrics and Adolescent Medicine, Hong Kong Children's Hospital, Hong Kong, China, ²Paediatrics and Adolescent Medicine, Hong Kong Children's Hospital, Hong Kong, China, ³Cardiothoracic Surgery, Queen Mary Hospital, Hong Kong, China

(871) Donor Derived Cell Free DNA, Gene Expression Profiles and Acute Rejection in Donation After Circulatory Death (DCD) Heart Transplant Recipients; Q. M. Bui¹, Y. Gernhofer², A. Birs³, E. Silver⁴, A. Argiro⁵, J. Cruz Rodriguez⁶, E. Adler⁷, M. Kearns⁸, M. Urey⁸, V. Pretorius⁹. ¹UC San Diego, San Diego, CA, ²University of the Incarnate Word School of Osteopathic Medicine, San Antonio, TX, ³University of California San Diego, La Jolla, CA, ⁴University of Connecticut School of Medicine, Farmington, CT, ⁵Careggi University Hospital, Florence, Italy, ⁶UC San Diego, La Jolla, CA, ⁷Univ of California, SD, La Jolla, CA, ⁸UC San Diego Health, La Jolla, CA, ⁹UCSD, La Jolla, CA

(872) Prevalence and Yield of Genetic Testing in Heart Transplant Patients; E. Silver¹, A. Argiro², Q. Bui³, A. Birs³, K. Hong³, E. Adler³. ¹University of Connecticut SoM, Farmington, CT, ²Careggi University Hospital, Florence, Italy, ³UC San Diego, La Jolla, CA

THURSDAY, 11 APRIL, 2024

4:30 - 5:30 p.m.

POSTER SESSION 2: Cardiothoracic Surgery (Non-CME)

Location: Poster Hall

Core Therapies: HEART, LUNG, MCS, PVD

Practice Areas: Cardiothoracic Surgery, Anesthesiology and Critical Care, Cardiology, Infectious Diseases, Nursing and Allied Health, Pathology, Pediatrics, Pharmacy, Pulmonology, Research and Immunology

Session Summary: Posters in this session include presentations on multiple topics where the Practice Areas of the research is focused in Cardiothoracic Surgery. Designated Poster Discussants will circulate through the poster hall during the session to engage poster presenters in quality discussions of their abstracts. **CME is not offered for poster sessions.**

Poster Discussants: Clemens Aigner, Austria, Cristiano Amarelli, Italy, Alejandro Bertolotti, Italy, Jose Luis Campo-Cañaveral de la Cruz, Spain, Pedro Catarino, USA, Lin-Chiang P Chou, USA, Stephen Clark, UK, Marc de Perrot, Canada, Caitlin Demarest, USA, Nhue Do, USA, Chidiebere Peter Echieh, Nigeria, Magdy El-Sayed Ahmed, USA, Fabian Emrich, Germany, Claudia Gidea, USA, Christian Heim, Germany, Ilker Iskender, Switzerland, Peter Ivak, Czech Republic, Ivan Knezevic, Slovenia, Akshay Kumar, USA, Nathaniel Langer, USA, Antonio Loforte, Italy, Lucian Lozonschi, USA, Allison McLarty, USA, Ezequiel Molina, USA, Nandini Nair, Basil Nasir, Canada, USA, René Novysedlák, Czech Republic, Alessandro Palleschi, Italy, Matthias Peltz, USA, Muhammad Rafiq, UK, Danny Ramzy, USA, Yazhini Ravi, USA, Sebastian Rojas, Germany, Fawwaz Shaw, USA, Yasuhiro Shudo, USA, Aleem Siddique, USA, Cumara Sivathanan, Singapore, Chiara Tessari, Italy, Zuzana Tucanova, Czech Republic, Tatsuaki Watanabe, USA, Roh Yanagida, USA, Ahmad Zeeshan, USA

(873) Outcomes in HeartMate 3 Left Ventricular Assist Device Patients Requiring Temporary Right Ventricular Assist Device Support; L. Coyle, R. Pedersen, C. Gallagher, N. Graney, L. Kukla, R. Paliga, V. Chau, G. Macaluso, S. Pauwaa, A. Tatoes, N. Narang. *Advocate Christ Medical Center, Oak Lawn, IL*

(874) Usefulness of Established Risk Scores in Predicting Right Heart Failure Requiring Temporary Right Ventricular Assist Device Support Following Left Ventricular Assist Device Implantation; L. Coyle, R. Pedersen, C. Gallagher, N. Graney, L. Kukla, R. Paliga, N. Narang, W. Cotts, M. Dela Cruz, A. Tatoes, V. Chau. *Advocate Christ Medical Center, Oak Lawn, IL*

(875) Does Cytokine Adsorption Improve Postoperative Course in Orthotopic Heart Transplantation?; R. Krey¹, A. Meyer¹, U. Tochtermann¹, W. Sommer², G. Warnecke², M. Karck¹, R. Arif¹. ¹Universitätsklinikum Heidelberg, Heidelberg, Germany, ²University of Kiel, Kiel, Germany

(876) Impact of Goal-Directed Perfusion Management During Orthotopic Heart Transplantation on Early Clinical Outcome; C. Volgmann¹, E. Joubert-Huebner¹, L. Schulte-Uentrop², Y. Al Assar¹, H. Reichenspurner¹, A. Bernhardt¹. ¹University Heart and Vascular Center Hamburg, Hamburg, Germany, ²University Medical Center Hamburg-Eppendorf, Hamburg, Germany

(877) Thoracic Organ Perfusion (TOP) Registry Annual Report - More Than 350 OCS Lung Transplants in the US; S. Huddleston¹, G. Looor², P. Garcha², M. Smith³, R. Walia⁴, S. Hashimi⁵, L. Schaheen⁶, T. Song⁷, A. Siddique⁸, N. Langer⁹, A. Lee¹⁰, J. Kukreja¹¹, M. Hartwig¹², H. Neme¹³, Y. Toyoda¹⁴, M. Daneshmand¹⁵, D. Neujahr¹⁵, L. Durham¹⁶, A. Ardehali¹⁷, E. Bush¹⁸, E. Suarez¹⁹, M. Hertz¹, G. Schwartz²⁰, T. Grazia²¹, G. Katlaps²², M. Qureshi²², E. Belli²³, K. Patel²³. ¹University of Minnesota, Minneapolis, MN, ²Baylor College of Medicine, Houston, TX, ³St. Joseph's Hosp & Med Center Norton Thoracic Institute, Phoenix, AZ, ⁴St. Joseph's Hospital and Medical Center Norton Thoracic Institute, Phoenix, AZ, ⁵Norton Thoracic Institute, Phoenix, AZ, ⁶Norton Thoracic Institute - St. Joseph's Hospital, Phoenix, AZ, ⁷University of Chicago, Chicago, IL, ⁸University of Nebraska Medical Center, Omaha, NE, ⁹Massachusetts General Hospital, Boston, MA, ¹⁰Stanford University, Palo Alto, CA, ¹¹University of California San Francisco, San Francisco, CA, ¹²Duke University Medical Center, Durham, NC, ¹³Henry Ford Hospital, Detroit, MI, ¹⁴Temple University School of Medicine, Philadelphia, PA, ¹⁵Emory University, Atlanta, GA, ¹⁶Medical College of Wisconsin, Milwaukee, WI, ¹⁷UCLA School of Medicine, Los Angeles, CA, ¹⁸Johns Hopkins, Baltimore, MD, ¹⁹Houston Methodist, Houston, TX, ²⁰Baylor Scott and White Health, Dallas, TX, ²¹Baylor University Medical Center, Dallas, TX, ²²Univ of South Florida, Tampa General Hospital, Tampa, FL, ²³University of South Florida, Tampa General, Tampa, FL

(878) Lungs from Donors with Chest Trauma Can Safely be Perfused on EVLP - and Used for Transplantation; P. M. Boehm¹, S. Auner¹, C. Hillebrand¹, S. Schwarz¹, A. Slama¹, T. Schweiger¹, E. Tschernko², C. Aigner¹, P. Jaksch¹, K. Hoetzenecker¹, A. Benazzo¹. ¹Department of Thoracic Surgery, Medical University of Vienna, Vienna, Austria, ²Department of Anesthesia, Intensive Care Medicine and Pain Medicine, Medical University of Vienna, Vienna, Austria

(879) Ex-Vivo Lung Perfusion: National Trends and Post-Transplant Outcomes; J. E. Williams¹, S. Schaefer¹, A. M. Williams², D. D. Odell³, K. H. Lagisetty³. ¹Surgery, University of Michigan, Ann Arbor, MI, ²Cardiothoracic Surgery, Duke, Durham, NC, ³Thoracic Surgery, University of Michigan, Ann Arbor, MI

(880) Grade 3 Primary Graft Dysfunction After Ex-Vivo Lung Perfusion is Associated with Better Short-Term Outcomes Compared to Direct Transplantation; A. Benazzo¹, J. Peel², M. Aversa³, S. Keshavjee⁴, M. Cypel⁵. ¹Medical University of Vienna, Wien, Austria, ²Latner Thoracic Surgery Research Laboratories, Toronto General Hospital Research Institute, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴UHN, Toronto, ON, Canada, ⁵University Health Network, Toronto, ON, Canada

(881) WITHDRAWN

(882) Comparison of Local Ventilation in Patients Very Early After Bilateral Lung Transplantation and Healthy Subjects Using Magnetic Resonance Imaging; G. H. Pöhler¹, A. Voskrebenev¹, J. Vogel-Claussen¹, F. Klimes¹, M. Heinze¹, J. Pantke¹, T. F. Kaireit¹, F. Wacker¹, A. Ruhparwar², M. Greer³, J. Salman², F. Ius². ¹Department of Diagnostic and Interventional Radiology, Hannover Medical School, Hannover, Germany, ²Clinic for Cardiothoracic, Vascular, and Transplantation Surgery, Hannover Medical School, Hannover, Germany, ³Pneumology, Hannover Medical School, Hannover, Germany

(883) Analysing the Utility of Single Lung Transplantation in Interstitial Lung Disease Using Discrete Event Simulation of Donor Organ Allocation; S. J. Kennedy¹, W. E. Scott¹, L. Freitas¹, R. Hogg², R. Johnson², J. Parmar³, A. Fisher¹. ¹Newcastle University, Newcastle upon Tyne, UK, ²Statistics and Clinical Research, NHS Blood and Transplant, Bristol, United Kingdom, ³Royal Papworth Hospital, Cambridge, UK

(884) Extended Criteria Lung Donors for Lung Transplantation in High Versus Low LAS Recipients: Should Different Acceptance Considerations Apply?; S. M. Klein¹, A. Dimitriou¹, A. Koch¹, C. Taube², M. Kamler¹, N. Pizanis¹. ¹Thoracic Transplantation, Westgerman Heartcenter Essen, University Hospital Essen, Essen, Germany, ²Pneumology, Ruhrlandklinik, University Hospital Essen, Essen, Germany

(885) Donation After Circulatory Death Has Similar Outcomes with Donation After Brain Death for Lung Transplantation; S. Y. Park¹, E. B. Hay-Arthur², H. Le², M. Schafer², J. R. Hoffman¹, M. T. Cain¹. ¹Department of Surgery, Division of Cardiothoracic Surgery, University of Colorado Anschutz Medical Campus, Aurora, CO, ²University of Colorado School of Medicine, Aurora, CO

(886) Worse Mortality and Graft Loss in Left versus Right Lung Transplants from Split Lung Donors; S. Y. Park¹, E. Bashian², N. Vigneshwar³, E. A. David¹, S. K. Randhawa¹, R. A. Meguid¹, J. D. Mitchell¹, A. L. Gray⁴, S. Arrigain⁵, E. A. Pomfret⁵, J. D. Schold⁵, M. T. Cain¹, J. R. Hoffman¹. ¹Dept of Surgery, Div of Cardiothoracic Surgery, Univ of Colorado Anschutz Medical Campus, Aurora, CO, ²Dept of Surgery, Virginia Commonwealth Univ School of Med, Richmond, VA, ³Dept of Surgery, Div of Cardiovascular and Thoracic Surgery, Duke Univ School of Med, Durham, NC, ⁴Dept of Medicine, Div of Pulmonary Sciences and Critical Care, Univ of Colorado Anschutz Medical Campus, Aurora, CO, ⁵Colorado Center for Transplantation Care, Research, and Education (CCTCARE), Univ of Colorado Anschutz Medical Campus, Aurora, CO

(887) Moderate Hypothermia with Retrograde Cerebral Perfusion Does Not Worsen Pulmonary Thromboendarterectomy Outcomes; S. Y. Park¹, H. Le², E. B. Hay-Arthur², M. Schafer³, C. Ghincea¹, T. M. Bull⁴, J. R. Hoffman¹, M. T. Cain¹. ¹Department of Surgery, Division of Cardiothoracic Surgery, University of Colorado Anschutz Medical Campus, Aurora, CO, ²University of Colorado School of Medicine, Aurora, CO, ³Department of Surgery, Division of Cardiothoracic Surgery, University of Utah School of Medicine, Salt Lake City, UT, ⁴Department of Medicine, Division of Pulmonary Sciences and Critical Care, University of Colorado Anschutz Medical Campus, Aurora, CO

(888) Outcomes of Lung Transplants Using Donors from Outside the Continental United States; R. T. Jenkins¹, E. L. Larson², A. L. Zhou², J. M. Ruck², C. Merlo², J. S. Ha², R. A. Riojas², E. L. Bush³. ¹Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Johns Hopkins, Baltimore, MD

(889) Donor Profile Changes with the Lung Composite Allocation Score; A. Krishnan, S. Elde, M. Fawad, E. Heng, A. Garrison, C. Ruaengsri, J. W. MacArthur, J. Woo, B. A. Guenthart. Cardiothoracic Surgery, Stanford University School of Medicine, Palo Alto, CA

(890) Impact of Hepatitis C Viremic Lung Donors on Waitlist Time and Outcomes in High-Risk Recipients; S. Hassanipour¹, J. Chen¹, M. Brzezinski², J. Price³, B. Trinh¹, T. Deuse¹, R. Florez⁴, S. Hays⁵, L. Leard⁵, J. Golden⁵, J. Singer⁵, J. Kukreja¹. ¹Division of Cardiothoracic Surgery, University of California San Francisco, San Francisco, CA, ²Department of Anesthesia, University of California San Francisco, San Francisco, CA, ³Division of Gastroenterology, University of California San Francisco, San Francisco, CA, ⁴Department of Pharmacy, University of California San Francisco, San Francisco, CA, ⁵Division of Pulmonary, Critical Care, and Sleep Medicine, University of California San Francisco, San Francisco, CA

(891) Predicted Total Lung Capacity is a Reliable Size-Matching Parameter in Lung Transplantation for Pulmonary Fibrosis; M. Franz, A. Mohssen, S. Tavit, N. de Manna, D. Boethig, D. Bobylev, T. Welte, M. Greer, N. Schwerk, A. Ruhparwar, A. Weymann, C. Kuehn, J. Salman, F. Ius. Hannover Medical School, Hannover, Germany

(892) Using Octogenarian Donors for Lung Transplantation Results in Good Short and Long-Term Outcome: A Single-Center Experience; C. Schoenaers¹, J. Van Slambrouck¹, C. M. Vandervelde¹, C. Vanluyten¹, H. Beeckmans², K. Denaux², P. De Leyn¹, H. Van Veer¹, L. Depypere¹, Y. Jansen¹, J. Pirenne¹, A. Provoost¹, A. Neyrinck³, S. Bouneb³, C. Ingels², B. Jacobs², D. E. Van Raemdonck¹, R. Vos², L. J. Ceulemans¹. ¹Thoracic Surgery, University Hospitals Leuven, Leuven, Belgium, ²University Hospitals Leuven, Leuven, Belgium, ³Anesthesiology, University Hospitals Leuven, Leuven, Belgium

- (893) Have Policy Changes Improved Geographical Disparities in Lung Transplantations? An Analysis of the United Network of Organ Sharing Database;** R. Sharma, V. Shah, M. Thornton, N. Nnadi, A. Pillai, D. Nelson, M. Wait, M. Peltz, V. Kaza, F. Torres, S. Keshavamurthy, W. Ring, J. Murala. *University of Texas Southwestern Medical Center, Dallas, TX*
- (894) The DCD Paradox: DCD Evaluations and Their Impact on Donor Lung Utilization;** H. D'Cunha, J. Padiyar, A. Latorre-Rodriguez, S. Tokman, R. Walia, R. Bremner, L. Schaheen. *Norton Thoracic Institute at St. Joseph's Hospital and Medical Center, Phoenix, AZ*
- (895) Healthcare Costs and Resource Utilization in the 1-Year Preceding Lung Transplantation;** R. Walia¹, S. Aryal², K. Morland³, B. Wu³, P. Classi³, M. Budev⁴. ¹*St. Joseph's Hospital and Medical Center Norton Thoracic Institute, Phoenix, AZ*, ²*Inova, Falls Church, VA*, ³*United Therapeutics Corporation, Research Triangle Park, NC*, ⁴*Cleveland Clinic, Cleveland, OH*
- (896) Racial Disparities in Minority Donors and Utilization in Lung Transplantation;** S. Gonipati¹, A. Kashem², Y. Toyoda², N. Shigemura³, A. Mishkin². ¹*Temple Univ, Philadelphia, PA*, ²*Temple Univ SoM, Philadelphia, PA*, ³*Temple Univ Health Sys and Lewis Katz SoM, Philadelphia, PA*
- (897) Racial and Ethnic Disparities in Lung Transplant Allocation and Outcomes;** M. Brown, H. Calvelli, S. Gonipati, A. Kashem, R. Yanagida, Y. Toyoda. *Division of Cardiovascular Surgery, Temple University Hospital, Philadelphia, PA*
- (898) Survival and PFT Changes Post Transplant in Patients with Idiopathic Pulmonary Fibrosis;** A. Ramirez¹, A. Kashem², H. Kehara³, R. Yanagida⁴, K. Krishan⁵, E. Leotta³, N. Shigemura⁶, Y. Toyoda². ¹*Temple Lewis Katz School of Medicine, Philadelphia, PA*, ²*Temple University School of Medicine, Philadelphia, PA*, ³*Temple University, Philadelphia, PA*, ⁴*Temple University Hospital, Philadelphia, PA*, ⁵*Temple University Hospital, Philadelphia, Philadelphia, PA*, ⁶*Temple University Health System and Lewis Katz School of Medicine, Philadelphia, PA*
- (899) Mortality in Single vs Double Lung Retransplant;** O. Follis¹, A. Kashem², H. Kehara³, R. Yanagida¹, K. Krishan⁴, E. Leotta¹, N. Shigemura⁵, Y. Toyoda². ¹*Temple Univ Hospital, Philadelphia, PA*, ²*Temple Univ School of Med, Philadelphia, PA*, ³*Temple Univ, Philadelphia, PA*, ⁴*Temple Univ Hospital, Philadelphia, Philadelphia, PA*, ⁵*Temple Univ Health System and Lewis Katz School of Med, Philadelphia, PA*
- (900) Risk Factors of Inhaled Tobramycin Related Nephrotoxicity Post Lung Transplantation;** M. Azuma¹, A. Kashem², A. Gillespie¹, A. He¹, H. Kehara³, N. Shigemura⁴, Y. Toyoda², I. Rakhman¹. ¹*Lewis Katz School of Medicine, Philadelphia, PA*, ²*Temple University School of Medicine, Philadelphia, PA*, ³*Temple University, Philadelphia, PA*, ⁴*Temple University Health System and Lewis Katz School of Medicine, Philadelphia, PA*
- (901) A Single-Center Analysis of Lung Transplantation Outcomes Comparing Donation After Circulatory Death and Donation After Brain Death;** A. Kashem, H. Calvelli, M. Azuma, H. Zhao, Y. Toyoda. *Lewis Katz School of Medicine at Temple University, Philadelphia, PA*
- (902) Ex Vivo Lung Perfusion is Effective in Lung Transplantation: A Multi-Center Registry Data Study;** A. Kashem¹, G. Loor², M. Hartwig³, D. Van Raemdonck⁴, M. Villavicencio⁵, F. Ius⁶, K. Ghadimi⁷, J. Salman⁶, S. Chandrashekar⁸, T. Machuca⁹, P. G. Sanchez¹⁰, K. Subramaniam¹¹, A. Neyrinck¹², H. Calvelli¹, M. Warnick¹, H. Zhao¹, S. Huddleston¹³, A. Osho¹⁴, E. D'Silva², U. Ramamurthy², A. Leon Pena², M. Salan-Gomez², A. Shaffer¹⁵, N. Langer¹⁴, A. Emtiazjoo¹⁶, Y. Toyoda¹. ¹*Lewis Katz School of Medicine at Temple Univ, Philadelphia, PA*, ²*Baylor College of Medicine, Houston, TX*, ³*Duke Univ Medical Center, Durham, NC*, ⁴*Univ Hosps Leuven, Leuven, Belgium*, ⁵*Mayo Clinic, Rochester, Rochester, MN*, ⁶*Hannover Medical School, Hannover, Germany*, ⁷*Duke University, Durham, NC*, ⁸*Emory Univ Hosp, Atlanta, GA*, ⁹*Univ of Miami, Miami, FL*, ¹⁰*Univ of Pittsburgh Medical Center, Pittsburgh, PA*, ¹¹*Univ of Pittsburgh Med Ctr Presbyterian Hosp, Pittsburgh, PA*, ¹²*Leuven Univ Hosps, Leuven, Belgium*, ¹³*Univ of Minnesota, Minneapolis, MN*, ¹⁴*Massachusetts General Hosp, Boston, MA*, ¹⁵*Univ of Minnesota, Minneapolis, MN*, ¹⁶*Univ of Florida, Gainesville, FL*
- (903) Time-Dependent Lung Transplant Survival Assessment After Previous Coronary Revascularization;** R. May¹, M. Azuma², M. A. Kashem³, Y. Toyoda³, N. Shigemura⁴, A. Mishkin⁵. ¹*Lewis Katz School of Medicine at Temple University, Philadelphia, PA*, ²*Lewis Katz School of Medicine, Philadelphia, PA*, ³*Division of Cardiovascular Surgery, Department of Surgery, Temple University Hospital, Philadelphia, PA*, ⁴*Temple University Hospital, Philadelphia, PA*, ⁵*Infectious Disease, Temple University Hospital, Philadelphia, PA*
- (904) Are Highly Sensitized Recipients at Increased Risk for Early or Late Graft Dysfunction After Lung Transplantation?;** H. Elgharably¹, K. Bauza², L. Thuita², W. Tsuang³, M. Budev³, J. Yun², K. McCurry². ¹*Thoracic & Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH*, ²*Cleveland Clinic, Cleveland, OH*, ³*Pulmonary Medicine, Cleveland Clinic, Cleveland, OH*
- (905) Lung Transplantation for COVID-19 Lung Failure: Does Bridging with ECMO Impact Outcomes?;** P. D. Cho¹, S. T. Kim², R. Biniwale², D. Sayah³, A. Ardehali². ¹*Drexel College of Med, West Reading, PA*, ²*UCLA School of Med, Los Angeles, CA*, ³*UCLA, Los Angeles, CA*
- (906) Does Donor-Recipient Age Mismatch Impact the Recipient's Survival in Lung Transplantation?;** P. D. Cho¹, S. T. Kim², Z. Shameem², C. C. Le², S. Lee², A. Ardehali². ¹*Drexel College of Medicine, Philadelphia, PA*, ²*UCLA School of Medicine, Los Angeles, CA*
- (907) Outcome of COVID-19 Positive Donor Lung Transplantation;** P. D. Cho¹, S. T. Kim², P. T. Gaynor², D. Sayah³, A. Ardehali². ¹*Drexel College of Medicine, West Reading, PA*, ²*UCLA School of Medicine, Los Angeles, CA*, ³*University of California, Los Angeles, Los Angeles, CA*
- (908) Eighteen-Year Single Center Experience with Lung Transplantation in Pediatric Patients Younger Than 12 Years Old;** D. Bobylev¹,

J. Carlens², N. D. De Manna¹, K. Aburahma¹, C. Mueller², A. Saipbaev¹, M. Greer³, A. Horke¹, C. Kuehn¹, M. Avsar¹, A. Weymann¹, A. Ruhparwar¹, N. Schwerk², J. Salman¹, F. Ius¹. ¹Dept of Cardiothoracic, Transplant and Vascular Surgery, Hannover Med School, Hannover, Germany, ²Dept of Paediatrics, Hannover Medical School, Hannover, Germany, ³Dept of Respiratory Med, Hannover Med School, Hannover, Germany

(909) Impact of Perioperative Gabapentinoid Use on Lung Transplant Outcomes; A. L. Zhou¹, J. M. Ruck¹, E. L. Larson¹, A. Akbar², A. J. Casillan³, J. S. Ha¹, A. B. Massie⁴, D. L. Segev⁴, C. A. Merlo⁵, E. L. Bush⁶. ¹Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, ²Department of Surgery, Johns Hopkins School of Medicine, Baltimore, MD, ³Department of Surgery, Johns Hopkins University, Baltimore, MD, ⁴Department of Surgery, NYU Grossman School of Medicine, New York, NY, ⁵Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Department of Surgery, Johns Hopkins, Baltimore, MD

(910) Factors Associated with Long-Term Survival in Lung Transplant Recipients Age =70 Years; A. L. Zhou¹, B. L. Shou¹, J. M. Ruck¹, A. F. Akbar², A. Kalra³, A. J. Casillan⁴, J. S. Ha¹, E. L. Bush¹, C. A. Merlo⁵. ¹Dept of Surgery, Johns Hopkins Univ School of Medicine, Baltimore, MD, ²Dept of Surgery, Johns Hopkins School of Medicine, Baltimore, MD, ³Dept of Surgery, Sidney Kimmel Medical College, Thomas Jefferson Univ, Philadelphia, PA, ⁴Dept of Surgery, Johns Hopkins Univ, Baltimore, MD, ⁵Dept of Medicine, Johns Hopkins Univ School of Medicine, Baltimore, MD

(911) Intraoperative Factors Associated with Acute Kidney Injury Following Lung Transplant; V. Hart¹, S. Iyengar¹, S. Miller², E. Sako¹, N. Das¹, L. Jones³, H. Key¹. ¹UT Health San Antonio, San Antonio, TX, ²UTSA, San Antonio, TX, ³University Health, San Antonio, TX

(912) Prevalence, Risk Factors and Prognosis of Bronchial Dehiscence After Lung Transplantation. A 10 Years Single Center Study; M. Spaes¹, C. Landais², F. Gonin³, T. Ngo³, D. Usturoi³, M. Glorion⁴, J. De Wolf⁴, C. Pricopi⁴, F. Parquin⁵, E. Cuquemelle⁵, O. Brugiere¹, A. Vallee², J. Messika⁵, A. Roux¹, E. Sage⁴, C. Picard¹. ¹Respiratory Care Department, Foch Hospital, Suresnes, France, ²Statistics and Epidemiology Department, Foch Hospital, Suresnes, France, ³Bronchoscopy Unit. Thoracic Surgery Department, Foch Hospital, Suresnes, France, ⁴Thoracic Surgery Department, Foch Hospital, Suresnes, France, ⁵Intensive Care Unit. Thoracic Surgery Department, Foch Hospital, Suresnes, France

(913) Does Ex Vivo Lung Perfusion Mitigate the Detrimental Effects of Primary Graft Dysfunction? A Propensity Matched Analysis of the United Network for Organ Sharing Database; D. A. Gouchoe¹, E. Y. Cui¹, D. Satija², M. C. Henn¹, C. T. Walk¹, K. Choi¹, V. Ramsammy³, N. A. Mokadam¹, A. M. Ganapathi¹, B. A. Whitson¹. ¹Division of Cardiac Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, ²The Ohio State University College of Medicine, Columbus, OH, ³The Ohio State University Wexner Medical Center, Columbus, OH

(914) Comparison of Perioperative Outcomes Between Living-Donor Lobar Lung Transplant Versus Deceased-Donor Lung Transplant; I. Sakanoue, D. Nakajima, M. Takahashi, S. Tanaka, Y. Yutaka, A. Ohsumi, H. Date. Thoracic Surgery, Kyoto University, Kyoto, Japan

(915) UK Experience of Direct Procurement of Lungs with Ongoing Abdominal Normothermic Regional Perfusion from Controlled DCD Donors; L. J. Williams¹, R. Hogg¹, S. Beale¹, A. Jothidasan², M. Husain², J. Dunning², B. Zych², P. Kaul³, S. Tsui³, A. Al Adhami³, J. Parmar³, P. Curry⁴, S. Messer⁴, P. Mohite⁴, R. Venkateswaran⁵, V. Mehta⁵, G. Meachery⁶, B. Ramesh⁶, J. Mascaro⁷, D. Quinn⁷, B. Raj², R. Sutcliffe⁵, S. Dharmic⁵, C. Johnston⁸, G. Pettigrew⁹, A. Olland¹⁰, A. Butler⁹, G. Hardman⁶, C. Watson⁹, I. Currie⁸, M. Berman³. ¹NHS Blood and Transplant, Bristol, United Kingdom, ²Royal Brompton & Harefield Hospitals, Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom, ³Royal Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom, ⁴Golden Jubilee University National Hospital, Glasgow, United Kingdom, ⁵Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, United Kingdom, ⁶Freeman Hospital, Newcastle Hospitals NHS Foundation Trust, Newcastle, United Kingdom, ⁷University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, ⁸The Royal Infirmary of Edinburgh, Edinburgh, United Kingdom, ⁹Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom, ¹⁰University Hospital Strasbourg, Strasbourg, France

(916) Primary Graft Dysfunction: Shifting from Static Grading to Temporal Classification; B. Ozsoy¹, J. Van Slambrouck², A. Khan¹, C. Vandervelde², C. Vanluyten², X. Jin², A. Barbarossa², J. Kaes¹, L. Schoonjans¹, R. Vos³, D. Van Raemdonck², P. Carmeliet¹, L. Ceulemans². ¹Center for Cancer Biology, Department of Oncology, VIB-KU Leuven, Leuven, Belgium, ²Department of Thoracic Surgery, University Hospitals Leuven, Leuven, Belgium, ³Department of Respiratory Diseases, University Hospitals Leuven, Leuven, Belgium

(917) The Presence of Cold Agglutinins in Recipients is a Risk Factor for Severe Primary Graft Dysfunction After Lung Transplantation; I. Moneke¹, A. Semmelmann², D. Schibilsky³, J. Kalbhenn², F. Emmerich⁴. ¹Department of Thoracic Surgery, Medical Center – University of Freiburg, Universitätsklinikum Freiburg, Freiburg, Germany, ²Department of Anaesthesiology and Intensive Care Medicine, Medical Center – University of Freiburg, Freiburg, Germany, ³University Heart Center, University Medical Center, Freiburg, Germany, ⁴Department of Immunohematology and Blood Transfusio, Medical Center – University of Freiburg, Freiburg, Germany

(918) Explanted Lung Cancer Identified During Lung Transplant: A Linked Analysis of the SRTR and the NCDB; R. Rebernick¹, J. Diaz Martinez², M. De Perrot³, M. Cypel⁴, S. Keshavjee⁵, R. Mamidi Reddy⁶, E. Wakeam⁷. ¹Medical Scientist Training Program, University of Michigan, Ann Arbor, MI, ²Biostatistics Research Unit, University Health Network, University of Toronto, Toronto, ON, Canada, ³Toronto General Hospital, Toronto, ON, Canada, ⁴University Health Network, Toronto, ON, Canada, ⁵UHN, Toronto, ON, Canada, ⁶Section of Thoracic Surgery, Department of Surgery, University of Michigan, Ann Arbor, MI, ⁷University of Toronto, Toronto, ON, Canada

(919) Efficacy of Lung Transplantation from Hepatitis C+ Donors; E. J. Bashian¹, E. E. Bashian², G. Gardner¹, M. Ambrosio³, W. Julliard⁴,

V. Kasirajan⁴, Z. Hashmi⁴. ¹Dept of Surgery, Virginia Commonwealth Univ, Richmond, VA, ²Scripps Research Institute, La Jolla, CA, ³Virginia Commonwealth Univ School of Med, Richmond, VA, ⁴Div of Cardiothoracic Surgery, Pauley Heart Center, VCU, Richmond, VA

(920) The Efficacy of Modified Frailty Scoring System for Korean Lung Transplant Patients to Predict Post-Transplant Outcomes; H. Kim¹, B. Park¹, Y. Yang¹, E. Kim², A. Woo², M. Park², J. Lee¹. ¹Department of Thoracic and Cardiovascular Surgery, Yonsei University, College of Medicine, Seoul, South Korea, ²Division of Pulmonology, Department of Internal Medicine, Yonsei University, College of Medicine, Seoul, South Korea

(921) The Outcomes of Old Age Lung Transplantation: National Multi-Institutional Cohort Study; H. Kim¹, B. Park¹, Y. Yang¹, A. Woo², M. Park², J. Lee¹. ¹Department of Thoracic and Cardiovascular Surgery, Yonsei University, College of Medicine, Seoul, South Korea, ²Division of Pulmonology, Department of Internal Medicine, Yonsei University, College of Medicine, Seoul, South Korea

(922) Factors Associated with Long Survival Following Single Lung Transplantation; A. Casillan¹, Z. Nauroz¹, J. Ruck¹, R. Riojas¹, J. Ha¹, A. Massie², D. Segev², C. Merlo¹, E. Bush¹. ¹Johns Hopkins University, Baltimore, MD, ²New York University, New York, NY

(923) ECMO as Bridge to Lung Transplantation. Experience in a Center in a Country with Low Donor Supply. Clínica Santa María, Santiago De Chile; V. Linacre¹, C. Paulsen², P. Salazar², C. Sepulveda³, M. Santelices⁴, D. Paredes⁵, T. Regueira⁶, R. Varas⁷, S. Viacava⁸, M. Fica¹. ¹Thoracic Surgery and Transplant, Clínica Santa María, Santiago, Chile, ²Cardiac Surgery and Transplant, Clínica Santa María, Santiago, Chile, ³Adult Respiratory Diseases, Clínica Santa María, Santiago, Chile, ⁴Thoracic Surgery, Clínica Santa María, Santiago, Chile, ⁵Thoracic Surgery, Clínica Santa María, Santiago, Chile, ⁶Intensive Care Unit, Clínica Santa María, Santiago, Chile, ⁷Complejo Asistencial Dr. Víctor Ríos Ruiz, Los Ángeles, Chile, ⁸Hospital Clínico Universidad Católica, Santiago, Chile

(924) Donor-Derived Cell-Free DNA for Early Detection of Rejection and Allograft Injury in Lung Transplant Recipients; G. Yavuz¹, J. Walter¹, K. Hirv², O. Wachter², A. Dick³, J. Kovacs¹, O. Glück¹, J. Zimmermann¹, S. Michel⁴, M. Irlbeck⁵, N. Kneidinger⁶, R. Hatz¹, J. Behr⁶, C. Schneider¹, T. Kauke¹. ¹Dept of Thoracic Surgery, Univ Hospital LMU Munich, Munich, Germany, ²MVZ Martinsried, Munich, Germany, ³Transfusion Medicine, Univ Hospital LMU Munich, Munich, Germany, ⁴Dept of Cardiac Surgery, Univ Hospital LMU Munich, Munich, Germany, ⁵Dept of Anesthesiology, Univ Hospital LMU Munich, Munich, Germany, ⁶Dept of Medicine V, Univ Hospital LMU Munich, Munich, Germany

(925) Donor-Derived Cell-Free DNA for Early Detection of Rejection and Allograft Injury in Lung Transplant Recipients; G. Yavuz¹, J. Walter¹, K. Hirv², O. Wachter², A. Dick³, J. Kovacs¹, O. Glück¹, J. Zimmermann¹, S. Michel⁴, M. Irlbeck⁵, N. Kneidinger⁶, R. Hatz¹, J. Behr⁶, C. Schneider¹, T. Kauke¹. ¹Department of Thoracic Surgery, University Hospital LMU Munich, Munich, Germany, ²MVZ Martinsried, Munich, Germany, ³Transfusion Medicine, University Hospital LMU Munich, Munich, Germany, ⁴Department of Cardiac Surgery, University Hospital LMU Munich, Munich, Germany, ⁵Department of Anesthesiology, University Hospital LMU Munich, Munich, Germany, ⁶Department of Medicine V, University Hospital LMU Munich, Munich, Germany

(926) Living-Donor Single-Lobe Lung Transplantation: A Single-Center Case Series; D. Nakajima, S. Tanaka, M. Takahashi, S. Nishikawa, Y. Yutaka, A. Ohsumi, H. Date. Thoracic Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan

(927) Bronchial Artery Revascularization: Establishing the Bar Inlung Transplantation; A. Tang¹, S. Unai¹, R. Mahboubi¹, G. Stockdale², L. Thuita³, J. Yun¹, E. Blackstone¹, M. Machuzak², C. Koval⁴, M. Budev², K. McCurry¹, G. Pettersson¹. ¹Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH, ²Pulmonary Medicine, Cleveland Clinic, Cleveland, OH, ³Heart Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OH, ⁴Infectious Disease, Cleveland Clinic Foundation, Cleveland, OH

(928) Single Versus Double Lung Transplant in the Elderly: A Propensity-Matched Analysis; N. Weingarten¹, A. Mehta¹, M. Budev¹, U. Ahmad², J. Yun¹, K. McCurry¹, H. Elgharably¹. ¹Cleveland Clinic, Cleveland, OH, ²Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates

(929) Impact of Diaphragmatic Plication on Lung Function Parameters and Long-Term Outcomes After Lung Transplantation; K. Nakanishi, C. Hillebrand, T. Schweiger, S. Schwarz, S. Taghavi, C. Aigner, P. Jaksch, K. Hoetzenecker. Department of Thoracic Surgery, Medical University of Vienna, Vienna, Austria

(930) The Effect of Cardiopulmonary Bypass on Survival After Lung Transplantation: The Royal Papworth Experience; A. Shafi, S. Das De, A. Al-Adhami, S. Poon, Z. Abdul Aziz, S. Aurovind, A. Page, B. Al-Alao, M. Berman, D. Jenkins, P. Kaul, M. Rafiq. Royal Papworth Hospital, Cambridge, United Kingdom

(931) Outcomes of Lung Transplantation for Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation Compared with Interstitial Pulmonary Fibrosis; B. Park¹, J. Lee², H. Kim³. ¹Yonsei University, Severance Hospital, Seoul, South Korea, ²Yonsei Univ Severance, Seoul, South Korea, ³Yonsei University, College of Medicine, Seoul, South Korea

(932) A Comparative Analysis of Cardiopulmonary Bypass and Extracorporeal Membrane Oxygenation in Lung Transplantation; S. Park, H. Lee, T. Yun, J. Park, B. Na, K. Na, I. Park, C. Kang, Y. Kim. Seoul National University Hospital, Seoul, South Korea

(933) Delayed Chest Closure Does Not Yield a Negative Impact on Early and Late Outcomes After Lung Transplantation; M. Takahashi, S. Tanaka, S. Nishikawa, Y. Yutaka, A. Ohsumi, M. Hamaji, D. Nakajima, H. Date. *Kyoto University Graduate School of Medicine, Kyoto, Japan*

(934) Bronchopleural Fistula After Lung Transplantation: A 15-Year Single-Center Experience; L. M. Heymans¹, J. Van Slambrouck², C. M. Vandervelde², C. Vanluyten², H. Beeckmans², A. Barbarossa¹, K. Denaux², P. De Leyn², H. Van Veer², L. Depypere², Y. Jansen², J. Pirenne², A. Provoost², A. Neyrinck², S. Bouneb², C. Ingels², B. Jacobs², C. Doms², R. Vos², D. Van Raemdonck², L. J. Ceulemans². ¹*KU Leuven, Leuven, Belgium*, ²*University Hospitals Leuven, Leuven, Belgium*

(935) Lung Transplant from Pediatric Donors to Adult Recipients. Single Center Experience; M. Vaculova, J. Kolarik, J. Simonek, M. Svorcova, J. Vachtenheim, R. Novysedlak, J. Tavandzis, J. Havlin, R. Lischke, J. Pozniak. *Prague Lung Transplant Program, 3rd Department of Surgery, First Faculty of Medicine, Charles University, University Hospital Motol, Prague, Czech Republic*

(936) Extra-Pleural Pneumonectomies for Lung Transplantation; R. E. Du, M. Giraldo Grueso, P. Parrino, J. Bansal, M. Bates, K. Webre, A. Bansal. *Ochsner Clinic Foundation, New Orleans, LA*

(937) Peri-Operative Strategy Using Central Venous-Arterial Extracorporeal Membrane Oxygenation in Lung Transplantation for Patients with Pulmonary Arterial Hypertension; M. Kawashima, C. Konoeda, K. Nakao, M. Nagano, Y. Cong, M. Sakayori, T. Yamaya, M. Yamaguchi, K. Otsubo, S. Yuhara, Y. Shimada, M. Sato. *The University of Tokyo Hospital, Tokyo, Japan*

(938) Fundoplication in Patients with Connective Tissue Disease Undergoing Lung Transplantation; H. A. Theeuwen¹, V. Yin², M. Bojko¹, C. Theriault², A. Ashrafi², J. S. Clothier¹, T. Harano¹, S. G. Patel¹, S. C. Wightman¹, G. M. Rosenberg¹, B. V. Udelsman¹, A. W. Kim¹, S. M. Atay¹. ¹*Department of Thoracic Surgery, Keck Medicine of the University of Southern California, Los Angeles, CA*, ²*Keck Medicine of the University of Southern California, Los Angeles, CA*

(939) Combined Lung-Liver Transplant: Recipient Risk Factors; B. J. Bao¹, E. G. Dunbar¹, Z. Rollins², J. Patel³, M. Ambrosio¹, D. A. Bruno⁴, W. Julliard³, V. Kasirajan³, Z. A. Hashmi³. ¹*VCU School of Medicine, Richmond, VA*, ²*Department of Surgery, Virginia Commonwealth University, Richmond, VA*, ³*Division of Cardiothoracic Surgery, Pauley Heart Center, Virginia Commonwealth University, Richmond, VA*, ⁴*Division of Abdominal Transplant Surgery, Hume-Lee Transplant Center, Virginia Commonwealth University, Richmond, VA*

(940) WITHDRAWN

(941) High Donor Sequence Number and Outcomes Following Lung Transplantation in the United States; S. T. Kim¹, P. Cho², R. Biniwale³, A. Der Hovanessian⁴, A. Ardehali⁵. ¹*University of California, Los Angeles, Los Angeles, CA*, ²*Drexel College of Medicine, Philadelphia, CA*, ³*David Geffen Sch of Med, UCLA, Los Angeles, CA*, ⁴*University of California Los Angeles, Los Angeles, CA*, ⁵*UCLA School of Medicine, Los Angeles, CA*

(942) Can we Predict Which Donation After Circulatory Death Lung Donor Will Expire?; S. T. Kim¹, P. Cho², M. Kwon³, M. Bowdish⁴, C. Martin⁵, D. Gjertson⁶, A. Ardehali⁷. ¹*David Geffen School of Medicine, UCLA, Los Angeles, CA*, ²*Drexel College of Medicine, Philadelphia, PA*, ³*UCLA Ronald Reagan Medical Center, Los Angeles, CA*, ⁴*Cedars-Sinai Medical Center, Los Angeles, CA*, ⁵*Methodist DeBakey Heart & Vascular Center, Houston Methodist Hospital, Houston, CA*, ⁶*UCLA, Los Angeles, CA*, ⁷*UCLA School of Medicine, Los Angeles, CA*

(943) Lung Transplantation Outcomes of Patients with Pulmonary Alveolar Microlithiasis the Largest Series from a Single Centre Experience; M. Y. Hashim¹, Y. R. Yousef¹, K. Y. Alkattan², R. Y. Abdulqawi³, M. Y. Migliore¹, W. Saleh⁴. ¹*Lung Health Center, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia*, ²*Alfaisal University KFSH, Riyadh, Saudi Arabia*, ³*King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia*, ⁴*King Faisal Spec. Hosp, Riyadh, Saudi Arabia*

(944) Impact of Total Allograft Ischemic Time on Heart-Lung Transplantation Outcomes in the United States; Y. Zhu, H. He, Y. Woo, Y. Shudo. *Stanford University, Stanford, CA*

(945) Outcomes and Risk Factors for Poor Graft Survival in Lung Transplant Recipients with BMI = 35 Kg/m² - A Single Center Experience; A. Moin¹, J. Braat², S. Biswas Roy¹, D. Razia², R. Walia¹, A. Arjuna¹. ¹*Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ*, ²*Creighton University School of Medicine - Phoenix Regional Campus, Phoenix, AZ*

(946) When to Wait, When to Act: A Single-Center Retrospective Review of Patients with Advanced Lung Disease Deemed 'Too Early' to List for Lung Transplantation; J. P. Braat¹, A. Moin², S. Biswas Roy², A. Taylor¹, A. M. Rajasekhar¹, K. Grief², R. Walia², A. Arjuna². ¹*Creighton University School of Medicine - Phoenix Regional Campus, Phoenix, AZ*, ²*Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ*

(947) Baseline Lung Allograft Dysfunction: Clinical Characteristics, Outcomes, and Contributing Factors; A. A. Leon Pena, M. Salan-Gomez, M. Sanders, R. Fernandez, P. Garcha, A. Mattar, A. Elsenousi, A. Shafii, G. Loo. *Baylor College of Medicine, Houston, TX*

(949) Initial Lab Findings After Second Generation Temporary Ventricular Assist Device Placement; J. M. Safadi¹, A. Acker², J. Wald¹,

A. Parikh¹, M. Cevasco³. ¹Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ²Division of Cardiovascular Surgery, University of Pennsylvania, Philadelphia, PA, ³Division of Cardiovascular Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA

(950) WITHDRAWN

(951) Effectiveness of Pump Exchange for Major Device Related Infection in Patients Receiving a Durable Left Ventricular Assist Device; S. Shapiro¹, M. Pienta¹, S. Zhou¹, S. Swaminathan¹, P. Chandanabhumma¹, C. Chenoweth¹, R. Hawkins¹, T. Cascino¹, K. Aaronson¹, J. Cowger², P. Malani¹, L. Cabrera¹, D. Likosky¹, F. Pagani¹. ¹University of Michigan, Ann Arbor, MI, ²Henry Ford Hospitals, Detroit, MI

(952) Impact of Device-Specific Infections on Patients Receiving Left Ventricular Assist Devices; A. Iyengar¹, J. Feinman², J. Jiang¹, S. Kim¹, A. Mathew², S. Golec¹, A. Rao², M. Helmers¹, K. Tauber¹, M. Asher¹, D. Rekhtman¹, C. Song¹, J. Wald¹, N. Moss², S. Itagaki², A. Anyanwu², M. Cevasco¹, A. Parikh². ¹University of Pennsylvania, Philadelphia, PA, ²Icahn School of Medicine at Mount Sinai, New York, NY

(953) Durability of Park Stitch in LVAD Supported Patients; C. L. Poh, S. Kumaraswamy, V. T. Chao, C. H. Lim, J. L. Soon, Z. B. Abdul Aziz, T. E. Tan. Department of Cardiothoracic Surgery, National Heart Centre Singapore, Singapore, Singapore

(954) The Liver Knows: Preoperative Meld Score as a Predictor of Outcome in Patients Undergoing Left Ventricular Assist Device Implantation; M. Elbayomi, R. Groß, P. Pathare, R. Tandler, M. Weyand, M. Kondruweit, O. Dewald, C. Heim. Department of Cardiothoracic Surgery, University of Erlangen-Nurnberg, Erlangen, Germany

(955) Algorithm to Reduce Inter-Rater Variability in Intermacs Patient Profile Assignment; K. Nassar¹, L. Cabrera¹, D. S. Likosky¹, K. D. Aaronson², J. Yang¹, F. Pagani¹. ¹Department of Cardiac Surgery, University of Michigan, Ann Arbor, MI, ²Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI

(956) Relationship Between Use of Preoperative Pulmonary Hypertension Therapy and Need for Postoperative Therapy in Patients Undergoing Pulmonary Endarterectomy for Chronic Thromboembolic Pulmonary Hypertension; R. Ralph-Edwards, L. Donahoe, J. Thenganatt, J. Moric, M. McInnis, J. Granton, M. De Perrot. Toronto General Hospital, Toronto, ON, Canada

(957) Comparison of CT Scoring in Chronic Thromboembolic Pulmonary Disease (CTED) versus Chronic Thromboembolic Pulmonary Hypertension (CTEPH); C. McQuade¹, G. Grafham², L. Donahoe², J. Granton², M. De Perrot³, M. McInnis⁴. ¹Joint Department of Medical Imaging, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Toronto General Hospital, Toronto, ON, Canada, ⁴University Health Network, Toronto, ON, Canada

(958) Impact of Preoperative Left Ventricular Ejection Fraction on Outcomes After Pulmonary Thromboendarterectomy for Chronic Thromboembolic Pulmonary Hypertension; G. E. Almodovar-Cruz, H. Hayashi, Y. Zhao, E. B. Rosenzweig, K. Takeda. Columbia University Irving Medical Center, New York, NY

(959) MicroRNA Expression Correlates with Clinical Presentation of Chronic Thromboembolic Pulmonary Hypertension; I. S. Martinez Lopez¹, T. Papisotiroopoulos¹, F. Schläpfer¹, S. Ulrich², I. Opitz¹, M. B. Kirschner¹. ¹Department of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland, ²Department of Pulmonology, University Hospital Zurich, Zurich, Switzerland

(960) High Preoperative Body Mass Index and Pulmonary Vascular Resistance Do Not Impact Survival After Pulmonary Thromboendarterectomy; S. M. Shah¹, D. Moros¹, K. Ayyat¹, G. Heresi², M. Tong¹, H. Elgharably¹. ¹Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland, OH, ²Department of Pulmonary and Critical Care Medicine, Cleveland Clinic, Cleveland, OH

(961) Effective Treatment of MDRA. Baumanniinfection in 3 Htx Patients: A Single Center Experience; D. Parigino¹, L. Giovannico², G. Fischetti³, V. Santeramo³, L. Savino³, A. M. Silva³, A. d'Errico Ramirez⁴, N. Di Bari¹, T. Bottio³, A. D. Milano³. ¹Università of Bari, Bari, Italy, ²Università degli Studi di Bari, Bari, Italy, ³University of Bari, Bari, Italy, ⁴Policlinico Hospital of Bari, Bari, Italy

THURSDAY, 11 APRIL, 2024

4:30 - 5:30 p.m.

POSTER SESSION 2: Infectious Diseases (Non-CME)

Location: Poster Hall

Core Therapies: HEART, LUNG, MCS, PVD

Practice Areas: Infectious Diseases, Anesthesiology and Critical Care, Cardiology, Cardiothoracic Surgery, Nursing and Allied Health, Pathology, Pediatrics, Pharmacy, Pulmonology, Research and Immunology

Session Summary: Posters in this session include presentations on multiple topics where the Practice Areas of the research is focused in Infectious Diseases. Designated Poster Discussants will circulate through the poster hall during the session to engage poster presenters in quality discussions of their abstracts. **CME is not offered for poster sessions.**

Poster Discussants: Myriam Aguilar Perez, Spain, Markus Barten, Germany, Kevin Chan, USA, Göran Dellgren, Sweden, Jonathan Hand, USA, Marta Hernández-Meneses, Spain, Michael Kiernan, USA, Gabriela Magda, USA, Aaron Mishkin, USA, Orla Morrissey, Australia, Minoru Ono, Japan, Yael Peled, Israel, Stephanie Pouch, USA, Cissy (Xin) Si, USA, Erik Verschuuren, Netherlands, Cameron Wolfe, USA, Ann Woolley, USA

(962) Pneumonia and Bloodstream-Infections During Intensive Care Unit Stay After Heart Transplant; R. Minucci¹, A. De Silvestri², C. Pellegrini³, P. Cambieri⁴, B. Cattadori⁴, R. Silvia⁴, A. Turco⁴, B. Mirko⁴, R. Bruno⁴, S. Pelenghi⁴, E. Seminari⁴. ¹*Clinica di Malattie Infettive, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy*, ²*Fondazione IRCCS Policlinico, Pavia, Italy*, ³*IRCCS Policlinico San Matteo Hospital - University of Pavia, Pavia, Italy*, ⁴*Fondazione IRCCS Policlinico San Matteo, Pavia, Italy*

(963) Crossing the Turbulent Hepatitis Sea: Use of Prophylactic Glecaprevir/Pibrentasvir to Facilitate Cardiothoracic Transplants from Hepatitis C Viremic Donors in Australia; F. Burrows¹, L. Carlos¹, B. Schnegg², D. Darley¹, G. Matthews³, P. MacDonald¹. ¹*St Vincent's Hospital, Sydney, Australia*, ²*Inselhospital, University Hospital, Bern, Switzerland*, ³*The Kirby Institute UNSW, Sydney, Australia*

(964) Increased Risk of Nocardia Infection with Atovaquone Prophylaxis in Cardiac Transplant Patients: A Critical Analysis; A. Robbins, J. Conway, R. Singh, R. Cole. *Piedmont Hospital, Atlanta, GA*

(965) Incidence and Outcomes of BKV in Simultaneous Heart-Kidney Transplant Recipients: A Multi-Center Review; M. M. Eiting¹, L. Woolley², J. Stehlik¹, K. Zukauckas¹, T. Larson¹, B. Sirandas¹, A. Chan¹, L. Smith¹, C. Truax¹. ¹*University of Utah Health Hospital & Clinics, Salt Lake City, UT*, ²*Veterans Affairs, Salt Lake City, UT*

(966) Nocardia Farcinica Pneumonia Successfully Treated with Tedizolid in a Heart Transplanted Patient; C. Bassoli¹, P. Giordani¹, M. Corbella², V. Monzillo², R. Bruno³, E. Seminari¹. ¹*Division of Infectious Diseases I, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy*, ²*Microbiology and Virology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy*, ³*Department of Medical, Surgical, Diagnostic and Pediatric Science, University of Pavia, Pavia, Italy*

(967) Viral Pericarditis Due to Cytomegalovirus in a Post-Transplant Patient: A Case Report; J. de la Fuente Mancera¹, F. Tenorio Bautista¹, A. Ruiz Beltran¹, J. Zamora Lezama¹, C. Guízar Sánchez¹, A. Álvarez Sangabriel¹, M. Aguilar Serrano¹, T. Patiño Gómez¹, A. Jordán Ríos². ¹*Instituto Nacional de Cardiología Dr. Ignacio Chávez, Mexico City, Mexico*, ²*Instituto Nacional de Cardiología Dr. Ignacio Chávez, México City, Mexico*

(968) Use of Letermovir as Secondary Prophylaxis in Cardiac Transplant Patient, Mismatch for CMV (d+/-), Resistant to Ganciclovir and Foscarnet; A. Sangani¹, G. Campanini², F. Puci¹, F. Truffelli¹, S. Lerta¹, R. Bruno³, E. Seminari¹. ¹*Division of Infectious Diseases I, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy*, ²*Microbiology and Virology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy*, ³*Department of Medical, Surgical, Diagnostic and Pediatric Science, University of Pavia, Pavia, Italy*

(969) Hepatitis C Infected Heart/Kidney Transplantation into HCV Uninfected Recipient Without Transmission; M. McCulloch, S. Tanna. *Inova Fairfax Medical Campus, Falls Church, VA*

(970) Adjunctive Cytogam and CMV Insight T-Cell Immunity Assay for Refractory CMV Disease in Heart Transplant Recipients - Single-Center Case Series of Challenging Cases; M. Valdo Giugni, R. Gottlieb, C. Spak. *Baylor University Medical Center, Dallas, TX*

(971) Kaposi Sarcoma Due to Possible Donor-Derived Human Herpesvirus-8 Infection in a Cardiac Transplant Recipient; E. Wilson¹, C. Glass², D. Range², J. M. Steinbrink³, C. R. Wolfe³, R. F. Riedel⁴, A. D. DeVore⁵, M. R. Heldman³. ¹*Department of Medicine, Duke University, Durham, NC*, ²*Department of Pathology, Duke University, Durham, NC*, ³*Division of Infectious Diseases, Department of Medicine, Duke University, Durham, NC*, ⁴*Division of Medical Oncology, Department of Medicine, Duke University, Durham, NC*, ⁵*Division of Cardiology, Department of Medicine, Duke University, Durham, NC*

- (972) Infections After Belatacept in Lung Transplant Recipients;** M. R. Heldman¹, J. L. Saullo¹, B. M. Menacham², J. A. Messina¹, S. Arif¹, J. M. Steinbrink¹, P. C. Tam¹, M. Carugati¹, C. R. Wolfe¹, A. W. Baker¹, E. K. Maziarz¹. ¹Division of Infectious Diseases, Department of Medicine, Duke University, Durham, NC, ²Department of Medicine, Division of Pulmonary, Allergy and Critical Care, Duke University, Durham, NC
- (973) Ex Vivo Lung Perfusion as a Novel Model System of the Lung Resident Humoral Immune Response to Influenza;** A. Nellore¹, C. Hoopes². ¹UAB Medicine, Birmingham, AL, ²Univ of Alabama (Birmingham), Birmingham, AL
- (974) COVID-19 Seropositive Donors Yield Comparable Post-Lung Transplant Outcomes;** C. Kurihara¹, T. Kaiho¹, T. Toyoda¹, B. Thomae¹, A. O'Boye², R. Tomic², J. Lysne², A. Bharat¹. ¹Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL
- (975) Racial and Ethnic Disparities in Transplantation of Lungs From HCV-Infected Donors into HCV-Negative Recipients;** H. Hannan¹, D. Goldberg². ¹University of Michigan, Ann Arbor, MI, ²University of Miami Miller School of Medicine, Miami, FL
- (976) Letermovir Use Following Lung Transplantation: A Single Center Review;** A. K. Mezocho, K. D. He, K. Whitaker, E. Blumberg, M. Crespo, A. Courtwright. University of Pennsylvania, Philadelphia, PA
- (977) Efficacy of CMV Immunoglobulin as Cytomegalovirus Prophylaxis in High Risk Lung Transplant Recipients;** J. D. Donkin¹, R. Girgis², C. K. Lawson³, H. Hassouna¹. ¹Infectious Disease, Corewell Health, Grand Rapids, MI, ²Pulmonology, Spectrum Health, Michigan State University, Grand Rapids, MI, ³Heart and Vascular Institute, Corewell Health, Grand Rapids, MI
- (978) Asymptomatic Viral Carriage in Lung Transplant Recipients and Donors on Day of Transplant;** K. Prakash¹, L. Cavey², V. Patel³, M. Eberlein³, R. Reed³, A. Charya³, A. Krupnick⁴, J. Rabin⁵, J. Baddley¹, G. Bittle⁴, H. Porterfield⁶, K. Saharia¹. ¹Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, ²University of Maryland School of Medicine, Baltimore, MD, ³Division of Pulmonary and Critical Care Medicine, University of Maryland School of Medicine, Baltimore, MD, ⁴Division of Thoracic Surgery, University of Maryland School of Medicine, Baltimore, MD, ⁵Department of Surgery, R Adams Cowley Shock Trauma Center, Baltimore, MD, ⁶Department of Lab Medicine, Clinical Center, National Institute of Health, Bethesda, MD
- (979) Utilization of Pseudomonas Eradication Protocols Amongst Lung Transplant Centers;** D. Charles¹, K. Saharia¹, E. Heil², J. Baddley¹, R. Reed¹, M. Eberlein¹, K. Prakash¹. ¹University of Maryland, Baltimore, MD, ²University of Maryland School of Pharmacy, Baltimore, MD
- (980) WITHDRAWN**
- (981) Experience with Pre- and Post-Exposure Prophylaxis with Tixagevimab and Cilgavimab in Lung Transplant Recipients;** P. Kinnunen¹, K. Lemström¹, A. Nykänen¹, J. Tikkanen². ¹Helsinki University Hospital, Helsinki, Finland, ²Helsinki University Central Hospital, Helsinki, Finland
- (982) Evaluation of a Program to Improve Vaccination Rates in Lung Transplant Candidates;** G. Shaw, S. Ivulich, M. Paraskeva, G. Snell. Alfred Hospital, Melbourne, Australia
- (983) Epidemiology of Enterococcus Infections in Lung and Heart Transplant Recipients;** J. M. Lum¹, S. Gadre², J. Wu³, K. Brizendine¹, C. Koval¹, N. Shrestha¹. ¹Infectious Diseases, Cleveland Clinic Foundation, Cleveland, OH, ²Pulmonology, Cleveland Clinic Foundation, Cleveland, OH, ³Pharmacy, Cleveland Clinic Foundation, Cleveland, OH
- (984) A 2-Year Review of the Use of Serum and Bronchoalveolar Lavage (BAL) Galactomannan (GM) Testing in Lung Transplant Recipients (LTRs) in Mater Misericordiae University Hospital (MMUH) 2021-2022;** C. F. O'Donnell¹, B. Lynch¹, L. O'Sullivan¹, A. Killarney¹, M. Murray², P. Riddell², M. Hannan¹. ¹Department of Clinical Microbiology, Mater Misericordiae University Hospital, Dublin 7, Ireland, ²Department of Lung Transplantation, Mater Misericordiae University Hospital, Dublin 7, Ireland
- (985) Hepatitis B Virus Reactivation in Lung Transplant Recipients with Previous Resolved Infection;** T. Brar¹, K. Grewal², A. Vo², A. Driver¹, A. Wright³, N. Partovi¹, R. Levy⁴, R. Nador⁴, C. Bergeron⁴, A. Kapasi⁴, J. Wilson⁴, J. Samuels⁴, R. Wright¹. ¹Pharmaceutical Sciences, Vancouver General Hospital, Vancouver, BC, Canada, ²Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ³Division of Infectious Diseases, Vancouver General Hospital, Vancouver, BC, Canada, ⁴Division of Respiratory Medicine, Vancouver General Hospital, Vancouver, BC, Canada
- (986) Intraleural Amphotericin B for Aspergillus Empyema After Lung Transplantation;** A. Driver¹, T. Brar¹, R. Wright¹, N. Partovi¹, J. Choi², J. Costa², R. Levy³, R. Nador³, C. Bergeron³, A. Kapasi³, J. Samuels³, J. Wilson³, J. Yee². ¹Pharmaceutical Sciences, Vancouver General Hospital, Vancouver, BC, Canada, ²Thoracic Surgery, Vancouver General Hospital, Vancouver, BC, Canada, ³Division of Respiratory Medicine, Vancouver General Hospital, Vancouver, BC, Canada

(987) An Unusual Presentation of Pulmonary Cryptococcosis in a Bilateral Lung Transplant Patient; G. Dawodu¹, D. Laskey¹, B. Housman¹, H. Seethamraju², S. Scheinin³. ¹Thoracic Surgery / Lung Transplantation, Icahn School of Medicine at Mount Sinai, New York, NY, ²Pulmonology / Lung Transplantation, Mount Sinai School of Medicine, New York, NY, ³Thoracic Surgery / Lung Transplantation, Mount Sinai, New York, NY

(988) WITHDRAWN

(989) WITHDRAWN

(990) Mycotic Aortic Infection with Exophiala Dermatitidis in a Lung Transplant Patient with Cystic Fibrosis; I. Bittiner, J. Samuel, B. Ramesh, S. Clark, A. Fisher, G. Meachery, A. Nair, J. Lordan. Freeman Hospital, Newcastle upon Tyne, United Kingdom

(991) Development of Maribavir-Resistant Cytomegalovirus Infection Following Treatment of Ganciclovir-Resistant Cytomegalovirus Infection; A. Hutchins, T. Pasley. Clinical Pharmacy, Houston Methodist Hospital, Houston, TX

(992) Multi-Drug Resistant Fusariosis Treated with Fosmanogepix in a Lung Transplant Patient; G. Wu¹, S. Ganesh¹, K. Forrester², S. Khan³. ¹Division of Pulmonary, Critical Care, and Sleep Medicine, University of Southern California, Los Angeles, CA, ²School of Pharmacy, University of Southern California, Los Angeles, CA, ³Infectious Diseases, University of Southern California, Los Angeles, CA

(993) Cryptococcal Meningitis in a Patient After LuTx: A Happy Ending After All; B. Pisova¹, M. Stefan¹, T. Kotowski¹, A. Dutkova¹, J. Havlin¹, L. Fila¹, E. Dvorackova², J. Berousek¹, M. Trojanek¹, R. Lischke¹. ¹University Hospital Motol, Prague, Czech Republic, ²Institute of Pharmacology, Charles University, Prague, Czech Republic

(994) A Tight Squeeze: Endobronchial Mucormycosis in a Heart-Lung Transplant Recipient; D. P. Kulkarni, N. Block, M. Pipeling. Duke University Medical Center, Durham, NC

(995) Characterization of Blood Stream Infections in Patients with Left Ventricular Assist Devices; N. Kumar, A. Merlo, R. Watkins, C. Doligalski, N. Ashraf, B. Footer, M. Byku, L. Bartelt. University of North Carolina, Chapel Hill, NC

(996) Predictors of Thoracotomy Infection After Less Invasive Left Ventricular Assist Device Implantation; S. A. Hoffman¹, A. Jones¹, B. R. Hauser¹, A. Elangovan¹, A. Goodman², B. Barney³, C. M. Hay⁴, I. Gosev², K. L. Wood². ¹School of Medicine and Dentistry, University of Rochester, Rochester, NY, ²Dept. of Surgery, University of Rochester Medical Center, Rochester, NY, ³Dept. of Clinical Nutrition, University of Rochester Medical Center, Rochester, NY, ⁴Dept. of Medicine, University of Rochester Medical Center, Rochester, NY

(997) WITHDRAWN

THURSDAY, 11 APRIL, 2024

4:30 - 5:30 p.m.

POSTER SESSION 2: Pathology (Non-CME)

Location: Poster Hall

Core Therapies: HEART, LUNG, MCS, PVD

Practice Areas: Pathology, Anesthesiology and Critical Care, Cardiology, Cardiothoracic Surgery, Infectious Diseases, Nursing and Allied Health, Pediatrics, Pharmacy, Pulmonology, Research and Immunology

Session Summary: Posters in this session include presentations on multiple topics where the Practice Areas of the research is focused in Pathology. Designated Poster Discussants will circulate through the poster hall during the session to engage poster presenters in quality discussions of their abstracts. **CME is not offered for poster sessions.**

Poster Discussants: Annalisa Angelini, Italy, Fiorella Calabrese, Italy, Gregory Fishbein, USA, Martin Goddard, UK, Michal Odermarsky, Sweden, Katharina Wassilew, UK

(998) Cause of Death for Heart Transplant: An Autopsy Study; C. Lin, J. Burk, J. Ritter, C. Bernadt. *Department of Pathology and Immunology, Washington University in St. Louis, St. Louis, MO*

(999) Fibrosis and Microvessel Disease are Common Findings on Endomyocardial Biopsy in Pediatric Heart Transplant Recipients; K. Watanabe¹, A. Haregu², N. Arva³, C. Laternser², N. Husain². ¹Cardiology, Texas Children's Hospital, Houston, TX, ²Cardiology, Lurie Children's Hospital of Chicago, Chicago, IL, ³Pathology, Lurie Children's Hospital of Chicago, Chicago, IL

(1000) Histopathologic Changes of Primary Graft Dysfunction of the Heart; M. Ospina-Romero¹, J. J. Schulte². ¹University of Wisconsin, Madison, WI, ²Pathology and Laboratory Medicine, The University of Wisconsin, Madison, WI

(1001) -Vessel-Associated Lymphoid Tissue (VALT), a Quilty-Like Lesion in Allograft Lungs; A. Wein, C. Bernadt, J. Ritter, C. Lin. *Washington University in St. Louis, St. Louis, MO*

(1002) A Video Reflexive Ethnography Study of Direct Patient-Pathologist Interactions in the Post-Heart and Lung Transplantation Setting; A. C. Roden¹, G. Asiedu², A. Regnier², M. Bois², J. Boland Froemming³, E. Yi², Y. Lo², N. Larson², K. Peters², E. Scharrer², X. Zhu², J. Scott³, M. Aubry³, J. Maleszewski³. ¹Laboratory Medicine and Pathology, Mayo Clinic Rochester, Rochester, MN, ²Mayo Clinic Rochester, Rochester, MN, ³Mayo Clinic, Rochester, MN

(1003) Evaluation of Plasma Donor-Derived Cell-Free DNA and the LASHA Scoring System as Complementary Tools in Lung Transplantation: Insights from a Prospective Single-Center Experience; F. Pezzuto¹, V. Tauro¹, C. De Chellis¹, F. Lunardi¹, M. Loy², E. Faccioli¹, M. Vadori¹, D. Biondini¹, S. Marinello², F. Braccioni², M. Schiavon¹, D. Levine³, E. Cozzi¹, F. Rea¹, F. Calabrese¹. ¹University of Padova, Padova, Italy, ²University Hospital of Padova, Padova, Italy, ³Stanford University, Stanford, CA

(1004) Subaortic Pannus Causing Complete Outlet Obstruction After Bioprosthetic Aortic Valve Replacement in Left Ventricular Assist Device Patient; R. J. Krishnaswamy¹, V. Sivasubramaniam², D. Robson¹, A. Watson¹, P. Jansz¹, C. S. Hayward¹, K. Muthiah¹. ¹Heart and Lung Transplant Unit, St Vincent's Hospital, Sydney, Australia, ²Department of Anatomical Pathology, St Vincent's Hospital, Sydney, Australia

THURSDAY, 11 APRIL, 2024

4:30 - 5:30 p.m.

POSTER SESSION 2: Pulmonology (Non-CME)

Location: Poster Hall

Core Therapies: HEART, LUNG, MCS, PVD

Practice Areas: Pulmonology, Anesthesiology and Critical Care, Cardiology, Cardiothoracic Surgery, Infectious Diseases, Nursing and Allied Health, Pathology, Pediatrics, Pharmacy, Research and Immunology

Session Summary: Posters in this session include presentations on multiple topics where the Practice Areas of the research is focused in Pulmonology. Designated Poster Discussants will circulate through the poster hall during the session to engage poster presenters in quality discussions of their abstracts. **CME is not offered for poster sessions.**

Poster Discussants: David Bennett, Italy, Marie Budev, USA, Satish Chandrashekar, USA, Juan Fernandez, USA, Meg Fregoso, USA, Reda Girgis, USA, Laurent Godinas, Belgium, Kieran Halloran, Canada, Are Holm, Norway, Peter Hopkins, Australia, Peter Jaksch, Austria, Arun Jose, USA, Angela Koutsokera, Switzerland, Adrian Christopher Lawrence, USA, James Lordan, UK, Erin Lowery, USA, Hannah Mannem, USA, Federica Meloni, Italy, Vijil Rahulan, India, Reinaldo Rampolla, USA, Benjamin Renaud-Picard, France, Leslie Seijo, USA, Vincent Valentine, USA, Adriana Valverde Zuniga, Costa Rica, Brigitte Willemse, Netherlands, Andrea Zajacova, Czech Republic

(1005) Pneumatosis Intestinalis After Lung Transplantation; A. Ishaq, P. I. Kumar, V. Kaza, A. Lawrence, S. Bollineni, L. D. Mahan, M. Mohanka, M. Wait, M. Peltz, L. Huffman, J. Murala, C. Heid, J. Weston, S. Keshavamurthy, F. Torres, I. Timofte. UTSW, Dallas, TX

(1006) Plasma Donor-Derived Cell-Free DNA Surveillance Can Direct Safe Reduction in Surveillance Bronchoscopy Procedures During the Initial Year After Lung Transplant; B. Small¹, D. Ross², S. Bhorade², J. P. Rosenheck¹. ¹Ohio State Univ, Columbus, OH, ²Natera, San Carlos, CA

(1007) Is Cystatin C a Predictor of CKD in Post Lung Transplant Patients?; J. Fernandez¹, M. Tellez², T. Pastrana Camacho³, I. Iupe², S. Kadir⁴, O. De La Cruz⁵, I. Chisti², T. Montrieff⁶, T. Murphy⁶, J. Salgado¹, T. Machuca⁷, A. Pelaez⁸. ¹Miami Transplant Inst, Univ of Miami, Miami, FL, ²Pulm and Critical Care, Univ of Miami, Miami, FL, ³Pharmacy, Jackson Memorial Hosp, Miami, FL, ⁴Jackson Health System, Miami, FL, ⁵Univ of Miami/Miami Transplant Inst/Jackson Memorial Hosp, Miami, FL, ⁶Surgery, Univ of Miami, Miami, FL, ⁷Univ of Miami, Miami, FL, ⁸Miami Transplant Inst, Miller SoM, Univ of Miami, Miami, FL

(1008) Temporal Analysis of dd-cfDNA Trajectory Within the First Year Following Lung Transplantation, A Registry Analysis; D. J. Levine¹, Y. Furuya², J. Gray², S. Aryal³, C. Ensor², D. F. Dilling⁴, N. Sharma⁵. ¹Stanford University, Palo Alto, CA, ²CareDx, Brisbane, CA, ³Inova, Fairfax, VA, ⁴Loyola University Chicago, Stritch School of Medicine, Maywood, IL, ⁵Brigham & Women's Hospital, Boston, MA

(1009) Patterns of Ventilation and Perfusion in the Early Post-Transplant Lung Allograft Using the Automatic Lung Parameter Estimator (ALPE); S. Dumschat¹, S. Kruszona², J. Salman², C. Falk³, A. Ruhparwar², T. Welte¹, F. Ius², M. Greer¹. ¹Dept. Respiratory Medicine and Infectious Diseases, Hannover Medical School, Hannover, Germany, ²Clinic for Cardiothoracic, Vascular, and Transplantation Surgery, Hannover Medical School, Hannover, Germany, ³Hannover Medical School, MHH, Hannover, Germany

(1010) Persistent Elevation in dd-cfDNA in Severe PGD Within the First Year After Lung Transplantation: A Registry Analysis; Y. Furuya¹, J. Gray¹, K. Qu¹, D. Byers². ¹CareDx, Brisbane, CA, ²Washington Univ Sch Med, St. Louis, MO

(1011) Mortality and Lung Allograft Outcomes in Lung Transplant Recipients with Post-Transplant COVID-19 Infection; K. Laothamatas, A. Rahbari, J. Hum, M. Sonnick, H. Robbins, L. Shah, A. DiMango, H. S. Grewal, G. Magda, J. Scheffert, G. Reilly, S. Patel, M. Indriolo, A. Miller, Y. Ko, J. Sonett, P. Lemaitre, B. P. Stanifer, F. D'Ovidio, L. Benvenuto, S. Arcasoy. Columbia University Medical Center, New York, NY

(1012) Association of Single versus Double Lung Transplant Status with Spirometry and Mortality After COVID-19; M. A. Sonnick¹, K. Laothamatas¹, A. Rahbari², J. Hum¹, L. Shah¹, A. DiMango¹, H. S. Grewal¹, G. Magda¹, J. Scheffert³, A. Miller¹, S. Patel¹, G. Reilly¹, P. Lemaitre⁴, B. P. Stanifer⁴, J. R. Sonett⁴, F. D'Ovidio⁴, H. Robbins¹, L. Benvenuto¹, S. M. Arcasoy¹. ¹Pulm and Critical Care, Columbia Univ, New York, NY, ²Medicine, Columbia Univ, New York, NY, ³Pharmacy, NewYork-Presbyterian/Columbia Univ Irving Medical Center, New York, NY, ⁴Thoracic Surgery, Columbia Univ, New York, NY

(1013) Efficacy of Convalescent Plasma for the Treatment of COVID-19 in Lung Transplant Recipients: A Multicenter French Study; A. Chaudhry¹, F. Gallais², S. Hirschi¹, T. Degot¹, A. Olland³, S. Colin De Verdier⁴, T. Villeneuve⁵, D. Horeau⁶, E. Chatron⁷, E. Blanchard⁸, R. Kessler¹, B. Renaud-Picard¹. ¹Serv de Pneum, Hôp Univ de Strasbourg, Strasbourg, France, ²Lab de Virologie, Hôp Univ, Strasbourg, France, ³Serv de Chirurgie Thor, Hôp Univ, Strasbourg, France, ⁴Serv de Pneum et Transpl Pulm, Hosp Foch, Suresnes, France, ⁵Service de Pneum, CHU de Toulouse, Toulouse, France, ⁶Service de Pneum, CHU de Nantes, Nantes, France, ⁷Service de Pneum, Hospices Civils de Lyon, Lyon, France, ⁸Service de Pneum et Transpl Pulm, CHU de Bordeaux, Bordeaux, France

(1014) Mycobacterial Infections Post Lung Transplantation - An Indian Experience; S. Priyaranjan¹, V. Rahulan², O. Tisekar³, M. Lalani², P. Dutta³, S. Attawar⁴. ¹Institute of Heart and Lung Transplant, KIMS Hospital, Hyderabad, India, ²Krishna Institute of Medical Sciences, Hyderabad, Hyderabad, India, ³KIMS Hospital, Hyderabad, India, ⁴KIMS Institute for Heart & Lung Transplantation, Hyderabad, India

(1015) Tuberculosis as a Risk Factor for Early Chronic Lung Allograft Dysfunction - An Indian Experience; S. Priyaranjan¹, V. Rahulan², O. Tisekar¹, M. Lalani², M. Negigowda³, U. Shah⁴, P. Dutta¹, S. Attawar⁵. ¹KIMS Hospital, Hyderabad, India, ²Krishna Institute of Medical Sciences, Hyderabad, Hyderabad, India, ³Institute of Heart and Lung Transplantation, KIMS Hyderabad, Hyderabad, India, ⁴Sir HN Reliance Hospitals, Mumbai, Mumbai, India, ⁵KIMS Institute for Heart & Lung Transplantation, Hyderabad, India

(1016) Point-of-Care Testing by PCR in Various Compartments for Suspected Lower Respiratory Tract Infection Following Lung Transplantation: A Prospective Study; J. Gottlieb¹, S. Simon², M. Strengert³. ¹Respiratory Medicine and Infectious Diseases, Hannover Medical School /German Center of Lung Research (DZL), Hannover, Germany, ²Respiratory Medicine and Infectious Diseases, Hannover Medical School, Hannover, Germany, ³Helmholtz Centre for Infection Research, Braunschweig, Germany

(1017) High Incidence of In-Hospital Venous Thromboembolism Early After Lung Transplantation Despite Thromboprophylaxis; D. Ruijgrok¹, J. Admiraal¹, L. Boersma², R. Schonwetter³, M. C. Post⁴, B. Luijk¹. ¹Pulmonary Diseases, UMC Utrecht, Utrecht, Netherlands, ²Anesthesiology, UMC Utrecht, Utrecht, Netherlands, ³Pulmonary Diseases, St. Antonius Hospital, Nieuwegein, Netherlands, ⁴Cardiology, St. Antonius Hospital, Nieuwegein, Netherlands

(1018) Incidence and Risk Factors of Venous Thromboembolism in Lung Transplant Recipients; K. Walter¹, M. Combs², E. Belloli², D. Lyu². ¹Pharmacy, University of Michigan, Ann Arbor, MI, MI, ²Medicine, Division of Pulmonary & Critical Care, University of Michigan, Ann Arbor, MI

(1019) Long-Term Survival of Lung Transplant Recipients with Connective Tissue Disease and Esophageal Dysfunction: An 11-Year Single-Center Experience; D. Sindu¹, A. R. Latorre-Rodríguez¹, S. Patel², R. Walia¹, L. W. Schaheen¹, M. A. Smith¹, S. K. Mittal¹, R. M. Bremner¹, S. Tokman¹. ¹Norton Thoracic Institute, St. Joseph's Hosp and MC, Phoenix, AZ, ²Creighton Univ SoM - Phoenix Regional Campus, Phoenix, AZ

(1020) Impact of Lung Transplant on DeMeester Score in Patients with Connective Tissue Disease and Gastroesophageal Reflux: An 11-Year Single-Center Experience; D. Sindu¹, A. R. Latorre-Rodríguez¹, S. Patel², R. Walia¹, L. Schaheen¹, M. A. Smith¹, S. K. Mittal¹, R. M. Bremner¹, S. Tokman¹. ¹Norton Thoracic Inst, St. Joseph's Hosp and MC, Phoenix, AZ, ²Creighton Univ SoM - Phoenix Reg. Campus, Phoenix, AZ

(1021) Clinical Utility of Plasma Donor-Derived Cell-Free DNA for Lung Allograft Surveillance: A Real-World Single Center Experience; D. Sindu, K. Grief, R. Walia, S. Tokman. Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ

(1022) Solid Organ Transplant or Transfusion-Associated Graft-versus-Host Disease in a Lung Transplant Recipient: An Uncertain Culprit with Lethal Complications; D. Sindu¹, B. Franz², I. Scott², H. Ayyad³, K. Gaines², K. McAnally¹, S. Tokman¹. ¹Norton Thoracic Institute, St. Joseph's Hosp and MC, Phoenix, AZ, ²Vitalant, Phoenix, AZ, ³Creighton Univ SoM - Phoenix Regional Campus, Phoenix, AZ

(1023) Dyspnea and Hypoxia in a 74-Year-Old Lung Transplant Recipient: Not Always Graft Rejection; D. Sindu, H. Mohamed, B. Buddhdev, R. Walia, A. Arjuna. Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ

(1024) Not Only Against Cytomegalovirus - Combined Prophylaxis with Antivirals and Specific Immunoglobulins Reduces Acute Rejection Rates; M. Fanetti, M. Messina, F. Perillo, L. Luzzi, P. Paladini, F. Franchi, F. Montagnani, E. Bargagli, A. Fossi, D. Bennett. University Hospital of Siena, Siena, Italy

(1025) Sequential Comparison of Mini Cryoprobe vs Flexible Forceps for Surveillance After Lung Transplantation; A. Barrios-Ruiz, A. Garza-Salas, A. Lee-Mateus, A. Khor, F. Alvarez, T. Narula, M. Baz, S. Z. Shah, S. Fernandez-Bussy, D. Abia-Trujillo. Mayo Clinic, Jacksonville, FL

(1026) ECMO Bridge to Bilateral Lung Transplant for Castleman Disease; S. Al-Bayati¹, J. P. Villamizar¹, T. Machuca², D. Buitrago², M. Pipkin², S. Manickavel², N. Sinha², A. Pelaez³, J. Salgado², J. Fernandez². ¹Jackson Memorial Hospital, Miami, FL, ²University of Miami, Miami, FL, ³Miami Transplant Institute, Miller School of Medicine, University of Miami, Miami, FL

(1027) Lung Transplantation in Patients with Hermansky-Pudlak Syndrome; J. D. Wilkinson, M. Fregoso, M. Wahl, J. Chun, A. B. Cochrane, A. Nyquist, C. Thomas, A. Singhal, V. Khangoora, C. S. King, A. Brown, O. A. Shlobin, S. D. Nathan, S. Aryal. Advanced Lung Disease and Lung Transplant, Inova Health System, Falls Church, VA

(1028) Delayed Presentation of Hyperammonemia Syndrome After Lung Transplant; J. D. Wilkinson¹, A. Patel², S. Tanna², A. Nyquist¹, C. Thomas¹, A. Singhal¹, V. Khangoora¹, O. A. Shlobin¹, S. D. Nathan¹, S. Aryal¹, C. S. King¹. ¹Advanced Lung Disease and Lung Transplant, Inova Health System, Falls Church, VA, ²Infectious Disease, Inova Health System, Falls Church, VA

(1029) Acute Hepatitis After Lung Transplant in a Recipient from Hep C Donor: The Chicken or the Egg Phenomenon?; M. Shacker¹,

J. P. Braat¹, A. Arjuna². ¹Creighton University School of Medicine, Phoenix, AZ, ²Norton Thoracic Institute, St. Joseph's Hosp and MC, Phoenix, AZ
(1030) Acute Tacrolimus Toxicity Due to Paxlovid Successfully Managed with Phenytoin After Lung Transplantation; C. J. White¹, S. Bailey¹, B. Murnion², M. Plit¹, D. Darley¹. ¹Lung Transplant & Thoracic Medicine Unit, St Vincent's Hospital, Sydney, Australia, ²Clinical Pharmacology Department, St Vincent's Hospital, Sydney, Australia

(1031) Successful Monoclonal Antibody Treatment for Acute Fibrinous Organising Pneumonia After Lung Transplantation; S. Bailey¹, C. White¹, V. Sivasubramaniam², M. Connellan³, M. Nicholls⁴, L. Honeysett⁵, C. Thomson¹, M. Plit¹, D. Darley¹. ¹Lung Transplant and Thoracic Medicine Unit, St. Vincent's Hospital, Sydney, Australia, ²Department of Pathology, St. Vincent's Hospital, Sydney, Australia, ³Cardiothoracic Surgical Unit, St. Vincent's Hospital, Sydney, Australia, ⁴Intensive Care Unit, St. Vincent's Hospital, Sydney, Australia, ⁵Lung and Heart Transplant Unit, St. Vincent's Hospital, Sydney, Australia

(1032) Nirmatrelvir-Ritonavir Drug Interactions Lead to Multi-Organ Dysfunction in a Lung Transplant Recipient; S. Deanda¹, M. Pon¹, W. Zaidi¹, R. Lee¹, D. Razia¹, A. Arjuna². ¹Creighton University School of Medicine - Phoenix Regional Campus, Phoenix, AZ, ²Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ

(1033) Scedosporium Brain Abscess in a Lung Transplant Recipient Treated with Belatacept; M. F. Levin¹, A. B. Cochrane¹, S. Tanna¹, A. Patel², L. Marinak³, M. Kopp¹, N. Sisseron⁴, A. Nyquist¹, C. Thomas⁵, A. Singhal⁵, V. Khangoora¹, C. S. King¹, O. A. Shlobin⁶, S. D. Nathan⁶, S. Aryal⁷. ¹Inova Fairfax Hospital, Falls Church, VA, ²Inova Health Systems, Falls Church, VA, ³Inova, Falls Church, VA, ⁴INOVA Hospital, Falls Church, VA, ⁵Inova Fairfax, Falls Church, VA, ⁶Advanced Lung Disease and Transplant Program, Inova Fairfax Hospital, Falls Church, VA, ⁷Advanced Lung Disease and Transplant Program, Inova, Falls Church, VA

(1034) Median Sternotomy Versus Clamshell Thoracotomy for Bilateral Lung Transplantation; S. Aryal¹, M. Levin², A. Chandel³, L. Marinak⁴, J. Wilkinson¹, A. Cochrane⁵, A. Nyquist⁵, C. Thomas⁶, A. Singhal⁶, V. Khangoora⁵, C. King⁵, O. Shlobin⁵, D. Tang⁴, S. Nathan⁵. ¹Inova Health System, Falls Church, VA, ²INOVA, Falls Church, VA, ³Pulmonology, Walter Reed Medical Center, Bethesda, MD, ⁴Inova, Falls Church, VA, ⁵Inova Fairfax Hospital, Falls Church, VA, ⁶Inova Fairfax, Falls Church, VA

(1035) An Uninvited Guest- Passenger Lymphocyte Syndrome in Bilateral Lung Transplant; R. A. Zudekoff¹, E. De Boer¹, J. Smith². ¹University of Colorado, Aurora, CO, ²University of Colorado School of Medicine, Aurora, CO

(1036) Acute Fibrinous Organizing Pneumonia Following Combined Heart-Lung Transplant in a Patient with Sarcoidosis-Related ILD and Isoniazid-Monoresistant PTB: A Case Report; O. Tisekar¹, V. Rahulan², S. Priyaranjan³, M. Lalani⁴, M. M⁵, M. N³, B. Manesh³, U. Shah⁶, P. Dutta³, S. Attawar⁷. ¹Inst of Heart and Lung Transplant, KIMS Hospital, Kharghar, India, ²Inst of Heart and Lung Transplant, Krishna Inst of Medical Sciences, Hyderabad, Hyderabad, India, ³Inst of Heart and Lung Transplant, KIMS Hospital, Hyderabad, India, ⁴Krishna Inst of Medical Sciences, Hyderabad, ⁵Inst of Heart and Lung Transplant, Krishna Inst of Medical Sciences, Hyderabad, India, ⁶Sir HN Reliance Hospitals, Mumbai, Mumbai, India, ⁷Inst of Heart and Lung Transplant, KIMS Inst for Heart & Lung Transplantation, Hyderabad, India

(1037) Lung Transplantation for Alpha-1-Antitrypsin Deficiency and Behçet's Disease: A Rare Association; A. C. Avila¹, F. Pola², S. dos Santos², J. P. Leão², L. G. Abdalla², L. M. Fernandes², S. Campos³, P. Bueno de Camargo³, P. Pego-Fernandes². ¹Thoracic Surgery, INCOR, São Paulo, Brazil, ²Lung Transplantation, INCOR, São Paulo, Brazil, ³Pulmonology, INCOR, São Paulo, Brazil

(1038) Persistent dd-cfDNA Elevation in a Stable Lung Transplant Recipient; K. Walker¹, J. Yau², S. Nandavaram¹. ¹University of Kentucky, Lexington, KY, ²CareDx, Lexington, KY

(1039) Disseminated Mycobacterium Tuberculosis Post Lung Transplantation; S. Verga¹, L. Burkart², J. Holt³, S. Nandavaram³. ¹Medical College of Wisconsin, Milwaukee, WI, ²CAMC, Charleston, WV, ³University of Kentucky, Lexington, KY

(1040) Hemophagocytic Lymphohistiocytosis: A Rare Diagnosis in the Immediate Aftermath of Lung Transplantation; L. Alshawa¹, B. Leahy², J. Rueckert³, A. Maskey¹, M. Anstead¹, S. Keshavamurthy⁴, S. Nandavaram⁵. ¹Medicine, University of Kentucky, Lexington, KY, ²University of Kentucky, Lexington, KY, ³Pathology, University of Kentucky, Lexington, KY, ⁴Surgery, University of Texas Southwestern Medical Center,, Dallas, TX, ⁵Surgery, University of Kentucky, Lexington, KY

(1041) Fatal Right Heart Failure Due to Pulmonary Tumor Emboli Syndrome in a Patient with Undiagnosed Colon Cancer; A. Moyo, S. Aryal, C. Thomas. Advanced Lung Disease and Transplant, Inova Schar Heart and Vascular Institute, Inova Fairfax Medical Campus, Falls Church, VA

(1042) Positive Cytomegalovirus in Bronchoalveolar Lavage in a Lung Transplant Recipient: Don't Brush It Off Yet; S. Biswas Roy¹, A. Moin¹, M. Shacker², J. P. Braat², A. Arjuna¹. ¹Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ, ²Creighton University School of Medicine - Phoenix Regional Campus, Phoenix, AZ

(1043) Molded by Care: A Case of Endobronchial Aspergillosis Managed Conservatively in a Lung Transplant Recipient; S. Biswas Roy¹, M. Shacker², A. Moin¹, A. Taylor², H. Mohamed¹, A. Arjuna¹. ¹Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ, ²Creighton University School of Medicine - Phoenix Regional Campus, Phoenix, AZ

- (1044) Late Living-Donor Kidney Transplantation After Living-Donor Lobar Lung Transplantation: Two Case Reports;** T. Ryuko, S. Sugimoto, T. Hayashi, M. Umeda, H. Choshi, H. Ujike, S. Kawana, Y. Kubo, S. Tanaka, K. Hashimoto, K. Miyoshi, M. Okazaki, S. Toyooka. *Okayama University Hospital, Okayama, Japan*
- (1045) Title: Clinical Outcomes of Lung Transplant Recipients with Myelodysplastic Syndrome and Short Telomere Syndrome;** P. Modi¹, K. Pennington¹, S. Shah², U. Goswami². ¹*Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN*, ²*Mayo Clinic, Phoenix, AZ*
- (1046) A Case of Living-Donor Lobar Lung Transplantation for Dyskeratosis Congenita;** M. Kobayashi, A. Ohsumi, M. Takahashi, S. Tanaka, Y. Yutaka, D. Nakajima, H. Date. *Kyoto University Hospital, Kyoto, Japan*
- (1047) Use of Dupilumab in Asthma Relapse After Lung Transplant;** A. Buscemi¹, L. Morlacchi¹, V. Rossetti¹, M. Cavallini¹, A. Palleschi², L. Rosso³, M. Mantero¹, M. Nosotti², F. Blasi¹. ¹*Internal Med Dept, Resp Unit and Cystic Fibrosis Adult Ctr, Fondazione IRCCS Ca' Granda Osp Maggiore Policlinico di Milano; Univ degli Studi di Milano, Milano, Italy*, ²*Thoracic Surg and Lung Transpl Unit, Fondazione IRCCS Ca' Granda Osp Maggiore Policlinico di Milano; Univ degli Studi di Milano, Milano, Italy*, ³*Thoracic Surg and Lung Transpl Unit, Fondazione IRCCS Ca' Granda Osp Maggiore Policlinico, Milano, Italy*
- (1048) Road to PML is Paved with Immunosuppression: Rare Case of PML After Lung Transplantation;** D. Shyu¹, J. Patil², J. Dunitz², A. Kumar², S. Kiel². ¹*Department of Medicine, University of Minnesota, Minneapolis, MN*, ²*Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Department of Medicine, University of Minnesota, Minneapolis, MN*
- (1049) ILD Strikes Back: Recurrence of Scleroderma-Related ILD After Lung Transplant;** D. Shyu¹, J. Patil², J. Dunitz², A. Kumar², S. Kiel². ¹*Department of Medicine, University of Minnesota, Minneapolis, MN*, ²*Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Department of Medicine, University of Minnesota, Minneapolis, MN*
- (1050) Treatment of De Novo Post Single Lung Transplant Pulmonary Hypertension;** Y. Wang¹, A. Guha¹, M. Botros¹, A. Goodarzi¹, H. J. Huang², S. Yau¹, J. Youssef¹, S. Sahay¹. ¹*Houston Methodist Hosp, Houston, TX*, ²*Houston Methodist J.C. Walter Jr. Transpl Ctr, Houston, TX*
- (1051) Acute Graft versus Host Disease in a Lung Transplant Recipient;** D. Scullin¹, R. Goetz², K. Wille³, V. Rusanov³, E. Gongora⁴, E. Orozco Hernandez⁵, C. Hoopes⁶, T. Kaleekal⁷. ¹*UAB Pulmonary Critical Care, Birmingham, AL*, ²*UAB, Birmingham, AL*, ³*University of Alabama at Birmingham, Birmingham, AL*, ⁴*Univ of Alabama Med Ctr, Birmingham, AL*, ⁵*UAB Medicine, Birmingham, AL*, ⁶*Univ of Alabama (Birmingham), Birmingham, AL*, ⁷*University of Alabama Birmingham, Birmingham, AL*
- (1052) A Case of Takotsubo Cardiomyopathy in a Bilateral Lung Transplant Recipient;** A. Shajihan, O. Shlobin, A. Nyquist, S. Aryal. *Inova Fairfax Hospital, Falls Church, VA*
- (1053) Post-Transplant Lymphoproliferative Disorder in a Lung Transplant Patient Presenting as an Isolated Solitary Liver Mass;** A. S. Nyquist, S. Aryal, C. King, O. Shlobin, V. Khangoora, A. Singhal, C. Thomas, J. Chun, M. Fregoso, S. Nathan. *Inova Fairfax Hosp, Falls Church, VA*
- (1054) Recurrence of Bronchiectasis Following Living Donor Lobar Lung Transplantation (LDLLT);** M. Hill Pierre-Louis, B. Keller. *Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, MA*
- (1055) Intersection of Cancer and Lung Transplant: To Transplant or Not?;** J. P. Villamizar Rivero, G. Rozenbaum, J. Fernandez, S. Al-Bayati, T. Machuca, A. Pelaez, M. Pipkin, D. Buitrago, J. Salgado. *University of Miami, Miami, FL*
- (1056) Catheter-Directed Therapy to Treat Submassive Pulmonary Emboli in Single Lung Transplant Patients;** M. Shawabkeh¹, R. Tomic¹, M. Venkata Subramani¹, C. Myers¹, J. Wright², A. Arunachalam¹, A. Joudi¹. ¹*Division of Pulmonary and Critical Care Medicine, Northwestern University - Feinberg School of Medicine, Chicago, IL*, ²*Division of Pulmonary and Critical Care Medicine, Northwestern Medicine, Chicago, IL*
- (1057) Colonic Perforation After Left Ventricular Assist Device Implantation;** A. Uysal¹, M. Qureshi², I. Dumitru³, D. Bandyopadhyay¹, D. Mathew¹, N. Mencer⁴, J. Prater¹, A. Arslan¹, C. Hunley¹, L. Uysal⁵, N. Lama⁶. ¹*Pulmonary Critical Care, Univ of South Florida, Tampa, FL*, ²*Pulmonary Critical Care Lung Transplantation, Univ of South Florida / Tampa General Hospital, Tampa, FL*, ³*Tampa General Hospital*, ⁴*Cardiology, University of South Florida, Tampa, FL*, ⁵*Loyola Univ Chicago School of Law, Chicago, IL*, ⁶*CT ICU, Tampa General Hospital, Tampa, FL*
- (1058) Over 200 Days on VV-ECMO as a Bridge to Lung Transplant in a 4-Year-Old: How Long is Too Long?;** D. Moreno McNeill¹, A. Schrader¹, D. Parrish¹, E. Melicoff-Portillo¹, K. Doane², J. Heinle³, C. Chartan⁴, M. C. Gazzaneo⁵. ¹*Ped Pulm, Texas Children's Hosp, Houston, TX*, ²*Ped Critical Care, Texas Children's Hospital, Houston, TX*, ³*Cardiothoracic Surgery, Texas Children's Hospital, Houston, TX*, ⁴*Ped Critical Care, Baylor CoM / Texas Children's Hosp, Houston, TX*, ⁵*Ped Critical Care, Baylor CoM/Texas Children's Hosp, Houston, TX*
- (1059) Use of Prostacyclin Analogs in LAM Patients with Severe Pulmonary Hypertension and Right Heart Failure;** A. Elshikh, D. Dilling,

J. Gagermeier, S. Quddus. *Loyola University Medical Center, Maywood, IL*

THURSDAY, 11 APRIL, 2024

4:30 - 5:30 p.m.

POSTER SESSION 2: Research and Immunology (Non-CME)

Location: Poster Hall

Core Therapies: HEART, LUNG, MCS, PVD

Practice Areas: Research and Immunology, Anesthesiology and Critical Care, Cardiology, Cardiothoracic Surgery, Infectious Diseases, Nursing and Allied Health, Pathology, Pediatrics, Pharmacy, Pulmonology

Session Summary: Posters in this session include presentations on multiple topics where the Practice Areas of the research is focused in Research and Immunology. Designated Poster Discussants will circulate through the poster hall during the session to engage poster presenters in quality discussions of their abstracts. **CME is not offered for poster sessions.**

Poster Discussants: François Carlier, Belgium, Anique Ducharme, Canada, Howard Eisen, USA, Kelley Hitchman, USA, Stephen Huddleston, USA, Stephen Juvet, Canada, Sumiha Karunakaran, Canada, Nandan Mondal, USA, Carolina Moore, USA, Eric Morrell, USA, Anthony Panos, USA, Eduardo Rame, USA, Lars Saemann, Germany, Ashish Sharma, USA, Gaurav Sharma, USA, Akira Shimamoto, Japan, Ulrich Stock, UK, Simon Urschel, Canada, Mrinalini Venkata Subramani, USA

(1061) Human Mesenchymal Cell Derived Exosomes as Preventive Therapy for Ischemia Reperfusion Injury in Lung Transplantation; L. Chacon¹, M. Salan-Gomez², R. Fernandez², G. Loor², C. Mendez¹. ¹Texas Heart Institute, Houston, TX, ²Baylor College of Med, Houston, TX

(1062) Extended Hypothermic Cardiac Preservation Using the VP.S ENCORE® Device Leads to Enhanced Cardiac Function in a Pilot Orthotopic Porcine Heart Transplant Study; K. Andrijauskaite¹, R. Veraza¹, R. P. Lopez¹, Z. Maxwell¹, I. Cano¹, E. C. Cisneros¹, M. Basurto¹, I. J. Jessop¹, M. D. Watt¹, G. Lamberson¹, A. Elgalad², M. Morales Garza³, L. Chacon², A. Shafii⁴, O. Frazier², L. Bunegin¹. ¹Vascular Perfusion Solutions, Inc., San Antonio, TX, ²Texas Heart Institute, Houston, TX, ³Univ of St. Thomas, Houston, TX, ⁴Baylor College of Medicine, Houston, TX

(1063) Prolonged Preservation of Pediatric Size Hearts Using the VP.S ENCORE® Hypothermic Oxygenated Machine Perfusion Device; R. Veraza, K. Andrijauskaite, R. P. Lopez, Z. Maxwell, I. Cano, E. C. Cisneros, M. Basurto, G. Lamberson, L. Bunegin. *Vascular Perfusion Solutions, Inc., San Antonio, TX*

(1064) Predicting Survival After Heart Transplantation: Validation of DRI, RSS and OPTN Risk Scores in the UK Transplant Registry; K. Wang¹, R. Hogg², S. Bhagra¹, S. Lim³, S. Pettit¹. ¹Royal Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom, ²Statistics and Clinical Research, NHS Blood and Transplant, Bristol, UK, ³University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

(1065) WITHDRAWN

(1067) Longitudinal Dynamics of SARS-CoV-2 Specific Humoral and Cellular Immune Responses in Patients on Waiting List and After Lung Transplantation; M. Huebner¹, J. Sauer¹, L. Ruhl¹, J. F. Kuehne¹, E. Chichelnitskiy¹, K. Beushausen¹, J. Keil¹, M. Schael², T. Welte², J. Gottlieb², F. Ius³, M. Greer², C. S. Falk¹. ¹Institute of Transplant Immunology, Hannover Medical School, Hannover, Germany, ²Department of Pneumology, Hannover Medical School, Hannover, Germany, ³Department for Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany

(1068) Characterization of Impella Sensitization in the Bridge-to-Heart-Transplantation Patients; J. S. Kim¹, I. K. Eng¹, I. Park², M. Hickey³, M. H. Kwon². ¹David Geffen School of Medicine at UCLA, Los Angeles, CA, ²Division of Cardiothoracic Surgery, UCLA Ronald Reagan Medical Center, Los Angeles, CA, ³UCLA Immunogenetics Center, Los Angeles, CA

(1069) Impact of a Novel Accessory for Left Ventricular Assist Devices on Hemolysis and Degradation of Von Willebrand Factor In Vitro; F. Meissner¹, D. Eichelkraut¹, M. Schimmel¹, M. Buechsel², M. Schoen¹, H. Vestner¹, M. Costa Galbas¹, M. Czerny¹, W. Bothe¹. ¹Department of Cardiovascular Surgery, Medical Center – University of Freiburg, Freiburg, Germany, ²Institute of Clinical Chemistry and Laboratory Medicine, Medical Center – University of Freiburg, Freiburg, Germany

FRIDAY, 12 APRIL, 2024

8:15 - 9:30 a.m.

SYMPOSIUM 27: One Size Does Not Fit All: Obesity in End-Stage Heart and Lung Disease

Location: Congress Hall

Core Therapies: HEART, LUNG, MCS, PVD

Practice Areas: Anesthesiology and Critical Care, Cardiology, Cardiothoracic Surgery, Infectious Diseases, Nursing and Allied Health, Pathology, Pediatrics, Pharmacy, Pulmonology, Research and Immunology

Session Summary: The worldwide prevalence of obesity nearly tripled between 1975 and 2016 and has now reached pandemic dimensions. People with obesity are less likely to be candidates for advanced heart and lung therapies, and have a higher incidence of complications after MCS and transplantation. With highly effective treatments for obesity, we finally have the tools to address this problem in our practices. But where do we start? This symposium will address (1) the effects of obesity on outcomes across all of our fields and (2) strategies for weight management in our clinical practices, including new medications and surgical approaches. A panel discussion with all speakers including audience Q&A, led by the session moderators, will conclude this session.

Moderators: Colin Church, BSC(Hons), PhD, FRCP, Golden Jubilee National Hospital, Glasgow, United Kingdom
Lenka Hoskova, MD, PhD, IKEM, Prague, Czech Republic

8:15 a.m. ***Two Birds With One Stone? Treating Obesity to Improve Outcomes in Heart Failure and Transplantation***

Peter MacDonald, MD, PhD, St. Vincent's Hospital, Sydney, Australia

Obesity both increases the risk of developing heart failure and decreases survival after heart transplantation. We will review the association between obesity and outcomes in heart failure and heart transplantation, and the potential for anti-obesity therapies to improve outcomes.

8:27 a.m. ***Managing Obese Patients on Mechanical Circulatory Support***

Esther Vorovich, MD, Northwestern University, Chicago, IL, USA

Obesity presents unique anatomic and logistical challenges to MCS while also influencing candidacy for subsequent transplantation. We will review outcomes for obese patients on MCS, challenges of MCS in obesity, and ways to overcome these challenges.

8:39 a.m. ***Quantifying Body Composition in Lung Transplantation: Is BMI the Best We Can Do?***

Michaela Anderson, MD, MS, University of Pennsylvania, Philadelphia, PA, USA

Obesity increases the risk of PGD and death after lung transplantation, while weight loss may improve post-transplant survival. Speaker will review the data supporting use of BMI in candidate selection, and discuss alternative measures of body composition-related risk in lung transplant candidates. Speaker will also discuss some of the physiology/biological mechanisms of obesity and how it links to inflammation.

8:51 a.m. ***The Past, Present, and Future of Anti-Obesity Treatments***

Haifa Lyster, PhD, FRPharmS, FFRPS, Royal Brompton, Harefield, United Kingdom

The world of anti-obesity medications is rapidly evolving. In this talk, we will review the physiology behind recently developed anti-obesity medications, the data for their use in our patient populations, and the future of obesity pharmacotherapy.

9:03 a.m. ***Innovative Approaches: Bariatric Surgery as Bridge to Heart and Lung Transplantation***

Nicolas Brozzi, MD, Cleveland Clinic Florida, Weston, FL, USA

This presentation will discuss experience performing bariatric surgery (including use of Impella support), on morbidly obese patients with advanced heart and lung failure with respect to patient selection, technical pitfalls, and early and mid-term outcomes.

9:15 a.m. ***Panel Discussion led by Moderators***

FRIDAY, 12 APRIL, 2024

8:15 - 9:30 a.m.

SYMPOSIUM 28: What Should Come First: Flow or Preservation? The Role of NRP in DCD Lung Procurement and Preservation (Non-CME)

Location: Forum Hall

Core Therapies: LUNG, HEART

Practice Areas: Cardiothoracic Surgery, Anesthesiology and Critical Care, Pulmonology

Session Summary: Two talks will describe the technical aspects of A-NRP and TA-NRP, and the options for lung procurement with each. Then there will be a PRO-CON debate + rebuttal on whether NRP will increase DCD lung utilization or not. The debate will be followed by panel discussion led by the session moderators. **No CME offered for this session.**

Moderators: Stephanie Chang, MD, NYU Langone Health, New York, NY, USA
Anne Olland, MD PhD, University Hospital Strasbourg, Strasbourg, France

8:15 a.m. ***DCD Lung Procurement with Abdominal Normothermic Regional Perfusion (NRP)***
David Gómez-de-Antonio, PhD, Hospital Universitario Puerta de Hierro Majadahonda., Madrid, Spain

The speaker will present the context and rationale for Abdominal NRP and discuss technique of direct lung procurement and preservation when combined with abdominal NRP; do's and don'ts; How these affect lung procurement strategies; bleeding risk during abdominal NRP? Temperatures?

8:25 a.m. ***DCD Lung Procurement with Thoracoabdominal Normothermic Regional Perfusion (NRP)***
Marius Berman, MD, FRCS (CTh), Royal Papworth Hospital, Cambridge, United Kingdom

The speaker will present the context and rationale for Thoracoabdominal-NRP and discuss technique of lung preservation and procurement in the setting of TA-NRP; do's and don'ts; How these affect lung procurement strategies; How to protect lungs from edema during TA-NRP?

8:35 a.m. ***DEBATE: NRP Will Increase Utilization of DCD Lungs (PRO)***
Pedro Catarino, MD, Cedars-Sinai, Los Angeles, CA, USA

The speaker will argue that DCD lungs during TA-NRP can be safely preserved, recovered and transplanted. Does NRP injure or allow evaluation of the lungs? Utilization data and outcome data will be discussed. Is technique important, especially A-NRP vs TA-NRP? Agonal period?

8:45 a.m. ***DEBATE: NRP Will Increase Utilization of DCD Lungs (CON)***
Shaf Keshavjee, MD, MSc, FRCSC, FACS, UHN, Toronto, ON, Canada

The speaker will argue that TA-NRP may damage good lungs so these may become no longer transplantable. Moreover, as all attention is focused on recovering and retrieving the DCD heart, DCD lungs may be forgotten and lower utilization is to be expected compared to direct procurement and preservation as with A-NRP. Does NRP injure or allow evaluation of the lungs? Utilization data as well as outcome data will be presented by the speaker. Is technique important, especially A-NRP vs TA-NRP? Impact of the agonal period on donor lung utilization will be discussed.

8:55 a.m. ***Panel Discussion led by Moderators***

FRIDAY, 12 APRIL, 2024

8:15 - 9:30 a.m.

SYMPOSIUM 29: Too Much! Debating Infectious Burdens of the (Pre-Transplant) Heart

Location: Panorama Hall

Core Therapies: HEART, MCS

Practice Areas: Infectious Diseases, Cardiology, Cardiothoracic Surgery, Pediatrics, Pharmacy

Session Summary: This session will present pros and cons of proceeding to heart transplantation in high-risk candidates with infection. A panel discussion with all speakers including audience Q&A, led by the session moderators, will conclude this session.

Moderators: Javier Carbone, MD, PhD, Hospital General Universitario Gregorio Marañón, Madrid, Spain
Jonathan Hand, MD, Ochsner Medical Center, New Orleans, LA, USA

8:15 a.m. **DEBATE; It's Now or Never: Transplant Adult Patients Despite Infection (PRO)**
Marta Hernandez Meneses, MD, PhD, Hospital Clínic de Barcelona, Barcelona, Spain

This speaker will introduce two case scenarios and then argue for proceeding with transplantation in Scenarios 1 and 2. Speaker will address antimicrobial treatment and prophylaxis and considerations regarding induction immunosuppression in these scenarios. Will speak 7 minutes/scenario. Scenario 1: 40 y/o male or female with well controlled HIV admitted with cardiogenic shock requires temporary percutaneous pump support. Listed for transplant but develops fever and blood culture grows Candida albicans. Scenario 2: 35 y/o male or female LVAD patient with driveline discharge and fever presents with cardiogenic shock requiring IABP. Blood culture growing MRSA.

8:30 a.m. **DEBATE: It's Now or Never: Transplant Adult Patients Despite Infection (CON)**
Cristiano Amarelli, MD, Monaldi Hospital, Napoli, Italy.

Speaker will argue for delaying transplantation in Scenarios 1 and 2 initially presented by PRO speaker and include how to address risks, antimicrobial treatment and prophylaxis, and considerations regarding induction immunosuppression in these scenarios. Will speak 7 minutes/scenario. Scenario 1: 40 y/o male or female with well controlled HIV admitted with cardiogenic shock requires temporary percutaneous pump support. Listed for transplant but develops fever and blood culture grows Candida albicans. Scenario 2: 35 y/o male or female LVAD patient with driveline discharge and fever presents with cardiogenic shock requiring IABP. Blood culture growing MRSA.

8:45 a.m. **DEBATE: Suspicious Minds: Delay Transplant in Pediatric Patients with Infection (PRO)**
Jonathan Edelson, MD, Children's Hospital of Philadelphia, Philadelphia, PA, USA

Speaker will introduce the two case scenarios and then argue for delaying transplantation in Scenarios 3 and 4 and include how to address risks, antimicrobial treatment and prophylaxis and considerations regarding induction immunosuppression in these scenarios. Will speak 7 minutes/scenario. Scenario 3: 5 y/o male or female with congenital CM called in for potential OHT and pre-operative RVP swab returns + for RSV (patient is asymptomatic). Scenario 4: 18 month old male or female on a durable ventricular assist device with Mycobacterium abscessus cannula infection.

9:00 a.m. **DEBATE: Suspicious Minds: Delay Transplant in Pediatric Patients with Infection (CON)**
Lara Danziger-Isakov, MD, MPH, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA

This speaker will argue against delaying transplant and proceeding with transplantation in Scenarios 3 and 4 previously presented by PRO speaker. Speaker will address antimicrobial treatment and prophylaxis and considerations regarding induction immunosuppression in these scenarios. Will speak 7 minutes/scenario. Scenario 3: 5 y/o male or female with congenital CM called in for potential OHT and pre-operative RVP swab returns + for RSV (patient is asymptomatic). Scenario 4: 18 month old male or female on a durable ventricular assist device with Mycobacterium abscessus cannula infection.

9:15 a.m. **Panel Discussion led by Moderators**

FRIDAY, 12 APRIL, 2024

8:15 - 9:30 a.m.

SYMPOSIUM 30: It's All About the Clots: Advancements in Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

Location: South Hall 1

Core Therapies: PVD, LUNG

Practice Areas: Cardiothoracic Surgery, Anesthesiology and Critical Care, Cardiology, Pathology, Pulmonology

Session Summary: The treatment options for chronic thromboembolic pulmonary hypertension (CTEPH) and chronic thromboembolic disease (CTED) are evolving. This session will focus on: choice of anticoagulation, medical therapy insights from French Registries, multimodal treatment approaches with PEA, BPA, and the follow-up of patients with CTEPH and CTED, providing new insights for the practicing clinician. A panel discussion with all speakers including audience Q&A, led by the session moderators, will conclude this session.

Moderators: Marion Delcroix, MD, PhD, University Hospital of Leuven, Leuven, Belgium
Michael Madani, MD, UC San Diego Health, Cardiovascular Institute, San Diego, CA, USA

8:15 a.m. *What Do We Really Know About Anticoagulants in CTEPH and CTED?*

Tara Veasey Rackley, PharmD, BCTXP, Allegheny General Hospital, Pittsburgh, PA, USA

This presentation will discuss choice of anticoagulation (DOAC versus KVA), potential complications of anticoagulant treatment in CTEPH, CTED and post-BPA/PEA, and management of therapy failure in acute on chronic pulmonary embolism.

8:30 a.m. *Medical Therapy for CTEPH: New Insights From Randomized Trials, Center Experience and Global Registries*

Marc Humbert, MD, PhD, University Paris-Saclay, Le Kremlin-Bicetre, France.

This presentation will focus on medical therapy options for CTEPH - before and after BPA/PEA - and timing considerations for initiating medical therapy to include novel management treatment patterns from global registries and expert centers, as well as available clinical randomized trials.

8:45 a.m. *Multimodal Interventions for CTEPH: Where Do We Start and Where Do We End?*

Marc De Perrot, MD, MSc, FRCSC, Toronto General Hospital, Toronto, ON, Canada

Timing and combination of BPA and PEA, with focus on distal CTEPH; which of these methods should be the treatment of choice and how to manage different cases by different approaches.

9:00 a.m. *What Happens After? Long-Term Follow-up of Patients with CTEPH and CTED*

Isabelle Opitz, MD, University Hospital Zürich, Zurich, Switzerland.

This is an overview of long-term follow-up of CTEPH and CTED patients, and the role of medical treatment post PEA, including discussion on contributing pathophysiological factors in long term management.

9:15 a.m. *Panel Discussion led by Moderators*

FRIDAY, 12 APRIL, 2024

8:15 - 9:30 a.m.

SYMPOSIUM 31: How Can Our Patients Successfully Cross the ECMO Bridge?

Location: South Hall 2

Core Therapies: MCS, HEART

Practice Areas: Cardiology, Anesthesiology and Critical Care, Cardiothoracic Surgery

Session Summary: Discuss best ventilator support practices, anticoagulation management, patient mobility, use and titration of vasoactive agents while on VA-ECMO support. A panel discussion with all speakers including audience Q&A, led by the session moderators, will conclude this session.

Moderators: Kavitha Muthiah, MBChB, PhD, St. Vincent's Hospital, Sydney, Australia
Aniket S. Rali, MD, Vanderbilt University Medical Center, Nashville, TN, USA

8:15 a.m. ***ECMO Cannulation Techniques, Left Ventricular Unloading Approaches, and Hemodynamic Management During VA-ECMO Support***

Ezequiel Molina, MD, Piedmont Heart Institute - Samsky AHF Center, Atlanta, GA, USA

Review VA-ECMO cannulation alternatives and the evidence behind venting strategies for more favorable outcomes.

8:27 a.m. ***Extra-Cardiac Care During VA-ECMO Support***

Alastair Proudfoot, PhD, Barts Health NHS Trust, London, United Kingdom

Focus on strategies to minimize extra cardiac complications while on VA-ECMO including infection prevention, nutritional optimization, volume status management, etc.

8:39 a.m. ***Pushing Boundaries: Rehabilitation and Physical Therapy in Patients on VA-ECMO Support***

Antonio Loforte, MD, PhD, University of Turin, Turin, Italy.

Analyze specific considerations for early mobilization, safe ambulation and rehabilitation in patients supported with VA-ECMO.

8:51 a.m. ***The Final Frontier in ECMO: ECPR and Mobile ECMO, Rescuing Patients from the Dead***

Guillaume Coutance, MD, PhD, Pitié-Salpêtrière Hospital, Paris, France.

Discuss recent advancements on ECPR initiation techniques and post procedure care. Highlight the capabilities of modern mobile ECMO units.

9:03 a.m. ***ECMO Exit Strategies***

Christopher Salerno, MD, University of Chicago, Chicago, IL, USA

Discuss different VA-ECMO exit strategies including heart recovery, bridge to bridge, durable LVAD, heart transplantation, and withdrawal of care.

9:15 a.m. ***Panel Discussion led by Moderators***

FRIDAY, 12 APRIL, 2024

8:15 - 9:30 a.m.

SYMPOSIUM 32: Sunday Bloody Sunday: Managing Anticoagulation in Durable MCS

Location: South Hall 3

Core Therapies: MCS, HEART

Practice Areas: Cardiology, Anesthesiology and Critical Care, Cardiothoracic Surgery

Session Summary: This session will highlight the recently published ISHLT guidelines, ARIES clinical trial and debate the use of direct oral anticoagulants in LVAD patients. A panel discussion with all speakers including audience Q&A, led by the session moderators, will conclude this session.

Moderators: Kirandeep Sidhu, MD, Hospital of the Univ of Pennsylvania, Philadelphia, PA, USA
Patricia Ging, MSc, Mater Misericordiae University Hospital, Dublin, Ireland

8:15 a.m. ***Come Together, Right Now, Over AC: Clinical Pearls from the ISHLT Consensus Document on Durable MCS Anticoagulation***

Ian Hollis, PharmD, BCPS-AQ, University of North Carolina Medical Center, Chapel Hill, NC, USA

This talk will review the newly published ISHLT antithrombotic recommendations for patients with continuous flow LVADs.

8:27 a.m. ***Should It Stay or Should It Go? Antiplatelet Therapy in Durable MCS***

Paul Christian Schulze, MD, PhD, University Hospital Jena, Jena, Germany

Antiplatelet agents are a recommended part of the antithrombotic protocol for CF-LVAD patients but the optimal drugs, doses, monitoring, and durations are in question. The speaker will tackle the question of when and where antiplatelet agents are helpful and when they may be able to be omitted. Additionally, the speaker will provide an update on the ARIES clinical trial in HM3 patients.

8:39 a.m. ***Bad Blood: Managing Anticoagulation in Durable MCS***

Daryl Nnani, PharmD, Montefiore Medical Center, Bronx, NY, USA

The speaker will highlight advances in managing outpatient anticoagulation therapy in durable MCS, including point of care testing, novel management strategies, and optimal INR targets for durable devices.

8:51 a.m. ***DEBATE: Blood, Sweat and Tears: DOACs Should Be Used in LVAD Patients (PRO)***

Christopher Hayward, MD, St Vincent's Hospital, Sydney, Australia

The presenter will discuss emerging data and practice patterns regarding the use of DOACs in durable MCS, reviewing patient selection criteria and optimal agents for use.

9:03 a.m. ***DEBATE: Blood, Sweat and Tears: DOACs Should Be Used in LVAD Patients (CON)***

Maya Guglin, MD, PhD, Indiana University Health, Indianapolis, IN, USA

This speaker will argue against using DOACs in durable MCS patients.

9:15 a.m. ***Panel Discussion led by Moderators***

FRIDAY, 12 APRIL, 2024

8:15 - 9:30 a.m.

SYMPOSIUM 33: You Want a Piece of Me? Pushing the Boundaries with Non-Invasive Heart Transplant Surveillance

Location: North Hall

Core Therapies: HEART

Practice Areas: Cardiology, Anesthesiology and Critical Care, Cardiothoracic Surgery, Nursing and Allied Health, Pathology, Pediatrics, Pharmacy, Research and Immunology

Session Summary: This session will discuss advances in non-invasive heart transplant surveillance starting with the interplay of de-novo DSA and donor derived cell free DNA (dd-cfDNA), the evolving role of micro-RNA for rejection screening followed by debated topics on patient selection and individual nuances. A panel discussion with all speakers including audience Q&A, led by the session moderators, will conclude this session.

Moderators: Anju Bhardwaj, MD, University of Texas/McGovern Med Sch, Houston, TX, USA
Eugene DePasquale, MD, University of Southern California, Los Angeles, CA, USA

8:15 a.m. **DEBATE: Forget the Biopsy: Screen All with Blood Testing (PRO)**
Shelley Hall, MD, Baylor University Medical Center, Dallas, TX, USA

This debate-style talk will focus in justify why all heart transplant recipients can be safely monitored with non-invasive surveillance.

8:25 a.m. **DEBATE: Forget the Biopsy: Screen All with Blood Testing (CON)**
Debra Isaac, MD, University of Calgary, Calgary, AB, Canada

This debate-style talk will Argue that only select heart transplant recipients are candidates for non-invasive rejection surveillance.

8:35 a.m. **Get a Piece of the Rock: What Only Biopsy Can Provide**
Annalisa Angelini, MD, University of Padua, Padua, Italy.

There is a movement in the field to minimize biopsies, and move to mostly noninvasive screening. This potentially ignores the valuable insights that can only be obtained through analysis of cardiac tissue on a serial basis. This talk will review the role of techniques such as Molecular Microscope, impact of Quilty lesions, microvascular coronary artery disease, and lipofuscin deposits.

8:45 a.m. **New Kids on the Block: Novel Biomarkers for Detection of Allograft Rejection and Function**
Palak Shah, MD, MS, Inova Heart and Vascular Institute, Falls Church, VA, USA

This talk will focus on novel biomarkers in allograft rejection and allograft function surveillance (like MMDX, exosomes).

8:55 a.m. **Molecular Diagnostic Cost vs Utility**
Mario Deng, MD, FACC, FESC, UCLA Medical Center, Los Angeles, CA, USA

This talk will focus on reviewing the costs and utility of cell free DNA, biomarkers, MMDx, gene expression profiling, in the care of post-transplant patients.

9:05 a.m. **Panel Discussion led by Moderators**

FRIDAY, 12 APRIL, 2024

10:00 - 11:15 a.m.

ORAL SESSION 22: LVAD Surgical Procedures for the Long Haul

Location: Congress Hall

Core Therapies: MCS

Practice Areas: Cardiothoracic Surgery, Anesthesiology and Critical Care, Cardiology, Nursing and Allied Health

Session Summary: The risk and benefits of concomitant surgical procedures during LVAD implantation remain controversial. This session will highlight how surgical approaches and additional procedures performed at the time of LVAD implantation may impact outcomes.

Each presenter will give a **10-minute** PowerPoint presentation, followed by a **5-minute** question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: Eric de Waal, MD PhD, University Medical Center Utrecht, Utrecht, Netherlands
Sebastian Rojas, MD, Heart and Diabetes Center, Bad Oeynhausen, Germany

10:00 a.m. **(107) Impact of Concomitant Aortic Valve Replacement in Patients with Mild-to-Moderate Aortic Valve Regurgitation Undergoing LVAD Implantation: Propensity Score-Matched Analysis of the EUROMACS Dataset**
A. Loforte¹, G. Nersesian², G. Gliozzi³, G. Gallone⁴, A. Spitaleri¹, F. Schoenrath², I. Netuka⁵, D. Zimpfer⁶, T. De By⁷, M. Boffini¹, I. Vendramin³, J. Gummert⁸, V. Falk², B. Meyns⁹, M. Rinaldi¹, E. Potapov². ¹Department of Surgical Sciences, City of Health and Science Hospital, Department of Cardiac Surgery, University of Turin, Turin, Italy, ²Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charite, Berlin, Germany, ³Department of Cardiac Surgery, S. Maria della Misericordia University Hospital of Udine, Udine, Italy, ⁴Department of Medical Sciences, City of Health and Science Hospital, Department of Cardiology, University of Turin, Turin, Italy, ⁵Department of Cardiovascular Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic, ⁶Department of Cardiothoracic Surgery, Medical University of Vienna, Vienna, Austria, ⁷EUROMACS, Windsor, United Kingdom, ⁸Department of Thoracic, Cardiac and Vascular Surgery, Herz und Diabeteszentrum NRW, Bad Oeynhausen, Germany, ⁹Department of Cardiac Surgery, University Hospital Leuven, Leuven, Belgium

10:10 a.m. **Q&A**

10:15 a.m. **(108) Cryoablation for Ventricular Arrhythmia During Left Ventricular Assist Device Implantation is Safe and Feasible: A Retrospective Cohort Study**
C. P. Wong, I. Bhatia, O. J. Lee, C. Ho. Queen Mary Hospital, Hong Kong, Hong Kong

10:25 a.m. **Q&A**

10:30 a.m. **(109) Incidence and Risk Factors for Early Stroke Following Durable Left Ventricular Assist Device (LVAD) Implantation: An STS Intermacs Analysis**
E. Molina¹, D. Goldstein², R. Cantor³, M. Kanwar⁴, D. Meyer⁵, U. Jorde², O. Saeed², K. Wood⁶, R. Rudraraju³, S. Lewis³, J. Kirklin³, F. Pagani⁷, A. Kilic⁸. ¹Piedmont Heart Institute - Samsky Advanced Heart Failure Center, Atlanta, GA, ²Montefiore Einstein Center for Heart and Vascular Care, New York, NY, ³Kirklin Solutions, Hoover, AL, ⁴Cardiovascular Institute at Allegheny Health Network, Pittsburgh, PA, ⁵Baylor Scott and White Health, Baylor University Medical Center, Dallas, TX, ⁶University of Rochester Medical Center, Rochester, NY, ⁷University of Michigan, Ann Arbor, MI, ⁸Medical University of South Carolina, Charleston, SC

10:40 a.m. **Q&A**

10:45 a.m. **(110) Mitral Regurgitation at the Time of Left Ventricular Assist Device Implantation - Should We Treat It or Not?**
H. Kohno¹, G. Matsumiya¹, Y. Saiki², K. Kinugawa³, M. Ono⁴. ¹Chiba University Hospital, Chiba, Japan, ²Tohoku Univ Grad Sch of Med, Sendai, Japan, ³University of Toyama, Toyama, Japan, ⁴The University of Tokyo Hospital, Tokyo, Japan

10:55 a.m. **Q&A**

11:00 a.m. **Late-Breaking Abstract Presentation:**

(111) Impact of Concomitant Surgical Procedures in a Randomized Controlled Trial of Aspirin Removal in Left Ventricular Assist Device Patients - An Analysis from The ARIES Trial
F. Pagani¹, M. R. Mehra². ¹Univ of Michigan, Ann Arbor, MI, ²Brigham and Women's Hospital and Harvard Med Sch, Boston, MA

11:10 a.m. **Q&A**

FRIDAY, 12 APRIL, 2024

10:00 - 11:15 a.m.

ORAL SESSION 23: Inequity and Inequality in Heart Transplantation: We Shall Overcome!?

Location: Forum Hall

Core Therapies: HEART

Practice Areas: Cardiology, Cardiothoracic Surgery, Pediatrics

Session Summary: Social determinants of health continue to influence heart transplant outcomes. This session addresses social and economic aspects that impact equity and equality in heart transplantation.

Each presenter will give a **10-minute** PowerPoint presentation, followed by a **5-minute** question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: Donna Hickling, AdvAPD, The Prince Charles Hospital, Queensland Health, Brisbane, Australia
Heike Spaderna, PhD, Trier University, Trier, Germany

10:00 a.m. **(112) Improved Equity in 1A, but Not 1B, Status Exceptions for Pediatric Heart Transplant Candidates with Pediatric Specific Review Board and Exception Guidance**
L. K. Wright¹, S. Culp², R. J. Gajarski³, D. Nandi¹. ¹Nationwide Children's Hospital, Columbus, OH, ²Center for Biostatistics, Department of Biomedical Informatics, The Ohio State University, Columbus, OH, ³Nationwide Children's Hospital, Columbus, OH

10:10 a.m. **Q&A**

10:15 a.m. **(113) The TEAMMATE Trial: Post-Transplant Outcomes and Social Determinants of Health**
L. A. Sleeper¹, T. P. Singh², K. P. Daly², J. C. Alejos³, S. R. Auerbach⁴, L. Barkoff⁵, M. J. Bock⁶, A. Butto⁷, W. F. Carlo⁸, C. Castleberry⁹, M. Chrisant¹⁰, S. Deshpande¹¹, W. J. Dreyer¹², B. Feingold¹³, J. Friedland-Little¹⁴, S. Gonzales¹⁵, S. A. Hollander¹⁵, A. Joong¹⁶, S. Kindel¹⁷, G. L. Klein², A. K. Lal¹⁸, J. Lamour¹⁹, I. Lytrivi²⁰, D. M. Peng²¹, J. W. Rossano²², T. D. Ryan²³, J. A. Su²⁴, D. Sutcliffe²⁵, S. Zangwill²⁶, C. S. Almond¹⁵. ¹Cardiology, Boston Children's Hosp, Boston, MA, ²Boston Children's Hosp, Boston, MA, ³UCLA Mattel Children's Hosp, Los Angeles, CA, ⁴Univ of Colorado, Aurora, CO, ⁵Lucile Packard Children's Hosp, Palo Alto, CA, ⁶Rady Children's Hosp / UCSD, San Diego, CA, ⁷Children's Healthcare of Atlanta, Atlanta, GA, ⁸Univ of Alabama, Birmingham, AL, ⁹Dell Med Sch at Univ of Texas in Austin, Austin, TX, ¹⁰Joe DiMaggio Children's Hosp, Hollywood, FL, ¹¹Children's National Hosp, George Washington Univ, Washington, DC, ¹²Baylor CoM, Houston, TX, ¹³UPMC Children's Hosp of Pittsburgh, Pittsburg, MA, ¹⁴Seattle Children's Hosp, Seattle, WA, ¹⁵Stanford Univ, Palo Alto, CA, ¹⁶Ann & Robert H. Lurie Children's Hosp of Chicago, Chicago, IL, ¹⁷Children's Hosp of Wisconsin, Milwaukee, WI, ¹⁸Univ of Utah, Salt Lake City, UT, ¹⁹Mount Sinai MC, New York City, NY, ²⁰Columbia Presbyterian Hosp, New York, New York City, NY, ²¹Univ of Michigan, Ann Arbor, MI, ²²The Children's Hosp of Philadelphia, Philadelphia, PA, ²³Cincinnati Children's Hosp MC, Cincinnati, OH, ²⁴Children's Hosp Los Angeles, Los Angeles, CA, ²⁵Children's Mercy Hosp, Kansas City, MO, ²⁶Phoenix Children's Hosp, Phoenix, AZ

10:25 a.m. **Q&A**

10:30 a.m. **(114) Socioeconomic Deprivation Predicts Worse Post-Transplant Survival in US Pediatric Heart Transplantation**
K. Kulshrestha¹, J. Greenberg¹, J. Kennedy², C. Chin¹, T. Ryan¹, S. de Loizaga Carney¹, K. Schneider¹, A. A. Divanovic¹, F. Zafar¹, D. L. Morales¹. ¹Heart Institute, Cincinnati Children's Hosp MC, Cincinnati, OH, ²Univ of Cincinnati MC, Cincinnati, OH

10:40 a.m. **Q&A**

10:45 a.m. **(115) Availability, Volumes, and Referral Strategies of Advanced Heart Failure Therapies in the Eastern Mediterranean Region: Results from The AHF-EMR Survey**
Y. Manla¹, J. Alburaiqi², F. Khaliel², M. Yacoub³, K. Shaker³, A. Amin⁴, R. Tarazi⁵, K. Alhumood⁶, H. Skouri⁷, A. Badr⁸, A. Bennis⁹, L. Abid¹⁰, A. Turk¹¹, A. Abdin¹², N. Elsammani¹³, N. Paktin¹⁴, S. Bhatti¹⁵, O. Bheleel¹⁶, H. Farhan¹⁷, K. Sulaiman¹⁸, A. Al-Motarreb¹⁹, M. AlQaseer²⁰, F. Bader¹. ¹Cleveland Clinic Abu Dhabi, Abu Dhabi, UAE, ²King Faisal Specialist Hosp & Res Ctr, Riyadh, Saudi Arabia, ³Aswan Heart Centre, Aswan, Egypt, ⁴Rajaie Cardiovascular, Med & Res Ctr, Tehran, Iran, ⁵Al-Dabbous Cardiac Center, Kuwait City, Kuwait, ⁶Al Salam Int'l Hosp, Kuwait City, Kuwait, ⁷American Univ of Beirut MC, Beirut, Lebanon, ⁸Hamad Med Corp, Doha, Qatar, ⁹Ctr of Cardiology, Casablanca, Morocco, ¹⁰Hedi Chaker Hosp, Sfax, Tunisia, ¹¹Advanced Heart Diseases Clinica, Amman, Jordan, ¹²Syrian Cardiovascular Assn, Damascus, Syria, ¹³Shaab Teaching Hosp, Khartoum, Sudan, ¹⁴Afghanistan Cardiovascular Society, Kabul, Afghanistan, ¹⁵Nat'l Inst of Cardiovascular Diseases, Karachi, Pakistan, ¹⁶Tripoli Univ Hosp, Tripoli, Libya, ¹⁷Iraqi Sci Council of Cardiology, Baghdad, Iraq, ¹⁸Nat'l Heart Center, Royal Hosp, Muscat, Oman, ¹⁹Sanaa Univ, Sana'a, Yemen, ²⁰King Fahad Specialist Hospital, Dammam, Saudi Arabia

10:55 a.m. **Q&A**

11:00 a.m.

(116) Social Deprivation Explains Racial Disparities in Heart Transplantation Outcomes

S. Madan¹, S. Ramineni², O. Saeed², J. Ovalle Ramos³, S. Forest⁴, D. Goldstein⁵, S. Patel⁶, U. Jorde⁴. ¹Montefiore Medical Center, New York, NY, ²Montefiore Medical Center/Albert Einstein College of Medicine, NYC, NY, ³Montefiore Medical Center / Albert Einstein College of Med, NYC, NY, ⁴Montefiore Med Ctr, NYC, NY, ⁵Montefiore, NYC, NY, ⁶Montefiore-Einstein, NYC, NY

11:10 a.m.

Q&A

FRIDAY, 12 APRIL, 2024

10:00 - 11:15 a.m.

ORAL SESSION 24: Uncovering Novel Diagnostics of CLAD: Secrets of Dumbledore's Lung

Location: South Hall 3

Core Therapies: LUNG

Practice Areas: Pulmonology, Pathology, Research and Immunology

Session Summary: Chronic lung allograft dysfunction (CLAD) is the main cause of late death after lung transplant. However, it remains very difficult to predict which patient will develop this allograft dysfunction and when. This session will introduce new diagnostic strategies for early detection of CLAD, using molecular analysis of transbronchial biopsies, airway mucosal biopsies, as well as airway brushings. New approaches to pulmonary testing with oscillometry and radiographic volumetry will also be described.

Each presenter will give a **10-minute** PowerPoint presentation, followed by a **5-minute** question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: Kelley Hitchman, MS, PhD, F(ACHI), University of Texas Health San Antonio, San Antonio, TX, USA
Eric Morrell, MD, University of Washington, Seattle, WA, USA

- 10:00 a.m. **(117) Exploring New Molecular Biomarkers in Transbronchial Biopsies from Patients with Chronic Lung Allograft Dysfunction: A Bicentric Longitudinal Study**
F. Lunardi¹, M. Orlandi², G. Benvenuto¹, F. Pezzuto¹, G. Comacchio², M. Loy², C. Giraudo¹, F. Braccioni², E. Cozzi¹, M. Boffini³, L. Delsedime³, F. P. Schena⁴, F. Rea¹, F. Calabrese¹. ¹University of Padova, Padova, Italy, ²Padova University Hospital, Padova, Italy, ³University of Turin, Turin, Italy, ⁴Schena Foundation, Bari, Italy
- 10:10 a.m. **Q&A**
- 10:15 a.m. **(118) Developing a Molecular Classifier to Predict Graft Loss in Lung Transplant Mucosal Biopsies**
P. T. Gauthier¹, M. Mackova¹, R. Hachem², J. Havlin³, A. Hirji⁴, P. Jaksch⁵, S. Juvet⁶, S. Keshavjee⁶, W. Klepetko⁷, D. Kreisel², B. Kubisa⁸, D. J. Levine⁹, R. Lischke³, M. Piotrowska⁸, J. Simonek³, G. Snell¹⁰, I. Timofte¹¹, J. Weinkauff⁴, G. Westall¹⁰, A. Zajacova³, K. Halloran⁴, P. Halloran⁴. ¹Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada, ²Washington Univ SoM, St. Louis, MO, ³Univ Hospital Motol, Prague, Czech Republic, ⁴Univ of Alberta, Edmonton, AB, Canada, ⁵Medical Univ Vienna, Vienna, Austria, ⁶UHN, Toronto, ON, Canada, ⁷Medical Univ of Vienna, Vienna, Austria, ⁸Pomeranian Medical Univ of Szczecin, Szczecin, Poland, ⁹Stanford Univ, Stanford, CA, ¹⁰Alfred Hospital, Melbourne, Australia, ¹¹Univ of Maryland, Baltimore, MD
- 10:25 a.m. **Q&A**
- 10:30 a.m. **(119) Multicenter Assessment of the Bronchiolar Brushing Molecular Inflammation Score, AIS2, to Identify Incipient CLAD and Mortality Risk**
R. Mohanty¹, K. Moghbeli², J. Singer¹, D. Calabrese¹, S. Hays¹, L. Leard¹, R. Shah¹, A. Venado¹, M. Kleinhenz¹, J. Golden¹, J. Kukreja¹, S. Lieber², R. Ward¹, C. Love¹, T. Martinu³, C. Iasella², C. Langelier¹, J. McDyer², J. R. Greenland¹. ¹UCSan Francisco, San Francisco, CA, ²Univ of Pittsburgh, Pittsburgh, PA, ³Toronto General Hospital/UHN, Toronto, ON, Canada
- 10:40 a.m. **Q&A**
- 10:45 a.m. **(120) Airway Oscillometry Reactance Area Provides Independent Prognostication for Graft Loss in Recipients with Chronic Lung Allograft Dysfunction**
D. Darley¹, K. Nilsen², J. Vazirani², B. Borg², B. Levvey², G. Snell³, M. Plit⁴, K. Tonga⁵. ¹St Vincent's Hospital Darlinghurst, Surry Hills, Australia, ²The Alfred Hospital, Melbourne, Australia, ³Alfred Hospital, Melbourne, Australia, ⁴St. Vincent's Hospital, Sydney, Australia, ⁵St Vincent's Hospital, Sydney, Australia
- 10:55 a.m. **Q&A**
- 11:00 a.m. **(121) Comparison of Plethysmographic Total Lung Capacity and Computed Tomography Volumetry in Lung Transplant Recipients (The ScanCLAD Study)**
R. Mikkeli¹, R. Kesävuori¹, A. Nykänen², J. Magnusson³, T. Lund⁴, I. Leuckfeld⁵, J. Svahn⁶, T. Mäkelä⁷, G. Dellgren⁸, P. Raivio². ¹Radiology, HUS Medical Imaging Ctr, Helsinki Univ Hosp and Univ of Helsinki, Helsinki, Finland, ²Cardiac Surgery, Heart and Lung Ctr, Helsinki Univ Hosp and Univ of Helsinki, Helsinki, Finland, ³Pulm, Transplant Institute, Sahlgrenska Univ Hosp, Gothenburg, Sweden, ⁴Cardiology, Section for Lung Transplantation, Rigshospet, Copenhagen, Denmark, ⁵Respiratory Medicine, Oslo Univ Hosp, Oslo, Norway, ⁶Pulm and Allergology, Skåne Univ Hosp, Lund, Sweden, ⁷HUS Medical Imaging Ctr, Helsinki Univ Hosp and Univ of Helsinki, Helsinki, Finland, ⁸CT Surgery, Transplant Institute, Sahlgrenska Univ Hosp, Gothenburg, Sweden
- 11:10 a.m. **Q&A**

FRIDAY, 12 APRIL, 2024

10:00 - 11:15 a.m.

ORAL SESSION 25: Primary Graft Dysfunction in Heart Transplantation: What's Hot in a Cold Case?

Location: South Hall 1

Core Therapies: HEART

Practice Areas: Cardiothoracic Surgery, Anesthesiology and Critical Care, Cardiology, Research and Immunology

Session Summary: The session will widely deal with an hot topic in Heart Transplantation with insights ranging from the prevalence and outcomes of PGD to its gene expression and finally to the attempts to reduce its incidence and improve outcomes.

Each presenter will give a **10-minute** PowerPoint presentation, followed by a **5-minute** question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: Jon Kobashigawa, MD, Cedars-Sinai Heart Institute, Los Angeles, CA, USA
Yasuhiro Shudo, MD, PhD, Stanford University, Palo Alto, CA, USA

10:00 a.m. **(122) Updates from the International Consortium on Primary Graft Dysfunction: An Interim Report and Important Themes**
L. K. Truby¹, Y. Moayed², F. Foroutan³, J. Han⁴, E. Henricksen⁵, H. Luikart⁵, E. Ródenas Alesina⁶, J. Guzman Bofarull⁷, D. Couto Mallon⁸, R. Moayedifar⁹, K. Takeda¹⁰, G. Kim¹¹, M. Crespo-Leiro⁸, J. Felius¹², S. Hall¹², A. D. DeVore¹³, J. B. Lerman¹³, M. Sabatino¹⁴, L. Potena¹⁵, M. Rivas-Lasarte¹⁶, J. Segovia-Cubero¹⁶, M. Farrero Torres¹⁷, M. Tremblay-Gravel¹⁸, P. Noly¹⁸, R. Miller¹⁹, S. Chih²⁰, B. Clarke²¹, M. Farr¹, C. Fan²², H. Ross²³, K. Khush⁵, A. Zuckermann²⁴. ¹UT Southwestern MC, Dallas, TX, ²UHN, Toronto, ON, Canada, ³Ted Rogers Ctr for Heart Res, Toronto, ON, Canada, ⁴Univ of Chicago MC, Chicago, IL, ⁵Stanford Univ, Palo Alto, CA, ⁶Hosp Univ Vall d'Hebron, Barcelona, Spain, ⁷Hosp Clinic, Barcelona, Spain, ⁸Univ Hosp A Coruna, La Coruna, Spain, ⁹Med Univ Vienna, Gen Hosp Vienna, Vienna, Austria, ¹⁰Columbia Univ, New York, NY, ¹¹Univ of Chicago, Chicago, IL, ¹²Baylor Univ MC, Dallas, TX, ¹³Duke Univ MC, Durham, NC, ¹⁴Inst of Card S.Orsola-Malpighi Hosp, Bologna, Italy, ¹⁵IRCCS Azienda Ospedaliero-Univ, Bologna, Italy, ¹⁶Hosp Puerta de Hierro, Madrid, Spain, ¹⁷Hosp Clinic, Barcelona, Spain, ¹⁸Montreal Heart Inst, Montreal, QC, Canada, ¹⁹Univ of Calgary, Calgary, ON, Canada, ²⁰Univ of Ottawa Heart Inst, Ottawa, ON, Canada, ²¹St. Paul's Hosp, Univ of British Columbia, Vancouver, BC, Canada, ²²UHN, Toronto, ON, Canada, ²³Toronto Gen Hosp, Toronto, ON, Canada, ²⁴Med Univ of Vienna, Vienna, Austria

10:10 a.m. **Q&A**

10:15 a.m. **(123) Primary Graft Dysfunction After Heart Transplant in Adults: A Gene Expression Analysis**
S. Steffen, F. Gaiotto, R. Honorado Santos, D. Filho, S. Gaspar, F. Marcondes-Braga, A. Pereira, E. Cunha-Neto, F. Bacal, J. Krieger, R. Kalil, F. Jatene. *Heart Inst - São Paulo Brazil, Sao Paulo, Brazil*

10:25 a.m. **Q&A**

10:30 a.m. **Late-Breaking Abstract Presentation:**

(124) Validation of a Machine Learning Primary Graft Dysfunction Risk Score in a Contemporary Heart Transplant Cohort: An Analysis of the International Consortium on PGD

Y. Moayed¹, L. Truby², C. Fan³, F. Foroutan⁴, E. Henricksen⁵, H. Luikart⁶, E. Ródenas Alesina³, J. Han⁷, D. Couto Mallon⁸, J. Guzman Bofarull⁹, M. Crespo-Leiro¹⁰, R. Moayedifar¹¹, G. Kim¹², J. Felius¹³, M. Sabatino¹⁴, L. Potena¹⁵, M. Lerman¹⁶, K. Takeda¹⁷, M. Tremblay-Gravel¹⁸, P. Noly¹⁸, R. Miller¹⁹, A. Zuckermann²⁰, B. Clarke²¹, M. Rivas-Lasarte²², S. Hall²³, J. Segovia-Cubero²⁴, M. Farrero Torres⁹, S. Chih²⁵, A. Devore¹⁶, M. Farr², H. Ross²⁶, K. Khush²⁷. ¹UHN, Toronto, ON, Canada, ²University of Texas Southwestern Medical Center, Dallas, TX, ³University Health Network, Toronto, ON, Canada, ⁴Ted Rogers Centre for Heart Research, Toronto, ON, Canada, ⁵Stanford Healthcare, Stanford, CA, ⁶Stanford Hospital, Stanford, CA, ⁷University of Chicago Medical Center, Chicago, IL, ⁸Unidad de Insuficiencia Cardiaca Avanzada y Trasplante Cardiaco, Hospital Universitario A Coruña, A Coruña, Spain, ⁹Hospital Clinic de Barcelona, Barcelona, Spain, ¹⁰Hospital Universitario A Coruña, A Coruña, Spain, ¹¹Medical University Vienna General Hospital Vienna, Vienna, Austria, ¹²University of Chicago, Chicago, IL, ¹³Baylor Univ Med Ctr, Baylor, TX, ¹⁴Institute of Cardiology S.Orsola-Malpighi Hospital, Bologna, Italy, ¹⁵IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, ¹⁶Duke Medical Center, Durham, NC, ¹⁷Columbia university, New York City, NY, ¹⁸Montreal Heart Institute, Montreal, QC, Canada, ¹⁹University of Calgary, Calgary, AB, Canada, ²⁰Medical University of Vienna, Vienna, Austria, ²¹St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada, ²²Hospital Puerta de Hierro, Madrid, Madrid, Spain, ²³Baylor University MC, Baylor, TX, ²⁴Hospital Puerta de Hierro, Madrid, Spain, Madrid, Spain, ²⁵University of Ottawa Heart Institute, Ottawa, ON, Canada, ²⁶Toronto General Hospital, Toronto, ON, Canada, ²⁷Stanford University, Stanford, CA

10:40 a.m. **Q&A**

10:45 a.m. **(125) Improved 2-Year Heart Transplant Survival with Moderate Hypothermic Donor Heart Preservation in the Guardian Heart Registry**

S. Silvestry¹, D. Meyer², S. Pham³, J. P. Jacobs⁴, Y. Shudo⁵, J. Schroder⁶, M. Leacche⁷, C. Sciortino⁸, H. Copeland⁹, M. E. Rodrigo¹⁰, K. Takeda¹¹, M. Kawabori¹², B. Mahesh¹³, L. Klein¹⁴, A. Vidic¹⁵, S. Patel¹⁶, D. D'Alessandro¹⁷. ¹AdventHealth Transplant

Inst, Orlando, FL, ²Baylor Scott and White Health, Baylor Univ MC, Dallas, TX, ³Mayo Clinic, Jacksonville, FL, ⁴Univ of Florida Health Shands, Gainesville, FL, ⁵Stanford Univ, Stanford, CA, ⁶Duke Univ MC, Durham, NY, ⁷Corewell Health, Grand Rapids, MI, ⁸Sentara Norfolk Gen Hosp, Norfolk, VA, ⁹Lutheran Med Group, Fort Wayne, IN, ¹⁰Medstar Washington Hosp Center, Washington DC, ¹¹Columbia Univ, New York, NY, ¹²Tufts MC, Boston, MA, ¹³Penn State Hershey MC, Hershey, PA, ¹⁴UC San Francisco, San Francisco, CA, ¹⁵Univ of Kansas MC, Kansas City, KS, ¹⁶Montefiore-Einstein, Bronx, NY, ¹⁷MGH, Boston, MA

10:55 a.m. **Q&A**

11:00 a.m. **(126) Fifteen Years Experience of Veno-Arterial Extracorporeal Membrane Oxygenation for Primary Graft Dysfunction After Heart Transplantation**

M. Laali¹, G. Coutance², S. Varnous³, A. Carillion⁴, C. D'Alessandro⁵, P. Demondion¹, G. Lebreton⁶, P. Leprince⁷. ¹*Thoracic and Cardiovascular Surgery, La Pitié Salpêtrière Hosp, Paris, France, ²Pitié-Salpêtrière Hosp, Paris, France, ³Hosp Pitie Salpetriere, Paris, France, ⁴Anesthesia And Intensiv Care Unit, La Pitié - Salpêtrière, Paris, France, ⁵La Pitie - Sapletriere Hosp, Paris, France, ⁶Hosp La Pitie, Paris, France, ⁷Hopital de La Pitie Salpetriere, Sorbonne Univ, Paris, France*

11:10 a.m. **Q&A**

FRIDAY, 12 APRIL, 2024

10:00 - 11:15 a.m.

ORAL SESSION 26: Pediatric VAD Therapy: Are We Really Doing Better?

Location: South Hall 2

Core Therapies: MCS

Practice Areas: Pediatrics, Anesthesiology and Critical Care, Cardiology, Cardiothoracic Surgery

Session Summary: In this session, the typical clinical challenges of pediatric VAD therapy will be discussed on the basis of multicenter data.

Each presenter will give a **10-minute** PowerPoint presentation, followed by a **5-minute** question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: David Sutcliffe, MD, Children's Mercy Hospital, Kansas City, MO, USA
Simon Urschel, MD, University of Alberta, Edmonton, AB, Canada

- 10:00 a.m. **(127) External Validation of a Risk Score Assessment for Pediatric Ventricular Assist Device Mortality**
M. Reaney¹, K. Boucek², A. Lorts³, D. Rosenthal⁴, K. Yan¹, J. Zhang¹, R. Niebler¹. ¹Medical College of Wisconsin, Children's Wisconsin, Wauwatosa, WI, ²Ochsner Clinic, New Orleans, LA, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Stanford University, Palo Alto, CA
- 10:10 a.m. **Q&A**
- 10:15 a.m. **(128) Long Term Ventricular Assist Devices in Children**
E. J. Mejia¹, D. Koehl², R. Cantor², J. Kirklin², D. Morales³, T. Perry³, K. Maeda⁴, K. Lin⁴, J. Edelson⁴, M. O'Connor⁴, C. Wittlieb-Weber⁴, J. Edwards⁴, J. Rossano⁴. ¹Ann & Robert Lurie Children's Hospital, Chicago, IL, ²Kirklin Solutions, Birmingham, AL, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Children's Hospital of Philadelphia, Philadelphia, PA
- 10:25 a.m. **Q&A**
- 10:30 a.m. **(129) The Outcomes of Temporary Mechanical Circulatory Support Using Paracorporeal Continuous Flow Pump in Children; A Multicenter Study Using ACTION Learning Network**
J. Moon¹, V. Sood¹, A. Lorts², M. Shezad², M. O'Connor³. ¹University of Michigan, Ann Arbor, MI, ²Cincinnati Children's Hospital, Cincinnati, OH, ³Children's Hospital of Philadelphia, Philadelphia, PA
- 10:40 a.m. **Q&A**
- 10:45 a.m. **(130) Clinical Features to Predict Weaning from Ventricular Assist Device in Pediatric Patients with Myocarditis**
N. Rolfs¹, T. Hecht², M. Boehne³, B. Opgen-Rhein¹, F. Anderheiden⁴, B. Wannenmacher⁵, M. Fischer⁶, B. Ruf⁷, K. Reineker⁸, M. Grafmann⁹, G. Wiegand¹⁰, P. Murin¹¹, E. Schwarzkopf¹, T. Pickardt¹², O. Miera¹, D. Messroghli¹³, S. Schubert², F. Seidel¹. ¹Department of Congenital Heart Disease – Pediatric Cardiology, Deutsches Herzzentrum der Charité, Berlin, Germany, ²Herz- und Diabeteszentrum NRW, Bad Oeynhausen, Germany, ³Department of Pediatric Cardiology and Intensive Care Medicine, Hannover Medical School, Hannover, Germany, ⁴University Hospital Erlangen, Erlangen, Germany, ⁵Heart Center Leipzig - University Hospital, Leipzig, Germany, ⁶Ludwig Maximilians University of Munich, Munich, Germany, ⁷Deutsches Herzzentrum München, Munich, Germany, ⁸University Heart Center Freiburg - Bad Krozingen, Freiburg, Germany, ⁹University Heart Center Hamburg, Hamburg, Germany, ¹⁰University Hospital Tuebingen, Tuebingen, Germany, ¹¹Department of Congenital Heart Surgery - Pediatric Heart Surgery, Deutsches Herzzentrum der Charité, Berlin, Germany, ¹²Competence Network for Congenital Heart Defects, Berlin, Germany, ¹³Dept of Cardiology, Angiology and Intensive Care Medicine, Deutsches Herzzentrum der Charité, Berlin, Germany
- 10:55 a.m. **Q&A**
- 11:00 a.m. **(131) Timing of Stroke in Children Supported by Ventricular Assist Devices - An ACTION Registry Report**
M. Shezad¹, J. Murray², M. Mehegan³, A. Lorts¹, M. O'Connor⁴, M. Rivkin⁵, J. Edelson⁴, D. Rosenthal², S. Law⁶, C. VanderPluym⁵. ¹Cincinnati Children's Hospital Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Stanford Children's, Palo Alto, CA, ³St Louis Children's Hos, St Louis, MO, ⁴Children's Hospital of Philadelphia, Philadelphia, PA, ⁵Boston Children's Hospital, Boston, MA, ⁶Columbia University, New York City, NY
- 11:10 a.m. **Q&A**

FRIDAY, 12 APRIL, 2024

10:00 - 11:15 a.m.

ORAL SESSION 27: How to Manage Infectious Threats After Lung Transplant: Magical Spells from Hogwarts!

Location: Panorama Hall

Core Therapies: LUNG

Practice Areas: Infectious Diseases, Cardiology, Cardiothoracic Surgery, Pharmacy, Pulmonology

Session Summary: These four oral abstracts will discuss risk factors and new tools for diagnosis and treatment of fungal, viral and bacterial infections post-lung transplant

Each presenter will give a **10-minute** PowerPoint presentation, followed by a **5-minute** question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: Margaret Hannan, MD, Mater Hospital, Dublin, Ireland
Flavio Pola, MD, Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina da USP, Sao Paulo, Brazil

10:00 a.m. **(132) Early and Late Invasive Aspergillosis in the First Year Post Lung Transplant (LT) - A Multicentre Study**
L. Walti¹, C. Crone², R. Bitterman³, R. Nadeem³, M. Helleberg⁴, M. Perch⁵, A. Perez Cortes Villalobos⁶, T. Martinu⁷, S. Keshavjee⁸, S. Husain³. ¹University Health Network, University of Toronto, Toronto, ON, Canada, ²CHIP/PERSIMUNE, University Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark, ³University Health Network, Toronto, ON, Canada, ⁴Departement of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark, ⁵Rigshospitalet, Copenhagen, Denmark, ⁶University Health Network, Toronto, ON, Canada, ⁷Toronto General Hospital/UHN, Toronto, ON, Canada, ⁸UHN, Toronto, ON, Canada

10:10 a.m. **Q&A**

10:15 a.m. **(133) Invasive Candidiasis Following Lung Transplant: An Assessment of Impact Utilizing a National Insurance Claims Cohort**
B. A. White¹, H. C. Heien², S. G. Peters¹, R. R. Razonable³, C. C. Kennedy¹, K. M. Pennington¹. ¹Pulmonary & Critical Care Medicine, Mayo Clinic, Rochester, MN, ²Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, ³Infectious Diseases, Mayo Clinic, Rochester, MN

10:25 a.m. **Q&A**

10:30 a.m. **(134) The Ability of an Electronic Nose to Distinguish Between Infections in Lung Transplant Recipients**
N. Wijbenga¹, C. E. Luijendijk¹, R. van Pel¹, B. J. Mathot¹, L. Seghers¹, D. Bos², O. C. Manintveld³, M. E. Hellemons¹. ¹Department of Respiratory Medicine and Erasmus MC Transplant Institute, Erasmus University Medical Center, Rotterdam, Netherlands, ²Department of Radiology & Nuclear Medicine and Epidemiology, Erasmus University Medical Center, Rotterdam, Netherlands, ³Department of Cardiology and Erasmus MC Transplant Institute, Erasmus University Medical Center, Rotterdam, Netherlands

10:40 a.m. **Q&A**

10:45 a.m. **(135) Use of Letemovir for Cytomegalovirus Prophylaxis in Lung Transplant**
H. Kleiboeker¹, J. Wang², N. Borkowski³, B. Miner³, M. Mahesi⁴, M. Venkata Subramani⁵, R. Tomic⁵, A. Arunachalam⁶, C. Myers⁷. ¹Pharmacy, Northwestern Memorial Hospital, Chicago, IL, ²Feinberg School of Medicine, Northwestern University, Chicago, IL, ³Division of Pulmonary and Critical Care, Northwestern Memorial Hospital, Chicago, IL, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Northwestern University, Chicago, IL, ⁶Northwestern Memorial Hospital, Chicago, IL, ⁷Northwestern Feinberg School of Medicine, Chicago, IL

10:55 a.m. **Q&A**

11:00 a.m. **(136) HOPE For a Bright Future**
P. Tam¹, J. Messina², J. Steinbrink², J. Reynolds³, A. Devore⁴, A. Baker², M. Carugati², B. Ni², I. schwartz², C. R. Wolfe². ¹Infectious Diseases, Duke University, Durham, NC, ²Infectious Disease, Duke University, Durham, NC, ³Pulmonology, Duke University, Durham, NC, ⁴Cardiology, Duke University, Durham, NC

11:10 a.m. **Q&A**

FRIDAY, 12 APRIL, 2024

10:00 - 11:15 a.m.

ORAL SESSION 28: Choose Wisely You Must: Pre-Heart Transplant Factors

Location: North Hall

Core Therapies: HEART

Practice Areas: Cardiology, Anesthesiology and Critical Care, Cardiothoracic Surgery

Session Summary: This session focuses on recipient factors including modality of bridging and pre-transplant characteristics.

Each presenter will give a **10-minute** PowerPoint presentation, followed by a **5-minute** question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: Clive Lewis, MA, MB, Bchir, PhD, FFICM, FRCP, Royal Papworth Hospital, Cambridge, United Kingdom
Claudius Mahr, DO, Medical City - Dallas, Dallas, TX, USA

- 10:00 a.m. **(137) Waitlist Time and Outcomes of Adult Congenital Heart Disease Patients Listed for Heart Transplantation**
A. F. Akbar¹, B. L. Shou², A. Kilic³, A. M. Cedars⁴. ¹Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Department of Surgery, Johns Hopkins Hospital, Baltimore, MD, ⁴Department of Medicine, Johns Hopkins Hospital, Baltimore, MD
- 10:10 a.m. **Q&A**
- 10:15 a.m. **(138) Outcomes After Ecmo Bridge to Heart Transplantation- Pre and Post-Heart Allocation Change**
A. S. Rali¹, H. Patel², A. Hernandez¹, M. Bacchetta¹, A. Shah¹, J. Lindenfeld³, K. Schlendorf¹. ¹Vanderbilt University Medical Center, Nashville, TN, ²Willis Knighton Health System, New Orleans, LA, ³Vanderbilt University, Nashville, TN
- 10:25 a.m. **Q&A**
- 10:30 a.m. **(139) Nonlinear Effect of Body Mass Index on Postoperative Survival Following Isolated Heart Transplant**
R. Dale¹, N. Bahatyrevich², M. Leipzig³, M. Currie¹. ¹Department of Cardiothoracic Surgery, Stanford University, Stanford, CA, ²Divisions of Cardiac and Thoracic Surgery, UC Davis Health, Davis, CA, ³Department of Cardiothoracic Surgery, Stanford University, Stanford, CA
- 10:40 a.m. **Q&A**
- 10:45 a.m. **(140) Evaluating Mid-Term Outcomes of COVID-19 Donor Heart Transplantation in the United States**
S. T. Kim¹, P. Cho², P. T. Gaynor³, A. Ardehali⁴. ¹David Geffen School of Medicine, UCLA, Los Angeles, CA, ²Drexel College of Medicine, Philadelphia, PA, ³University of California, Los Angeles, Los Angeles, CA, ⁴UCLA School of Medicine, Los Angeles, CA
- 10:55 a.m. **Q&A**
- 11:00 a.m. **(141) Young at Heart: Survival Among Septuagenarian Heart Transplant Recipient Has Decreased Over the Past Decade**
E. Henricksen¹, B. Wayda², J. Teuteberg², H. Luikart², J. Njoroge², B. Guenthart², K. Khush². ¹Stanford Health Care, Stanford, CA, ²Stanford University, Stanford, CA
- 11:10 a.m. **Q&A**

FRIDAY, 12 APRIL, 2024

11:45 a.m. – 12:45 p.m.

SPECIAL SESSION 3: In the Name of Cardiogenic Shock - CSWG at ISHLT

Location: Congress Hall

Core Therapies: MCS, HEART

Practice Areas: Cardiology, Cardiothoracic Surgery

Session Summary: In this interactive session, we have invited members of the Cardiogenic Shock Working Group (CSWG) and ISHLT to showcase their ongoing work in the field of cardiogenic shock and areas of potential inter-disciplinary collaboration within ISHLT.

CME is not offered for this session.

Moderators: Nir Uriel, MD, New York Presbyterian, New York, NY, USA.
Van-Khue Ton, MD, PhD. Massachusetts General Hospital, Boston, MA, USA
Maryjane Farr, MD, MSc. University of Texas Southwestern Medical Center, Dallas, TX, USA
Elric Zweck, MD, University of Dusseldorf, Dusseldorf, Germany

11:45 a.m. ***Why Cardiogenic Shock 'Belongs' With ISHLT***
Ulrich Jorde, MD, Montefiore Medical Center, Bronx, NY, USA

11:48 a.m. ***Introduction to the Cardiogenic Shock Working Group***
Jaime Hernandez Montfort, MD, MPH, MSc, Baylor Scott and White Health, Austin, TX, USA

11:56 a.m. ***Our Five Years of Scientific Journey in Cardiogenic Shock***
Manreet Kanwar, MD, Allegheny General Hospital, Pittsburgh, PA, USA

12:04 p.m. ***Translating Registry Data to the Bedside (IMACS to CSWG to Temple)***
Jaime Hernandez Montfort, MD, MPH, MSc, Baylor Scott and White Health, Austin, TX, USA

12:12 p.m. ***So... Where To, From Here? Next Steps for CSWG Projects***
Song Li, MD, Medical City Healthcare, Dallas, TX, USA

12:20 p.m. ***Questions/Open Forum***

FRIDAY, 12 APRIL, 2024

1:15 - 2:30 p.m.

SYMPOSIUM 34: Let's Get Critical: RV Failure in the Setting of Pulmonary Hypertension

Location: Congress Hall

Core Therapies: PVD, MCS

Practice Areas: Cardiology, Anesthesiology and Critical Care, Cardiothoracic Surgery, Pathology, Pediatrics, Pharmacy, Pulmonology

Session Summary: Treatment and assessment of acute RV failure in the setting of pulmonary hypertension presents complex challenges, especially for early career specialists. Five expert speakers from around the globe will address these issues. A panel discussion with all speakers including audience Q&A, led by the session moderators, will conclude this session.

Moderators: Mads Andersen, MD, PhD, Aarhus University Hospital, Aarhus, Denmark
Rebecca Klingbeil, DNP, CRNA, ARNP, Mayo Clinic, Jacksonville, FL, USA

1:15 p.m. ***Acute RV Failure Presentation and Epidemiology Across the Life Span***
Maria Giovanna Trivieri, MD, PhD, Mount Sinai, New York, NY, USA

This presentation will discuss the overall presentation and causes of acute and chronic RV failure, in infants, children, adults.

1:27 p.m. ***Beyond Numbers: What Can the Waveforms Teach Us?***
Sergio Caravita, MD, PhD, University of Bergamo, Bergamo; and Ospedale S Luca IRCCS Istituto Auxologico Italiano, Milano, Italy.

Focus on interpretation of hemodynamic waveforms in PH and their implications on diagnosis and prognosis.

1:39 p.m. ***State-of-the-Art Echocardiography, Including Provocative Maneuvers and CMR Evaluation of the RV: The New Standard?***
Katherine Kearney, MD, St Vincent's Hospital, Sydney, Australia

This presentation will discuss echocardiographic assessment of the RV including 4D, deformation analysis, and stress echocardiographic (both exercise and pharmacologic). This presentation will discuss the CMR assessment of the RV, including invasive CMR.

1:51 p.m. ***Beat It: How Do I Manage Hypoxemia, RHF, and Arrhythmias in PH?***
Ryan Tedford, MD, Medical University of South Carolina, Charleston, SC, USA

This talk focuses on critical care aspects of acute RV failure in the context of infection in the patient with PH; emerging pharmacological treatments in RV failure.

2:03 p.m. ***We Didn't Start the Fire: Timing, Approach and Management of ECMO Bridge for the PH Patient***
Archer Martin, MD, Mayo Clinic, Jacksonville, FL, USA

This talk will discuss the nuances of optimal deployment of ECMO support as a bridge to transplantation in the pulmonary hypertension patient and the evidence and clinical strategy behind designing a successful intraoperative hemodynamic management of a PH patient on ECMO.

2:15 p.m. ***Panel Discussion led by Moderators***

FRIDAY, 12 APRIL, 2024

1:15 - 2:30 p.m.

SYMPOSIUM 35: No Guts No Glory: Fearless Expansions of the Lung Transplant Donor Pool

Location: Forum Hall

Core Therapies: LUNG, PVD

Practice Areas: Cardiothoracic Surgery, Anesthesiology and Critical Care, Infectious Disease

Session Summary: Each speaker will present a brief clinical vignette followed by a presentation focusing on expanding the donor pool with the respective emerging donor populations. A panel discussion with all speakers including audience Q&A, led by the session moderators, will conclude this session.

Moderators: Fabio Ius, MD, Hannover Medical School, Hannover, Germany
Erin Lowery, MD, MS, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA

1:15 p.m. ***The Lung Donor with Multidrug Resistant Gram-Negative Bacteremia or Candidemia***
Orla Morrissey, MD, PhD, Alfred Health, Melbourne, Australia

Donors, including lung donors, are at risk for MDR GNR infections and their proportion is predicted to increase, thus we need to adapt the use of novel beta lactams to safely expand the lung donor pool.

1:25 p.m. ***Make It Go Away: Donor Malignancy***
Brian Keller, MD, PhD, Massachusetts General Hospital, Boston, MA, USA

Malignancy in the organ donor raises the possibility of disease transmission to the organ recipient. The speaker will discuss data on donor to recipient malignancy transmission and considerations when evaluating the donor with known or suspected malignancy as well as cancer at time of procurement.

1:35 p.m. ***How Long is Too Long? Mechanical Ventilation in Donors***
Jesper Magnusson, MD, PhD, Sahlgrenska University Hospital, Gothenburg, Sweden

Prolonged mechanical ventilation can lead to infection, barotrauma and ventilator-induced lung injury. Some donors may require prolonged mechanical ventilation prior to death despite having no apparent injuries to the lungs. How long is too long on mechanical ventilation prior to donation?

1:45 p.m. ***Take My Breath Away: Drowning and Asphyxiation in Donors***
Sarah Tsou, MD, University of California, San Francisco, San Francisco, CA, USA

Variability exists in acceptance practices surrounding donor hanging, asphyxiation or drowning. Direct lung hypoxia, infection and aspiration risks are considerations in these controversial donors. Anecdotal experiences prevail despite emerging evidence that these donors may be safe for transplant.

1:55 p.m. ***Good Lungs for Bad Recipients and Bad Lungs for Good Recipients: Balancing the Risk in Lung Transplantation***
Wiebke Sommer, MD, University of Kiel, Kiel, Germany

This talk will focus on the overall risk of lung transplantation, focusing on donor and recipient derived risk factors and what organ is suitable for recipients in different stages of end-stage lung disease. The talk will approach the utilization of extended criteria donor lungs and discuss what recipient cohort benefits when receiving marginal.

2:05 p.m. ***Panel Discussion led by Moderators***

FRIDAY, 12 APRIL, 2024

1:15 - 2:30 p.m.

SYMPOSIUM 36: It's All Relative: How Much is Too Much for Heart and Lung Transplantation

Location: South Hall 3

Core Therapies: HEART, LUNG

Practice Areas: Cardiology, Cardiothoracic Surgery, Nursing and Allied Health, Pediatrics, Pharmacy, Pulmonology

Session Summary: We regularly evaluate patients with relative risks to transplant. Clearly defined and adhered to contraindications can vary between centers, teams, and clinicians. Certain patient factors, such as adolescent/young adult age and health disparity/equity considerations, further murky the waters. This session will review various relative contraindications and challenge the speakers to discuss whether a patient should or should not be considered for transplant in different scenarios per the existing (or non-existing) literature. A panel discussion with all speakers including audience Q&A, led by the session moderators, will conclude this session.

Moderators: Julia Dumfarth, MD, PhD, University Clinic Innsbruck, Innsbruck, Austria
Edward Horn, PharmD, University of Pittsburgh MC, Pittsburgh, PA, USA

1:15 p.m. ***It Was Just One Time: Prior Illicit Substance Use or Abuse***

Kristine McKenna, PhD, Seattle Children's Hospital, Seattle, WA, USA

Abstinence from substances is a common pre-transplant requirement, but what if it was just 1 time use? What if the abstinence period has been 2 months instead of 3 or 6 and the patient is becoming sicker? The speaker will review data regarding substance use and transplant outcomes with consideration of relative risks vs contraindications. Case Question: Should we transplant a 17 year old male with CHD who is not a VAD candidate in shock with cocaine use 2 months ago with negative toxicology screen at admit?

1:27 p.m. ***Cry Me a Liver: Heart Transplant in the Setting of Liver Disease***

Andrew Morley-Smith, MRCP, PhD, Harefield Hospital, Harefield, United Kingdom

A patient may have liver disease but not qualify for dual organ transplant. Will heart transplant be beneficial? What management approaches or medications need to be considered? Case Question: Should we transplant a 55 year old male patient with stage 3 bridging fibrosis?

1:39 p.m. ***Are We There Yet? Transplantation From VA-ECMO***

Pierre-Emmanuel Noly, MD, PhD, Montreal Heart Institute, Montreal, QC, Canada

A comprehensive overview of risk assessment of the candidate on VA-ECMO will be provided including review of current literature scores, challenges, assessment limitations (i.e., pulmonary vascular resistance) and optimization strategies. Case Question: Should we transplant a 45-year-old female patient on VA-ECMO post cardiac arrest and cardiogenic shock secondary to anterior STEMI with severe left ventricular systolic dysfunction, moderate-size apical thrombus, and underlying nonrevascularizable multivessel disease?

1:51 p.m. ***How Do We Stack Up? Patients With Multiple Relative Contraindications***

Maria Crespo-Leiro, MD, Hospital Universitario A Coruña, A Coruña, Spain

Is it 3 strikes and you're out? This speaker will discuss how to decide when the combination of multiple risk factors ultimately tip the balance to risk over benefit. The speaker will pull from experience and describe when patients have proven them wrong (or right) following transplant. Case Question: Should we transplant a 24-year-old single mother presenting for re-transplant in setting of failed graft following non-adherence in adolescent years with current (legal/medical) marijuana use with moderate renal dysfunction and a BMI of 35.

2:03 p.m. ***Don't Let Me Down: Under-representation of Patients with Comorbidities, How Do We Treat Them?***

Kelly Bryce, PhD, Henry Ford Hospital, Detroit, MI, USA

Ethical challenges and moral conundrums are common to our everyday work in pediatric and adult transplant/MCS medicine. At times, our roles as responsible organ stewards can be complicated by caring relationships with our own patients and their families, group decision making and personal biases, and the necessity to ensure equitable access to organ transplantation across racial and socioeconomic strata. This speaker will focus on ethical frameworks for transplant candidacy decision making while highlighting the interplays with moral distress for transplant clinicians.

2:15 p.m. ***Panel Discussion led by Moderators***

FRIDAY, 12 APRIL, 2024

1:15 - 2:30 p.m.

SYMPOSIUM 37: The Secret Sauce: Maximizing Patient Longevity with Durable LVAD Therapy

Location: South Hall 1

Core Therapies: MCS, HEART

Practice Areas: Cardiology, Cardiothoracic Surgery, Nursing and Allied Health, Pharmacy

Session Summary: Optimization of durable VADs is a complex process that requires the expertise of a VAD team. This symposium will have multidisciplinary experts discussing key aspects of VAD patient care to enhance long term survival in our patients. A panel discussion with all speakers including audience Q&A, led by the session moderators, will conclude this session.

Moderators: Jennifer Cook, MD, University of Cincinnati, Cincinnati, OH, USA
Scott Silvestry, MD, Orlando, FL, USA

1:15 p.m. ***Planning Out Long-Term Success After LVAD: Lessons From the 2023 Durable MCS Guidelines***
Diyar Saeed, MD, PhD, Heart Center Niederrhein, Krefeld, Germany

Discuss the top 10 clinical practice recommendations from the updated 2023 ISHLT guidelines for the management of mechanical circulatory support patients that highlight enhancements/best practices for long term survival.

1:27 p.m. ***Medical Optimization with GDMT: When, How, Who?***
Bailey Colvin, PharmD, WVU Medicine Ruby Memorial Hospital, Morgantown, WV, USA

Discuss timing and order of initiation of heart failure GDMT, "preferred" GDMT classes in LVAD patients, their role in promoting myocardial recovery, mitigating GI bleeding, and address gaps in research and highlight the need for future studies.

1:39 p.m. ***It's All in the Numbers: Hemodynamic Monitoring for Optimization in Durable MCS***
Emil Najjar, MD, PhD, Karolinska University Hospital, Stockholm, Sweden

Speaker will discuss strategies for hemodynamic optimization of durable MCS patients, including right heart catheterization and remote hemodynamic monitoring devices.

1:51 p.m. ***A Picture is Worth 1000 RPMS: Echocardiographic Optimization in Durable MCS***
Nir Uriel, MD, New York Presbyterian, New York, NY, USA

Speaker will review key parameters to assess during routine echocardiographic studies and the role of echocardiographic optimization in durable MCS.

2:03 p.m. ***Holding the Line: Best Practices for Driveline Management in Contemporary Devices***
Ka Lee Kerk, BN, RN, National Heart Centre, Singapore, Singapore

Speaker will discuss best practices for driveline management, highlighting findings from the 2023 ISHLT MCS guidelines and the upcoming ICCAC workforce recommendations.

2:15 p.m. ***Panel Discussion led by Moderators***

FRIDAY, 12 APRIL, 2024

1:15 - 2:30 p.m.

SYMPOSIUM 38: Traversing the Age Continuum: Hot Topics Bridging Pediatric and Adult Transplant

Location: South Hall 2

Core Therapies: HEART

Practice Areas: Pediatrics, Cardiology, Cardiothoracic Surgery, Nursing and Allied Health, Pharmacy

Session Summary: This session will bridge the worlds of pediatric and adult heart transplantation to discuss novel therapies and approaches across the age continuum. This will include discussion of ABO incompatible transplantation beyond infancy, desensitization in the setting of multiple cardiac surgeries, and multi-organ transplant in adults with Fontan physiology.

Moderators: David Peng, MD, University of Michigan, Ann Arbor, MI, USA
Madeleine Townsend, MD, Cleveland Clinic Children's, Cleveland, OH, USA

1:15 p.m. **"This Had Better Work!" A History of ABO Incompatible Heart Transplantation**
Lori West, MD, DPhil, University of Alberta, Edmonton, AB, Canada

ABO incompatible heart transplantation stems from research demonstrating infants are born without isohemagglutinin titers. The first ABOi heart transplant was performed at the Hospital for Sick Children in 1996. The speaker will review the growing worldwide experience and impact of ABOi transplant on efficient allocation of organs.

1:30 p.m. **ABOi Heart Transplant: Where Do We Go From Here?**
Jacob Simmonds, Great Ormond Street Hospital for Children, London, United Kingdom

ABOi heart transplant has had successful results in young children. Utilizing recent advances in anti-B-cell therapy as well as antibody removal techniques may make ABOi transplantation accessible to a wider and older population of transplant candidates in the future. This talk will highlight the potential opportunities and limits of ABO incompatibility in older patients with higher titers.

1:45 p.m. **What About the (Sensitized) Elephant in the Room?**
Chesney Castleberry, MD, Dell Medical School at the University of Texas in Austin, Austin, TX, USA

This talk will feature a review of available desensitization therapies, including newer agents such as IL-6 blockers, co-stimulator blockade, anti-CD38 antibodies as well as management strategies of sensitized patients with positive virtual crossmatches in the era of decreased utilization of cytotoxic T cell crossmatch.

2:00 p.m. **DEBATE: The Failing Fontan - Lily Livered? Heart-Only Transplant is the Best Plan (PRO)**
Leigh Reardon, MD, UCLA, Los Angeles, CA, USA

This debate talk will focus on ACHD patients with end-stage HF and Fontan. There were 2 recent JACC papers on this topic, one with risk assessment for adverse outcomes and the other on combined heart-liver transplant. The case debated will be a 20-year-old with banded varices and mild splenomegaly on ultrasound. No portal hypertension, stage 3 bridging fibrosis on biopsy. Mild chronic ascites but no paracenteses. Mild liver nodules, no hepatocellular carcinoma. The first speaker will take the vantage point that heart-only transplant is indicated.

2:12 p.m. **DEBATE: The Failing Fontan - Lily Livered? Heart-Only Transplant is the Best Plan (CON)**
Kathleen Simpson, MD, University of Colorado Denver, Denver, CO, USA

This talk will be focused on ACHD patients with end-stage HF and Fontan. There were 2 recent JACC papers on this topic, one with risk assessment for adverse outcomes and the other on combined heart-liver transplant. The case debated will be a 20-year-old with banded varices and mild splenomegaly on ultrasound. No portal hypertension, stage 3 bridging fibrosis on biopsy. Mild chronic ascites but no paracenteses. Mild liver nodules, no hepatocellular carcinoma. The second speaker will take the vantage point of heart-liver transplant is indicated.

2:24 p.m. **Q&A led by Moderators**

FRIDAY, 12 APRIL, 2024

1:15 - 2:30 p.m.

SYMPOSIUM 39: Getting Creative with Immunosuppression After Lung Transplantation

Location: Panorama Hall

Core Therapies: LUNG, HEART

Practice Areas: Pulmonology, Cardiology, Cardiothoracic Surgery, Pharmacy, Research and Immunology

Session Summary: Many patients continue to suffer undesirable effects of immunosuppression. This session will address the possibilities of individualized immunosuppression after lung transplantation. In addition, the session will look at "novel" immunosuppression for lung transplant, though with standard commercially available immunosuppressants. After each speaker's presentation, the session moderators will lead a brief audience Q&A segment.

Moderators: Alice Gray, MD, University of Colorado, Aurora, CO, USA
Are Holm, MD, PhD, Oslo University Hospital, Oslo, Norway

1:15 p.m. ***Functional Monitoring of Immunosuppression Post Lung Transplant***

Laurie Snyder, MD, MHS, Duke University, Durham, NC, USA

The speaker will outline how current immunosuppressive regimens work, and what data has been published to demonstrate functional monitoring of immunosuppression post solid organ transplant, with particular focus on lung transplant. In addition, the speaker will also outline how future studies can be designed towards tailored immunosuppression to have an impact on clinical practice.

1:27 p.m. **Q&A**

1:30 p.m. ***Viral Load Guided Immunosuppression***

Mark Greer, MB, BCh, Hannover Medical School, Hannover, Germany

The speaker will present current knowledge about using viral load (EBV, TTV etc.) to monitor immunosuppression in solid organ transplant.

1:42 p.m. **Q&A**

1:45 p.m. ***Induction: If Not For Everyone, For Who?***

Madeline Morrison, PharmD, BCTXP, Vanderbilt University Medical Center, Nashville, TN, USA

Induction therapy is used in about 1/2 of lung transplants. Is there potential to increase the use of induction without increasing the concern for rejection? Is there an advantage of one induction agent over another?

1:57 p.m. **Q&A**

2:00 p.m. ***Minimizing of Immunosuppression After Lung Transplant: Current Evidence for Reducing or Replacing Standard Immunosuppression***

Asbjørn Lunnan, PharmD, Oslo University Hosp, Oslo, Norway

The speaker will outline the risks associated with current immunosuppressive regimens and the current evidence for reducing the dose of CNI, MMF or steroids. The focus should be on which patients should be considered for reducing or replacing standard immunosuppression.

2:12 p.m. **Q&A**

2:15 p.m. ***Novel Therapeutic Options to Reduce Standard Maintenance Immunosuppression After Lung Transplant***

Steven Ivulich, B.Pharm, PhD, Alfred Hospital, Melbourne, Australia

The speaker will outline the current available evidence for alternative immunosuppressants that can be utilized as therapeutic options when standard immunosuppression cannot be tolerated. These include everolimus, belatacept and potentially others. These options are not likely to replace any other agent, but on a patient-by-patient basis there may be some benefit. This talk will address who, when, and why we could consider these agents.

2:27 p.m. **Q&A**

FRIDAY, 12 APRIL, 2024

1:15 - 2:30 p.m.

SYMPOSIUM 40: How Can You Mend a Broken New Heart

Location: North Hall

Core Therapies: HEART

Practice Areas: Cardiology, Anesthesiology and Critical Care, Cardiothoracic Surgery, Nursing and Allied Health, Pediatrics, Pharmacy, Research and Immunology

Session Summary: A review of the evidence on how to effectively treat PGF with an emphasis on the timely use of ECMO, and showing the similarities and differences of the same in DCD donors. The review also covers the effective recognition, prevention and treatment of vasoplegia in transplant patients after durable MCS support. Re-transplantation of the heart in the first year after primary transplantation due to poor results leads to unnecessary loss of the organ and deepens the disparity between donors and recipients. A panel discussion with all speakers including audience Q&A, led by the session moderators, will conclude this session.

Moderators: Marco Masetti, MD, PhD, IRCCS S. Orsola Malpighi, University of Bologna, Bologna, Italy
Bojan Vrtovec, MD, PhD, UMC Ljubljana, Ljubljana, Slovenia

1:15 p.m. ***Post-Transplant PGD: Do We Need ECMO and When?***

Yasbanoo Moayed, MD, UHN, Toronto, ON, Canada

This talk will discuss the challenges of patients with post-transplant PGD, with an emphasis on the timely use of ECMO.

1:27 p.m. ***DCD Heart - Post Transplant PGD: Is Everything the Same?***

Filip Rega, MD, PhD, University Hospitals Leuven, Leuven, Belgium

This lecture presents the similarities, but especially the differences, in the appearance and recognition of PGF after heart transplantation from DCD donors. The emphasis is on prevention, recognition and treatment with timely use of ECMO.

1:39 p.m. ***Is Pre-Transplant MCS Killing My New Heart? Vasoplegia After Transplantation in Patients on Durable Mechanical Heart Support***

Lauren Truby, MD, MS, UT Southwestern Medical Center, Dallas, TX, USA

This talk will focus on the vasoplegia after transplantation in patients on durable mechanical heart support. Tips and tricks to better medical management.

1:51 p.m. ***Tell Me What To Do for Successful MCS in Heart Transplant Recipients: Transplanted Heart Dysfunction in the First Year After Primary Transplantation***

Holger Buchholz, MD, University of Alberta Hospital, Edmonton, AB, Canada

This talk will focus on MCS use in heart tx recipients with late allograft dysfunction (in the first year). Tips and tricks to better selection and practical use of durable MCS (LVAD, RVAD, BiVAD, TAH) as a bridge to retransplantation, to avoid retransplantation in the first year after primary transplantation.

2:03 p.m. ***Panel Discussion led by Moderators***

FRIDAY, 12 APRIL, 2024

3:00 - 4:15 p.m.

ORAL SESSION 29: Embarrassment of Riches: Getting to "Yes" for More Heart Donors

Location: Congress Hall

Core Therapies: HEART

Practice Areas: Cardiology, Cardiothoracic Surgery

Session Summary: With the already expressed disproportion between the number of donors and recipients, this disparity is deepened by the non-acceptance of a high percentage of organs. New experiences are pushing the boundaries of marginal donors and marginal hearts in favor of increasing the number of transplanted patients with equivalent outcome.

Each presenter will give a **10-minute** PowerPoint presentation, followed by a **5-minute** question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: Gregor Poglajen, MD, PhD, University Medical Center, Ljubljana, Slovenia
Vivek Rao, MD, PhD, Toronto General Hospital, Toronto, ON, Canada

- 3:00 p.m. **(142) Just a Number? Donor Age and (Lack of) Associated Reasons for Heart Offer Refusal in the Donor Heart Study**
A. C. Bhowmik¹, B. Wayda², H. Luikart², Y. Weng³, S. Zhang³, R. P. Wood⁴, J. Nieto⁴, T. Groat⁵, N. Neidlinger⁶, K. K. Khush².
¹Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, ²Cardiology, Stanford University School of Medicine, Palo Alto, CA, ³Quantitative Sciences Unit, Stanford University School of Medicine, Palo Alto, CA, ⁴LifeGift Organ Procurement Organization, Houston, TX, ⁵Trauma, Critical Care, and Acute Care Surgery, Oregon Health and Science University, Portland, OR, ⁶Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI
- 3:10 p.m. **Q&A**
- 3:15 p.m. **(143) Incorporating Donor Variables Improves Accuracy of One-Year Post-Transplant Survival Prediction for Adult Heart Transplant Recipients**
K. A. Lazenby¹, K. Zhang², N. Narang³, W. F. Parker². ¹University of Chicago Pritzker School of Medicine, Chicago, IL, ²Department of Medicine, University of Chicago, Chicago, IL, ³Advocate Christ Medical Center, Chicago, IL
- 3:25 p.m. **Q&A**
- 3:30 p.m. **(144) The Effect of Donor Distance on Post-Transplant Mortality**
D. Rekhman¹, C. Song¹, A. Iyengar², N. Weingarten², M. Shin², S. Kim¹, J. Jiang¹, M. Asher¹, M. Helmers², M. Cevasco², P. Atluri².
¹Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ²Division of Cardiovascular Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA
- 3:40 p.m. **Q&A**
- 3:45 p.m. **(145) Reasons for Donor Heart Offer Refusal Often Contradict Objective Cardiac Diagnostic Findings: Results from the Donor Heart Study**
B. Wayda¹, H. Luikart², Y. Weng³, S. Zhang³, R. P. Wood⁴, J. Nieto⁴, T. Groat⁵, N. Neidlinger⁶, D. Malinoski⁵, J. Zaroff⁷, K. K. Khush². ¹Stanford Cardiovascular Institute, Stanford University School of Medicine, Palo Alto, CA, ²Cardiology, Stanford University School of Medicine, Palo Alto, CA, ³Quantitative Sciences Unit, Stanford University School of Medicine, Palo Alto, CA, ⁴LifeGift Organ Procurement Organization, Houston, TX, ⁵Trauma, Critical Care, and Acute Care Surgery, Oregon Health and Science University, Portland, OR, ⁶Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁷Cardiology, Kaiser San Francisco Medical Center, San Francisco, CA
- 3:55 p.m. **Q&A**
- 4:00 p.m. **(146) Utilizing Machine Learning Clustering Trees to Risk Stratify Exception patients in Heart Transplantation**
R. Dale¹, G. Anyetei-Anum², N. Bahatyrevich³, K. Pines¹, M. Leipzig¹, M. Currie¹. ¹Department of Cardiothoracic Surgery, Stanford University, Stanford, CA, ²Mayo Clinic Alix School of Medicine, Rochester, MN, ³Divisions of Cardiac and Thoracic Surgery, UC Davis Health, Davis, CA
- 4:10 p.m. **Q&A**

FRIDAY, 12 APRIL, 2024

3:00 - 4:15 p.m.

ORAL SESSION 30: Novel Ideas in Lung Preservation: From Inspiration to Innovation

Location: Forum Hall

Core Therapies: LUNG

Practice Areas: Cardiothoracic Surgery, Pulmonology, Research and Immunology

Session Summary: The session is highlighting innovations around lung preservation with a focus on novel developments in ex vivo lung perfusion.

Each presenter will give a 10-minute PowerPoint presentation, followed by a 5-minute question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: Gabriel Loor, MD. Baylor College of Medicine, Houston, TX, USA
Sebastian Michel, MD. Ludwig Maximilian University, Munich, Germany

3:00 p.m. **Late-Breaking Abstract Presentation:**

(147) 5 Year Outcomes Following Ex Vivo Lung Perfusion Using a Centralized Lung Evaluation System at a Dedicated Facility

J. Mallea¹, J. D'Cunha², P. Sanchez³, Z. Kon⁴, R. Pierson⁵, C. Keller¹, D. Erasmus⁶, M. Hartwig⁷, D. Dilling⁸, A. Brown⁹, W. Lynch¹⁰, M. R. Sketch¹¹, D. Cella¹¹, M. Roberts¹², K. McCurry¹³. ¹Mayo Clinic Florida, Jacksonville, FL, ²Mayo Clinic Arizona, Phoenix, AZ, ³University of Pittsburgh MC, Pittsburgh, PA, ⁴Northwell Health, Manhasset, NY, ⁵Massachusetts General Hospital, Boston, MA, ⁶Vanderbilt University Medical Center, Nashville, TN, ⁷Duke University Medical Center, Durham, NC, ⁸Loyola University Chicago, Stritch School of Medicine, Maywood, IL, ⁹Inova Fairfax Hospital, Falls Church, VA, ¹⁰University of Michigan, Ann Arbor, MI, ¹¹United Therapeutics Corporation, Research Triangle Park, NC, ¹²Lung Biotechnology PBC, Silver Spring, MD, ¹³Cleveland Clinic, Cleveland, OH

3:10 p.m. **Q&A**

3:15 p.m. **(148) Membraneless Perfusion - A Novel Technique for Ex Vivo Lung Perfusion**

G. Garza¹, A. Wang², J. Yune¹, Y. Zhang¹, J. Montagne¹, G. Loesch Siebiger³, K. Yamanashi⁴, P. Oliveira¹, L. Del Sorbo⁵, M. Liu⁵, S. Keshavjee⁶, M. Cypel¹. ¹Latner Thoracic Research Laboratories, UHN, Toronto, ON, Canada, ²Toronto Gen Hosp Research Inst, Toronto, ON, Canada, ³Latner Thoracic Research Laboratories, Univ of Toronto, Toronto, ON, Canada, ⁴Latner Thoracic Research Laboratories, Toronto Gen Hosp Research Inst, UHN, Toronto, ON, Canada, ⁵Latner Thoracic Research Laboratories, Toronto Gen Hosp, Toronto, ON, Canada, ⁶Latner Thoracic Research Laboratories, UHN, Toronto, ON, Canada

3:25 p.m. **Q&A**

3:30 p.m. **(149) Novel Preservation Method to Allow Expanded Use of Lungs in Uncontrolled Donation After Circulatory Death**

H. Ujike¹, S. Tanaka², T. Hayashi¹, M. Umeda¹, T. Ryuko¹, H. Choshi¹, S. Kawana¹, Y. Kubo¹, K. Matsubara³, K. Hashimoto², K. Miyoshi², M. Okazaki², S. Sugimoto², S. Toyooka². ¹Okayama Univ Graduate SoM, Dentistry, and Pharmaceutical Sciences, Okayama, Japan, ²Okayama Univ Hosp, Okayama, Japan, ³Hiroshima City Hiroshima Citizens Hosp, Hiroshima, Japan

3:40 p.m. **Q&A**

3:45 p.m. **(150) A Multi-Modal Machine-Learning Approach that Combines Imaging and Functional Data Obtained During Ex Vivo Lung Perfusion Significantly Improves Prediction of Transplant Outcomes**

B. T. Chao¹, J. Ma², M. G. Van Iderstine¹, M. C. McInnis³, X. Zhou¹, J. Valero¹, M. Cypel¹, M. Liu¹, B. Wang⁴, A. T. Sage⁵, S. Keshavjee¹. ¹Latner Thoracic Research Laboratories, University Health Network, Toronto, ON, Canada, ²Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada, ³Division of Cardiothoracic Imaging, University Health Network, Toronto, ON, Canada, ⁴Vector Institute, University of Toronto, Toronto, ON, Canada, ⁵Latner Thoracic Research Laboratories, Toronto General Hospital, Toronto, ON, Canada

3:55 p.m. **Q&A**

4:00 p.m. **(151) Cell-Free DNA in Ex-Vivo Lung Perfusate is Associated with Low-Quality Lungs**

H. Yamamoto, A. Sundby, J. Allen, S. Zhu, A. Akhter, G. Wilson, S. Keshavjee, J. Yeung. Toronto Lung Transplant Program and Latner Thoracic Research Laboratories, Toronto General Hospital Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada

4:10 p.m. **Q&A**

FRIDAY, 12 APRIL, 2024

3:00 - 4:15 p.m.

ORAL SESSION 31: Insights from LVAD Registries: Myocardial Recovery

Location: South Hall 3

Core Therapies: MCS

Practice Areas: Cardiology, Cardiothoracic Surgery, Pediatrics, Pharmacy

Session Summary: The session provides multi-center and/or registry based insights on myocardial recovery following LVAD implantation.

Each presenter will give a **10-minute** PowerPoint presentation, followed by a **5-minute** question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: Minoru Ono, MD, PhD, The University of Tokyo Hospital, Tokyo, Japan
Palak Shah, MD, MS, Inova Heart and Vascular Institute, Falls Church, VA, USA

3:00 p.m. **(152) Explantation of Durable Ventricular Assist Device for Myocardial Functional Recovery in Children: A Report from The Action Registry**

B. Langanecha¹, A. Jeewa¹, I. Adachi², C. Mavroudis³, M. Shezad⁴, R. Butts⁵, S. R. Auerbach⁶, C. VanderPluym⁷, M. Zinn⁸, S. Kindel⁹, D. Sutcliffe¹⁰, S. Khan¹¹, J. Byrnes¹², A. Lorts¹³, C. Castleberry¹⁴, B. Mettler¹⁵, M. Absi¹⁶, D. Rosenthal¹⁷, A. Joong¹⁸, S. Law¹⁹, D. Nandi²⁰, L. May²¹, J. Parent²², J. Conway²³, H. Tunuguntla², O. Aljohani²⁴, M. Bleiweis²⁵, M. O'Connor³, K. Hope²⁶. ¹The Hosp for Sick Children, Toronto, ON, Canada, ²Texas Children's Hosp, Houston, TX, ³Children's Hosp of Philadelphia, Philadelphia, PA, ⁴Cincinnati Children's Hosp, Cincinnati, OH, ⁵Children's MC of Dallas/UT Southwestern, Dallas, TX, ⁶Univ of Colorado, Aurora, CO, ⁷Boston Children's Hosp, Boston, MA, ⁸Children's Hosp of Pittsburgh, Pittsburgh, PA, ⁹Children's Hosp of Wisconsin, Milwaukee, WI, ¹⁰Children's Mercy Hosp, Kansas, MO, ¹¹Children's National, Washington, DC, ¹²Children's of Alabama, Birmingham, AL, ¹³Cincinnati Children's Hosp MC, Cincinnati, OH, ¹⁴Dell Med Sch at UT in Austin, Austin, TX, ¹⁵Johns Hopkins Children's Ctr, Baltimore, MD, ¹⁶Univ of Tennessee HSC, Memphis, TN, ¹⁷Stanford Univ, Palo Alto, CA, ¹⁸Ann & Robert H. Lurie Children's Hosp, Chicago, IL, ¹⁹Columbia Univ, New York, NY, ²⁰Nationwide Children's Hosp, Columbus, OH, ²¹Univ of Utah, Salt Lake City, UT, ²²Indiana Univ SoM, Indianapolis, IN, ²³Stollery Children's Hosp, Edmonton, AB, Canada, ²⁴UCSF, Benioff Children's Hosps, Oakland, CA, ²⁵UF Health Congenital Heart Ctr, Gainesville, FL, ²⁶Texas Children's Hosp, Baylor CoM, Houston, TX

3:10 p.m. **Q&A**

3:15 p.m. **(336) Changes in Right Ventricular Function and Pulmonary Hemodynamics During LVAD Support and Impact on Outcomes After LVAD Discontinuation: VAD Wean Registry Analysis**

V. Kittipibul¹, D. Ceken², S. Russell³, A. Damlin², M. J. Eriksson², M. Carlsson², E. Najjar⁴, M. Kanwar⁵, I. Adachi⁶, P. Tang⁷, V. Topkara⁸, S. Patel⁹, S. Drakos¹⁰, R. Agarwal¹. ¹Duke Univ Medical Center, Durham, NC, ²Karolinska Institutet, Stockholm, Sweden, ³Duke Univ School of Medicine, Durham, NC, ⁴Karolinska Univ Hosp, Stockholm, Sweden, ⁵Allegheny General Hosp, Pittsburgh, PA, ⁶Children's Hosp, Houston, TX, ⁷Univ of Michigan, Ann Arbor, MI, ⁸Columbia Univ New York Presbyterian Hosp, New York, NY, ⁹Montefiore-Einstein, New York, NY, ¹⁰Univ of Utah, Salt Lake City, UT

3:25 p.m. **Q&A**

3:30 p.m. **(154) Derivation and Validation of a Multicenter Model to Identify Candidates for Advanced HF Therapies with High Potential to Achieve Post-LVAD Reverse Cardiac Remodeling**

E. Maneta¹, I. Taleb¹, C. P. Kyriakopoulos¹, E. Dranow¹, O. Wever-Pinzon¹, C. H. Selzman¹, R. Singh², M. A. Psotka², E. J. Birks³, M. S. Slaughter⁴, S. C. Koenig⁴, K. Hoffman⁵, M. Guglin⁶, S. C. Silvestry⁷, A. Vidic⁷, N. Y. Raval⁷, M. R. Mehra⁸, J. A. Cowger⁹, L. Parker¹⁰, E. Tseliou¹, J. Stehlik¹, R. Alharethi¹, A. G. Kfoury¹, T. C. Hanff¹, J. C. Fang¹, K. Sideris¹, J. Goldstein¹, M. Nelson¹, R. Karra¹⁰, M. K. Kanwar⁵, P. Shah², S. G. Drakos¹. ¹Utah Cardiac Recovery (UCAR) Program (Univ of Utah Health and School of Medicine, Intermountain Medical Center, George E. Wahlen Department of Veterans Affairs Medical Center), Salt Lake City, UT, ²Inova Heart & Vascular Institute, Falls Church, VA, ³Univ of Louisville, Louisville, KY; Univ of Kentucky, Lexington, KY, ⁴Univ of Louisville, Louisville, KY, ⁵Allegheny Health Network, Pittsburgh, PA, ⁶Univ of Kentucky, Lexington, KY, ⁷Advent Health Transplant Institute, Orlando, FL, ⁸Brigham and Women's Hosp and Harvard Medical School, Boston, MA, ⁹Henry Ford Hosps, Detroit, MI, ¹⁰Duke Univ Medical Center, Durham, NC

3:40 p.m. **Q&A**

3:45 p.m. **(155) Defining Optimal Criteria for LVAD Weaning in HF Patients with an Improvement in Cardiac Structure and Function: A VAD Wean Registry Analysis**

V. K. Chetram¹, P. Bagchi², S. Patel³, D. Tang¹, M. Kanwar⁴, E. Potapov⁵, I. Adachi⁶, S. Lundgren⁷, A. Ravichandran⁸, A. Yehya⁹, D. Goldstein³, F. Gustafsson¹⁰, E. Birks¹¹, S. Drakos¹², P. Shah¹. ¹Inova Schar Heart and Vascular, Falls Church, VA, ²Department

of Biostatistics & Bioinformatics, The George Washington Univ, Washington, DC, ³Montefiore-Einstein Medical Center, New York, NY, ⁴Allegheny General Hosp, Pittsburgh, PA, ⁵German Heart Institute, Berlin, Germany, ⁶Children's Hosp, Houston, TX, ⁷Univ of Nebraska Medical Center, Omaha, NE, ⁸Ascension St. Vincent Indianapolis, Indianapolis, IN, ⁹Sentara Heart Hosp, Norfolk, VA, ¹⁰Univ of Copenhagen-RigsHosp, Copenhagen, Denmark, ¹¹Univ of Kentucky, Lexington, KY, ¹²Univ of Utah, Salt Lake City, UT

3:55 p.m.

Q&A

4:00 p.m.

(156) Myocardial Functional Improvement is Associated with Improved HF-Related Outcomes in Patients While on Durable LVAD: An STS INTERMACS Analysis

E. Maneta¹, C. P. Kyriakopoulos¹, B. D. Horne², R. Alharethi¹, R. Butschek¹, I. Taleb¹, K. Sideris¹, E. Tseliou¹, J. Aadland¹, M. Nelson¹, T. C. Hanff¹, J. Stehlik¹, C. H. Selzman¹, O. Wever-Pinzon¹, S. G. Drakos¹. ¹Utah Cardiac Recovery (UCAR) Program (Univ of Utah Health and School of Medicine, Intermountain Medical Center, George E. Wahlen Department of Veterans Affairs Medical Center), Salt Lake City, UT, ²Intermountain Medical Center Heart Institute, Salt Lake City, Utah; Division of Cardiovascular Medicine, Department of Medicine, Stanford Univ, Stanford, CA

4:10 p.m.

Q&A

FRIDAY, 12 APRIL, 2024

3:00 - 4:15 p.m.

ORAL SESSION 32: What's New in PVD: Updates on Management and Outcomes from Registries and Clinical Trials

Location: South Hall 1

Core Therapies: PVD

Practice Areas: Pulmonology, Cardiology, Cardiothoracic Surgery

Session Summary: This session will cover highlight the top abstracts related to management and outcomes in pulmonary vascular disease. Including novel studies from contemporary registries, and key results from recently completed clinical trials.

Each presenter will give a **10-minute** PowerPoint presentation, followed by a **5-minute** question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: Mardi Gomberg-Maitland, MD, MSc, George Washington University, Washington, DC, USA
Marc Simon, MD, MS, University of California San Francisco, San Francisco, CA, USA

3:00 p.m. **(157) Survival in Pulmonary Arterial Hypertension (PAH) for 669 Patients Treated with Selexipag in Clinical Practice: Insights from EXPOSURE**

S. Soderberg¹, P. Escribano Subias², C. O'Donovan³, A. Muller⁴, M. Fontana⁵, T. J. Lange⁶, S. Gaine⁷. ¹Department of Public Health and Clinical Medicine, Medicine, Umeå University, Umeå, Sweden, ²Pulmonary Hypertension Unit, Cardiology Department, CIBERCV, Hospital 12 De Octubre, Madrid, Spain, ³Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson & Johnson, Global Medical Affairs, Allschwil, Switzerland, ⁴Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson & Johnson, Global Epidemiology, Allschwil, Switzerland, ⁵Janssen-Cilag S.p.A, Statistics and Decision Sciences, Cologno Monzese, Italy, ⁶Department of Pulmonology, Kreisklinik Bad Reichenhall and Faculty of Medicine, Regensburg University, Regensburg, Germany, ⁷National Pulmonary Hypertension Unit, Mater Misericordiae University Hospital, Dublin, Ireland

3:10 p.m. **Q&A**

3:15 p.m. **(158) Impact of Preoperative Body Mass Index on Long-Term Survival and Functional Outcomes After Pulmonary Endarterectomy: Results from the UK National Cohort**

S. Chiu¹, K. Bunclark², P. Appenzeller², H. Ghani², J. Cannon², F. Taghavi², C. Ng², S. Tsui², J. Pepke-Zaba², D. Jenkins². ¹Northwestern Medicine, Chicago, IL, ²Royal Papworth Hospital, Cambridge, United Kingdom

3:25 p.m. **Q&A**

3:30 p.m. **(159) The Landscape of Referral for Lung Transplantation in Pulmonary Arterial Hypertension: A Report From the Phar**

N. A. Kolaitis¹, J. P. Singer¹, M. Chakinala², A. Hemnes³, G. Heresi⁴, P. Leary⁵, O. Shlobin⁶, C. Ventetulo⁷, T. De Marco¹. ¹University of California, San Francisco, San Francisco, CA, ²Washington Univ Sch of Med, St. Louis, CA, ³Vanderbilt University Medical Center, Nashville, CA, ⁴Cleveland Clinic, Cleveland, OH, ⁵Univesity of Washington, Seattle, WA, ⁶Inova Fairfax Hospital, Falls Church, VA, ⁷Brown University, Providence, RI

3:40 p.m. **Q&A**

3:45 p.m. **(160) Evaluation of Seralutinib Treatment Effect Across Four Risk Tools in the TORREY Study in Pulmonary Arterial Hypertension (PAH)**

R. L. Benza¹, R. Osterhout², S. Hoffman², R. T. Zamanian³, A. R. Hemnes⁴, R. N. Channick⁵, K. M. Chin⁶, R. P. Frantz⁷, A. Ghofrani⁸, L. S. Howard⁹, V. V. McLaughlin¹⁰, J. Vachiery¹¹, L. S. Zisman², M. Cravets², J. Bruey², R. F. Roscigno², D. Mottola², R. Aranda², O. Sitbon¹². ¹Mount Sinai Icahn School of Medicine, New York, NY, ²Gossamer Bio, Inc., San Diego, CA, ³Stanford Univ Med Ctr, Stanford, CA, ⁴Vanderbilt University Medical Center, Nashville, TN, ⁵UCLA Medical Center, Los Angeles, CA, ⁶UT Southwestern Med Ctr, Dallas, TX, ⁷Mayo Clinic, Rochester, MN, ⁸Univ of Giessen, Giessen, Germany, ⁹Imperial College Healthcare NHS Trust, London, United Kingdom, ¹⁰University of Michigan, Ann Arbor, MI, ¹¹HUB Hôpital Erasme, Brussels, Belgium, ¹²Université Paris-Saclay, Le Kremlin-Bicêtre, France

3:55 p.m. **Q&A**

4:00 p.m. **Late-Breaking Abstract Presentation:**

(161) Consistency of the Efficacy and Safety Profile of Sotatercept across Baseline Cardiac Index Subgroups: A Pooled Analysis of STELLAR and PULSAR Trials

M. Gomberg-Maitland¹, D. B. Badesch², J. R. Gibbs³, E. Grunig⁴, M. M. Hoepfer⁵, M. Humbert⁶, G. Kopec⁷, V. V. McLaughlin⁸, G. Meyer⁹, K. M. Olsson⁵, I. Preston¹⁰, S. Rosenkranz¹¹, R. Souza¹², A. Waxman¹³, L. Perchenet¹⁴, J. Strait¹⁴, A. Xing¹⁴, A. O. Johnson-Levonas¹⁴, A. G. Cornell¹⁴, J. de Oliveira Pena¹⁴, H. Ghofrani¹⁵. ¹George Washington University, Washington, DC, ²University of Colorado, Anschutz

Medical Campus, Aurora, CO, ³National Heart and Lung Institute, Imperial College London, London, United Kingdom, ⁴Thoraxklinik-Heidelberg and the German Center for Lung Research, Heidelberg, Germany, ⁵Hannover Medical School and the German Center for Lung Research, Hannover, Germany, ⁶Universite Paris-Saclay, INSERM Unite Mixte de Recherche en Sante 999, Hopital Bicetre (Assistance Publique-Hopitaux de Paris), Le Kremlin-Bicetre, France, ⁷The Pulmonary Circulation Center, Department of Cardiac and Vascular Diseases, Jagiellonian University Medical College, John Paul II Hospital in Krakow, Krakow, Poland, ⁸University of Michigan, Ann Arbor, MI, ⁹Irmadade da Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Brazil, ¹⁰Tufts Medical Center, Boston, MA, ¹¹Department of Cardiology, and Cologne Cardiovascular Research Center (CCRC), Heart Center, University Hospital Cologne, Cologne, Germany, ¹²Instituto do Coração, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ¹³Brigham and Woman's Hospital, Boston, MA, ¹⁴Merck & Co., Inc, Rahway, NJ, ¹⁵Department of Internal Medicine, Justus-Liebig-University Giessen, Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Giessen, Germany

4:10 p.m.

Q&A

FRIDAY, 12 APRIL, 2024

3:00 - 4:15 p.m.

ORAL SESSION 33: Psychosocial and Developmental Considerations Across the Heart Transplant Lifespan

Location: South Hall 2

Core Therapies: HEART

Practice Areas: Nursing and Allied Health, Cardiology, Cardiothoracic Surgery, Pediatrics

Session Summary: This session will feature noteworthy science on psychosocial and developmental factors important to heart failure, pre-transplant, and post-transplant outcomes across pediatric and adult patient populations.

Each presenter will give a **10-minute** PowerPoint presentation, followed by a **5-minute** question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: Melissa Cousino, PhD. University of Michigan, Ann Arbor, MI, USA
Michael Petty, PhD, RN, APRN, CNS, CCNS, Minnesota Health Fairview, Univ of Minnesota MC, Minneapolis, MN, USA

- 3:00 p.m. **(162) Pre-Transplant Psychosocial Evaluation Characteristics and Associations with Pediatric Heart Transplant Outcomes**
V. Melo¹, K. Puri², V. Jack³, E. Ormiston³, J. Spinner², K. Watanabe², S. Choudhry³, H. Tunuguntla³, J. Price³, W. Dreyer⁴, K. Hope⁵. ¹Department of Pediatrics, Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine, Houston, TX, ³Texas Children's Hospital, Houston, TX, ⁴Baylor College of Med, Houston, TX, ⁵Texas Children's Hospital, Baylor College of Medicine
- 3:10 p.m. **Q&A**
- 3:15 p.m. **(163) Pediatric and Emerging Adult Heart Transplant Recipients Lost to Follow-Up: Risk Factors and Outcomes**
E. Kalb¹, K. Watanabe¹, K. Hope², K. Puri³, J. Spinner³, H. Tunuguntla¹, S. Denfield³, J. Price¹, W. Dreyer³, S. Choudhry¹. ¹Texas Children's Hospital, Houston, TX, ²Texas Children's Hospital, Baylor College of Medicine, Houston, TX, ³Baylor College of Medicine, Houston, TX
- 3:25 p.m. **Q&A**
- 3:30 p.m. **(164) In-Hospital Outcomes After Cardiac Transplantation in Patients with Neurodevelopmental Disorders: Insights from The National Inpatient Sample 2011-2019**
I. Ergui¹, L. Grazette². ¹Jackson Memorial Hospital, Miami, FL, ²University of Miami, Miller School of Medicine, Miami, FL
- 3:40 p.m. **Q&A**
- 3:45 p.m. **(165) The Effect of Everolimus vs Calcineurin Inhibitors on Quality of Life 11 Years After Heart Transplantation: The Results of a Randomized Controlled Trial (Schedule Trial)**
I. Grov¹, A. Relbo Authen¹, N. Bergh², K. Rolid³, F. Gustafsson⁴, H. Eiskjaer⁵, G. Radegran⁶, E. Gude¹, S. Arora¹, A. Andreassen¹, T. Halden⁷, K. Broch¹, L. Gullestad⁸. ¹Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway, ²Sahlgrenska University Hospital, Gothenburg, Sweden, ³The Research Council of Norway, Oslo, Norway, ⁴Department of Cardiology, Copenhagen University Hospital, Copenhagen, Denmark, ⁵Aarhus University Hospital, Aarhus, Denmark, ⁶The Section for Heart Failure and Valvular Disease, Skåne University Hospital and Lund University, Lund, Sweden, ⁷Novartis Norge AS, Oslo, Norway, ⁸K.G. Jebsen Cardiac Research Centre and Center for Heart Failure Research, Faculty of Medicine, University of Oslo, Oslo, Norway
- 3:55 p.m. **Q&A**
- 4:00 p.m. **(166) Role of KCCQ Overall Summary Score in Predicting Mortality in Heart Failure Patients**
A. Daniels¹, J. Patel¹, M. Kittleson¹, M. White², A. Velleca³, I. Kim⁴, E. Kransdorf¹, L. Czer¹, F. Esmailian¹, J. Kobashigawa¹. ¹Cedars-Sinai Smidt Heart Institute, Los Angeles, CA, ²Cedars-Sinai Comprehensive Transplant Center, Los Angeles, CA, ³Cedars-Sinai Smidt Heart Institute and Comprehensive Transplant Center, Los Angeles, CA, ⁴Keimyung University Dongsan Hospital, Daegu, South Korea
- 4:10 p.m. **Q&A**

FRIDAY, 12 APRIL, 2024

3:00 - 4:15 p.m.

ORAL SESSION 34: Treatments for CLAD Reimagined: Quidditch Through the Ages

Location: Panorama Hall

Core Therapies: LUNG

Practice Areas: Pulmonology, Cardiothoracic Surgery, Research and Immunology

Session Summary: Chronic lung allograft dysfunction (CLAD) continues to be the major cause of late mortality in lung transplant recipients. Will we ever find a cure or prevention strategy? This session will present new data focused on potential prevention or treatment, including anti-reflux surgery, immunometabolism, stem cell infusion, lymphoid irradiation, and tolerance induction.

Each presenter will give a **10-minute** PowerPoint presentation, followed by a **5-minute** question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: Kieran Halloran, MD, MSc, University of Alberta, Edmonton, AB, Canada
Andrea Zajacova, MD, Prague Lung Transplant Program, Prague, Czech Republic

3:00 p.m. **(167) Comparing Delayed versus Simultaneous Bone Marrow Transplantation to Achieve Lung Allograft Tolerance in Non-Human Primates**
S. M. Landino¹, J. Nawalaniec¹, J. O¹, A. Dehnadi¹, N. Hays¹, J. Muoio¹, C. Winter¹, I. Hanekamp¹, J. Madsen², J. S. Allan³. ¹Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA, ²Center for Transplantation Sciences, Division of Cardiac Surgery, Massachusetts General Hospital, Boston, MA, ³Center for Transplantation Sciences, Division of Thoracic Surgery, Massachusetts General Hospital, Boston, MA

3:10 p.m. **Q&A**

3:15 p.m. **(168) Targeting Immunometabolism in Chronic Lung Transplant Rejection**
M. Cano¹, F. Liao², C. Chen³, D. Zhou², Z. Liu², J. Zhu², K. Pugh⁴, R. Ebenezer¹, D. Byers¹, S. Brody¹, R. Hachem¹, A. Gelman⁵. ¹Pulmonary and Critical Care Medicine, Washington University School of Medicine, Saint Louis, MO, ²Surgery, Washington University School of Medicine, Saint Louis, MO, ³Pulmonary and Critical Care Medicine, UT Southwestern Medical Center, Dallas, TX, ⁴Cell and Developmental Biology, University of Michigan, Ann Arbor, MI, ⁵Surgery and Immunology and Pathology, Washington University School of Medicine, Saint Louis, MS

3:25 p.m. **Q&A**

3:30 p.m. **(169) Mesenchymal Stromal Cells as Rescue Therapy for Refractory Chronic Lung Allograft Dysfunction: Analysis of Immunoregulatory Effects In Vitro and Preliminary Data of Safety In Vivo**
S. Lettieri¹, S. Bozzini², E. Bozza², C. Bagnera², D. Briganti³, K. Mucaj¹, G. Melloni⁴, P. Comoli⁵, F. Meloni³. ¹Pneumology Unit, IRCCS Policlinico San Matteo Foundation, Pavia, Italy, ²IRCCS Policlinico San Matteo Foundation, Pavia, Italy, ³Transplant Center, IRCCS Policlinico San Matteo Foundation, Pavia, Italy, ⁴Thoracic Surgery, IRCCS Policlinico San Matteo Foundation, Pavia, Italy, ⁵Pediatric Oncology/Cell Factory, IRCCS Policlinico San Matteo Foundation, Pavia, Italy

3:40 p.m. **Q&A**

3:45 p.m. **(170) Safety and Efficacy of Total Lymphoid Irradiation in the Treatment of Chronic Lung Allograft Dysfunction**
A. P. Hakiman¹, F. Filippidis², R. Njafuh³, M. Carby³, K. Dave³, J. Dunning³, A. Reed³, P. Hoskin⁴, V. Gerovasili³. ¹School of Public Health, Imperial College London, London, United Kingdom, ²Department of Primary Care and Public Health, School of Public Health, Imperial College London, London, United Kingdom, ³Department of Cardiothoracic Transplantation and Mechanical Circulatory Support, Royal Brompton and Harefield Hospitals, Part of Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom, ⁴Mount Vernon Cancer Centre, Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom

3:55 p.m. **Q&A**

4:00 p.m. **(171) Anti-Reflux Surgery for Prevention of CLAD Onset After Lung Transplantation: The Earlier the Better? A Single-Center Series of 284 Patients**
A. Hamid¹, A. Vallée², S. Rong¹, S. De Miranda¹, O. Boche¹, J. Rouillet-Audy¹, M. Stern¹, D. Grenet¹, L. Beaumont¹, F. Parquin¹, S. Colin De Verdier¹, C. Picard¹, B. Zuber¹, J. Devaquet¹, J. Fessler³, M. Le Guen¹, J. De Wolf⁴, C. Pricopi¹, M. Glorion¹, E. Sage¹, A. Roux¹, O. Brujière¹. ¹Hôpital Foch, Suresnes, France, ²Service d'Épidémiologie et Santé Publique, Hôpital Foch, Suresnes, France, ³Foch Lung Transplant Group, Suresnes, France, ⁴Centre Hospitalier Universitaire de Lille, Lille, France

4:10 p.m. **Q&A**

FRIDAY, 12 APRIL, 2024

3:00 - 4:15 p.m.

ORAL SESSION 35: The Immunology of Cardiac Allograft Tolerance and Rejection: New Answers to Old Questions?

Location: North Hall

Core Therapies: HEART, MCS

Practice Areas: Research and Immunology, Anesthesiology and Critical Care, Cardiology, Cardiothoracic Surgery, Nursing and Allied Health, Pathology, Pediatrics

Session Summary: In this session we will discuss Basic Science questions regarding the immunology of rejection and tolerance. Abstracts feature apoptosis, ferroptosis and signaling pathways and hematopoietic neonatal tolerance.

Each presenter will give a **10-minute** PowerPoint presentation, followed by a **5-minute** question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: Nina Pilat, MSc, PhD, Medical University of Vienna (MUW), Vienna, Austria
Victoria Reams, PharmD, BCTXP, UF Health, Gainesville, FL, USA

- 3:00 p.m. **(172) Modulation of Programmed Cell Death Mechanisms in Human Hearts Donated After Circulatory Death**
N. K. Mondal¹, S. Li¹, K. V. Nordick¹, A. E. Elsenousi¹, R. Bhattacharya¹, A. Mattar¹, C. Hochman-Mendez², T. K. Rosengart¹, K. K. Liao¹. ¹Department of Surgery, Baylor College of Medicine, Houston, TX, ²Regenerative Medicine Research, Texas Heart Institute, Houston, TX
- 3:10 p.m. **Q&A**
- 3:15 p.m. **(173) Blocking Signaling Pathways Like Notch and Hedgehog Reduces Chronic Rejection in a Murine Aortic Transplant Model**
M. Scheunchen¹, C. Gräbner¹, A. Kuckhahn¹, J. Distler², B. Spriewald³, M. Ramsperger-Gleixner¹, O. Dewald¹, C. Heim¹. ¹Dep. of Cardiac Surgery, University Hospital Erlangen, Erlangen, Germany, ²Dep. of Internal Medicine 3 and Institute for Clinical Immunology, University Hospital Erlangen, Erlangen, Germany, ³Dep. of Internal Medicine 5, University Hospital Erlangen, Erlangen, Germany
- 3:25 p.m. **Q&A**
- 3:30 p.m. **(174) Persistent Alterations in Gene Expression Despite Phenotypic Normalization in a Non-Ischemic Mouse Model of Heart Failure Recovery: Are ECM and Ferroptosis Genes the Key for Complete, Sustained Recovery?**
K. A. Patel¹, M. Krishnamoorthi², L. W. Moore¹, A. Bhimaraj¹. ¹J.C. Walter Jr. Transplant Center, Houston Methodist Hospital, Houston, TX, ²Houston Methodist Hospital, Houston, TX
- 3:40 p.m. **Q&A**
- 3:45 p.m. **(175) Normothermic Ex Vivo Heart Perfusion with Exosomes from Mesenchymal Stem Cells Improves Graft Function in Donation After Circulatory Death Hearts via Pi3k/akt Pathway**
C. Niu¹, Z. Zhang¹, W. Lei¹, X. Wang², L. Xu¹, J. Ji¹, X. Pan¹, P. Zhou¹, S. Zheng¹. ¹Department of Cardiovascular Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, ²Department of Human Anatomy, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China
This presenter is also one of five finalists for the 2024 Early Career Scientist Award. Winner will be announced after the meeting.
- 3:55 p.m. **Q&A**
- 4:00 p.m. **(176) Neonatal Tolerance to Heart Transplants Induced with Neonatal Allogeneic Liver Cells: Trafficking, Interactions and Fates of Donor Cell Types**
R. A. Bascom, K. Tao, L. J. West. University of Alberta, Edmonton, AB, Canada
- 4:10 p.m. **Q&A**

FRIDAY, APRIL 12, 2024

4:30 - 5:30 p.m.

MINI ORAL 08: All About Preservation: Save My Heart

Location: Congress Hall

Core Therapies: HEART

Practice Areas: Cardiothoracic Surgery, Cardiology, Nursing and Allied Health, Pathology, Research and Immunology

Session Summary: This session focuses on donor heart preservation techniques including hypothermic and normothermic approaches.

Each presenter will give a 4-minute "rapid fire" PowerPoint summation of the key learning points of the research, followed by a 2-minute question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: Ravi Kumar Ratnagiri, MD, DM. MGM Hospital, Chennai, India,
Sean Pinney, MD. Mount Sinai Morningside, New York, NY, USA

- 4:30 p.m. **Late-Breaking Abstract Presentation:**
(299) Randomized Trial to Evaluate the Safety and Efficacy of the Sherpa Pak Device versus Cold Storage of Donor Hearts in Transplantation: A Pilot Study
F. Esmailian¹, A. Stotland¹, J. Patel¹, D. Emerson¹, J. Mirocha², M. Bowdish¹, P. Catarino¹, D. Megna¹, T. Gunn¹, M. Raffei¹, O. Babalola¹, A. Daniels¹, M. Kittleson¹, D. Chang¹, E. Kransdorf¹, A. Nikolova¹, J. Chikwe¹, J. Kobashigawa¹. ¹Cedars-Sinai Smidt Heart Institute, Los Angeles, CA, ²Cedars-Sinai Medical Center, Los Angeles, CA
- 4:34 p.m. **Q&A**
- 4:36 p.m. **(300) Extended Normothermic Ex Situ Heart Perfusion without Functional Decline**
M. T. Vervoorn¹, S. Van Tuijl², E. M. Ballan¹, S. E. Kaffka Genaamd Dengler¹, S. C. De Jager¹, J. P. Sluijter¹, P. A. Doevendans¹, N. P. van der Kaaij¹. ¹UMC Utrecht, Utrecht, Netherlands, ²LifeTec Group, Eindhoven, Netherlands
- 4:40 p.m. **Q&A**
- 4:42 p.m. **(301) Determination of the Optimal Temperature for Organ Preservation through Analysis of the Guardian Registry**
D. D'Alessandro¹, D. Meyer², S. Pham³, Y. Stukov⁴, J. Jacobs⁴, A. Vidic⁵, A. Zuckermann⁶. ¹MGH, Boston, MA, ²Baylor Scott and White Health, Baylor University Medical Center, Dallas, TX, ³Mayo Clinic Jacksonville, Jacksonville, FL, ⁴University of Florida, Gainesville, FL, ⁵University of Kansas Health System, Kansas City, KS, ⁶Medical University of Vienna, Vienna, Austria
- 4:46 p.m. **Q&A**
- 4:48 p.m. **(302) Non-Invasive Beating Heart Video Kinematics Correlate with Cardiac Function During Ex-Vivo Perfusion**
B. Ayers, G. Olverson, A. Aguirre, S. Rabi, A. Osho, D. D'Alessandro. Division of Cardiac Surgery, Massachusetts General Hospital, Boston, MA
- 4:52 p.m. **Q&A**
- 4:54 p.m. **(303) Reduced Risk of Cardiovascular-Related Death Associated with Moderate Hypothermic Donor Heart Preservation in the Guardian Heart Registry**
A. Zuckermann¹, U. Boston², A. Eixerés Esteve³, J. P. Jacobs⁴, S. Pham⁵, K. Takeda⁶, M. Kawabori⁷, Y. Shudo⁸, A. Vidic⁹, M. Leacche¹⁰, M. Rodrigo¹¹, D. Meyer¹², R. Venkateswaran¹³, B. Karner¹⁴, J. Bustamante Munguira¹⁵, J. Schroder¹⁶, B. Mahesh¹⁷, S. Silvestry¹⁸, D. D'Alessandro¹⁹. ¹Medical University of Vienna, Vienna, Austria, ²Le Bonheur Children's Hosp, Memphis, TN, ³12 de Octubre, Madrid, Spain, ⁴University of Florida Health Shands, Gainesville, FL, ⁵Mayo Clinic, Jacksonville, FL, ⁶Columbia University, New York, NY, ⁷Tufts Medical Center, Boston, MA, ⁸Stanford University, Stanford, CA, ⁹University of Kansas Health System, Kansas City, KS, ¹⁰Corewell Health, Grand Rapids, MI, ¹¹Medstar Washington Hospital Center, Washington DC, DC, ¹²Baylor Scott and White Health, Baylor University Medical Center, Dallas, TX, ¹³Wythenshawe Hospital, Manchester, United Kingdom, ¹⁴Medical University of Graz, Graz, Austria, ¹⁵Clinico Universitario de Valladolid, Valladolid, Spain, ¹⁶Duke University Medical Center, Durham, NC, ¹⁷Penn State Hershey Medical Center, Hershey, PA, ¹⁸AdventHealth Transplant Institute, Orlando, FL, ¹⁹MGH, Boston, MA
- 4:58 p.m. **Q&A**
- 5:00 p.m. **(304) Eliminating Ischemia: Sustaining Cardiac Function During Donor Procurement**
M. Fawad¹, Y. Zhu¹, S. Elde¹, A. Krishnan¹, J. McNulty¹, B. Chadwick¹, Y. Wang², C. Lu¹, M. Massey¹, W. Trope³, J. Simmons¹, S. Lee¹, C. Stark¹, S. Walsh¹, A. Venkatesh¹, M. Vergel¹, S. E. Oh¹, C. Huynh¹, J. Yang¹, G. Cywinska¹, J. MacArthur¹, Y. Shudo¹, C.

Ruaengsri¹, J. Woo¹, B. A. Guenthart¹. ¹Stanford University, Palo Alto, CA, ²University of Michigan, Ann Arbor, MI, ³Yale University, New Haven, CT

5:04 p.m. **Q&A**

5:06 p.m. **(305) Post-Transplant Survival in Heart Transplantation Using Normothermic Regional Perfusion (NRP) vs. Direct Procurement and Perfusion (DPP) in Donation After Circulatory Determination of Death**

G. Ran¹, A. Wall², N. Narang³, K. Khush⁴, J. Hoffman⁵, W. Parker⁶. ¹University of Chicago Pritzker School of Medicine, Chicago, IL, ²Annette C. and Harold C. Simmons Transplant Institute, Baylor University Medical Center, Dallas, TX, ³Advocate Heart Institute, Advocate Christ Medical Center, Chicago, IL, ⁴Stanford University, Stanford, CA, ⁵University of Colorado School of Medicine, Aurora, CO, ⁶University of Chicago Medicine, Chicago, IL

5:10 p.m. **Q&A**

5:12 p.m. **(306) Transcriptomic Response of Human Donor Hearts to Temperature-Controlled Storage**

G. Sharma¹, R. Vela¹, L. Powell¹, C. R. Malloy², M. Jessen¹, M. Peltz¹. ¹Cardiovascular and Thoracic Surgery, UT Southwestern Medical Center, Dallas, TX, ²Advanced Imaging Research Center, UT Southwestern Medical Center, Dallas, TX

5:16 p.m. **Q&A**

5:18 p.m. **(307) Organ Care System Heart Perfusion (OHP) Registry Annual Report - DBD Heart Transplants Clinical Outcomes**

M. Villavicencio¹, L. Klein², J. Schroder³, G. Couper⁴, S. Ohira⁵, R. Davis⁶, J. Haft⁷, S. Pham⁸, M. Daneshmand⁹, D. Pham¹⁰, D. D'Alessandro¹¹, B. Sun¹², D. Goldstein¹³, D. Meyer¹⁴, L. Lozonschi¹⁵, R. Malyala¹⁶, F. Esmailian¹⁷, H. Mallidi¹⁸, K. Takeda¹⁹, P. Spencer²⁰, D. Kaczorowski²¹, M. Funamoto²², L. Durham²³, Y. Shudo²⁴, A. Shaffer²⁵, J. Stehlik²⁶, S. Pinney²⁷, M. Farr²⁸, C. Milano³, J. Pal²⁹. ¹Cardiovascular Surgery, Mayo Clinic, Rochester, MN, ²University of California San Francisco, San Francisco, CA, ³Duke University Medical Center, Durham, NC, ⁴Tufts Medical Center, Boston, MA, ⁵Westchester Medical Center, New York Medical College, Westchester, NY, ⁶Yale University, New Haven, CT, ⁷University of Michigan - Michigan Medicine, Ann Arbor, MI, ⁸Mayo Clinic, Jacksonville, FL, ⁹Emory University, Atlanta, GA, ¹⁰Northwestern Medicine, Chicago, IL, ¹¹MGH, Boston, MA, ¹²Abbott Northwestern Hospital, Minneapolis, MN, ¹³Montefiore Medical Center, New York, NY, ¹⁴Baylor Scott and White Health, Baylor University Medical Center, Dallas, TX, ¹⁵University of South Florida, Tampa General Hospital, Tampa, FL, ¹⁶University of Kentucky, Lexington, KY, ¹⁷Cedars-Sinai Heart Institute, Los Angeles, CA, ¹⁸Brigham and Women's Hospital / HMS, Boston, MA, ¹⁹Columbia University, New York, NY, ²⁰Mayo Clinic, Rochester, MN, ²¹University of Pittsburgh Medical Center, Pittsburgh, PA, ²²Methodist Specialty and Transplant Hospital, San Antonio, TX, ²³Medical College of Wisconsin, Milwaukee, WI, ²⁴Stanford University, Palo Alto, CA, ²⁵Univ of Minnesota, Minneapolis, MN, ²⁶University of Utah, Salt Lake City, UT, ²⁷Mount Sinai Morningside, New York, NY, ²⁸University of Texas Southwestern Medical Center, Dallas, TX, ²⁹University of Washington, Seattle, WA

5:22 p.m. **Q&A**

5:24 p.m. **(308) Assessment of Extended Criteria Donor Hearts with Resonance Raman Spectroscopy During Normothermic Machine Perfusion**

E. O. Ajenu¹, M. Lopera Higueta¹, M. Bolger-Chen¹, K. T. Nguyen¹, G. Olverson², G. Singh¹, D. Vincent³, P. Romfh⁴, S. Rabi², A. Osho², S. N. Tessier¹. ¹Center for Engineering in Medicine and Surgery, Massachusetts General Hospital, Boston, MA, ²Division of Cardiac Surgery, Corrigan Minehan Heart Center, Massachusetts General Hospital, Boston, MA, ³VentriFlo Inc, Pelham, NH, ⁴Pendar Technologies LLC, Cambridge, MA

5:28 p.m. **Q&A**

FRIDAY, 12 APRIL, 2024

4:30 - 5:30 p.m.

MINI ORAL 09: Safe Preservation, Transportation, and Evaluation of Donor Lungs: Voldermort's Mode of Death

Location: Forum Hall

Core Therapies: LUNG

Practice Areas: Cardiothoracic Surgery, Anesthesiology and Critical Care, Pulmonology, Research and Immunology

Session Summary: Abstracts in this mini-oral session are focused on impact of donor's mode of death and new methods for hypothermic and normothermic preservation, conditioning, and transportation of donor lungs.

Each presenter will give a **4-minute** "rapid fire" PowerPoint summation of the key learning points of the research, followed by a **2-minute** question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: Laurens Ceulemans, MD, PhD, University Hospitals Leuven, Leuven, Belgium
Stephen Huddleston, MD, PhD, University of Minnesota, Minneapolis, MN, USA

- 4:30 p.m. **(309) Impact of Donor Hypoxic-Ischemic Brain Injury on Lung Transplant Outcomes**
A. F. Akbar¹, A. L. Zhou¹, J. M. Ruck², N. White³, A. Kalra⁴, A. J. Casillan², J. S. Ha², C. A. Merlo⁵, E. L. Bush², S. Cho⁶. ¹Dept of Surgery, Johns Hopkins Univ SoM, Baltimore, MD, ²Dept of Surgery, Johns Hopkins Hosp, Baltimore, MD, ³Queensland Univ of Tech, Brisbane, Australia, ⁴Sidney Kimmel Med Coll, Thomas Jefferson Univ, Philadelphia, PA, ⁵Dept of Med, Johns Hopkins Hospital, Baltimore, MD, ⁶Dept of Neurology, Johns Hopkins Hosp, Baltimore, MD
- 4:34 p.m. **Q&A**
- 4:36 p.m. **(310) Significant Hypertension During Agonal Phase in Donation After Circulatory Death Donors Might be a Risk Factor of Pulmonary Edema in Clinical Lung Transplantation**
T. Okamoto¹, K. Ayyat¹, A. Tantawi¹, H. Elgharably¹, S. Unai¹, J. J. Yun¹, M. Budev², K. R. McCurry¹. ¹Department of Thoracic & Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH, ²Department of Pulmonary Medicine, Cleveland Clinic, Cleveland, OH
- 4:40 p.m. **Q&A**
- 4:42 p.m. **(311) Contextual Effects of Donor Lung Factors on Post-Transplant Survival**
C. J. Lehr¹, J. E. Dalton², E. N. Dewey², P. R. Gunsalus², J. Rose³, M. Valapour¹. ¹Pulmonary Medicine, Cleveland Clinic, Cleveland, OH, ²Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, ³Center for Community Health Integration, Case Western Reserve University, Cleveland, OH
- 4:46 p.m. **Q&A**
- 4:48 p.m. **Late-Breaking Abstract Presentation:**
(640) Extending Cold Ischemic Time in Lung Transplant. Largest Published Cohort Utilizing Lungguard
M. M. Botros¹, C. Tanabe², A. Alsaghayer³, D. Ren⁴, E. Suarez⁵, H. Huang⁶. ¹Medicine, Houston Methodist Hospital, Houston, TX, ²Medicine, Houston Methodist, Houston, TX, ³Houston Methodist Hospital, Houston, TX, ⁴Cardiovascular Surgery, Houston Methodist Hospital, Houston, TX, ⁵Cardiovascular Surgery, Houston Methodist, Houston, TX, ⁶Medicine, Houston Methodist J.C. Walter Jr. Transplant Center, Houston, TX
- 4:52 p.m. **Q&A**
- 4:54 p.m. **(313) Extension of Ischemic Time with Controlled Hypothermic Lung Preservation Facilitates Time-Shifting Practice and Expansion of the Donor Pool**
H. J. Huang¹, N. Langer², J. Haney³, P. Sanchez⁴, P. Carrott⁵, L. J. Ceulemans⁶, J. Kukreja⁷, E. L. Bush⁸, M. Hartwig⁹. ¹Houston Methodist J.C. Walter Jr. Transplant Ctr, Houston, TX, ²Massachusetts Gen Hosp, Boston, MA, ³Duke Univ, Durham, NC, ⁴Univ of Pittsburgh MC, Pittsburgh, PA, ⁵Univ of Virginia, Charlottesville, VA, ⁶Univ Hospitals Leuven, Leuven, Belgium, ⁷Univ of California San Francisco, San Francisco, CA, ⁸Johns Hopkins, Baltimore, MD, ⁹Duke University MC, Durham, NC
- 4:58 p.m. **Q&A**
- 5:00 p.m. **(314) Measuring Donor Lung Temperature in Clinical Lung Transplantation: Controlled Hypothermic Storage versus Static Ice Storage**
I. Cenic¹, J. Van Slambrouck², E. Prisciandaro², A. Provoost², A. Barbarossa¹, C. M. Vandervelde², X. Jin¹, R. Novyzedlák¹, P. De Leyn², H. Van Veer², L. Depypere², Y. Jansen², J. Pirenne², D. Van Raemdonck², L. J. Ceulemans². ¹KU Leuven, Leuven, Belgium, ²University Hospitals Leuven, Leuven, Belgium

- 5:04 p.m. **Q&A**
- 5:06 p.m. **(315) Evaluation of Ventilation at 10°C as the Optimal Storage Condition for Donor Lungs in a Murine Transplant Model**
M. A. Hill, M. Tennant, R. O'Neil, T. Rajab, B. C. Gibney. *Medical University of South Carolina, Charleston, SC*
- 5:10 p.m. **Q&A**
- 5:12 p.m. **(316) 5-Year Outcomes of the Organ Care System (OCS) Lung EXPAND Pivotal International Trial**
G. Loo¹, F. Ius², D. Van Raemdonck³, N. Langer⁴, M. Smith⁵, J. Kukreja⁶, M. Hartwig⁷, A. Ardehali⁸, S. Huddleston⁹. ¹*Baylor Coll of Med, Houston, TX*, ²*Hannover Med Sch, Hannover, Germany*, ³*Univ Hospitals Leuven, Leuven, Belgium*, ⁴*Mass Gen Hosp, Boston, MA*, ⁵*St. Joseph's Hosp & MC Norton Thoracic Inst, Phoenix, AZ*, ⁶*Univ of California, San Francisco, San Francisco, CA*, ⁷*Duke Univ MC, Durham, NC*, ⁸*UCLA SoM, Los Angeles, CA*, ⁹*Univ of Minnesota, Minneapolis, MN*
- 5:16 p.m. **Q&A**
- 5:18 p.m. **(317) Effects of Organ Transport Distance in Lung Transplant with Ex Vivo Lung Perfusion**
E. L. Larson¹, R. Jenkins¹, J. Ruck¹, A. Zhou¹, A. Rizaldi¹, A. Casillan¹, J. Ha¹, C. Merlo¹, E. Bush². ¹*Johns Hopkins University School of Medicine, Baltimore, MD*, ²*Johns Hopkins, Baltimore, MD*
- 5:22 p.m. **Q&A**
- 5:24 p.m. **(318) Towards the Digital Lung: A Deep Learning Approach to Simulating Physiological Lung Function During Ex Vivo Lung Perfusion**
X. Zhou¹, L. Del Sorbo², O. Hough³, T. Borrillo³, M. Grubert Van Iderstine⁴, B. T. Chao⁵, L. Orsini⁴, J. Valero³, M. Cypel³, B. Wang⁶, S. Keshavjee³, A. T. Sage⁷. ¹*Toronto Lung Transplant Program and Latner Thoracic Research Laboratories, University Health Network, Toronto, ON, Canada*, ²*Toronto General Hospital, Toronto, ON, Canada*, ³*University Health Network, Toronto, ON, Canada*, ⁴*University Health Network, Toronto, ON, Canada*, ⁵*University Health Network - Toronto General Hospital, Toronto, ON, Canada*, ⁶*Vector Institute, Toronto, ON, Canada*, ⁷*University Health Network, Toronto, ON, Canada*
- 5:28 p.m. **Q&A**

FRIDAY, 12 APRIL, 2024

4:30 - 5:30 p.m.

MINI ORAL 10: Big Data, Big Questions: Outcomes in Heart Transplantation

Location: South Hall 3

Core Therapies: HEART

Practice Areas: Cardiology, Cardiothoracic Surgery, Nursing and Allied Health

Session Summary: Registries such as UNOS are large and provide data to generate insights that affect practice. This session focuses on insights from larger datasets and looks at post transplant outcomes as well as candidate selection.

Each presenter will give a **4-minute** "rapid fire" PowerPoint summation of the key learning points of the research, followed by a **2-minute** question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: Goran Dellgren, MD, PhD, Sahlgrenska University Hospital, Goteborg, Sweden
Claudia Gidea, MD, Newark Beth Israel Medical Center, Newark, NJ, USA

4:30 p.m. **(319) Overnight Heart Transplantation is Associated with Inferior Survival: A UNOS Registry Analysis**
Y. Hong, N. Hess, L. Ziegler, A. Dorken-Gallastegi, M. Abdullah, N. Iyanna, I. Sultan, G. Hickey, M. Keebler, D. Kaczorowski.
University of Pittsburgh Medical Center, Pittsburgh, PA

4:34 p.m. **Q&A**

4:36 p.m. **(320) Increased Renal Complications After the 2018 UNOS Policy Change: A Linked Analysis of the Scientific Registry of Transplant Recipients and Medicare Claims**
S. C. Silvestry¹, T. Alexy², A. G. Fiedler³, M. Kanwar⁴, E. J. Molina⁵, A. A. Morris⁶, K. L. Wood⁷, D. M. Yaranov⁸, Y. Yu⁹, J. Chuang⁹, A. T. Connolly⁹, R. L. Kormos¹⁰, F. D. Pagani¹¹. ¹AdventHealth Transplant Institute, Orlando, FL, ²Department of Medicine, Division of Cardiology, University of Minnesota, Minneapolis, MN, ³University of California San Francisco, San Francisco, CA, ⁴Cardiovascular Institute at Allegheny Health Network, Pittsburgh, PA, ⁵Piedmont Heart Institute, Atlanta, GA, ⁶Emory University School of Medicine, Atlanta, GA, ⁷Division of Cardiac Surgery, University of Rochester Medical Center, Rochester, NY, ⁸Baptist Memorial Hospital, Memphis, TN, ⁹Abbott, Santa Clara, CA, ¹⁰Abbott, Austin, TX, ¹¹Department of Cardiac Surgery, University of Michigan, Ann Arbor, MI

4:40 p.m. **Q&A**

4:42 p.m. **(322) Malignancy and Survival in Cardiac Allograft Recipients Pre and Post Year 2000 - A SRTR Database Analysis**
N. Nair¹, D. Du². ¹Medicine/Cardiology, Penn State Health/Milton S Hershey Med Ctr, Hershey, PA, ²Industrial Engineering, Texas Tech University, Lubbock, TX

4:46 p.m. **Q&A**

4:48 p.m. **(323) Novel Machine Learning Models for Predicting 3 Year Survival in Adult Heart Transplant**
Z. Brennan, M. Bowdish, J. Chikwe, P. Catarino, D. Megna, D. Emerson. Cedars-Sinai Medical Center, Los Angeles, CA

4:52 p.m. **Q&A**

4:54 p.m. **(324) Association of Center Volume with Post-Transplant Survival After the 2018 US Heart Allocation Policy Change**
S. Zeng¹, K. Lazenby¹, M. White², S. Tolmie³, W. Parker². ¹University of Chicago Pritzker School of Medicine, Chicago, IL, ²University of Chicago Medicine, Chicago, IL, ³University of Chicago, Pritzker School of Medicine, Chicago, IL

4:58 p.m. **Q&A**

5:00 p.m. **(325) The Long-Term Outcomes of Patients with Chemotherapy-Induced Cardiomyopathy Undergoing Heart Transplantation**
M. Mazur¹, A. Carmona Rubio², J. Herrmann³, K. Meleveedu⁴, O. Ali⁵, W. Tang¹. ¹Heart and Vascular Institute, Kaufman Center for Heart Failure, Cleveland Clinic Foundation, Cleveland, OH, ²Heart and Vascular Institute, Kaufman Center for Heart Failure, Cleveland Clinic, Cleveland, OH, ³Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, ⁴Department of Hematology and Oncology, Bone Marrow Transplant, University of Connecticut Health Center, Farmington, CT, ⁵Heart and Vascular Institute, Penn State Milton S. Hershey Medical Center, Hershey, PA

5:04 p.m. **Q&A**

5:06 p.m. **(326) Impact of the 2018 UNOS Allocation Change on Severe Primary Graft Dysfunction: A Report from the International Consortium on PGD**

L. K. Truby¹, Y. Moayedifar², F. Foroutan³, J. Han⁴, E. Henricksen⁵, H. Luikart⁵, E. Ródenas Alesina⁶, J. Guzman Bofarull⁷, D. Couto Mallon⁸, R. Moayedifar⁹, K. Takeda¹⁰, G. Kim¹¹, M. Crespo-Leiro⁸, J. Felius¹², S. Hall¹², A. D. DeVore¹³, J. B. Lerman¹³, M. Sabatino¹⁴, L. Potena¹⁵, M. Rivas-Lasarte¹⁶, J. Segovia-Cubero¹⁷, M. Farrero Torres⁷, M. Tremblay-Gravel¹⁸, P. Noly¹⁸, R. Miller¹⁹, S. Chih²⁰, A. Zuckermann²¹, C. Fan²², H. Ross²³, K. Khush⁵, M. Farr¹. ¹UT Southwestern Medical Center, Dallas, TX, ²UHN, Toronto, ON, Canada, ³Ted Rogers Centre for Heart Research, Toronto, ON, Canada, ⁴University of Chicago Medical Center, Chicago, IL, ⁵Stanford University, Palo Alto, CA, ⁶University Hospital, Barcelona, Spain, ⁷Hospital Clinic de Barcelona, Barcelona, Spain, ⁸Hospital Universitario A Coruña, La Coruna, Spain, ⁹Medical University Vienna General Hospital Vienna, Vienna, Austria, ¹⁰Columbia University, New York, NY, ¹¹University of Chicago, Chicago, IL, ¹²Baylor University Medical Center, Dallas, TX, ¹³Duke University Medical Center, Durham, NC, ¹⁴Institute of Cardiology S.Orsola-Malpighi Hospital, Bologna, Italy, ¹⁵IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, ¹⁶Hospital Puerta de Hierro, Madrid, Madrid, Spain, ¹⁷Hospital Puerta de Hierro, Madrid, Spain, Madrid, Spain, ¹⁸Montreal Heart Institute, Montreal, QC, Canada, ¹⁹University of Calgary, Calgary, AB, Canada, ²⁰University of Ottawa Heart Institute, Ottawa, ON, Canada, ²¹Medical University of Vienna, Vienna, Austria, ²²University Health Network, Toronto, ON, Canada, ²³Toronto General Hospital, Toronto, ON, Canada

5:10 p.m.

Q&A

5:12 p.m.

(327) A Comprehensive Risk Score to Predict One Year Mortality After Heart-Lung Transplantation

A. Krishnan, E. Heng, S. Elde, A. Garrison, M. Fawad, C. Ruaengsri, B. A. Guenthart, J. Woo, J. W. MacArthur. *Cardiothoracic Surgery, Stanford University School of Medicine, Palo Alto, CA*

5:16 p.m.

Q&A

5:18 p.m.

(328) Geographic Variation in Rank Priority Waiting Time in the United States Heart Allocation System

M. Kosztowski¹, J. Rogers², A. Schutz³, G. Loo³, K. Liao³, A. Shafii³. ¹Baylor - Texas Heart Institute, Houston, TX, ²Texas Heart Institute, Houston, TX, ³Baylor College of Medicine, Houston, TX

5:22 p.m.

Q&A

FRIDAY, 12 APRIL, 2024

4:30 - 5:30 p.m.

MINI ORAL 11: LVAD Outcomes and Predictive Modeling

Location: South Hall 1

Core Therapies: MCS

Practice Areas: Cardiology, Cardiothoracic Surgery, Nursing and Allied Health, Pediatrics, Pharmacy

Session Summary: Pediatric ACTION outcomes will be discussed along with predictive models, novel infection LVAD prevention strategies and risk scores, and VAD Wean Registry results.

Each presenter will give a **4-minute** "rapid fire" PowerPoint summation of the key learning points of the research, followed by a **2-minute** question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: Jaime Hernandez Montfort, MD, MPH, MSc, Baylor Scott and White Health, Austin, TX, USA
Angela Velleca, MHDS, BSN, RN, CCTC, Cedars-Sinai Smidt Heart Institute, Los Angeles, CA, USA

- 4:30 p.m. **(329) Predictive Model of the Sustainability of Favorable Response After LVAD Weaning in HF Patients: A VAD Wean Registry Analysis**
E. Maneta¹, C. P. Kyriakopoulos¹, E. Dranow¹, T. C. Hanff¹, J. Stehlik¹, O. Wever-Pinzon¹, E. Potapov², J. Schmitto³, P. Shah⁴, M. Papatheanasiou⁵, P. Billia⁶, C. H. Selzman¹, S. Patel⁷, S. G. Drakos¹. ¹Utah Cardiac Recovery (UCAR) Program (University of Utah Health and School of Medicine, Intermountain Medical Center, George E. Wahlen Department of Veterans Affairs Medical Center), Salt Lake City, UT, ²Department of Cardiothoracic and Vascular Surgery, German Heart Center Berlin, Berlin, Germany; DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany, ³Hannover Medical School, Hannover, Germany, ⁴Inova Heart and Vascular Institute, Falls Church, VA, ⁵University of Duisburg-Essen, West German Heart and Vascular Center, Essen, Germany, ⁶University of Toronto, University Health Network, Toronto, ON, Canada, ⁷Division of Cardiology, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY
- 4:34 p.m. **Q&A**
- 4:36 p.m. **(330) Collective Five Year ACTION VAD Registry Experience**
J. Edelson¹, A. Raskin², M. Absi³, D. Bearl⁴, C. Bonilla Ramirez⁵, N. Do⁴, C. Knoll⁶, A. Lorts⁵, H. Martinez⁷, K. Maeda¹, M. O'Connor¹, D. Rosenthal⁸, M. Shezad⁵, B. Wisotzkey⁶, R. Niebler². ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Children's Wisconsin, Milwaukee, WI, ³University of Tennessee Health Science Center, Memphis, TN, ⁴Vanderbilt University, Nashville, TN, ⁵Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Phoenix Children's Hospital, Phoenix, AZ, ⁷Le Bonheur Children's Hospital, Memphis, TN, ⁸Stanford University, Palo Alto, CA
- 4:40 p.m. **Q&A**
- 4:42 p.m. **(331) Cystatin C- Based Estimated Glomerular Filtration Rate: A Predictive Metric for Long-Term Heartmate 3 Survival**
G. M. Mondellini, A. Pinsino, M. A. Hynds, A. Vinogradsky, A. Ladanyi, G. Sayer, Y. Kaku, N. Uriel, K. Takeda, S. A. Husain, S. Mohan, P. C. Colombo, M. Yuzefpolskaya. Columbia University Irving Medical Center, New York, NY
- 4:46 p.m. **Q&A**
- 4:48 p.m. **(332) Clinical Outcomes and Complications in Pediatric Ventricular Assist Devices Implanted as Bridge to Candidacy**
C. Knoll¹, D. Mattia¹, B. Wisotzkey¹, L. Wright², M. Shezad³, S. Hollander⁴. ¹Phoenix Children's Hospital, Phoenix, AZ, ²Nationwide Children's Hospital, Washington DC, DC, ³Cincinnati Children's Hospital, Cincinnati, OH, ⁴Stanford University, Palo Alto, CA
- 4:52 p.m. **Q&A**
- 4:54 p.m. **(333) A Curricular Interprofessional Intervention Can Reduce Depression Symptoms in MCS Patients - A Multi-Center, Randomized Controlled Trial**
C. Kugler¹, H. Spielmann², W. Albert³, P. Staus⁴, S. Semmig-Koenze⁵, T. Bertsche⁴, K. Tigges-Limmer⁶. ¹Institute of Nursing Science, Albert-Ludwigs University Freiburg, Freiburg, Germany, ²University of Freiburg, Faculty of Medicine, Institute of Nursing Science, Freiburg, Germany, ³German Heart Center Charite Berlin, Berlin, Germany, ⁴Freiburg University, Freiburg, Germany, ⁵Heart Center Leipzig, Leipzig, Germany, ⁶HDZ NRW Clinic for Thoracic + Cardiovascular Sur, Bad Oeynhausen, Germany
- 4:58 p.m. **Q&A**
- 5:00 p.m. **(334) Degree of Pre-Implant LV Dilation Does Not Preclude Favorable Outcome Post LVAD Weaning: A VAD Wean Registry Analysis**
J. Schurr¹, S. Drakos², S. Patel³, I. Sobol⁴, B. Sun⁵, N. Fida⁶, D. Zimpfer⁷, M. Papatheanasiou⁸, J. Wald⁹. ¹Medicine, University of

Pennsylvania, Philadelphia, PA, ²University of Utah, Salt Lake City, UT, ³Montefiore-Einstein, New York, NY, ⁴Weill Cornell Medicine-New York Presbyterian, New York, NY, ⁵Minneapolis Heart Institute, Minneapolis, MN, ⁶Houston Methodist Hospital, Houston, TX, ⁷Medical University of Vienna, Vienna, Austria, ⁸University of Duisburg-Essen, West German Heart and Vascular Center, Essen, Germany, ⁹University of Pennsylvania, Philadelphia, PA

5:04 p.m.

Q&A

5:06 p.m.

(335) Long Term Use of Implantable Left Ventricular Assist Devices in Pediatric Patients

H. Tunuguntla¹, J. Cho¹, S. Choudhry¹, J. Spinner², K. Puri², K. Hope³, K. Watanabe¹, W. Dreyer⁴, J. Price¹, C. Broda², D. Wilson¹, B. Elias¹, I. Adachi¹. ¹Texas Children's Hospital, Houston, TX, ²Baylor College of Medicine, Houston, TX, ³Texas Children's Hospital, Baylor College of Medicine, Houston, TX, ⁴Baylor College of Med, Houston, TX

5:10 p.m.

Q&A

5:12 p.m.

(1172) The Role of Cardiopulmonary Exercise Testing for Predicting Outcomes After LVAD Weaning, a VAD Wean Registry Study

D. Ceken¹, A. Damlin², D. E. Loewenstein¹, P. Shah³, E. J. Birks⁴, G. W. Hickey⁵, J. L. Mignone⁶, F. Gustafsson⁷, S. R. Patel⁸, S. G. Drakos⁹, M. J. Eriksson¹, M. Carlsson¹, E. Najjar¹⁰. ¹Clinical Physiology, Karolinska Institutet, Stockholm, Sweden, ²Cardiology and Clinical Physiology, Karolinska Institutet, Stockholm, Sweden, ³Inova Heart and Vascular Institute, Falls Church, VA, ⁴University of Kentucky, Lexington, KY, ⁵UPMC Pittsburgh, Pittsburgh, PA, ⁶Swedish Medical Center, Seattle, WA, ⁷Rigshospitalet, Copenhagen, Denmark, ⁸Montefiore-Einstein, New York, NY, ⁹University of Utah, Salt Lake City, UT, ¹⁰Cardiology, Karolinska Institutet, Stockholm, Sweden

5:16 p.m.

Q&A

5:18 p.m.

(337) The Minnesota Pectoralis Risk Score Predicts Right Ventricular Failure After LVAD Implantation

T. Chaikijurajai¹, C. Siems¹, R. John¹, J. Schultz¹, T. Alexy¹, V. Maharaj¹, A. Shaffer¹, F. Kamdar¹, M. Pritzker¹, D. Garry¹, T. Thenappan¹, J. Estep², B. Ramu¹, R. Cogswell¹. ¹University of Minnesota, Minneapolis, MN, ²Cleveland Clinic Florida, West Palm Beach, FL

5:22 p.m.

Q&A

5:24 p.m.

(338) Sex-Specific Differences in Outcomes of Patients Weaned from Durable Left Ventricular Assist Devices (LVAD) - A VAD Wean Registry Analysis

V. Ton¹, C. Yturralde¹, M. Kanwar², P. Shah³, A. Vest⁴, G. Kim⁵, B. Pisani⁶, S. Drakos⁷, S. Patel⁸. ¹Massachusetts General Hospital, Boston, MA, ²Allegheny General Hospital, Pittsburgh, PA, ³Inova Heart and Vascular Institute, Fairfax, VA, ⁴Tufts Medical Center, Boston, MA, ⁵University of Chicago, Chicago, IL, ⁶Atrium Health Wake Forest Baptist Medical Center, Winston-Salem, NC, ⁷University of Utah, Salt Lake City, UT, ⁸Montefiore-Einstein, New York, NY

5:28 p.m.

Q&A

FRIDAY, 12 APRIL, 2024

4:30 - 5:30 p.m.

MINI ORAL 12: Don't Go Breaking My Heart: Detecting and Treating Rejection in Heart Transplantation

Location: South Hall 2

Core Therapies: HEART

Practice Areas: Research and Immunology, Cardiology, Cardiothoracic Surgery, Pathology

Session Summary: This rapid-fire abstracts session spans the heart rejection spectrum from DSA (HLA and non-HLA), cell free DNA, predictive scores, and therapies.

Each presenter will give a **4-minute** "rapid fire" PowerPoint summation of the key learning points of the research, followed by a **2-minute** question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: Alessia Giarraputo, MS, University of Padova, Padova, Italy
Timea Teszak, MD, Semmelweis University Heart and Vascular Centre, Budapest, Hungary

4:30 p.m. **(339) HLA Mismatches Identified by a Novel Algorithm Predict Risk of Antibody-Mediated Rejection from DnDSA**
X. Zhang¹, N. Reinsmoen², J. Kobashigawa³. ¹Cedars Sinai Medical Center, Los Angeles, CA, ²Independent Consultant, Scottsdale, AZ, ³Cedars-Sinai Heart Institute, Los Angeles, CA

4:34 p.m. **Q&A**

4:36 p.m. **(340) Plasma Cell-Free DNA Chromatin Immunoprecipitation Distinguishes Acute Rejection Subtypes After Heart Transplantation**

M. Jang¹, O. Oluwayose², T. Andargie¹, T. Markowitz², W. Park¹, H. Kong¹, N. Redekar², T. Hill², J. Lack², R. Brower¹, T. Intrieri³, H. Luikart³, G. Berry³, C. Marboe⁴, P. Shah⁵, K. Khush³, H. Valantine³, S. Agbor-Enoh¹. ¹NHLBI, NIH, Bethesda, MD, ²NIAID, NIH, Bethesda, MD, ³Stanford University School of Medicine, Palo Alto, CA, ⁴Columbia University Vagelos College of Physicians & Surgeons, New York, NY, ⁵Inova Heart and Vascular Institute, Fairfax, VA

4:40 p.m. **Q&A**

4:42 p.m. **(341) Association of HLA Mismatch and Treatment for Rejection within the First Year After Heart Transplantation**

L. K. Truby, A. Jawaid, F. Hussain, C. Wrobel, N. Hendren, S. Garg, R. Morlend, H. Beaini, E. Hardin, F. Araj, J. T. Thibodeau, M. Drazner, J. L. Grodin, C. Lacelle, M. Peltz, M. Farr. UT Southwestern Medical Center, Dallas, TX

4:46 p.m. **Q&A**

4:48 p.m. **(342) Antithymocyte Globulin as an Adjunctive Therapy for Antibody-Mediated Rejection in Heart Transplant Recipients More Consistently Decreased Donor-Specific HLA Antibodies and Histopathologic Grading Than PP/IVIG Alone**

D. Huang¹, Y. Rochlani¹, C. Díez-López², S. Patel¹, S. Madan¹, C. Gjelaj¹, O. Saeed¹, J. Shin¹, D. Sims¹, J. Borgi³, S. Forest³, D. Goldstein³, U. Jorde¹, S. Vukelic¹. ¹Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, The Bronx, NY, ²Bellvitge Hospital, Barcelona, Spain, ³Department of Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, The Bronx, NY

4:52 p.m. **Q&A**

4:54 p.m. **(343) Impact of MIC-A Antibodies on Antibody Mediated Rejection (ABMR). Molecular Microscope Results (MMDx)**

A. Fernandez Valledor¹, C. M. Moeller¹, C. Lee¹, G. Rubinstein¹, J. Baranowska¹, S. Rahman¹, A. Rahman¹, D. Oren¹, K. Oh¹, D. Bae¹, K. Theodoropoulos¹, D. Lotan¹, E. Lin¹, P. Colombo¹, E. M. DeFilippis¹, M. Yuzefpolskaya¹, V. Topkara¹, J. Fried¹, J. Raikhelkar¹, D. Majure², K. Clerkin¹, F. Latif¹, G. T. Sayer¹, N. Uriel¹. ¹Division of Cardiology, Center of Advanced Cardiac Care, Columbia University Irving Medical Center, New York, NY, ²Weill Cornell Medical College, New York, NY

4:58 p.m. **Q&A**

5:00 p.m. **(344) Coexistence of Acute Cellular and Humoral Rejection in Heart Allograft: The Relationship with Circulating Antihla Antibodies**

M. Fedrigo, A. Confente, G. Brigiari, M. Gasparella, I. Barison, G. Toscano, N. Pradegan, C. Tessari, G. Gerosa, E. Cozzi, A. Angelini. University of Padova, Padova, Italy

5:04 p.m. **Q&A**

5:06 p.m. **(345) Allosensitized Cardiac Transplant Recipients Treated with CD38-Antibody Daratumumab Show Histomorphologic Signs of PAMR in Biopsies without Clinical Signs of Rejection**

M. Nackenhorst¹, C. Atteneder², K. Uyanik-Uenal², J. Goekler², A. Aliabadi², H. Regele¹, A. Zuckermann². ¹Department of Pathology, Medical University of Vienna, Vienna, Austria, ²Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria

5:10 p.m. **Q&A**

5:12 p.m. **(346) Follow Up of Circulating Donor Specific Antibodies in Heart Transplanted Patients: Experience of a Single-Centre**
M. Fedrigo¹, M. Gasparella¹, I. Barison², G. Brigiari¹, A. Confente¹, G. Toscano¹, N. Pradegan¹, C. Tessari¹, C. Castellani¹, G. Gerosa¹, E. Cozzi¹, A. Angelini². ¹University of Padova, Padova, Italy, ²University of Padua, Padova, Italy

5:16 p.m. **Q&A**

5:18 p.m. **(347) Value of PIRCHE-II Score Determination in Risk Stratification of Rejection and Long-Term Graft Survival in Heart Transplantation**

A. Aloisio¹, M. Masetti¹, E. Zaffagnini², L. Cocchiarella¹, L. Marcantoni³, L. Borgese⁴, L. Giovannini¹, A. Zanetti⁵, S. Manfroi⁵, L. Potena¹. ¹Heart Failure and Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, ²Immunogenetics and transplant biology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, ³Internal Medicine Unit for the Treatment of Severe Organ Failure, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, ⁴Heart Failure and Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, University of Bologna, Bologna, Italy, ⁵Immunogenetics and Transplant Biology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy

5:22 p.m. **Q&A**

5:24 p.m. **(348) Correlation Between Donor-Derived Cell-Free DNA (dd-cfDNA) and Molecular Microscope (MMDx) in Heart Transplant Recipients**

C. M. Moeller¹, A. Fernandez Valledor¹, D. Oren¹, G. Rubinstein¹, S. Slomovich¹, J. Baranowska¹, C. Lee¹, S. Rahman¹, K. Oh¹, D. Bae¹, J. Raikhelkar¹, V. Topkara¹, P. Colombo¹, M. Yuzefpolskaya¹, D. Lotan¹, E. M. DeFilippis¹, K. Theodoropoulos¹, J. Fried¹, E. Lin¹, D. Majure², K. Clerkin¹, F. Latif¹, G. Sayer¹, N. Uriel¹. ¹Columbia University Irving Medical Center, New York, NY, ²Weill Cornell Medical College, New York, NY

5:28 p.m. **Q&A**

FRIDAY, 12 APRIL, 2024

4:30 - 5:30 p.m.

MINI ORAL 13: Lung Path From Donor-to-Recipient: the Order of the Phoenix

Location: Panorama Hall

Core Therapies: LUNG

Practice Areas: Pulmonology, Anesthesiology and Critical Care, Cardiothoracic Surgery, Nursing and Allied Health, Research and Immunology

Session Summary: This session focuses on donor supply, allocation and modification.

Each presenter will give a **4-minute** "rapid fire" PowerPoint summation of the key learning points of the research, followed by a **2-minute** question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: Alessandro Palleschi, MD, University of Milan; Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy
Edward Cantu, MD, MSCE. University of Pennsylvania, Philadelphia, PA, USA

- 4:30 p.m. **(349) Predicting Donor Supply and Waitlist Compatibility Under the Composite Allocation Score**
J. E. Dalton¹, C. J. Lehr², J. Rose³, M. F. Swiler¹, P. R. Gunsalus¹, M. Valapour². ¹Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, ²Pulmonary Medicine, Cleveland Clinic, Cleveland, OH, ³Center for Community Health Integration, Case Western Reserve University, Cleveland, OH
- 4:34 p.m. **Q&A**
- 4:36 p.m. **(350) The Effect of Donor-Recipient Race-Matching on Lung Transplantation Survival Rates: An Analysis of the United Network of Organ Sharing Database**
V. Shah¹, R. Sharma², M. Thornton³, C. Heid², A. Lawrence⁴, V. Kaza⁴, F. Torres⁴, M. Peltz², M. Wait², W. Ring², J. S. Murala². ¹UT Southwestern Medical School, UT Southwestern Medical Center, Dallas, TX, ²Department of Cardiovascular and Thoracic Surgery, UT Southwestern Medical Center, Dallas, TX, ³Cecil H. and Ida Green Center for Reproductive Biology Sciences, UT Southwestern Medical Center, Dallas, TX, ⁴Division of Pulmonary and Critical Care Medicine, UT Southwestern Medical Center, Dallas, TX
- 4:40 p.m. **Q&A**
- 4:42 p.m. **(351) Higher Donor Sequence Numbers are Not Associated with Worse Lung Transplant Outcomes**
A. Casillan¹, E. Larson¹, J. Ruck¹, A. Zhou¹, J. Ha¹, A. Massie², P. Shah¹, D. Segev², C. Merlo¹, E. Bush¹. ¹Johns Hopkins University, Baltimore, MD, ²New York University, New York, NY
- 4:26 p.m. **Q&A**
- 4:48 p.m. **(352) Paradoxical Behavior: Probability of Accepting a Donor Lung Decreases with Decreasing Donor Availability**
J. Rose¹, P. R. Gunsalus², C. J. Lehr³, M. F. Swiler², M. Valapour³, J. E. Dalton². ¹Center for Community Health Integration, Case Western Reserve University, Cleveland, OH, ²Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, ³Pulmonary Medicine, Cleveland Clinic, Cleveland, OH
- 4:52 p.m. **Q&A**
- 4:54 p.m. **(353) Donation After Circulatory Death (DCD) Lung Transplant Outcomes in the United States**
S. S. Li¹, M. Funamoto², S. Rabi¹, N. Langer³, R. Singh³, E. Michel³, A. Kreso³, A. Osho³. ¹Surgery, Massachusetts General Hospital, Boston, MA, ²Cardiac Surgery, Houston Methodist Hospital, San Antonio, TX, ³Massachusetts General Hospital, Boston, MA
- 4:58 p.m. **Q&A**
- 5:00 p.m. **(354) Trend in Lung Donation from Circulatory Death Donors in European Countries**
E. L. Hofstetter¹, A. Ruhparwar², F. Ius², J. Gottlieb³, J. Cifrian Martinez⁴, J. LeCocq⁵, G. Manna⁶. ¹HealthStrat Consulting, Munich, Germany, ²Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany, ³Department of Respiratory Medicine and Infectious Diseases OE 6870, Hannover Medical School, Hannover, Germany, ⁴Respiratory Department, Marqués de Valdecilla University Hospital, Santander, Spain, ⁵Medical Affairs, Zambon USA Ltd., Morristown, NJ, ⁶Medical Affairs, Zambon S.p.A., Milan, Italy
- 5:04 p.m. **Q&A**
- 5:06 p.m. **(355) Lung Transplant Graft Outcomes from Organs Recovered in Independent versus Hospital-Based Donor Care Units**
E. A. Vail¹, X. Wang², D. E. Schaubel², P. P. Reese³, E. Cantu⁴, M. P. Kerlin⁵, M. D. Neuman¹, J. D. Christie⁵. ¹Anesthesiology and Critical Care, University of Pennsylvania, Philadelphia, PA, ²Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA, ³Renal-Electrolyte and Hypertension Division, Department of Medicine, University of

Pennsylvania, Philadelphia, PA, ⁴Surgery, University of Pennsylvania, Philadelphia, PA, ⁵Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Pennsylvania, Philadelphia, PA

5:10 p.m.

Q&A

5:12 p.m.

(356) ABO Genotype and its Relation on Histo-Blood Antigen Expression and Regeneration Following Removal - Potential Significance in ABO Incompatible Transplantation

A. Wang¹, K. Mesaki¹, J. Yune¹, Y. Zhang¹, J. Montagne¹, T. Lima¹, G. Loesch Siebiger¹, K. Yamanashi¹, G. Garza¹, P. Rahfeld², C. Cserti³, M. Aversa¹, S. Withers², J. Kizhakkedathu², M. Liu¹, S. Juvet¹, S. Keshavjee¹, M. Cypel¹. ¹University Health Network, Toronto, ON, Canada, ²University of British Columbia, Vancouver, BC, Canada, ³Transfusion Medicine & Hematology, University Health Network, Toronto, ON, Canada

5:16 p.m.

Q&A

5:18 p.m.

(357) The Second Time Around: Re-Evaluating Lung Retransplant Outcomes in the Lung Allocation Score Era

B. Shou, A. Zhou, J. M. Ruck, A. Akbar, A. Kalra, A. Casillan, J. Ha, C. Merlo, E. Bush. Johns Hopkins University School of Medicine, Baltimore, MD

5:22 p.m.

Q&A

5:24 p.m.

(358) Silicone Additive Manufacturing of Artificial Lungs

M. Gort¹, S. Arni², J. F. Schumacher², T. Aigner³, K. van Tilburg³, S. David⁴, G. Lang², M. Kirschner², M. Meboldt¹, I. Schmitt-Opitz². ¹Product Development Group Zurich, Department of Mechanical and Process Engineering, ETH Zurich, Zürich, Switzerland, ²Department of Thoracic Surgery, University Hospital Zurich, Zürich, Switzerland, ³Department of Cardiac Surgery, University Hospital Zurich, Zürich, Switzerland, ⁴Institute of Intensive Care Medicine, University Hospital Zurich, Zürich, Switzerland

5:28 p.m.

Q&A

FRIDAY, 12 APRIL, 2024

4:30 - 5:30 p.m.

MINI ORAL 14: Basics of Research in Lung Allograft Dysfunction and Destruction of Horduxes

Location: North Hall

Core Therapies: LUNG

Practice Areas: Research and Immunology, Pulmonology, Pathology

Session Summary: In this session, attendees will gain new insights into novel research on lung allograft dysfunction.

Each presenter will give a **4-minute** "rapid fire" PowerPoint summation of the key learning points of the research, followed by a **2-minute** question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: Federica Pezzuto, University of Padova, Padova, Italy
Assem Ziady, PhD, Cincinnati Children's Hospital, Cincinnati, OH, USA

- 4:30 p.m. **(359) Developing a Molecular Classifier to Predict Graft Loss in Lung Transplant Transbronchial Biopsies**
P. T. Gauthier¹, M. Mackova¹, R. Hachem², J. Havlin³, A. Hirji⁴, P. Jaksch⁵, S. Juvet⁶, S. Keshavjee⁶, W. Klepetko⁷, D. Kreisel², B. Kubisa⁸, D. J. Levine⁹, R. Lischke³, M. Piotrowska⁸, J. Simonek³, G. Snell¹⁰, I. Timofte¹¹, J. Weinkauff⁴, G. Westall¹⁰, A. Zajacova³, K. Halloran⁴, P. Halloran⁴. ¹Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada, ²Washington University School of Medicine, St. Louis, MO, ³University Hospital Motol, Prague, Czech Republic, ⁴University of Alberta, Edmonton, AB, Canada, ⁵Medical University Vienna, Vienna, Austria, ⁶University Health Network, Toronto, ON, Canada, ⁷Medical University of Vienna, Vienna, Austria, ⁸Pomeranian Medical University of Szczecin, Szczecin, Poland, ⁹Stanford University, Stanford, CA, ¹⁰Alfred Hospital, Melbourne, Australia, ¹¹University of Maryland, Baltimore, MD
- 4:34 p.m. **Q&A**
- 4:36 p.m. **(360) Signs of Aspiration on Lung Allograft Transbronchial Biopsy are Associated with Reflux, Airway Bile Acids, and Chronic Lung Allograft Dysfunction (CLAD)**
R. Ramendra¹, K. Zhang², P. Bell³, L. Levy³, P. Pal², D. Hwang⁴, E. Huszti⁵, M. Aversa³, A. Sage³, S. Keshavjee³, T. Martinu³.
¹Ajmera Transplant, University Health Network, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Toronto Lung Transplant Program, Toronto, ON, Canada, ⁴Sunnybrook Health Sciences Centre, Toronto, ON, Canada, ⁵University Health Network, Toronto, ON, Canada
- 4:40 p.m. **Q&A**
- 4:40 p.m. **(361) Soluble Immune Check Point Receptors Could be Feasible Markers of Rejection in Lung Transplanted Patients?**
I. Righi¹, D. Trabattoni², C. Fenizia³, C. Vanetti², L. Morlacchi³, V. Rossetti¹, F. Damarco¹, M. Cattaneo¹, M. Nosotti³, L. Rosso⁴, M. Clerici³. ¹Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy, ²Department of Biomedical and Clinical Science, University of Milan, Milan, Italy, ³Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy, ⁴Department of Pathophysiology and Transplantation, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy
- 4:46 p.m. **Q&A**
- 4:48 p.m. **(362) Pulmonary Function Stability After Lung Transplantation is Associated with Decreased Lung Damage Markers in BALF**
L. Arike¹, K. Johansson¹, A. Ermund¹, M. Greer², T. Pelaseyed¹, J. Westin³, G. C. Hansson¹, J. Magnusson⁴. ¹Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden, ²Hannover Medical School, Hannover, Germany, ³Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska University Hospital, Gothenburg, Sweden, ⁴Department of Pulmonology, Institute of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden
- 4:52 p.m. **Q&A**
- 4:54 p.m. **(363) Unsupervised Analysis of Gene Expression Data to Identify Lung Transplant Rejection Phenotypes**
M. Sablik¹, N. Belousova², F. Mezine¹, J. Dagobert¹, M. Raynaud¹, P. Bruneval¹, O. Aubert¹, C. Lefaucheur¹, A. Loupy¹, A. Roux².
¹Paris Institute for Transplantation and Organ Regeneration, Université Paris Cité, INSERM, U-970, AP-HP, Paris, France, ²Lung Transplantation Department, Foch Hospital, Suresnes, France
- 4:58 p.m. **Q&A**

- 5:00 p.m. **(364) Quantitative CT Scan Analysis of Healthy Lung Transplant Recipients Correlates with Lung Function in a Multicenter Prospective Cohort**
M. P. Combs¹, A. Bell², M. McInnis³, M. Dianti³, J. M. Diamond⁴, S. Simpson⁵, T. Martinu³, C. J. Galbán², V. N. Lama⁶. ¹Medicine, University of Michigan, Ann Arbor, MI, ²Radiology, University of Michigan, Ann Arbor, MI, ³Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada, ⁴Medicine, University of Pennsylvania, Philadelphia, PA, ⁵Radiology, University of Pennsylvania, Philadelphia, PA, ⁶Medicine, Emory University, Atlanta, GA
- 5:04 p.m. **Q&A**
- 5:06 p.m. **(365) Characterization of Pro-Fibrotic Functions of Osteopontin-Expressing Pulmonary Macrophages in Chronic Lung Allograft Dysfunction**
A. Duong¹, S. Moshkelgosha¹, L. Glass¹, A. Wong¹, M. Liu¹, B. Hinz², S. Juvet¹, T. Martinu¹. ¹Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada, ²Keenan Research Institute for Biomedical Science, St Michael's Hospital, Toronto, ON, Canada
- 5:10 p.m. **Q&A**
- 5:12 p.m. **(366) Evidence of an Intra-graft CD8+ PD1+ Memory T Cell - CD68+ PDL1+ Macrophage Axis in Human Chronic Lung Allograft Dysfunction**
S. Karunakaran¹, S. Moshkelgosha², B. Renaud-Picard², A. Duong², J. Al-Refae², M. Cheung³, D. Hedley³, T. Martinu⁴, S. Juvet⁴. ¹Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada, ²Toronto General Hospital Research Institute, Toronto, ON, Canada, ³Ontario Cancer Institute, Princess Margaret Cancer Centre, Toronto, ON, Canada, ⁴Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada
- 5:16 p.m. **Q&A**
- 5:18 p.m. **(367) Multiplexing Droplet Digital PCR Assays to Detect Allograft Injury in Lung Transplant Recipients**
M. Jang, W. Park, T. Andargie, R. Brower, H. Kong, S. Agbor-Enoh. NHLBI, NIH, Bethesda, MD
- 5:22 p.m. **Q&A**
- 5:24 p.m. **(368) Abnormal CD4/CD8 Ratio Prior to Lung Transplantation is Linked to Significantly Decreased Survival**
A. Zajacova¹, M. Guney², E. Dvorackova³, F. Casas-Mendez¹, K. Vyskocilova¹, T. Kotowski¹, A. Dutkova¹, D. Rakita¹, L. Fila¹, R. Lischke⁴, J. Havlin⁴. ¹Prague Lung Transplant Program, Department of Pneumology, Second Faculty of Medicine, Charles University, University Hospital Motol, Prague, Czech Republic, ²Second Faculty of Medicine, Charles University, Prague, Czech Republic, ³Institute of Pharmacology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁴Prague Lung Transplant Program, 3rd Department of Surgery, First Faculty of Medicine, Charles University, University Hospital Motol, Prague, Czech Republic
- 5:28 p.m. **Q&A**

FRIDAY, 12 APRIL, 2024

4:30 - 5:30 p.m.

POSTER SESSION 3: Cardiology (Non-CME)

Location: Poster Hall

Core Therapies: HEART, LUNG, MCS, PVD

Practice Areas: Cardiology, Anesthesiology and Critical Care, Cardiothoracic Surgery, Infectious Diseases, Nursing and Allied Health, Pathology, Pediatrics, Pharmacy, Pulmonology, Research and Immunology

Session Summary: Posters in this session include presentations on multiple topics where the Practice Areas of the research is focused in Cardiology. Designated Poster Discussants will circulate through the poster hall during the session to engage poster presenters in quality discussions of their abstracts. **CME is not offered for poster sessions.**

Poster Discussants: Mustafa Ahmed, USA, Sophia Airhart, USA, Arif Albulushi, USA, Tamas Alexy, USA, Rami Alharethi, USA, Markus Barten, Germany, Sven-Erik Bartfay, Sweden, Javier Castrodeza, Spain, Anique Ducharme, Canada, Howard Eisen, USA, Alejandro Folch Sandoval, USA, Mardi Gomberg-Maitland, USA, Jose Gonzalez Costello, Spain, Hanno Grahn, Germany, Thomas Hanff, USA, George Javorsky, Australia, Jamie Kennedy, USA, Kyung-Hee Kim, South Korea, Matthew Lander, USA, Clive Lewis, UK, Renzo Loyaga-Rendon, USA, Marco Masetti, Italy, Juan Ortega-Legaspi, USA, Carlos Ortiz-Bautista, Spain, Yael Peled, Israel, Gregor Poglajen, Slovenia, Eduardo Rame, USA, Siavosh Saatee, USA, Christian Said, Canada, George Sokos, USA, Swethika Sundaravel, USA, George Vetrovec, USA, Rayan Yousefzai, USA

(1070) Natural Outcome of Isolated Right Ventricular Dysfunction Immediately After Heart Transplantation; M. Kittleson¹, J. Patel¹, A. Nikolova¹, M. White², N. Bhatnagar¹, A. Kanungo¹, M. Lee¹, E. Chow¹, J. Moriguchi¹, D. Geft¹, L. Czer¹, F. Esmailian¹, J. Kobashigawa¹. ¹Cedars-Sinai Smidt Heart Institute, Los Angeles, CA, ²Cedars-Sinai Comprehensive Transplant Center, Los Angeles, CA

(1071) Prediction of Post-Transplant Lymphoproliferative Disorder (PTLD) Using Light Gradient-Boosting Machine (lightgbm); N. Nair¹, H. Johnston², D. Du². ¹Medicine/Cardiology, Penn State Health/Milton S Hershey Med Ctr, Hershey, PA, ²Industrial, Manufacturing & Systems Engineering, Texas Tech University, Lubbock, TX

(1072) Correlation of Liver Fibrosis on Ultrasound Elastography and Liver Biopsy After Fontan Operation: Is Non-Invasive Always Better?; Y. Lo Yau, J. Coppola, D. Lopez-Colon, M. Purlee, D. Gupta. Congenital Heart Center, University of Florida, Gainesville, FL

(1073) Association of Obesity and Graft Failure in Heart Transplant for Adults with Congenital Heart Disease; R. D. Byrne, S. J. Dolgner, C. R. Broda, S. Choudhry. Baylor College of Medicine / Texas Children's Hospital, Houston, TX

(1074) Outcomes of Complex Adult Congenital Heart Disease Patients Supported with a Fully Magnetically Levitated Ventricular Assist Device at a Single Center; R. D. Byrne¹, W. C. Frankel², A. P. Nair³, S. Choudhry¹, H. P. Tunuguntla¹, I. Adachi¹, C. Dezfulian¹, E. J. Hickey¹, C. R. Broda¹. ¹Baylor CoM / Texas Children's Hospital, Houston, TX, ²Cleveland Clinic, Cleveland, OH, ³Texas Heart Institute, Houston, TX

(1075) Medium to Long-Term Ventricular Assist Device Support in Adults with Congenital Heart Disease: The Baylor St. Luke's Medical Center / Texas Children's Hospital Experience; R. D. Byrne¹, W. C. Frankel², A. P. Nair³, H. P. Tunuguntla¹, S. Choudhry¹, I. Adachi¹, E. J. Hickey¹, A. Civitello³, C. R. Broda¹. ¹Baylor College of Medicine / Texas Children's Hospital, Houston, TX, ²Cleveland Clinic, Cleveland, OH, ³Texas Heart Institute, Houston, TX

(1076) A Children's Hospital-Based Care Model for Pediatric and Adult Fontan Patients: Transplant Referral Patterns and Outcomes; A. Reed¹, A. Middleton², K. Anton³, C. Honzo², S. Schofield², D. Young², S. Miyamoto⁴, R. M. Jacobsen². ¹Children's Hospital Colorado, Aurora, CO, ²Children's Hospital Colorado, Aurora, CO, ³Children's Hospital of Colorado, Aurora, CO, ⁴Pediatrics, Children's Hospital Colorado, Aurora, CO

(1077) Prevalence of Advanced Heart Failure in the Obese Population: A Study From the National Inpatient Sample Database; F. A. Napoli¹, R. Aleman¹, D. A. Baran², J. L. Navia¹, C. A. Sheffield¹, M. A. Velez³, J. A. Estep³, N. Brozzi¹. ¹CardioThoracic Surgery, Cleveland Clinic Florida, Weston, FL, ²Cardiology, Cleveland Clinic Heart, Vascular and Thoracic Institute, Weston, FL, ³Cardiology, Cleveland Clinic Florida, Weston, FL

(1324) Prevalence and Risk Factors of Cardiac Abnormalities in Patients with End-Stage Renal Disease; D. M. Torpoco Rivera¹, A. Jain², G. Kapur², M. Nakdali¹, S. Aggarwal¹, S. Sehgal¹. ¹Pediatric Cardiology, Children's Hospital of Michigan, Detroit, MI, ²Pediatric Nephrology, Children's Hospital of Michigan, Detroit, MI

(1078) Differential Effect of Ethnicity on the Waitlist and Post-Heart Transplant Outcomes in the United States; D. Marsy¹, C. Kelty², S. Orey¹, M. Dickinson¹, R. Grayburn¹, N. Shrestha¹, R. Sadler³, E. McNeely¹, R. Loyaga-Rendon¹. ¹Corewell Health West, Grand Rapids, MI, ²Indiana University School of Medicine, Indianapolis, IN, ³Michigan State University, East Lansing, MI

- (1079) Clinician Assessed Versus Objective Measures of Frailty in Left Ventricular Assist Device Patients;** R. S. Steinberg¹, J. Cowger², B. Hsi³, A. Morris⁴, A. Nohria⁵, S. Hall³, A. Nayak³. ¹Emory University School of Medicine, Atlanta, GA, ²Henry Ford Hospitals, Detroit, MI, ³Baylor University Medical Center, Dallas, TX, ⁴Emory University, Atlanta, GA, ⁵Brigham & Women's Hospital, Boston, MA
- (1080) Racial and Ethnic Disparities in De-Novo Donor Specific Antibodies (DSA) and Rejection Rates in Heart Transplant Recipients Assessed by Molecular Microscope;** D. Oren¹, C. M. Moeller¹, A. Fernandez Valledor¹, G. Rubinstein¹, J. Baranowska¹, S. Rahman¹, C. Lee¹, K. Oh¹, D. Bae¹, J. K. Raikhelkar¹, V. Topkara¹, M. Yuzefpolskaya¹, P. Colombo¹, D. Lotan¹, E. M. DeFilippis¹, K. Theodoropoulos¹, J. Fried¹, E. Lin¹, D. Majure², K. Clerkin¹, F. Latif¹, G. Sayer¹, N. Uriel¹. ¹Columbia Univ Irving MC, New York, NY, ²Weill Cornell Medical College, New York, NY
- (1081) Effects of Belatacept Therapy on Gene Expression Profiling and Rejection in Heart Transplant Recipients: A Molecular Microscope (MMDx) Evaluation;** D. Oren¹, A. Fernandez Valledor¹, C. M. Moeller¹, G. Rubinstein¹, J. Baranowska¹, S. Rahman¹, C. Lee¹, K. Oh¹, D. Bae¹, J. Raikhelkar¹, V. Topkara¹, M. Yuzefpolskaya¹, P. Colombo¹, D. Lotan¹, E. M. DeFilippis¹, K. Theodoropoulos¹, J. Fried¹, E. Lin¹, D. Majure², K. Clerkin¹, F. Latif¹, G. Sayer¹, N. Uriel¹. ¹Columbia University Irving Medical Center, New York, NY, ²Weill Cornell Medical College, New York, NY
- (1082) Characteristics and Outcomes of Patients Receiving Advanced Heart Failure Therapies from a Safety-Net Hospital in the United States;** N. Hendren¹, S. Carter², L. Truby³, J. Nixon³, F. Hussain³, A. Jawaid³, C. Wrobel³, E. Hardin³, S. Garg³, J. Grodin³, R. Morlend³, J. Thibodeau³, F. Araj³, M. Drazner³, M. Peltz³, J. De Lemos³, S. Das¹, M. Farr³. ¹Parkland Health, Dallas, TX, ²University of Utah, Salt Lake City, UT, ³University of Texas Southwestern Medical Center, Dallas, TX
- (1083) Clinical Course of Obese Advanced Heart Failure Patients Who Underwent Bariatric Surgery;** D. Kim¹, J. Youn², I. Kim³, J. Choi¹, E. Kransdorf⁴, D. Chang⁵, M. Kittleson⁶, J. Patel⁷, F. Esmailian⁶, J. Kobashigawa⁸. ¹Samsung MC, Seoul, South Korea, ²Seoul St. Mary's Hospital, The Catholic Univ of Korea, Seoul, South Korea, ³Keimyung Univ Dongsan Hospital, Daegu, South Korea, ⁴Cedars-Sinai, ⁵Univ Cardiovascular Medical Group, LA, CA, ⁶Cedars-Sinai Heart Institute, LA, CA, ⁷Cedars-Sinai Smidt Heart Institute, LA, CA, ⁸Cedars-Sinai Heart Institute
- (1084) Safety and Efficacy of Semaglutide Therapy in Advanced Heart Failure Patients Awaiting Heart Transplantation;** G. Poglajen¹, S. Frljak¹, G. Zemljic¹, A. Cerar¹, I. Knezevic², B. Vrtovec¹. ¹Advanced Heart Failure and Transplantation Center, Dept. of Cardiology, UMC Ljubljana, Ljubljana, Slovenia, ²University Medical Centre Ljubljana, Ljubljana, Slovenia
- (1085) LVAD Bridge to Transplant and Rejection Assessed by Molecular Microscope;** G. Rubinstein¹, A. Fernandez Valledor², C. M. Moeller², S. Slomovich², D. Oren², J. Baranowska², S. Rahman², C. Lee², K. Oh², D. Bae², V. Topkara², D. Lotan², E. M. DeFilippis², K. Theodoropoulos², J. Raikhelkar², J. Fried², E. Lin², D. Majure³, K. Clerkin², M. Yuzefpolskaya², P. Colombo², G. Sayer², F. Latif², N. Uriel². ¹Columbia University Irving Medical Center and Jacobi Medical Center - Albert Einstein College of Medicine, New York, NY, New York, New York, NY, ²Columbia University Irving Medical Center, New York, NY, ³Weill Cornell Medical College, New York, NY
- (1086) Genotype Analysis of LVOT Gradient Measurements in Patients Receiving Mavacamten for Obstructive Hypertrophic Cardiomyopathy?;** S. A. Chandrasekhar¹, C. K. Cornelio², A. C. Miranda², R. Wu¹. ¹Heart Failure Center, Heart & Vascular Institute, University of South Florida Morsani College of Medicine and Tampa General Hospital, Tampa, FL, ²University of South Florida Taneja College of Pharmacy, Tampa, FL
- (1087) Mavacamten Use for Obstructive Hypertrophic Cardiomyopathy and Effect on Beta-Blocker Therapy in an Academic Institution;** S. A. Chandrasekhar¹, C. K. Cornelio², R. Wu¹, A. C. Miranda². ¹Heart Failure Center, Heart & Vascular Institute, University of South Florida Morsani College of Medicine and Tampa General Hospital, Tampa, FL, ²University of South Florida Taneja College of Pharmacy, Tampa, FL
- (1088) The Association Between Body Mass Index, Exercise Capacity, and Health-Related Quality of Life in Heart Transplant Recipients;** K. Broch¹, S. Holmen¹, K. Rolid², K. Englund³, C. M. Østby¹, E. Gude⁴, A. K. Andreassen⁵, L. Gullestad⁶. ¹Oslo University Hospital, Oslo, Norway, ²The Research Council of Norway, Oslo, Norway, ³Akershus University Hospital, Lorenskog, Norway, ⁴Oslo Univ Hosp, Oslo, Norway, ⁵Oslo University Hosp, Oslo, Norway, ⁶Oslo Univ Hospital, Oslo, Norway
- (1089) Increasing Recognition of Causes of HFpEF in Australia Over Time;** N. Raftopoulos¹, L. Nedkoff¹, N. Bart². ¹The Victor Chang Cardiac Research Institute, Sydney, Australia, ²St Vincent's Hospital, Sydney, Australia
- (1090) Donor-Recipient Matching Following Donation After Circulatory Determination of Death;** L. K. Truby¹, Y. Moayed², B. Mueller², C. Fan², F. Foroutan³, H. Ross⁴, K. K. Khush⁵, M. Farr¹. ¹UT Southwestern Medical Center, Dallas, TX, ²UHN, Toronto, ON, Canada, ³Ted Rogers Centre for Heart Research, Toronto, ON, Canada, ⁴Toronto General Hospital, Toronto, ON, Canada, ⁵Stanford University, Palo Alto, CA
- (1091) The Role of PCSK9 Inhibition in the Care of Heart Transplant Recipients: A Single-Center Case Series;** A. R. Gorrai, F. Araj, D. Teiber, S. Garg, R. Morlend, J. T. Thibodeau, M. Peltz, M. Farr, L. Truby. University of Texas Southwestern Medical Center, Dallas, TX
- (1092) Comparison of Hemodynamics in Patients Bridged to Transplant with Temporary vs Durable LVAD;** K. Drezek, A. Ramsay, A. Pico, J. Guiry, T. Winship, V. Ton, G. Lewis, D. D'Alessandro, E. Coglianese. Massachusetts General Hospital, Boston, MA

(1093) Transferrin Saturation < 20% Identifies Prognostically Relevant Iron Deficiency (ID) Better Than Conventional ID Criteria in Advanced HFREF Population; V. Melenovsky, J. Benes, D. Jenca, P. Wohlfahrt, I. Jurcova, M. Kotrc, A. Jabor, K. Kroupova. *Institute for Clin. and Exp. Medicine - IKEM, Prague, Czech Republic*

(1094) Hypertrophic Cardiomyopathy Patients Have More Adverse Hemodynamic Profiles on Pre-Transplant Cardiopulmonary Exercise Testing; R. J. Shah, C. Lee, A. Fernandez Valledor, R. Goldsmith, G. Sayer, N. Uriel. *Cardiology, Columbia University Irving Medical Center, New York, NY*

(1095) Early Donor Derived Cell-Free DNA Ratios Can Help Predict Future Rejection in Heart Transplant Recipients; D. J. Miklin¹, K. Ravi², K. Qu³, A. Cochran², M. Ackerman², R. Cartus², M. Fong², K. Pandya², A. Vaidya², A. Wolfson², J. Nattiv², M. Stachel², J. Kobulnik³, E. DePasquale². ¹North Shore University Hospital, Manhasset, NY, ²University of Southern California, Los Angeles, CA, ³CareDx, Brisbane, CA

(1096) The Influence of Patients' Native Language on Hospital Outcomes Among Patients Admitted with Heart Failure; S. Chaparro¹, M. Rubens¹, M. Roy¹, A. Saxena¹, G. Vaidean², J. Jimenez¹. ¹Baptist Health South Florida, Miami, FL, ²Florida International University, Miami, FL

(1097) Utility of Combined Donor-Derived Cell-Free DNA and Peripheral Gene Expression Profiling in Heart Transplant Recipients; C. M. Moeller¹, A. Fernandez Valledor¹, D. Oren¹, A. Rahman¹, G. Rubinstein¹, J. Baranowska¹, S. Rahman¹, C. Lee¹, D. Lotan¹, K. Oh¹, D. Bae¹, J. K. Raikhelkar¹, V. K. Topkara¹, M. Yuzefpolskaya¹, P. C. Colombo¹, E. M. DeFilippis¹, Y. Mehlman¹, K. Theodoropoulos¹, J. A. Fried¹, E. Lin¹, D. Majure², K. J. Clerkin¹, F. Latif¹, G. T. Sayer¹, N. Uriel¹. ¹Columbia University Irving Medical Center, New York, NY, ²Weill Cornell Medical College, New York, NY

(1098) Impact and Outcomes of Induction Therapy on Donor-Derived Cell-Free DNA Levels and Peripheral Gene-Expression Profiling in Heart Transplant Recipients; C. M. Moeller¹, A. Fernandez Valledor¹, D. Oren¹, A. Rahman¹, J. Baranowska¹, C. Lee¹, D. Bae¹, S. Rahman¹, M. Regan¹, E. DeFilippis¹, K. Oh¹, G. Rubinstein¹, D. Lotan¹, M. Yuzefpolskaya¹, K. J. Clerkin¹, P. Colombo¹, D. Majure², J. Fried¹, K. Theodoropoulos¹, J. Raikhelkar¹, F. Latif¹, G. T. Sayer¹, N. Uriel¹. ¹Columbia University Irving Medical Center, New York, NY, ²Weill Cornell Medical College, New York, NY

(1099) Predictive Models Refine Physician Prognostication: A Secondary Analysis Evaluating Integrated Model and Physician Prognostic Estimates in Heart Failure Patients with Reduced Left Ventricular Ejection Fraction; A. Alba¹, T. Buchan¹, S. Saha¹, C. Fan¹, S. Poon², A. Al-Hesayen³, M. Toma⁴, S. Zieroth⁵, K. Anderson⁶, C. Demers⁷, F. Amin⁸, L. Porepa⁹, S. Chih¹⁰, N. Giannetti¹¹, V. Rac¹, H. Ross¹, G. Guyatt⁸. ¹Peter Munk Cardiac Centre - University Health Network, Toronto, ON, Canada, ²University of Toronto Toronto General Hospital, Toronto, ON, Canada, ³St. Michaels Hospital, Toronto, ON, Canada, ⁴Providence Health Care, Vancouver, BC, Canada, ⁵St Boniface General Hosp, Winnipeg, MB, Canada, ⁶University of Dalhousie, Halifax, NS, Canada, ⁷Hamilton General Hospital, Hamilton, ON, Canada, ⁸McMaster University, Hamilton, ON, Canada, ⁹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁰University of Ottawa Heart Institute, Ottawa, ON, Canada, ¹¹McGill University, Montreal, QC, Canada

(1100) Heart Transplant Patient Perspectives on Endomyocardial Biopsies; H. Kim¹, V. Cusi¹, M. McLennon¹, R. Fielding-Miller², J. Cruz Rodriguez¹, J. Chak¹, M. Urey¹, P. J. Kim¹. ¹University of California San Diego, La Jolla, CA, ²Herbert Wertheim School of Public Health, University of California San Diego, La Jolla, CA

(1101) Snapshot of a Heart Transplant Centre Population in the United Kingdom; W. Akhtar, H. Sharpe, L. Weeks, H. Lyster, J. Dunning, A. Morley-Smith, F. Riesgo Gil, O. Dar. *Royal Brompton & Harefield Hospitals, London, United Kingdom*

(1102) A Retrospective Audit of the Relationship Between Rehabilitation and Frailty in Advanced Heart or Lung Disease; V. Dinesh¹, R. Pierce¹, L. Hesper¹, M. Wong², L. El Sabbagh², L. Honeysett¹, P. Brown², K. Delbaere³, A. Havryk⁴, P. S. MacDonald⁵. ¹Heart Transplant Unit, St Vincent's Hospital, Darlinghurst, Australia, ²Graduate School of Biomedical Engineering, University of New South Wales, Sydney, Australia, ³Falls, Balance & Injury Research Centre, Neuroscience Research Australia, Sydney, Australia, ⁴Lung Transplant Unit, St Vincent's Hospital, Darlinghurst, Australia, ⁵Heart Transplant Unit, St. Vincent's Hospital, Darlinghurst, Australia

(1103) Impact of Neighborhood Factors on Exercise Capacity in Children with Hypertrophic Cardiomyopathy; I. R. Masood, L. Wang, A. L. Roberts, H. Stanley, J. Rossano, M. O'Connor, K. Lin, C. Wittlieb-Weber, H. Ahmed, J. Edwards, V. Tam, J. B. Edelson. *Children's Hospital of Philadelphia, Philadelphia, PA*

(1104) Longitudinal Cost Analysis for Pediatric Cardiac Transplant Recipients; K. Yan¹, S. Kindel², A. Duffin², G. Stendahl², K. Crum³, C. Lockard⁴, B. Damon⁴, J. Soslow³, M. Samyn². ¹Medical College of Wisconsin, Milwaukee, WI, ²Medical College of Wisconsin / Herma Heart Institute at Children's Wisconsin, Milwaukee, WI, ³Vanderbilt University, Nashville, TN, ⁴Carle Foundation Hospital, Urbana, IL

(1105) Outcomes of Young Adults Undergoing Heart Transplant at Pediatric vs Adult Transplant Centers; J. Schauer¹, J. Friedland-Little², C. Hartje-Dunn², B. Hong², M. Kemna², Y. Law², K. Spencer², E. Albers². ¹Columbia University Medical Center, New York, NY, ²Seattle Children's Hospital, Seattle, WA

- (1106) The Utility of C1Q Assay in Pediatric Heart Transplant Donor Selection;** A. Raskin¹, A. Pan², C. Chin³. ¹Children's Wisconsin, Milwaukee, WI, ²Medical College of Wisconsin, Milwaukee, WI, ³Cincinnati Children's Hospital, Cincinnati, OH
- (1107) Monotherapy in Heart Transplantation Proves to Be Safe While Followed by T-Cell Immune Function Testing;** M. Kittleson, J. Patel, E. Kransdorf, R. Cole, A. Kanungo, M. Lee, N. Bhatnagar, E. Jeong, J. Moriguchi, L. Czer, D. Emerson, J. Kobashigawa. Cedars-Sinai Smidt Heart Institute, Los Angeles, CA
- (1108) Settling the Issue: Does Neupogen Increase the Risk of Rejection After Heart Transplant?;** D. Chang, J. Patel, M. Kittleson, E. Kransdorf, N. Bhatnagar, A. Kanungo, M. Lee, M. Hamilton, A. Hage, D. Megna, L. Czer, J. Kobashigawa. Cedars-Sinai Smidt Heart Institute, Los Angeles, CA
- (1109) Is Targeting Lower Tacrolimus Levels During the First Year After Heart Transplant Safe/Effective?;** M. Kittleson, D. Chang, J. Patel, D. Geft, G. Jamer, N. Bhatnagar, M. Lee, A. Kanungo, L. Stern, B. Azarbal, L. Czer, F. Esmailian, J. Kobashigawa. Cedars-Sinai Smidt Heart Institute, Los Angeles, CA
- (1110) SGLT2 Inhibitors in Patients with Advanced Heart Failure Awaiting Heart Transplant: Preliminary Results from The SGLT2i-HT Study;** G. Gallone¹, S. Pidello¹, E. Bertarelli¹, A. Tedeschi², D. Maione³, G. Cacioli⁴, N. Pradegan⁵, C. Tessari⁵, C. Di Nora⁶, A. Verde², E. Perna², C. Raineri¹, M. Marro¹, E. Simonato¹, F. Breviario⁷, F. Cavallier⁷, C. Amarelli⁸, A. Turco⁷, I. Vendramin⁶, G. Gerosa⁵, L. Scelsi⁷, P. Lilla Della Monica⁴, G. Sinagra³, A. Garascia², M. Merto³, M. Rinaldi¹, G. M. De Ferrari¹, M. Boffini¹. ¹University of Turin, Turin, Italy, ²"De Gasperis" Cardio Center, Niguarda Hospital, Milano, Italy, ³Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste, Trieste, Italy, ⁴Azienda Ospedaliera San Camillo Forlanini, Roma, Italy, ⁵University of Padova, Padova, Italy, ⁶Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy, ⁷Fondazione IRCSS S. Matteo Pavia, Pavia, Italy, ⁸Monaldi Hospital, Napoli, Italy
- (1111) The First Implementation of On-Site MMDx in Heart Transplant Care in Europe: The Initial Experiences;** V. Melenovsky¹, L. Hoskova¹, L. Matiskova¹, P. Hrubá², P. Halloran³, M. Mackova⁴, I. Netuka⁵, L. Voska⁶, O. Viklicky⁷. ¹Cardiology, Institute for Clin. and Exp. Medicine - IKEM, Prague, Czech Republic, ²Transplantation Laboratory, Institute for Clin. and Exp. Medicine - IKEM, Prague, Czech Republic, ³Alberta Transplant Applied Genomics Centre (ATAGC), University of Alberta, Edmonton, AB, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵Cardiosurgery, Institute for Clin. and Exp. Medicine - IKEM, Prague, Czech Republic, ⁶Pathology, Institute for Clin. and Exp. Medicine - IKEM, Prague, Czech Republic, ⁷Nephrology, Institute for Clin. and Exp. Medicine - IKEM, Prague, Czech Republic
- (1112) Safety and Efficacy of Belatacept in Heart Transplant Patients with Chronic Kidney Disease or Intolerance to Calcineurin Inhibitors;** A. Yehya, P. Ham, A. Pearston, A. Ingemi, D. Cohan, J. Mandel, A. Badiye, J. Herre. Sentara Norfolk General Hospital, Norfolk, VA
- (1113) The Effect of the Total Daily Dose of Midodrine in Heart Failure Patients with Reduced Ejection Fraction on Overall Mortality and Heart Failure Hospitalizations;** J. P. Thurber¹, C. M. Schinderle¹, J. F. Edwards¹, A. Yehya². ¹Eastern Virginia Medical School, Norfolk, VA, ²Sentara Heart Hospital, Norfolk, VA
- (1114) Weight-Adjusted Rabbit Antithymocyte Globulin Induction and Outcomes in Heart Transplantation;** E. Bebawi¹, M. Tremblay-Gravel², P. Noly³, J. Boulet², S. de Denus⁴, A. Fortier², M. Carrier³, Y. Lamarche³, G. Giraldeau², M. Liszkowski², M. Parent², A. Ducharme². ¹Medicine, Centre Hospitalier de l'Université de Montréal, University of Montreal, Montreal, QC, Canada, ²Cardiology, Montreal Heart Institute, University of Montreal, Montreal, QC, Canada, ³Cardiac Surgery, Montreal Heart Institute, University of Montreal, Montreal, QC, Canada, ⁴Pharmacy, Montreal Heart Institute, University of Montreal, Montreal, QC, Canada
- (1115) Comparison of Everolimus with Calcineurin Inhibitors in Maintenance Immunosuppression;** A. Yilmaz, D. E. Sert, U. Kervan, S. S. Kocabeyoglu, M. Gevrek, S. Kucuker, M. Ozatik, E. Sener. Cardiovascular Surgery, Ankara Bilkent City Hospital, Ankara, Turkey
- (1116) Does It Make a Difference? Generic versus Brand-Name Immunosuppression Following Heart Transplant: An Analysis of the UNOS Database;** A. Mahajan¹, J. Park², T. Moore², W. Baker³, M. Mohamed¹, T. Oliveira¹, C. Sai-Sudhakar⁴, C. Zoni⁴, Y. Ravi⁴. ¹University of Connecticut School of Medicine, Farmington, CT, ²University of Connecticut, Storrs, CT, ³UConn School of Pharmacy, Storrs, CT, ⁴Cardiothoracic Surgery, University of Connecticut Health Center, Farmington, CT
- (1117) Efficacy of Letemovir for CMV Prophylaxis in Heart Transplant Recipients with Moderate to High Risk CMV Serostatus;** C. Lee¹, S. Rahman¹, J. Baranowska¹, C. M. Moeller¹, A. Fernandez Valledor¹, G. Rubenstein¹, D. Oren¹, K. Oh¹, D. Bae¹, J. Raikhelkar¹, D. Lotan¹, E. M. DeFilippis¹, K. Theodoropoulos¹, J. Fried¹, K. Clerkin¹, F. Latif¹, V. Topkara¹, M. Yuzefpolskaya¹, P. Colombo¹, E. Lin¹, D. Majure², G. Sayer¹, N. Uriel¹, J. Choe³. ¹Columbia Univ Irving MC, New York, NY, ²Weill Cornell Med College, New York, NY, ³NewYork-Presbyterian Hosp, New York, NY
- (1118) Impact of Induction Therapy on Gene Expression Profiling and Donor Derived Cell Free DNA;** R. Dhingra¹, L. Bellumkonda², A. Vaidya³, L. Chen⁴, A. Jawaid⁴, E. Czinn⁴, K. Pinney⁵, S. Wang⁵, S. Patel⁵, L. Jenkins⁶, E. DePasquale³, A. Guha⁷, N. Uriel⁸. ¹Univ of Wisconsin, Madison, WI, ²Yale Univ, New Haven, CT, ³Keck Medical Center of USC, Los Angeles, CA, ⁴University of Rochester Medical Center, Rochester, NY, ⁵CareDx, Brisbane, CA, ⁶Medical Affairs, CareDx, Chicago, IL, ⁷Houston Methodist Hospital, Houston, TX, ⁸New York Presbyterian, New York, NY

(1119) One of a Kind: A Rare Case of Cardiac Transplantation in a Patient with Eosinophilic Endomyocardial Fibrosis; D. Retcho¹, K. Girgis¹, J. Celenza-Salvatore¹, C. Gidea¹, F. Ali¹, M. Montgomery¹, N. Hochbaum¹, B. Fyfe-Kirschner², S. Kapoor¹. ¹Newark Beth Israel Medical Center, Newark, NJ, ²Robert Wood Johnson School of Medicine, New Brunswick, NJ

(1120) Left Bundle Branch Pacing in an Orthotopic Heart Transplant Patient with Heart Failure and Reduced Ejection Fraction; R. Gomez Sanchez, A. Carta Bergaz, J. Castrodeza, E. Zatarain, A. Arenal Maiz, J. Bermejo. Hosp Gen Univ Gregorio Marañon, Madrid, Spain

(1121) Identification and Clinical Course of Novel Pathogenic Variant of Transthyretin Amyloid Cardiomyopathy: P.arg54Iys; M. Jung, S. Kim, M. Jung, J. Youn. Seoul St Mary's Hospital, Seoul, South Korea

(1122) Refractory Hypoxia After LVAD Implantation: Mind the Hole; Z. Jedeon¹, K. Singh², I. Konstantinidis², A. Pillai², P. Vlismas³, J. Gluck³, A. Ali⁴, J. Hammond⁴, A. Jaiswal³. ¹Cardiology, University of Connecticut- Hartford Hospital, Hartford, CT, ²Medicine, University of Connecticut, Farmington, CT, ³Cardiology, Hartford Hospital, Hartford, CT, ⁴Cardiothoracic Surgery, Hartford Hospital, Hartford, CT

(1123) Temporary Mechanical Circulatory Support to Heart Transplant in Patients with Significant Pulmonary Hypertension: A Bridge Not Too Far?; Z. Jedeon¹, A. Pillai², K. Singh², I. Konstantinidis², A. Ali³, J. Gluck⁴, A. Jaiswal⁴. ¹Cardiology, University of Connecticut- Hartford Hospital, Hartford, CT, ²Medicine, University of Connecticut, Farmington, CT, ³Cardiothoracic surgery, Hartford Hospital, Hartford, CT, ⁴Cardiology, Hartford Hospital, Hartford, CT

(1124) Amyloid Unmasked: A Rare Case of Apolipoprotein A- IV Cardiac Amyloidosis; M. Pelter¹, G. Fishbein¹, J. Theis², E. PcPhail², D. Cruz¹. ¹UCLA Medical Center, Los Angeles, CA, ²Mayo Clinic, Rochester, MN

(1125) The Great Masquerader: Lymphocytic Myocarditis Masking as Cardiac Sarcoidosis: A Case of Severe Non-Ischemic Cardiomyopathy and Ventricular Tachycardia Storm; M. Mederos Liriano, A. Doddi, J. Avalon, M. Awad, J. D. Mills, M. Caccamo. WVU Medicine, Morgantown, WV

(1126) A Blood Conservation Approach to Peri-Transplant Care Informed by Successful Heart Transplantation in a Jehovah's Witness; A. Oseran¹, K. Brown¹, E. Coglianese², D. Zlotoff¹, B. Yang¹, I. Mastoris³, M. Doucette¹, E. Michel¹, C. Newton-Cheh¹, A. Bagchi¹, R. Pierson¹, D. D'Alessandro², G. Lewis⁴. ¹Massachusetts General Hospital, Boston, MA, ²MGH, Boston, MA, ³Massachusetts General Hospital Heart Center, Boston, MA, ⁴Massachusetts Gen Hosp, Boston, MA

(1127) Between Metrics and Measures: KCCQ, CPET, and HF Prognosis; M. Z. Abushaban¹, M. Abu Suailiek¹, H. Alkharabsheh¹, D. Al-Khatib¹, O. Asad², A. Z. Turk³. ¹University of Jordan, Amman, Jordan, ²Jordan University of Science and Technology, Irbid, Jordan, ³The Advanced Heart Diseases Center, Amman, Jordan

(1128) WITHDRAWN

(1129) Hypertrophic Cardiomyopathy and Rare Genetic Mutations; M. Heringer¹, G. Campos², S. Mangini³, S. Moraes², F. Bacal⁴. ¹Advanced Heart Failure and Heart Transplantation, Hospital Israelita Albert Einstein, São Paulo, Brazil, ²Hospital Israelita Albert Einstein, São Paulo, Brazil, ³Heart Institute, São Paulo, Brazil, ⁴University of Sao Paulo, São Paulo, Brazil

(1130) A Case of Heart Transplantation in a Patient with Pulmonary Hypertension: The Ups and Downs of Reactive Pulmonary Vascular Disease; K. Callichurn¹, A. Sharma², M. Saad³, A. Anyanwu⁴, J. Contreras³, N. Moss³, M. Trivieri⁵. ¹Advanced Heart Failure & Cardiac Transplantation, Mount Sinai Hospital, New York, NY, ²Icahn School of Medicine at Mount Sinai, New York, NY, ³Mount Sinai Hospital, New York, NY, ⁴Mount Sinai Med Ctr, New York, NY, ⁵Icahn School of Medicine, New York, NY

(1131) Multidisciplinary Management of Active Cardiac Sarcoidosis with Ventricular Tachycardia; A. Singh, E. Flattery, R. Donnino, N. Narula, C. Barbhuiya, R. I. Goldberg. NYU Grossman School of Medicine, New York, NY

(1132) Massive Left Ventricular Pseudoaneurysm Presenting as Cardiogenic Shock Following Myocardial Infarction; A. Singh, E. Flattery, R. Donnino, N. Narula, R. I. Goldberg, A. Galloway, S. Bernard. NYU Grossman School of Medicine, New York, NY

(1133) Cardiac Recovery and Improved Outcomes During Left Ventricular Assist Device Support: The First Heart-Mate 3 in Argentina; C. B. Putaro, E. F. Giordanino, G. Ganum, F. Soto Arevalo, L. Favaloro, M. F. Renedo, R. R. Favaloro. Hospital Universitario Fundacion Favaloro, Buenos Aires, Argentina

(1134) Beta Blocker Withdrawal and Restoration of Sinus Rhythm in Physiology-Guided Management of Restrictive Heart Failure with Preserved Ejection Fraction; E. Flattery¹, A. Reyentovich¹, R. I. Goldberg², B. Kadosh², M. DiVita¹, J. Alvarez-Cardona¹, T. Saraon¹. ¹Division of Cardiology, NYU Langone Medical Center, New York, NY, ²NYU Langone Medical Center, New York, NY

(1135) Successful Orthotopic Heart Transplant in a Patient with Light Chain Multiple Myeloma Complicated by End-Stage Cardiac Amyloidosis; E. Flattery¹, J. Alvarez-Cardona¹, F. Davies², D. E. Smith³, N. Moazami³, A. Reyentovich¹. ¹Division of Cardiology, NYU Langone Medical Center, New York, NY, ²Division of Hematology and Medical Oncology, NYU Langone Medical Center, New York, NY, ³Division of Cardiothoracic Surgery, NYU Langone Medical Center, New York, NY

(1136) Fulminant Lymphocytic Myocarditis with Acute Biventricular Failure: The Role of Mechanical Circulatory Support; A. Aijaz¹, S. Shoukat², R. Sharma³, S. Farooq⁴, H. Ashraf⁵, B. Akkanti⁶, I. Hussain⁷, A. Bhardwaj⁸, S. Nathan⁹, M. Patel², I. Gregoric², B. Kar². ¹Advanced Heart Failure and Transplant Cardiology, Houston Methodist Hospital, Houston, TX, ²Advanced Heart Failure and Transplant Cardiology, University of Texas Health Science Center at Houston, Houston, TX, ³Cardiology, University of Washington, Seattle, WA, ⁴Pulmonary and Critical Care Medicine, University of Texas Health Science Center at Houston, Houston, TX, ⁵Cardiology, University of Texas Health Science Center at Houston, Houston, TX, ⁶Pulmonary and Critical Care Medicine, UT Houston Memorial Hermann Hospital, Houston, TX, ⁷Advanced Heart Failure and Transplant Cardiology, Houston Methodist Hosp, Houston, TX, ⁸Advanced Heart Failure and Transplant Cardiology, University of Texas/McGovern Medical School, Houston, Texas, Houston, TX, ⁹Advanced Heart Failure and Transplant Cardiology, University of Houston Health Science Center- Advanced Heart Failure, Houston, TX

(1137) Implantable Pulmonary Artery Pressure Sensor Monitoring in a Heart Transplant Recipient; J. M. Lindekens¹, E. Webb², D. Fisher², S. Huang², J. Vasconcellos², S. Alishetti², E. Lin³, F. Latif⁴, G. Sayer⁵, N. Uriel⁶, K. Axsom², E. M. DeFilippis⁵. ¹Center for Advanced Cardiac Care, Columbia University Medical Center, New York, NY, ²Columbia University, New York, NY, ³Columbia Univ Med Ctr, New York, NY, ⁴NY Presbyterian Hospital, New York, NY, ⁵Columbia University Irving Medical Center, New York, NY, ⁶New York Presbyterian, New York, NY

(1138) Interatrial Shunt: A "Hole in Time" to Delay Cardiac Retransplantation in Late Graft Dysfunction; J. Guzman Bofarull¹, E. Solé González, I. Forado Benatar, N. Velásquez, E. Torrecilla, J. Casal, L. Izquierdo, P. Caravaca, A. Garcia Alvarez, M. Castellà, E. Sandoval, M. Castel, O. Abdul-Jawad, M. Farrero Torres. Hospital Clínic de Barcelona, Barcelona, Spain

(1139) Rejection Unmasks a Surprise; I. Morales-Rey¹, J. Guzman Bofarull², I. Forado², E. Sole², P. Caravaca², E. Sandoval¹. ¹Cardiovascular Surgery Department, Hospital Clínic, Barcelona, Spain, ²Cardiology Department, Hospital Clínic, Barcelona, Spain

(1140) Successful Simultaneous Heart-Kidney Transplant in a Patient with MT-TL1 Melas Cardiomyopathy; J. Arriola-Montenegro¹, M. Mutschler¹, R. Cogswell¹, T. Alexy¹, R. John², R. Voeller², V. Humphreville³, A. Aggarwal⁴, V. Maharaj¹. ¹Medicine, Division of Cardiology, University of Minnesota, Minneapolis, MN, ²Surgery, Division of Cardiothoracic Surgery, University of Minnesota, Minneapolis, MN, ³Surgery, Division of Transplant Surgery, University of Minnesota, Minneapolis, MN, ⁴Pediatrics, Division of Genetics and Metabolism, University of Minnesota, Minneapolis, MN

(1141) An Elusive Chagas Reactivation Mimicking an Acute Cellular Rejection After a Heart Transplant: The Importance of Pursuing the Diagnosis; A. Martin-Centellas¹, F. Hernandez Perez¹, P. Gil Bernabe², M. Rivas-Lasarte¹, C. Mitroi¹, R. Garrido Gonzalez¹, A. Matutano Muñoz¹, M. Gomez Bueno¹, C. Salas Anton², J. Segovia-Cubero¹. ¹Cardiology Service, Hospital Universitario Puerta de Hierro de Majadahonda, Majadahonda, Madrid, Spain, ²Pathological Anatomy Service, Hospital Universitario Puerta de Hierro de Majadahonda, Majadahonda, Madrid, Spain

(1142) Two Successful Unplanned Pregnancies in a 33-Year-Old Woman After Heart Transplantation for Peripartum Cardiomyopathy; L. Triguero Llonch¹, E. Garcia Romero², L. Galián Gay³, M. Goya⁴, L. Herrador-Galindo¹, C. Diez-Lopez², F. de Frutos¹, J. Gonzalez-Costello². ¹Department of Cardiology. Bioheart Group (IDIBELL), Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Spain, ²Department of Cardiology. Bioheart Group (IDIBELL). Ciber Cardiovascular Group (CIBER-CV), Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Spain, ³Department of Cardiology. Ciber Cardiovascular Group (CIBER-CV), Hospital Universitari Vall d'Hebron, Barcelona, Spain, ⁴Department of Obstetrics. Universitat Autònoma de Barcelona, Hospital Universitari Vall d'Hebron, Barcelona, Spain

(1143) Discordant Donor-Derived Cell-Free DNA and Endomyocardial Biopsy Scores; M. Topor¹, A. B. Cochrane², A. Thatcher¹, K. Busa¹, M. Maydosz¹, S. Ma¹, C. Falke¹, K. Schillinger³, C. Murphey³, A. Rollins¹, J. Kennedy¹. ¹Inova Schar Heart and Vascular, Falls Church, VA, ²Inova Fairfax Hospital, Falls Church, VA, ³Applied Immunogenetics Laboratory, Owings Mills, MD

(1144) Extensive Metastatic Calcification After Heart Transplant; E. M. Olson¹, K. Y. Lin¹, J. B. Edelson¹, J. W. Rossano¹, C. A. Wittlieb-Weber¹, J. J. Edwards¹, K. Maeda², K. Restaino¹, C. Boyle¹, L. Ha¹, M. J. O'Connor¹. ¹Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA, ²Cardiothoracic Surgery, Children's Hospital of Philadelphia, Philadelphia, PA

(1145) Prolonged Survival Despite Ventricular Arrhythmias in Heterotopic Heart Transplantation; M. Konicoff, F. Riesgo Gil, A. Morley-Smith, O. Dar, J. Dunning. Cardiothoracic Transplantation, Harefield Hospital. Guy's and St Thomas's NHS Foundation Trust, London, United Kingdom

(1146) Orthotopic Heart and Multi-Organ Transplantation in AL Amyloidosis; S. Perdakis¹, A. Kao², M. Barat², J. A. McCain², E. Adler³, K. Hong⁴, V. Pretorius⁵, M. Kearns⁶, C. Costello⁷, A. Jeong⁷, R. Khedraki⁸, M. Urey⁶. ¹Division of Cardiovascular Medicine, UC San Diego, San Diego, CA, ²UC San Diego, San Diego, CA, ³Univ of California, SD, San Diego, CA, ⁴UCSD, San Diego, CA, ⁵UCSD, San Diego, CA, ⁶UC San Diego Health, San Diego, CA, ⁷Moore UCSD Cancer Center, UC San Diego, San Diego, CA, ⁸Prebys Cardiovascular Institute, San Diego, CA

(1147) Characteristics and Outcomes of Patients with Cardiac Amyloidosis Requiring Organ Transplant; S. Perdakis¹, A. Kao², M. Barat¹, J. McCain², E. Adler³, K. Hong⁴, V. Pretorius⁵, M. Kearns⁶, R. Khedra⁷, M. Urey⁶. ¹UC San Diego, San Diego, CA, ²Division of Cardiovascular Medicine, UC San Diego, San Diego, CA, ³Univ of California, SD, San Diego, CA, ⁴Division of Cardiovascular Medicine, University of California, San Diego, San Diego, CA, ⁵UCSD, San Diego, CA, ⁶UC San Diego Health, San Diego, CA, ⁷Prebys Cardiovascular Institute, San Diego, CA

(1148) Rise of the Machines: The Utilization of Technology for Triple-Organ Transplantation; F. Azar, E. Margolin, N. Reddy, A. Birs, A. Brubaker, G. Schnickel, K. Mekeel, J. Parekh, J. Berumen, M. Kearns, V. Pretorius, E. Adler, H. Tran, K. Hong, M. Shah, A. Khan, V. Ajmera, I. Vodkin, B. Jackson, M. Urey. UC San Diego, San Diego, CA

(1149) CABG for Coronary Allograft Vasculopathy - Still a Viable Option?; A. Fardman, Y. Wasserstrum, L. Sternik, A. Morgan, J. Lavee, Y. Peled. Chaim Sheba Medical Center, Tel Hashomer, Israel

(1150) Heart and Kidney Transplantation in Hereditary ATTR Amyloidosis and Smoldering Myeloma: A Multidisciplinary Approach; G. Vaidya, A. Kolodziej, T. Alnabelsi, I. Ebong, A. Castellanos, C. Iragavarapu, G. Monohan, W. O'Connor, E. Birks. University of Kentucky, Lexington, KY

(1151) Early Onset Pancytopenia Post Heart Transplant: Calcineurin Inhibitor-Induced Thrombotic Microangiopathy versus Cytomegalovirus Infection; L. Feeney¹, K. Ripley², J. Herre¹, A. Yehya¹. ¹Advanced Heart Failure and Transplant, Sentara Medical Group, Norfolk, VA, ²Sentara Transplant Infectious Disease, Sentara Medical Group, Norfolk, VA

(1152) Ex Vivo Myocardial Slices Unveil Reversibility in Chemotherapy-Induced Cardiotoxicity; I. R. Kelters¹, J. S. van der Geest¹, V. Sampaio-Pinto², P. M. Zwetsloot³, A. J. Teske³, T. P. De Boer⁴, N. P. van der Kaaij⁵, J. P. Sluijter¹, L. W. Van Laake⁶. ¹Experimental Cardiology Laboratory, Department of Cardiology, Division of Heart & Lungs, University Medical Center Utrecht, Utrecht, Netherlands, ²Utrecht Regenerative Medicine Center, Circulatory Health Laboratory, University Utrecht, Department, University Medical Center Utrecht, Utrecht, Netherlands, ³Department of Cardiology, Division of Heart & Lungs, University Medical Center Utrecht, Utrecht, Netherlands, ⁴Department of Medical Physiology, Division of Heart & Lungs, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Department of Cardiothoracic Surgery, Division of Heart & Lungs, UMC Utrecht, Utrecht, Netherlands, ⁶Department of Cardiology, Division of Heart & Lungs, UMC Utrecht, Utrecht, Netherlands

(1153) Tacrolimus Induced Colonic Injury - A Not So Uncommon Foe?; J. Amione Guerra, A. Aijaz, J. Gorthi. Houston Methodist Hospital, Houston, TX

(1154) Heart Transplantation in a Patient with Active Thyroid Cancer; Y. Mehlman¹, M. Yuzefpolskaya¹, J. Fried¹, K. Clerkin¹, D. Bae¹, E. DeFilippis¹, K. Oh¹, K. Theodoropoulos¹, S. Lee¹, P. Colombo¹, E. Lin¹, F. Latif¹, G. Sayer¹, N. Uriel², J. Raikhelkar¹. ¹Columbia University Irving Medical Center, New York, NY, ²New York Presbyterian, New York, NY

(1155) Apolipoprotein A-IV Amyloidosis Found Incidentally on an Explanted Heart in a Patient with Congenital Heart Disease; C. Succar, M. Toma, B. Clarke, S. Virani, J. Bashir, A. Cheung, K. Lichtenstein, C. Lai, M. Davis. Saint Paul's Hospital-University of British Columbia, Vancouver, BC, Canada

(1156) Posterior Ischemic Optic Neuropathy After Heart Transplant; C. Succar, S. Hickman, W. Chiu, M. Toma, S. Virani, B. Clarke, M. Davis, J. Bashir, A. Cheung, K. Lichtenstein. St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada

(1157) Shifting Strategies: Heart Transplant as a Bridge to Chemotherapy in Cardiac AI Amyloidosis; O. Abou Hassan, L. Nikolaidis, Y. Khariton, D. Wencker, J. Schmittner, E. Chukwu, H. Dandapantula, T. Generette, M. Bahe, A. Malhotra, J. Hernandez Montfort. Baylor Scott and White Health, Temple, TX

(1158) Heart Transplant in an Immigrant in Brazil: A Learning Experience of a Worldwide Ethical, Legal and Cultural Challenge; L. C. Hastenteufel¹, P. Alves², L. Orlandin¹, M. F. Grossini², R. I. Viana², M. Rosses², F. C. de Vasconcellos², F. Scolari¹, N. Clausell¹, L. A. Goldraich¹. ¹Cardiology, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, ²Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil

(1159) Favorable Response to Daratumumab in the Treatment of Antibody Mediated Rejection in Pediatric Heart Transplant; M. S. Najor¹, D. M. Peng², A. McCormick², H. Lim², G. Simmons¹, S. Stoll¹, A. Huebschman³, N. Sinicropi², B. Giacobbe², M. Zamberlan², K. Shumacher², M. Cusick¹. ¹Pathology, U Michigan, Ann Arbor, MI, ²Pediatrics-Cardiology, U Michigan, Ann Arbor, MI, ³Pharmacy, U Michigan, Ann Arbor, MI

(1160) End-Stage Heart Failure After Hydroxychloroquine Exposure in a Teenager; R. Lalli¹, A. Power¹, D. M. Levy², A. Nagy³, C. Haller⁴, L. R. Brandao⁵, O. Zaulan⁶, B. Langaneecha¹, A. Maurich¹, K. George¹, L. Fazari¹, A. Jeewa¹. ¹Division of Cardiology, The Hospital for Sick Children, Toronto, ON, Canada, ²Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ³Department of Laboratory Medicine and Pathobiology, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Division of Cardiac Surgery, The Hospital for Sick Children, Toronto, ON, Canada, ⁵Division of Hematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada, ⁶Department of Critical Care Medicine, The Hospital for Sick Children, Toronto, ON, Canada

- (1161) Initial Experience of Sodium-Glucose Cotransporter 2 Inhibitors in Adolescents with Heart Failure Due to Muscular Dystrophy;** A. A. Chaudhary¹, E. Kramer¹, D. Weber², H. Ahmed¹, M. J. O'Connor¹, J. B. Edelson¹, J. J. Edwards¹, K. Y. Lin¹, J. W. Rossano¹, C. A. Wittlieb-Weber¹, J. H. Berger¹. ¹Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA, ²Endocrinology, Children's Hospital of Philadelphia, Philadelphia, PA
- (1162) Emergency Cardiac Transplant for Refractory Cardiac Arrest Resuscitated with Extracorporeal CardioPulmonary Resuscitation (ECPR) in an 18-Month-Old Baby;** S. Thangavel, S. Vilvanathan, R. Ratnagiri, S. Rao, K. Balakrishnan. MGM Healthcare, Chennai, India
- (1163) Late Antibody Mediated Rejection (AMR) Treatment: A Work in Progress!**; S. Thangavel, S. Vilvanathan, R. Ratnagiri, S. Rao, K. Balakrishnan. MGM Healthcare, Chennai, India
- (1164) Quantifying Total Cell-Free DNA in a Heart Transplant Patient with Acute Cellular Rejection;** A. Alge¹, M. Rodich¹, K. Nyikos¹, A. Porter², K. Crabtree², K. Morris³, A. Ravichandran³. ¹Renal and Cardiac Transplant/VAD Services, Ascension St. Vincent Indianapolis, Indianapolis, IN, ²Natera, Inc., Austin, TX, ³Ascension St. Vincent Indianapolis, Indianapolis, IN
- (1165) Heart Transplantation in a Patient with Endomyocardial Fibrosis: Suspected Disease Recurrence;** L. Herrador-Galindo¹, C. Díez-López¹, J. Gayan Ordas², E. García-Romero¹, P. Catalá-Ruiz¹, E. Claver-Garrido¹, R. Llatjós¹, R. Bascompte-Claret², L. Triguero-Llonch¹, L. Rosenfeld¹, F. De Frutos-Seminario¹, S. Ibañez-Caballero¹, V. Gumucio¹, M. Potocnik¹, M. Barrionuevo-Sanchez¹, J. González-Costello¹. ¹Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain, ²University Hospital Arnau de Vilanova, Lleida, Spain
- (1166) Daratumumab for Refractory AMR Rejection After Adolescent Heart Transplant;** J. Skowronski, E. Horn, Q. Xu, M. Keebler. University of Pittsburgh Medical Center, Pittsburgh, PA
- (1167) The Kinetics of Donor-Derived Cell-Free DNA During Treatment of Allograft Rejection in a Highly Sensitized Heart Transplant Recipient;** C. Aseervatham, D. Iyer, K. Dulnuan. Rutgers - Robert Wood Johnson Medical School, New Brunswick, NJ
- (1168) Use of Tocilizumab for AT1R Antibody Mediated Rejection in a Heart Transplant Recipient;** R. Cartus¹, A. Wolfson¹, E. Han¹, J. Nattiv¹, K. Pandya¹, M. Fong², M. Stachel¹, A. Vaidya¹. ¹Keck Medicine of USC, Los Angeles, CA, ²University of Southern California, Los Angeles, CA
- (1169) Thinking Outside the Box: dd-cfDNA and Gene-Expression Profiling in Combined Heart-Liver Transplantation (CHLT);** R. Cartus¹, M. Ackerman², A. Cochran³, A. Sertic³, S. Villalon⁴, M. Fong¹, J. Nattiv³, K. Pandya³, M. Stachel³, A. Wolfson², R. Lee⁵, A. Vaidya⁴. ¹University of Southern California, Los Angeles, CA, ²Keck Medicine of USC, Los Angeles, CA, ³USC, Los Angeles, CA, ⁴Keck Medical Center of USC, Los Angeles, CA, ⁵University of Southern CA Keck School of Medicine, Los Angeles, CA
- (1170) Should Living Alone be an Absolute Contraindication to HeartMate 3 Implantation: A Single Center Experience;** A. Ladanyi¹, C. Shahidi¹, F. Cali¹, M. R. Carey¹, S. Deluty², G. M. Mondellini¹, A. Pinsino¹, V. R. Feldman², G. Sayer¹, Y. Kaku¹, N. Uriel¹, K. Takeda¹, P. C. Colombo¹, M. Yuzefpolskaya¹. ¹Columbia University Irving Medical Center, New York, NY, ²New York Presbyterian Hospital, New York, NY
- (1171) Prediction of Patient Self-Management for Heartmate 3 LVAD;** S. Mayer¹, A. Ladanyi¹, G. Alonzo², B. Murphy², K. Fidlow², J. Green³, J. Willey¹, M. Carey¹, M. Yuzefpolskaya¹, P. C. Colombo¹, S. R. Millis⁴, M. Pavol¹. ¹Columbia University, New York, NY, ²New York Presbyterian-Columbia University, New York, NY, ³New York Presbyterian-Columbia University, New York Presbyterian-Weill Cornell, New York, NY, ⁴Wayne State University School of Medicine, Detroit, MI
- (1173) Predictors of Successful Discontinuation of LVAD Support in LVAD-Related Complications and Partial Myocardial Recovery: VAD Wean Registry Analysis;** V. Kittipibul¹, S. Russell², C. Milano¹, C. Patel¹, F. Sera³, S. Silvestry⁴, S. Rojas⁵, T. Gyoten⁶, A. Cheung⁷, B. Sun⁸, E. Birks⁹, S. Patel¹⁰, S. Drakos¹¹, R. Agarwal¹. ¹Duke University Medical Center, Durham, NC, ²Duke University School of Medicine, Durham, NC, ³Osaka University, Osaka, Japan, ⁴AdventHealth Transplant Institute, Orlando, FL, ⁵Heart and Diabetes Center Bad Oeynhausen, Bad Oeynhausen, Germany, ⁶University of Tokyo, Tokyo, Japan, ⁷St. Paul's Hospital, Vancouver, BC, Canada, ⁸Minneapolis Heart Institute, Minneapolis, MN, ⁹University of Kentucky, Lexington, KY, ¹⁰Montefiore-Einstein, New York, NY, ¹¹University of Utah, Salt Lake City, UT
- (1174) Impact of HF Etiology on the Sustainability of Favorable Response After LVAD Weaning: A VAD Wean Registry Analysis;** E. Maneta¹, C. P. Kyriakopoulos¹, E. Dranow¹, T. C. Hanff¹, J. Stehlik¹, O. Wever-Pinzon¹, R. Cogswell², J. Schultz², A. Schwartzman³, K. Shah⁴, G. MacGowan⁵, S. Schueler⁶, D. Zimpfer⁷, U. Jorde⁸, C. H. Selzman¹, S. Patel⁸, S. G. Drakos¹. ¹Utah Cardiac Recovery (UCAR) Program (University of Utah Health and School of Medicine, Intermountain Medical Center, George E. Wahlen Department of Veterans Affairs Medical Center), Salt Lake City, UT, ²Department of Medicine, Division of Cardiology, University of Minnesota School of Medicine, Minneapolis, MN, ³Maine Medical Center, Portland, ME, ⁴Department of Medicine, Virginia Commonwealth University, Richmond, VA, ⁵Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ⁶Department of Cardiothoracic Surgery, Newcastle upon Tyne Freeman Hospital, Newcastle upon Tyne, United Kingdom, ⁷Department of Cardiac Surgery, Medical University Vienna, Vienna, Austria, ⁸Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY

- (1175) Sacubitril-Valsartan Improves Blood Pressure Control and Contributes to Positive Left Ventricular Remodelling in Heartmate 3 LVAD Supported Patients;** P. D. Callan, S. Shaw, J. Hooper, S. Kore, R. Venkateswaran. Wythenshawe Cardiothoracic Transplant Unit, Manchester Foundation Trust, Manchester, United Kingdom
- (1176) Myocardial Recovery in Contemporary CF-LVADs and Association with Outcomes - A VAD Wean Registry Analysis;** N. Fida¹, H. Kundu², F. Ishaq², A. Bhimaraj¹, A. Vidic³, S. G. Drakos⁴, S. R. Patel⁵. ¹Cardiology, Houston Methodist Hospital, Houston, TX, ²Cardiology, Houston Methodist, Houston, TX, ³University of Kansas Health System, Kansas City, KS, ⁴Cardiology, University of Utah Health & School of Medicine, Salt Lake City, UT, ⁵Cardiology, Montefiore-Einstein, Bronx, NY
- (1177) Angiotensin Receptor Antagonist/Nepriylsin Inhibitor Tolerance in LVAD Recipients;** A. Rabon, A. Thomas, F. Tibayan, J. Steiner. Oregon Health and Science University, Portland, OR
- (1178) Impact of Gender and Age on Daily Activity Levels in LVAD Recipients During Long-Term Follow-Up;** M. S. Delfiner¹, A. Parikh¹, M. Genuardi¹, K. Sidhu¹, J. Ortega-Legaspi¹, J. H. Snider², J. Miller², H. Vidula¹. ¹Advanced Heart Failure and Transplant Cardiology, Perelman School of Medicine at The University of Pennsylvania, Philadelphia, PA, ²ActiCare Health, Inc., Livermore, CA
- (1179) Impella 5.5 for Frailty and SCAI D-E Shock: Impact on Post-OHT Outcomes;** R. Barriola Rubarth, E. Margolin, M. Fortich, M. Woodham, N. Reddy, G. Bhattal, H. Tran. UC San Diego Health, San Diego, CA
- (1180) Assessing Patient Satisfaction After Left Ventricular Assist Device;** J. Oribabor¹, J. McElliott², N. Baecher², A. Shirin², S. McNitt², B. Carlson², L. Fingerut², E. McKinley², J. Choi², L. Chen², A. Godishala², S. Thomas², M. Tallman², I. Gosev², K. Wood², S. Sears³, I. Goldenberg², S. McIntosh², J. Alexis². ¹Univ of Pennsylvania, Philadelphia, PA, ²Univ of Rochester MC, Rochester, NY, ³East Carolina Univ, Greenville, NC
- (1181) Innovative Technique for Left Ventricular Assist Device Deactivation: A Description Case;** H. Bernardi, V. Simioni, M. Lizandro, P. Pires, C. Romero, D. Belfort, B. Biselli, M. Avila, S. Ayub-Ferreira, F. Jatene, F. S. de Brito Junior. Heart Institute (InCor) FMUSP, São Paulo, Brazil
- (1182) The Need for (less) Squeeze? Disopyramide for Adverse LV Remodeling with Long-Term LVAD Support;** S. M. Beldock, M. Ahmed, J. Vilaro, A. Parker, J. Aranda, M. Al-Ani. Cardiovascular Medicine, University of Florida, Gainesville, FL
- (1183) Successfully Treated Gastric Cancer with Prolonged Discontinuation of Antithrombotic Therapy After Left Ventricular Assist Device Implantation;** Y. Park¹, H. Lee², B. Sohn², J. Kim³, H. Chung³, S. Hong¹. ¹Department of Cardiology, Bucheon Sejong Hospital, Bucheon, South Korea, ²Department of Thoracic and Cardiovascular Surgery, Bucheon Sejong Hospital, Bucheon, South Korea, ³Division of Pediatric Cardiology, Bucheon Sejong Hospital, Bucheon, South Korea
- (1184) Left Ventricular Assist Device Implantation in Patient with Localized Stenosis at a Distal Anastomotic Site of the Ascending Aorta After Bentall's Surgery;** T. Hamaya, T. Sato, Y. Mori, Y. Kobayashi, S. Takenaka, T. Temma, K. Kamiya, T. Nagai, T. Anzai. Hokkaido University Graduate School of Medicine, Hokkaido, Japan
- (1185) Left Ventricle Assist Device as a Treatment for Burned Out Hypertrophic Obstructive Cardiomyopathy;** R. Sadraldin¹, A. Bakhsh², A. Alkhalidi³, M. Bin Hudhud². ¹Prince Sultan Cardiac Center, Riyadh, Saudi Arabia, ²PSCC, Riyadh, Saudi Arabia, ³King Abdulaziz Medical Center, Riyadh, Saudi Arabia
- (1186) Infective Endocarditis at the Inflow Cannula of Left Ventricular Assist Device After Barefoot Walking;** I. Kim¹, H. Lee², S. Lee³, J. Kim³, H. Kim³, I. Hwang³, S. Park³, S. Kyung Sub³, Y. Kim³, W. Chang³, J. Kim³, H. Kim³, N. Park³. ¹Keimyung University Dongsan Hospital, Dalseo-Gu, South Korea, ²Keimyung University, Dongsan Hospital, Daegu, South Korea, ³Keimyung University Dongsan Hospital, Daegu, South Korea
- (1187) A Case of Percutaneous Decommissioning and Subsequent Surgical Explantation of a Heartmate 3 LVAD: A Two-Step Hybrid Approach;** A. Challa, M. J. Thomas, C. Bianco, K. Felpel, L. Lagazzi, G. Sokos, M. Caccamo. West Virginia University, Morgantown, WV
- (1188) Prolonged HeartMate 3 LVAD Pump off Without Irreversible Complications;** D. Syed, M. Jones, K. Shanklin, L. Michalak, D. Williams, A. Tatoes, A. Tatoes, K. Marinescu, T. Suboc, G. Nair. Rush University Medical Center, Chicago, IL
- (1189) Low Flow Alarms in Disguise: Unraveling the Mystery of Extrinsic Outflow Graft Obstruction;** L. Racharla¹, D. Jagasia¹, K. Sidhu², S. B. Prenner², M. Genuardi¹, V. Ferrari¹, H. Vidula¹, T. Wang¹. ¹University of Pennsylvania, Philadelphia, PA, ²Hospital of the University of Pennsylvania, Philadelphia, PA
- (1190) Management of Threatened Pump Thrombosis with Heartmate II LVAD with Central Apposition Suture: Complex Decision Making and a Clinical Refresher;** M. Saad¹, M. Cagliostro², J. Roldan¹, S. Itagaki³, K. Mahmood¹, A. Anyanwu⁴, N. Moss¹. ¹Mount Sinai Hospital, New York, NY, ²Icahn SoM at Mount Sinai, New York, NY, ³Mount Sinai MC Mount Sinai Hospital, New York, NY, ⁴Mount Sinai Med Ctr, New York, NY

(1191) A Novel Indication for TAVR: Targeting Aortic Stenosis in a Patient with LVAD Outflow Graft Obstruction; V. Sriramoju, J. Hammond, J. Bell, A. Scatola, S. Arora, R. Hagberg, T. Azemi, X. Mai. *Hartford HealthCare, Hartford, CT*

(1192) Pulseless Paradoxus in a Heartmate3 Recipient with Cardiac Tamponade; H. Beaini¹, F. Hussain², A. Jawaid³, L. Truby⁴, K. Ginder³, R. Zimmerman⁴, S. Waller¹, A. Josey¹, M. Goral³, M. Thomas³, D. Varghese¹, M. Edwards¹, N. Hendren⁵, M. Peltz¹, M. Farr⁴, F. Araj⁶. ¹UT Southwestern Medical Center, Dallas, TX, ²University of Texas - Southwestern Medical Center, Dallas, TX, ³UT Southwestern, Dallas, TX, ⁴University of Texas Southwestern Medical Center, Dallas, TX, ⁵Merck, Dallas, TX, ⁶UT Southwestern Medical Center, Dallas, Texas, Dallas, TX

(1193) Percutaneous Left Atrial Appendage Occlusion Devices and Continuous Flow LVAD Thrombosis: An Occult Source of VAD Thrombosis?; H. Beaini¹, F. Hussain², A. Jawaid³, L. Truby⁴, M. Thomas³, D. Varghese¹, M. Edwards¹, M. Peltz¹, R. Morlend¹, A. Amin⁵, M. Farr⁴, P. Mammen¹, F. Araj¹. ¹UT Southwestern Medical Center, Dallas, TX, ²University of Texas - Southwestern Medical Center, Dallas, TX, ³UT Southwestern, Dallas, TX, ⁴University of Texas Southwestern Medical Center, Dallas, TX, ⁵Texas Health Resources, Fort Worth, TX

(1194) A Case of Durable Biventricular Support Alongside Mechanical Aortic and Mitral Valves; Y. Wasserstrum, Y. Peled, L. Sternik, R. Beigel, A. Kogan, A. Morgan, A. Fardman. *Levi Heart Institute, Sheba Medical Center, Ramat-Gan, Israel*

(1195) Illuminating the Shadows: Multidetector Computed Tomography as a Guiding Light in a Challenging Case of Myocardial Recovery Under LVAD Support; A. Maestro Benedicto¹, M. Tauron², D. Viladés¹, L. Rodríguez¹, L. López López¹, M. Doñate¹, T. Koller³, C. Moliner¹, C. Simon¹, M. de Antonio¹, A. Pomares¹, V. Brossa Loidi¹, N. Mesado¹, J. Aran¹, A. Villalobos¹, F. Riesgo Gil⁴, A. Ginel², S. Mirabet Perez⁵. ¹Cardiology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ²Cardiac Surgery, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ³Anesthesiology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁴Harefield Hospital, Harefield, United Kingdom, ⁵Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

(1196) When LVAD Support is Just Too Much - A Case of Accelerated Myocardial Recovery with LVAD; J. N. Njoroge, P. Mamic. *Stanford University, Palo Alto, CA*

(1197) Using Intracardiac Echocardiography Along with Transaortic Gradient to Clinch the Diagnosis in a Complicated LVAD Patient; S. Singh, A. Behfar. *Mayo Clinic, Rochester, MN*

(1199) Double Bridge Approach for Treatment of Acute Mitral Regurgitation from Ruptured Chordae; A. Badiye¹, R. K. Bahniwal², R. Vashist¹, C. M. Sciortino¹, P. M. Lavigne¹, M. R. Summers¹. ¹Sentara Health, Norfolk, VA, ²Internal Medicine, Eastern Virginia Medical School, Norfolk, VA

(1200) Recurrent Migration of a Protekduo Right Ventricular Assist Device: A Case Report; A. Rezvani¹, S. Bandeali², A. Bhimaraj³. ¹Internal Medicine, Texas A and M and Houston Methodist, Houston, TX, ²Texas Heart and Vascular Specialists, Houston Methodist Hospital, Houston, TX, ³Houston Methodist Hospital, Houston, TX

(1201) Stability of True Left Ventricular Wireless Endocardial Receiver-Electrodes Compatible with Safe Impella Bridge - A Case Report; M. Valdo Giugni¹, S. Kindsvater², F. Giugni³, C. Guerrero-Miranda⁴, M. Alom⁵, R. Gottlieb¹. ¹Baylor University Medical Center, Dallas, TX, ²Baylor Scott & White The Heart Hospital, Plano, TX, ³University of Texas Southwestern, Dallas, TX, ⁴Baylor Medical University Medical Center, Baylor Scott and White, Dallas, TX, ⁵Baylor University Medical Center/The Heart Hospital Plano, Dallas, TX

(1202) Aortic Root Thrombosis After Temporary Mechanical Circulatory Support Implantation - A Case Report; R. Molnár, P. Lesný, E. Goncalvesová. *Dept of Cardiology, Faculty of Med Comenius Univ and National Inst of Cardiovascular Diseases, Bratislava, Slovakia*

(1203) Single Center Experience of Extra-Corporeal Cardiopulmonary Resuscitation; R. Sampath-Kumar, D. Chu, P. Mylavarapu, A. Custer, A. Birs, M. Odish, C. Yi, E. Pentony, M. Urey, T. Pollema, R. Sell, E. Mahmud, H. Tran. *UC San Diego Health, San Diego, CA*

(1204) Heart and Lung Transplant in a Patient with Relapsed AL Amyloidosis; A. Birs, M. Urey, E. Adler, V. Pretorius, M. Kearns, E. Golts, A. Kao, G. Yung, A. Kafi, C. Lin, C. Costello, K. Afshar. *UC San Diego Health, San Diego, CA*

(1205) WITHDRAWN

(1206) Impella 5.5 Assisted Combined Liver-Kidney Transplantation; Y. A. He¹, A. Bhimaraj², L. Chou³, E. E. Suarez¹. ¹Cardiovascular Surgery, Houston Methodist Hospital, Houston, TX, ²Cardiology, Houston Methodist Hospital, Houston, TX, ³Surgery, UC Davis Health, Sacramento, CA

(1207) Combined Inari Thrombectomy and PFO Closure in a Young Patient with Massive PE and Multiple Embolic Events; B. Sadeh¹, A. Milwidsky². ¹Tel Aviv Medical Center, Tel Aviv, Israel, ²Tel-Aviv Medical Center, Tel Aviv, Israel

(1208) Pulmonary Arterial Hypertension Associated to Tyrosine Kinase Inhibitor - A Case Report; K. Alpkvist¹, J. Papageorgiou¹, K. Jansson². ¹University Hospital in Linköping, Sweden, Linköping, Sweden, ²Linköping Univ Hosp, Linköping, Sweden

(1209) Uptitration of Pulmonary Arterial Hypertension Therapies: Transition From Oral Selexipag to Parenteral Treprostinil; M. Krishnan¹, M. Gomberg-Maitland², J. M. Dias-Douglas¹, J. Sherner¹, J. Choi¹. ¹MedStar Washington Hospital Center, Washington, DC, ²George Washington University, Washington, DC

(1210) WITHDRAWN

(1211) A Patient with Dextrocardia, Situs Inversus Totalis, and Congenitally Corrected Transposition of the Great Arteries Receives a VAD Using a Minimally Invasive Approach; J. Iskandar¹, A. Jawaid², K. Wood¹, I. Gosev¹, N. Atallah-Yunes¹, N. Atallah-Yunes¹, J. Alexis³, P. Charla¹. ¹University of Rochester Medical Center, Rochester, NY, ²UT Southwestern, Dallas, TX, ³Univ Rochester Med Ctr, Rochester, NY

(1212) A Patient with Ebstein's Anomaly Receives a Transplanted Heart with Unexpected Long QT; E. Hassell, J. Iskandar, M. Aktas, L. Chen, A. Godishala. University of Rochester Medical Center, Rochester, NY

FRIDAY, 12 APRIL, 2024

4:30 - 5:30 p.m.

POSTER SESSION 3: Cardiothoracic Surgery (Non-CME)

Location: Poster Hall

Core Therapies: HEART, LUNG, MCS, PVD

Practice Areas: Cardiothoracic Surgery, Anesthesiology and Critical Care, Cardiology, Infectious Diseases, Nursing and Allied Health, Pathology, Pediatrics, Pharmacy, Pulmonology, Research and Immunology

Session Summary: Posters in this session include presentations on multiple topics where the Practice Areas of the research is focused in Cardiothoracic Surgery. Designated Poster Discussants will circulate through the poster hall during the session to engage poster presenters in quality discussions of their abstracts. **CME is not offered for poster sessions.**

Poster Discussants: Clemens Aigner, Austria, Cristiano Amarelli, Italy, Alejandro Bertolotti, Italy, Lin-Chiang P Chou, USA, Stephen Clark, UK, Hiroshi Date, Japan, Christian Heim, Germany, Ilker Iskender, Switzerland, Peter Ivak, Czech Republic, Mitsuaki Kawashima, Japan, Ahmet Kilic, USA, Ivan Knezevic, Slovenia, Virginia Linacre, Chile, Antonio Loforte, Italy, Lucian Lozonschi, USA, Archer Martin, USA, Aurelie Merlo, USA, Ezequiel Molina, USA, Nandan Mondal, USA, Basil Nasir, Canada, René Novyzedlák, Czech Republic, Minoru Ono, Japan, Alessandro Palleschi, Italy, Anthony Panos, USA, Matthias Peltz, USA, Salwa Rahman, USA, Danny Ramzy, USA, Yazhini Ravi, USA, Jun-Neng Roan, Taiwan, Sebastian Rojas, Germany, Fawwaz Shaw, USA, Akira Shimamoto, Japan, Cumara Sivathasan, Singapore, Ulrich Stock, UK, Benjamin Sun, USA, Zuzana Tucanova, Czech Republic, Roh Yanagida, USA, Ahmad Zeeshan, USA

(1213) Heart Transplant Outcomes in Higher Risk Recipients; Z. Rollins¹, G. Gardner¹, M. Ambrosio², I. Tchoukina³, K. Shah³, J. Chery⁴, V. Kasirajan⁴, Z. A. Hashmi⁴. ¹Department of Surgery, Virginia Commonwealth University, Richmond, VA, ²School of Medicine, Virginia Commonwealth University, Richmond, VA, ³Division of Cardiology, Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, ⁴Division of Cardiothoracic Surgery, Pauley Heart Center, Virginia Commonwealth University, Richmond, VA

(1214) Outcomes of Cardiopulmonary Resuscitated Donor Hearts in Cardiac Transplantation; Z. Rollins¹, G. Gardner¹, E. Bashian¹, M. Ambrosio², I. Tchoukina³, K. Shah³, J. Chery⁴, V. Kasirajan⁴, Z. Hashmi⁴. ¹Department of Surgery, Virginia Commonwealth University, Richmond, VA, ²School of Medicine, Virginia Commonwealth University, Richmond, VA, ³Division of Cardiology, Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, ⁴Division of Cardiothoracic Surgery, Pauley Heart Center, Virginia Commonwealth University, Richmond, VA

(1215) Impact of Initial Hematocrit Levels During Direct Procurement and Perfusion on the Likelihood of Primary Graft Dysfunction in Donation After Circulatory Death Heart Transplant Patients; E. Odekunle¹, A. Makarem², G. Olverson³, K. Drezek², E. Michel², D. D'Alessandro², A. Osho², S. Rabi². ¹Rutgers New Jersey Medical School, Newark, NJ, ²Cardiac Surgery Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³University of Rochester School of Medicine and Dentistry, Rochester, NY

(1216) Heart Transplantation Learning Curve at a High-Volume Center in Northeast Brazil; D. L. Ferraz¹, V. Monteiro², C. Cunha², F. Figueira², I. Silva², R. Carneiro², M. Oliveira Filha², A. Lapa², P. Xavier², M. Lira², B. Castro². ¹Cardiovascular Surgery, Instituto de Medicina Integral Professor Fernando Figueira, Recife, Brazil, ²Instituto de Medicina Integral Professor Fernando Figueira, Recife, Brazil

(1217) Surgeon Years of Experience and Survival After Heart Transplantation; A. F. Akbar¹, A. L. Zhou¹, J. M. Ruck², D. Paneitz², S. Rokui², B. L. Shou³, R. A. Riojas², A. Polanco², A. Kilic². ¹Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, ²Department of Surgery, Johns Hopkins Hospital, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD

(1218) Across Borders: Outcomes of Heart Transplant from Non-Mainland Donors; E. L. Larson¹, R. Jenkins¹, A. Zhou¹, D. Paneitz¹, A. Kilic². ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²The Johns Hopkins University, Baltimore, MD

(1219) Impact of Donor Center Volume on Heart Transplant Outcomes; E. L. Larson¹, R. Jenkins¹, A. Zhou¹, A. Rizaldi¹, D. Paneitz¹, A. Kilic². ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²The Johns Hopkins University, Baltimore, MD

(1220) Experiencing Life with a Heart Transplant: The Patients' Perspective; E. L. Larson, M. M. Shah, A. J. D'Amiano, J. Buchanan, M. Daskam, K. Y. Chen, K. Shagena, A. Kilic. Johns Hopkins Hospital, Baltimore, MD

(1221) Potential for Expanding the Donor Pool: Outcomes of Heart Transplantation Using Donors Over 50 Years of Age; T. Taguchi¹, D. Yoshioka¹, S. Fukushima², K. Tonai², N. Tadokoro², N. Kawamoto², S. Kainuma², Y. Yanagino¹, Y. Misumi¹, A. Kawamura¹, T. Kawamura¹, M. Kawamura¹, S. Saito¹, T. Watanabe³, Y. Tsukamoto³, S. Miyagawa¹. ¹Cardiovascular Surgery, Osaka University Hospital, Suita, Japan, ²Cardiac Surgery, National Cerebral and Cardiovascular Center, Suita, Japan, ³Transplant Medicine, National Cerebral and Cardiovascular Center, Suita, Japan

- (1222) Regional Variation and One-Year Outcomes of Heart Transplantation from Donation After Circulatory Death Donors in the United States;** K. Patel, M. Moroi, K. Rajesh, P. Kurlansky, Y. Zhao, A. Lin, F. Latif, G. Sayer, N. Uriel, Y. Naka, K. Takeda. *Columbia University Irving Medical Center, New York, NY*
- (1223) Heart Transplant and Education: Analyzing Educational Disparities in Cardiac Transplants Across US Regions;** T. Oliveira¹, R. Patel¹, A. Mahajan², M. Dean³, C. Lemoine⁴, C. Sai-Sudhakar⁴, Y. Ravi⁴, C. Zoni⁴. ¹University of Connecticut School of Medicine - UConn Health, Farmington, CT, ²University of Connecticut School of Medicine, Farmington, CT, ³Virginia Commonwealth University, Richmond, VA, ⁴University of Connecticut Health Center, Farmington, CT
- (1224) Global Longitudinal Strain Analysis on Ventricular Function, Evaluated Six Months to One Year Post Transplant, for Hearts Donated After Cardiac and Brain Death;** G. Olverson¹, D. Giao¹, A. Sonny², V. Mehta², L. Gibson², R. Singh¹, S. A. Brownlee¹, K. Drezek¹, R. Asija³, Z. Yunong¹, A. Makarem¹, C. C. Chukwudi¹, E. Michel¹, S. Rabi¹, D. D'Alessandro¹, A. Osho¹. ¹Division of Cardiac Surgery, Massachusetts General Hospital, Boston, MA, ²Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Boston, MA, ³Department of Surgery, Community Memorial Health Systems, Ventura, CA
- (1225) Renal Recovery in LVAD Recipients Requiring Renal Replacement Therapy: Preoperative Renal Failure is Better;** A. Cho¹, J. Perrier¹, A. Jones¹, M. Hoque¹, B. Hauser¹, S. Hoffman¹, A. Elangovan¹, A. Goodman¹, I. Gosev², K. Wood². ¹University of Rochester School of Medicine, Rochester, NY, ²Department of Surgery; Division of Cardiac Surgery, University of Rochester Medical Center, Rochester, NY
- (1226) Improved Post-Transplant Outcomes in Blood Group O Recipients Through Controlled Hypothermic Preservation;** M. Rodrigo¹, S. Silvestry², Y. Shudo³, J. Schroder⁴, A. Vidic⁵, K. Takeda⁶, D. Meyer⁷, D. D'Alessandro⁸. ¹Medstar Washington Hosp Ctr, Washington DC, ²AdventHealth Transplant Inst, Orlando, FL, ³Stanford Univ, Stanford, CA, ⁴Duke Univ MC, Durham, NC, ⁵Univ of Kansas Health System, Kansas City, KS, ⁶Columbia Univ, New York, NY, ⁷Baylor Scott and White Health, Baylor Univ MC, Dallas, TX, ⁸MGH, Boston, MA
- (1227) Outcomes of Surgical Tricuspid Valve Intervention After Heart Transplant;** O. Haddad¹, M. Alomari², M. Bitargil², S. Pham³, R. Daly⁴, K. Landolfo², P. Garg², M. El-Sayed Ahmed², P. Patel³, B. Sareyyupoglu². ¹NorthShore University Hospital, Manhasset, NY, ²Mayo Clinic, Jacksonville, FL, ³Mayo Clinic Florida, Jacksonville, FL, ⁴Mayo Clinic, Rochester, MN
- (1228) A Center's 12 Year Experience in Heart Transplant with Patients Who Decline Blood Transfusion;** E. Gonzales¹, K. Moore¹, M. Wilson¹, D. Bassette¹, V. Hwang¹, S. Jain¹, V. Jeevanandam². ¹The University of Chicago, Chicago, IL, ²University of Chicago Medical Center, Chicago, IL
- (1229) Pulmonary Arterial Pulsatility Index Predicts Mechanical Circulatory Support Following Heart Transplantation;** I. Yim¹, S. Pettit², S. Bhagra³, M. Berman⁴, N. Drury⁵, S. Lim⁶. ¹Transplant Unit, Royal Papworth Hospital, Cambridge, UK, ²Royal Papworth Hospital, Cambridge, UK, ³Royal Papworth Hospital NHS Foundation Trust, Cambridge, UK, ⁴Papworth Hospital, Cambridge, UK, ⁵Queen Elizabeth Hospital, University Hospitals Birmingham, Birmingham, UK, ⁶University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
- (1230) Older Donor Hearts for Heart Transplantation;** P. D. Cho¹, S. T. Kim², D. Cruz³, L. A. Saddic III², A. Ardehali². ¹Drexel College of Medicine, Philadelphia, PA, ²UCLA School of Medicine, Los Angeles, CA, ³UCLA Medical Center, Los Angeles, CA
- (1231) Donor Hearts with Low EF for Heart Transplantation;** P. D. Cho¹, S. T. Kim², J. Ho³, A. Nsair⁴, A. Ardehali². ¹Drexel College of Medicine, Philadelphia, PA, ²UCLA SoM, Los Angeles, CA, ³UCLA, Los Angeles, CA, ⁴UCLA Ronald Regan Medical Center, Los Angeles, CA
- (1232) Characterizing the Impact of Donor Sequence Number on Outcomes Following Heart Transplantation;** S. T. Kim¹, P. Cho², D. Vucicevic³, A. Ardehali⁴. ¹David Geffen School of Medicine, UCLA, Los Angeles, CA, ²Drexel College of Medicine, Philadelphia, PA, ³UCLA, Los Angeles, CA, ⁴UCLA School of Medicine, Los Angeles, CA
- (1233) Cutting to the Bone: Impact of Redo Sternotomy on Outcome of Adult Heart Transplant;** J. D. Hoang¹, E. J. Henricksen¹, A. Varshney², M. Sanchez¹, C. Chen¹, F. Castillo¹, T. Koyano³, J. Teuteberg², K. Khush², H. Luikart⁴, A. Subramanian², Y. Moayed⁵, R. Tayyar¹, Y. Shudo². ¹Stanford Health, Stanford, CA, ²Stanford Univ, Stanford, CA, ³Stanford Med, Stanford, CA, ⁴Stanford Hosp, Stanford, CA, ⁵UHN, Toronto, Canada
- (1234) Does Early Recovery of Kidney Function Post-Heart Transplantation Impact Long-Term Survival?;** B. Barodi¹, L. Kugathasan², C. Fan², S. Saha², T. Buchan³, D. Horne⁴, A. Alba³, V. Rao⁵. ¹Cardiac Surgery, Toronto General Hospital, Toronto, ON, Canada, ²University Health Network, Toronto, ON, Canada, ³Toronto General Hospital, Toronto, ON, Canada, ⁴Cardiac Surgery, Dalhousie University, Halifax, NS, Canada, ⁵Toronto General Hospital, Toronto, ON, Canada
- (1235) Patient Outcomes Following Emergency Ventricular Assist Device Implantation During High-Urgency Waiting Period for Heart Transplantation;** L. Roehrich¹, I. Just¹, P. Lanmueller¹, F. Kaufmann¹, J. Stein¹, L. Kopp Fernandes¹, C. Knosalla¹, F. Hennig¹, E. Potapov¹, S. Ott², J. Knierim³, B. O'Brien², V. Falk¹, F. Schoenrath¹. ¹Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charité, Berlin, Germany, ²Department of Cardiac Anesthesiology and Intensive Care Medicine, Deutsches Herzzentrum der Charité, Berlin, Germany, ³Paulinenkrankenhaus, Berlin, Germany

(1236) A High Pulmonary-to-Systemic Arterial Elastance Ratio is a Powerful Predictor of Poor Outcomes After Heart Transplantation: A Clinical Study with Physiological Insights from Digital Twin Models; G. Rajagopalan¹, K. Balakrishnan², K. Suresh Rao², R. Ravi Kumar², R. Krishna Kumar¹. ¹Indian Institute of Technology Madras, Chennai, India, ²MGM Healthcare, Chennai, India

(1237) Heart Transplantation in Older Recipients: Single-Center Long-Term Outcomes and Risk Analysis; N. Pradegan¹, G. Guerra¹, C. Tessari¹, A. Gambino¹, A. D'Onofrio¹, V. Tarzia², G. Toscano¹, A. Angelini³, G. GEROSA¹. ¹University of Padova, Padova, Italy, ²University of Padova, Italy, ³University of Padua, Padova, Italy

(1238) Preoperative Amiodarone Use Does Not Affect Pacemaker Implantation After Heart Transplantation; A. E. Vels¹, L. C. Kieviet², M. K. Szymanski², M. G. van der Meer², N. P. van der Kaaij¹, L. W. Van Laake², A. E. Tuinenburg², K. A. Jacob¹, E. E. van Aarnhem¹, M. I. Oerlemans². ¹Cardiothoracic Surgery, UMC Utrecht, Utrecht, Netherlands, ²Cardiology, UMC Utrecht, Utrecht, Netherlands

(1239) Causal Nonlinear Dose Response Analysis of Predicted Heart Mass Mismatching; R. Dale¹, M. Leipzig¹, N. Bahatyrevich², M. Currie¹. ¹Department of Cardiothoracic Surgery, Stanford University, Stanford, CA, ²Divisions of Cardiac and Thoracic Surgery, UC Davis Health, Davis, CA

(1240) Donor-Recipient Sex-Mismatching in Isolated Heart Transplant Confers No Postoperative Risk as Established by Equivalence Testing and Causal Estimation; R. Dale¹, M. Leipzig¹, N. Bahatyrevich², K. Pines¹, Q. Chen³, J. Teuteberg⁴, J. Woo⁴, M. Currie¹. ¹Department of Cardiothoracic Surgery, Stanford University, Stanford, CA, ²Divisions of Cardiac and Thoracic Surgery, UC Davis Health, Davis, CA, ³Cedars Sinai Medical Center, Los Angeles, CA, ⁴Stanford University School of Medicine, Stanford, CA

(1241) Determinants of Poor Survival After Heart Transplant in Patients with Renal Dysfunction. A Clinical Study with Physiological Insights from a Mathematical Model; K. Balakrishnan¹, G. Rajagopalan², R. Krishna Kumar², K. Suresh Rao¹, R. Ravi kumar¹. ¹MGM Healthcare, Chennai, India, ²Indian Institute of Technology Madras, Chennai, India

(1242) Donor-Recipient Characteristics in Cardiac Transplantation: Does Donor CPR Affect Longitudinal Survival?; Y. Stukov¹, M. Purlee¹, G. Peek², M. Bleiweis³, J. Jacobs⁴. ¹Congenital Heart Center, Division of Cardiovascular Surgery, Department of Surgery, University of Florida, Gainesville, FL, ²Congenital Heart Center, Division of Cardiovascular Surgery, Department of Surgery, University of Florida, Gainesville, FL, ³UF Health Congenital Heart Center, Gainesville, FL, ⁴Congenital Heart Center, Departments of Surgery and Pediatrics, University of Florida, Gainesville, FL

(1243) How is Recipient Survival Following Heart Transplantation Impacted by Donor Cancer History? ; C. Lemoine¹, C. R. Zoni², M. Dean³, J. Silverman³, B. Whitson⁴, Y. Ravi⁵, C. Sai-Sudhakar³. ¹General Surgery, University of Connecticut Health, Farmington, CT, ²Cardiothoracic Surgery, University of Connecticut Health, Farmington, CT, ³University of Connecticut Health, Farmington, CT, ⁴Ohio State University, Columbus, OH, ⁵University of Connecticut Health Center, Farmington, CT

(1244) Are Regional Variations of Heart Transplant Survival Related to Differences in Obesity?; C. Lemoine¹, L. Copeland², C. R. Zoni¹, M. Dean¹, J. Silverman³, B. Whitson⁴, Y. Ravi⁵, C. Sai-Sudhakar¹. ¹University of Connecticut Health, Farmington, CT, ²University of Massachusetts Chan Medical School, Worcester, MA, ³University of Connecticut School of Medicine, Farmington, CT, ⁴Ohio State University, Columbus, OH, ⁵University of Connecticut Health Centre, Farmington, CT

(1245) Effectiveness of Early Tele-Rehabilitation Program in Heart Transplant Recipients; C. Tessari¹, M. Vecchiato², A. Gasperetti², A. Bortolato², F. Francini Pesenti², S. Vigili de Kreutzberg², C. Cavalli², N. Pradegan¹, G. Toscano², G. Gerosa³. ¹University of Padova, Padova, Italy, ²University Hospital of Padova, Padova, Italy, ³Az. Osp. Padova Az. Osp. Padova, Padova, Italy

(1246) Outcomes of Pediatric Patients Transferred for Berlin Heart Excor Implantation; T. Kido¹, M. Taira², T. Watanabe¹, J. Narita³, H. Ishida⁴, R. Ishii³, T. Ueno⁵, S. Miyagawa¹. ¹Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Osaka, Japan, ²Osaka University Osaka University Hospital, Osaka, Japan, ³Osaka University Graduate School of Medicine, Osaka, Japan, ⁴Osaka University Graduate School of Medicine, Os, Japan, ⁵Osaka University Cardiovascular Surgery, Osaka, Japan

(1247) A Single Institutional Experience of Heart Transplantation in Children with Functional Single Ventricle; J. Moon¹, A. Naeem¹, T. Lancaster¹, M. Si², V. Sood¹. ¹University of Michigan, Ann Arbor, MI, ²University of California Los Angeles, Los Angeles, CA

(1248) Has Long-Term Survival in Pediatric Heart Transplantation Changed over Time?; A. Mehdizadeh-Shrifi¹, K. Kulshrestha¹, H. Ahmed¹, A. Ramineni¹, C. Chin², S. Hogue¹, S. Stark³, A. Ashfaq¹, D. Morales¹. ¹Division of Cardiothoracic Surgery, The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Department of Pediatrics, The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

(1249) Adaptive Growth of Heart Valves in Pediatric Orthotopic Heart Transplants; C. Medina, B. Aykut, H. Foote, D. Overbey, J. Turek. Duke University Medical Center, Durham, NC

(1250) Contemporary US Trends in Discharge Medication Regimens After Pediatric Heart Transplant; K. Kulshrestha, A. Mehdizadeh-Shrifi, S. Hogue, C. Chin, T. Ryan, D. G. Lehenbauer, D. L. Morales. *Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH*

(1251) Incidence and Predictors of Primary Graft Dysfunction After Cardiac Transplantation; I. Lepore Lagerberg¹, J. Oras², A. Pivodic³, G. Dellgren⁴. ¹Cardiothoracic Surgery and Transplant Institute, University of Gothenburg, Gothenburg, Sweden, ²Anesthesia and Intensive Care, Sahlgrenska University Hospital, Gothenburg, Sweden, ³Ophthalmology, Sahlgrenska Univ Hospital, Gothenburg, Sweden, ⁴Cardiothoracic Surgery and Transplant Institute, Sahlgrenska University Hospital, Göteborg, Sweden

(1252) Infusion of Del Nido Cardioplegia Prior to Donor Heart Implantation Minimizes Severe Primary Graft Dysfunction After Heart Transplantation; A. Ali¹, A. Jaiswal², A. Conelius³, M. Figorito³, A. Giacco³, K. Cirillo³, M. Vilas Novas¹, J. Gluck², A. Feingold², J. Radojevic², J. Hammond¹. ¹Cardiac Surgery, Hartford Hospital, Hartford, CT, ²Cardiology, Hartford Hospital, Hartford, CT, ³Perfusion, Hartford Hospital, Hartford, CT

(1253) Cold Static Storage Combined with Intraoperative Cardioplegia Protection Strategy Yields Low Primary Graft Dysfunction; M. Dorsey, L. James, S. Chen, M. Allison, S. Shrivastava, N. Roa-Vidal, N. Moazami, D. Smith. *NYU Langone Health, New York, NY*

(1254) Characterization of Post-Transplant Clinical Outcomes in Patients with Elevated AT1R Antibodies Bridged to Heart Transplantation with Ventricular Assist Device; I. K. Eng¹, J. S. Kim¹, M. H. Kwon², E. C. DePasquale³, M. C. Deng⁴, E. F. Reed⁵, M. J. Hickey⁵. ¹David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, ²Division of Cardiothoracic Surgery, University of California, Los Angeles, Los Angeles, CA, ³Division of Cardiology, University of Southern California, Los Angeles, CA, ⁴Division of Cardiology, University of California, Los Angeles, Los Angeles, CA, ⁵Department of Pathology and Laboratory Medicine, UCLA Immunogenetics Center, University of California, Los Angeles, Los Angeles, CA

(1255) Could be Model for End-Stage Liver Dysfunction Score Useful in Predicting Positive Outcome Following ECMO Implant to Treat Early Graft Dysfunction Following Heart Transplant ?; P. Totaro¹, F. Amoroso¹, L. Cavallotti¹, E. Kushta¹, B. Cattadori¹, M. Aiello¹, C. Pellegrini², S. Pelenghi¹. ¹Cardiac Surgery, IRCCS Foundation Hospital San Matteo, Pavia, Italy, ²IRCCS Foundation Hospital San Matteo - University of Pavia, Pavia, Italy

(1256) A Case with Cobalamin-C-Deficiency and Severe Heart Failure Resolved by LVAD Implantation and Subsequent Heart Transplantation; C. Hjalmarsson¹, C. Backelin¹, N. Bergh¹, A. Thoren², J. L. Sloane³, I. Manoli³, C. Venditti³, G. Dellgren⁴. ¹Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden, ²Anaesthesiology and Intensive Care Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden, ³National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ⁴Cardiothoracic Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden

(1257) Supporting a Pediatric Jehovah's Witness Patient on a Ventricular Assist Device to Transplantation; M. Brickler, S. Kindel, M. Mitchell, A. Raskin. *Children's Wisconsin, Milwaukee, WI*

(1258) Successful Transplantation of Long-Distance Hearts Using Ex-Vivo Preservation System in the Pediatric Population: An Early Case Series; P. S. Choi¹, C. Ruaengsri¹, T. Nasirov¹, J. C. Dykes², S. A. Hollander², D. N. Rosenthal², E. Martin¹, M. R. Ma¹. ¹Cardiothoracic Surgery, Stanford University, Lucile Packard Children's Hospital, Palo Alto, CA, ²Pediatrics (Cardiology), Stanford University, Lucile Packard Children's Hospital, Palo Alto, CA

(1259) Salvage Surgery for Recurrent Main Pulmonary Artery Sarcoma; B. Battilana¹, H. Etienne¹, M. Brown², I. Tudorache³, M. Schmiady³, I. Opitz⁴. ¹Department of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland, ²Department of Oncology, University Hospital Zurich, Zurich, Switzerland, ³Department of Cardiac Surgery, University Hospital Zurich, Zurich, Switzerland, ⁴Department of Thoracic Surgery, Universitätsspital Zürich, Zurich, Switzerland

(1260) Management of HIT Prior to Heart Transplant on Temporary MCS; C. Lannon¹, A. Guha¹, A. Bhimaraj¹, C. M. Martin¹, A. He¹, E. E. Suarez¹, L. Chou². ¹DeBakey Heart & Vascular Center, Houston Methodist Hospital, Houston, TX, ²University of California Davis Medical Center, Sacramento, CA

(1261) Ecpella Bridge to Heart Transplantation for a Large Ischemic Ventricular Septal Defect and Refractory Ventricular Arrhythmias; R. Fajardo¹, T. Guenther¹, A. Baber¹, J. Dollerschell¹, J. Hermsen¹, Y. Xia². ¹University of Wisconsin, Madison, WI, ²University of Wisconsin, Madison, WI

(1262) Successful Lung Transplantation from a 94-Years-Old Donor Questions the Discussion on Calendar versus Biological Age; J. Van Slambrouck¹, A. Provoost¹, B. Schockaert², A. Barbarossa¹, C. Van Der Stukken³, C. Vanluyten¹, T. Nawrot³, D. Van Raemdonck¹, B. Vanaudenaerde⁴, R. Vos¹, L. J. Ceulemans¹. ¹University Hospitals Leuven, Leuven, Belgium, ²AZ Delta, Roeselare, Belgium, ³UHasselt, Hasselt, Belgium, ⁴KU Leuven, Leuven, Belgium

- (1263) **Backtable Pulmonary Thromboendarterectomy (PTE) on Donor Lungs with Recent Massive Pulmonary Emboli and Chronic Thromboembolic Disease Prior to Transplantation;** A. M. Williams, R. Khosravi, S. Voigt, J. Haney. *Cardiothoracic Surgery, Duke University, Durham, NC*
- (1264) **Lung Transplantation in a Recipient with True Tracheal Bronchus;** T. Salem¹, W. Saleh², K. Alkattan³, M. Migliore¹, M. Y. Hashim¹. ¹King Faisal specialist Hospital & Research center, Riyadh, Saudi Arabia, ²King Faisal Spec. Hosp, Riyadh, Saudi Arabia, ³Alfaisal University KFSH, Riyadh, Saudi Arabia
- (1265) **Surgical Strategy on Lung Transplantation for Kartagener's Syndrome;** N. Date, D. Nakajima, M. Takahashi, S. Tanaka, Y. Yutaka, A. Ohsumi, H. Date. *Department of Thoracic Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan*
- (1266) **Bilateral Lung Transplantation for Pulmonary Emphysema Associated with Cutis Laxa;** A. Matsumoto, A. Ohsumi, H. Date. *Thoracic Surgery, Kyoto University Hospital, Kyoto, Japan*
- (1267) **Right Single Lung Transplantation After Left Pneumonectomy;** C. Girard¹, A. Mehta¹, K. McCurry², S. Alparslan³. ¹Cleveland Clinic Foundation, Cleveland, OH, ²Cleveland Clinic, Cleveland, OH, ³Baskent University, Ankara, Turkey
- (1268) **Malakoplakia Mimicking Endobronchial Tumor After Lung Transplantation;** J. Blasioli Costa¹, A. Mah², G. Bizjak¹, J. Choi¹, A. McGuire¹, J. Yee¹, T. Brar³, C. Bergeron⁴, R. Nador⁴, R. Levy⁴. ¹Thoracic Surgery, Vancouver General Hospital, Vancouver, BC, Canada, ²Infectious Disease, Vancouver General Hospital, Vancouver, BC, Canada, ³Pharmacy, Vancouver General Hospital, Vancouver, BC, Canada, ⁴Lung Transplant Respiriology, Vancouver General Hospital, Vancouver, BC, Canada
- (1269) **Successful Bilateral Lung Transplantation for a Patient with Severe Post-COVID-19 Fibrosis and a History of Multiple Thoracic Procedures;** H. Kim¹, B. Park¹, Y. Yang¹, A. Woo², M. Park², J. Lee¹. ¹Department of Thoracic and Cardiovascular Surgery, Yonsei University, College of Medicine, Seoul, South Korea, ²Division of Pulmonology, Department of Internal Medicine, Yonsei University, College of Medicine, Seoul, South Korea
- (1270) **Evidence of Chronic Thromboembolic Disease During Ex Vivo Lung Perfusion of DBD Donor Lungs;** P. M. Boehm¹, S. Auner¹, C. Atteneder², N. Fruhmant¹, C. Aigner¹, S. Taghavi¹, K. Hoetzenecker¹, A. Benazzo¹, S. Schwarz¹. ¹Department of Thoracic Surgery, Medical University of Vienna, Vienna, Austria, ²Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria
- (1271) **Bilateral Lung Transplantation Combining Pulmonary Artery Reconstruction for Giant Pulmonary Artery Aneurysm with Severe Pulmonary Artery Hypertension;** P. Chou, W. Chen. *Division of Thoracic Surgery, Chang Gung Memorial Hospital, Taoyuan, Taiwan*
- (1272) **EVLP and Inflammatory Cascade Control for Lung Transplantation in a Buried Donor;** T. Papisotiroopoulos, L. Hoyos Mejia, L. György, I. Opitz. *University Hospital of Zurich, Zurich, Switzerland*
- (1273) **Paraesophageal Hernia Repair in a Lung Transplant Recipient: Is It Safe?;** M. Shacker¹, L. Schaheen², J. Padiyar³. ¹Creighton University School of Medicine, Phoenix, AZ, ²Norton Thoracic Institute - St. Joseph's Hospital, Phoenix, AZ, ³Dignity Health Norton Thoracic Inst, Phoenix, AZ
- (1274) **Lung Transplant in Pulmonary Alveolar Microlithiasis 2 Cases of Successful Treatment;** F. Pola¹, S. Lucas Santos², M. Razuk Filho², L. Gustavo Abdall², P. Oliveira Melo², L. Matos Fernandes², S. Vidal Campos², P. Pego-Fernandes². ¹Lung Transplant Group, Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina da USP, Sao Paulo, Brazil, ²Lung Transplant Group, Instituto do Coracao, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil
- (1275) **Life-Threatening Asthma Attacks After Lung Transplantation from an Asthmatic Donor;** J. Park, S. Park, T. Yun, B. Na, K. Na, H. Lee, I. Park, C. Kang, Y. Kim. *Seoul National University Hospital, Seoul, South Korea*
- (1276) **Combined Heart and Lung Transplantation Across Preformed Donor-Specific Antibodies Using a Peritransplant Desensitization Protocol;** P. Wand¹, S. Kruszona¹, M. Avsar¹, D. de Manna¹, K. Aburahma¹, M. Franz¹, M. Greer², A. Weymann¹, A. Ruhparwar¹, A. Niehaus¹, J. Salman¹, C. Falk³, F. Ius¹. ¹Hannover Medical School, Clinic for Cardiothoracic, Vascular, and Transplantation Surgery, Hannover, Germany, ²Hannover Medical School, Department of Respiratory Medicine, Hannover, Germany, ³Hannover Medical School, Institute of Transplant Immunology, Hannover, Germany
- (1277) **Successful Multi-Organ Transplant in Highly Sensitized Patients with Positive Crossmatch Donor;** B. Thomae¹, T. Kaiho¹, A. Bharat¹, D. Christopher², S. Nadig², C. Kurihara¹. ¹Division of Thoracic Surgery, Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Division of Transplant, Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL
- (1278) **Isolated Right Heart Stress-Induced Cardiomyopathy After Lung Transplant;** B. Thomae, T. Kaiho, A. Bharat, C. Kurihara. *Division of Thoracic Surgery, Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL*

(1279) Post-Transplant Lung Herniation and Infarction After Clamshell Thoracotomy; J. Tavandzis¹, R. Novyzedlák¹, F. Mošna², Z. Ozaniak Střížová³, V. Suchánek⁴, J. Simonek¹, J. Vachtenheim¹, M. Svorcova¹, J. Pozniak¹, J. Kolarik¹, J. Havlin¹, R. Lischke¹. ¹Prague Lung Transplant Program, 3rd Department of Surgery, First Faculty of Medicine, Charles Univ and Univ Hospital Motol, Prague, Czech Republic, Prague, Czech Republic, ²Department of Anaesthesiology, Resuscitation and Intensive Care Medicine, 2nd Medical Faculty, Charles Univ and Univ Hospital Motol, Prague, Czech Republic, ³Department of Immunology, 2nd Faculty of Medicine, Charles Univ and Motol Univ Hospital, Prague, Czech Republic, ⁴Department of Imaging Methods, 2nd Faculty of Medicine, Charles Univ and Motol Univ Hospital, Prague, Czech Republic

(1280) Hyperbaric Oxygen Therapy as an Adjunct to Wound Healing in Anastomotic Dehiscence After Lung Transplant; T. S. Kaleekal¹, J. N. Coster², R. S. Goetz¹, D. S. Scullin¹, V. S. Rusanov¹, K. S. Wille¹, E. S. Orozco Hernandez³, E. S. Gongora³, C. S. Hoopes³. ¹Division of Pulmonary, Critical Care and Allergy Medicine, University of Alabama at Birmingham, Birmingham, AL, ²Cardiothoracic Surgery, UPMC, Pittsburgh, PA, ³Department of Cardiothoracic Surgery, University of Alabama at Birmingham, Birmingham, AL

(1281) In the Current Era, is Pre-Operative Colonoscopy Screening for INTERMACS 1 and 2 Destination Therapy LVAD Warranted?; R. E. Du¹, M. Giraldo Grueso¹, S. Desai², S. Krim¹, J. Bansal¹, K. Webre¹, P. Parrino¹, M. Krista¹, A. Bansal¹. ¹Ochsner Clinic Foundation, New Orleans, LA, ²Ochsner, New Orleans, LA

(1282) Long Term Functional Outcomes in Patients with Covid-19 Requiring Extracorporeal Membranous Oxygenation Support; J. Eisenga¹, K. McCullough², G. Moubarak³, E. Shih⁴, R. Vaishnav⁵, J. Sheasby⁶, D. Myers⁴, O. Awad⁴, J. DiMaio⁴, T. George⁴. ¹Baylor University Medical Center, Dallas, TX, ²Baylor Scott & White Research Institute, Plano, TX, ³Baylor The Heart Hospital, Plano, TX, ⁴Baylor Scott and White The Heart Hospital Plano, Plano, TX, ⁵Baylor Scott and White Research Institute, Plano, TX, ⁶Baylor Scott & White The Heart Hospital - Plano, Plano, TX

(1283) The Impact of Early Readmission on Patient Functional Status Following Left Ventricular Assist Device Implantation; J. Eisenga¹, K. McCullough², J. DiMaio¹, G. Moubarak¹, M. Kashyap³, G. Milligan⁴, N. Kabra¹, A. Rusia¹, A. Afzal⁵, D. Rawitscher¹, T. George¹. ¹Baylor Scott and White The Heart Hospital Plano, Plano, TX, ²Baylor Scott & White Research Institute, Plano, TX, ³Baylor Scott and White Research Institute, Plano, TX, ⁴Baylor University Medical Center, Dallas, TX, ⁵Baylor Scott and White The Heart Hospital Plano, Dallas, TX

(1284) Durable versus Temporary Left-Ventricular Assist Devices versus Extracorporeal Membrane Oxygenation for Bridging to Orthotopic Heart Transplantation: A Meta-Analysis; L. Saemann¹, S. Maier², M. Kohl³, A. Simm¹, G. Szabó¹. ¹Department of Cardiac Surgery, University Hospital Halle, Halle (Saale), Germany, ²Department of Cardiac Surgery, University Hospital Freiburg, Freiburg im Breisgau, Germany, ³Faculty Medical and Life Sciences, Furtwangen University of Applied Sciences, Villingen-Schwenningen, Germany

(1285) Verticalization Therapy: Safety and Efficacy in the Cardiac Surgery ICU; J. Cornett¹, A. Chan², H. Aronow³, S. Hsu¹, D. Dayrit⁴, J. Pamu⁵, J. Chavez¹, M. Nurok¹, D. Emerson¹, J. Chikwe¹, D. Megna¹, P. Catarino¹, T. Gunn¹, B. Coleman⁶. ¹6SCCT: Cardiac-Surgical ICU, Cedars-Sinai Medical Center, Los Angeles, CA, ²6SCCT: Cardiac-Surgical ICU, Cedars Sinai Medical Center, Los Angeles, CA, ³Nursing Research Department, Cedars-Sinai Medical Center, Los Angeles, CA, ⁴Cedars-Sinai Medical Center, Los Angeles, CA, ⁵Diet & Nutrition Department, Cedars Sinai Medical Center, Los Angeles, CA, ⁶Nursing Research Department, Cedars Sinai Medical Center, Los Angeles, CA

(1286) First Case of a Failing Right Ventricle in a Patient with CCTGA Treated with Transvasal Microaxial Flow Pump; B. Fathallah, M. Medina, G. D. Duerr, A. L. Emrich, H. Treede, M. Oezkur. Department of Cardiac and Vascular Surgery, University Medical Center of the Johannes Gutenberg University, Mainz, Germany

(1287) Application of Transvasal Microaxial Flow Pump for Surgical Aortic Valve Replacement in Patient with Severely Reduced Ejection Fraction; B. Fathallah, M. Medina, H. Treede, M. Oezkur. Department of Cardiac and Vascular Surgery, University Medical Center of the Johannes Gutenberg University, Mainz, Germany

(1288) Ascending Aorta Smoke Masquerading as Massive Thrombus in a Patient Bridged from Venous Arterial ECMO to Heart Transplantation; A. Kumar¹, E. Flattery², J. Thankachen², T. P. Jan¹, A. Reyentovich², B. Kadosh², D. Smith¹, N. Moazami³. ¹Cardiothoracic Surgery, NYU Langone Health, New York, NY, ²Cardiology, NYU Langone Health, New York City, NY, ³Cardiothoracic Surgery, NYU Langone Health, New York City, NY

(1289) Acclimation of Right Ventricular Function After Durable Left Ventricular Assist Device Support; S. Burki¹, A. Hadi², C. Link², C. Alpert², M. Lander², H. Kassir², M. Kanwar², C. Lee². ¹Cardiothoracic Surgery, Allegheny Health Network, Pittsburgh, PA, ²Allegheny Health Network, Pittsburgh, PA

(1290) Pump Supporting a Pump- Trials and Tribulations!; A. Bhardwaj¹, M. Patel², I. Salas-De-Armas³, H. Devineni⁴, S. Kumar⁵, S. Nathan⁶, B. Kar⁷, I. Gregoric⁸. ¹Advanced Heart Failure & Transplant, University of Texas/McGovern Medical School, Houston, Texas, Houston, TX, ²ACTAT, University of Texas Health Science Center at Houston, Houston, TX, ³ACTAT, Center for Advanced Heart Failure, Houston, TX, ⁴Advanced Heart Failure & Transplant, UT Houston-Memorial Hermann, Houston, TX, ⁵ACTAT, University of Texas Health Science Center, Houston, TX, ⁶Advanced Heart Failure & Transplant, University of Houston Health Science Center- Advanced Heart Failure, Houston, TX, ⁷ACTAT, University of Texas Health Science Center at Houston, Houston, TX, ⁸ACTAT, Univ of Texas, Houston, TX

- (1291) Complex Management of a Young Cardiomyopathy Patient Leading to Durable LVAD;** Y. Tan¹, T. Malik¹, N. Hendren², E. Hardin², S. Teotia³, S. Reznik¹, M. Farr², M. Peltz¹. ¹Cardiovascular and Thoracic Surgery, University of Texas Southwestern, Dallas, TX, ²Cardiology, University of Texas Southwestern, Dallas, TX, ³Plastic Surgery, University of Texas Southwestern, Dallas, TX
- (1292) Successful Management of Mycotic Visceral Aneurysms in a LVAD Patient: Navigating Postoperative Challenges;** K. Wermine, S. Gohar, R. Milhoan, B. Youree, V. Ramarathnam, M. Alqaim. Baylor Scott and White Health, Fort Worth, TX
- (1293) Omental Wrapping for Refractory Driveline Infection After HeartMate 3 Implantation;** A. V. Vinogradsky¹, M. A. Hynds¹, Y. Kaku¹, T. Arnell¹, A. Powers¹, M. Yuzefpolskaya², P. Colombo¹, G. Sayer¹, N. Uriel¹, Y. Naka¹, K. Takeda¹. ¹Columbia University Irving Medical Center, New York, NY, ²Columbia University Medical Center, New York, NY
- (1294) Left Ventricular Assist Device as a Bridge to Recovery in an Infant with Anomalous Left Coronary Artery from the Pulmonary Artery;** M. Hanuna¹, C. Müller¹, L. Rosenthal², F. Kari², N. Haas³, C. Hagl¹, J. Hörer², S. Michel². ¹Department of Cardiac Surgery, LMU University Hospital, Munich, Germany, ²Division of Congenital and Pediatric Heart Surgery, Department of Cardiac Surgery, LMU University Hospital, Munich, Germany, ³Department of Pediatric Cardiology and Intensive Care, LMU University Hospital, Munich, Germany
- (1295) Minimally Invasive Relief of Severe HeartMate 3 Outflow Graft Obstruction via Subxiphoid Approach;** R. J. Pepe¹, F. K. Soliman², J. Cai³, J. Grewal³, K. Dulnuan³, M. Huang³, D. Iyer³, M. Takebe¹, A. Lemaire¹, H. Ikegami¹, M. Russo¹, L. Y. Lee¹, G. Sunagawa¹. ¹Department of Surgery, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ²Department of Surgery, Columbia University Irving Medical Center, New York, NY, ³Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ
- (1296) 133-Day Mechanical Circulatory Support with Impella 5.5 as Bridge to Transplant;** R. J. Pepe¹, F. K. Soliman², J. Grewal¹, K. Dulnuan¹, M. Huang¹, D. Iyer¹, M. Takebe¹, A. Lemaire¹, H. Ikegami¹, M. Russo¹, L. Y. Lee¹, G. Sunagawa¹. ¹Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ²Columbia University Irving Medical Center, New York, NY
- (1297) Dilemma at Low-Volume Heart Transplant Center Provides the Potential for Extended Impella 5.5 Use as a Bridge to Heart Transplant;** R. J. Pepe¹, F. K. Soliman², J. Grewal¹, K. Dulnuan¹, M. Huang¹, D. Iyer¹, M. Takebe¹, A. Lemaire¹, H. Ikegami¹, M. Russo¹, L. Y. Lee¹, G. Sunagawa¹. ¹Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ²Columbia University Irving Medical Center, New York, NY
- (1298) Does Preemptive Impella 5.5 Insertion Reduce Operative Risk in High-Risk Cardiac Surgery?;** C. Echih¹, A. Ryan¹, A. Cherian¹, Y. Rohilla², K. Wang³, M. Hamidi³, T. Kazui³. ¹College of Medicine, University of Arizona, Tucson, AZ, ²University of Arizona, Tucson, AZ, ³Banner University Medical Center, Tucson, AZ
- (1299) Heparin Free Zone: 100 Days of Impella 5.5 Support with Argatroban in a Patient with HIT;** J. S. Newman¹, V. Demekhin², G. L. Piper², S. Tohme¹, O. Haddad², Z. Kon², C. Saikus². ¹Cardiovascular and Thoracic Surgery, Northwell Health, Manhasset, NY, ²Northwell Health, Manhasset, NY
- (1300) Cytokine Storm Alleviated Using a Haemofilter in Venovenous Extracorporeal Membrane Oxygenation;** M. Elbayomi, K. Steger, C. Heim. Department of Cardiothoracic Surgery, University of Erlangen-Nurnberg, Erlangen, Germany

FRIDAY, 12 APRIL, 2024

4:30 - 5:30 p.m.

POSTER SESSION 3: Nursing and Allied Health (Non-CME)

Location: Poster Hall

Core Therapies: HEART, LUNG, MCS, PVD

Practice Areas: Nursing and Allied Health, Anesthesiology and Critical Care, Cardiology, Cardiothoracic Surgery, Infectious Diseases, Pathology, Pediatrics, Pharmacy, Pulmonology, Research and Immunology

Session Summary: Posters in this session include presentations on multiple topics where the Practice Areas of the research is focused in Nursing and Allied Health. Designated Poster Discussants will circulate through the poster hall during the session to engage poster presenters in quality discussions of their abstracts. **CME is not offered for poster sessions.**

Poster Discussants: Kelly Bryce, USA, Fabienne Dobbels, Belgium, Meg Fregoso, USA, Louise Fuller, Australia, Donna Hickling, Australia, Peter Hopkins, Australia, Rebecca Klingbeil, USA, Christiane Kugler, Germany, Michael Petty, USA, Axel Rahmel, Germany, Aditi Singhvi, India

(1301) Is Race Associated with Health-Related Quality of Life in Older Patients After Advanced Cardiac Surgical Therapies?;

J. Dixon-Evans¹, A. Andrei¹, T. Wu¹, K. Mazurek², S. Clay², K. Grady¹. ¹Northwestern Univ, Chicago, IL, ²Northern Illinois Univ, Dekalb, IL

(1302) Utilization of a Cardiac Trained Palliative Care Advance Practice Provider: Benefits to Care Delivery;

P. Swistowicz¹, K. Chickerillo², K. Meehan³, V. Jeevanandam³. ¹University of Chicago Medicine, Chicago, IL, ²University of Chicago, Chicago, IL, ³University of Chicago Medical Center, Chicago, IL

(1303) 1 Year Experience with Routine Abdominal-Pelvic CT Scan Screening in Patients Under Evaluation for Heart Transplantation;

M. Doucette, J. Duston, M. Wilson, C. Griskowitz, C. Prasad, F. Moreno, A. Minasian, G. Lewis. Massachusetts General Hospital, Boston, MA

(1304) Elevated dd-cfDNA Levels in a Post-Heart Transplant Patient with Pulmonary Embolism: A Case Study;

C. Janetzke¹, J. Pintens², N. Gaglianello³, E. Raichlin², D. Spruell⁴, K. Baxter³, J. Jackson³. ¹Froedtert Hospital, Wauwatosa, WI, ²Froedtert Hospital & Medical College of Wisconsin, Wauwatosa, WI, ³Medical College of Wisconsin, Wauwatosa, WI, ⁴Natera, Austin, TX

(1305) Fat-Soluble Vitamin Levels in Supplemented versus Non-Supplemented Individuals with Cystic Fibrosis Following Lung

Transplantation; B. Doyle¹, A. P. Madden¹, T. Ronnie¹, D. F. Dilling². ¹Loyola University Medical Center, Maywood, IL, ²Loyola University Chicago, Stritch School of Medicine, Maywood, IL

(1306) Genomic Research Alliance for Transplantation GRAFT: A Model to Access Patients and Promote NHLBI DIR Research;

R. Brower, S. Agbor-Enoh. National Institutes of Health, Bethesda, MD

(1307) Let Us Shock You! Multidisciplinary Team Approach to Cardiogenic Shock Improves Patient Outcomes and Reduces

Complications; J. Hajj¹, A. Kilic², B. Houston³, A. Carnicelli³, L. Witer², J. D. McMurray⁴, L. Bunting¹, K. Dodson¹, M. Summer⁵, J. Yourshaw⁶. ¹Medical University of South Carolina, Charleston, SC, ²Cardiothoracic Surgery, Medical University of South Carolina, Charleston, SC, ³Cardiology, Medical University of South Carolina, Charleston, SC, ⁴Critical Care Anesthesia, Medical University of South Carolina, Charleston, SC, ⁵Heart & Vascular Quality/Safety, Medical University of South Carolina, Charleston, SC, ⁶Cardiology, Med Univ of South Carolina, Charleston, SC

(1308) A Multidisciplinary Protocol for Anticoagulation Reversal in Left Ventricular Assist Device Patients Presenting with Intracranial

Hemorrhage; Y. Wu, S. Baudart, D. Wimer, S. Fanous, M. Hom, L. Klein. University of California San Francisco, San Francisco, CA

(1309) A Silver Lining in the VAD Sky: A Prospective Randomized Controlled Study of Driveline Dressing;

S. Baudart¹, L. Klein². ¹Mechanical Circulatory Support, AHF CCC, UCSF, San Francisco, CA, ²Advanced Heart Failure Comprehensive Care Center, University of California San Francisco, San Francisco, CA

(1310) Frailty Assessment in Prospective LVAD Candidates: An International Survey;

M. J. Clancy¹, S. Schroeder², Y. Wu³. ¹Occupational Therapy, Thomas Jefferson University, Philadelphia, PA, ²Mechanical Circulatory Support, Bryan Heart, Lincoln, NE, ³Mechanical Circulatory Support, UCSF, San Francisco, CA

(1311) Nutritional Risk Assessment and Adverse Events in Patients Undergoing Left Ventricular Assist Device Implantation - A Retrospective Cohort Study Using Hospital Information System;

I. Milaniak¹, L. Tomaszek¹, M. Kaleta², S. Wiśniowska-Śmiałek², I. Górkiewicz-Kot², G. Wasilewski², K. Wierzbicki². ¹Andrzej Frycz Modrzewski Krakow Univ Krakow, Poland, ²John Paul II Hosp, Krakow, Poland

(1312) VAD Remote Patient Monitoring (RPM): A Readmission Review; K. Meehan¹, J. H. Snider², J. Miller², A. Chincó³, V. Jeevanandam⁴.
¹University of Chicago Medical Center, Chicago, IL, ²ActiCare Health, Livermore, CA, ³University of Chicago Medicine, Chicago, IL, ⁴University of Chicago Medical Center

(1313) Examining Longitudinal Health-Related Quality of Life from the Quality of Life in Patients with Left Ventricular Assist Device Questionnaire; S. E. Schroeder¹, K. Sandau², C. Lee³. ¹Division of MCS, Bryan Heart, Lincoln, NE, ²University of Minnesota, Minneapolis, MN, ³Boston College, Boston, MA

(1314) Highs and Lows of Life with a Left Ventricular Assist Device: Multi-Dimensional Perspectives; S. E. Schroeder¹, K. Sandau², C. Lee³.
¹Bryan Heart, Lincoln, NE, ²University of Minnesota, Minneapolis, MN, ³Boston College, Boston, MA

(1315) International Survey: Ventricular Assist Device Program Staffing Structure and the Role of VAD Coordinator; Y. Wu¹, N. Richards², T. Robbins³, J. McLean⁴, S. Wright⁵, T. Schloeglhofer⁶. ¹University of California San Francisco Medical Center, San Francisco, CA, ²University of Kansas Health System, Kansas City, KS, ³Einstein Medical Center Philadelphia, Philadelphia, PA, ⁴Alfred Health, Melbourne, Australia, ⁵Medtronic, Minneapolis, MN, ⁶Medical University of Vienna, Vienna, Austria

(1316) ECMO Care Beyond Decannulation : A Nurse Driven Wound Care Protocol; A. Basic¹, E. Smith¹, S. Baudart², J. Holte³, J. Smith⁴.
¹Intensive Cardiac Care, UCSF, San Francisco, CA, ²MCS, Advanced Heart Failure Comprehensive Care Center, UCSF, San Francisco, CA, ³UCSF, San Francisco, CA, ⁴Cardiothoracic Surgery, University of California San Francisco, San Francisco, CA

FRIDAY, 12 APRIL, 2024

4:30 - 5:30 p.m.

POSTER SESSION 3: Pediatrics (Non-CME)

Location: Poster Hall

Core Therapies: HEART, LUNG, MCS, PVD

Practice Areas: Pediatrics, Anesthesiology and Critical Care, Cardiology, Cardiothoracic Surgery, Infectious Diseases, Nursing and Allied Health, Pathology, Pharmacy, Pulmonology, Research and Immunology

Session Summary: Posters in this session include presentations on multiple topics where the Practice Areas of the research is focused in Pediatrics. Designated Poster Discussants will circulate through the poster hall during the session to engage poster presenters in quality discussions of their abstracts. **CME is not offered for poster sessions.**

Poster Discussants: Shah Nawaz Amdani, USA, Estela Azeka, Brazil, Christian Benden, Switzerland, Matthew Bock, USA, Chesney Castleberry, USA, Jennifer Conway, Canada, Nhue Do, USA, Paul Estes, USA, Lakshmi Gokanapudy Hahn, USA, Jason Goldberg, USA, Jeffrey Gossett, USA, Dipankar Gupta, USA, Marta Hernández-Meneses, Spain, Steven Kindel, USA, Sonya Kirmani, USA, Ken Knecht, USA, Aine Lynch, Canada, Levent Midyat, USA, Michal Odermarsky, Sweden, David Peng, USA, Christina Phelps, USA, Sowmith Rangu, USA, Marc Schecter, USA, Janet Scheel, USA, Brigitte Willemse, Netherlands

(1317) Percutaneous Coronary Intervention in Pediatric Transplant Recipients- Delaying the Inevitable; M. S. Purlee¹, J. Coppola¹, D. Lopez-Colon¹, M. Bleiweis², J. Jacobs¹, G. Peek¹, F. Fricker³, B. Pietra⁴, H. Vyas¹, J. Fudge¹, D. Gupta⁵. ¹University of Florida, Gainesville, FL, ²UF Health Congenital Heart Center, Gainesville, FL, ³Congenital Hrt Ctr @ UF Hlth, Gainesville, FL, ⁴University of Florida Congenital Heart Center, Gainesville, FL, ⁵UF College of Medicine, Gainesville, FL

(1318) Pulse Wave Velocity in Pediatric Heart Transplant Recipients- A Marker of Vascular Health; J. Coppola¹, H. Vyas¹, M. Killian², D. Lopez-Colon¹, D. Gupta³. ¹University of Florida, Gainesville, FL, ²Florida State Univ, Tallahassee, FL, ³UF College of Medicine, Gainesville, FL

(1319) Triheptanoin Use for Severe Neonatal Cardiomyopathy Secondary to Mitochondrial Trifunctional Protein Deficiency- A First Report; J. Coppola¹, M. Boothe¹, A. McGuinness¹, Y. Lo Yau¹, M. Brock¹, G. Peek¹, M. Bleiweis², H. Blanchette³, J. Rackley⁴, E. Martin⁵, L. Coleman⁵, F. Fricker⁶, B. Pietra⁷, D. Gupta⁸. ¹University of Florida, Gainesville, FL, ²UF Health Congenital Heart Center, Gainesville, FL, ³UF Health Shands, ⁴UF Hlth/Shands TX Ctr, Gainesville, FL, ⁵UF Health, Gainesville, FL, ⁶Congenital Hrt Ctr @ UF Hlth, Gainesville, FL, ⁷University of Florida Congenital Heart Center, Gainesville, FL, ⁸UF College of Medicine, Gainesville, FL

(1320) Distribution of Donor-Derived Cell-Free DNA Levels in Pediatric Heart Transplant Recipients; K. Oreschak¹, K. Mohib¹, M. Everitt², B. Feingold³. ¹CareDx, Brisbane, CA, ²Children's Hospital Colorado, Aurora, CO, ³UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA

(1321) Trends in Medication Adherence Across the Posttransplant Period in Pediatric Organ Transplant Recipients; M. Killian, C. Little, S. Mayewski. College of Social Work, Florida State University, Tallahassee, FL

(1322) Inter-Dose Variability of Immunosuppressant Medication Among Adolescent Heart Transplants During Video Directly Observed Therapy; M. Killian¹, S. E. Mayewski¹, S. E. Brumm¹, D. Gupta². ¹College of Social Work, Florida State University, Tallahassee, FL, ²Congenital Heart Center, Department of Pediatrics, UF College of Medicine, Gainesville, FL

(1323) Empowering Adolescent Heart Transplant Patients: A Medication Adherence Pilot Study; D. M. Torpoco Rivera¹, J. Blake¹, B. Leite², L. Kelm¹, R. Garcia Soriano³, C. Stewart¹, S. Sehgal¹. ¹Pediatric Cardiology, Children's Hospital of Michigan, Detroit, MI, ²Pediatric Cardiology, Children's Hospital of Michigan, Detroit, MI, ³Pediatric Cardiology, Children's Healthcare of Atlanta, Atlanta, GA

(1325) Mightee: Motivational Interviewing and Group Heart Transplant Exercise and Education, a Pilot Study; J. Edelson¹, L. Schneider², S. O'Malley¹, J. Somogie², J. Huang³, N. Li¹, C. Boyle¹, M. O'Connor¹, S. Paridon¹, K. Lin⁴, J. Rossano⁵, M. Lane-Fall³, M. Cousino⁶. ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Stanford University, Palo Alto, CA, ³University of Pennsylvania, Philadelphia, PA, ⁴Children's Hosp of Philadelphia, Philadelphia, PA, ⁵The Children's Hospital, Philadelphia, PA, ⁶University of Michigan, Ann Arbor, MI

(1326) Identifying the Environmental Determinants of Health-Related Quality of Life in Children After Heart Transplant; J. Edelson¹, J. Huang², Z. Wang¹, D. Lefkowitz³, M. O'Connor¹, R. White⁴, L. Ha¹, C. Wittlieb-Weber¹, J. Rossano⁵, K. Lin⁶, M. Lane-Fall⁷, M. O'Byrne⁸. ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³Children's Hospital of Philadelphia, Philadelphia, PA, ⁴The Children's Hospital of Philadelphia, Philadelphia, PA, ⁵The Children's Hospital, Philadelphia, PA, ⁶Children's Hosp of Philadelphia, Philadelphia, PA, ⁷University of Pennsylvania, Philadelphia, PA, ⁸CHOP, Philadelphia, PA

(1327) Anthracycline-Induced Cardiotoxicity - An Endothelial Perspective; M. Kasturi¹, K. Attal², C. M. Clemente¹, E. Tan², Y. Lim¹, R. Wang¹, C. Chen¹. ¹Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, ²Royal College of Surgeons in Ireland, Dublin, Ireland

(1328) Persistence of Frailty at 6 Months After Heart Transplant in Outpatient Pediatric Recipients: What More Can We Do?; K. E. Simpson¹, M. Gordon², M. D. Everitt¹. ¹Pediatrics, University of Colorado Denver, Aurora, CO, ²Children's Hospital of Colorado, Aurora, CO

(1329) Development of a Digital Therapeutic Program to Empower Pediatric Heart Failure Management; S. Wali¹, D. Balmer-Minnes², J. Cafazzo³, A. Jeewa⁴. ¹Ted Rogers Centre for Heart Research, University Health Network, Toronto, ON, Canada, ²Hospital for Sick Children, Toronto, ON, Canada, ³Centre for Digital Therapeutics, University Health Network, Toronto, ON, Canada, ⁴The Hospital for Sick Children, Toronto, ON, Canada

(1330) Practice Variation in Anticoagulation Management of Outpatient Pediatric Cardiomyopathy Patients: Survey of ACTION Providers; M. Townsend¹, M. J. O'Connor², J. A. Spinner³, S. Amdani¹, J. Conway⁴. ¹Pediatric Cardiology, Cleveland Clinic Children's Hospital, Cleveland, OH, ²Pediatric Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA, ³Pediatric Cardiology, Baylor College of Medicine, Houston, TX, ⁴Pediatric Cardiology, Stollery Children's Hospital, Edmonton, AB, Canada

(1331) A Pediatric Heart Failure Registry: The Time for Action is Now; J. Spinner¹, T. Duganiero², N. D'Souza², B. Kroschwitz³, R. Butts⁴, D. Nandi⁵, K. Simpson⁶, C. Almond⁷, J. Conway⁸, D. Peng⁹, A. Lorts². ¹Baylor College of Medicine, Houston, TX, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Cincinnati Children's Hospital Medical Center, Cincinnati, TX, ⁴Children's Medical Center of Dallas/University of Texas Southwestern, Dallas, TX, ⁵Nationwide Children's Hospital, Columbus, OH, ⁶University of Colorado Denver, Denver, CO, ⁷Stanford University, Palo Alto, CA, ⁸Stollery Children's Hospital, Edmonton, AB, Canada, ⁹University of Michigan, Ann Arbor, MI

(1332) Acute Decompensated Heart Failure in Children Presenting with Preserved Ejection Fraction; Z. Chughtai¹, C. Chen¹, J. Dykes¹, R. Yokota¹, E. Profita¹, J. Murray¹, J. Schmidt¹, N. Boramanand¹, C. S. Almond². ¹Stanford University, Palo Alto, CA, ²Pediatrics, Stanford University, Palo Alto, CA

(1333) Patient-Reported Outcomes in Pediatric VAD Recipients: ACTION Findings Stratified by Device; L. May¹, M. Cousino², L. Smyth³, M. McQueen⁴, T. Hunter⁵, C. Ventresco⁶, K. Fields⁷, J. Murray⁸, D. Machado⁹, M. Shezad¹⁰, D. Rosenthal¹¹, K. Engelhardt¹², M. Mehegan¹³, D. Mokshagundam¹⁴, M. Ploutz¹⁵, A. Lorts⁷, E. Blume⁶. ¹University of Utah, Cottonwood Heights, UT, ²University of Michigan, Ann Arbor, MI, ³Cincinnati Children's Hospital, Cincinnati, OH, ⁴Transplant Families, Phoenix, AZ, ⁵Michigan Medicine Mott Children's Hospital, Ann Arbor, MI, ⁶Boston Children's Hospital, Boston, MA, ⁷Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁸Stanford Children's, Palo Alto, CA, ⁹University of Florida, Miami, FL, ¹⁰Cincinnati Children's Hospital, Cincinnati, OH, ¹¹Stanford University, Palo Alto, CA, ¹²Phoenix Children's Hospital, Phoenix, AZ, ¹³St Louis Children's Hospital, St. Louis, MO, ¹⁴Washington University in St Louis, St. Louis, MO, ¹⁵University of Utah, Salt Lake City, UT

(1334) Safety of Erythropoiesis-Stimulating Agents for Pediatric Berlin EXCOR VAD Patients; C. Heyrend¹, M. Ploutz², B. Bucher¹, R. Jackson³, E. Wicker¹, M. Profsky¹, L. May⁴. ¹Primary Children's Hospital, Salt Lake City, UT, ²University of Utah, Salt Lake City, UT, ³Primary Children's Hospital, Salt Lake City, UT, ⁴University of Utah, Cottonwood Heights, UT

(1335) Cardiac Magnetic Resonance Imaging can Differentiate Rejection on Molecular Gene Expression Profiling in Pediatric Heart Transplant Recipients; K. Watanabe¹, D. Magnetta², J. D. Robinson², C. K. Rigsby³, N. Husain². ¹Texas Children's Hospital, Houston, TX, ²Cardiology, Lurie Children's Hospital of Chicago, Chicago, IL, ³Radiology, Lurie Children's Hospital of Chicago, Chicago, IL

(1336) Pulmonary Vein Stenosis in Pediatric Heart Transplant Recipients: A Single-Center Case Series; D. Mokshagundam, A. Kamsheh, L. Gokanapudy Hahn, A. Ybarra, J. Scheel, C. Canter. Washington University in St Louis, St Louis, MO

(1337) Dapagliflozin Use in Children with Heart Failure Undergoing Heart Transplantation; D. M. Newland¹, Y. M. Law², E. L. Albers², R. Ali¹, J. M. Friedland-Little², M. S. Kemna², L. R. Knorr¹, T. L. Nemeth¹, K. L. Spencer², B. J. Hong². ¹Department of Pharmacy, Seattle Children's Hospital, Seattle, WA, ²Pediatric Cardiology, Seattle Children's Hospital, Seattle, WA

(1338) Perception vs. Reality: Reported and Objective Measures of Physical Activity in Children with Hypertrophic Cardiomyopathy (HCM); C. Fortin-Moore¹, A. Jeewa², S. Lemaire-Paquette³, T. Pidborochynski¹, M. Khoury¹, C. Cunningham¹, S. Dhillon⁴, N. Alami Laroussi⁵, L. Vaujois⁶, F. Dallaire³, K. Armstrong⁷, D. Schantz⁸, W. Mawad⁹, T. Bradley¹⁰, J. Conway¹. ¹University of Alberta, Stollery Children's Hospital, Edmonton, AB, Canada, ²The Hospital for Sick Children, Toronto, ON, Canada, ³Université de Sherbrooke, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada, ⁴Dalhousie University IWK Children's Heart Center, Halifax, NS, Canada, ⁵Université de Montréal, Centre Hospitalier Universitaire Sainte-Justine, Montreal, QC, Canada, ⁶Université Laval, Centre Hospitalier Universitaire de Québec, Québec, QC, Canada, ⁷University of British Columbia, BC Children's Hospital, Vancouver, BC, Canada, ⁸Health Sciences Centre, Children's Hospital, Winnipeg, MB, Canada, ⁹McGill University Health Centre, Montreal Children's Hospital, Montreal, QC, Canada, ¹⁰University of Saskatchewan, Jim Pattison Children's Hospital, Saskatoon, SK, Canada

(1339) Helping Teens Cope: A Virtual Interprofessional Coronary Angiogram Information Session; L. Scavuzzo¹, A. Marrato², S. Spataro², A. Dipchand¹. ¹The Hospital for Sick Children, Toronto, ON, Canada, ²Hospital for Sick Children, Toronto, ON, Canada

(1340) Dapagliflozin for Graft Dysfunction After Pediatric Heart Transplant; E. L. Profita¹, L. Barkoff², J. Lee², S. Hollander¹, S. Gonzales³, K. Wujcik², C. Almond¹. ¹Department of Pediatrics, Stanford University, Palo Alto, CA, ²Lucile Packard Children's Hospital Stanford, Palo Alto, CA, ³Stanford University School of Medicine, Palo Alto, CA

(1341) The ECHO-Ez Pediatric Trial: Study Design and Rationale for Evaluating the Predictive Value of ECHO-Ez a Novel Non-Invasive Algorithm for Early Detection of Treated Rejection; S. Amdani¹, R. Boucek², E. Frandsen³, L. Hernandez⁴, B. Soriano⁵, S. Miyamoto⁶, D. Gupta⁷, B. Pietra⁸, D. Moguillansky⁹, T. Karamlou¹. ¹Cleveland Clinic, Cleveland, OH, ²Enduring Hearts, Marietta, GA, ³Loma Linda University, Loma Linda, CA, ⁴Joe DiMaggio Children's Hospital, Hollywood, FL, ⁵Seattle Children's Hospital, Seattle, WA, ⁶Children's Hospital Colorado, Denver, CO, ⁷UF College of Medicine, Gainesville, FL, ⁸University of Florida Congenital Heart Center, Gainesville, FL, ⁹University of Florida, Gainesville, FL

(1342) Donor-Derived Cell-Free DNA in Pediatric Heart Transplant Patients; A. Butto¹, S. Jandu¹, D. Long¹, W. Mahle¹, V. Ravichandran², C. Mao¹. ¹Children's Healthcare of Atlanta, Atlanta, GA, ²CareDx, Brisbane, CA

(1343) Less Invasive Acute Rejection Surveillance Within the First Year After Pediatric Heart Transplantation - Clinical Outcomes from a Low-Intensity Biopsy Center; L. M. Rosenthal¹, L. M. Müller¹, F. Danne¹, M. M. Freitag², M. Yigitbasi¹, A. Krauss¹, O. Miera¹, K. Schmitt¹, F. Berger¹, F. Lunze¹. ¹Congenital Heart Disease - Pediatric Cardiology, German Heart Center of Charité Berlin, Berlin, Germany, ²Institute for Biometry and Clinical Epidemiology, Charité Universitaetsmedizin Berlin, Berlin, Germany

(1344) Outcomes of Pediatric Chemotherapy Induced Cardiomyopathy Needing Heart Transplant- An Multi-Institutional Analysis of UNOS Database; K. Raja¹, S. Lunos¹, S. M. Peer¹, S. Deshpande², T. Alexy¹, N. Rodgers¹, P. Sinha¹. ¹University of Minnesota, Minneapolis, MN, ²Children's National Hospital, George Washington University, Washington, DC

(1345) Socioeconomic Status and Major Adverse Transplant Events in Pediatric Heart Transplant Recipients; C. Hartje-Dunn¹, K. Gauvreau², H. Bastardi², K. P. Daly², E. Blume², T. Singh². ¹Seattle Children's Hospital, Seattle, WA, ²Boston Children's Hospital, Boston, MA

(1346) Panel Reactive Antibody, Crossmatch Status, and Outcomes in Pediatric Heart Transplant Recipients with Congenital Heart Disease: An Analysis of the United Network for Organ Sharing Database; M. J. O'Connor, X. Zhang, L. Bennett, C. Vu, H. Ahmed, J. Edwards, K. Lin, K. Maeda, J. Rossano, J. Edelson. Children's Hospital of Philadelphia, Philadelphia, PA

(1347) Heart Transplantation for Malignant Arrhythmia: Indications and Outcomes; J. Atallah¹, S. Urschel¹, J. Kirklin², R. Cantor², H. Zhao², J. Motiuk¹, T. Hoffman³, M. Weisert⁴, I. Lytrivi⁵, N. Singh⁶, E. Azeka⁷, C. Wittlieb-Weber⁸. ¹Pediatrics, University of Alberta, Edmonton, AB, Canada, ²Kirklin Solutions, Hoover, AL, ³UNC Children's Heart Center, Chapel Hill, NC, ⁴Children's Hospital Los Angeles, Los Angeles, CA, ⁵Columbia Presbyterian Hospital, New York, New York, NY, ⁶Children's Wisconsin, Milwaukee, WI, ⁷University of Sao Paulo, Sao Paulo, Brazil, ⁸Children's Hospital of Philadelphia, Philadelphia, PA

(1348) Pediatric Coronary Angiography in the Teammate Trial: Angiographic Core Interpretation over the First 3 Years Post Transplant; S. R. Auerbach¹, K. P. Daly², M. D. Everitt¹, L. A. Sleeper³, L. P. Browne⁴, L. J. Malone⁴, E. L. Albers⁵, J. C. Alejos⁶, R. Ameduri⁷, A. Barnes⁸, A. Butto⁹, W. F. Carlo¹⁰, C. Castleberry¹¹, M. Chrisant¹², S. Deshpande¹³, W. J. Dreyer¹⁴, B. Feingold¹⁵, S. Gonzales¹⁶, S. A. Hollander¹⁶, F. Howard¹⁷, D. T. Hsu¹⁸, S. J. Kindel¹⁹, G. L. Klein², M. A. Kuhn²⁰, A. K. Lal²¹, J. Lee²², M. Lu², I. Lytrivi²³, J. Mentee²⁴, E. Pahl Schuette²⁵, D. M. Peng²⁶, J. W. Rossano²⁷, T. D. Ryan²⁸, D. L. Sutcliffe²⁹, S. Zangwill³⁰, C. S. Almond¹⁶, S. D. Miyamoto¹. ¹Pediatrics, Div of Cardiology, Univ of Colorado Anschutz Med Campus and Children's Hosp Colorado, Aurora, CO, ²Cardiology, Boston Children's Hosp, Boston, MA, ³Cardiology, Boston Children's Hosp, Boston, MA, ⁴Radiology, Section of Pediatric Radiology, Univ of Colorado Anschutz Medical Campus and Children's Hosp Colorado, Aurora, CO, ⁵Seattle Children's Hosp, Seattle, WA, ⁶Pediatrics, Div of Cardiology, UCLA Mattel Children's Hosp, Los Angeles, CA, ⁷Pediatrics, Div of Cardiology, Mayo Clinic, Rochester, MN, ⁸Pediatrics, Div of Cardiology, Children's Mercy Kansas City, Kansas City, MO, ⁹Pediatrics, Div of Cardiology, Emory Univ SoM, Children's Healthcare of Atlanta, Atlanta, GA, ¹⁰Pediatrics, Div of Cardiology, Univ of Alabama at Birmingham SoM, Birmingham, AL, ¹¹Pediatrics, Div of Cardiology, Dell Med Sch at the Univ of Texas in Austin, Austin, TX, ¹²Pediatrics, Div of Cardiology, Joe DiMaggio Children's Hosp, Hollywood, FL, ¹³Pediatrics, Div of Cardiology, George Washington Univ, Children's National Hosp, Washington, DC, ¹⁴Pediatrics, Div of Cardiology, Baylor College of Med, Houston, TX, ¹⁵Pediatrics, Div of Cardiology, UPMC Children's Hosp of Pittsburgh, Pittsburgh, PA, ¹⁶Pediatrics, Div of Cardiology, Stanford Univ, Stanford, CA, ¹⁷Cardiology, Boston Children's Hosp, Boston, MA, ¹⁸Pediatrics, Div of Cardiology, Albert Einstein SoM, Children's Hosp at Montefiore, Bronx, NY, ¹⁹Pediatrics, Div of Cardiology, Medical College of Wisconsin, Children's Hosp of Wisconsin, Milwaukee, WI, ²⁰Pediatrics, Div of Cardiology, Loma Linda Univ, Loma Linda, CA, ²¹Pediatrics, Div of Cardiology, Univ of Utah, Salt Lake City, UT, ²²Lucile Packard Children's Hosp Stanford Children's Health, Palo Alto, CA, ²³Pediatrics, Div of Cardiology, Columbia Presbyterian Hosp, New York, New York, NY, ²⁴Pediatrics, Div of Cardiology, Keck SoM, USC, Children's Hosp Los Angeles, Los Angeles, CA, ²⁵Pediatrics, Div of Cardiology, Northwestern Feinberg SoM, Lurie Children's Hosp, Chicago, IL, ²⁶Pediatrics, Div of Cardiology, Univ of Michigan, Ann Arbor, MI, ²⁷Pediatrics, Div of Cardiology, CHOP, Philadelphia, PA, ²⁸Pediatrics, Div of Cardiology, Cincinnati Children's Hosp MC, Cincinnati, OH, ²⁹Pediatrics, Div of Cardiology, Children's Mercy Hosp, Kansas City, MO, ³⁰Pediatrics, Div of Cardiology, Phoenix Children's Hosp, Phoenix, AZ

(1349) Machine Learning for Predicting Waitlist Survival in Pediatric Patients Awaiting Heart Transplantation; F. Haregu, R. Dixon, M. Porter, J. Scharff, M. McCulloch. *University of Virginia, Charlottesville, VA*

(1350) Using Machine Learning to Assess the Predictive Power of Donor Characteristics in Pediatric Heart Transplant Outcomes; M. D. Porter¹, J. R. Sharff², R. Dixon³, F. Haregu⁴, M. McCulloch⁴. ¹*Data Science and Systems & Information Engineering, University of Virginia, Charlottesville, VA*, ²*Systems & Information Engineering, University of Virginia, Charlottesville, VA*, ³*Data Science, University of Virginia, Charlottesville, VA*, ⁴*Pediatrics, University of Virginia Children's Hospital, Charlottesville, VA*

(1351) Global Pediatric Experience Using Controlled Moderate Hypothermia: A Subgroup Analysis of the GUARDIAN Heart Registry; U. Boston¹, A. Zuckermann², Y. Stukov³, J. Bustamante-Munguira⁴, T. Nasirov⁵, A. O'Donnell⁶, D. Morales⁷, J. Jacobs⁸. ¹*Le Bonheur Children's Hosp, Memphis, TN*, ²*Medical University of Vienna, Vienna, Austria*, ³*University of Florida, Gainesville, FL*, ⁴*Clinico Universitario de Valladolid, Valladolid, Spain*, ⁵*Lucile Packard Children's Hospital - Stanford, Stanford, CA*, ⁶*Cincinnati Children's Hospital, Cincinnati, OH*, ⁷*Cincinnati Children's Hospital Medical Center, Cincinnati, OH*, ⁸*University of Florida Health Shands, Gainesville, FL*

(1353) Early Conversion from Tacrolimus- to Everolimus-Based Immunosuppression in Pediatric Heart Transplant Recipients for Renal Insufficiency; K. Wujcik¹, L. Barkoff¹, J. Lee¹, S. A. Hollander², C. Chen², S. Gonzales², E. Profita², C. Almond². ¹*Lucile Packard Children's Hospital Stanford Children's Health, Palo Alto, CA*, ²*Stanford University, Palo Alto, CA*

(1354) Impact of UNOS Policy Change on Resource Utilization Related to Pediatric Heart Transplant; B. Alsoufi¹, J. Trivedi², S. R. Deshpande³. ¹*Pediatric Cardiac Surgery, University of Louisville, Louisville, KY*, ²*University of Louisville, Louisville, KY*, ³*Pediatric Cardiology, Children's National Hospital, George Washington University, Washington, DC*

(1355) Effects of Fluconazole Discontinuation on the Pharmacokinetics of Immunosuppression in Pediatric Heart Transplant Recipients; C. Vo, S. Zangwill, B. Wisotzkey, A. Colon, J. Churosh, A. Kimbro, S. Grohall, A. Aldieri. *Phoenix Children's, Phoenix, AZ*

(1356) Non-HLA Antibodies in Transplantation: A Multi-Center Collaborative Towards Developing a Strategy for Testing; C. Iler¹, J. Backowski², H. Bastardi³, C. Boyle⁴, C. Buesking², S. Daneman⁵, L. Ha⁴, A. Huston⁶, N. Sinicropi⁷, R. White⁴, S. Deshpande¹. ¹*Advanced Cardiac Therapies and Heart Transplant, Children's National Hosp, Washington, DC*, ²*Heart Transplant, St. Louis Children's Hosp, St. Louis, MO*, ³*Advanced Cardiac Therapies and Heart Transplant, Children's Hospital of Boston, Boston, MA*, ⁴*Pediatric Heart Failure and Transplant, Children's Hosp of Philadelphia, Philadelphia, PA*, ⁵*Pediatric Heart Transplant, Children's MC of Dallas, Dallas, TX*, ⁶*Pediatric Heart and Lung Transplant, UPMC Children's Hosp of Pittsburgh, Pittsburgh, PA*, ⁷*Pediatric Heart Failure and Heart Transplant, C.S. Mott Children's Hospital, Ann Arbor, MI*

(1358) Plasma and Bronchoalveolar Fluid Proteomes Identify Similar Pathways Associated with Allograft Dysfunction in Individual LTx Recipients with Different Underlying Conditions; M. E. Siefert¹, E. J. Skala¹, A. S. Potter², D. Hayes², A. Ziady¹. ¹*Division of Bone Marrow Transplantation, Cincinnati Children's Hospital Medical Center, Cincinnati, OH*, ²*Heart Institute/Pulmonary Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH*

(1359) Trends in Pediatric Lung Transplantation Following the Height of the COVID-19 Pandemic; N. Avdimiretz¹, C. Benden². ¹*Division of Pulmonary Medicine, Pediatric Lung Transplantation, Stanford University, Palo Alto, CA*, ²*Faculty of Med, Univ of Zürich, Zürich, Switzerland*

(1360) Paediatric Lung Transplantation for Childhood Interstitial Lung Disease Shows Favorable Outcome Compared with LuTx for Cystic Fibrosis or Pulmonary Hypertension; H. Schneider¹, F. Länger², F. Ius³, C. Müller¹, K. Schütz¹, D. Bobylev³, J. Salman³, N. Schwerk¹, J. Carlens¹. ¹*Clinic for Paediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany*, ²*Institute for Pathology, UK Aachen, Aachen, Germany*, ³*Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany*

(1361) Use of Letermovir for Cytomegalovirus Prophylaxis in Pediatric Lung Transplant Patients; N. Bhatt¹, E. A. Moulton², E. Melicoff-Portillo³, A. Schrader³. ¹*Pharmacy, Texas Children's Hospital, Houston, TX*, ²*Infectious Diseases, Baylor College of Medicine, Houston, TX*, ³*Pediatric Pulmonology, Baylor College of Medicine, Houston, TX*

(1362) CfVAD Support in Small Single Ventricle Patients < 10kg; M. S. Iqbal¹, R. Davies², J. Lantz³, S. Carrington⁴, B. Loreitha⁵, R. Butts⁶. ¹*UTSW, Dallas, TX*, ²*Children's Health, UT Southwestern, Dallas, TX*, ³*Children's Health, Dallas, TX*, ⁴*Children's Health Dallas, Dallas, TX*, ⁵*Children's Medical Center Dallas, Dallas, TX*, ⁶*Children's Medical Center of Dallas/University of Texas Southwestern, Dallas, TX*

(1363) Improved Metrics After Implementation of a Clinical Stroke Pathway for Children on Ventricular Assist Devices; J. Murray¹, A. Fasbinder¹, C. Almond², H. Shin¹, S. Lee², J. Dykes², K. Ryan², D. Rosenthal², M. Navaratnam², K. Jackson¹, M. Ma², E. Martin², P. Rist³, S. Chen². ¹*Stanford Children's Health, Palo Alto, CA*, ²*Stanford University, Palo Alto, CA*, ³*Harvard School of Public Health, Boston, MA*

(1364) Pulsatile versus Continuous Flow Ventricular Assist Device as a Bridge to Transplantation for the Pediatric Failing Fontan; E. Seymour¹, H. Tunuguntla², S. Sosa¹, K. Hope², J. Spinner², A. Ankola³, I. Adachi⁴, K. Puri³. ¹*Pediatrics-Critical Care Medicine, Texas Children's Hospital, Houston, TX*, ²*Pediatrics-Cardiology, Texas Children's Hospital, Houston, TX*, ³*Pediatrics-Critical Care Medicine and Cardiology, Texas Children's Hospital, Houston, TX*, ⁴*Surgery-Congenital Heart Surgery, Texas Children's Hospital, Houston, TX*

(1365) First North American Experience with The Berlin Heart Active Driver; T. Pidborochynski¹, H. Buchholz², D. Ly³, L. Mowat³, D. Freed⁴, D. Jonker⁴, M. Al-Aklabi⁴, P. Holinski⁴, V. Anand⁴, J. Conway⁴. ¹Pediatrics, University of Alberta, Edmonton, AB, Canada, ²Cardiac Surgery, University of Alberta Hospital, Edmonton, AB, Canada, ³University of Alberta Hospital, Edmonton, AB, Canada, ⁴Stollery Children's Hospital, Edmonton, AB, Canada

(1366) Utility of 3D Printed Models for Ventricular Assist Device Placement in Congenital Heart Disease: Preliminary Results from a Prospective Clinical Trial; K. M. Farooqi¹, A. Aidala², S. Law³, C. Sanchez¹, O. Saeed⁴, D. Shimbo¹, U. Jorde⁴, Y. Naka⁵, A. J. Einstein¹, E. Bacha⁶. ¹Columbia University Irving Medical Center, New York, NY, ²Mailman School of Public Health, New York, NY, ³Columbia University, New York, NY, ⁴Montefiore MC, Bronx, NY, ⁵New York Presbyterian Hosp, New York, NY, ⁶Morgan Stanley Children's Hosp of NY-Presbyterian, New York, NY

(1367) Influence of Steroid Administration on Inflammatory and Hematologic Parameters in Pediatric VAD Inflammation; A. A. Ankola¹, H. P. Tunuguntla¹, K. Hope², B. Elias¹, I. Adachi¹, J. A. Spinner¹, S. Choudhry¹, J. Price¹, W. Dreyer¹, K. Puri¹. ¹Texas Children's Hospital, Houston, TX, ²Texas Children's Hospital, Baylor College of Medicine, Houston, TX

(1368) Safety and Efficacy of Intravenous Iron Sucrose in Children with Cardiac Disease; S. B. Shulman¹, E. D. Blume², K. Gauvreau², N. Bachiri², R. Williams², R. L. Kobayashi². ¹Tufts University SoM, Boston, MA, ²Dept of Cardiology, Boston Children's Hosp, Boston, MA

(1369) Improving Outcomes in Mechanical Circulatory Support in Failing Glenn Physiology; R. L. Kobayashi¹, R. J. Williams¹, P. Estes¹, C. Milligan¹, K. P. Daly¹, C. Ventresco¹, F. Fynn-Thompson², C. J. VanderPluym¹. ¹Cardiology, Boston Children's Hospital, Boston, MA, ²Cardiac Surgery, Boston Children's Hospital, Boston, MA

(1370) Exploring Factors Associated with Prolonged Intubation After Ventricular Assist Device Implantation in Children; D. Tolani, S. Rangu, J. C. Dykes, M. Ma, E. Martin, J. Murray, A. Fasbinder, D. Rosenthal, C. dela Cruz, D. Kwiatkowski, C. Almond. Lucile Packard Children's Hospital/Stanford University, Palo Alto, CA

(1371) The Use of Pulmonary Hypertension Target Therapy in Patients with Pulmonary Vein Disease: Single Center Experience; R. Morales-Demori¹, A. Qureshi², E. Whalen³, N. Varghese³. ¹Critical Care, Texas Children's Hospital, Houston, TX, ²Cardiology, Texas Children's Hospital, Houston, TX, ³Pulmonary, Texas Children's Hospital, Houston, TX

(1372) Toxic Milk- Should We Still be Afraid of Breastfeeding While on Tacrolimus Therapy: A Case Study; A. Kuczaj¹, A. Danel², S. Warwas¹, P. Przybyłowski¹, J. Śliwka¹, S. Pawlak¹, I. Trzcińska³, T. Hrapkiewicz¹. ¹Department of Cardiac, Vascular and Endovascular Surgery and Transplantology, Faculty of Medical Sciences in Zabrze. Medical Univ of Silesia, Zabrze, Poland, ²Dept of Lung Diseases and Tuberculosis, Faculty of Medical Sciences in Zabrze. Medical Univ of Silesia, Zabrze, Poland, ³Silesian Center for Heart Diseases in Zabrze, Zabrze, Poland

(1373) Successful Utilization of Organ Care System in Three Pediatric Heart Transplant Recipients; L. Yu, J. N. Johnson, R. C. Daly, J. A. Dearani, E. H. Stephens, M. A. Villavicencio, F. A. Reynolds, R. K. Ameduri. Mayo Clinic, Rochester, MN

(1374) Isolated Heart Transplantation Needing Mechanical Circulatory Support in Elevated Pulmonary Vascular Resistance; M. John¹, J. Rosenblum¹, F. R. Shaw². ¹Emory Univ/Children's Healthcare of Atlanta, Atlanta, GA, ²Emory Univ/Children's Health Care of Atlanta, Atlanta, GA

(1375) HeartWare™ HVAD Support Without Anticoagulation; M. Masilamani¹, E. Greengard², J. N. Johnson¹, R. Ameduri¹. ¹Department of Pediatrics and Adolescent Medicine, Division of Pediatric Cardiology, Mayo Clinic, Rochester, MN, ²Department of Pediatrics, Division of Hematology and Oncology, University of Minnesota, Minneapolis, MN

(1376) To VAD or Not VAD? How to Get to Heart Transplant in a Child with Duchenne Muscular Dystrophy; A. Garg, A. Joong, K. Gambetta, M. Monge, P. Thrush. Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL

(1377) T-Cell Lymphoma Masquerading as Cellular Mediated Rejection in a Heart Transplant Patient; A. Garg, S. O'Brien, J. Weinstein, N. Arva, S. Gong, P. Thrush, K. Gambetta. Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL

(1378) WITHDRAWN

(1379) Ex Vivo Normothermic Perfusion Use for Pediatric Heart Transplant Recipients; M. Lynn, L. Radel, M. Iqbal, N. Baez Hernandez, M. Bano, R. Davies, R. Butts. Children's Health/University of Texas Southwestern, Dallas, TX

(1380) Donation After Circulatory Death: Changing the Timeline of Pediatric Heart Transplant Recipients; M. Lynn, S. Ghaleb, L. Radel, M. Iqbal, N. Baez Hernandez, M. Bano, R. Davies, R. Butts. Children's Health/University of Texas Southwestern, Dallas, TX

(1381) Hybrid Palliation as Bridge to Heart Transplantation in Neonatal Dilated Cardiomyopathy; M. R. Varma¹, R. K. Singh¹, M. Argilla¹,

S. Chakravarti¹, A. Ludomirsky¹, M. Martinez¹, J. McKinstry¹, R. S. Mosca², R. M. Rogoff¹, S. Saharan¹, T. Kumar². ¹*Division of Pediatric Cardiology, NYU Langone Medical Center and NYU Grossman School of Medicine, New York, NY*, ²*Department of Cardiothoracic Surgery, NYU Langone Medical Center and NYU Grossman School of Medicine, New York, NY*

(1382) How Much Can the Liver Handle? Management of Early Portal Hypertension in a Pediatric Patient with Fontan Circulatory Failure; H. Ahmed¹, K. Saarela², L. Bohuta², J. Friedland-Little². ¹*Children's Hosp of Philadelphia, Philadelphia, PA*, ²*Seattle Children's Hosp, Seattle, WA*

(1383) Follow Your Heart but Protect Your Brain: Management of Recurrent Subdural Hematomas in a Pediatric Patient with End-Stage Heart Failure; H. Ahmed¹, J. Murray², H. Do², K. Maeda³, S. Chen². ¹*Children's Hospital of Philadelphia, Philadelphia, PA*, ²*Stanford University, Palo Alto, CA*, ³*Children's Hospital of Philadelphia, Philadelphia, PA*

(1384) Feasibility and Utility of 24-Hour Ambulatory Blood Pressure Monitoring in Pediatric Heart Transplant Patients; S. Hussain, A. Wilson, M. Wilde, J. Parent. *Pediatric Cardiology and Nephrology, Riley Hospital for Children at Indiana University Health, Indianapolis, IN*

(1385) Surprise AMR: Unexpected Complication in Lung Transplant for CVID Bronchiectasis; D. S. Moreno McNeill¹, K. Patel², A. Schrader¹, M. Gazzaneo¹, E. Melicoff-Portillo¹, N. Cortes-Santiago², S. Nicholas³. ¹*Pediatric Pulmonology, Texas Children's Hospital, Houston, TX*, ²*Pathology, Texas Children's Hospital, Houston, TX*, ³*Allergy and Immunology, Texas Children's Hospital, Houston, TX*

(1386) Successful NTM Eradication and Lung Transplantation in Pediatric CF Patients; X. Si¹, C. Burton², O. G. Vanderkooi³, M. McKinney⁴, D. Lien², N. Avdimiretz¹. ¹*Stanford University, Palo Alto, CA*, ²*University of Alberta, Edmonton, AB, Canada*, ³*University of Calgary, Calgary, AB, Canada*, ⁴*Children's Hospital of Los Angeles, Los Angeles, CA*

(1387) Cannula Issues in Pediatric VAD Therapy: The Not So Innocent Bystander; S. Oliver¹, H. Buchholz², T. Pidborochynski³, D. Jonker¹, P. Holinski¹, V. Anand¹, J. Conway¹. ¹*Stollery Children's Hospital, Edmonton, AB, Canada*, ²*Cardiac Surgery, University of Alberta Hospital, Edmonton, AB, Canada*, ³*Pediatrics, University of Alberta, Edmonton, AB, Canada*

(1388) Rejection and Graft Vasculopathy Secondary to Effects of Crohn's Disease in a Heart-Transplanted Child; S. Oliver¹, J. Conway², D. Freed², H. Huynh², M. Khoury¹, C. Kluthe², L. West¹, S. Urschel¹. ¹*University of Alberta, Edmonton, AB, Canada*, ²*Stollery Children's Hospital, Edmonton, AB, Canada*

(1389) WITHDRAWN

(1390) Pioneering Successful Transplantation with a Ventricular Assist Device in Fontan Failure: The First Experience in South Korea; H. Chung¹, J. Kim¹, Y. Park², C. Lee³, S. Kim¹. ¹*Department of Pediatrics, Bucheon Sejong Hospital, Bucheon-si, South Korea*, ²*Department of Internal Medicine, Bucheon Sejong Hospital, Bucheon-si, South Korea*, ³*Department of Thoracic and Cardiovascular Surgery, Bucheon Sejong Hospital, Bucheon-si, South Korea*

FRIDAY, 12 APRIL, 2024

4:30 - 5:30 p.m.

POSTER SESSION 3: Pharmacy (Non-CME)

Location: Poster Hall

Core Therapies: HEART, LUNG, MCS, PVD

Practice Areas: Pharmacy, Anesthesiology and Critical Care, Cardiology, Cardiothoracic Surgery, Infectious Diseases, Nursing and Allied Health, Pathology, Pediatrics, Pulmonology, Research and Immunology

Session Summary: Posters in this session include presentations on multiple topics where the Practice Areas of the research is focused in Pharmacy. Designated Poster Discussants will circulate through the poster hall during the session to engage poster presenters in quality discussions of their abstracts. **CME is not offered for poster sessions.**

Poster Discussants: Fay Burrows, Australia, Kevin Chan, USA, Bailey Colvin, USA, Livia Goldraich, Brazil, Ed Horn, USA, Amy Kiskaddon, USA, Jill Krisl, USA, Daryl Nnani, USA, Tara Rackley, USA

(1391) The Impact of Statin Intensity on Early Progression of Cardiac Allograft Vasculopathy; X. Huang¹, M. Yuzefpolskaya², P. C. Colombo², D. L. Jennings¹. ¹Long Island Univ/NewYork-Presbyterian Hospital, New York, NY, ²NewYork-Presbyterian Hospital/Columbia Univ, New York, NY

(1392) Comparison of Basiliximab and Anti-Thymocyte Globulin as Induction Therapy for Simultaneous Heart-Kidney Transplantation in the Contemporary Era; X. Huang¹, B. Carver², J. Choe², D. Salerno², T. Shertel², P. C. Colombo³, M. Yuzefpolskaya³, D. L. Jennings¹. ¹Long Island University/NewYork-Presbyterian Hospital, New York, NY, ²NewYork-Presbyterian Hospital, New York, NY, ³NewYork-Presbyterian Hospital/Columbia University, New York, NY

(1393) Comparison of Cytomegalovirus Infection Risk Following 3 or 6 Months of Valganciclovir Prophylaxis Among Donor Seropositive/Recipient Seronegative Heart Transplant Recipients; V. Leclerc, N. Chateauvert. Institut Universitaire de Cardiologie et de Pneumologie de Québec-Université Laval, Quebec City, QC, Canada

(1394) Characterization of Infectious Prophylaxis and Complications in Simultaneous Heart-Liver Transplant Recipients; B. Steiner, A. Loethen, A. Reticker, R. Lavelle, L. Potter. University of Chicago Medicine, Chicago, IL

(1395) Evaluation of the Impact of Pharmacist Transitions of Care Interventions in Hospitalized Heart Failure Patients; D. Lisi¹, R. Martin². ¹Pharmacy, Emory Healthcare, Atlanta, GA, ²Denver Health and Hospital Authority, Denver, CO

(1396) Time to Therapeutic Tacrolimus Trough and Renal Impairment in Heart Transplant Recipients: Limited Association?; T. M. Lawrecki¹, M. Tomeczkovicz¹, C. Nguyen², A. Roska², K. V. Benig², D. Chhabra³, M. Dela Cruz², G. Macaluso², S. Pauwaa², M. T. Kabbany², A. Joshi², J. Monaco², J. Pillarella², C. Sciamanna², W. Cotts², P. Pappas⁴, N. Narang², V. Q. Chau². ¹Pharmacy, Advocate Christ Medical Center, Oak Lawn, IL, ²Advanced Heart Failure, Cardiac Transplant, and Mechanical Circulatory Support, Advocate Christ Medical Center, Oak Lawn, IL, ³Kidney Transplant, Advocate Christ Medical Center, Oak Lawn, IL, ⁴Cardiothoracic Surgery, Advocate Christ Medical Center, Oak Lawn, IL

(1397) Eculizumab as Rescue Therapy for Severe Acute Antibody Mediated Rejection in Heart Transplant Recipients; M. Tomeczkovicz¹, T. Lawrecki¹, N. Narang¹, M. Dela Cruz¹, I. Balanlayos¹, A. Jaramillo¹, V. Q. Chau¹, A. Joshi¹, M. T. Kabbany¹, G. Macaluso¹, J. Monaco¹, S. Pauwaa¹, J. Pillarella¹, C. Sciamanna¹, W. G. Cotts². ¹Advocate Christ Medical Center, Oak Lawn, IL, ²Advanced Heart Failure, Cardiac Transplant, and Mechanical Circulatory Support, Advocate Christ Medical Center, Oak Lawn, IL

(1398) Challenging the Conventional Wisdom of Apixaban Dose Adjustments in Heart Transplants on Posaconazole with and without Dialysis; R. Lee¹, E. Henriksen¹, D. Kim², H. Luikart², Y. Moayedi³, J. Teuteberg⁴, K. Khush⁵. ¹Pharmacy, Stanford Health Care, Stanford, CA, ²Cardiac Transplant, Stanford Health Care, Stanford, CA, ³University Health Network, Toronto, ON, Canada, ⁴Cardiac Transplant, Stanford University, Stanford, CA, ⁵Stanford University, Stanford, CA

(1399) Any Switch Way: Cure of Donor-Derived HCV Infection after Changing DAA Therapy Due to Drug Interactions; K. S. Coffman¹, T. Carcella¹, F. Bartlett², M. Lange¹, C. Harris¹, C. Perez¹. ¹Medical University of South Carolina, Charleston, SC, ²MUSC Health, Charleston, SC

(1400) A Comparative Study Between Single vs Standard Two Doses of Basiliximab in Lung Transplantation; A. T. Logan¹, M. Qureshi², M. Martin³, H. Zerdo⁴, K. Patel². ¹Pharmacy, Tampa General Hospital, Tampa, FL, ²University of South Florida / Tampa General Hospital, Tampa, FL, ³USF Health Taneja College of Pharmacy/Tampa General Hospital, Tampa, FL, ⁴Pharmacy, USF Health Taneja College of Pharmacy/Tampa General Hospital, Tampa, FL

(1401) Evaluating the Utility of Glucagon-Like Peptide 1 Receptor Agonists in Potential Lung Transplant Candidates Requiring Weight Loss Prior to Transplant; L. Goebel, M. Long, K. Paplaczyk, R. Tomic, M. Venkata Subramani, A. Arunachalam, C. Myers. *Northwestern Medicine, Chicago, IL*

(1402) Evaluating the Tolerability of Glucagon-Like Peptide-1 Receptor Agonists in Lung Transplant Recipients; C. Walshe¹, M. Anderson², J. Diamond², S. Witek¹, T. Claridge¹. ¹Hospital of the University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA

(1403) Development of a Tacrolimus Dosing Simulation Tool After Lung Transplantation by Artificial Neural Network; H. Choshi, K. Miyoshi, M. Tanioka, H. Arai, T. Hayashi, M. Umeda, T. Ryuko, H. Ujike, S. Kawana, Y. Kubo, K. Hashimoto, S. Tanaka, M. Okazaki, S. Sugimoto, S. Toyooka. *Okayama University Hospital, Okayama, Japan*

(1404) Assessing the Relationship Between Pre-Operative Opioid Use and Outcomes of Patients with Cystic Fibrosis Undergoing Lung Transplantation; A. Leng¹, J. M. Ruck¹, J. S. Ha¹, E. Bush¹, C. Merlo². ¹Division of Thoracic Surgery, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, ²Division of Pulmonary Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD

(1405) The Rationale for Therapeutic Drug Monitoring of Isavuconazole in a Lung Transplant Recipient; A. Zajacova¹, M. Sima², J. Havlin³, E. Klapkova⁴, R. Lischke³, O. Slanar², E. Dvorackova². ¹Prague Lung Transplant Program, Department of Pneumology, Second Faculty of Medicine, Charles University, University Hospital Motol, Prague, Czech Republic, ²Institute of Pharmacology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ³Prague Lung Transplant Program, 3rd Department of Surgery, First Faculty of Medicine, Charles University, University Hospital Motol, Prague, Czech Republic, ⁴Department of Medical Chemistry and Clinical Biochemistry, Second Faculty of Medicine, Charles University, University Hospital Motol, Prague, Czech Republic

(1406) Daratumumab for Antibody Mediated Rejection in Lung Transplant; L. Shitanishi¹, D. Brezhnev¹, L. Zaffiri¹, R. Rampolla². ¹Cedars Sinai Medical Center, Los Angeles, CA, ²Cedars-Sinai, Los Angeles, CA

(1407) Perioperative Cefepime Pharmacokinetics Using Therapeutic Drug Monitoring; K. Paplaczyk¹, N. Rhodes¹, E. Weslander¹, T. Kaiho², A. Valadez³, C. Kurihara², S. Galvin⁴, G. Reed³, K. Leonida³. ¹Pharmacy, Northwestern Memorial Hospital, Chicago, IL, ²Division of Thoracic Surgery, Northwestern University, Chicago, IL, ³Midwestern University, Downers Grove, IL, ⁴Infectious Disease, Northwestern University, Chicago, IL

(1408) Through the Looking Glass: Tacrolimus and the Rare Complication of Optic Neuritis in Transplant Recipients; L. Jones¹, H. Keyt². ¹University Health, San Antonio, TX, ²UT Health San Antonio, San Antonio, TX

(1409) Assessing a Conservative Anticoagulation Protocol Following Gastrointestinal Bleeding in Patients with a HeartMate 3 LVAD; B. Tabor, A. Mardis, L. Straw. *Prisma Health, Columbia, SC*

(1410) Efficacy and Safety of SGLT2 Inhibitors in Patients with a LVAD; E. Preheim, L. Straw, A. Mardis. *Prisma Health, Columbia, SC*

(1411) Sodium Glucose Co-Transporter 2 Inhibitor Use in HeartMate 3 Patients; F. Cali¹, A. Ladanyi¹, A. Pinsino¹, K. Antler², J. Murphy², G. M. Mondellini¹, Y. Kaku¹, G. Sayer¹, N. Uriel¹, K. Takeda¹, P. C. Colombo¹, D. Jennings¹, M. Yuzefpolskaya¹. ¹Columbia University Irving Medical Center, New York, NY, ²New York Presbyterian Hospital, New York, NY

FRIDAY, 12 APRIL, 2024

4:30 - 5:30 p.m.

POSTER SESSION 3: Pulmonology (Non-CME)

Location: Poster Hall

Core Therapies: HEART, LUNG, MCS, PVD

Practice Areas: Pulmonology, Anesthesiology and Critical Care, Cardiology, Cardiothoracic Surgery, Infectious Diseases, Nursing and Allied Health, Pathology, Pediatrics, Pharmacy, Research and Immunology

Session Summary: Posters in this session include presentations on multiple topics where the Practice Areas of the research is focused in Pulmonology. Designated Poster Discussants will circulate through the poster hall during the session to engage poster presenters in quality discussions of their abstracts. **CME is not offered for poster sessions.**

Poster Discussants: Myriam Aguilar Perez, Spain, David Bennett, Italy, Brandi Bottiger, USA, Marie Budev, USA, Satish Chandrashekar, USA, Marc de Perrot, Canada, Göran Dellgren, Sweden, Alex Dragnich, USA, Juan Fernandez, USA, Reda Girgis, USA, Laurent Godinas, Belgium, Peter Jaksch, Austria, Arun Jose, USA, Basha Khan, India, Angela Koutsokera, Switzerland, Adrian Christopher Lawrence, USA, James Lordan, UK, Gabriela Magda, USA, Federica Meloni, Italy, Nicolas J Mueller, Switzerland, Vijil Rahulan, India, Reinaldo Rampolla, USA, Andrew Sage, Canada, Ashish Sharma, USA, Gaurav Sharma, USA, Vincent Valentine, USA, Adriana Valverde Zuniga, Costa Rica, Mrinalini Venkata Subramani, USA, Erik Verschuuren, Netherlands, Rajat Walia, USA

(1412) Racial and Socioeconomic Disparities in Lung Transplant Waitlisting; R. A. Zudekoff¹, K. Calhoun², J. Smith², A. Gray², S. Arrigain³, R. Lopez Moscoso³, J. Schold³. ¹University of Colorado Department of Medicine, Aurora, CO, ²University of Colorado Division of Pulmonary Sciences and Critical Care, Aurora, CO, ³University of Colorado Department of Surgery, Aurora, CO

(1413) Association of Neighborhood-Level Social Disinvestment with Worse Survival After Lung Transplant is Mediated by Individual Insurance Status; O. Amubieya¹, N. J. Jackson¹, S. Weigt¹, J. Belperio². ¹UCLA, Los Angeles, CA, ²UCLA Pulmonary & C C Med, Los Angeles, CA

(1414) Access to Transplant Through Novel Approaches to Weight Loss (ACTNOW): Implementation and Early Outcomes with Solid Organ Transplant Candidate-Targeted Weight Loss Clinic; A. Reticker¹, C. Kelley¹, A. Guinane¹, J. Boznos¹, R. Jablonski². ¹The University of Chicago, Chicago, IL, ²Pulmonary and Critical Care Medicine, The University of Chicago, Chicago, IL

(1415) Does Timing Matter: Assessing the Impact of Nighttime Lung Transplantation on Patient Outcomes; L. Ezzat, R. Abdulqawi, R. A. Saleh, K. M. Alkattan, W. Saleh, M. Hashim, D. K. Mohamed, E. A. Al-Mutairy. Lung Health Centre Department, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia

(1416) Strategies to Increase DCD Lung Transplantation; S. Nandavaram, J. Watkins, M. Anstead. University of Kentucky, Lexington, KY

(1417) Cold Static Preservation at 10°C and Delirium Following Lung Transplant; T. Kaderi, A. Yuen, L. Shitanishi, D. Barnes, R. Rampolla, L. Zaffiri. Cedars Sinai Medical Center, Los Angeles, CA

(1418) Impact of Concomitant Abdominal Transplant and Lung Transplant: An Outcomes Analysis from The ISHLT Database; R. Wilson¹, B. Langlais², B. Aqel³, J. D'Cunha⁴, P. Reck dos Santos⁴. ¹Mayo Clinic Alix School of Medicine, Mayo Clinic, Phoenix, AZ, ²Department of Quantitative Health Sciences, Mayo Clinic, Phoenix, AZ, ³Department of Gastroenterology and Hepatology, Mayo Clinic, Phoenix, AZ, ⁴Department of Cardiothoracic Surgery, Mayo Clinic, Phoenix, AZ

(1419) Outcomes of Combined Liver-Lung Transplant in Pediatric Patients with Cystic Fibrosis: An ISHLT Study; R. Wilson¹, B. Langlais², B. Aqel³, J. D'Cunha⁴, P. Reck dos Santos⁴. ¹Mayo Clinic Alix School of Medicine, Mayo Clinic, Phoenix, AZ, ²Department of Quantitative Health Sciences, Mayo Clinic, Phoenix, AZ, ³Department of Gastroenterology and Hepatology, Mayo Clinic, Phoenix, AZ, ⁴Department of Cardiothoracic Surgery, Mayo Clinic, Phoenix, AZ

(1420) Does HLA Mismatch Between Donors and Recipients Influence Postoperative Outcomes in Cadaveric Lung Transplants?; H. Kayawake¹, M. Takahashi², S. Tanaka², Y. Yamada³, Y. Yutaka², A. Ohsumi², D. Nakajima², H. Date². ¹Kobe City Medical Center General Hospital, Kobe, Japan, ²Kyoto University, Kyoto, Japan, ³Kyoto Katsura Hospital, Kyoto, Japan

(1421) Feasibility Study of Bronchoalveolar Donor-Derived Cell Free DNA as Diagnostic Biomarker of Graft Health; Z. Kovacs¹, K. Hoetzenecker², P. Jaksch¹, P. Boehm², A. Benazzo², S. Auner³, C. Hillebrand³, G. Murakoezy³, I. Fae³, G. Fischer³, D. Koren³. ¹Department of Thoracic Surgery, Medical University Vienna, Vienna, Austria, ²Department of Thoracic Surgery, Medical University of Vienna, Vienna, Austria, ³Medical University of Vienna, Vienna, Austria

(1422) Lung Transplantation for Short-Telomere Interstitial Lung Disease: Outcomes from an Australian Cohort; L. Zhang¹, V. P. Lutzky¹, S. H. Apte¹, P. L. Groves¹, M. E. Tan¹, S. Watson², P. Hopkins¹, D. Chambers¹, J. Mackintosh¹. ¹Queensland Lung Transplant Service, The Prince Charles Hospital, Brisbane, Australia, ²Department of Thoracic Medicine, The Prince Charles Hospital, Brisbane, Australia

(1423) Pretransplant Left Ventricular Ejection Fraction Did Not Impact Short-Term Survival in Lung Recipients; D. Razia¹, A. Saugstad¹, J. Braat¹, M. Wang¹, C. James¹, R. Walia², R. Vijaykrishnan³, A. Arjuna². ¹Creighton University School of Medicine - Phoenix Regional Campus, Phoenix, AZ, ²Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ, ³St. Joseph's Hospital and Medical Center, Phoenix, AZ

(1424) Clinical Implications of Early vs Late Development of Donor-Specific Antibodies After Lung Transplant; D. Sindu¹, N. Kohler², G. Bitar², B. Franz³, C. Mitchell³, C. Pham⁴, K. Grief¹, R. Walia¹, S. Tokman¹. ¹Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ, ²Creighton University School of Medicine - Phoenix Regional Campus, Phoenix, AZ, ³Vitalant, Phoenix, AZ, ⁴St. Joseph's Hospital and Medical Center, Phoenix, AZ

(1425) Survival Analysis and Surgical Considerations in Lung Transplantation for Silicosis: Single vs. Double Lung Transplants; M. Dotan¹, D. Rosengarten², K. Azem³, S. Fein³, Y. Shostak⁴, D. Shitenberg⁵, Y. Peysakhovich⁶, Y. Barac⁶, O. Shtraichman⁵, M. R. Kramer⁵. ¹Pulmonary Institute, Schneider Children's Medical Center of Israel, Petach Tikva; and, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ²Pulmonary Institute, Rabin Medical Center, Beilinson Hospital, Petach Tikva, and Department of Anesthesiology, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel, ³Department of Anesthesiology, Rabin Medical Center, Beilinson Hospital, Petach Tikva, and Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ⁴Faculty of Medicine, Tel Aviv University, Tel Aviv, and Department of Medicine D, Rabin Medical Center, Petach Tikva, Israel, ⁵Faculty of Medicine, Tel Aviv University, Tel Aviv, and Pulmonary Institute, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel, ⁶Faculty of Medicine, Tel Aviv University, Tel Aviv, and Cardiothoracic Surgery, Rabin Medical Center, Petach Tikva, Israel

(1426) Enhancing Assistant Diagnosis Robust and Accuracy Through AI-Driven Radiographic Analysis and Reasoning; B. Yue¹, Y. Yan², M. Huang¹, J. Chen¹. ¹The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China, ²Westlake University, Hangzhou, China

(1427) Association of Donor Derived Cell-Free DNA Fractions with Acute Rejection and Pulmonary Infections in Lung Transplant Recipients; S. Pasupneti, H. Mudgett, E. Mann, S. Jacobs, J. Mooney, G. Dhillon. Stanford University, Stanford, CA

SATURDAY, 13 APRIL, 2024

8:00 - 9:15 a.m.

ORAL SESSION 36: Mysteries of Acute Cellular Rejection and Inflammation: Lungs and the Half-Blood Prince Part II

Location: South Hall 3

Core Therapies: LUNG

Practice Areas: Pulmonology, Cardiothoracic Surgery, Infectious Diseases, Research and Immunology

Session Summary: This session will present new research in the field of acute lung allograft rejection and inflammation. Acute cellular rejection remains one of the strongest risk factors for chronic rejection and improved understanding of mechanisms and potential biomarkers and treatments is greatly needed. Novel research strategies and animal models will be discussed.

Each presenter will give a **10-minute** PowerPoint presentation, followed by a **5-minute** question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: Marlene Cano, MD, PhD, Washington University School of Medicine, St. Louis, MO, USA
Benjamin Renaud-Picard, MD, PhD, Nouvel Hopital Civil, Strasbourg, France

8:00 a.m. **(177) AAV Delivery of PD-L1 with Concomitant CTLA-4 Immunoglobulin Attenuates Acute Cellular Rejection in a Rat Lung Transplant Model**

L. Alderete¹, R. Kahan¹, Q. Gao¹, M. Zhang¹, N. Abraham¹, T. Gonzalez², M. Song¹, J. Carney³, A. Hassan¹, K. Nakata⁴, B. Hughes¹, N. Aykun¹, A. Asokan², A. Barbas¹, M. Hartwig⁴. ¹Department of Surgery, Duke University Medical Center, Durham, NC, ²Department of Molecular Genetics & Microbiology, Duke University, Durham, NC, ³Department of Pathology, Duke University Medical Center, Durham, NC, ⁴Department of Surgery, Division of Cardiovascular and Thoracic Surgery, Duke University Medical Center, Durham, NC

This presenter is also one of five finalists for the 2024 Early Career Scientist Award. Winner will be announced after the meeting.

8:10 a.m. **Q&A**

8:15 a.m. **(178) Dysfunctional Regulatory T Cells Characterize Acute Cellular Rejection in Lung Transplant Recipients**

M. M. Khan¹, A. Potter², M. M. Banday¹, D. Hayes³, N. S. Sharma⁴. ¹BWH, Boston, MA, ²Cincinnati Childrens, Cincinnati, OH, ³Cincinnati Children's Hospital Medical Center / University of Cincinnati, Cincinnati, OH, ⁴Brigham & Women's Hospital, Boston, MA

8:25 a.m. **Q&A**

8:30 a.m. **(179) Aberrant IL-33 Signaling Modulates Extracellular Matrix Remodeling and is Associated with Acute Cellular Rejection in Lung Transplant Recipients**

M. Banday¹, M. Khan¹, N. Sharma². ¹Brigham and Womens, Boston, MA, ²Brigham & Women's Hospital, Boston, MA

8:40 a.m. **Q&A**

8:45 a.m. **(180) Longitudinal Lower Airway Microbial Signatures of Acute Cellular Rejection in Lung Transplantation**

J. G. Natalini¹, K. K. Wong¹, N. C. Nelson¹, B. G. Wu¹, D. Rudym¹, M. B. Lesko¹, S. Qayum¹, T. C. Lewis², S. H. Chang³, J. C. Chan³, T. C. Geraci³, F. A. Tiripicchio², Y. Li¹, C. Wang⁴, H. Li⁴, J. Schnier¹, P. Pamar¹, I. J. Mahoney¹, T. Malik¹, F. Darawshy¹, I. Sulaiman¹, R. Singh¹, D. E. Collazo¹, M. Chang¹, S. Patel¹, Y. Kyeremateng¹, C. McCormick¹, C. R. Barnett¹, J. J. Tsay¹, S. R. Brosnahan¹, S. Singh¹, H. I. Pass³, L. F. Angel¹, L. N. Segal¹. ¹Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, New York University Grossman School of Medicine, New York, NY, ²NYU Langone Transplant Institute, NYU Langone Health, New York, NY, ³Department of Cardiothoracic Surgery, New York University Grossman School of Medicine, New York, NY, ⁴Department of Population Health, New York University Grossman School of Medicine, New York, NY

8:55 a.m. **Q&A**

9:00 a.m. **(181) Engraftment of Alveolar Macrophages from Human LT Recipients into Immunodeficient Mice as a Tool to Study Mechanisms of Lung Allograft Inflammation**

S. Moshkelgosh¹, Y. Suzuki¹, A. Duong¹, J. Oliver¹, T. Martinu¹, S. Juvet¹. Toronto Lung Transplant Program, University Health Network, Toronto, ON, Canada

9:10 a.m. **Q&A**

SATURDAY, 13 APRIL, 2024

8:00 - 9:15 a.m.

ORAL SESSION 37: Cardiac Allograft Vasculopathy: New Insights

Location: South Hall 1

Core Therapies: HEART

Practice Areas: Cardiology, Cardiothoracic Surgery, Research and Immunology

Session Summary: Presentations on the latest clinical and imaging research in CAV.

Each presenter will give a **10-minute** PowerPoint presentation, followed by a **5-minute** question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: Christian Heim, MD PhD MHBA, University of Erlangen, Erlangen, Germany
Andriana Nikolova, MD, Cedars Sinai Medical Center, Los Angeles, CA, USA

8:00 a.m. **(182) Waitlist Mortality for Patients with Cardiac Allograft Vasculopathy Under the 2018 UNOS Donor Heart Allocation System**

B. S. Kadosh¹, S. S. Patel², S. Sidhu¹, A. B. Massie², S. Golob³, R. Goldberg³, N. Moazami³, A. Reyentovich¹. ¹Medicine, NYU Langone Health, New York, NY, ²Surgery, NYU Langone Health, New York, NY, ³NYU Langone Health, New York, NY

8:10 a.m. **Q&A**

8:15 a.m. **(183) Myocardial Blood Flow Assessment with PET Improves Risk Stratification Among HT Recipients with CAV1**

N. Prasad, E. S. Harris, D. Skoll, J. Fried, V. S. Topkara, J. Raikhelkar, E. M. DeFilippis, F. Latif, M. Yuzefpolskaya, P. C. Colombo, G. Sayer, N. Uriel, A. J. Einstein, K. J. Clerkin. *Columbia University Irving Medical Center, New York, NY*

8:25 a.m. **Q&A**

8:30 a.m. **Late-Breaking Abstract Presentation:**

(1066) Pilot Experience with Heart After Liver Transplantation with Domino (HALT-D) for Highly Allosensitized Recipients: Midterm Outcomes

I. Dimarakis¹, S. Lin², A. Karatasakis², R. Bhattacharya³, E. Chou-Wu⁴, I. Gimferrer⁴, N. Leca⁵, R. Bakthavatsalam⁶, M. Sturdevant⁶, A. Stempien-Otero², D. A. Fishbein², J. Pal¹. ¹Division of Cardiothoracic Surgery, University of Washington, Seattle, WA, ²Division of Cardiology, University of Washington, Seattle, WA, ³Division of Gastroenterology, University of Washington, Seattle, WA, ⁴HLA/Immunogenetics Laboratory, Bloodworks Northwest, Seattle, WA, ⁵Division of Nephrology, University of Washington, Seattle, WA, ⁶Department of Surgery, University of Washington, Seattle, WA

8:40 a.m. **Q&A**

8:45 a.m. **(184) Re-Evaluating Natriuretic Peptides as Biomarkers of Cardiac Allograft Vasculopathy**

K. Patel, A. Yadalam, M. E. Gold, P. Patel, J. Waller, A. S. Gillet, A. Panagopoulos, A. Alkhoder, Z. Siddiqui, O. Khawaja, H. Allaqaband, S. Sakr, A. Rahbar, Y. Haroun, H. Hashmi, A. Shamim, K. Ejaz, D. Gupta, W. Book, A. A. Quyyumi. *Emory University, Atlanta, GA*

8:55 a.m. **Q&A**

9:00 a.m. **(185) Epicardial and Microvascular CAV are Associated with Restrictive Physiology After Heart Transplantation**

E. S. Harris, N. Prasad, J. A. Fried, V. K. Topkara, J. Raikhelkar, E. M. DeFilippis, F. Latif, M. Yuzefpolskaya, P. C. Colombo, G. Sayer, N. Uriel, K. Clerkin. *Milstein Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, NY*

9:10 a.m. **Q&A**

SATURDAY, 13 APRIL, 2024

8:00 - 9:15 a.m.

ORAL SESSION 38: Higher, Further, Faster: Optimization of LVAD Hemodynamics

Location: South Hall 2

Core Therapies: MCS

Practice Areas: Cardiology, Anesthesiology and Critical Care, Cardiothoracic Surgery, Nursing and Allied Health, Pharmacy

Session Summary: This session will dive into methods to optimize cardiac function in your LVAD patients.

Each presenter will give a **10-minute** PowerPoint presentation, followed by a **5-minute** question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: Christoph Knosalla, MD, Deutsches Herzzentrum der Charité, Berlin, Germany
Amin Yehya, MD, MSc, Sentara Heart Hospital, Norfolk, VA, USA

8:00 a.m. **(186) Phenotyping of Left Ventricular Volume Unloading During Echocardiographic Speed Ramp Tests and Non-Invasive Heartmate 3 Snoopy Monitoring**
H. Al Asadi¹, A. K. Schaefer¹, T. Abart¹, G. Widhalm¹, C. Marko¹, R. Moayedifar¹, J. Riebandt¹, D. Wiedemann¹, D. Zimpfer¹, T. Schloeglhofer². ¹Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria, ²Department of Cardiac Surgery, Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Ludwig Boltzmann Institute for Cardiovascular Research, Vienna, Austria

8:10 a.m. **Q&A**

8:15 a.m. **(187) Optimized or Not? International Practices for VAD Speed Optimization**
J. McLean¹, Y. Wu², K. Marz³, T. Schloeglhofer⁴. ¹Heart and Lung Transplant Services, Alfred Health, Melbourne, Australia, ²Advanced Heart Failure Comprehensive Care Center, University of California San Francisco, San Francisco, CA, ³Advanced Heart Failure, Mechanical Circulatory Support, Ochsner Health, New Orleans, LA, ⁴Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria

8:25 a.m. **Q&A**

8:30 a.m. **(188) Right Ventriculo-Arterial Coupling Assessment by High-Fidelity Hemodynamic Measurements in Patients Undergoing Left Ventricular Assist Device Implantation**

A. Nicoara¹, K. Hunter², C. Culp¹, M. Cooter Wright¹, A. D. Cherry¹, J. Schroder³, R. Krasuski⁴, C. Milano³, J. Keenan³, M. Podgoreanu¹. ¹Anesthesiology, Duke University, Durham, NC, ²Biomedical Engineering, University of Colorado, Denver, CO, ³Surgery, Duke University Medical Center, Durham, NC, ⁴Pediatrics, Duke University, Durham, NC

8:40 a.m. **Q&A**

8:45 a.m. **(189) Normalized Hemodynamics at Submaximal Exercise in Patients with Left Ventricular Assist Devices (LVAD)**

V. Ton, A. Minasian, K. Drezek, C. Yturralde, S. Charounipha, J. Rouvina, C. White, A. Kowal, J. Camuso, T. Logan, K. Milley, A. Dempsey, E. Coglianese, I. Mastoris, A. Osho, E. Michel, D. D'Alessandro, G. D. Lewis. Massachusetts General Hospital, Boston, MA

8:55 a.m. **Q&A**

9:00 a.m. **(190) Utility of CardioMEMS HF System Data in Management of Patients Supported with Durable Left Ventricular Assist Devices (INTELLECT 3-HF Study)**

M. Khorsandi¹, I. Dimarakis¹, S. Lin², R. Zhang¹, J. Pal¹. ¹Cardiothoracic Surgery, University of Washington Medical Center, Seattle, WA, ²Cardiology, University of Washington Medical Center, Seattle, WA

9:10 a.m. **Q&A**

SATURDAY, 13 APRIL, 2024

8:00 - 9:15 a.m.

ORAL SESSION 39: Perioperative ECMO and Surgical Techniques for Lung Transplantation: Avoiding Dementors in Thoraxkaban

Location: Panorama Hall

Core Therapies: LUNG

Practice Areas: Cardiothoracic Surgery, Anesthesiology and Critical Care, Pediatrics, Pulmonology

Session Summary: We will showcase studies that examine surgical strategy and their relationships to improving outcomes after lung transplantation. This session explores various surgical techniques, perioperative ECMO strategies, and highlights an up and coming randomized controlled trial comparing ECMO vs off pump strategies.

Each presenter will give a **10-minute** PowerPoint presentation, followed by a **5-minute** question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: Kevin Chan, MD, Michigan Medicine, Ann Arbor, MI, USA
Alessandra Verzelloni Sef, Harefield Hospital, Royal Brompton and Harefield Hospitals, Harefield, United Kingdom

- 8:00 a.m. **(191) Lung Transplant Using Extra-Corporeal Membrane Oxygenation: Outcomes and Predictors of Conversion to Cardiopulmonary Bypass**
S. Huddleston¹, G. Loo², Q. Zhang², M. Salan-Gomez², N. D. de Manna³, D. Van Raemdonck⁴, M. Hartwig⁵, A. Leon Pena², Q. Luo⁶, R. Li⁷, M. Villavicencio⁸, N. Langer⁹, A. Emtiazjoo¹⁰, S. Chandrashekar¹¹, T. Machuca¹², A. Neyrinck¹³, A. Kashem¹⁴, R. Kelly¹, N. Lemke¹⁵, K. Subramaniam¹⁶, G. Warnecke¹⁷, F. lus¹⁸, J. Campo¹⁹, Y. Toyoda¹⁴. ¹University of Minnesota, Minneapolis, MN, ²Baylor CoM, Houston, TX, ³Cardiothoracic, Transplantation, Hannover Med Sch, Hannover, Germany, ⁴Univ Hospitals Leuven, Leuven, Belgium, ⁵Duke Univ MC, Durham, NC, ⁶Univ of Minnesota MC, Minneapolis, MN, ⁷George Washington, Washington, DC, ⁸Mayo Clinic, Rochester, MN, ⁹Mass Gen Hosp, Boston, MA, ¹⁰Univ of Florida, Gainesville, FL, ¹¹Emory Univ Hosp, Atlanta, GA, ¹²Univ of Miami, Miami, FL, ¹³Leuven Univ Hospitals, Leuven, Belgium, ¹⁴Temple Univ SoM, Philadelphia, PA, ¹⁵U of Minnesota, Minneapolis, MN, ¹⁶Univ of Pittsburgh MC Presbyterian Hosp, Pittsburgh, PA, ¹⁷Univ of Heidelberg, Heidelberg, Germany, ¹⁸Hannover Med Sch, Hannover, Germany, ¹⁹Hosp Puerta de Hierro, Madrid, Spain
- 8:10 a.m. **Q&A**
- 8:15 a.m. **(192) Outcomes of Candidates Bridged to Lung Transplant Using Non-Intubated Extracorporeal Membrane Oxygenation**
A. L. Zhou¹, A. F. Akbar², J. M. Ruck¹, M. R. Jennings¹, A. Kalra³, E. L. Larson¹, A. J. Casillan¹, J. S. Ha¹, C. A. Merlo⁴, E. L. Bush¹. ¹Surgery, Johns Hopkins Univ SoM, Baltimore, MD, ²Surgery, Johns Hopkins SoM, Baltimore, MD, ³Surgery, Sidney Kimmel Medical College, Thomas Jefferson Univ, Philadelphia, PA, ⁴Medicine, Johns Hopkins Univ SoM, Baltimore, MD
- 8:25 a.m. **Q&A**
- 8:30 a.m. **(193) Concomitant Heart and Lung Surgery During Lung Transplantation**
M. Azuma¹, A. Kashem², R. Yanagida³, N. Shigemura⁴, Y. Toyoda². ¹Lewis Katz School of Medicine, Philadelphia, PA, ²Temple University School of Medicine, Philadelphia, PA, ³Temple University Hospital, Philadelphia, PA, ⁴Temple University Health System and Lewis Katz School of Medicine, Philadelphia, PA
- 8:40 a.m. **Q&A**
- 8:45 a.m. **Late-Breaking Abstract Presentation:**
(638) Multicenter Open-Label Tacrolimus Inhalation Powder Trial Evaluating Safety, Tolerability, Efficacy and Pharmacokinetics (pk) in Lung Transplant (Itx) Recipients with Significant Renal Impairment
G. Snell¹, B. Levvey², G. Westall¹, D. Christensen³, C. Hudson³, Z. Mikhak³. ¹Alfred Hospital, Melbourne, Australia, ²The Alfred Hospital, Melbourne, Australia, ³TFF Pharmaceuticals, Fort Worth, TX
- 8:55 a.m. **Q&A**
- 9:00 a.m. **Late-Breaking Abstract Presentation:**
(948) One-Year Outcomes of Remote Ex-Vivo Lung Perfusion in the Real-World Setting
A. J. Trindade¹, C. Demarest¹, W. D. Tucker¹, B. S. Petree¹, J. W. Stokes¹, S. M. Pham², M. Thomas², M. Bacchetta¹, J. Mallea². ¹Vanderbilt University Medical Center, Nashville, TN, ²Mayo Clinic, Jacksonville, FL
- 9:10 a.m. **Q&A**

SATURDAY, 13 APRIL, 2024

8:00 - 9:15 a.m.

ORAL SESSION 40: This is your Heart on Drugs - Pharmaceutical Therapies in Heart Transplant

Location: North Hall

Core Therapies: HEART

Practice Areas: Pharmacy, Cardiology, Cardiothoracic Surgery

Session Summary: This session includes pharmacy therapeutics research in patients across the continuum of end-stage heart failure to post-transplant.

Each presenter will give a **10-minute** PowerPoint presentation, followed by a **5-minute** question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: Megan Greene, PharmD, Children's Hospital Colorado, Denver, CO, USA
Daryl Nnani, PharmD, Montefiore Medical Center, Bronx, NY, USA

- 8:00 a.m. **(195) CD38-Antibody Daratumumab in Allosensitized Recipients for Heart Transplantation: Outcomes and 3-Years of Single-Centre Experience**
C. Atteneder¹, R. Moayedifar¹, D. Koren², G. Fischer², M. Nackenhorst³, K. Uyanik-Uenal¹, J. Goekler¹, G. Boehmig⁴, A. Aliabadi-Zuckermann¹, A. Zuckermann¹. ¹Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria, ²Department of Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, Austria, ³Department of Pathology, Medical University of Vienna, Vienna, Austria, ⁴Department of Medicine III, Medical University of Vienna, Vienna, Austria
- 8:10 a.m. **Q&A**
- 8:15 a.m. **(196) Dot Your I's and Check Your T's? Impact of Various T Cell Monitoring Methods on Heart Transplant Outcomes**
E. Henricksen¹, K. Khush², R. Lee¹, T. Intieri², H. Luikart², D. Kim², A. Skoda², A. Subramanian², B. Wayda², M. B. ZHANG², R. Imai¹, T. Le¹, U. Wang¹, Y. Moayed³, K. Sallam², S. Hsiao², F. Haddad², Y. Shudo², J. Teuteberg². ¹Transplant, Stanford Health Care, Stanford, CA, ²Stanford University, Stanford, CA, ³UHN, Toronto, ON, Canada
- 8:25 a.m. **Q&A**
- 8:30 a.m. **(197) Incidence and Risk Factors for Rejection After Conversion to Sirolimus-Based Immunosuppression in Orthotopic Heart Transplant Recipients**
S. Inglis, M. Abbas, R. Asleh, S. Kushwaha, A. Clavell, M. Villavicencio, P. Spencer, R. Daly, A. Behfar, A. Rosenbaum. *Mayo Clinic, Rochester, MN*
- 8:40 a.m. **Q&A**
- 8:45 a.m. **(198) Diabetes Therapy with Novel Agents After Heart Transplant: A Multi-Institutional Analysis**
L. Brinker, K. Sideris, R. Singh, M. Nevers, G. Wei, S. Hartsell, A. Sarwal, C. Kyriakopoulos, E. Maneta, S. Drakos, T. Hanff, S. Carter, J. Fang, M. Cho, S. Beddhu, J. Stehlik. *University of Utah, Salt Lake City, UT*
- 8:55 a.m. **Q&A**
- 9:00 a.m. **(199) Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss in End-Stage Heart Failure Patients Considered for Heart Transplantation**
S. Jeyakumar¹, R. Jeyakumar¹, D. Robson², L. Honeysett², L. Raven², R. Campos Deveza e Silva², A. Jabbour², E. Kotlyar², A. Keogh², J. Greenfield², P. MacDonald², C. Hayward², K. Muthiah². ¹University of New South Wales, Sydney, Australia, ²St. Vincent's Hospital, Sydney, Australia
- 9:10 a.m. **Q&A**

SATURDAY, 13 APRIL, 2024

9:30 - 11:00 a.m.

PLENARY 3: General Session III

Location: Congress Hall

Core Therapies: HEART, LUNG, MCS, PVD

Practice Areas: Anesthesiology and Critical Care, Cardiology, Cardiothoracic Surgery, Infectious Diseases, Nursing and Allied Health, Pathology, Pediatrics, Pharmacy, Pulmonology, Research and Immunology

Session Summary: General Sessions at ISHLT2024 offer engaging speakers, comprehensive scientific reviews, and featured abstracts highlighting critical research in a range of fields.

Moderators: Christian Benden, MD, MBA, FCCP, University of Zürich, Zurich, Switzerland
Kiran Khush, MD, MAS, Stanford University, Palo Alto, CA, USA

9:31 a.m. **Early Career Featured Video**

9:32 a.m. **Awards Presentations**

Kathleen Grady, PhD, RN, MS, FAAN, Northwestern University, Chicago, IL, USA

Presentation of ISHLT's 2024 Research Grants and Scientific Abstract Award winners.

10:03 a.m. **Featured Late-Breaking Abstract Presentation:**

(2) The Assist CLAD Study - Mesenchymal Stromal Cell Therapy in Chronic Lung Allograft Dysfunction

D. C. Chambers¹, G. Westall², D. Darley³, A. Glanville³, M. Malouf³, M. Musk⁴, M. Sturm⁵, C. Holmes-Liew⁶, S. Lawrence⁴, D. Bushell², L. Holsworth², N. Lawson⁴, L. Singleton³, S. Timmins¹, D. Enever¹, H. Wildermuth¹, O. Daka¹, B. Cooper¹, S. H. Apte¹, A. Pham¹, S. Haines², L. Zhang¹, M. Tan¹, P. Groves¹, V. P. Lutzky¹, B. Levvey², Y. Cristiano², M. Yaw⁴, L. Winks¹, B. O'Sullivan¹, T. de Silva⁷, M. Trotter¹, A. Carew¹, M. Holmes⁶, A. Fiene¹, C. Divithotawela¹, J. A. Mackintosh¹, S. Yerkovich⁸, G. Snell², P. Hopkins¹. ¹Queensland Lung Transplant Service, The Prince Charles Hospital, Brisbane, Australia, ²The Alfred Hospital, Melbourne, Australia, ³St. Vincent's Hospital, Sydney, Australia, ⁴Fiona Stanley Hospital, Perth, Australia, ⁵Isopogen Pty Ltd, Western Australia, Australia, ⁶Royal Adelaide Hospital, Adelaide, Australia, ⁷Queensland University of Technology, Brisbane, Australia, ⁸Menzies School of Health Research and Faculty of Health, Queensland University of Technology, Brisbane, Australia

10:13 a.m. **Q&A with Interactive Discussant**

Tereza Martinu, MD, MHS, Toronto General Hospital/UHN, Toronto, ON, Canada

10:20-11 a.m. **PRESIDENT'S DEBATE: The Future of Transplantation is Centralized Organ Donor Management**

The pro-con debaters will illustrate how centralization of donor management may impact transplantation activity versus maintaining these activities "in-house" at donor hospitals as most institutions have managed this historically. Both speakers may from different sides discuss and illustrate how centralization (or not) may impact donor management to optimize donor procurement outcomes and increase viable organs, spur innovations in technologies such as NRP, and streamline the use of machines to optimize organs. The economic, legal, and ethical concerns for different donor approaches will be considered, including in the light of commercialization of organ optimization. Each speaker will have 15 minutes for their argument followed by 5 minutes for rebuttal.

10:20 a.m. **PRO:** Dirk Van Raemdonck, MD, PhD, University Hospitals Leuven, Leuven, Belgium

10:35 a.m. **CON:** Daniel Goldstein, MD, Montefiore, Bronx, NY, USA

10:50 a.m. **Rebuttals**

SATURDAY, 13 APRIL, 2024

11:30 a.m. - 12:45 p.m.

SYMPOSIUM 41: Live Long and Prosper: Improving Survival in Cardiogenic Shock

Location: Congress Hall

Core Therapies: MCS, HEART

Practice Areas: Cardiology, Anesthesiology and Critical Care, Cardiothoracic Surgery, Nursing, Allied Health, Pulmonology

Session Summary: Expert speakers will discuss the current gaps in diagnosis, prognostication and treatment. A panel discussion with all speakers including audience Q&A, led by the session moderators, will conclude this session.

Moderators: Maria Renedo, MD, Fundacion Favaloro, Buenos Aires, Argentina
Gerin Stevens, MD, PhD, Northwell, Manhasset, NY, USA

11:30 a.m. ***Captain's Log - Hour 24: What Should Occur in the First "Golden Day" of Shock Treatment?***

Van-Khue Ton, MD, PhD, Massachusetts General Hospital, Boston, MA, USA

Discuss timely diagnosis of shock, placement of invasive hemodynamic monitoring, medical management, inotropic therapy and timing of escalation of care to ECMO vs temporary MCS.

11:40 a.m. ***Boggles the Mind: Under-utilization of Temporary MCS in Women and Under-represented Populations***

Johanna Contreras, MD, MSc, Mount Sinai, New York, NY, USA

Women are more likely to be diagnosed with cardiogenic shock at a later stage when they are sicker and less likely to benefit from MCS. This talk will focus on highlighting the underutilization of temporary MCS in women and minorities and reviewing options of care for hub and spoke models.

11:50 a.m. ***The Game of Life: Cardiogenic Shock Resource Utilization***

Alexander Bernhardt, MD, University Heart and Vascular Center Hamburg, Hamburg, Germany

Discuss factors that should be considered when managing patients with cardiogenic shock in resource rich and resource limited centers.

12:00 p.m. ***Managing Risk: Rapid Transfer or Stabilize First?***

Leonardo Salazar, MD, Fundacion Cardiovascular de Colombia, Floridablanca, Colombia.

Discuss factors that should be considered when deciding when to hold a patient at a satellite center versus transfer to a tertiary center.

12:10 p.m. ***Engage, Mr. Data! Artificial Intelligence's Role in Shock Diagnosis and Treatment***

Elric Zweck, MD, University Hospital Düsseldorf, Düsseldorf, Germany

Discuss how AI can help aide the diagnosis and treatment strategies in cardiogenic shock.

12:25 p.m. ***Panel Discussion led by Moderators***

SATURDAY, 13 APRIL, 2024

11:30 a.m. - 12:45 p.m.

SYMPOSIUM 42: Against All Odds: Medical Management of Multiorgan Heart Transplant Recipients

Location: South Hall 3

Core Therapies: HEART

Practice Areas: Cardiology, Anesthesiology and Critical Care, Cardiothoracic Surgery, Infectious Diseases, Nursing and Allied Health, Pediatrics, Pharmacy, Research and Immunology

Session Summary: This session will focus on the current evidence on when to refer patients with multiorgan failure for simultaneous cardiac transplantation and secondary organ, how these patients are bridged with mechanical circulatory support, discuss intraoperative/perioperative management of multiorgan heart transplant recipients, and their outcomes. A panel discussion with all speakers including audience Q&A, led by the session moderators, will conclude this session.

Moderators: Nhue Do, MD, Vanderbilt University, Nashville, TN, USA
Jill Krisl, PharmD, Houston Methodist Hospital, Houston, TX, USA

11:30 a.m. ***Why Stop At The Heart? Multiorgan Transplantation: Who and When?***
Heather Ross, MD, MHSc, FRCPC, UHN Toronto General Hospital, Toronto, ON, Canada

This talk will discuss the challenges of patients with multiorgan failure, when to refer them for multiorgan cardiac transplantation, and how best to minimize poor outcomes in these patients – how soon is too soon, and how late is too late.

11:45 a.m. ***Bridging Patients Listed for Multiorgan Cardiac Transplantation With MCS***
Ivan Netuka, MD, PhD, IKEM Institute for Clinical and Experimental Medicine, Prague, Czech Republic

This talk will discuss how patients with multiorgan failure listed for simultaneous cardiac transplantation and secondary organ are bridged with MCS and impact on post-transplant survival.

12:00 p.m. ***Intraoperative And Postoperative Management of Patients Undergoing Combined Heart-Liver Transplantation***
Theresa Gelzinis, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

This talk will focus on the perioperative aspects of combined heart-liver transplantation, including accurate and precise hemodynamic monitoring, better understanding and management of hemodynamic profiles, fluid management, prolonged vasoplegia and surgical considerations.

12:15 p.m. ***Outcomes of Multiorgan Cardiac Transplantation***
Hrvoje Gasparovic, MD, PhD, University Hospital Center, Zagreb, Croatia

This talk will focus on early and late outcomes in multiorgan cardiac transplantation recipients, including current evidence for perioperative immunosuppressive strategies to minimize adverse outcomes.

12:30 p.m. ***Panel Discussion led by Moderators***

SATURDAY, 13 APRIL, 2024

11:30 a.m. - 12:45 p.m.

SYMPOSIUM 43: A Hard Day's Night: Challenges in Managing Group 2 and Group 3 PH

Location: South Hall 1

Core Therapies: PVD, LUNG

Practice Areas: Cardiology, Anesthesiology and Critical Care, Cardiothoracic Surgery, Nursing and Allied Health, Pathology, Pediatrics, Pharmacy, Pulmonology

Session Summary: This session will focus on the unique challenges of management of patients with group 2 and group 3 pulmonary hypertension. It will cover challenges of diagnosis, surgical considerations, medical therapies, and advanced surgical therapies. A panel discussion with all speakers including audience Q&A, led by the session moderators, will conclude this session.

Moderators: John Aubert, MD, Centre Hosp Univ Vaudois et Univ de Lausanne, Lausanne, Switzerland
Raymond Benza, MD, Mount Sinai Icahn School of Medicine, New York, NY, USA

11:30 a.m. ***I've Got a Feeling: Diagnosis and risk assessment in Group 2 and Group 3 PH***
Clara Hjalmarsson, MD, PhD, Sahlgrenska University Hospital, Gothenburg, Sweden

This talk will discuss the current challenges of diagnosing and assessing risk for group 2 and group 3 PH adult and pediatric patients. Diagnosis is complicated by the presence of co-morbid disease states and hemodynamic assessment is fraught with challenges in both populations. This talk provides an overview of diagnostic and assessment challenges in this group, and reviews strategies used to overcome diagnostic dilemmas.

11:42 a.m. ***Back in the OR: Perioperative Considerations in Patients with Group 2 and Group 3 PH***
Katherine Kozarek, MD, University of Wisconsin-Madison, Madison, WI, USA

The speaker will focus on the unique risk assessment in preparation for non-transplant surgery and procedures in adult and pediatric patients with group 2 and group 3 pulmonary hypertension. The talk will cover anesthesia risk stratification, unique perioperative management, and post-operative pitfalls common in patients with Group 2 and Group 3 PH.

11:54 a.m. ***Sgt Pepper's Not-So-Lonely Hearts: Medical and Interventional Therapies for Group 2 PH***
Celine Dewachter, MD PhD, Erasme Hospital, Brussels, Belgium

The speaker will discuss the current evidence for medical and interventional therapies in Group 2 adult and pediatric patients. They will discuss considerations for utilizing certain medical therapies (e.g., concomitant disease state, drug interactions) as well as practical application for selecting advanced interventional and surgical therapies.

12:06 p.m. ***Here Comes the Drugs: Medical Therapies for Group 3***
Amy Kiskaddon, PharmD, MBA, Johns Hopkins All Children's Hospital, St. Petersburg, FL, USA

The speaker will discuss the current evidence for medical therapies in Group 3 adult and pediatric patients, considerations for utilizing certain medical therapies (e.g., concomitant disease state, drug interactions) as well as practical application for selecting therapies.

12:18 p.m. ***Don't Let Me Down: What We Learned From Failed Trials in Group 2 and Group 3 PH***
Nicholas A. Kolaitis, MD MAS, UCSF, San Francisco, CA, USA

The speaker will discuss the multiple failed clinical trials in Group 2 and Group 3 PH. The talk will discuss why some trials have been unsuccessful, how to select the correct patient population for clinical trials, and how future Group 2 and Group 3 PH trials should be designed.

12:30 p.m. ***Panel Discussion led by Moderators***

SATURDAY, 13 APRIL, 2024

11:30 a.m. - 12:45 p.m.

SYMPOSIUM 44: Dream or Reality? Durable LVADs for Myocardial Recovery

Location: South Hall 2

Core Therapies: MCS, HEART

Practice Areas: Cardiology, Cardiothoracic Surgery, Pediatrics

Session Summary: Registry data suggests myocardial recovery remains exceedingly rare with durable LVAD support. This session is intended to summarize real-world outcomes and clinical trial data, share best practices on developing a recovery program, and debate strategies for managing younger patients with a high potential for myocardial recovery. A panel discussion with all speakers including audience Q&A, led by the session moderators, will conclude this session.

Moderators: Gillian Grafton, DO, Henry Ford Hospital, Detroit, MI, USA
Daniel N. Silverman, MD, Medical University of South Carolina, Charleston, SC, USA

11:30 a.m. ***How to Implement a Systematic Strategy to Promote and Assess Myocardial Recovery***
Cesar Guerrero-Miranda, MD, FACC, Baylor University MC, Baylor Scott and White, Dallas, TX, USA

Myocardial recovery with or without an LVAD needs an organized effort in identifying patients, promoting recovery, and appropriately assessing the timing of readiness for explant.

11:42 a.m. ***What Can Pediatric Hearts Teach Us About Recovery?***
Shelley Miyamoto, MD, Children's Hospital Colorado, Aurora, CO, USA

Studies of pediatric hearts suggest greater myocardial plasticity and the ability to reverse remodel more readily than adults. What can the adult community learn from children with heart failure.

11:54 a.m. ***Case Presentation: 36-year-old Male with NICM and Cardiogenic Shock***
Thomas Hanff, MD, MSCE, MPH, University of Utah, Salt Lake City, UT, USA

Case Presentation to introduce the debate.

12:06 p.m. ***DEBATE: Young Patients with a NICM Should Receive an LVAD First and Delay Transplant (PRO)***
Stephan Schueler, MD, PhD, FRCS, Newcastle upon Tyne Hospitals, Freeman Hospital, Newcastle upon Tyne Hospitals, United Kingdom

Speaker will highlight how LVAD therapy may lead to recovery and prolong patient longevity in young patients with a non-ischemic cardiomyopathy.

12:18 p.m. ***DEBATE: Young Patients with a NICM Should Receive an LVAD First and Delay Transplant (CON)***
Michael Zakliczynski, MD, Jan Mikulicz-Radecki University Teaching Hospital, Wroclaw, Poland.

This talk will argue that patients should be expedited to heart transplant when young, avoiding an LVAD and going straight to transplant.

12:30 p.m. ***Panel Discussion led by Moderators***

SATURDAY, 13 APRIL, 2024

11:30 a.m. - 12:45 p.m.

SYMPOSIUM 45: Flattening the Survival Curve: Improving First Year Post-Transplant Survival for Kids and Adults

Location: Panorama Hall

Core Therapies: HEART, MCS

Practice Areas: Pediatrics, Anesthesiology and Critical Care, Cardiology, Cardiothoracic Surgery, Nursing, Pharmacy, Research and Immunology

Session Summary: This session will discuss how to improve survival in the perioperative period. The main topics will focus on the risk factors, management of recipients pre-transplant, nutrition, fragility, drugs, and how to improve the survival during the first year post-heart transplantation in pediatric and adult populations. A panel discussion with all speakers including audience Q&A, led by the session moderators, will conclude this session.

Moderators: David Baran, MD, Cleveland Clinic Heart, Vascular and Thoracic Institute, Weston, FL, USA
Chesney Castleberry, MD, Dell Medical School at the University of Texas in Austin, Austin, TX, USA

11:30 a.m. ***What are the Limiting Factors to the Early Survival Post-Transplant, and Have We Improved Over Time?***

Anne Dipchand, MD, The Hospital for Sick Children, Toronto, ON, Canada

This talk will focus on the factors that impact early survival post-transplant (ie: diagnosis, patient selection etc) in pediatric and adult populations, and the trends in early outcomes over time.

11:42 a.m. ***How Do We Optimize the Pre-Transplant Period to Improve Early Post-Transplant Survival?***

Estela Azeka, MD, University of Sao Paulo, Sao Paulo, Brazil.

This talk will focus on the role of medical and device management in the pre-transplant period and the impact on early outcomes in pediatric and adult populations. This may include the role of nutrition; role of heart failure management including special consideration in congenital patients; role of VADs.

11:54 a.m. ***What Can We Do in the ICU to Improve Post-Transplant Survival?***

Annemarie Krauss, German Heart Center Berlin, Berlin, Germany

This talk will focus on management of the patient post-transplant: topics may recognizing and treating RV failure, approach to primary graft dysfunction and vasoplegia.

12:06 p.m. ***Do the Other Organs Matter: Managing Co-Morbidities for Early Success***

Kevin Daly, MD, Boston Children's Hospital, Boston, MA, USA

This talk will focus on topics such as approaches to acute kidney injury/renal failure (and balance with immunosuppression), navigating infection risks and managing residual issues in in pediatric and adult patients with congenital heart disease (cyanosis, PLE, etc).

12:18 p.m. ***Panel Discussion led by Moderators***

SATURDAY, 13 APRIL, 2024

11:30 a.m. - 12:45 p.m.

SYMPOSIUM 46: Acute Lung Allograft Dysfunction (ALAD): From Bench to Bedside

Location: North Hall

Core Therapies: LUNG, HEART, MCS, PVD

Practice Areas: Pulmonology, Anesthesiology and Critical Care, Infectious Diseases, Pediatrics, Pharmacy, Research and Immunology

Session Summary: Lung transplant recipients experience acute declines in lung allograft function, ranging from mild to life-threatening. This symposium will address acute lung allograft dysfunction (ALAD) as an entity and identify urgent priorities for diagnosis, therapy, and research. A panel discussion with all speakers including audience Q&A, led by the session moderators, will conclude this session.

Moderators: Angela Koutsokera, MD, PhD, Lausanne University Hospital, Lausanne, Switzerland
Ciara Shaver, MD, PhD, Vanderbilt University Medical Center, Nashville, TN, USA

11:30 a.m. ***What is ALAD? Definitions, Uncertainties, Pathogenesis, and Research Priorities***
Stephen Juvet, MD, PhD, University Health Network, Toronto, ON, Canada

This talk will introduce competing definitions for ALAD from the literature and describe the immunology and physiology that drive acute airway rejection pathology. This presentation will also develop a framework for defining ALAD in research studies and identify key priorities for future research.

11:42 a.m. ***Pathologic Findings and Molecular Diagnostics in ALAD***
Fiorella Calabrese, MD, University of Padova, Padova, Italy.

Pathologic correlates of ALAD have been a particular challenge. While acute cellular rejection and lymphocytic bronchiolitis may cause ALAD, these findings are typically absent. Recent data suggest that organizing pneumonia and acute lung injury may be important pathologic features in ALAD. Further, molecular diagnostics may offer insights even when histology is bland.

11:54 a.m. ***Animal Models of ALAD***
Tereza Martinu, MD, MHS, Toronto General Hospital/UHN, Toronto, ON, Canada

This talk will describe approaches to studying ALAD and the onset of fibrotic airway rejection. These models, including animal orthotopic lung transplantation, heterotopic tracheal transplant, genetic and pharmacological approaches, variably reflect our understanding of human ALAD and have important limitations. Analytic strategies including histology, flow cytometry, lung function, and protein-based assays will be reviewed in the context of developing therapeutics.

12:06 p.m. ***ALAD in Pediatric Lung Transplant Recipients***
Christian Benden, MD, MBA, FCCP, University of Zürich, Zürich, Switzerland.

This presentation will cover diagnosis and management of ALAD in pediatric patients, with a focus on specific challenges to detecting ALAD in pediatric patients and emerging diagnostic approaches. Insights from the pediatric population may inform the adult population.

12:18 p.m. ***Clinical Management of ALAD: Outpatient to ICU***
Robin Vos, MD, PhD, UZ Leuven, Leuven, Belgium

This talk will describe the spectrum of presentations and management strategies for ALAD, including emerging diagnostic and immune suppression strategies to manage transplant recipients ranging from outpatient to critically ill and prevent progression to CLAD.

12:30 p.m. ***Panel Discussion led by Moderators***

SATURDAY, 13 APRIL, 2024

1:00 - 2:15 p.m.

ORAL SESSION 41: Cardiac Antibody Mediated Rejection: New Diagnostic and Prognostic Approaches

Location: Congress Hall

Core Therapies: HEART

Practice Areas: Cardiology, Cardiothoracic Surgery, Nursing and Allied Health, Pathology, Research and Immunology

Session Summary: This session features abstracts with a focus on molecular assays and novel diagnostics and their ability to predict outcomes and prognosis.

Each presenter will give a **10-minute** PowerPoint presentation, followed by a **5-minute** question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: Carmela Tan, MD, Cleveland Clinic, Cleveland, OH, USA
Johanna Contreras, MD, MSc, Mount Sinai, New York, NY, USA

1:00 p.m. **(200) AlloSure Stratifies Prognosis of Asymptomatic AMR**
S. Patel¹, A. Alam², P. Shah³, N. Uriel⁴, Y. Fu⁵, M. Zhou⁵, L. Shen⁵, K. Qu⁵, K. Oreschak⁵, K. Foster⁵. ¹Montefiore-Einstein, New York City, NY, ²New York University Medical Center, New York City, NY, ³Inova Heart and Vascular Institute, Falls Church, VA, ⁴New York Presbyterian, New York City, NY, ⁵CareDx, Brisbane, CA

1:10 p.m. **Q&A**

1:15 p.m. **(201) Cell-Free DNA Identifies High-Risk Donor Specific Antibodies in Heart Transplant Recipients**
J. Goldberg¹, Y. Xu², X. Tian², A. Bon², G. Eleanor³, R. Brower², M. Jang², H. Kong², T. Andargie², W. Park², S. Najjar⁴, I. Tchoukina⁵, K. Shah⁵, S. Hsu⁶, M. Rodrigo⁴, C. Marboe⁷, G. Berry⁸, H. Valentine⁸, P. Shah¹, S. Agbor-Enoh². ¹Inova Heart and Vascular Institute, Falls Church, VA, ²National Heart, Lung, and Blood Institute, Bethesda, MD, ³Weill Cornell Medical College, New York, NY, ⁴MedStar Health, Washington, DC, ⁵Virginia Commonwealth University, Richmond, VA, ⁶Johns Hopkins University School of Medicine, Baltimore, MD, ⁷Columbia University Vagelos College of Physicians & Surgeons, New York, NY, ⁸Stanford University School of Medicine, Palo Alto, CA

1:25 p.m. **Q&A**

1:30 p.m. **(202) Correlation Between Donor-Specific Antibodies and Molecular Microscope Results in Heart Transplant Recipients**
C. M. Moeller¹, A. Fernandez Valledor¹, D. Oren¹, G. Rubinstein¹, J. Baranowska¹, S. Rahman¹, C. Lee¹, Y. Mehlman¹, D. Lotan¹, D. Bae¹, K. Oh¹, K. Theodoropoulos¹, E. M. DeFilippis¹, J. Fried¹, E. Lin¹, V. Topkara¹, M. Yuzefpolskaya¹, P. Colombo¹, D. Majure², K. Clerkin¹, J. Raikhelkar¹, F. Latif¹, N. Uriel¹, G. Sayer¹. ¹Division of Cardiology, Center of Advanced Cardiac Care, Columbia University Irving Medical Center, New York, NY, ²Weill Cornell Medical College, New York, NY

1:40 p.m. **Q&A**

1:45 p.m. **(203) Impact of Innate Rejection on Graft Survival in Heart Transplantation: Preliminary Findings on Missing-Self Induced Microvascular Rejection**
A. Aloisio¹, A. Koenig², M. Masetti¹, V. Dubois³, C. Saison³, L. Borgese¹, L. Giovannini¹, L. Marcantoni⁴, L. Botta⁵, S. Manfroï⁶, O. Thauinat⁷, L. Potena¹. ¹Heart Failure and Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, ²INSERM U1111, Université Claude Bernard Lyon I, CNRS UMR5308, Ecole Normale Supérieure de Lyon, Lyon, France, ³French National Blood Service (EFS), HLA Laboratory, Décines-Charpieu, France, ⁴Internal Medicine Unit for the Treatment of Severe Organ Failure, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, ⁵Cardiac Surgery Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, ⁶Immunogenetics and Transplant Biology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, ⁷CIRI, INSERM U1111, Université Claude Bernard Lyon I, CNRS UMR5308, Ecole Normale Supérieure de Lyon, Lyon, France

1:55 p.m. **Q&A**

2:00 p.m. **(204) Long Term Outcome of First-Year C1q Positive Donor Specific Antibodies After Heart Transplantation**
D. Chang, J. Patel, M. Kittleson, M. Welton, N. Bhatnagar, A. Kanungo, M. Lee, Z. Wakefield, M. Hamilton, A. Hage, L. Czer, P. Catarino, J. Kobashigawa. Cedars-Sinai Smidt Heart Institute, Los Angeles, CA

2:10 p.m. **Q&A**

SATURDAY, 13 APRIL, 2024

1:00 - 2:15 p.m.

ORAL SESSION 42: Lungs Retrieved at Zweinstein: Do You Fancy My Donor Lung?

Location: South Hall 3

Core Therapies: LUNG

Practice Areas: Cardiothoracic Surgery, Anesthesiology and Critical Care, Pediatrics, Pulmonology

Session Summary: Abstracts in this session are focused on tools to increase the lung donor pool and lung acceptance rate. Outcome after lung transplantation from older age and DCD donors will be discussed.

Each presenter will give a **10-minute** PowerPoint presentation, followed by a **5-minute** question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: John Dark, MB, FRCS, Newcastle University, Newcastle upon Tyne, United Kingdom
Aleem Siddique, MBBS, University of Nebraska Medical Center, Omaha, NE, USA

- 1:00 p.m. **(205) Predictors of Intraoperative Donor Lung Turndown After Initial Acceptance**
A. F. Akbar¹, A. L. Zhou², J. M. Ruck³, A. Kalra⁴, A. J. Casillan³, J. S. Ha³, C. A. Merlo⁵, E. L. Bush³. ¹Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Department of Surgery, Johns Hopkins Hospital, Baltimore, MD, ⁴Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, ⁵Department of Medicine, Johns Hopkins Hospital, Baltimore, MD
- 1:10 p.m. **Q&A**
- 1:15 p.m. **(206) The Respiratory Physiotherapy, a New Tool to Increase the Lung Donors Pool**
I. Bello¹, G. Ballesteros², B. Garcés³, J. Mercabal⁴, D. Paredes⁵, M. Peñalver¹, E. Miñambres⁶, Á. Suarez⁷, A. Gómez⁸, B. Pascual², G. Sánchez-Etayo⁹, D. Martí¹, E. Navas⁸, A. Gómez⁹, M. Boada¹⁰, L. Grando¹⁰, B. Dominguez-Gil¹¹, A. Sandiumenge⁸. ¹Hospital Clínic, Barcelona, Spain, ²Hospital Universitario Vall d'Hebron, Barcelona, Spain, ³Transplant Coordination Department, Hospital Germans Trias i Pujol, Badalona, Spain, ⁴Hospital Germans Trias i Pujol, Badalona, Spain, ⁵Transplant Coordination Department, Hospital Clínic, Barcelona, Spain, ⁶Transplant Coordination Department, Hospital Universitario Marqués de Valdecillas, Santander, Spain, ⁷Hospital Universitario Marqués de Valdecillas, Santander, Spain, ⁸Transplant Coordination Department, Hospital Universitario Vall d'Hebron, Barcelona, Spain, ⁹Rehabilitation, Hospital Universitario Vall d'Hebron, Barcelona, Spain, ¹⁰Thoracic Surgery, Hospital Clínic, Barcelona, Spain, ¹¹ONT, Madrid, Spain
- 1:25 p.m. **Q&A**
- 1:30 p.m. **(207) Satisfactory Short and Long-Term Outcomes from Careful Selection of Older Donors for Lung Transplantation: An Australian Single-Centre Experience**
S. Dutta¹, A. Iyer¹, A. Watson¹, M. Connellan¹, E. Granger¹, M. Plit², P. Jansz¹, D. Darley². ¹Department of Cardiothoracic and Transplant Surgery, St Vincent's Hospital Sydney, Darlinghurst, Australia, ²Department of Lung Transplantation, St Vincent's Hospital Sydney, Darlinghurst, Australia
- 1:40 p.m. **Q&A**
- 1:45 p.m. **(208) Controlled Donation After Circulatory Death Lung Transplantation in University Hospital Zurich: 10-years' Experience**
L. Hoyos Mejía¹, T. Papatotopoulos², G. Lang³, I. Iskender², M. Schuurmans⁴, R. Hage², I. Opitz⁵. ¹Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland, ²University Hospital Zurich, Zurich, Switzerland, ³University of Vienna, Vienne, Austria, ⁴Univ of Zurich, Zurich, Switzerland, ⁵Universitätsspital Zürich, Zurich, Switzerland
- 1:55 p.m. **Q&A**
- 2:00 p.m. **(209) Outcomes in Donation After Circulatory Death Pediatric Lung Transplants: An Analysis of the ISHLT Registry**
H. Ahmed¹, S. Hogue¹, K. Kulshrestha¹, M. Hossain², Y. Zhang², A. Ashfaq¹, D. Morales¹, D. Hayes³. ¹The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Cincinnati Children's Hospital Medical Center / University of Cincinnati, Cincinnati, OH
- 2:10 p.m. **Q&A**

SATURDAY, 13 APRIL, 2024

1:00 - 2:15 p.m.

ORAL SESSION 43: One, Two, Buckle My Shoe: Group I & II Pulmonary Hypertension Assessment

Location: South Hall 1

Core Therapies: PVD

Practice Areas: Cardiology, Cardiothoracic Surgery, Pathology, Pulmonology, Research and Immunology

Session Summary: This session will investigate the utility of existing risk prediction models and diagnostic criteria in pulmonary hypertension as well as explore information yielded from echocardiography, micro computed tomography and histologic analyses.

Each presenter will give a **10-minute** PowerPoint presentation, followed by a **5-minute** question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: Teresa De Marco, MD, FACC, UCSF, San Francisco, CA, USA
Micheal McInnis, MD, University Health Network, Toronto, ON, Canada

- 1:00 p.m. **(210) Remodeling of the Endothelial Extracellular Matrix (ECM) Drives Smooth Muscle Cell Hyperplasia in Pulmonary Hypertension Due to Left Heart Disease**
N. Nambiar Veetil¹, T. Gransar¹, S. Liu², V. Falk¹, M. M. Kucherenko¹, W. M. Kübler², C. Knosalla³. ¹Department of Cardiothoracic Surgery, Deutsches Herzzentrum der Charité (DHZC), Berlin, Germany, ²Institute of Physiology, Charité Universitätsmedizin Berlin, Berlin, Germany, ³Department of Cardiothoracic Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany
- 1:10 p.m. **Q&A**
- 1:15 p.m. **(211) Pulmonary Vasculopathy in Heart Failure: Is the New Threshold > 2 Wood Units Relevant in Advanced HF Population ?**
V. Melenovsky, H. Al-Hiti, A. Reichenbach, D. Jenca, J. Benes, K. Kroupova, M. Kotrc. *Institute for Clin. and Exp. Medicine - IKEM, Prague, Czech Republic*
- 1:25 p.m. **Q&A**
- 1:30 p.m. **(212) Micro-CT Based Approach to Quantitatively Evaluate Vascular Changes in Pulmonary Arterial Hypertension**
G. Aerts¹, L. Willems¹, R. Anthonissen¹, B. De Jonghe¹, J. Michiels¹, R. Celen¹, J. Verhaegen¹, A. Vermaut¹, V. Geudens¹, C. Hooft¹, P. Kerckhof¹, H. Beeckmans¹, J. Kaes¹, Y. Mohamady¹, L. Hardy¹, J. Van Slambrouck², B. Tielemans¹, B. Weynand², L. Ceulemans², R. Vos², G. Gayan-Ramirez¹, C. Belge², T. Verbelen², V. Greetje¹, M. Delcroix², R. Quarck¹, B. Vanaudenaerde¹, L. Godinas². ¹KU Leuven, Leuven, Belgium, ²UZ Leuven, Leuven, Belgium
- 1:40 p.m. **Q&A**
- 1:45 p.m. **(213) Diagnostic Accuracy of Automatic Tricuspid Regurgitation Jet Velocity for Detecting Pulmonary Hypertension**
M. Salehi¹, S. Alabed¹, M. Sharkey¹, A. Maiter¹, K. Dwivedi¹, T. Yardibi², M. Selej³, A. Hameed⁴, A. Charalampopoulos⁴, D. Kiely⁴, A. J. Swift¹. ¹University of Sheffield, Sheffield, United Kingdom, ²Janssen Pharmaceuticals Research & Development, San Francisco, CA, ³Janssen Pulmonary Hypertension, San Francisco, CA, ⁴Sheffield Teaching Hospitals, Sheffield, United Kingdom
- 1:55 p.m. **Q&A**
- 2:00 p.m. **(214) Prediction of Long-Term Survival by Three Risk Assessment Models in Patients with Pulmonary Arterial Hypertension: A SPAHR Analysis**
C. Hjalmarsson¹, T. Thakur², T. Weiss³, E. Björklund⁴, J. Papageorgiou⁵, G. Radegran⁶, S. Soderberg⁷, H. Wahlander⁸, D. Lautsch², B. Kjellström⁹. ¹Cardiology, Sahlgrenska University Hospital, Göteborg, Sweden, ²MSD, Rahway, NJ, ³Center for Observational and Real-World Evidence (CORE), MSD, Rahway, NJ, ⁴Cardiology, Akademiska Sjukhuset, Uppsala, Sweden, ⁵Cardiology, University Hospital in Linköping, Sweden, Linköping, Sweden, ⁶Cardiology, Skane University Hospital, Lund, Sweden, ⁷Umeå University, Dept of Public Health and Clinical Medicine, Umeå, Sweden, ⁸Pediatric Heart Center, The Queen Silvia Children's Hospital, Sahlgrenska University Hospital, Gothenburg, Sweden, ⁹Clinical Sciences Lund, Clinical Physiology, Lund University and Skåne University Hospital, Lund, Sweden
- 2:10 p.m. **Q&A**

SATURDAY, 13 APRIL, 2024

1:00 - 2:15 p.m.

ORAL SESSION 44: Spin Doctors and Heart Hotties: Unleashing the Future of MCS Devices

Location: South Hall 2

Core Therapies: MCS

Practice Areas: Cardiothoracic Surgery, Anesthesiology and Critical Care, Cardiology, Nursing and Allied Health, Pediatrics, Research and Immunology

Session Summary: This session will provide insights into the latest developments and first clinical results of novel mechanical circulatory support devices, including advancements addressing the unmet needs of total artificial hearts and the failing Fontan population. Additionally, this session will address the user-centered design of new LVAD peripherals.

Each presenter will give a **10-minute** PowerPoint presentation, followed by a **5-minute** question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: Peter Ivak, M.D., Ph.D., IKEM, Prague, Czech Republic
Maryl Johnson, MD, University of Wisconsin, Madison, WI, USA

- 1:00 p.m. **(215) Long-Term Outcomes of a Novel Fully Magnetically Levitated Ventricular Assist Device for the Treatment of Advanced Heart Failure in China**
X. Wang, X. Zhou, H. Chen, J. Du, L. Zou, P. Qing, F. Duan, S. Yuan, J. Shi, B. Ji, S. Hu. *State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China*
- 1:10 p.m. **Q&A**
- 1:15 p.m. **(216) HeartMate 3 LVAD Outflow Graft Velocity Profile as Simplified Marker for Left Ventricular Unloading in Echocardiographic Speed Ramp Tests**
A. Schaefer, T. Abart, G. Widhalm, J. Riebandt, A. Kahrovic, C. Marko, G. Laufer, D. Wiedemann, D. Zimpfer, T. Schloeglhofer. *Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria*
- 1:25 p.m. **Q&A**
- 1:30 p.m. **(217) Development of a Destination Therapy Right Heart Replacement Pump for Failing Fontan Patients**
W. J. Weiss¹, R. Newswanger¹, C. Jhun¹, C. Scheib¹, K. Bohnenberger¹, J. Cysyk¹, J. Clark², J. Myers², I. Jenelle³, G. Rosenberg¹. ¹*Surgery, Penn State College of Medicine, Hershey, PA*, ²*Pediatrics, Penn State College of Medicine, Hershey, PA*, ³*Comparative Medicine, Penn State College of Medicine, Hershey, PA*
- 1:40 p.m. **Q&A**
- 1:45 p.m. **(218) The Effect of Rotational Speed Modulated Right Ventricular Assist Device on Hemodynamics in the Application of Continuous-Flow Biventricular Assist Device**
A. Umeki¹, T. Nishinaka¹, K. Imoto¹, T. Murakami¹, S. Imaoka¹, T. Mizuno¹, T. Tsukiya¹, M. Ono². ¹*National Cerebral and Cardiovascular Center, Osaka, Japan*, ²*The University of Tokyo Hospital, Tokyo, Japan*
- 1:55 p.m. **Q&A**
- 2:00 p.m. **(219) Enhancing Usability and Safety: Comparative Evaluation of Corwave and Heartmate 3 LVAD Peripherals in Simulated Scenarios**
G. Widhalm¹, T. Abart¹, K. Ebenberger¹, A. Berger², J. Riebandt¹, D. Wiedemann¹, D. Zimpfer¹, M. Wagner², T. Schloeglhofer¹. ¹*Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria*, ²*Division of Neonatology, Pediatric Intensive Care and Neuropediatrics, Medical University of Vienna, Vienna, Austria*
- 2:10 p.m. **Q&A**

SATURDAY, 13 APRIL, 2024

1:00 - 2:15 p.m.

ORAL SESSION 45: Post Pediatric Heart Transplant Survival, Immunosuppression, and Rejection Monitoring

Location: Panorama Hall

Core Therapies: HEART

Practice Areas: Pediatrics, Anesthesiology and Critical Care, Cardiology, Cardiothoracic Surgery, Pathology

Session Summary: This session will present the advances in posttransplant recipient care. The impact of primary graft failure, prolonged length of stay after pediatric transplantation, surveillance of rejection and length stay after transplantation

Each presenter will give a **10-minute** PowerPoint presentation, followed by a **5-minute** question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: Caron Burch, RN, MSN, FNP, CCTC, Dell Children's Hospital, Austin, TX, USA
Janet Scheel, MD, Washington University in St Louis, St. Louis, MO, USA

- 1:00 p.m. **(220) Adverse Events Occur Frequently in the Teammate Trial Cohort: Comparison by Treatment Group During 30 Months of Follow Up**
K. P. Daly¹, T. P. Singh¹, L. A. Sleeper¹, J. C. Alejos², R. K. Ameduri³, S. R. Auerbach⁴, N. Bansal⁵, L. Barkoff⁶, A. Barnes⁷, M. J. Bock⁸, A. Butto⁹, R. Butts¹⁰, W. F. Carlo¹¹, C. Castleberry¹², M. Chrisant¹³, S. Deshpande¹⁴, W. J. Dreyer¹⁵, B. Feingold¹⁶, J. Friedland-Little¹⁷, S. A. Hollander¹⁸, A. Joong¹⁹, G. L. Klein¹, A. K. Lal²⁰, J. Messere¹, J. Lee²¹, M. Lu¹, I. Lytrivi²², S. D. Miyamoto²³, D. M. Peng²⁴, A. Punnoose²⁵, J. W. Rossano²⁶, T. Ryan²⁷, J. A. Su²⁸, S. Zangwill²⁹, C. S. Almond¹⁸. ¹Boston Children's Hospital, Boston, MA, ²UCLA Mattel Children's Hosp, Los Angeles, CA, ³Mayo Clinic, Rochester, MN, ⁴University of Colorado, Aurora, CO, ⁵Mount Sinai Kravis Children's Hospital, New York, NY, ⁶Lucile Packard Children's Hospital, Palo Alto, CA, ⁷Children's Mercy Kansas City, Kansas City, MO, ⁸Rady Children's Hospital / UC San Diego, San Diego, CA, ⁹Children's Healthcare of Atlanta, Atlanta, GA, ¹⁰Children's Medical Center of Dallas/University of Texas Southwestern, Dallas, TX, ¹¹University of Alabama, Birmingham, AL, ¹²Dell Medical School at the University of Texas in Austin, Austin, TX, ¹³Joe DiMaggio Children's Hospital, Hollywood, FL, ¹⁴Children's National Hospital, George Washington University, Washington, DC, ¹⁵Baylor College of Med, Houston, TX, ¹⁶UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, ¹⁷Seattle Children's Hospital, Seattle, WA, ¹⁸Stanford University, Palo Alto, CA, ¹⁹Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ²⁰University of Utah, Salt Lake City, UT, ²¹Lucile Packard Children's Hospital Stanford Children's Health, Palo Alto, CA, ²²Columbia Presbyterian Hospital, New York, New York City, NY, ²³Children's Hospital Colorado, Aurora, CO, ²⁴University of Michigan, Ann Arbor, MI, ²⁵Children's Hospital of Wisconsin, Milwaukee, WI, ²⁶The Children's Hospital of Philadelphia, Philadelphia, PA, ²⁷Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²⁸Children's Hospital Los Angeles, Los Angeles, CA, ²⁹Phoenix Children's Hospital, Phoenix, AZ
- 1:10 p.m. **Q&A**
- 1:15 p.m. **(221) Factors Associated with Prolonged Length of Stay After Pediatric Heart Transplantation**
S. Rangu¹, E. Profita², C. Chen², S. Hollander², M. Ma³, E. Martin³, L. Barkoff⁴, D. Kwiatkowski², A. Shin², C. Almond². ¹Stanford Cardiovascular Institute, Stanford University, Palo Alto, CA, ²Pediatric Cardiology, Stanford University, Palo Alto, CA, ³Cardiac Surgery, Stanford University, Palo Alto, CA, ⁴Lucile Packard Children's Hospital, Palo Alto, CA
- 1:25 p.m. **Q&A**
- 1:30 p.m. **(222) Impact of Primary Graft Failure: Analysis of the PHTS Database**
J. Conway¹, T. Pidborochynski², J. Kirklin³, R. Cantor³, H. Zhao³, A. Sheybani⁴, J. Lamour⁵, L. G. Hahn⁶, L. Collins⁷, J. Laks⁸, D. H. Freed⁹. ¹Stollery Children's Hospital, Edmonton, AB, Canada, ²Pediatrics, University of Alberta, Edmonton, AB, Canada, ³Kirklin Solutions, Hoover, AL, ⁴Nemours Children's Hospital, Wilmington, DE, ⁵Mount Sinai Medical Center, New York, NY, ⁶Washington University in St. Louis, St. Louis, MO, ⁷University of Alabama at Birmingham, Birmingham, AL, ⁸Johns Hopkins All Children's Hospital, St. Petersburg, FL, ⁹Cardiac Surgery, University of Alberta, Edmonton, AB, Canada
- 1:40 p.m. **Q&A**
- 1:45 p.m. **(223) How Well Does the Molecular Microscope Diagnostic System (MMDx) Correlate with Traditional Pathologic Biopsy Interpretation in a Pediatric Heart Transplant Population?**
C. Milligan, T. P. Singh, G. Nava, M. Clark, R. Kobayashi, P. Estes, C. Carreon, A. Al-Ibraheemi, L. A. Sleeper, K. P. Daly. Boston Children's Hospital, Boston, MA
- 1:55 p.m. **Q&A**

2:00 p.m.

(224) Correlation of Donor-Derived Cell-Free DNA to Rejection Events in Pediatric Heart Transplant Recipients

S. A. Bravo, L. D. Akabas, A. D. Simonelli, W. A. Zuckerman, M. E. Richmond, I. D. Lytrivi. *Pediatrics, Columbia University Irving Medical Center, New York, NY*

2:10 p.m.

Q&A

SATURDAY, 13 APRIL, 2024

1:00 - 2:15 p.m.

ORAL SESSION 46: Lung Primary Graft Dysfunction, the Cursed Child

Location: North Hall

Core Therapies: LUNG

Practice Areas: Pulmonology, Anesthesiology and Critical Care, Cardiothoracic Surgery, Pathology, Pharmacy, Research and Immunology

Session Summary: All aspects of PGD from prediction, models, inflammatory markers and treatment.

Each presenter will give a **10-minute** PowerPoint presentation, followed by a **5-minute** question and answer period with the audience, led by the session moderators. The presenter will remain at the podium during the Q&A segment.

Moderators: Marie Budev, DO, MPH, Cleveland Clinic, Cleveland, OH, USA
Unmil Shah, MD, DNB, KIMS, Secunderabad, Telangana, & Sir HN Reliance Hospitals, Mumbai, India

- 1:00 p.m. **(225) Novel Anti-CD94 Treatment Reduces Mouse and Human Experimental Pulmonary Ischemia-Reperfusion Injury**
T. Tsao¹, L. Qiu¹, A. Shemesh¹, A. Millan Hernandez¹, K. Shi², J. Richardson², R. Bharti¹, J. Santos¹, L. Lanier¹, M. Looney¹, J. Greenland¹, D. R. Calabrese¹. ¹University of California, San Francisco, San Francisco, CA, ²DrenBio, Foster City, CA
- 1:10 p.m. **Q&A**
- 1:15 p.m. **(226) Human Lung Spheroid Cell Exosomes Protect Against Lung Ischemia-Reperfusion Injury in a Prolonged Warm Ischemia Porcine DCD Model**
R. V. Ribeiro¹, D. L. Segamanasinghe², S. T. Aldin², S. Altarabsheh², G. Knop², F. Al-Azzam², F. A. Reynolds³, A. Richman³, C. Colby³, H. L. Zeman³, J. Mallea⁴, Y. Jing⁵, K. Cheng⁶, S. Saddoughi². ¹Thoracic Surgery, Mayo Clinic, Rochester, MN, ²Cardiovascular Surgery, Mayo Clinic, Rochester, MN, ³Critical Care Medicine, Mayo Clinic Florida, Jacksonville, FL, ⁵Xsome Biotech Inc., Raleigh, NC, ⁶Biomedical Engineering, Columbia University, New York, NY
- 1:25 p.m. **Q&A**
- 1:30 p.m. **Late-Breaking Abstract Presentation:**
(312) Safety Endpoints of the '10°C vs 4°C Lung Preservation Randomized-Controlled Trial' - An Interim Analysis
M. Cypel¹, A. Trindade², J. Campo-Canaeral de la Cruz³, A. Ali¹, S. Schwarz⁴, M. Bacchetta², S. Keshavjee¹, E. Wakeam¹, K. Hoetzenecker⁴. ¹University of Toronto, Toronto, ON, Canada, ²Vanderbilt University Medical Center, Nashville, TN, ³Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain, ⁴Medical University of Vienna, Vienna, Austria
- 1:40 p.m. **Q&A**
- 1:45 p.m. **(227) mt-DNA Aggravation Primary Graft Dysfunction Inflammatory Response Through GSDMD Dependent cGAS-STING-NLRP3 Feedback Loop**
X. Yang¹, J. Chen¹, M. Huang², J. Zhao³. ¹Department of Lung Transplant, Second Affiliated Hospital, Zhejiang University School of Medicine, HangZhou, China, ²General ICU, The Second Affiliated Hospital Zhejiang University School of Medicine, HangZhou, China, ³Second Affiliated Hospital, Zhejiang University School of Medicine, HangZhou, China
- 1:55 p.m. **Q&A**
- 2:00 p.m. **Late-Breaking Abstract Presentation:**
(228) A Double-Blind, Randomized Controlled Study Evaluating Allogeneic Adipose Tissue Derived Mesenchymal Stromal Cell Therapy to Reduce Primary Graft Dysfunction After Lung Transplantation
A. A. Qayyum¹, T. Lund², P. Bredahl Jensen³, K. Jensen², M. Haack-Sørensen¹, A. Ekblond¹, M. J. Nørgaard¹, H. Møller-Sørensen⁴, A. B. Mathiasen⁵, C. J. Moeller⁶, S. B. Rørvig⁷, A. Kalhauge⁸, H. Bruunsgaard⁹, J. Kastrup¹, M. Perch². ¹Cardiology Stem Cell Centre, Rigshospitalet, Copenhagen, Denmark, ²Cardiology, Section for Lung Transplantation, Rigshospitalet, Copenhagen, Denmark, ³Thoracic Anesthesiology and Intensive, Rigshospitalet, Copenhagen, Denmark, ⁴Thoracic Anesthesiology and Intensive Care, Rigshospitalet, Copenhagen, Denmark, ⁵Cardiology, Rigshospitalet, Copenhagen, Denmark, ⁶CardioThoracic Surgery, Rigshospitalet, Copenhagen, Denmark, ⁷Pathology, Rigshospitalet, Copenhagen, Denmark, ⁸Radiology, Rigshospitalet, Copenhagen, Denmark, ⁹Clinical Immunology, Rigshospitalet, Copenhagen, Denmark
- 2:10 p.m. **Q&A**